Our	O
data	O
suggest	O
that	O
lipoxygenase	B
metabolites	I
activate	O
ROI	O
formation	O
which	O
then	O
induce	O
IL	B
-	I
2	I
expression	O
via	O
NF	B
-	I
kappa	I
B	I
activation	O
.	O

Human	O
immunodeficiency	O
virus	O
type	O
2	O
(	O
HIV	O
-	O
2	O
)	O
,	O
like	O
HIV	O
-	O
1	O
,	O
causes	O
AIDS	O
and	O
is	O
associated	O
with	O
AIDS	O
cases	O
primarily	O
in	O
West	O
Africa	O
.	O

This	O
is	O
the	O
first	O
description	O
of	O
an	O
HIV	B
-	I
2	I
enhancer	I
element	I
which	O
displays	O
such	O
monocyte	O
specificity	O
,	O
and	O
no	O
comparable	O
enhancer	B
element	I
has	O
been	O
clearly	O
defined	O
for	O
HIV	O
-	O
1	O
.	O

While	O
a	O
nuclear	B
factor	I
(	O
s	O
)	O
from	O
both	O
peripheral	O
blood	O
monocytes	O
and	O
T	O
cells	O
binds	O
the	O
peri	B
-	I
kappa	I
B	I
site	I
,	O
electrophoretic	O
mobility	O
shift	O
assays	O
suggest	O
that	O
either	O
a	O
different	O
protein	O
binds	O
to	O
this	O
site	O
in	O
monocytes	O
versus	O
T	O
cells	O
or	O
that	O
the	O
protein	O
recognizing	O
this	O
enhancer	B
element	I
undergoes	O
differential	O
modification	O
in	O
monocytes	O
and	O
T	O
cells	O
,	O
thus	O
supporting	O
the	O
transfection	O
data	O
.	O

Understanding	O
the	O
monocyte	O
-	O
specific	O
function	O
of	O
the	O
peri	B
-	I
kappa	I
B	I
factor	I
may	O
ultimately	O
provide	O
insight	O
into	O
the	O
different	O
role	O
monocytes	O
and	O
T	O
cells	O
play	O
in	O
HIV	O
pathogenesis	O
.	O

Distinct	O
signaling	O
properties	O
identify	O
functionally	O
different	O
CD4	B
epitopes	I
.	O

Whereas	O
different	O
anti	B
-	I
CD4	I
mAb	I
or	O
HIV	B
-	I
1	I
gp120	I
could	O
all	O
trigger	O
activation	O
of	O
the	O
protein	B
tyrosine	I
kinases	I
p56lck	B
and	O
p59fyn	B
and	O
phosphorylation	O
of	O
the	O
Shc	B
adaptor	I
protein	I
,	O
which	O
mediates	O
signals	O
to	O
Ras	B
,	O
they	O
differed	O
significantly	O
in	O
their	O
ability	O
to	O
activate	O
NF	B
-	I
AT	I
.	O

To	O
address	O
potential	O
mechanisms	O
by	O
which	O
estrogens	O
suppress	O
erythropoiesis	O
,	O
we	O
have	O
examined	O
their	O
effects	O
on	O
GATA	B
-	I
1	I
,	O
an	O
erythroid	B
transcription	I
factor	I
that	O
participates	O
in	O
the	O
regulation	O
of	O
the	O
majority	O
of	O
erythroid	B
cell	I
-	I
specific	I
genes	I
and	O
is	O
necessary	O
for	O
full	O
maturation	O
of	O
erythrocytes	O
.	O

ER	B
-	O
mediated	O
repression	O
of	O
GATA	B
-	I
1	I
activity	O
occurs	O
on	O
an	O
artificial	B
promoter	I
containing	O
a	O
single	O
GATA	B
-	I
binding	I
site	I
,	O
as	O
well	O
as	O
in	O
the	O
context	O
of	O
an	O
intact	B
promoter	I
which	O
is	O
normally	O
regulated	O
by	O
GATA	B
-	I
1	I
.	O

In	O
coimmunoprecipitatio	O
experiments	O
using	O
transfected	O
COS	O
cells	O
,	O
GATA	B
-	I
1	I
and	O
ER	B
associate	O
in	O
a	O
ligand	O
-	O
dependent	O
manner	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

The	O
transcriptional	O
response	O
of	O
the	O
IL	B
-	I
2R	I
alpha	I
gene	I
to	O
stimulation	O
by	O
IL	B
-	I
1	I
+	O
IL	B
-	I
2	I
is	O
biphasic	O
.	O

It	O
also	O
primes	O
cells	O
to	O
become	O
IL	B
-	I
2	I
responsive	O
and	O
thereby	O
prepares	O
the	O
second	O
phase	O
,	O
in	O
which	O
IL	B
-	I
2	I
induces	O
a	O
100	O
-	O
fold	O
further	O
increase	O
in	O
IL	B
-	I
2R	I
alpha	I
transcripts	I
.	O

Transient	O
transfection	O
experiments	O
show	O
that	O
several	O
elements	O
in	O
the	O
promoter	B
-	I
proximal	I
region	I
of	O
the	O
IL	B
-	I
2R	I
alpha	I
gene	I
contribute	O
to	O
IL	B
-	I
1	I
responsiveness	O
,	O
most	O
importantly	O
an	O
NF	B
-	I
kappa	I
B	I
site	I
conserved	O
in	O
the	O
human	B
and	I
mouse	I
gene	I
.	O

IL	B
-	I
2	I
responsiveness	O
,	O
on	O
the	O
other	O
hand	O
,	O
depends	O
on	O
a	O
78	B
-	I
nucleotide	I
segment	I
1	O
.	O
3	O
kilobases	O
upstream	O
of	O
the	O
major	B
transcription	I
start	I
site	I
.	O

Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
is	O
known	O
to	O
infect	O
B	O
cells	O
and	O
epithelial	O
cells	O
.	O

The	O
appearance	O
of	O
the	O
BamHI	B
ZLF	I
-	I
1	I
gene	I
product	I
,	O
ZEBRA	B
,	O
by	O
RT	O
-	O
PCR	O
,	O
was	O
observed	O
within	O
8	O
hr	O
of	O
infection	O
.	O

Transcripts	O
encoding	O
gp350	B
/	I
220	I
,	O
the	O
major	B
coat	I
protein	I
of	O
EBV	O
,	O
were	O
identified	O
,	O
but	O
we	O
did	O
not	O
find	O
any	O
evidence	O
of	O
transcription	O
from	O
the	O
LMP	B
-	I
2A	I
or	O
EBER	B
-	I
1	I
loci	I
in	O
infected	O
thymocytes	O
.	O

The	O
main	O
difference	O
is	O
that	O
with	O
thymocytes	O
,	O
no	O
evidence	O
could	O
be	O
found	O
that	O
the	O
virus	O
ever	O
circularizes	O
.	O

Rather	O
,	O
EBV	O
remains	O
in	O
a	O
linear	O
configuration	O
from	O
which	O
replicative	B
genes	I
are	O
transcribed	O
.	O

Several	O
recent	O
studies	O
have	O
implicated	O
Jak	O
kinases	O
in	O
the	O
signaling	O
pathway	O
induced	O
by	O
IL	B
-	I
2	I
.	O

We	O
demonstrate	O
,	O
through	O
the	O
deletion	O
of	O
the	O
human	B
UDG	I
promoter	I
sequences	I
,	O
that	O
expression	O
of	O
E2F	B
-	I
1	I
activates	O
the	O
UDG	B
promoter	I
through	O
several	O
E2F	B
sites	I
.	O

Overexpression	O
of	O
UDG	B
in	O
Saos	O
2	O
cells	O
was	O
observed	O
to	O
delay	O
growth	O
late	O
in	O
G1	O
phase	O
and	O
transiently	O
arrest	O
these	O
cells	O
from	O
progressing	O
into	O
the	O
S	O
phase	O
.	O

Cellular	O
and	O
molecular	O
mechanisms	O
of	O
IFN	B
-	I
gamma	I
production	O
induced	O
by	O
IL	B
-	I
2	I
and	O
IL	B
-	I
12	I
in	O
a	O
human	O
NK	O
cell	O
line	O
.	O

In	O
addition	O
,	O
when	O
used	O
together	O
IL	B
-	I
2	I
and	O
IL	B
-	I
12	I
synergized	O
in	O
the	O
induction	O
of	O
IFN	B
-	I
gamma	I
and	O
GM	B
-	I
CSF	I
and	O
this	O
synergy	O
was	O
attributed	O
to	O
an	O
increased	O
accumulation	O
and	O
stability	O
of	O
the	O
IFN	B
-	I
gamma	I
and	I
GM	I
-	I
CSF	I
mRNAs	I
.	O

To	O
investigate	O
the	O
signaling	O
pathways	O
involved	O
in	O
the	O
gene	O
induction	O
,	O
five	O
inhibitors	O
,	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
,	O
transforming	B
growth	I
factor	I
-	I
beta	I
,	O
cycloheximide	O
,	O
genistein	O
,	O
and	O
staurosporine	O
A	O
,	O
were	O
used	O
in	O
analyzing	O
the	O
effects	O
of	O
IL	B
-	I
2	I
and	O
IL	B
-	I
12	I
on	O
NK3	O
.	O
3	O
cells	O
.	O

In	O
addition	O
,	O
IL	B
-	I
2	I
but	O
not	O
IL	B
-	I
12	I
induced	O
nuclear	B
factors	I
NF	B
-	I
kappa	I
B	I
and	O
AP1	B
,	O
and	O
regulation	O
of	O
the	O
nuclear	O
levels	O
of	O
these	O
two	O
DNA	B
binding	I
protein	I
complexes	I
is	O
correlated	O
with	O
IFN	O
-	O
gamma	O
and	O
GM	O
-	O
CSF	O
gene	O
expression	O
.	O

One	O
substrate	O
is	O
p95vav	B
,	O
which	O
is	O
expressed	O
exclusively	O
in	O
hematopoietic	O
and	O
trophoblast	O
cells	O
.	O

Furthermore	O
,	O
p95vav	B
synergizes	O
with	O
TCR	B
stimulation	O
in	O
inducing	O
NFAT	O
-	O
and	O
interleukin	O
-	O
2	O
-	O
dependent	O
transcription	O
.	O

Furthermore	O
,	O
the	O
activating	O
function	O
of	O
p95vav	B
is	O
blocked	O
by	O
FK506	O
,	O
suggesting	O
that	O
its	O
activity	O
also	O
depends	O
on	O
calcineurin	B
.	O

alpha	B
B	I
is	O
the	O
mouse	B
homologue	I
of	O
human	B
AML1	I
gene	I
detected	O
at	O
the	O
breakpoints	O
of	O
t	O
(	O
8	O
;	O
21	O
)	O
and	O
t	O
(	O
3	O
;	O
21	O
)	O
myeloid	O
leukemias	O
.	O

We	O
examined	O
alpha	B
A1	I
(	O
an	O
alpha	B
A	I
-	I
gene	I
product	I
)	O
and	O
alpha	B
B1	I
and	O
alpha	B
B2	I
(	O
two	O
alpha	B
B	I
-	I
encoded	I
isomers	I
)	O
for	O
their	O
effects	O
on	O
the	O
GM	B
-	I
CSF	I
promoter	I
.	O

Although	O
further	O
studies	O
are	O
required	O
to	O
determine	O
the	O
precise	O
role	O
of	O
PEBP2	B
in	O
the	O
GM	B
-	I
CSF	I
promoter	O
activity	O
,	O
the	O
present	O
findings	O
suggested	O
the	O
importance	O
of	O
the	O
relative	O
ratio	O
of	O
different	O
PEBP2	B
isoforms	I
in	O
regulating	O
the	O
levels	O
of	O
the	O
promoter	O
activity	O
.	O

IFN	B
-	I
gamma	I
priming	O
of	O
monocytes	O
enhances	O
LPS	O
-	O
induced	O
TNF	B
production	O
by	O
augmenting	O
both	O
transcription	O
and	O
MRNA	O
stability	O
.	O

The	O
induction	O
of	O
cytokine	B
expression	O
in	O
monocytes	O
/	O
macrophages	O
by	O
bacterial	B
endotoxin	I
or	O
lipopolysaccharide	O
is	O
a	O
critical	O
,	O
highly	O
regulated	O
host	O
defence	O
response	O
.	O

The	O
increased	O
transcriptional	O
rate	O
correlated	O
with	O
a	O
marked	O
increase	O
in	O
nuclear	B
factor	I
-	I
kappa	I
B	I
activity	O
in	O
these	O
cells	O
as	O
determined	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
using	O
a	O
consensus	B
NF	I
-	I
kappa	I
B	I
oligonucleotide	I
.	O

Consistent	O
with	O
the	O
increased	O
mRNA	B
stability	O
,	O
the	O
duration	O
of	O
mRNA	B
accumulation	O
was	O
longer	O
following	O
LPS	O
stimulation	O
in	O
primed	O
monocytes	O
,	O
in	O
addition	O
to	O
being	O
of	O
greater	O
magnitude	O
.	O

H	O
-	O
89	O
substantially	O
suppressed	O
LPS	O
-	O
induced	O
TNF	B
mRNA	I
accumulation	O
in	O
unprimed	O
cells	O
,	O
but	O
had	O
no	O
effect	O
on	O
primed	O
monocytes	O
following	O
LPS	O
stimulation	O
.	O

A	O
Myc	B
-	I
associated	I
zinc	I
finger	I
protein	I
binding	I
site	I
is	O
one	O
of	O
four	O
important	O
functional	B
regions	I
in	O
the	O
CD4	B
promoter	I
.	O

Since	O
the	O
terminal	O
events	O
of	O
erythropoiesis	O
are	O
controlled	O
by	O
the	O
glycoprotein	B
hormone	I
erythropoietin	I
(	O
Epo	B
)	O
,	O
we	O
investigated	O
whether	O
the	O
expression	O
or	O
activity	O
of	O
the	O
TAL1	B
gene	I
and	O
its	O
protein	B
products	I
were	O
affected	O
by	O
Epo	B
in	O
splenic	O
erythroblasts	O
from	O
mice	O
infected	O
with	O
an	O
anemia	O
-	O
inducing	O
strain	O
of	O
Friend	O
virus	O
(	O
FVA	O
cells	O
)	O
.	O

The	O
role	O
of	O
shared	B
receptor	I
motifs	I
and	O
common	B
Stat	I
proteins	I
in	O
the	O
generation	O
of	O
cytokine	B
pleiotropy	O
and	O
redundancy	O
by	O
IL	B
-	I
2	I
,	O
IL	B
-	I
4	I
,	O
IL	B
-	I
7	I
,	O
IL	B
-	I
13	I
,	O
and	O
IL	B
-	I
15	I
.	O

IL	B
-	I
13	I
Induced	O
the	O
same	O
complexes	O
as	O
IL	B
-	I
4	I
,	O
a	O
finding	O
explained	O
by	O
our	O
studies	O
implicating	O
IL	B
-	I
4R	I
as	O
a	O
shared	O
component	O
of	O
the	O
receptors	B
.	O

Control	O
of	O
I	B
kappa	I
B	I
-	I
alpha	I
proteolysis	O
by	O
site	O
-	O
specific	O
,	O
signal	O
-	O
induced	O
phosphorylation	O
.	O

When	O
either	O
serine	O
-	O
32	O
or	O
serine	O
-	O
36	O
of	O
I	B
kappa	I
B	I
-	I
alpha	I
was	O
mutated	O
,	O
the	O
protein	O
did	O
not	O
undergo	O
signal	O
-	O
induced	O
phosphorylation	O
or	O
degradation	O
,	O
and	O
NF	B
-	I
kappa	I
B	I
could	O
not	O
be	O
activated	O
.	O

Regulation	O
of	O
transcription	O
of	O
the	O
human	B
erythropoietin	I
receptor	I
gene	I
by	O
proteins	O
binding	O
to	O
GATA	B
-	I
1	I
and	I
Sp1	I
motifs	I
.	O

Erythropoietin	B
(	O
Epo	B
)	O
,	O
the	O
primary	O
regulator	O
of	O
the	O
production	O
of	O
erythroid	O
cells	O
,	O
acts	O
by	O
binding	O
to	O
a	O
cell	B
surface	I
receptor	I
(	O
EpoR	B
)	O
on	O
erythroid	O
progenitors	O
.	O

Interestingly	O
,	O
when	O
we	O
mutated	O
the	O
Sp1	B
site	I
,	O
resulting	O
in	O
a	O
marked	O
decrease	O
in	O
hEpoR	B
promoter	I
activity	O
,	O
we	O
could	O
restore	O
transactivation	O
by	O
increasing	O
GATA	B
-	I
1	I
levels	O
in	O
OCIM1	O
cells	O
.	O

These	O
data	O
suggest	O
that	O
while	O
GATA	B
-	I
1	I
can	O
transactivate	O
the	O
EpoR	B
promoter	I
,	O
the	O
level	O
of	O
hEpoR	B
gene	I
expression	O
does	O
not	O
depend	O
on	O
GATA	B
-	I
1	I
alone	O
.	O

The	O
deduced	O
amino	O
acid	O
sequence	O
similarity	O
to	O
the	O
proteins	O
encoded	O
by	O
these	O
two	O
latter	O
genes	O
is	O
approximately	O
65	O
%	O
and	O
includes	O
domains	O
and	O
amino	O
acid	O
residues	O
(	O
the	O
leucine	B
zipper	I
-	I
like	I
and	O
the	O
RGD	B
domain	I
,	O
a	O
serine	O
and	O
a	O
histidine	O
residue	O
in	O
the	O
NH2	B
-	I
and	O
in	O
the	O
COOH	B
-	I
terminal	I
portion	I
of	O
the	O
protein	O
,	O
respectively	O
)	O
postulated	O
to	O
be	O
important	O
for	O
nm23	B
function	O
.	O

Treatment	O
of	O
U937	O
with	O
IFN	B
-	I
gamma	I
for	O
9	O
hr	O
in	O
the	O
presence	O
of	O
cycloheximide	O
led	O
to	O
super	O
-	O
induction	O
of	O
Fc	B
gamma	I
RI	I
expression	O
.	O

Genomic	O
sequence	O
upstream	O
of	O
the	O
Fc	B
gamma	I
RIC	I
gene	I
was	O
cloned	O
and	O
subjected	O
to	O
primer	O
extension	O
analysis	O
,	O
which	O
demonstrated	O
a	O
single	O
transcription	B
initiation	I
site	I
without	O
a	O
TATA	B
box	I
.	O

Double	B
-	I
stranded	I
GIRE	I
sequence	I
,	O
but	O
not	O
a	O
scrambled	B
sequence	I
,	O
was	O
specifically	O
bound	O
by	O
nuclear	B
proteins	I
from	O
IFN	O
-	O
gamma	O
treated	O
U937	O
cells	O
.	O

The	O
Fc	B
gamma	I
RIC	I
GIRE	I
is	O
homologous	O
to	O
the	O
IFN	B
-	I
gamma	I
activation	I
sequence	I
(	O
GAS	B
)	O
of	O
the	O
guanylate	B
binding	I
protein	I
and	O
to	O
X	B
box	I
elements	I
of	O
class	B
II	I
MHC	I
genes	I
.	O

In	O
HTLV	O
-	O
I	O
-	O
infected	O
cord	O
blood	O
lymphocytes	O
,	O
the	O
transition	O
from	O
IL	B
-	I
2	I
-	O
dependent	O
to	O
IL	B
-	I
2	I
-	O
independent	O
growth	O
correlated	O
with	O
the	O
acquisition	O
of	O
a	O
constitutively	O
activated	O
Jak	B
-	B
STAT	I
pathway	O
,	O
which	O
suggests	O
that	O
this	O
pathway	O
participates	O
in	O
HTLV	O
-	O
I	O
-	O
mediated	O
T	O
cell	O
transformation	O
.	O

Nitric	O
oxide	O
selectively	O
reduces	O
endothelial	O
expression	O
of	O
adhesion	B
molecules	I
and	O
proinflammatory	B
cytokines	I
.	O

In	O
a	O
concentration	O
-	O
dependent	O
manner	O
,	O
NO	O
inhibited	O
interleukin	B
(	I
IL	I
)	I
-	I
1	I
alpha	O
-	O
stimulated	O
VCAM	B
-	I
1	I
expression	O
by	O
35	O
-	O
55	O
%	O
as	O
determined	O
by	O
cell	O
surface	O
enzyme	O
immunoassays	O
and	O
flow	O
cytometry	O
.	O

Inhibition	O
of	O
endogenous	O
NO	O
production	O
by	O
L	O
-	O
N	O
-	O
monomethyl	O
-	O
arginine	O
also	O
induced	O
the	O
expression	O
of	O
VCAM	B
-	I
1	I
,	O
but	O
did	O
not	O
augment	O
cytokine	O
-	O
induced	O
VCAM	B
-	I
1	I
expression	O
.	O

Murine	B
macrophage	I
inflammatory	I
protein	I
1	I
alpha	I
(	O
MIP	B
-	I
1	I
alpha	I
)	O
and	O
its	O
human	B
equivalent	I
(	O
GOS19	B
,	O
LD78	B
,	O
or	O
AT464	B
)	O
are	O
members	O
of	O
the	O
-	B
C	I
-	I
C	I
family	I
of	O
low	B
-	I
molecular	I
-	I
weight	I
chemokines	I
.	O

It	O
also	O
induces	O
chemotaxis	O
and	O
inflammatory	O
responses	O
in	O
mature	O
cell	O
types	O
.	O

One	O
member	O
,	O
ICK	B
-	I
1A	I
,	O
behaves	O
as	O
a	O
strong	B
negative	I
regulator	I
.	O

We	O
provide	O
evidence	O
for	O
an	O
additional	O
binding	B
site	I
,	O
the	O
MIP	B
-	I
1	I
alpha	I
nuclear	I
protein	I
(	I
MNP	I
)	I
site	I
,	O
which	O
overlaps	O
the	O
ICK	B
-	I
1	I
site	I
.	O

The	O
signal	O
is	O
subsequently	O
propagated	O
through	O
the	O
activation	O
of	O
Raf	B
-	I
1	I
,	O
MEK	B
,	O
and	O
MAP	B
kinases	I
as	O
shown	O
by	O
their	O
increased	O
autophosphorylation	O
in	O
vitro	O
and	O
phosphorylation	O
in	O
situ	O
.	O

We	O
conclude	O
that	O
IL	B
-	I
5	I
induced	O
signals	O
are	O
propagated	O
through	O
two	O
distinct	O
pathways	O
:	O
(	O
1	O
)	O
Lyn	B
-	O
-	O
>	O
Ras	B
-	O
-	O
>	O
Raf	B
-	I
1	I
-	O
-	O
>	O
MEK	B
-	O
-	O
>	O
MAP	B
kinase	I
and	O
(	O
2	O
)	O
Jak2	B
-	O
-	O
>	O
STAT1	B
.	O

The	O
retinoblastoma	B
gene	I
product	I
negatively	O
regulates	O
transcriptional	O
activation	O
mediated	O
by	O
the	O
human	B
cytomegalovirus	I
IE2	I
protein	I
.	O

We	O
found	O
that	O
the	O
retinoblastoma	B
susceptibility	I
gene	I
product	I
(	O
Rb	B
)	O
dramatically	O
suppressed	O
this	O
IE2	B
transactivation	O
of	O
various	B
promoters	I
.	O

However	O
,	O
the	O
relationship	O
remains	O
controversial	O
according	O
to	O
the	O
tumor	O
cell	O
types	O
and	O
experimental	O
system	O
,	O
with	O
conflicting	O
results	O
from	O
different	O
research	O
groups	O
.	O

And	O
there	O
was	O
no	O
statistically	O
significant	O
difference	O
in	O
NDP	B
kinase	I
expression	O
between	O
SCC	O
with	O
metastasis	O
and	O
SCC	O
without	O
metastasis	O
.	O

Retinoblastoma	B
protein	I
(	O
RB	B
)	O
is	O
a	O
tumor	O
suppressor	O
and	O
functions	O
as	O
a	O
transcriptional	B
repressor	I
by	O
binding	O
and	O
inactivating	O
the	O
transactivator	B
E2F	I
-	I
I	I
.	O

RB	O
-	O
defective	O
tumor	O
lines	O
are	O
non	O
-	O
inducible	O
for	O
MHC	B
class	I
II	I
by	O
IFN	B
-	I
gamma	I
,	O
or	O
very	O
weakly	O
inducible	O
,	O
but	O
transfection	O
of	O
2	O
different	O
lines	O
with	O
RB	B
expression	I
vectors	I
re	O
-	O
establishes	O
or	O
substantially	O
enhances	O
class	O
II	O
inducibility	O
.	O

We	O
also	O
examined	O
the	O
IFN	B
-	I
gamma	I
induction	O
of	O
CIITA	B
in	O
RB	B
-	O
defective	O
lines	O
.	O

We	O
have	O
recently	O
demonstrated	O
that	O
stimulation	O
of	O
human	O
T	O
and	O
natural	O
killer	O
cells	O
with	O
IL	B
-	I
12	I
induces	O
tyrosine	O
phosphorylation	O
of	O
the	O
Janus	B
family	I
tyrosine	I
kinase	I
JAK2	B
and	O
Tyk2	B
,	O
implicating	O
these	O
kinases	B
in	O
the	O
immediate	O
biochemical	O
response	O
to	O
IL	B
-	I
12	I
.	O

Furthermore	O
,	O
we	O
show	O
that	O
IL	B
-	I
12	I
stimulates	O
formation	O
of	O
a	O
DNA	B
-	I
binding	I
complex	I
that	O
recognizes	O
a	O
DNA	O
sequence	O
previously	O
shown	O
to	O
bind	O
STAT	B
proteins	I
and	O
that	O
this	O
complex	O
contains	O
STAT4	B
.	O

DESIGN	O
:	O
The	O
effects	O
of	O
hypercortisolaemia	O
,	O
hyperthermia	O
and	O
cellular	O
composition	O
on	O
number	O
of	O
glucocorticoid	B
receptors	I
per	O
cell	O
and	O
their	O
affinity	O
were	O
evaluated	O
,	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
,	O
in	O
peripheral	O
blood	O
mononuclear	O
leucocytes	O
of	O
control	O
subjects	O
and	O
in	O
patients	O
with	O
sepsis	O
or	O
septic	O
shock	O
.	O

RESULTS	O
:	O
Hypercortisolaemia	O
,	O
in	O
vitro	O
,	O
resulted	O
in	O
a	O
decreased	O
affinity	O
and	O
a	O
decreased	O
binding	O
capacity	O
of	O
the	O
glucocorticoid	B
receptor	I
.	O

Integrin	O
-	O
mediated	O
tyrosine	O
phosphorylation	O
and	O
cytokine	B
message	O
induction	O
in	O
monocytic	O
cells	O
.	O

The	O
tyrosine	O
kinase	O
inhibitors	O
genistein	O
and	O
herbimycin	O
A	O
block	O
both	O
integrin	B
-	O
mediated	O
tyrosine	O
phosphorylation	O
and	O
increases	O
in	O
IL	B
-	I
1	I
beta	I
message	O
levels	O
,	O
indicating	O
a	O
causal	O
relationship	O
between	O
the	O
two	O
events	O
.	O

These	O
observations	O
indicate	O
that	O
the	O
Syk	B
tyrosine	O
kinase	O
may	O
be	O
an	O
important	O
component	O
of	O
an	O
integrin	B
signaling	O
pathway	O
in	O
monocytic	O
cells	O
,	O
leading	O
to	O
activation	O
of	O
NF	B
-	I
kappa	I
B	I
and	O
to	O
increased	O
levels	O
of	O
cytokine	B
messages	O
.	O

To	O
determine	O
if	O
New	O
World	O
primates	O
express	O
an	O
inhibitor	O
that	O
influences	O
glucocorticoid	B
receptor	I
(	O
GR	B
)	O
binding	O
characteristics	O
,	O
we	O
examined	O
[	O
3H	O
]	O
dexamethasone	O
binding	O
in	O
cytosol	O
prepared	O
from	O
B95	O
-	O
8	O
lymphoid	O
cells	O
,	O
derived	O
from	O
the	O
cotton	O
top	O
tamarin	O
(	O
Saguinus	O
oedipus	O
)	O
,	O
in	O
combination	O
with	O
cytosol	O
prepared	O
from	O
human	O
or	O
rat	O
tissues	O
.	O

Kinetic	O
studies	O
using	O
mixed	O
cytosol	O
indicated	O
that	O
B95	O
-	O
8	O
cytosol	O
did	O
not	O
affect	O
the	O
apparent	O
dissociation	O
rate	O
of	O
[	O
3H	O
]	O
dexamethasone	O
.	O

The	O
results	O
further	O
demonstrated	O
the	O
activation	O
of	O
S6	B
kinase	I
(	O
pp90rsk	B
)	O
,	O
evidenced	O
by	O
phosphorylation	O
of	O
S6	B
and	O
serum	O
response	O
factor	O
(	O
SRF	O
)	O
peptides	O
,	O
in	O
PWM	O
treated	O
B	O
cells	O
.	O

We	O
have	O
recently	O
found	O
a	O
novel	O
conserved	B
motif	I
in	O
the	O
promoters	B
of	O
several	O
T	B
-	I
cell	I
-	I
expressed	I
cytokines	I
[	O
human	B
interleukin	I
-	I
2	I
,	I
-	I
4	I
,	I
-	I
5	I
and	I
-	I
13	I
and	O
human	B
and	I
mouse	I
granulocyte	I
/	I
macrophage	I
-	I
colony	I
stimulating	I
factor	I
(	O
GM	B
-	I
CSF	I
)	O
]	O
.	O

In	O
transfection	O
assays	O
,	O
the	O
human	B
GM	I
-	I
CSF	I
element	I
has	O
a	O
strong	O
positive	O
effect	O
on	O
the	O
expression	O
of	O
a	O
reporter	B
gene	I
by	O
the	O
human	O
T	O
cell	O
line	O
Jurkat	O
J6	O
upon	O
stimulation	O
.	O

In	O
different	O
genes	B
,	O
the	O
core	B
sequences	I
are	O
separated	O
by	O
integer	O
numbers	O
of	O
helical	O
turns	O
.	O

Aspirin	O
inhibits	O
nuclear	B
factor	I
-	I
kappa	I
B	I
mobilization	O
and	O
monocyte	O
adhesion	O
in	O
stimulated	O
human	O
endothelial	O
cells	O
.	O

These	O
effects	O
of	O
aspirin	O
were	O
not	O
related	O
to	O
the	O
inhibition	O
of	O
cyclooxygenase	B
activity	O
,	O
since	O
indomethacin	O
was	O
ineffective	O
.	O

Activation	O
of	O
NF	B
-	I
kappa	I
B	I
by	O
various	O
cellular	O
stimuli	O
involves	O
the	O
phosphorylation	O
and	O
subsequent	O
degradation	O
of	O
its	O
inhibitor	O
,	O
I	B
kappa	I
B	I
alpha	I
,	O
although	O
the	O
underlying	O
mechanism	O
remains	O
unclear	O
.	O

Together	O
,	O
these	O
results	O
suggest	O
that	O
phosphorylation	O
of	O
I	B
kappa	I
B	I
alpha	I
,	O
mediated	O
through	O
both	O
the	O
TNF	B
-	I
alpha	I
-	O
inducible	O
and	O
the	O
PP	B
-	I
2A	I
-	I
opposing	I
kinases	I
,	O
may	O
serve	O
to	O
target	O
I	B
kappa	I
B	I
alpha	I
for	O
proteasome	B
-	O
mediated	O
degradation	O
.	O

The	O
5	B
'	I
flanking	I
region	I
of	O
the	O
human	B
alpha	I
-	I
globin	I
gene	I
is	O
highly	O
G	O
+	O
C	O
rich	O
and	O
contains	O
multiple	O
copies	O
of	O
the	O
consensus	B
sequence	I
for	O
the	O
Sp1	B
binding	I
site	I
.	O

Finally	O
,	O
we	O
show	O
by	O
both	O
footprint	O
analysis	O
and	O
functional	O
assays	O
that	O
the	O
ability	O
of	O
the	O
G	B
+	I
C	I
-	I
rich	I
region	I
to	O
increase	O
alpha	B
-	I
globin	I
promoter	I
activity	O
from	O
a	O
stably	O
integrated	O
alpha	B
-	I
globin	I
gene	I
is	O
mediated	O
by	O
its	O
multiple	B
binding	I
sites	I
for	O
the	O
transcription	B
factor	I
Sp1	B
.	O

LFA	B
-	I
3	I
induced	O
moderate	O
levels	O
of	O
AP	B
-	I
1	I
,	O
but	O
did	O
not	O
influence	O
the	O
levels	O
of	O
NF	B
-	I
kappa	I
B	I
,	O
while	O
B7	B
costimulation	O
strongly	O
induced	O
both	O
AP	B
-	I
1	I
and	O
substantially	O
enhanced	O
NF	B
-	I
kappa	I
B	I
binding	I
proteins	I
.	O

The	O
Ah	B
receptor	I
recognizes	O
DNA	B
binding	I
sites	I
for	O
the	O
B	B
cell	I
transcription	I
factor	I
,	O
BSAP	B
:	O
a	O
possible	O
mechanism	O
for	O
dioxin	O
-	O
mediated	O
alteration	O
of	O
CD19	B
gene	I
expression	O
in	O
human	O
B	O
lymphocytes	O
.	O

In	O
addition	O
,	O
the	O
Ah	B
receptor	I
complex	I
recognized	O
a	O
DNA	B
binding	I
site	I
for	O
B	B
cell	I
lineage	I
-	I
specific	I
activator	I
protein	I
(	O
BSAP	B
)	O
in	O
the	O
promoter	B
region	I
of	O
the	O
human	O
CD19	B
gene	I
which	O
is	O
similar	O
to	O
the	O
consensus	B
Ah	I
receptor	I
DNA	I
binding	I
site	I
.	O

We	O
recently	O
identified	O
a	O
differentiation	B
inhibitory	I
factor	I
(	O
I	B
-	I
factor	I
)	O
in	O
mouse	O
myeloid	O
leukemia	O
M1	O
cells	O
as	O
a	O
murine	B
homolog	I
of	O
the	O
human	B
nm23	I
-	I
H2	I
gene	I
product	I
.	O

In	O
the	O
present	O
experiment	O
,	O
we	O
examined	O
the	O
effect	O
of	O
nm23	B
proteins	I
on	O
various	O
differentiation	O
induction	O
systems	O
of	O
human	O
leukemic	O
cells	O
including	O
HL	O
-	O
60	O
,	O
U937	O
,	O
HEL	O
/	O
S	O
,	O
KU812F	O
,	O
K562	O
,	O
and	O
HEL	O
cells	O
.	O

Delayed	O
administration	O
of	O
rBPI21	B
also	O
affected	O
LPS	O
-	O
mediated	O
activation	O
of	O
the	O
nuclear	B
factor	I
,	O
NF	B
-	I
kappa	I
B	I
.	O

Two	O
to	O
4	O
h	O
following	O
LPS	O
addition	O
to	O
endothelial	O
cells	O
,	O
when	O
NF	B
-	I
kappa	I
B	I
was	O
already	O
activated	O
,	O
addition	O
of	O
rBPI21	B
resulted	O
in	O
marked	O
reduction	O
of	O
NF	B
-	I
kappa	I
B	I
detectable	O
at	O
4	O
or	O
6	O
h	O
.	O

GM	B
-	I
CSF	I
and	O
IL	B
-	I
2	I
share	O
common	O
control	O
mechanisms	O
in	O
response	O
to	O
costimulatory	O
signals	O
in	O
T	O
cells	O
.	O

Antigen	O
complexed	O
with	O
major	B
histocompatibility	I
complex	I
class	I
I	I
or	I
II	I
molecules	I
on	O
the	O
surface	O
of	O
antigen	O
presenting	O
cells	O
interacts	O
with	O
the	O
T	B
cell	I
receptor	I
(	O
TCR	B
)	O
on	O
the	O
surface	O
of	O
T	O
cells	O
and	O
initiates	O
an	O
activation	O
cascade	O
.	O

Costimulatory	O
signals	O
,	O
such	O
as	O
activation	O
of	O
the	O
CD28	B
cell	I
surface	I
molecule	I
on	O
T	O
cells	O
,	O
lead	O
to	O
activation	O
through	O
a	O
distinct	O
region	O
of	O
the	O
granulocyte	B
-	I
macrophage	I
colony	I
-	I
stimulating	I
factor	I
(	I
GM	I
-	I
CSF	I
)	I
promoter	I
.	O

Human	O
T	O
leukemia	O
virus	O
type	O
1	O
(	O
HTLV	O
-	O
1	O
)	O
infects	O
T	O
cells	O
and	O
can	O
lead	O
to	O
increase	O
GM	B
-	I
CSF	I
expression	O
.	O

This	O
observation	O
,	O
together	O
with	O
the	O
fact	O
that	O
both	O
GM	B
-	I
CSF	I
and	O
IL	B
-	I
2	I
respond	O
to	O
TCR	B
signals	O
via	O
NFAT	B
,	O
implies	O
a	O
high	O
degree	O
of	O
conservation	O
in	O
the	O
regulation	O
of	O
cytokine	B
gene	O
expression	O
in	O
T	O
cells	O
.	O

3	O
.	O
Danazol	O
decreased	O
the	O
transcription	O
rate	O
of	O
ER	B
gene	I
to	O
approximately	O
50	O
%	O
in	O
monocytes	O
in	O
a	O
run	O
-	O
on	O
assay	O
.	O

Formation	O
of	O
the	O
NFAT	B
-	I
1	I
transcriptional	I
complex	I
on	O
the	O
IL	B
-	I
2	I
promoter	I
is	O
essential	O
for	O
IL	B
-	I
2	I
transcription	O
.	O

WIN	O
53071	O
inhibited	O
IL	B
-	I
2	I
production	O
induced	O
in	O
the	O
calcium	O
-	O
dependent	O
PMA	O
and	O
ionomycin	O
pathway	O
.	O

We	O
examined	O
mRNA	B
levels	O
of	O
various	O
V	B
-	I
ATPase	I
subunits	O
during	O
differentiation	O
of	O
both	O
native	O
monocytes	O
and	O
the	O
cell	O
line	O
THP	O
-	O
1	O
,	O
and	O
found	O
that	O
transcriptional	O
and	O
post	O
-	O
transcriptional	O
mechanisms	O
could	O
account	O
for	O
increases	O
in	O
cell	O
V	B
-	I
ATPase	I
content	O
.	O

From	O
nuclear	O
runoff	O
experiments	O
,	O
we	O
found	O
that	O
one	O
subunit	O
in	O
particular	O
,	O
the	O
B2	B
isoform	I
(	O
Mr	O
=	O
56	O
,	O
000	O
)	O
,	O
was	O
amplified	O
primarily	O
by	O
transcriptional	O
means	O
.	O

Primer	O
extension	O
and	O
ribonuclease	B
protection	O
analyses	O
indicate	O
a	O
single	O
major	B
transcriptional	I
start	I
site	I
.	O

We	O
transfected	O
promoter	B
-	I
luciferase	I
reporter	I
plasmids	I
into	O
THP	O
-	O
1	O
cells	O
to	O
define	O
sequences	O
that	O
mediate	O
transcriptional	O
control	O
during	O
monocyte	O
differentiation	O
.	O

We	O
have	O
examined	O
the	O
function	O
of	O
these	O
elements	O
in	O
Burkitt	O
'	O
s	O
lymphoma	O
cells	O
(	O
Ramos	O
and	O
Daudi	O
)	O
as	O
well	O
as	O
a	O
T	O
lymphocytic	O
cell	O
line	O
(	O
Jurkat	O
)	O
.	O

Okadaic	O
acid	O
augments	O
PMA	O
-	O
as	O
well	O
as	O
calcium	O
-	O
mediated	O
activation	O
of	O
c	B
-	I
fos	I
,	O
and	O
has	O
little	O
or	O
no	O
effect	O
when	O
combined	O
with	O
cAMP	O
.	O

The	O
main	O
difference	O
between	O
Ramos	O
(	O
B	O
cells	O
)	O
and	O
Jurkat	O
(	O
T	O
cells	O
)	O
in	O
the	O
regulation	O
of	O
c	B
-	I
fos	I
is	O
that	O
cAMP	O
plus	O
calcium	O
is	O
strongly	O
synergistic	O
in	O
Jurkat	O
and	O
is	O
without	O
effect	O
in	O
Ramos	O
.	O

These	O
results	O
suggest	O
that	O
cell	O
-	O
specific	O
patterns	O
of	O
synergy	O
are	O
an	O
essential	O
feature	O
for	O
c	B
-	I
fos	I
induction	O
and	O
may	O
be	O
relevant	O
for	O
c	B
-	I
fos	I
control	O
through	O
B	B
and	I
T	I
cell	I
antigen	I
receptors	I
.	O

Multiple	O
signals	O
are	O
required	O
for	O
function	O
of	O
the	O
human	B
granulocyte	I
-	I
macrophage	I
colony	I
-	I
stimulating	I
factor	I
gene	I
promoter	I
in	O
T	O
cells	O
.	O

These	O
results	O
imply	O
that	O
at	O
least	O
three	O
signals	O
are	O
required	O
to	O
activate	O
the	O
GM	B
-	I
CSF	I
proximal	I
promoter	I
,	O
and	O
that	O
the	O
signals	O
impinge	O
on	O
distinct	O
transcription	B
factors	I
that	O
bind	O
to	O
the	O
hCLEO	B
and	I
NF	I
-	I
kappa	I
B	I
regions	I
of	O
the	O
promoter	B
.	O

In	O
this	O
report	O
,	O
we	O
show	O
that	O
in	O
monocytes	O
and	O
T	O
cells	O
IL	B
-	I
10	I
stimulates	O
tyrosine	O
phosphorylation	O
of	O
the	O
signal	B
transducers	I
and	O
activators	B
of	I
transcription	I
,	O
STAT1	B
alpha	I
and	O
STAT3	B
,	O
in	O
a	O
differential	O
manner	O
such	O
that	O
the	O
relative	O
formation	O
of	O
homo	B
-	I
and	I
heterodimers	I
varies	O
between	O
the	O
two	O
cell	O
types	O
.	O

IL	B
-	I
10	I
treatment	O
of	O
both	O
T	O
cells	O
and	O
monocytes	O
results	O
in	O
the	O
ligand	O
-	O
induced	O
tyrosine	O
phosphorylation	O
of	O
tyk2	B
and	O
Jak1	B
,	O
but	O
not	O
Jak2	B
or	O
Jak3	B
.	O

Selective	O
modulation	O
of	O
immune	O
responsiveness	O
by	O
IL	B
-	I
10	I
in	O
cells	O
such	O
as	O
monocytes	O
and	O
T	O
cells	O
may	O
result	O
in	O
part	O
from	O
the	O
differential	O
activation	O
of	O
STAT	B
protein	I
pairs	I
.	O

However	O
,	O
the	O
real	O
effect	O
of	O
hormones	O
involved	O
in	O
ovulation	O
is	O
expressed	O
by	O
biological	O
modifications	O
on	O
target	O
tissues	O
.	O

They	O
also	O
display	O
constitutively	O
high	O
levels	O
of	O
p59fyn	B
and	O
CD3	B
zeta	I
tyrosine	O
phosphorylation	O
.	O

The	O
generation	O
of	O
second	O
messengers	O
in	O
T	O
cells	O
normally	O
leads	O
to	O
downstream	O
signaling	O
that	O
results	O
in	O
transcriptional	O
activation	O
of	O
the	O
IL	B
-	I
2	I
gene	I
.	O

Levels	O
of	O
the	O
octamer	O
,	O
NF	B
-	I
kappa	I
B	I
(	O
p50	B
-	I
p65	I
heterodimer	I
)	O
,	O
and	O
AP	B
-	I
1	I
transcriptional	I
factors	I
are	O
constitutively	O
elevated	O
in	O
freshly	O
isolated	O
Ipr	O
CD4	O
-	O
8	O
-	O
T	O
cells	O
,	O
consistent	O
with	O
the	O
activated	O
phenotype	O
of	O
these	O
cells	O
.	O

We	O
demonstrate	O
that	O
cross	O
-	O
linking	O
CD30	B
with	O
an	O
anti	O
-	O
CD30	B
-	O
specific	O
monoclonal	O
antibody	O
,	O
which	O
mimics	O
the	O
described	O
biological	O
activities	O
of	O
the	O
CD30	B
ligand	I
(	O
CD30L	B
)	O
,	O
results	O
in	O
HIV	O
expression	O
.	O

Type	B
II	I
major	I
histocompatibility	I
complex	I
combined	O
immune	O
deficiency	O
(	O
type	O
II	O
MHC	B
CID	O
or	O
bare	O
lymphocyte	O
syndrome	O
)	O
is	O
a	O
congenital	O
immunodeficiency	O
disease	O
characterized	O
by	O
absent	O
MHC	B
class	I
II	I
expression	O
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
CIITA	B
is	O
an	O
MHC	B
class	I
II	I
gene	I
-	I
specific	I
transcription	I
activator	I
.	O

The	O
transcription	O
activation	O
function	O
is	O
provided	O
by	O
the	O
N	B
-	I
terminal	I
acidic	I
domain	I
(	O
amino	B
acids	I
26	I
-	I
137	I
)	O
,	O
which	O
is	O
experimentally	O
exchangeable	O
with	O
a	O
heterologous	B
viral	I
transcription	I
-	I
activating	I
domain	I
.	O

These	O
results	O
demonstrate	O
that	O
P	B
-	I
selectin	I
,	O
through	O
its	O
ligands	O
on	O
monocytes	O
,	O
may	O
locally	O
regulate	O
cytokine	B
secretion	O
in	O
inflamed	O
tissues	O
.	O

Here	O
,	O
we	O
report	O
that	O
nitric	O
oxide	O
(	O
NO	O
)	O
activates	O
p21ras	B
in	O
human	O
T	O
cells	O
as	O
evidenced	O
by	O
an	O
increase	O
in	O
GTP	B
-	I
bound	I
p21ras	I
.	O

In	O
vitro	O
studies	O
using	O
pure	B
recombinant	I
p21ras	I
demonstrate	O
that	O
the	O
activation	O
is	O
direct	O
and	O
reversible	O
.	O

Circular	O
dichroism	O
analysis	O
reveals	O
that	O
NO	O
induces	O
a	O
profound	O
conformational	O
change	O
in	O
p21ras	B
in	O
association	O
with	O
GDP	O
/	O
GTP	O
exchange	O
.	O

Furthermore	O
,	O
we	O
demonstrate	O
that	O
p21ras	B
is	O
essential	O
for	O
NO	O
-	O
induced	O
downstream	O
signaling	O
,	O
such	O
as	O
NF	B
-	I
kappa	I
B	I
activation	O
,	O
and	O
that	O
endogenous	O
NO	O
can	O
activate	O
p21ras	B
in	O
the	O
same	O
cell	O
.	O

These	O
studies	O
identify	O
p21ras	B
as	O
a	O
target	O
of	O
the	O
same	O
cell	O
.	O

These	O
studies	O
identify	O
p21ras	B
as	O
a	O
target	O
of	O
NO	O
in	O
T	O
cells	O
and	O
suggest	O
that	O
NO	O
activates	O
p21ras	B
by	O
an	O
action	O
which	O
mimics	O
that	O
of	O
guanine	B
nucleotide	I
exchange	I
factors	I
.	O

In	O
the	O
present	O
study	O
we	O
analyzed	O
the	O
control	O
of	O
IL	B
-	I
2	I
promoter	I
activity	O
in	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
-	O
transformed	O
B	O
cell	O
clones	O
which	O
are	O
capable	O
of	O
secreting	O
IL	B
-	I
2	I
at	O
a	O
low	O
level	O
after	O
stimulation	O
with	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
and	O
the	O
Ca2	O
+	O
ionophore	O
ionomycin	O
.	O

Transient	O
transfections	O
using	O
reporter	B
constructs	I
with	O
multiples	O
of	O
transcription	B
factor	I
binding	I
sites	I
from	O
the	O
IL	B
-	I
2	I
promoter	I
[	O
distal	B
nuclear	I
factor	I
(	I
NF	I
)	I
-	I
AT	I
,	O
proximal	B
NF	I
-	I
AT	I
,	O
AP	B
-	I
1	I
/	I
Octamer	I
(	O
UPS	B
)	O
or	O
NF	B
-	I
chi	I
B	I
(	O
TCEd	B
)	O
sites	O
]	O
were	O
performed	O
.	O

In	O
EBV	O
-	O
transformed	O
B	O
clones	O
,	O
the	O
chi	B
B	I
site	I
exerted	O
the	O
strongest	O
inducible	O
activity	O
;	O
the	O
NF	B
-	I
AT	I
binding	I
sites	I
showed	O
either	O
no	O
or	O
only	O
weak	O
activity	O
compared	O
to	O
Jurkat	O
T	O
cells	O
.	O

In	O
seven	O
EBV	O
-	O
B	O
cell	O
clones	O
or	O
lines	O
differing	O
in	O
their	O
capacity	O
to	O
secrete	O
IL	B
-	I
2	I
,	O
the	O
activity	O
of	O
the	O
IL	B
-	I
2	I
promoter	I
correlated	O
well	O
with	O
the	O
status	O
of	O
IL	B
-	I
2	I
secretion	O
.	O

Latent	B
membrane	I
protein	I
-	I
1	I
induces	O
cyclin	B
D2	I
expression	O
,	O
pRb	B
hyperphosphorylation	O
,	O
and	O
loss	O
of	O
TGF	B
-	I
beta	I
1	I
-	O
mediated	O
growth	O
inhibition	O
in	O
EBV	O
-	O
positive	O
B	O
cells	O
.	O

Here	O
,	O
we	O
show	O
that	O
the	O
presence	O
of	O
either	O
wild	O
-	O
type	O
EBV	O
or	O
its	O
transforming	B
latent	I
membrane	I
protein	I
-	I
1	I
(	O
LMP	B
-	I
1	I
)	O
results	O
in	O
the	O
loss	O
of	O
TGF	B
-	I
beta	I
1	I
-	O
mediated	O
growth	O
inhibition	O
in	O
human	O
B	O
cells	O
.	O

Does	O
thyroidectomy	O
,	O
radioactive	O
iodine	O
therapy	O
,	O
or	O
antithyroid	O
drug	O
treatment	O
alter	O
reactivity	O
of	O
patients	O
'	O
T	O
cells	O
to	O
epitopes	O
of	O
thyrotropin	B
receptor	I
in	O
autoimmune	O
thyroid	O
diseases	O
?	O

A	O
further	O
decrease	O
in	O
the	O
T	O
cell	O
reactivity	O
to	O
TSHR	B
peptides	O
was	O
observed	O
3	O
-	O
6	O
months	O
after	O
surgery	O
.	O

Six	O
to	O
8	O
weeks	O
after	O
RAI	O
therapy	O
,	O
the	O
number	O
of	O
patients	O
responding	O
to	O
any	O
peptide	O
and	O
the	O
average	O
number	O
of	O
recognized	O
peptides	O
increased	O
.	O

The	O
reactivity	O
of	O
T	O
cell	O
lines	O
in	O
different	O
groups	O
reflected	O
a	O
pattern	O
similar	O
to	O
PBMC	O
after	O
treatment	O
.	O

TSHR	B
antibody	I
and	O
microsomal	B
antibody	I
levels	O
decreased	O
after	O
surgery	O
,	O
but	O
increased	O
after	O
RAI	O
therapy	O
.	O

We	O
have	O
identified	O
an	O
in	O
vivo	O
footprint	O
over	O
the	O
PuF	B
site	I
on	O
the	O
translocated	O
c	B
-	I
myc	I
allele	I
in	O
Burkitt	O
'	O
s	O
lymphoma	O
cells	O
.	O

Transfection	O
experiments	O
with	O
c	B
-	I
myc	I
promoter	I
constructs	I
in	O
both	O
DHL	O
-	O
9	O
and	O
Raji	O
cells	O
revealed	O
that	O
the	O
PuF	B
site	I
functioned	O
as	O
a	O
positive	B
regulatory	I
element	I
in	O
B	O
cells	O
with	O
a	O
drop	O
in	O
activity	O
with	O
mutation	O
of	O
this	O
site	O
.	O

Electromobility	O
shift	O
assays	O
utilizing	O
this	O
sequence	O
demonstrated	O
binding	O
of	O
a	O
fetal	B
and	I
erythroid	I
-	I
specific	I
protein	I
.	O

These	O
results	O
indicate	O
that	O
the	O
5	B
'	I
-	I
UTR	I
of	O
the	O
gamma	B
-	I
gene	I
contains	O
sequences	O
that	O
may	O
be	O
important	O
for	O
its	O
transcriptional	O
and	O
developmental	O
regulation	O
.	O

However	O
,	O
this	O
deletion	O
mutation	O
prevented	O
the	O
induced	O
phosphorylation	O
,	O
degradative	O
loss	O
,	O
and	O
functional	O
release	O
of	O
I	B
kappa	I
B	I
alpha	I
from	O
NF	B
-	I
kappa	I
B	I
in	O
Tax	O
-	O
expressing	O
cells	O
.	O

Alanine	O
substitutions	O
introduced	O
at	O
two	O
serine	O
residues	O
positioned	O
within	O
this	O
N	B
-	I
terminal	I
regulatory	I
region	I
of	O
I	B
kappa	I
B	I
alpha	I
also	O
yielded	O
constitutive	O
repressors	O
that	O
escaped	O
from	O
Tax	B
-	O
induced	O
turnover	O
and	O
that	O
potently	O
inhibited	O
immune	O
activation	O
pathways	O
for	O
NF	B
-	I
kappa	I
B	I
induction	O
,	O
including	O
those	O
initiated	O
from	O
antigen	B
and	I
cytokine	I
receptors	I
.	O

In	O
contrast	O
,	O
introduction	O
of	O
a	O
phosphoserine	O
mimetic	O
at	O
these	O
sites	O
rectified	O
this	O
functional	O
defect	O
,	O
a	O
finding	O
consistent	O
with	O
a	O
causal	O
linkage	O
between	O
the	O
phosphorylation	O
status	O
and	O
proteolytic	O
stability	O
of	O
this	O
cytoplasmic	B
inhibitor	I
.	O

Together	O
,	O
these	O
in	O
vivo	O
studies	O
define	O
a	O
critical	O
signal	O
response	O
domain	O
in	O
I	B
kappa	I
B	I
alpha	I
that	O
coordinately	O
controls	O
the	O
biologic	O
activities	O
of	O
I	B
kappa	I
B	I
alpha	I
and	O
NF	B
-	I
kappa	I
B	I
in	O
response	O
to	O
viral	O
and	O
immune	O
stimuli	O
.	O

Human	O
prostatic	O
epithelial	O
cells	O
from	O
an	O
androgen	O
-	O
dependent	O
LNCaP	O
cell	O
line	O
were	O
examined	O
in	O
response	O
to	O
conditioned	O
medium	O
(	O
CM	O
)	O
derived	O
from	O
phytohemagglutinin	O
(	O
PHA	O
)	O
-	O
stimulated	O
lymphocytes	O
.	O

Cell	O
morphology	O
showed	O
dendritic	O
processes	O
extending	O
from	O
cytoplasm	O
and	O
other	O
neuroendocrine	O
cell	O
characteristics	O
.	O

These	O
included	O
vimentin	B
,	O
correlating	O
to	O
cell	O
shape	O
changes	O
,	O
cytokeratins	B
8	I
and	I
18	I
,	O
associated	O
with	O
differentiated	O
cell	O
types	O
of	O
prostate	O
epithelia	O
,	O
and	O
neuron	B
-	I
specific	I
enolase	I
and	O
serotonin	O
,	O
associated	O
with	O
neuroendocrine	O
cells	O
.	O

Human	O
peripheral	O
blood	O
monocytes	O
responded	O
to	O
stimulation	O
of	O
platelet	B
-	I
activating	I
factor	I
(	O
PAF	B
)	O
with	O
up	O
-	O
regulation	O
of	O
the	O
transcript	O
for	O
heparin	B
-	I
binding	I
epidermal	I
growth	I
factor	I
-	I
like	I
growth	I
factor	I
(	O
HB	B
-	I
EGF	I
)	O
,	O
a	O
potent	B
mitogen	I
for	O
vascular	O
smooth	O
muscle	O
cells	O
.	O

This	O
function	O
of	O
PAF	B
was	O
observed	O
at	O
nanomolar	O
concentrations	O
of	O
the	O
ligand	O
,	O
starting	O
at	O
30	O
min	O
after	O
stimulation	O
.	O

These	O
functions	O
of	O
PAF	B
appeared	O
to	O
be	O
mediated	O
through	O
the	O
cell	B
surface	I
PAF	I
receptors	I
,	O
as	O
two	O
PAF	B
receptor	O
antagonists	O
,	O
WEB	O
2086	O
and	O
L	O
-	O
659	O
,	O
989	O
,	O
blocked	O
both	O
the	O
up	O
-	O
regulation	O
of	O
HB	B
-	I
EGF	I
mRNA	I
and	O
kappa	O
B	O
binding	O
activity	O
induced	O
by	O
PAF	B
.	O

The	O
antagonists	O
,	O
however	O
,	O
had	O
no	O
effect	O
on	O
phorbol	O
ester	O
-	O
induced	O
up	O
-	O
regulation	O
of	O
HB	B
-	I
EGF	I
mRNA	I
and	O
kappa	O
B	O
binding	O
activity	O
.	O

Several	O
criteria	O
indicated	O
that	O
the	O
defect	O
in	O
this	O
cell	O
line	O
influences	O
the	O
activity	O
of	O
an	O
isotype	B
-	I
specific	I
transcription	I
factor	I
.	O

The	O
DQB	B
X2	I
-	I
box	I
was	O
able	O
to	O
restore	O
expression	O
to	O
the	O
silent	B
DRA	I
reporter	I
construct	I
.	O

Moreover	O
,	O
replacement	O
of	O
the	O
DQB	B
X2	I
-	I
box	I
with	O
the	O
DRA	B
X2	I
-	I
box	I
markedly	O
diminished	O
the	O
activity	O
of	O
the	O
DQB	B
promoter	I
in	O
the	O
mutant	O
cell	O
.	O

ZEBRA	B
is	O
a	O
bZIP	B
transcriptional	I
activator	I
which	O
binds	O
as	O
a	O
dimer	O
to	O
7	B
-	I
bp	I
response	I
elements	I
within	O
EBV	B
promoters	I
and	O
is	O
directly	O
involved	O
in	O
the	O
stimulation	O
of	O
virus	O
replication	O
at	O
the	O
EBV	B
lytic	I
origin	I
.	O

Both	O
chimeras	O
were	O
found	O
to	O
transactivate	O
model	O
and	O
native	O
promoters	O
at	O
equivalent	O
or	O
better	O
levels	O
than	O
ZEBRA	B
itself	O
.	O

These	O
activation	O
domains	O
restored	O
ZEBRA	B
'	O
s	O
ability	O
to	O
induce	O
early	B
antigen	I
and	O
to	O
stimulate	O
origin	O
replication	O
to	O
levels	O
that	O
were	O
equal	O
to	O
or	O
greater	O
than	O
those	O
of	O
wild	O
type	O
.	O

Because	O
these	O
are	O
the	O
characteristics	O
of	O
a	O
signal	B
transducer	I
and	I
activator	I
of	I
transcription	I
(	I
Stat	I
)	I
protein	I
,	O
we	O
determined	O
whether	O
antibodies	B
to	I
Stat	I
proteins	I
will	O
interfere	O
with	O
gel	O
mobility	O
shift	O
and	O
found	O
that	O
antibodies	B
to	I
IL	I
-	I
4	I
Stat	I
,	O
also	O
known	O
as	O
Stat6	B
,	O
but	O
not	O
antibodies	B
to	O
other	O
Stat	B
proteins	I
,	O
interfere	O
with	O
the	O
formation	O
of	O
the	O
IL	B
-	I
4	I
NAF	I
complex	I
.	O

Monoallelic	O
expression	O
of	O
TAL1	B
was	O
observed	O
in	O
the	O
leukemic	O
cells	O
of	O
all	O
patients	O
(	O
8	O
of	O
8	O
)	O
bearing	O
a	O
TAL1	B
gene	I
rearrangement	O
.	O

In	O
the	O
leukemic	O
cells	O
of	O
patients	O
without	O
detectable	O
TAL1	B
rearrangements	O
,	O
TAL1	B
transcription	O
occurred	O
in	O
either	O
a	O
monoallelic	O
(	O
3	O
of	O
7	O
patients	O
)	O
or	O
a	O
biallelic	O
(	O
4	O
of	O
7	O
patients	O
)	O
fashion	O
.	O

Expression	O
of	O
erythroid	B
-	I
specific	I
genes	I
in	O
acute	O
megakaryoblastic	O
leukaemia	O
and	O
transient	O
myeloproliferative	O
disorder	O
in	O
Down	O
'	O
s	O
syndrome	O
.	O

Acute	O
megakaryoblastic	O
leukaemia	O
(	O
M7	O
)	O
and	O
transient	O
myeloproliferative	O
disorder	O
in	O
Down	O
'	O
s	O
syndrome	O
(	O
TMD	O
)	O
are	O
characterized	O
by	O
rapid	O
growth	O
of	O
abnormal	O
blast	O
cells	O
which	O
express	O
megakaryocytic	B
markers	I
.	O

Erythroid	B
-	I
specific	I
mRNAs	I
encoding	O
gamma	B
-	I
globin	I
and	O
erythroid	B
delta	I
-	I
aminolevulinate	I
synthase	I
were	O
found	O
to	O
be	O
expressed	O
in	O
blasts	O
from	O
most	O
of	O
these	O
cases	O
,	O
indicating	O
that	O
majorities	O
of	O
the	O
blasts	O
in	O
M7	O
and	O
TMD	O
cases	O
have	O
erythroid	O
and	O
megakaryocytic	O
phenotypes	O
.	O

These	O
results	O
suggest	O
that	O
M7	O
blasts	O
and	O
TMD	O
blasts	O
correspond	O
to	O
the	O
erythroid	O
/	O
megakaryocytic	O
bipotential	O
progenitor	O
cells	O
.	O

In	O
this	O
paper	O
,	O
the	O
expression	O
of	O
this	O
gene	O
in	O
blood	O
cells	O
was	O
first	O
investigated	O
in	O
fractions	O
of	O
nucleated	O
cells	O
,	O
revealing	O
predominant	O
expression	O
of	O
the	O
Ah	B
receptor	I
gene	I
in	O
the	O
monocyte	O
fraction	O
.	O

The	O
incubation	O
with	O
transforming	B
growth	I
factor	I
beta	I
1	I
and	O
1	O
alpha	O
,	O
25	O
-	O
dihydroxyvitamin	O
D3	O
resulted	O
in	O
a	O
5	O
-	O
to	O
7	O
-	O
fold	O
increase	O
of	O
AhR	B
mRNA	I
.	O

In	O
vitro	O
translated	O
Spi	B
-	I
B	I
protein	I
can	O
bind	O
to	O
PU	B
.	I
1	I
binding	I
sites	I
in	O
myeloid	B
promoters	I
and	O
transactivate	O
these	O
promoters	B
in	O
nonmyeloid	O
cells	O
.	O

In	O
contrast	O
,	O
PU	B
.	I
1	I
is	O
expressed	O
at	O
high	O
levels	O
not	O
only	O
in	O
monocytes	O
and	O
macrophages	O
but	O
also	O
in	O
neutrophils	O
,	O
indicating	O
that	O
PU	B
.	I
1	I
can	O
activate	O
gene	O
expression	O
in	O
both	O
major	O
myeloid	O
lineages	O
.	O

The	O
promoters	B
were	O
used	O
without	O
enhancers	B
,	O
or	O
with	O
enhancers	B
derived	O
from	O
the	O
beta	B
-	I
globin	I
locus	I
control	I
region	I
and	O
the	O
alpha	B
-	I
globin	I
HS	I
-	I
40	I
enhancer	I
.	O

When	O
transfected	O
into	O
K562	O
cells	O
,	O
which	O
express	O
zeta	B
-	I
globin	I
,	O
comparable	O
amounts	O
of	O
activity	O
were	O
obtained	O
from	O
the	O
-	B
557	I
and	I
-	I
417	I
zeta	I
-	I
luciferase	I
constructs	I
and	O
the	O
alpha	B
-	I
luciferase	I
constructs	I
when	O
no	O
enhancers	B
or	O
the	O
alpha	B
-	I
globin	I
locus	I
enhancers	I
were	O
used	O
.	O

This	O
element	O
requires	O
GATA	B
-	I
1	I
and	O
additional	B
unknown	I
factors	I
for	O
maximal	O
activity	O
.	O

To	O
address	O
this	O
issue	O
,	O
mutationally	O
active	O
PKC	B
-	I
alpha	I
,	I
-	I
epsilon	I
,	I
or	I
-	I
zeta	I
have	O
been	O
transfected	O
into	O
T	O
cells	O
and	O
the	O
consequences	O
for	O
T	O
cell	O
activation	O
determined	O
.	O

Accordingly	O
,	O
the	O
effects	O
of	O
the	O
constitutively	B
active	I
PKCs	I
were	O
compared	O
to	O
the	O
effects	O
of	O
mutationally	O
activated	O
p21ras	B
.	O

The	O
ability	O
of	O
PKC	B
-	I
epsilon	I
to	O
induce	O
transactivation	O
of	O
NF	B
-	I
AT	I
-	I
1	I
and	O
AP	B
-	I
1	I
was	O
similar	O
to	O
the	O
stimulatory	O
effect	O
of	O
a	O
constitutively	B
activated	I
p21ras	I
.	O

These	O
results	O
indicate	O
selective	O
functions	O
for	O
different	O
PKC	B
isotypes	I
in	O
T	O
cells	O
.	O

Moreover	O
,	O
the	O
data	O
comparing	O
the	O
effects	O
of	O
activated	B
Ras	I
and	O
PKC	B
mutants	I
suggest	O
that	O
PKC	B
-	I
alpha	I
,	O
p21ras	B
,	O
and	O
PKC	B
-	I
epsilon	I
are	O
not	O
positioned	O
linearly	O
on	O
a	O
single	O
signal	O
transduction	O
pathway	O
.	O

Differences	O
in	O
binding	O
of	O
glucocorticoid	B
receptor	I
to	O
DNA	O
in	O
steroid	O
-	O
resistant	O
asthma	O
.	O

We	O
examined	O
the	O
ability	O
of	O
nuclear	O
translocated	O
glucocorticoid	B
receptors	I
to	O
bind	O
to	O
their	O
DNA	B
binding	I
sites	I
(	O
GRE	B
)	O
using	O
electrophoretic	O
mobility	O
shift	O
assays	O
in	O
PBMC	O
from	O
patients	O
with	O
steroid	O
-	O
sensitive	O
and	O
steroid	O
-	O
resistant	O
asthma	O
.	O

Scatchard	O
analysis	O
of	O
glucocorticoid	B
receptor	I
-	O
GRE	B
binding	O
showed	O
no	O
change	O
in	O
binding	O
affinity	O
but	O
did	O
show	O
a	O
reduced	O
number	O
of	O
receptors	B
available	O
for	O
DNA	O
binding	O
in	O
the	O
steroid	O
-	O
resistant	O
patients	O
.	O

Interleukin	B
-	I
5	I
signaling	O
in	O
human	O
eosinophils	O
involves	O
JAK2	B
tyrosine	I
kinase	I
and	O
Stat1	B
alpha	I
.	O

Signaling	O
by	O
a	O
wide	O
variety	O
of	O
cytokines	B
,	O
including	O
interferons	B
,	O
interleukins	B
,	O
and	O
growth	B
factors	I
,	O
involves	O
activation	O
of	O
JAK	B
kinases	I
and	O
Stat	B
(	I
Signal	I
transducers	I
and	I
activators	I
of	I
transcription	I
)	I
proteins	I
.	O

From	O
supershift	O
experiments	O
it	O
was	O
concluded	O
that	O
one	O
DNA	B
-	I
binding	I
complex	I
contained	O
Stat1	B
alpha	I
,	O
probably	O
as	O
a	O
homodimer	O
.	O

It	O
was	O
found	O
that	O
the	O
propagation	O
of	O
the	O
Tat	B
mutants	I
containing	O
wild	B
-	I
type	I
LTRs	I
was	O
less	O
efficient	O
than	O
that	O
of	O
the	O
LTR	B
-	I
modified	I
Tat	I
mutants	I
.	O

Here	O
we	O
show	O
that	O
the	O
lymphoid	B
-	I
specific	I
transcription	I
factor	I
Oct	I
-	I
2A	I
plays	O
a	O
critical	O
role	O
in	O
HLA	B
-	I
DRA	I
gene	I
expression	O
in	O
class	O
II	O
-	O
positive	O
B	O
cell	O
lines	O
,	O
and	O
that	O
the	O
high	B
mobility	I
group	I
protein	I
(	O
HMG	B
)	O
I	B
/	I
Y	I
binds	O
to	O
multiple	O
sites	O
within	O
the	O
DRA	B
promoter	I
,	O
including	O
the	O
Oct	B
-	I
2A	I
binding	I
site	I
.	O

We	O
conclude	O
that	O
distinct	O
sets	O
of	O
transcription	B
factors	I
are	O
involved	O
in	O
the	O
two	O
modes	O
of	O
HLA	B
-	I
DRA	I
expression	O
,	O
and	O
that	O
HMG	B
I	I
/	I
Y	I
may	O
be	O
important	O
for	O
B	O
cell	O
-	O
specific	O
expression	O
,	O
and	O
is	O
essential	O
for	O
IFN	B
-	I
gamma	I
induction	O
.	O

In	O
lymphoblastoid	O
cell	O
lines	O
,	O
six	O
EBV	B
-	I
encoded	I
nuclear	I
antigens	I
(	O
EBNA1	B
,	I
2	I
,	I
3A	I
,	I
3B	I
,	I
3C	I
,	I
-	I
LP	I
)	O
,	O
three	O
latent	B
membrane	I
proteins	I
(	O
LMP1	B
,	O
2A	B
,	O
2B	B
)	O
,	O
and	O
two	O
nuclear	B
RNAs	I
(	O
EBERs	B
)	O
are	O
expressed	O
.	O

In	O
EBV	O
-	O
positive	O
cases	O
of	O
Hodgkin	O
'	O
s	O
disease	O
,	O
the	O
EBERs	B
,	O
EBNA1	B
,	O
and	O
the	O
LMPs	B
are	O
expressed	O
(	O
latency	O
II	O
)	O
,	O
whereas	O
in	O
Burkitt	O
'	O
s	O
lymphoma	O
(	O
BL	O
)	O
only	O
the	O
EBERs	B
and	O
EBNA1	B
have	O
been	O
detected	O
(	O
latency	O
I	O
)	O
.	O

Expression	O
of	O
LMP1	B
was	O
seen	O
in	O
variable	O
proportions	O
of	O
tumor	O
cells	O
in	O
two	O
cases	O
and	O
EBNA2	B
was	O
detected	O
in	O
some	O
tumor	O
cells	O
in	O
three	O
other	O
cases	O
.	O

Also	O
,	O
the	O
BZLF1	B
trans	I
-	I
activator	I
protein	I
was	O
expressed	O
in	O
a	O
few	O
tumor	O
cells	O
in	O
6	O
cases	O
,	O
indicating	O
entry	O
into	O
the	O
lytic	O
cycle	O
.	O

A	O
phenotypic	O
drift	O
from	O
latency	O
I	O
to	O
latency	O
III	O
has	O
been	O
observed	O
previously	O
in	O
some	O
BL	O
cell	O
lines	O
.	O

Our	O
results	O
suggest	O
that	O
a	O
similar	O
phenomenon	O
may	O
occur	O
in	O
BL	O
in	O
vivo	O
and	O
indicate	O
that	O
the	O
operational	O
definition	O
of	O
EBV	O
latencies	O
is	O
not	O
easily	O
applied	O
to	O
human	O
tumors	O
.	O

Eosinophils	O
were	O
purified	O
from	O
peripheral	O
blood	O
by	O
discontinuous	O
Percoll	O
gradients	O
and	O
stimulated	O
with	O
IL	B
-	I
5	I
.	O

Immunosuppression	O
has	O
been	O
often	O
associated	O
with	O
the	O
course	O
of	O
malignant	O
diseases	O
.	O

Whereas	O
PHA	B
-	O
induced	O
proliferation	O
of	O
PBMCs	O
derived	O
from	O
patients	O
with	O
breast	O
cancer	O
preoperatively	O
was	O
significantly	O
decreased	O
when	O
compared	O
with	O
data	O
obtained	O
in	O
healthy	O
control	O
individuals	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
the	O
degree	O
of	O
the	O
defect	O
in	O
PHA	B
-	O
induced	O
proliferation	O
of	O
PBMCs	O
depended	O
upon	O
the	O
tumour	O
burden	O
as	O
manifested	O
by	O
tumour	O
size	O
and	O
axillary	O
lymph	O
node	O
involvement	O
(	O
P	O
<	O
0	O
.	O
003	O
in	O
each	O
case	O
)	O
.	O

PHA	B
-	O
induced	O
proliferation	O
of	O
PBMCs	O
dropped	O
significantly	O
in	O
patients	O
who	O
received	O
adjuvant	O
chemotherapy	O
consisting	O
of	O
cyclophosphamide	O
,	O
methotrexate	O
and	O
fluorouracil	O
(	O
CMF	O
)	O
after	O
an	O
observation	O
period	O
of	O
6	O
months	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
,	O
but	O
not	O
in	O
patients	O
under	O
adjuvant	O
treatment	O
with	O
tamoxifen	O
only	O
.	O

We	O
thus	O
conclude	O
that	O
PHA	B
-	O
induced	O
proliferation	O
of	O
PBMCs	O
derived	O
from	O
patients	O
with	O
breast	O
cancer	O
depends	O
upon	O
the	O
tumour	O
load	O
and	O
is	O
a	O
good	O
clinical	O
predictor	O
for	O
the	O
further	O
course	O
of	O
the	O
disease	O
.	O

A	O
previously	O
unrecognized	O
element	O
,	O
located	O
downstream	O
of	O
the	O
start	B
site	I
of	I
transcription	I
in	O
the	O
first	O
exon	B
of	O
the	O
DR	B
alpha	I
gene	I
,	O
has	O
been	O
defined	O
that	O
enhances	O
promoter	O
activity	O
up	O
to	O
eightfold	O
in	O
a	O
position	O
-	O
dependent	O
manner	O
.	O

The	O
nuclear	O
factor	O
binds	O
to	O
the	O
DR	B
alpha	I
and	I
DP	I
alpha	I
element	I
but	O
not	O
to	O
the	O
element	O
in	O
the	O
DQ	B
alpha	I
gene	I
.	O

One	O
of	O
the	O
genes	O
that	O
encodes	O
a	O
CBF	B
alpha	I
subunit	I
is	O
AML1	B
,	O
also	O
called	O
Cbf	B
alpha	I
2	I
.	O

Three	O
different	O
isoforms	O
of	O
CBF	B
beta	I
were	O
also	O
tested	O
for	O
transcriptional	O
activity	O
on	O
the	O
SL3	B
enhancer	I
.	O

These	O
results	O
indicated	O
that	O
at	O
least	O
in	O
certain	O
cell	O
types	O
,	O
the	O
maximum	O
activity	O
of	O
CBF	B
required	O
both	O
subunits	O
.	O

We	O
also	O
examined	O
whether	O
CBF	B
could	O
distinguish	O
a	O
1	O
-	O
bp	O
difference	O
between	O
the	O
enhancer	O
core	O
of	O
SL3	O
and	O
the	O
core	O
of	O
the	O
nonleukemogenic	O
virus	O
,	O
Akv	O
.	O

However	O
,	O
no	O
combination	O
of	O
CBF	B
alpha	I
and	O
CBF	B
beta	I
subunits	O
that	O
we	O
tested	O
was	O
able	O
to	O
distinguish	O
the	O
1	O
-	O
bp	O
difference	O
in	O
transcription	O
assays	O
.	O

Using	O
electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSA	O
)	O
,	O
we	O
now	O
show	O
that	O
,	O
in	O
monocytes	O
stimulated	O
with	O
LPS	O
or	O
TNF	B
alpha	I
,	O
IL	B
-	I
10	I
inhibits	O
nuclear	O
stimulation	O
of	O
nuclear	B
factor	I
kappa	I
B	I
(	O
NF	B
kappa	I
B	I
)	O
,	O
a	O
transcription	B
factor	I
involved	O
in	O
the	O
expression	O
of	O
inflammatory	B
cytokine	I
genes	I
.	O
Several	O
other	O
transcription	B
factors	I
including	O
NF	O
-	O
IL	B
-	I
6	I
,	O
AP	B
-	I
1	I
,	O
AP	B
-	I
2	I
,	O
GR	B
,	O
CREB	B
,	O
Oct	B
-	I
1	I
,	O
and	O
Sp	B
-	I
1	I
are	O
not	O
affected	O
by	O
IL	B
-	I
10	I
.	O

Furthermore	O
,	O
compounds	O
such	O
as	O
tosylphenylalanyl	O
chloromethyl	O
ketone	O
and	O
pyrrolidinedithiocar	O
that	O
are	O
known	O
to	O
selectively	O
inhibit	O
NF	B
kappa	I
B	I
activation	O
block	O
cytokine	O
gene	O
transcription	O
in	O
LPS	O
-	O
stimulated	O
monocytes	O
.	O

Taken	O
together	O
,	O
these	O
results	O
suggest	O
that	O
inhibition	O
of	O
NF	B
kappa	I
B	I
activation	O
may	O
be	O
an	O
important	O
mechanism	O
for	O
IL	B
-	I
10	I
suppression	O
of	O
cytokine	O
gene	O
transcription	O
in	O
human	O
monocytes	O
.	O

In	O
addition	O
,	O
this	O
TR2RE	B
-	I
SV40	I
can	O
function	O
as	O
a	O
repressor	O
to	O
suppress	O
the	O
transcriptional	O
activities	O
of	O
both	O
SV40	B
early	I
and	I
late	I
promoters	I
.	O

We	O
have	O
analyzed	O
CBF	B
beta	I
-	I
MYH11	I
fusion	I
transcripts	I
by	O
RT	O
-	O
PCR	O
in	O
myelomonocytic	O
leukemias	O
,	O
with	O
or	O
without	O
eosinophilia	O
,	O
to	O
determine	O
whether	O
their	O
presence	O
correlates	O
with	O
morphology	O
.	O

Fifty	O
-	O
three	O
cases	O
(	O
11	O
AML	O
M4Eo	O
;	O
1	O
AML	O
M4	O
with	O
atypical	O
abnormal	O
eosinophils	O
(	O
AML	O
M4	O
`	O
`	O
Eo	O
'	O
'	O
)	O
;	O
29	O
AML	O
M4	O
;	O
8	O
AML	O
M5	O
;	O
3	O
CMML	O
;	O
and	O
1	O
AML	O
M2	O
with	O
eosinophilia	O
)	O
were	O
analyzed	O
.	O

Both	O
cases	O
tested	O
also	O
showed	O
MYH11	B
genomic	O
rearrangement	O
.	O

Follow	O
-	O
up	O
of	O
three	O
patient	O
showed	O
residual	O
positivity	O
in	O
apparent	O
complete	O
remission	O
.	O

HIV	B
-	I
1	I
Tat	I
potentiates	O
TNF	B
-	O
induced	O
NF	B
-	I
kappa	I
B	I
activation	O
and	O
cytotoxicity	O
by	O
altering	O
the	O
cellular	O
redox	O
state	O
.	O

In	O
HeLa	O
cells	O
stably	O
transfected	O
with	O
the	O
HIV	B
-	I
1	I
tat	I
gene	I
(	O
HeLa	O
-	O
tat	O
cells	O
)	O
,	O
expression	O
of	O
the	O
Tat	B
protein	I
enhanced	O
both	O
TNF	B
-	O
induced	O
activation	O
of	O
NF	B
-	I
kappa	I
B	I
and	O
TNF	B
-	O
mediated	O
cytotoxicity	O
.	O

Thus	O
,	O
Mn	B
-	I
SOD	I
RNA	O
protein	O
levels	O
and	O
activity	O
were	O
markedly	O
reduced	O
in	O
the	O
presence	O
of	O
Tat	B
.	O

The	O
use	O
of	O
glucocorticoids	O
in	O
acute	O
lymphoblastic	O
leukemia	O
of	O
childhood	O
.	O

Glucocorticoids	O
have	O
been	O
included	O
in	O
almost	O
all	O
treatment	O
regimens	O
for	O
childhood	O
acute	O
lymphoblastic	O
leukemia	O
for	O
decades	O
.	O

New	O
data	O
on	O
the	O
pharmacokinetics	O
,	O
pharmacodynamics	O
,	O
and	O
molecular	O
mechanisms	O
of	O
action	O
of	O
glucocorticoids	O
have	O
suggested	O
alternative	O
approaches	O
in	O
ALL	O
.	O

Blast	O
sensitivity	O
to	O
glucocorticoids	O
correlates	O
closely	O
with	O
sensitivity	O
to	O
other	O
,	O
putatively	O
non	O
-	O
cross	O
-	O
resisting	O
agents	O
and	O
with	O
outcome	O
after	O
multi	O
-	O
agent	O
therapy	O
,	O
suggesting	O
overlapping	O
mechanisms	O
of	O
action	O
,	O
and	O
focusing	O
attention	O
on	O
the	O
determinants	O
of	O
the	O
threshold	O
for	O
apoptosis	O
.	O

Expression	O
of	O
the	O
Epstein	B
-	I
Barr	I
virus	I
(	I
EBV	I
)	I
latent	I
membrane	I
protein	I
1	I
(	I
LMP	I
-	I
1	I
)	I
oncogene	I
is	O
regulated	O
by	O
the	O
EBV	B
nuclear	I
protein	I
2	I
(	I
EBNA	I
-	I
2	I
)	I
transactivator	I
.	O

EBNA	B
-	I
2	I
is	O
known	O
to	O
interact	O
with	O
the	O
cellular	B
DNA	I
-	I
binding	I
protein	I
J	B
kappa	I
and	O
is	O
recruited	O
to	O
promoters	B
containing	O
the	O
GTGGGAA	O
J	B
kappa	I
recognition	I
sequence	I
.	O

The	O
minimal	B
EBNA	I
-	I
2	I
-	I
responsive	I
LMP	I
-	I
1	I
promoter	I
includes	O
one	O
J	B
kappa	I
-	I
binding	I
site	I
,	O
and	O
we	O
now	O
show	O
that	O
mutation	O
of	O
that	O
site	O
,	O
such	O
that	O
J	B
kappa	I
can	O
not	O
bind	O
,	O
reduces	O
EBNA	B
-	I
2	I
responsiveness	O
by	O
60	O
%	O
.	O

To	O
identify	O
other	O
factors	O
which	O
interact	O
with	O
the	O
LMP	B
-	I
1	I
EBNA	I
-	I
2	I
response	I
element	I
(	O
E2RE	B
)	O
,	O
a	O
-	B
236	I
/	I
-	I
145	I
minimal	I
E2RE	I
was	O
used	O
as	O
a	O
probe	O
in	O
an	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O

LBF4	B
is	O
B	O
-	O
and	O
T	O
-	O
cell	O
specific	O
and	O
recognizes	O
the	O
PU	B
.	I
1	I
GGAA	I
core	I
sequence	I
as	O
shown	O
by	O
methylation	O
interference	O
.	O

The	O
efficacy	O
of	O
serotonin	O
reuptake	O
inhibitors	O
(	O
SRIs	O
)	O
is	O
uncertain	O
,	O
and	O
response	O
predictors	O
are	O
unavailable	O
.	O

Abnormal	O
fast	O
feedback	O
and	O
negative	O
feedback	O
of	O
the	O
hypothalamic	O
-	O
pituitary	O
-	O
adrenal	O
axis	O
implicates	O
a	O
dampened	O
limbic	B
-	I
hippocampal	I
glucocorticoid	I
type	I
II	I
receptor	I
(	O
GCII	B
)	O
.	O

We	O
hypothesized	O
that	O
lymphocyte	B
GCII	I
is	O
altered	O
in	O
adolescent	O
MDD	O
and	O
could	O
serve	O
as	O
a	O
marker	O
for	O
response	O
to	O
SRIs	O
.	O

The	O
role	O
of	O
NFATp	B
in	O
cyclosporin	B
A	I
-	I
sensitive	I
tumor	I
necrosis	I
factor	I
-	I
alpha	I
gene	I
transcription	O
.	O

Thus	O
,	O
although	O
the	O
kappa	B
3	I
element	I
has	O
little	O
sequence	O
similarity	O
to	O
other	O
NFATp	B
-	I
binding	I
sites	I
,	O
it	O
appears	O
to	O
function	O
as	O
a	O
cyclosporin	B
-	I
sensitive	I
promoter	I
element	I
in	O
T	O
cells	O
by	O
virtue	O
of	O
its	O
ability	O
to	O
bind	O
NFATp	B
.	O

By	O
contrast	O
,	O
three	O
lymphoblastoid	O
cell	O
lines	O
(	O
immortalized	O
in	O
vitro	O
with	O
Epstein	O
-	O
Barr	O
virus	O
)	O
were	O
weakly	O
positive	O
and	O
MNDA	B
was	O
up	O
-	O
regulated	O
by	O
interferon	B
-	I
alpha	I
(	O
IFN	B
-	I
alpha	I
)	O
treatment	O
.	O

The	O
results	O
varied	O
with	O
the	O
agent	O
,	O
cell	O
type	O
,	O
and	O
stage	O
of	O
differentiation	O
.	O

Changes	O
in	O
MNDA	B
expression	O
occurred	O
slowly	O
(	O
hours	O
to	O
days	O
)	O
,	O
suggesting	O
that	O
MNDA	B
could	O
mediate	O
changes	O
realized	O
over	O
a	O
long	O
period	O
.	O

EBNA	B
-	I
2	I
is	O
able	O
to	O
trans	O
-	O
activate	O
the	O
expression	O
of	O
the	O
LMP	B
gene	I
in	O
several	O
cell	O
lines	O
.	O

Various	O
reports	O
have	O
delineated	O
the	O
cis	B
-	I
acting	I
elements	I
of	O
the	O
LMP	B
promoter	I
through	O
which	O
EBNA	B
-	I
2	I
mediates	O
trans	O
-	O
activation	O
.	O

These	O
complexes	O
were	O
destroyed	O
by	O
detergent	O
.	O

Enhanced	O
Ig	B
synthesis	O
is	O
a	O
result	O
of	O
coordinated	O
transcriptional	O
activation	O
of	O
Ig	B
genes	I
without	O
promoter	O
or	O
isotype	O
specificity	O
,	O
and	O
differential	O
accumulation	O
of	O
the	O
mRNA	B
encoding	O
the	O
secreted	O
form	O
of	O
Ig	B
heavy	I
chain	I
.	O

It	O
is	O
saturable	O
and	O
subject	O
to	O
negative	O
control	O
when	O
IL	B
-	I
6	I
stimulation	O
is	O
prolonged	O
.	O

Thus	O
,	O
differentiation	O
of	O
B	O
cells	O
with	O
IL	B
-	I
6	I
in	O
vitro	O
recapitulates	O
the	O
hallmarks	O
of	O
terminal	O
B	O
differentiation	O
in	O
vivo	O
;	O
Oct	B
-	I
2	I
may	O
have	O
a	O
role	O
in	O
this	O
process	O
.	O

We	O
have	O
previously	O
shown	O
that	O
treatment	O
of	O
Jurkat	O
T	O
cells	O
with	O
phytohemaglutinin	B
(	O
PHA	B
)	O
and	O
the	O
phorbol	O
ester	O
,	O
PMA	O
,	O
activated	O
transcription	O
initiation	O
from	O
the	O
IL	B
-	I
3	I
gene	I
.	O

We	O
also	O
examined	O
the	O
function	O
of	O
the	O
IL	B
-	I
3	I
CK	I
-	I
1	I
/	I
CK	I
-	I
2	I
elements	I
that	O
are	O
present	O
in	O
many	O
cytokine	B
genes	I
and	O
found	O
that	O
they	O
acted	O
as	O
a	O
repressor	O
of	O
basal	O
level	O
expression	O
when	O
cloned	O
upstream	O
of	O
a	O
heterologous	B
promoter	I
but	O
were	O
also	O
inducible	O
by	O
PMA	O
/	B
PHA	I
.	O

Glucocorticoids	O
have	O
an	O
inhibitory	O
effect	O
on	O
inflammatory	O
and	O
immune	O
responses	O
,	O
and	O
this	O
may	O
be	O
through	O
the	O
modulation	O
of	O
transcription	B
factor	I
binding	O
to	O
DNA	O
.	O

TNF	O
-	O
alpha	O
,	O
IL	O
-	O
1	O
beta	O
and	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
treatment	O
increased	O
AP	B
-	I
1	I
and	O
NF	O
kappa	O
B	O
DNA	O
binding	O
by	O
up	O
to	O
200	O
%	O
but	O
decreased	O
CREB	B
binding	O
(	O
38	O
%	O
)	O
over	O
a	O
60	O
-	O
min	O
time	O
course	O
.	O

This	O
may	O
be	O
an	O
important	O
molecular	O
site	O
of	O
steroid	O
action	O
.	O

During	O
the	O
induction	O
of	O
anergy	O
,	O
T	O
cells	O
are	O
phenotypically	O
similar	O
to	O
cells	O
responding	O
to	O
an	O
immunogenic	O
stimulus	O
.	O

When	O
restimulated	O
,	O
however	O
,	O
anergic	O
T	O
cells	O
fail	O
to	O
up	O
-	O
regulate	O
transcription	O
of	O
the	O
IL	B
-	I
2	I
gene	I
and	O
in	O
consequence	O
do	O
not	O
produce	O
IL	B
-	I
2	I
.	O

The	O
effect	O
of	O
BDP	O
was	O
greatly	O
dependent	O
on	O
the	O
presence	O
of	O
Zn	O
+	O
+	O
ions	O
in	O
the	O
preparation	O
,	O
since	O
the	O
augmenting	O
effect	O
was	O
abolished	O
if	O
BDP	O
did	O
not	O
contain	O
zinc	O
.	O

The	O
receptor	O
concentration	O
,	O
as	O
measured	O
by	O
staining	O
and	O
steroid	O
binding	O
test	O
,	O
varied	O
considerably	O
but	O
showed	O
no	O
clear	O
correlation	O
to	O
clinical	O
response	O
.	O

Using	O
a	O
highly	O
sensitive	O
mutation	O
screening	O
assay	O
of	O
the	O
DNA	B
-	I
and	I
the	I
steroid	I
-	I
binding	I
region	I
,	O
none	O
of	O
the	O
treated	O
patients	O
revealed	O
any	O
mutation	O
,	O
suggesting	O
that	O
the	O
glucocorticoid	B
receptor	I
in	O
the	O
CLL	O
patients	O
tested	O
is	O
not	O
altered	O
in	O
these	O
domains	O
.	O

Expression	O
of	O
the	O
kappa	O
immunoglobulin	O
light	O
chain	O
gene	O
requires	O
developmental	O
-	O
and	O
tissue	O
-	O
specific	O
regulation	O
by	O
trans	B
-	I
acting	I
factors	I
which	O
interact	O
with	O
two	O
distinct	O
enhancer	B
elements	I
.	O

Methylation	O
studies	O
indicated	O
that	O
the	O
tal	B
-	I
15	I
'	I
GC	I
-	I
rich	I
region	I
behaves	O
like	O
a	O
CpG	B
island	I
,	O
hypomethylated	O
in	O
normal	O
cells	O
,	O
and	O
methylated	O
de	O
novo	O
on	O
transcriptionally	B
inactive	I
alleles	I
in	O
established	O
cell	O
lines	O
.	O

M	O
-	O
TAT	O
is	O
a	O
cytokine	O
-	O
dependent	O
cell	O
line	O
with	O
the	O
potential	O
to	O
differentiate	O
along	O
the	O
erythroid	O
and	O
megakaryocytic	O
lineages	O
.	O

In	O
contrast	O
,	O
the	O
addition	O
of	O
GM	B
-	I
CSF	I
to	O
the	O
M	O
-	O
TAT	O
/	O
EPO	O
cell	O
culture	O
decreased	O
the	O
amount	O
of	O
hemoglobin	O
,	O
even	O
in	O
the	O
presence	O
of	O
EPO	B
,	O
indicating	O
that	O
the	O
EPO	B
signal	O
for	O
erythroid	O
differentiation	O
is	O
suppressed	O
by	O
GM	B
-	I
CSF	I
.	O

Transient	O
chloramphenicol	B
acetyltransferase	I
assay	O
revealed	O
that	O
the	O
region	O
containing	O
E2F	B
binding	I
site	I
had	O
a	O
strong	O
promoter	O
activity	O
,	O
and	O
introduction	O
of	O
the	O
mutation	O
at	O
the	O
E2F	B
binding	I
site	I
resulted	O
in	O
a	O
significant	O
loss	O
of	O
the	O
activity	O
.	O

E2F	B
-	I
1	I
and	I
DP	I
-	I
1	I
mRNAs	I
were	O
not	O
detectable	O
in	O
granulocytes	O
,	O
monocytes	O
and	O
resting	O
T	O
-	O
lymphocytes	O
but	O
were	O
induced	O
after	O
the	O
mitogenic	O
stimulation	O
of	O
T	O
-	O
lymphocytes	O
.	O

Association	O
of	O
alterations	O
in	O
NF	B
-	I
kappa	I
B	I
moieties	I
with	O
HIV	O
type	O
1	O
proviral	O
latency	O
in	O
certain	O
monocytic	O
cells	O
.	O

Human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
replication	O
is	O
controlled	O
by	O
a	O
complex	O
array	O
of	O
virally	B
encoded	I
and	I
cellular	I
proteins	I
.	O

The	O
NFATd	B
element	I
,	O
which	O
binds	O
the	O
transcription	B
factor	I
NFAT	B
-	I
1	I
and	O
is	O
very	O
active	O
in	O
T	O
cells	O
,	O
is	O
only	O
weakly	O
active	O
in	O
one	O
B	O
clone	O
and	O
not	O
at	O
all	O
in	O
another	O
.	O

This	O
parallels	O
the	O
increased	O
I	B
kappa	I
B	I
alpha	I
synthesis	O
secondary	O
to	O
increased	O
I	B
kappa	I
B	I
alpha	I
gene	O
transcription	O
,	O
i	O
.	O
e	O
.	O
,	O
increased	O
RNA	O
and	O
transcriptional	O
activity	O
of	O
its	O
promoter	O
-	O
enhancer	O
.	O

Transcriptional	O
activity	O
of	O
p105	B
is	O
also	O
increased	O
in	O
infected	O
cells	O
and	O
is	O
also	O
mediated	O
by	O
NF	B
-	I
kappa	I
B	I
through	O
a	O
specific	O
kappa	B
B	I
motif	I
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
an	O
activation	B
-	I
deficient	I
glucocorticoid	I
receptor	I
mutant	I
is	O
as	O
effective	O
as	O
the	O
wild	B
-	I
type	I
receptor	I
in	O
repression	O
of	O
AP	B
-	I
1	I
activity	O
,	O
inhibition	O
of	O
interleukin	B
-	I
2	I
production	O
,	O
inhibition	O
of	O
c	B
-	I
myc	I
expression	O
and	O
induction	O
of	O
apoptosis	O
.	O

HIV	O
type	O
1	O
protease	B
activation	O
of	O
NF	B
-	I
kappa	I
B	I
within	O
T	O
lymphoid	O
cells	O
.	O

It	O
has	O
been	O
reported	O
that	O
HIV	B
-	I
1	I
protease	I
may	O
cleave	O
the	O
NF	B
-	I
kappa	I
B	I
precursor	O
to	O
its	O
active	O
form	O
in	O
vitro	O
.	O

Insertion	O
of	O
this	O
chimeric	B
promoter	I
(	O
ISG15	B
LTR	I
)	O
upstream	O
of	O
the	O
human	B
IFNA2	I
gene	I
directed	O
high	O
levels	O
of	O
IFN	B
synthesis	O
in	O
Tat	O
-	O
expressing	O
cells	O
,	O
while	O
this	O
promoter	O
was	O
not	O
responsive	O
to	O
tumor	B
necrosis	I
factor	I
alpha	I
-	O
mediated	O
activation	O
.	O

Selected	O
transfected	O
clones	O
produced	O
low	O
levels	O
of	O
IFN	B
A	I
(	O
IFNA	B
)	O
constitutively	O
,	O
and	O
their	O
abilities	O
to	O
express	O
interleukin	B
-	I
2	I
and	O
interleukin	B
-	I
2	I
receptor	I
upon	O
stimulation	O
with	O
phytohemagglutinin	B
and	O
phorbol	O
myristate	O
acetate	O
were	O
retained	O
.	O

Flow	O
cytometric	O
analysis	O
also	O
showed	O
that	O
at	O
72	O
h	O
of	O
virus	O
exposure	O
fewer	O
T	O
cells	O
from	O
the	O
elderly	O
produced	O
interferon	B
-	I
gamma	I
(	O
IFN	B
-	I
gamma	I
)	O
,	O
suggesting	O
a	O
link	O
between	O
the	O
magnitude	O
of	O
the	O
Fos	B
and	O
Jun	B
and	O
IFN	B
-	I
gamma	I
responses	O
.	O

The	O
regulation	O
of	O
HIV	O
by	O
retinoic	O
acid	O
correlates	O
with	O
cellular	O
expression	O
of	O
the	O
retinoic	B
acid	I
receptors	I
.	O

Even	O
a	O
moderate	O
increase	O
in	O
the	O
cellular	O
cysteine	O
supply	O
elevates	O
the	O
intracellular	O
glutathione	O
(	O
GSH	O
)	O
and	O
glutathione	O
disulfide	O
(	O
GSSG	O
)	O
levels	O
and	O
potentiates	O
immunological	O
functions	O
of	O
lymphocytes	O
in	O
vitro	O
.	O

As	O
signal	O
transduction	O
is	O
facilitated	O
by	O
prooxidant	O
conditions	O
,	O
we	O
propose	O
that	O
the	O
well	O
-	O
known	O
immunological	O
consequences	O
of	O
GSH	O
depletion	O
ultimately	O
may	O
be	O
results	O
of	O
the	O
accompanying	O
GSSG	O
deficiency	O
.	O

The	O
second	O
abnormality	O
in	O
kappa	O
B	O
-	O
binding	O
activity	O
in	O
T	O
cells	O
from	O
these	O
patients	O
is	O
that	O
RelA	B
,	O
a	O
member	O
of	O
the	O
Rel	B
homology	I
family	I
which	O
is	O
part	O
of	O
the	O
normal	O
NF	B
-	I
kappa	I
B	I
complex	I
,	O
was	O
not	O
induced	O
in	O
the	O
nucleus	O
following	O
activation	O
.	O

Cord	O
blood	O
cultures	O
showed	O
an	O
additive	O
combination	O
of	O
`	O
`	O
adult	O
'	O
'	O
and	O
`	O
`	O
fetal	O
'	O
'	O
patterns	O
.	O

Our	O
studies	O
also	O
demonstrate	O
that	O
under	O
anemic	O
stress	O
,	O
recruitment	O
of	O
fetal	O
progenitors	O
may	O
occur	O
in	O
adulthood	O
.	O

Taken	O
together	O
,	O
our	O
data	O
suggest	O
that	O
two	O
interactive	O
mechanisms	O
regulate	O
monocytic	B
I	I
kappa	I
B	I
alpha	I
/	I
MAD	I
-	I
3	I
mRNA	I
levels	O
.	O

In	O
extracts	O
from	O
nonstimulated	O
cells	O
the	O
receptor	O
is	O
recovered	O
in	O
an	O
inducible	O
cytoplasmic	O
form	O
associated	O
with	O
the	O
90	B
-	I
kDa	I
heat	I
shock	I
protein	I
(	O
hsp90	B
)	O
,	O
a	O
molecular	B
chaperone	I
.	O

It	O
was	O
not	O
possible	O
to	O
reconstitute	O
dioxin	B
receptor	I
function	O
with	O
proteins	O
expressed	O
in	O
wheat	O
germ	O
lysate	O
.	O

In	O
line	O
with	O
these	O
observations	O
,	O
reticulocyte	O
lysate	O
but	O
not	O
wheat	O
germ	O
lysate	O
promoted	O
the	O
association	O
of	O
de	O
novo	O
synthesized	O
dioxin	B
receptor	I
with	O
hsp90	B
.	O

Induction	O
of	O
transcription	B
factors	I
in	O
human	O
T	O
lymphocytes	O
by	O
aspirin	O
-	O
like	O
drugs	O
.	O

Protein	B
kinase	I
C	I
is	O
not	O
a	O
downstream	O
effector	O
of	O
p21ras	B
in	O
activated	O
T	O
cells	O
.	O

Data	O
is	O
presented	O
,	O
using	O
the	O
potent	O
and	O
selective	O
PKC	B
inhibitor	O
Ro	O
31	O
-	O
8425	O
and	O
transient	O
expression	O
of	O
a	O
constitutively	O
active	O
ras	O
mutant	O
,	O
which	O
clearly	O
shows	O
that	O
PKC	B
is	O
not	O
downstream	O
of	O
p21ras	B
in	O
the	O
induction	O
of	O
NF	B
-	I
AT	I
and	O
AP	B
-	I
1	I
transcriptional	O
activity	O
and	O
in	O
the	O
expression	O
of	O
IL	B
-	I
2	I
in	O
human	O
Jurkat	O
T	O
cells	O
.	O

The	O
signaling	O
pathways	O
involving	O
PKC	B
activation	O
,	O
calcium	O
mobilization	O
and	O
ras	B
activation	O
combine	O
to	O
provide	O
the	O
necessary	O
components	O
for	O
production	O
of	O
IL	B
-	I
2	I
during	O
T	O
cell	O
activation	O
.	O

Here	O
,	O
we	O
report	O
that	O
stimulation	O
through	O
the	O
IL	B
-	I
2R	I
induced	O
tyrosine	O
phosphorylation	O
and	O
subsequent	O
nuclear	O
translocation	O
of	O
stat3	B
,	O
a	O
newly	O
identified	O
member	O
of	O
the	O
signal	B
transducers	I
and	I
activators	I
of	I
transcription	I
(	I
STAT	I
)	I
family	I
of	O
proteins	O
.	O

Apart	O
from	O
stat3	B
,	O
another	O
cytoplasmic	B
protein	I
was	O
tyrosine	O
phosphorylated	O
and	O
subsequently	O
translocated	O
to	O
the	O
nucleus	O
in	O
response	O
to	O
IL	B
-	I
2	I
.	O

This	O
protein	O
had	O
an	O
apparent	O
molecular	O
mass	O
of	O
84	O
kDa	O
and	O
was	O
not	O
recognized	O
by	O
stat3	B
or	O
stat1	B
mAb	I
or	O
antisera	O
.	O

Taken	O
together	O
,	O
we	O
report	O
that	O
IL	B
-	I
2	I
induces	O
tyrosine	O
phosphorylation	O
and	O
subsequent	O
nuclear	O
translocation	O
of	O
stat3	B
and	O
an	O
as	O
yet	O
undefined	O
84	B
-	I
kDa	I
protein	I
in	O
antigen	O
-	O
specific	O
human	O
T	O
cell	O
lines	O
.	O

Human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
I	O
Tax	B
activation	O
of	O
NF	B
-	I
kappa	I
B	I
/	I
Rel	I
involves	O
phosphorylation	O
and	O
degradation	O
of	O
I	B
kappa	I
B	I
alpha	I
and	O
RelA	B
(	O
p65	B
)	O
-	O
mediated	O
induction	O
of	O
the	O
c	B
-	I
rel	I
gene	I
.	O

The	O
tax	O
gene	O
product	O
of	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV	O
-	O
I	O
)	O
is	O
a	O
potent	O
transcriptional	B
activator	I
that	O
both	O
stimulates	O
viral	O
gene	O
expression	O
and	O
activates	O
an	O
array	O
of	O
cellular	B
genes	I
involved	O
in	O
T	O
-	O
cell	O
growth	O
.	O

In	O
contrast	O
to	O
prior	O
in	O
vitro	O
studies	O
,	O
at	O
least	O
a	O
fraction	O
of	O
the	O
phosphorylated	O
form	O
of	O
I	B
kappa	I
B	I
alpha	I
remains	O
physically	O
associated	O
with	O
the	O
NF	B
-	I
kappa	I
B	I
complex	I
in	O
vivo	O
but	O
is	O
subject	O
to	O
rapid	O
degradation	O
,	O
thereby	O
promoting	O
the	O
nuclear	O
translocation	O
of	O
the	O
active	O
NF	B
-	I
kappa	I
B	I
complex	I
.	O

Therefore	O
we	O
investigated	O
the	O
modifications	O
imposed	O
on	O
NF	B
-	I
kappa	I
B	I
/	I
I	I
kappa	I
B	I
components	I
following	O
stimulation	O
and	O
show	O
that	O
the	O
final	O
step	O
of	O
NF	B
-	I
kappa	I
B	I
induction	O
in	O
vivo	O
involves	O
phosphorylation	O
of	O
several	O
members	O
of	O
the	O
NF	B
-	I
kappa	I
B	I
/	I
I	I
kappa	I
B	I
protein	I
families	I
.	O

Isolation	O
of	O
differentially	O
expressed	O
sequence	O
tags	O
from	O
steroid	O
-	O
responsive	O
cells	O
using	O
mRNA	B
differential	O
display	O
.	O

Although	O
much	O
is	O
known	O
about	O
the	O
structure	O
and	O
function	O
of	O
steroid	O
receptors	O
,	O
relatively	O
few	O
cell	O
-	O
specific	O
steroid	O
-	O
regulated	O
genes	O
have	O
been	O
isolated	O
and	O
characterized	O
.	O

In	O
this	O
paper	O
we	O
describe	O
results	O
using	O
mRNA	B
differential	O
display	O
reverse	B
transcriptase	I
PCR	O
(	O
DDPCR	O
)	O
to	O
identify	O
and	O
isolate	O
short	O
cDNA	O
sequence	O
tags	O
from	O
thymocyte	O
and	O
prostate	O
cells	O
under	O
various	O
hormone	O
conditions	O
.	O

GIG10	B
is	O
a	O
novel	O
sequence	O
and	O
GIG18	B
is	O
the	O
mouse	O
homologue	O
of	O
a	O
human	B
expressed	I
sequence	I
tag	I
isolated	O
from	O
activated	O
B	O
lymphocytes	O
.	O

We	O
have	O
shown	O
that	O
,	O
within	O
the	O
thymus	O
,	O
a	O
population	O
of	O
large	O
,	O
immature	O
cells	O
expresses	O
CD21	B
.	O

EBV	O
altered	O
the	O
activation	O
responses	O
of	O
immature	O
thymocytes	O
in	O
vitro	O
.	O

This	O
function	O
was	O
a	O
result	O
of	O
the	O
interaction	O
of	O
EBV	O
with	O
its	O
receptor	O
,	O
CD21	B
,	O
but	O
was	O
caused	O
by	O
infection	O
rather	O
than	O
surface	O
signaling	O
,	O
because	O
neither	O
specific	B
mAb	I
nor	O
the	O
P3HR	O
-	O
1	O
strain	O
of	O
virus	O
mimicked	O
the	O
effect	O
of	O
B95	O
-	O
8	O
.	O

Consistent	O
with	O
the	O
activity	O
of	O
B95	B
-	I
8	I
,	O
EBNA	B
-	I
2	I
transcripts	I
were	O
identified	O
within	O
infected	O
thymocyte	O
populations	O
.	O

A	O
second	O
transcript	O
was	O
identified	O
as	O
encoding	O
the	O
recently	O
characterized	O
RAZ	B
,	O
which	O
also	O
is	O
associated	O
with	O
replicative	O
infection	O
.	O

The	O
regulation	O
of	O
nuclear	B
factor	I
(	I
NF	I
)	I
-	I
kappa	I
B	I
activation	O
by	O
the	O
T	B
cell	I
receptor	I
(	I
TcR	I
)	I
/	I
CD3	I
complex	I
in	O
primary	O
human	O
T	O
cells	O
has	O
been	O
studied	O
at	O
various	O
times	O
after	O
activation	O
.	O

p50	B
.	I
c	I
-	I
rel	I
heterodimers	I
were	O
also	O
detected	O
bound	O
to	O
this	O
sequence	O
at	O
early	O
time	O
points	O
(	O
7	O
-	O
16	O
h	O
;	O
early	O
)	O
,	O
and	O
both	O
remained	O
active	O
at	O
later	O
time	O
points	O
(	O
40	O
h	O
;	O
late	O
)	O
after	O
activation	O
.	O

These	O
results	O
indicate	O
that	O
the	O
regulation	O
of	O
NF	B
-	I
kappa	I
B	I
activation	O
during	O
T	O
cell	O
activation	O
by	O
TcR	B
/	I
CD3	I
signals	O
is	O
biphasic	O
:	O
TcR	B
/	I
CD3	I
triggers	O
its	O
immediate	O
translocation	O
,	O
which	O
is	O
transient	O
if	O
no	O
TNF	B
-	I
alpha	I
is	O
present	O
.	O

The	O
cis	B
-	I
acting	I
region	I
,	O
GM	B
-	I
kappa	I
B	I
/	I
GC	I
-	I
box	I
(	O
positions	B
-	I
95	I
and	O
-	B
73	I
)	O
,	O
within	O
the	O
murine	B
GM	I
-	I
CSF	I
gene	I
promoter	I
is	O
required	O
for	O
maximal	O
induction	O
by	O
stimulation	O
with	O
phorbol	O
-	O
12	O
-	O
myristate	O
acetate	O
(	O
PMA	O
)	O
and	O
calcium	O
ionophore	O
(	O
A23187	O
)	O
in	O
T	O
cells	O
.	O

We	O
report	O
here	O
that	O
three	O
copies	O
of	O
the	O
GC	B
-	I
box	I
can	O
functionally	O
compensate	O
for	O
the	O
GM	B
-	I
kappa	I
B	I
/	I
GC	I
-	I
box	I
region	I
,	O
suggesting	O
that	O
the	O
GC	O
-	O
motif	O
can	O
function	O
independently	O
of	O
the	O
GM	B
-	I
kappa	I
B	I
motif	I
.	O

A	O
factor	O
that	O
regulates	O
the	O
class	B
II	I
major	I
histocompatibility	I
complex	I
gene	I
DPA	B
is	O
a	O
member	O
of	O
a	O
subfamily	O
of	O
zinc	B
finger	I
proteins	I
that	O
includes	O
a	O
Drosophila	B
developmental	I
control	I
protein	I
.	O

It	O
encodes	O
a	O
protein	O
predicted	O
to	O
contain	O
688	O
amino	O
acid	O
residues	O
,	O
including	O
11	O
zinc	B
finger	I
motifs	I
of	O
the	O
C2H2	B
type	I
in	O
the	O
C	B
-	I
terminal	I
region	I
,	O
that	O
are	O
Kruppel	O
-	O
like	O
in	O
the	O
conservation	O
of	O
the	O
H	B
/	I
C	I
link	I
sequence	I
connecting	O
them	O
.	O

One	O
of	O
the	O
Drosophila	B
sequences	I
,	O
ttk	B
,	O
is	O
a	O
developmental	B
control	I
gene	I
,	O
while	O
a	O
second	O
does	O
not	O
contain	O
a	O
zinc	B
finger	I
region	I
but	O
encodes	O
a	O
structure	O
important	O
in	O
oocyte	O
development	O
.	O

This	O
protein	O
appears	O
to	O
require	O
both	O
the	O
S	B
and	I
J	I
elements	I
,	O
which	O
are	O
separated	O
by	O
10	O
bp	O
for	O
optimal	O
binding	O
.	O

These	O
initial	O
pathways	O
culminate	O
in	O
a	O
common	O
pathway	O
through	O
which	O
all	O
of	O
the	O
stimulating	O
agents	O
ultimately	O
signal	O
NF	B
-	I
kappa	I
B	I
activation	O
.	O

This	O
Oct	B
-	I
2	I
-	O
dependent	O
transactivation	O
is	O
inhibited	O
by	O
RA	O
.	O

We	O
also	O
show	O
that	O
both	O
Fos	B
and	O
Jun	B
components	O
of	O
the	O
AP	B
-	I
1	I
factors	O
participate	O
in	O
the	O
OAP40	B
complex	I
.	O

OAP	B
confers	O
to	O
Oct	B
-	I
2	I
responsivity	O
to	O
both	O
TPA	O
/	O
Ca2	O
+	O
and	O
RA	O
,	O
since	O
specific	O
mutations	O
of	O
the	O
AP	B
-	I
1	I
/	I
OAP	I
-	I
binding	I
site	I
significantly	O
reduce	O
the	O
transactivation	O
by	O
Oct	B
-	I
2	I
in	O
response	O
to	O
TPA	O
and	O
Ca2	O
+	O
and	O
abolish	O
the	O
inhibition	O
by	O
RA	O
.	O

Therefore	O
,	O
we	O
propose	O
that	O
the	O
TPA	O
/	O
calcium	O
-	O
activated	O
AP	B
-	I
1	I
/	B
OAP	I
element	O
is	O
the	O
main	O
target	O
of	O
positive	O
or	O
negative	O
regulatory	O
signals	O
influencing	O
the	O
IL	B
-	I
2	I
octamer	I
motif	I
,	O
through	O
synergism	O
with	O
Oct	B
-	I
2	I
and	O
antagonism	O
by	O
RAR	B
.	O

As	O
in	O
XSCID	O
,	O
X	O
-	O
chromosome	O
inactivation	O
in	O
obligate	O
carriers	O
of	O
XCID	O
was	O
nonrandom	O
in	O
T	O
and	O
B	O
lymphocytes	O
.	O

Both	O
pyrrolidine	O
dithiocarbamate	O
,	O
an	O
oxidant	O
scavenger	O
,	O
and	O
N	O
-	O
acetyl	O
-	O
cysteine	O
,	O
a	O
precursor	O
of	O
the	O
endogenous	O
antioxidant	O
glutathione	O
,	O
inhibited	O
stimulation	O
of	O
macrophage	O
procoagulant	O
activity	O
by	O
LPS	O
.	O

An	O
NF	B
-	I
kappa	I
B	I
binding	O
site	O
is	O
an	O
essential	O
component	O
of	O
the	O
element	O
but	O
alone	O
is	O
not	O
sufficient	O
to	O
account	O
for	O
the	O
activity	O
or	O
the	O
specificity	O
of	O
the	O
element	O
.	O

Thapsigargin	O
(	O
TG	O
)	O
,	O
an	O
inhibitor	O
of	O
Ca	B
(	I
2	I
+	I
)	I
-	I
ATPase	I
,	O
depletes	O
intracellular	O
Ca2	O
+	O
stores	O
and	O
induces	O
a	O
sustained	O
Ca2	O
+	O
influx	O
without	O
altering	O
phosphatidyl	O
inositol	O
levels	O
.	O

A	O
similar	O
increase	O
in	O
IL	B
-	I
2R	I
alpha	I
by	O
TG	O
was	O
also	O
observed	O
in	O
human	O
peripheral	O
T	O
cells	O
.	O

However	O
,	O
TG	O
and	O
PMA	O
exhibited	O
a	O
synergistic	O
action	O
on	O
IL	B
-	I
2R	I
alpha	I
expression	O
,	O
suggesting	O
that	O
TG	O
and	O
PMA	O
induce	O
IL	B
-	I
2R	I
alpha	I
through	O
distinct	O
pathways	O
.	O

PMA	B
-	I
but	I
not	I
TG	I
-	I
induced	I
IL	I
-	I
2R	I
alpha	I
is	O
inhibited	O
by	O
the	O
PKC	B
inhibitor	O
H7	O
,	O
whereas	O
TG	B
-	I
but	I
not	I
PMA	I
-	I
induced	I
IL	I
-	I
2R	I
alpha	I
was	O
inhibited	O
by	O
cholera	O
toxin	O
,	O
forskolin	O
and	O
1	O
,	O
9	O
-	O
dideoxy	O
forskolin	O
.	O

The	O
agent	O
,	O
17	O
beta	O
-	O
estradiol	O
,	O
but	O
not	O
17	O
alpha	O
-	O
estradiol	O
,	O
significantly	O
reduced	O
PMNs	O
chemotaxis	O
to	O
FMLP	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
(	O
control	O
vs	O
estrogen	O
10	O
(	O
-	O
10	O
)	O
-	O
(	O
-	O
6	O
)	O
M	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Physiological	O
concentrations	O
of	O
estradiol	O
significantly	O
reduced	O
the	O
chemotaxis	O
of	O
PMNs	O
(	O
10	O
(	O
-	O
10	O
)	O
mol	O
)	O
.	O

Pre	O
-	O
incubation	O
with	O
clomiphene	O
or	O
tamoxifen	O
which	O
are	O
estrogen	O
receptor	O
antagonists	O
,	O
eliminated	O
the	O
inhibitory	O
effect	O
of	O
17	O
beta	O
-	O
estradiol	O
on	O
the	O
chemotaxis	O
of	O
PMNs	O
,	O
restoring	O
it	O
to	O
the	O
control	O
level	O
.	O

In	O
addition	O
,	O
the	O
level	O
of	O
estradiol	O
in	O
human	O
plasma	O
,	O
which	O
PMNs	O
were	O
drawn	O
,	O
showed	O
a	O
close	O
,	O
inverse	O
correlation	O
with	O
the	O
PMNs	O
chemotaxis	O
to	O
FMLP	O
(	O
r	O
=	O
-	O
0	O
.	O
821	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

Two	O
gel	B
shift	I
complexes	I
(	O
Mono	B
A	I
and	O
Mono	B
B	I
)	O
were	O
formed	O
with	O
separate	O
sequence	O
elements	O
within	O
this	O
region	O
.	O

Furthermore	O
,	O
multimerized	B
region	I
II	I
sequence	I
elements	I
enhanced	O
the	O
activity	O
of	O
a	O
heterologous	O
thymidine	O
kinase	O
promoter	O
in	O
monocytic	O
cells	O
but	O
not	O
other	O
cell	O
types	O
tested	O
.	O

Pyrrolidine	O
dithiocarbamate	O
,	O
a	O
potent	O
inhibitor	O
of	O
nuclear	B
factor	I
kappa	I
B	I
(	O
NF	B
-	I
kappa	I
B	I
)	O
activation	O
,	O
prevents	O
apoptosis	O
in	O
human	O
promyelocytic	O
leukemia	O
HL	O
-	O
60	O
cells	O
and	O
thymocytes	O
.	O

However	O
,	O
PDTC	O
failed	O
to	O
inhibit	O
the	O
endonuclease	B
activity	O
contained	O
in	O
the	O
whole	O
cell	O
lysates	O
.	O

Since	O
PDTC	O
has	O
both	O
antioxidant	O
and	O
metal	O
-	O
ion	O
chelating	O
activities	O
,	O
we	O
tested	O
the	O
effects	O
of	O
N	O
-	O
acetyl	O
-	O
L	O
-	O
cysteine	O
(	O
NAC	O
)	O
(	O
antioxidant	O
)	O
or	O
o	O
-	O
phenanthroline	O
(	O
OP	O
)	O
(	O
metal	O
-	O
ion	O
chelator	O
)	O
on	O
the	O
induction	O
of	O
apoptosis	O
.	O

PKC	O
-	O
zeta	O
cells	O
expressed	O
a	O
more	O
differentiated	O
phenotype	O
as	O
assessed	O
by	O
changes	O
in	O
morphology	O
,	O
surface	O
antigen	O
expression	O
,	O
and	O
lysosomal	B
enzyme	I
activities	O
and	O
were	O
distinct	O
from	O
parental	O
U937	O
cells	O
stimulated	O
to	O
differentiate	O
by	O
exposure	O
to	O
phorbol	O
esters	O
.	O

Increased	O
expression	O
of	O
the	O
c	B
-	I
jun	I
protooncogene	O
and	O
an	O
increase	O
in	O
AP	B
-	I
1	I
binding	O
activity	O
in	O
PKC	O
-	O
zeta	O
cells	O
provides	O
a	O
potential	O
mechanism	O
for	O
explaining	O
the	O
altered	O
differentiation	O
status	O
of	O
this	O
cell	O
.	O

It	O
is	O
surprising	O
that	O
the	O
faster	B
-	I
migrating	I
complex	I
was	O
composed	O
also	O
of	O
p50	B
and	O
p65	B
.	O

OBF	B
-	I
1	I
,	O
a	O
novel	B
B	I
cell	I
-	I
specific	I
coactivator	I
that	O
stimulates	O
immunoglobulin	B
promoter	I
activity	O
through	O
association	O
with	O
octamer	B
-	I
binding	I
proteins	I
.	O

The	O
OBF	B
-	I
1	I
mRNA	I
is	O
expressed	O
in	O
a	O
highly	O
cell	O
-	O
specific	O
manner	O
,	O
being	O
most	O
abundant	O
in	O
B	O
cells	O
and	O
essentially	O
absent	O
in	O
most	O
of	O
the	O
other	O
cells	O
or	O
tissues	O
tested	O
.	O

The	O
first	O
early	O
-	O
induced	O
peak	O
was	O
transient	O
and	O
likely	O
corresponds	O
to	O
the	O
well	O
documented	O
typical	O
junB	B
mRNA	I
,	O
stimulated	O
in	O
response	O
to	O
numerous	O
growth	B
factors	I
,	O
including	O
IL	B
-	I
6	I
.	O

Second	O
,	O
tyrphostin	O
,	O
a	O
tyrosine	O
kinase	O
inhibitor	O
,	O
impaired	O
the	O
expression	O
of	O
the	O
first	O
but	O
not	O
the	O
second	O
junB	B
mRNA	I
peak	O
.	O

Erythropoietin	B
(	O
Epo	B
)	O
,	O
granulocyte	B
/	I
macrophage	I
colony	I
stimulating	I
factor	I
(	O
GM	B
-	I
CSF	I
)	O
,	O
and	O
interleukin	B
3	I
(	O
IL	B
-	I
3	I
)	O
promoted	O
the	O
growth	O
of	O
NS	O
-	O
Meg	O
cells	O
.	O

Ten	O
-	O
day	O
exposure	O
to	O
Epo	B
induced	O
mature	O
erythroblasts	O
and	O
red	O
cells	O
.	O

These	O
benzidine	O
-	O
positive	O
cells	O
were	O
positive	O
for	O
hemoglobin	B
F	O
staining	O
.	O

The	O
T	B
cell	I
surface	I
molecule	I
CD28	B
binds	O
to	O
ligands	O
on	O
accessory	O
cells	O
and	O
APCs	O
,	O
playing	O
an	O
important	O
costimulatory	O
role	O
in	O
the	O
response	O
of	O
T	O
cells	O
to	O
Ags	B
.	O

Our	O
knowledge	O
of	O
the	O
intracellular	O
signaling	O
pathways	O
coupled	O
to	O
this	O
receptor	O
is	O
incomplete	O
.	O

Enhanced	O
responsiveness	O
to	O
nuclear	B
factor	I
kappa	I
B	I
contributes	O
to	O
the	O
unique	O
phenotype	O
of	O
simian	O
immunodeficiency	O
virus	O
variant	O
SIVsmmPBj14	O
.	O

In	O
a	O
wide	O
range	O
of	O
cell	O
types	O
,	O
the	O
basal	O
transcriptional	O
activity	O
of	O
the	O
LTR	B
from	O
SIVsmmPBj14	O
was	O
found	O
to	O
be	O
2	O
-	O
to	O
4	O
.	O
5	O
-	O
fold	O
higher	O
than	O
that	O
of	O
an	O
LTR	B
from	O
a	O
non	O
-	O
acutely	O
pathogenic	O
strain	O
.	O

Mutagenesis	O
studies	O
,	O
and	O
the	O
use	O
of	O
a	O
reporter	O
construct	O
containing	O
an	O
enhancerless	O
promoter	O
,	O
indicate	O
that	O
these	O
transcriptional	O
effects	O
are	O
due	O
principally	O
to	O
the	O
22	B
-	I
bp	I
sequence	I
duplication	I
and	O
the	O
NF	B
kappa	I
B	I
site	I
contained	O
within	O
it	O
.	O

In	O
such	O
cells	O
,	O
DNA	O
binding	O
activity	O
of	O
NF	B
-	I
kappa	I
B	I
can	O
be	O
detected	O
without	O
intentional	O
stimulation	O
.	O

This	O
nuclear	B
NF	I
-	I
kappa	I
B	I
was	O
still	O
present	O
when	O
contaminant	O
LPS	O
was	O
removed	O
by	O
ultrafiltration	O
and	O
when	O
serum	O
was	O
omitted	O
.	O

Using	O
LPS	O
-	O
free	O
and	O
serum	O
-	O
free	O
conditions	O
,	O
constitutive	O
NF	B
-	I
kappa	I
B	I
can	O
be	O
detected	O
in	O
different	O
cell	O
lines	O
of	O
the	O
monocytic	O
lineage	O
(	O
HL60	O
,	O
U937	O
,	O
THP	O
-	O
1	O
,	O
Mono	O
Mac	O
1	O
and	O
Mono	O
Mac	O
6	O
)	O
,	O
but	O
not	O
in	O
Molt	O
4	O
T	O
cells	O
or	O
K562	O
stem	O
cells	O
.	O

The	O
constitutive	O
NF	B
-	I
kappa	I
B	I
appears	O
to	O
be	O
functionally	O
active	O
,	O
since	O
a	O
low	O
level	O
of	O
tumour	B
necrosis	I
factor	I
(	I
TNF	I
)	I
transcript	I
is	O
detectable	O
in	O
monocytes	O
,	O
and	O
this	O
level	O
can	O
be	O
increased	O
by	O
blocking	O
transcript	O
degradation	O
using	O
cycloheximide	O
.	O

In	O
contrast	O
,	O
SCL	B
mRNA	I
levels	O
did	O
not	O
decrease	O
significantly	O
between	O
day	O
7	O
and	O
day	O
14	O
cells	O
,	O
suggesting	O
that	O
posttranscriptional	O
mechanisms	O
are	O
largely	O
responsible	O
for	O
the	O
decrease	O
in	O
SCL	B
protein	I
observed	O
.	O

In	O
BFU	O
-	O
E	O
-	O
derived	O
colonies	O
cultured	O
with	O
Steel	B
factor	I
,	O
colony	O
size	O
was	O
significantly	O
increased	O
compared	O
to	O
control	O
.	O

Activated	O
macrophages	O
contribute	O
to	O
chronic	O
inflammation	O
by	O
the	O
secretion	O
of	O
cytokines	B
and	O
proteinases	B
.	O

Tumor	B
necrosis	I
factor	I
alpha	I
(	O
TNF	B
alpha	I
)	O
is	O
particularly	O
important	O
in	O
this	O
process	O
because	O
of	O
its	O
ability	O
to	O
regulate	O
other	O
inflammatory	O
mediators	O
in	O
an	O
autocrine	O
and	O
paracrine	O
fashion	O
.	O

We	O
present	O
data	O
to	O
show	O
that	O
the	O
expression	O
of	O
TNF	B
alpha	I
is	O
regulated	O
by	O
the	O
transcription	B
factor	I
C	B
/	I
EBP	I
beta	I
(	O
NF	B
-	I
IL6	I
)	O
.	O

Calcium	B
/	I
calmodulin	I
-	I
dependent	I
protein	I
kinase	I
II	I
downregulates	O
both	O
calcineurin	O
and	O
protein	O
kinase	O
C	O
-	O
mediated	O
pathways	O
for	O
cytokine	B
gene	I
transcription	O
in	O
human	O
T	O
cells	O
.	O

However	O
,	O
the	O
role	O
of	O
CaM	B
-	I
K	I
II	I
remains	O
unknown	O
.	O

We	O
have	O
used	O
mutants	O
of	O
these	O
kinases	B
and	O
phosphatases	B
(	O
gamma	B
B	I
*	I
CaM	I
-	I
K	I
and	O
delta	B
CaM	I
-	I
AI	I
,	O
respectively	O
)	O
to	O
explore	O
their	O
relative	O
role	O
in	O
cytokine	B
gene	I
transcription	O
and	O
their	O
interactions	O
with	O
PKC	B
-	O
dependent	O
signaling	O
systems	O
.	O

When	O
both	O
mutants	O
were	O
used	O
in	O
combination	O
,	O
gamma	B
B	I
*	I
CaM	I
-	I
K	I
inhibited	O
the	O
induction	O
of	O
the	O
IL	B
-	I
2	I
promoter	I
by	O
delta	B
CaM	I
-	I
AI	I
.	O

Similar	O
results	O
were	O
obtained	O
when	O
a	O
construct	O
containing	O
the	O
IL	B
-	I
4	I
promoter	I
also	O
was	O
used	O
.	O

Induction	O
of	O
TaxI	B
in	O
a	O
human	O
T	O
-	O
cell	O
line	O
Jurkat	O
carrying	O
the	O
TaxI	B
gene	I
under	O
the	O
metallothionein	B
promoter	I
led	O
to	O
increases	O
in	O
mRNA	B
and	O
surface	O
expression	O
of	O
ICAM	B
-	I
I	I
.	O

Three	O
other	O
ATL	O
cell	O
lines	O
(	O
TL	O
-	O
OmI	O
,	O
H582	O
,	O
HuT102	O
)	O
were	O
found	O
to	O
have	O
little	O
mRNA	B
for	O
the	O
LFA	B
-	I
I	I
beta	I
chain	I
(	O
CD18	B
)	O
.	O

H582	O
and	O
HuT102	O
were	O
also	O
negative	O
for	O
the	O
LFA	B
-	I
I	I
alpha	I
chain	I
(	I
CDIIa	I
)	I
mRNA	I
.	O

Infection	O
with	O
Theileria	O
annulata	O
induces	O
expression	O
of	O
matrix	B
metalloproteinase	I
9	I
and	O
transcription	B
factor	I
AP	B
-	I
1	I
in	O
bovine	O
leucocytes	O
.	O

T	O
.	O
annulata	O
-	O
infected	O
leucocytes	O
produce	O
a	O
number	O
of	O
novel	O
metalloproteinase	B
activities	O
.	O

One	O
of	O
these	O
,	O
previously	O
called	O
B1	B
,	O
is	O
a	O
97	B
-	I
kDa	I
protein	I
which	O
is	O
secreted	O
in	O
large	O
amounts	O
and	O
has	O
been	O
purified	O
from	O
protein	O
-	O
free	O
,	O
conditioned	O
medium	O
.	O

In	O
addition	O
we	O
assayed	O
the	O
level	O
of	O
mRNA	B
encoding	O
c	B
-	I
Fos	I
,	O
a	O
common	O
component	O
of	O
AP	B
-	I
1	I
and	O
observed	O
that	O
it	O
was	O
indeed	O
up	O
-	O
regulated	O
in	O
infected	O
cells	O
.	O

We	O
generated	O
conditional	O
EBV	O
mutants	O
by	O
expressing	O
EBNA2	B
as	O
chimeric	B
fusion	I
protein	I
with	O
the	O
hormone	O
binding	O
domain	O
of	O
the	O
estrogen	B
receptor	I
on	O
the	O
genetic	O
background	O
of	O
the	O
virus	O
.	O

These	O
data	O
suggest	O
that	O
EBV	O
is	O
using	O
a	O
common	O
pathway	O
for	O
B	O
-	O
cell	O
activation	O
bypassing	O
the	O
requirement	O
for	O
antigen	O
,	O
T	O
-	O
cell	O
signals	O
and	O
growth	B
factors	I
.	O

The	O
synergistic	O
antigen	B
receptor	I
initiated	O
signals	O
are	O
mediated	O
through	O
protein	B
kinase	I
C	I
because	O
they	O
can	O
be	O
mimicked	O
by	O
the	O
phorbol	O
ester	O
,	O
12	O
-	O
O	O
-	O
tetradecanoylphorbol	O
-	O
13	O
-	O
acetate	O
,	O
but	O
not	O
with	O
calcium	O
ionophores	O
;	O
and	O
are	O
staurosporine	O
sensitive	O
but	O
cyclosporine	O
resistant	O
.	O

The	O
IL	B
-	I
1	I
-	O
induced	O
NF	B
-	I
kappa	I
B	I
DNA	O
nuclear	O
localization	O
is	O
transient	O
and	O
can	O
be	O
prolonged	O
either	O
by	O
an	O
antigen	O
receptor	O
-	O
initiated	O
signal	O
or	O
by	O
inhibiting	O
protein	O
synthesis	O
.	O

A	O
synthetic	O
oligodeoxyribonucleo	O
containing	O
an	O
SP1	B
-	I
box	I
(	O
5	O
'	O
-	O
GGGCGG	O
)	O
could	O
compete	O
with	O
factors	O
binding	O
to	O
the	O
12	B
-	I
bp	I
insert	I
.	O

Functional	O
Myc	B
-	I
Max	I
heterodimer	I
is	O
required	O
for	O
activation	O
-	O
induced	O
apoptosis	O
in	O
T	O
cell	O
hybridomas	O
.	O

T	O
cell	O
hybridomas	O
respond	O
to	O
activation	O
signals	O
by	O
undergoing	O
apoptotic	O
cell	O
death	O
,	O
and	O
this	O
is	O
likely	O
to	O
represent	O
comparable	O
events	O
related	O
to	O
tolerance	O
induction	O
in	O
immature	O
and	O
mature	O
T	O
cells	O
in	O
vivo	O
.	O

Computer	O
analysis	O
of	O
the	O
SM	B
protein	I
sequence	O
showed	O
a	O
C	B
terminal	I
section	I
of	O
SM	B
to	O
be	O
related	O
to	O
genome	B
positional	I
homologues	I
of	O
four	O
other	O
herpesviruses	O
and	O
revealed	O
consensus	B
CKII	I
sites	I
near	O
the	O
N	B
termini	I
of	O
the	O
EBV	B
SM	I
protein	I
,	O
the	O
herpes	B
simplex	I
virus	I
(	I
HSV	I
)	I
ICP27	I
protein	I
and	O
the	O
herpesvirus	B
saimiri	I
(	I
HVS	I
)	I
open	I
reading	I
frame	I
57	I
protein	I
.	O

Mutagenesis	O
of	O
the	O
CKII	B
site	O
in	O
SM	B
made	O
no	O
difference	O
to	O
the	O
transactivation	O
in	O
this	O
transient	O
transfection	O
assay	O
.	O

The	O
proto	B
-	I
oncogene	I
c	I
-	I
fos	I
is	O
an	O
immediate	B
-	I
early	I
gene	I
,	O
and	O
one	O
of	O
the	O
first	O
genes	O
transcribed	O
after	O
stimulation	O
of	O
most	O
cells	O
with	O
a	O
variety	O
of	O
ligands	O
.	O

The	O
serum	B
response	I
element	I
(	O
SRE	B
)	O
in	O
the	O
c	B
-	I
fos	I
regulatory	I
region	I
participates	O
in	O
induction	O
of	O
transcription	O
by	O
various	O
growth	B
factors	I
and	O
by	O
phorbol	O
esters	O
and	O
subsequent	O
squelching	O
of	O
transcription	O
.	O

Band	B
A	I
contains	O
the	O
serum	B
response	I
factor	I
plus	O
additional	O
factor	O
(	O
s	O
)	O
.	O

The	O
phosphorylated	O
tyrosine	O
residue	O
itself	O
is	O
important	O
for	O
the	O
protein	O
-	O
protein	O
interaction	O
.	O

RJ	O
2	O
.	O
2	O
.	O
5	O
is	O
a	O
human	O
B	O
cell	O
mutant	O
derived	O
from	O
the	O
Burkitt	O
lymphoma	O
Raji	O
cell	O
which	O
is	O
defective	O
in	O
the	O
AIR	O
-	O
1	O
locus	O
function	O
.	O

Thus	O
,	O
the	O
use	O
of	O
DNase	B
I	I
allowed	O
us	O
,	O
for	O
the	O
first	O
time	O
,	O
to	O
correlate	O
the	O
AIR	B
-	I
1	I
locus	I
defect	I
with	O
class	B
II	I
promoter	I
occupancy	O
alterations	O
and	O
distinguish	O
these	O
alterations	O
from	O
the	O
ones	O
observed	O
in	O
phenotypically	O
similar	O
but	O
genetically	O
distinct	O
MHC	O
class	O
II	O
-	O
negative	O
cells	O
.	O

The	O
interleukin	B
2	I
receptor	I
alpha	I
-	I
chain	I
(	I
IL	I
-	I
2R	I
alpha	I
)	I
gene	I
is	O
rapidly	O
and	O
potently	O
induced	O
in	O
T	O
cells	O
in	O
response	O
to	O
mitogenic	O
stimuli	O
.	O

This	O
element	O
had	O
maximal	O
activity	O
in	O
lymphoid	O
cells	O
,	O
paralleling	O
the	O
cell	O
type	O
specificity	O
of	O
Elf	B
-	I
1	I
expression	O
.	O

Elf	B
-	I
1	I
physically	O
associated	O
with	O
HMG	B
-	I
I	I
and	O
with	O
NF	B
-	I
kappa	I
B	I
p50	B
and	O
c	B
-	I
Rel	I
in	O
vitro	O
,	O
suggesting	O
that	O
protein	O
-	O
protein	O
interactions	O
might	O
functionally	O
coordinate	O
the	O
actions	O
of	O
the	O
upstream	B
and	I
downstream	I
positive	I
regulatory	I
elements	I
.	O

Northern	O
blot	O
analysis	O
showed	O
that	O
a	O
majority	O
of	O
these	O
genes	O
were	O
expressed	O
at	O
comparable	O
levels	O
in	O
U	O
-	O
937	O
and	O
HeLa	O
cells	O
.	O

Among	O
258	O
X	O
chromosome	O
-	O
containing	O
sperm	O
,	O
19	O
%	O
had	O
a	O
repeat	O
number	O
equal	O
to	O
the	O
donor	B
'	I
s	I
somatic	I
DNA	I
(	O
47	O
repeats	O
)	O
,	O
66	O
%	O
were	O
expansions	O
and	O
15	O
%	O
were	O
contractions	O
.	O

Aspirin	O
-	O
like	O
drugs	O
can	O
protect	O
human	O
T	O
lymphocytes	O
against	O
benzoquinone	O
cytotoxicity	O
:	O
evidence	O
for	O
a	O
NAD	B
(	I
P	I
)	I
H	I
:	I
quinone	I
reductase	I
-	O
dependent	O
mechanism	O
.	O

The	O
expression	O
of	O
the	O
QR	B
gene	I
is	O
regulated	O
by	O
the	O
transcription	B
factor	I
AP	B
-	I
1	I
.	O

Both	O
drugs	O
protected	O
the	O
cells	O
against	O
BQ	O
cytotoxicity	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
,	O
e	O
.	O
g	O
.	O
,	O
sodium	O
diclofenac	O
at	O
15	O
microM	O
reduced	O
the	O
fraction	O
of	O
BQ	O
-	O
treated	O
dead	O
cells	O
by	O
70	O
%	O
.	O

ALDs	O
induced	O
QR	B
activity	O
in	O
the	O
M4	O
cells	O
in	O
the	O
same	O
range	O
of	O
concentrations	O
that	O
protected	O
the	O
cells	O
against	O
BQ	O
toxicity	O
.	O

A	O
good	O
linear	O
correlation	O
,	O
with	O
an	O
r	O
value	O
of	O
0	O
.	O
91	O
,	O
between	O
the	O
ED50	O
values	O
for	O
the	O
differentiation	O
-	O
inducing	O
activity	O
towards	O
HL	O
-	O
60	O
cells	O
and	O
that	O
towards	O
NB4	O
cells	O
was	O
found	O
.	O

These	O
findings	O
suggest	O
a	O
molecular	O
mechanism	O
of	O
positive	O
regulation	O
of	O
PAFR	B
gene	O
expression	O
by	O
PAF	B
through	O
NF	B
-	I
kappa	I
B	I
,	O
possibly	O
by	O
a	O
phosphorylation	O
reaction	O
involving	O
protein	B
kinase	I
C	I
by	O
PAF	B
.	O

One	O
gene	O
,	O
two	O
transcripts	B
:	O
isolation	O
of	O
an	O
alternative	O
transcript	O
encoding	O
for	O
the	O
autoantigen	B
La	I
/	I
SS	I
-	I
B	I
from	O
a	O
cDNA	B
library	I
of	O
a	O
patient	O
with	O
primary	O
Sjogrens	O
'	O
syndrome	O
.	O

The	O
B	B
cell	I
-	I
associated	I
surface	I
molecule	I
CD40	I
functions	O
to	O
regulate	O
B	O
cell	O
responses	O
.	O

The	O
activation	O
is	O
rapid	O
and	O
is	O
mediated	O
through	O
a	O
tyrosine	O
kinase	O
-	O
dependent	O
pathway	O
.	O

These	O
inhibitors	O
specifically	O
prevented	O
degradation	O
of	O
I	B
kappa	I
B	I
alpha	I
and	O
nuclear	O
translocation	O
of	O
c	B
-	I
Rel	I
/	I
p65	I
heterodimers	I
.	O

In	O
contrast	O
,	O
TPCK	O
and	O
TLCK	O
did	O
not	O
block	O
induction	O
of	O
an	O
immediate	B
-	I
early	I
gene	I
encoding	O
the	O
transcription	B
factor	I
,	O
Egr	B
-	I
1	I
.	O

The	O
median	O
dissociation	O
constant	O
(	O
Kd	O
)	O
was	O
similar	O
in	O
all	O
three	O
groups	O
of	O
patients	O
and	O
in	O
healthy	O
women	O
(	O
mean	O
+	O
/	O
-	O
S	O
.	O
D	O
.	O
(	O
range	O
)	O
:	O
PHP	O
,	O
1	O
.	O
2	O
+	O
/	O
-	O
1	O
.	O
0	O
(	O
0	O
.	O
2	O
-	O
4	O
)	O
x	O
10	O
(	O
-	O
10	O
)	O
M	O
;	O
SH	O
,	O
0	O
.	O
6	O
+	O
/	O
-	O
0	O
.	O
4	O
(	O
0	O
.	O
2	O
-	O
1	O
.	O
2	O
)	O
x	O
10	O
(	O
-	O
10	O
)	O
M	O
;	O
RT	O
,	O
1	O
.	O
1	O
+	O
/	O
-	O
0	O
.	O
5	O
(	O
0	O
.	O
4	O
-	O
1	O
.	O
9	O
)	O
x	O
10	O
(	O
-	O
10	O
)	O
M	O
;	O
controls	O
,	O
1	O
.	O
0	O
+	O
/	O
-	O
0	O
.	O
6	O
(	O
0	O
.	O
3	O
-	O
2	O
.	O
6	O
)	O
x	O
10	O
(	O
-	O
10	O
)	O
M	O
)	O
.	O
However	O
,	O
the	O
maximal	O
binding	O
capacity	O
(	O
Nmax	O
)	O
was	O
significantly	O
enhanced	O
in	O
PHP	O
(	O
3	O
.	O
9	O
+	O
/	O
-	O
1	O
.	O
9	O
(	O
1	O
.	O
3	O
-	O
7	O
.	O
6	O
)	O
fmol	O
/	O
10	O
(	O
7	O
)	O
cells	O
vs	O
.	O
2	O
.	O
3	O
+	O
/	O
-	O
0	O
.	O
9	O
(	O
1	O
.	O
1	O
-	O
4	O
.	O
4	O
)	O
fmol	O
/	O
10	O
(	O
7	O
)	O
cells	O
in	O
controls	O
;	O
P	O
=	O
0	O
.	O
0006	O
)	O
and	O
decreased	O
in	O
SH	O
(	O
0	O
.	O
8	O
+	O
/	O
-	O
0	O
.	O
5	O
(	O
0	O
.	O
2	O
-	O
1	O
.	O
6	O
)	O
fmol	O
/	O
10	O
(	O
7	O
)	O
cells	O
vs	O
.	O
2	O
.	O
3	O
+	O
/	O
-	O
0	O
.	O
9	O
(	O
1	O
.	O
1	O
-	O
4	O
.	O
4	O
)	O
fmol	O
/	O
10	O
(	O
7	O
)	O
cells	O
in	O
controls	O
;	O
P	O
=	O
0	O
.	O
0001	O
)	O
,	O
whereas	O
no	O
changes	O
were	O
seen	O
in	O
RT	O
(	O
2	O
.	O
3	O
+	O
/	O
-	O
0	O
.	O
7	O
(	O
1	O
.	O
2	O
-	O
3	O
.	O
3	O
)	O
fmol	O
/	O
10	O
(	O
7	O
)	O
cells	O
vs	O
.	O
2	O
.	O
3	O
+	O
/	O
-	O
0	O
.	O
9	O
(	O
1	O
.	O
1	O
-	O
4	O
.	O
4	O
)	O
fmol	O
/	O
10	O
(	O
7	O
)	O
cells	O
in	O
controls	O
)	O
.	O

Changes	O
of	O
calcitriol	B
receptors	I
in	O
primary	O
and	O
secondary	O
hyperparathyroidism	O
could	O
magnify	O
the	O
consequences	O
of	O
disturbances	O
in	O
serum	O
concentration	O
of	O
calcitriol	O
itself	O
and	O
might	O
play	O
an	O
important	O
role	O
in	O
the	O
development	O
of	O
secondary	O
hyperparathyroidism	O
in	O
uremia	O
.	O

Studies	O
of	O
these	O
females	O
show	O
that	O
the	O
XIST	B
locus	I
on	O
their	O
tiny	B
ring	I
X	I
chromosomes	I
is	O
either	O
not	O
present	O
or	O
not	O
expressed	O
.	O

As	O
XIST	B
transcription	O
is	O
well	O
correlated	O
with	O
inactivation	O
of	O
the	O
X	B
chromosome	I
in	O
female	O
somatic	O
cells	O
and	O
spermatogonia	O
,	O
nonexpression	O
of	O
the	O
locus	O
even	O
when	O
it	O
is	O
present	O
suggests	O
that	O
these	O
chromosomes	B
are	O
transcriptionally	O
active	O
.	O

We	O
examined	O
the	O
transcriptional	O
activity	O
of	O
ring	O
X	B
chromosomes	I
lacking	O
XIST	B
expression	O
(	O
XISTE	O
-	O
)	O
,	O
from	O
three	O
females	O
with	O
severe	O
phenotypes	O
.	O

The	O
increase	O
in	O
IL	B
-	I
2	I
gene	O
expression	O
triggered	O
by	O
CD28	B
involves	O
a	O
kappa	B
B	I
-	I
like	I
sequence	I
in	O
the	O
5	B
'	I
-	I
regulatory	I
region	I
of	O
the	O
IL	B
-	I
2	I
promoter	I
,	O
called	O
CD28	B
-	I
responsive	I
element	I
.	O

Here	O
we	O
report	O
that	O
CD28	B
engagement	O
,	O
however	O
,	O
exerts	O
opposite	O
effects	O
on	O
the	O
transcription	B
factor	I
AP	I
-	I
1	I
.	O

The	O
activity	O
of	O
constructs	O
containing	O
5	B
'	I
deletion	I
mutants	I
of	O
the	O
alpha	B
4	I
gene	I
promoter	I
was	O
compared	O
in	O
transfection	O
assays	O
into	O
cell	O
lines	O
that	O
express	O
alpha	B
4	I
and	O
cell	O
lines	O
that	O
do	O
not	O
.	O

The	O
sequence	O
between	O
position	O
-	B
42	I
and	I
-	I
76	I
base	I
pairs	I
(	O
bp	O
)	O
was	O
required	O
for	O
efficient	O
transcription	O
in	O
cells	O
that	O
express	O
alpha	B
4	I
,	O
but	O
it	O
showed	O
no	O
activity	O
in	O
HeLa	O
cells	O
,	O
which	O
do	O
not	O
express	O
alpha	B
4	I
.	O

When	O
all	O
three	O
sites	O
were	O
present	O
,	O
a	O
second	O
complex	O
`	O
`	O
a	O
'	O
'	O
was	O
detected	O
,	O
which	O
contains	O
an	O
unknown	O
member	O
of	O
the	O
Ets	B
family	I
.	O

Formation	O
of	O
complex	O
a	O
was	O
cell	O
-	O
type	O
specific	O
and	O
correlated	O
with	O
a	O
high	O
level	O
of	O
transcription	O
.	O

This	O
arrangement	O
of	O
Ets	B
sites	I
,	O
coupled	O
with	O
the	O
tissue	O
-	O
and	O
developmental	O
-	O
specific	O
expression	O
of	O
Ets	B
members	I
,	O
likely	O
play	O
a	O
key	O
role	O
in	O
defining	O
the	O
pattern	O
of	O
alpha	B
4	I
integrin	I
.	O

Antiandrogens	O
result	O
in	O
protection	O
of	O
both	O
the	O
hinge	B
region	I
and	O
C	B
-	I
terminus	I
of	O
the	O
androgen	B
receptor	I
agonist	O
proteolytic	O
attack	O
,	O
whereas	O
other	O
studies	O
showed	O
that	O
antiestrogens	O
and	O
antiprogestagens	O
expose	O
the	O
C	B
-	I
terminal	I
end	I
of	O
the	O
ligand	B
binding	I
domain	I
of	O
their	O
respective	O
receptors	O
to	O
protease	B
.	O

However	O
,	O
reagents	O
such	O
as	O
nerve	B
growth	I
factor	I
(	O
NGF	B
)	O
and	O
the	O
phorbol	O
ester	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
(	O
PMA	O
)	O
,	O
which	O
induce	O
phenotypical	O
differentiation	O
of	O
the	O
SH	O
-	O
SY5Y	O
neuroblastoma	O
cell	O
line	O
,	O
activated	O
NF	B
-	I
kappa	I
B	I
,	O
but	O
only	O
in	O
that	O
particular	O
cell	O
line	O
.	O

To	O
identify	O
ets	B
-	I
related	I
transcriptional	I
regulators	I
expressed	O
in	O
pre	O
-	O
B	O
lymphocytes	O
that	O
may	O
interact	O
with	O
either	O
the	O
pi	B
or	O
the	O
microB	B
site	I
,	O
we	O
have	O
used	O
a	O
PCR	O
approach	O
with	O
degenerate	O
oligonucleotides	O
encoding	O
conserved	O
sequences	O
in	O
all	O
members	O
of	O
the	O
ets	B
family	I
.	O

We	O
have	O
cloned	O
the	O
gene	O
for	O
a	O
new	O
ets	B
-	I
related	I
transcription	I
factor	I
,	O
ERP	B
(	O
ets	B
-	I
related	I
protein	I
)	O
,	O
from	O
the	O
murine	O
pre	O
-	O
B	O
cell	O
line	O
BASC	O
6C2	O
and	O
from	O
mouse	O
lung	O
tissue	O
.	O

Full	O
-	O
length	O
ERP	B
expresses	O
only	O
negligible	O
DNA	O
-	O
binding	O
activity	O
by	O
itself	O
.	O

Two	O
cis	B
-	I
acting	I
elements	I
GM	B
-	I
kappa	I
B	I
/	I
GC	I
-	I
box	I
and	O
CLE0	B
,	O
of	O
the	O
granulocyte	B
-	I
macrophage	I
colony	I
-	I
stimulating	I
factor	I
(	I
GM	I
-	I
CSF	I
)	I
gene	I
are	O
required	O
for	O
maximal	O
induction	O
in	O
Jurkat	O
T	O
cells	O
by	O
costimulation	O
with	O
phorbol	O
-	O
12	O
-	O
myristate	O
acetate	O
(	O
PMA	O
)	O
and	O
Ca2	O
+	O
ionophore	O
(	O
A23187	O
)	O
.	O

Nonpituitary	B
human	I
prolactin	I
gene	I
transcription	O
is	O
independent	O
of	O
Pit	B
-	I
1	I
and	O
differentially	O
controlled	O
in	O
lymphocytes	O
and	O
in	O
endometrial	O
stroma	O
.	O

Our	O
experiments	O
also	O
show	O
that	O
activated	O
PR	B
does	O
not	O
confer	O
direct	O
transcriptional	O
control	O
on	O
the	O
dPRL	B
promoter	I
.	O

One	O
of	O
the	O
nuclear	B
factors	I
(	O
NFs	B
)	O
that	O
regulates	O
the	O
response	O
of	O
the	O
IL	B
-	I
5	I
promoter	I
to	O
cAMP	O
and	O
PMA	O
has	O
properties	O
similar	O
to	O
NF	B
for	O
activated	O
t	O
cell	O
.	O

JNK	B
is	O
involved	O
in	O
signal	O
integration	O
during	O
costimulation	O
of	O
T	O
lymphocytes	O
.	O

T	O
lymphocyte	O
activation	O
and	O
interleukin	B
-	I
2	I
(	O
IL	B
-	I
2	I
)	O
production	O
require	O
at	O
least	O
two	O
signals	O
,	O
generated	O
by	O
phorbol	O
ester	O
(	O
TPA	O
)	O
and	O
Ca2	O
+	O
ionophore	O
or	O
costimulation	O
of	O
the	O
T	B
cell	I
receptor	I
(	O
TCR	B
)	O
and	O
the	O
CD28	B
auxiliary	I
receptor	I
.	O

Full	O
activation	O
of	O
the	O
MAP	B
kinases	I
that	O
phosphorylate	O
the	O
Jun	B
activation	I
domain	I
,	O
JNK1	B
and	O
JNK2	B
,	O
required	O
costimulation	O
of	O
T	O
cells	O
with	O
either	O
TPA	O
and	O
Ca2	O
+	O
ionophore	O
or	O
antibodies	O
to	O
TCR	B
and	O
CD28	B
.	O

The	O
effect	O
of	O
a	O
liposomal	O
formulation	O
of	O
methylprednisolone	O
(	O
MPL	O
)	O
on	O
the	O
inhibition	O
of	O
lymphocyte	O
proliferation	O
in	O
spleen	O
cells	O
was	O
investigated	O
following	O
IV	O
dosing	O
in	O
rats	O
.	O

Liposomes	O
do	O
not	O
alter	O
the	O
suppressive	O
action	O
of	O
MPL	O
when	O
placed	O
in	O
lymphocyte	O
culture	O
.	O

Inhibition	O
effects	O
versus	O
time	O
were	O
described	O
by	O
a	O
pharmacodynamic	O
model	O
using	O
MPL	O
concentrations	O
in	O
plasma	O
as	O
an	O
input	O
function	O
.	O

In	O
vivo	O
protein	O
-	O
DNA	O
contacts	O
are	O
detectable	O
at	O
Ii	B
kappa	I
B	I
-	I
1	I
in	O
cell	O
lines	O
in	O
which	O
this	O
site	O
is	O
functional	O
as	O
either	O
a	O
positive	B
or	I
negative	I
regulator	I
.	O

Ii	B
kappa	I
B	I
-	I
2	I
is	O
a	O
site	O
of	O
positive	O
regulation	O
in	O
B	O
-	O
cell	O
lines	O
and	O
a	O
site	O
of	O
negative	O
regulation	O
in	O
H9	O
T	O
cells	O
,	O
myelomonocytic	O
,	O
and	O
glial	O
cell	O
lines	O
.	O

Again	O
,	O
in	O
vitro	O
supershift	O
studies	O
indicate	O
that	O
the	O
presence	O
of	O
p50	B
,	O
p52	B
,	O
p65	B
,	O
and	O
cRel	B
correlates	O
with	O
positive	O
function	O
whereas	O
the	O
presence	O
of	O
only	O
p50	B
and	O
p52	B
correlates	O
with	O
negative	O
function	O
.	O

OBJECTIVE	O
:	O
To	O
determine	O
whether	O
activation	O
of	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
replication	O
in	O
tumour	O
cells	O
of	O
AIDS	O
-	O
related	O
non	O
-	O
Hodgkin	O
'	O
s	O
lymphoma	O
(	O
ARNHL	O
)	O
is	O
correlated	O
with	O
CD4	B
+	I
cell	O
counts	O
and	O
influences	O
antibody	O
response	O
to	O
EBV	O
[	O
anti	B
-	I
Z	I
Epstein	I
-	I
Barr	I
replicative	I
activator	I
(	O
ZEBRA	B
)	O
,	O
anti	B
-	I
early	I
antigen	I
(	O
EA	B
)	O
,	O
anti	B
-	I
viral	I
capsid	I
antigen	I
(	O
VCA	B
)	O
]	O
.	O

DESIGN	O
:	O
Retrospective	O
study	O
based	O
on	O
immunohistochemistry	O
and	O
in	O
situ	O
hybridization	O
to	O
detect	O
EBV	O
replicative	O
gene	O
products	O
in	O
tissue	O
samples	O
from	O
patients	O
affected	O
by	O
ARNHL	O
and	O
correlation	O
with	O
CD4	B
+	I
cell	O
counts	O
and	O
results	O
of	O
EBV	O
serology	O
(	O
including	O
anti	O
-	O
ZEBRA	B
activity	O
)	O
in	O
sera	O
from	O
the	O
same	O
patients	O
.	O

In	O
cells	O
stimulated	O
with	O
anti	B
-	I
CD3	I
mAb	I
,	O
PGE2	B
inhibited	O
cell	O
proliferation	O
and	O
the	O
production	O
of	O
all	O
the	O
cytokines	B
examined	O
.	O

Addition	O
of	O
rIL	B
-	I
2	I
fully	O
restored	O
the	O
proliferative	O
response	O
and	O
partially	O
restored	O
the	O
production	O
of	O
IL	B
-	I
4	I
and	O
IL	B
-	I
5	I
,	O
but	O
not	O
that	O
of	O
other	O
cytokines	B
.	O

It	O
seems	O
therefore	O
that	O
PGE2	B
,	O
by	O
elevating	O
cAMP	O
levels	O
,	O
interferes	O
with	O
the	O
activation	O
pathway	O
for	O
NF	B
-	I
kappa	I
B	I
but	O
not	O
for	O
NF	B
-	I
AT	I
,	O
AP	B
-	I
1	I
or	O
CLE0	B
binding	I
protein	I
.	O

Moreover	O
,	O
rapamycin	O
,	O
an	O
inhibitor	O
of	O
pp70S6K	B
activation	O
,	O
had	O
no	O
effect	O
on	O
induction	O
of	O
EGR	B
-	I
1	I
expression	O
.	O

In	O
contrast	O
,	O
analysis	O
of	O
pp90rsk	B
activity	O
by	O
phosphorylation	O
of	O
a	O
peptide	O
derived	O
from	O
S6	B
protein	I
demonstrated	O
stimulation	O
of	O
this	O
kinase	B
in	O
TPA	O
-	O
treated	O
U	O
-	O
937	O
,	O
and	O
not	O
TUR	O
,	O
cells	O
.	O

PDTC	O
or	O
N	O
-	O
acetylcysteine	O
dose	O
dependently	O
reduced	O
TNF	B
-	I
induced	I
VCAM	I
-	I
1	I
but	O
not	O
ICAM	B
-	I
1	I
surface	I
protein	I
(	O
also	O
in	O
human	O
umbilical	O
arterial	O
endothelial	O
cells	O
)	O
and	O
mRNA	O
expression	O
(	O
by	O
70	O
%	O
at	O
100	O
mumol	O
/	O
L	O
PDTC	O
)	O
in	O
HUVECs	O
as	O
assessed	O
by	O
flow	O
cytometry	O
and	O
polymerase	O
chain	O
reaction	O
.	O

We	O
have	O
identified	O
a	O
`	B
`	I
two	I
-	I
handed	I
'	I
'	I
zinc	I
finger	I
protein	I
,	O
denoted	O
ZEB	B
,	O
the	O
DNA	O
-	O
binding	O
specificity	O
of	O
which	O
mimics	O
that	O
of	O
the	O
cellular	B
repressor	I
.	O

By	O
employing	O
a	O
derivative	O
E	B
box	I
that	O
binds	O
ZEB	B
but	O
not	O
E2A	B
,	O
we	O
have	O
shown	O
that	O
the	O
repressor	B
is	O
active	O
in	O
B	O
cells	O
and	O
the	O
IgH	B
enhancer	I
is	O
silenced	O
in	O
the	O
absence	O
of	O
binding	O
competition	O
by	O
bHLH	B
proteins	I
.	O

Effects	O
of	O
the	O
antisense	O
myb	O
expression	O
on	O
hemin	O
-	O
and	O
erythropoietin	O
-	O
induced	O
erythroid	O
differentiation	O
of	O
K562	O
cells	O
.	O

In	O
order	O
to	O
elucidate	O
the	O
role	O
of	O
c	B
-	I
myb	I
gene	I
in	O
erythroid	O
differentiation	O
of	O
K562	O
cell	O
induced	O
by	O
hemin	B
(	O
Hm	B
)	O
and	O
erythropoietin	B
(	O
Epo	B
)	O
,	O
we	O
constructed	O
recombinant	B
plasmid	I
that	O
could	O
produce	O
antisense	B
myb	I
RNA	I
after	O
induction	O
with	O
dexamethasone	O
.	O

During	O
treatment	O
with	O
Hm	B
,	O
K562	O
cells	O
constitutively	O
expressed	O
c	B
-	I
myb	I
mRNA	I
,	O
and	O
50	O
%	O
of	O
them	O
began	O
to	O
synthesize	O
hemoglobin	B
(	O
Hb	B
)	O
.	O

We	O
investigated	O
whether	O
non	O
-	O
abortive	O
maternal	O
infections	O
would	O
compromise	O
fetal	O
brain	O
development	O
and	O
alter	O
hypothalamic	O
-	O
pituitary	O
-	O
adrenocortical	O
(	O
HPA	O
)	O
axis	O
functioning	O
when	O
adult	O
.	O

The	O
adult	O
male	O
progeny	O
(	O
3	O
mo	O
old	O
)	O
of	O
both	O
experimental	O
groups	O
showed	O
increased	O
basal	O
plasma	O
corticosterone	O
levels	O
.	O

Both	O
groups	O
showed	O
substantial	O
decreases	O
in	O
mineralocorticoid	O
(	O
MR	O
)	O
and	O
glucocorticoid	O
receptor	O
(	O
GR	O
)	O
levels	O
in	O
the	O
hippocampus	O
,	O
a	O
limbic	O
brain	O
structure	O
critical	O
for	O
HPA	O
axis	O
regulation	O
,	O
whereas	O
GR	B
concentrations	O
in	O
the	O
hypothalamus	O
were	O
unchanged	O
and	O
in	O
anterior	O
pituitary	O
were	O
slightly	O
increased	O
.	O

HRBC	O
and	O
LPS	O
indeed	O
stimulated	O
the	O
maternal	O
immune	O
system	O
as	O
revealed	O
by	O
specific	O
anti	B
-	I
HRBC	I
antibody	I
production	O
and	O
enhanced	O
IL	O
-	O
1	O
beta	O
mRNA	O
expression	O
in	O
splenocytes	O
,	O
respectively	O
.	O

NM23	B
was	O
identified	O
in	O
a	O
system	O
of	O
murine	O
melanoma	O
cell	O
lines	O
,	O
in	O
which	O
an	O
inverse	O
relationship	O
was	O
found	O
between	O
NM23	B
expression	O
and	O
metastatic	O
ability	O
.	O

The	O
transmission	O
of	O
signals	O
from	O
the	O
membrane	O
to	O
the	O
nucleus	O
is	O
mediated	O
principally	O
through	O
the	O
action	O
of	O
protein	B
tyrosine	I
and	I
serine	I
/	I
threonine	I
kinases	I
.	O

Fos	B
kinase	I
may	O
play	O
a	O
role	O
in	O
transcriptional	O
regulation	O
through	O
its	O
capacity	O
to	O
phosphorylate	O
c	B
-	I
Fos	I
at	O
a	O
site	O
required	O
for	O
expression	O
of	O
the	O
transcriptional	O
transrepressive	O
activity	O
of	O
this	O
molecule	O
.	O

Each	O
of	O
the	O
remaining	O
four	O
patients	O
also	O
yielded	O
at	O
least	O
one	O
type	O
-	O
specific	O
T	O
-	O
cell	O
clone	O
reactive	O
with	O
an	O
HSV	O
-	O
2	O
epitope	O
mapping	O
to	O
approximately	O
0	O
.	O
67	O
to	O
0	O
.	O
73	O
map	O
units	O
.	O

Human	O
T	O
-	O
cell	O
clones	O
reactive	O
with	O
gC	B
and	O
VP16	B
are	O
reported	O
here	O
for	O
the	O
first	O
time	O
.	O

We	O
studied	O
genomic	B
DNA	I
and	O
RNA	O
extracted	O
from	O
the	O
patient	O
'	O
s	O
peripheral	O
leucocytes	O
in	O
order	O
to	O
determine	O
the	O
origin	O
of	O
the	O
basophils	O
.	O

The	O
RAR	B
alpha	I
rearranged	O
band	O
in	O
the	O
Southern	O
blot	O
analysis	O
and	O
a	O
chimaeric	B
product	I
of	O
PML	B
-	I
RAR	I
alpha	I
by	O
polymerase	O
chain	O
reaction	O
were	O
strongly	O
visible	O
before	O
ATRA	O
treatment	O
,	O
but	O
at	O
the	O
time	O
of	O
maximal	O
basophilia	O
both	O
of	O
them	O
were	O
markedly	O
diminished	O
.	O

Activation	O
of	O
the	O
interleukin	B
6	I
gene	I
by	O
Mycobacterium	O
tuberculosis	O
or	O
lipopolysaccharide	O
is	O
mediated	O
by	O
nuclear	B
factors	I
NF	I
-	I
IL6	I
and	O
NF	B
-	I
kappa	I
B	I
[	O
published	O
erratum	O
appears	O
in	O
Proc	O
Natl	O
Acad	O
Sci	O
U	O
S	O
A	O
1995	O
Apr	O
11	O
;	O
92	O
(	O
8	O
)	O
:	O
3632	O
]	O

In	O
this	O
regard	O
,	O
the	O
cytokine	B
interleukin	B
6	I
(	O
IL	B
-	I
6	I
)	O
may	O
play	O
a	O
role	O
in	O
the	O
clinical	O
manifestations	O
and	O
pathological	O
events	O
of	O
tuberculosis	O
infection	O
.	O

LAM	B
and	O
LPS	O
were	O
potent	O
inducers	O
of	O
IL	B
-	I
6	I
gene	I
expression	O
in	O
peripheral	O
blood	O
monocytes	O
.	O

Two	O
nuclear	B
factor	I
NF	I
-	I
IL6	I
(	O
positions	O
-	B
153	I
to	I
-	I
145	I
and	O
-	O
83	O
to	O
-	O
75	O
)	O
and	O
one	O
nuclear	B
factor	I
NF	I
-	I
kappa	I
B	I
(	I
positions	I
-	I
72	I
to	I
-	I
63	I
)	I
motifs	I
are	O
present	O
within	O
this	O
fragment	O
.	O

We	O
conclude	O
that	O
the	O
NF	B
-	I
IL6	I
and	I
NF	I
-	I
kappa	I
B	I
sites	I
mediate	O
IL	B
-	I
6	I
induction	O
in	O
response	O
to	O
both	O
LPS	O
and	O
LAM	B
,	O
acting	O
as	O
bacterial	B
or	I
mycobacterial	I
response	I
elements	I
.	O

Using	O
FACS	O
,	O
Northern	O
blotting	O
,	O
and	O
nuclear	O
run	O
-	O
on	O
analyses	O
,	O
we	O
demonstrate	O
that	O
the	O
up	O
-	O
regulation	O
of	O
CD14	B
expression	O
during	O
monocytic	O
cell	O
maturation	O
is	O
regulated	O
mainly	O
at	O
the	O
level	O
of	O
gene	O
transcription	O
,	O
and	O
that	O
new	O
protein	O
synthesis	O
is	O
required	O
for	O
CD14	B
induction	O
.	O

This	O
region	O
contains	O
two	O
binding	B
sites	I
for	O
the	O
Sp1	B
transcription	I
factor	I
.	O

UV	O
irradiation	O
and	O
H2O2	O
treatment	O
of	O
T	O
lymphocytes	O
induce	O
protein	O
tyrosine	O
phosphorylation	O
and	O
Ca2	O
+	O
signals	O
similar	O
to	O
those	O
observed	O
following	O
biological	O
stimulation	O
.	O

Similarly	O
,	O
Jurkat	O
T	O
cell	O
lines	O
deficient	O
in	O
CD3	O
or	O
CD45	O
expression	O
also	O
gave	O
impaired	O
UV	O
responses	O
.	O

Inhibition	O
of	O
the	O
differentiation	O
of	O
human	O
myeloid	O
cell	O
lines	O
by	O
redox	O
changes	O
induced	O
through	O
glutathione	O
depletion	O
.	O

The	O
glutathione	O
-	O
depleting	O
agent	O
diethyl	O
maleate	O
(	O
DEM	O
)	O
prevented	O
the	O
development	O
of	O
differentiated	O
features	O
in	O
response	O
to	O
phorbol	O
esters	O
,	O
including	O
adherence	O
of	O
the	O
cells	O
to	O
plastic	O
surfaces	O
and	O
repression	O
of	O
the	O
myeloperoxidase	B
and	I
CD34	I
genes	I
.	O

This	O
nuclear	B
complex	I
was	O
activated	O
by	O
LPS	O
with	O
kinetics	O
that	O
preceded	O
induction	O
of	O
the	O
TF	B
gene	I
.	O

Human	O
immunodeficiency	O
virus	O
type	O
1	O
Nef	O
protein	O
down	O
-	O
regulates	O
transcription	B
factors	I
NF	B
-	I
kappa	I
B	I
and	O
AP	B
-	I
1	I
in	O
human	O
T	O
cells	O
in	O
vitro	O
after	O
T	O
-	O
cell	O
receptor	O
stimulation	O
.	O

To	O
define	O
the	O
mechanism	O
of	O
action	O
of	O
the	O
Nef	B
protein	O
,	O
the	O
signal	O
transduction	O
pathways	O
which	O
may	O
be	O
affected	O
in	O
T	O
cells	O
by	O
constitutive	O
expression	O
of	O
the	O
nef	O
gene	O
were	O
examined	O
.	O

Stimulation	O
of	O
T	O
cells	O
with	O
tumor	O
necrosis	O
factor	O
,	O
interleukin	O
-	O
1	O
,	O
or	O
lipopolysaccharide	O
resulted	O
in	O
the	O
recruitment	O
of	O
transcriptional	O
factors	O
to	O
a	O
similar	O
level	O
whether	O
or	O
not	O
the	O
cells	O
expressed	O
the	O
nef	O
gene	O
.	O

When	O
cells	O
were	O
preincubated	O
with	O
dihydrolipoic	O
acid	O
(	O
0	O
.	O
2	O
mM	O
)	O
the	O
expression	O
of	O
c	B
-	I
fos	I
mRNA	I
was	O
suppressed	O
at	O
30	O
min	O
after	O
stimulation	O
of	O
TPA	O
(	O
0	O
.	O
5	O
microM	O
)	O
whereas	O
in	O
the	O
case	O
of	O
preincubation	O
of	O
alpha	O
-	O
lipoic	O
acid	O
(	O
0	O
.	O
2	O
microM	O
)	O
,	O
the	O
expression	O
was	O
enhanced	O
at	O
30	O
min	O
.	O

This	O
resulted	O
in	O
only	O
a	O
partial	O
inhibition	O
of	O
TNF	B
-	O
or	O
PMA	O
-	O
induced	O
HIV	O
replication	O
in	O
U1	O
cells	O
,	O
and	O
no	O
detectable	O
effect	O
on	O
HIV	O
replication	O
in	O
chronically	O
infected	O
U937	O
cells	O
.	O

Another	O
limitation	O
is	O
that	O
antioxidant	O
concentrations	O
high	O
enough	O
to	O
block	O
NK	B
-	I
kappa	I
B	I
activation	O
were	O
shown	O
to	O
have	O
a	O
suppressive	O
effect	O
on	O
immune	O
functions	O
in	O
vitro	O
,	O
because	O
NAC	O
and	O
BHA	O
blocked	O
IL	O
-	O
2	O
-	O
induced	O
PBMC	O
proliferation	O
.	O

We	O
have	O
developed	O
a	O
three	O
-	O
layer	O
Percoll	O
density	O
gradient	O
that	O
allows	O
separation	O
of	O
the	O
different	O
granules	O
and	O
vesicles	O
from	O
human	O
neutrophils	O
;	O
in	O
particular	O
,	O
it	O
allows	O
separation	O
of	O
specific	O
and	O
gelatinase	O
granules	O
.	O

This	O
allows	O
us	O
to	O
characterize	O
these	O
two	O
granule	O
populations	O
with	O
regard	O
to	O
their	O
content	O
of	O
membrane	B
proteins	I
,	O
which	O
become	O
incorporated	O
into	O
the	O
plasma	O
membrane	O
during	O
exocytosis	O
.	O

Furthermore	O
,	O
we	O
found	O
that	O
20	O
%	O
to	O
25	O
%	O
of	O
both	O
the	O
adhesion	B
protein	I
Mac	I
-	I
1	I
and	O
the	O
NADPH	B
-	I
oxidase	I
component	I
cytochrome	I
b558	B
is	O
localized	O
in	O
gelatinase	B
granules	O
.	O

This	O
shows	O
that	O
gelatinase	B
granules	O
are	O
functionally	O
important	O
relative	O
to	O
specific	O
granules	O
in	O
mediating	O
early	O
inflammatory	O
responses	O
.	O

Treatment	O
of	O
human	O
resting	O
T	O
cells	O
with	O
phorbol	O
esters	O
strongly	O
induced	O
the	O
expression	O
of	O
IL	B
-	I
2R	I
alpha	I
and	O
the	O
activation	O
of	O
NF	B
.	I
kappa	I
B	I
.	O

Rather	O
,	O
the	O
data	O
indicate	O
that	O
mitogen	O
increases	O
the	O
levels	O
of	O
a	O
nuclear	O
factor	O
(	O
s	O
)	O
that	O
dimerizes	O
with	O
CREB	B
.	O

We	O
have	O
examined	O
the	O
effect	O
of	O
alpha	O
-	O
tocopherol	O
(	O
alpha	O
-	O
tcp	O
)	O
on	O
one	O
cellular	O
event	O
in	O
atherosclerotic	O
plaque	O
development	O
,	O
monocyte	O
adhesion	O
to	O
stimulated	O
endothelial	O
cells	O
(	O
ECs	O
)	O
.	O

Agonist	O
-	O
induced	O
monocytic	O
cell	O
adhesion	O
,	O
but	O
not	O
basal	O
adhesion	O
,	O
was	O
inhibited	O
in	O
a	O
time	O
-	O
and	O
concentration	O
-	O
dependent	O
manner	O
by	O
alpha	O
-	O
tcp	O
.	O

Central	O
nervous	O
system	O
-	O
derived	O
cells	O
express	O
a	O
kappa	O
B	O
-	O
binding	O
activity	O
that	O
enhances	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
transcription	O
in	O
vitro	O
and	O
facilitates	O
TAR	B
-	O
independent	O
transactivation	O
by	O
Tat	B
.	O

Tat	B
transactivation	O
mediated	O
by	O
the	O
kappa	B
B	I
domain	I
is	O
sufficient	O
to	O
allow	O
replication	O
of	O
TAR	B
-	O
deleted	O
mutant	O
HIV	O
-	O
1	O
in	O
astrocytes	O
.	O

For	O
one	O
of	O
these	O
proteins	O
,	O
p57	B
,	O
binding	O
to	O
the	O
IRES	B
correlates	O
with	O
translation	O
.	O

Retinoid	B
-	I
like	I
receptors	I
play	O
a	O
central	O
role	O
in	O
hormonal	O
responses	O
by	O
forming	O
heterodimers	B
with	O
other	O
nuclear	B
hormone	I
receptors	I
.	O

Hence	O
,	O
PPAR	B
can	O
positively	O
or	O
negatively	O
influence	O
TH	O
action	O
depending	O
on	O
TRE	B
structure	O
and	O
THR	B
isotype	I
.	O

Comparison	O
of	O
retinoic	O
acid	O
and	O
phorbol	O
myristate	O
acetate	O
as	O
inducers	O
of	O
monocytic	O
differentiation	O
.	O

Several	O
human	O
myeloid	O
leukemia	O
cell	O
lines	O
growing	O
in	O
vitro	O
can	O
be	O
induced	O
to	O
differentiate	O
to	O
more	O
mature	O
monocyte	O
/	O
macrophage	O
-	O
like	O
cells	O
by	O
treatment	O
with	O
protein	B
kinase	I
C	I
-	O
activating	O
phorbol	O
esters	O
,	O
such	O
as	O
PMA	O
.	O

Lymphoid	O
cells	O
transformed	O
by	O
Abelson	O
murine	O
leukemia	O
virus	O
have	O
provided	O
one	O
of	O
the	O
classic	O
models	O
for	O
study	O
of	O
early	O
B	O
-	O
cell	O
development	O
and	O
immunoglobulin	B
rearrangement	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
light	B
-	I
chain	I
gene	I
structure	I
was	O
examined	O
in	O
pre	O
-	O
B	O
cells	O
transformed	O
by	O
temperature	O
-	O
sensitive	O
mutants	O
of	O
the	O
Abelson	O
virus	O
and	O
in	O
derivatives	O
that	O
survive	O
at	O
the	O
nonpermissive	O
temperature	O
because	O
they	O
express	O
a	O
human	B
BCL	I
-	I
2	I
gene	I
.	O

Our	O
studies	O
reveal	O
that	O
inactivation	O
of	O
the	O
v	B
-	I
abl	I
protein	I
tyrosine	I
kinase	I
triggers	O
high	O
-	O
frequency	O
rearrangement	O
of	O
kappa	B
and	I
lambda	I
light	I
-	I
chain	I
genes	I
.	O

Expression	O
and	O
genomic	O
configuration	O
of	O
GM	B
-	I
CSF	I
,	O
IL	B
-	I
3	I
,	O
M	B
-	I
CSF	I
receptor	I
(	O
C	B
-	I
FMS	I
)	O
,	O
early	B
growth	I
response	I
gene	I
-	I
1	I
(	O
EGR	B
-	I
1	I
)	O
and	O
M	B
-	I
CSF	I
genes	I
in	O
primary	O
myelodysplastic	O
syndromes	O
.	O

The	O
expression	O
of	O
the	O
M	B
-	I
CSF	I
gene	I
,	O
that	O
has	O
been	O
recently	O
reassigned	O
to	O
the	O
short	B
arm	I
of	I
chromosome	I
1	I
(	O
lp	B
)	O
,	O
was	O
also	O
investigated	O
.	O

Similar	O
analysis	O
of	O
poly	B
(	I
A	I
)	I
RNA	I
from	O
a	O
variety	O
of	O
adult	O
tissues	O
demonstrated	O
HB9	B
transcripts	O
in	O
pancreas	O
,	O
small	O
intestine	O
,	O
and	O
colon	O
.	O

The	O
observed	O
increase	O
in	O
IL	B
-	I
2	I
levels	O
might	O
facilitate	O
virus	O
spread	O
from	O
or	O
to	O
T	O
cells	O
.	O

Recent	O
reports	O
demonstrated	O
that	O
ionizing	O
radiation	O
in	O
the	O
dose	O
range	O
of	O
2	O
-	O
50	O
Gy	O
results	O
in	O
expression	O
of	O
NF	B
-	I
kappa	I
B	I
in	O
human	O
KG	O
-	O
1	O
myeloid	O
leukemia	O
cells	O
and	O
human	O
B	O
-	O
lymphocyte	O
precursor	O
cells	O
;	O
the	O
precise	O
mechanism	O
involved	O
and	O
the	O
significance	O
are	O
not	O
yet	O
known	O
.	O

The	O
present	O
report	O
demonstrates	O
that	O
even	O
lower	O
doses	O
of	O
ionizing	O
radiation	O
,	O
0	O
.	O
25	O
-	O
2	O
.	O
0	O
Gy	O
,	O
are	O
capable	O
of	O
inducing	O
expression	O
of	O
NF	B
-	I
kappa	I
B	I
in	O
EBV	O
-	O
transformed	O
244B	O
human	O
lymphoblastoid	O
cells	O
.	O

The	O
expression	O
of	O
the	O
p50	B
and	I
p65	I
NF	I
-	I
kappa	I
B	I
subunits	I
was	O
also	O
shown	O
to	O
be	O
regulated	O
differentially	O
after	O
exposures	O
to	O
1	O
.	O
0	O
and	O
2	O
.	O
0	O
Gy	O
.	O

The	O
two	O
human	B
GATA3	I
zinc	I
fingers	I
are	O
encoded	O
by	O
two	O
separate	O
exons	B
highly	O
conserved	O
with	O
those	O
of	O
GATA1	B
,	O
but	O
no	O
other	O
structural	O
homologies	O
between	O
these	O
two	O
genes	O
can	O
be	O
found	O
.	O

The	O
human	B
and	I
mouse	I
GATA3	I
transcription	I
units	I
start	O
at	O
a	O
major	B
initiation	I
site	I
.	O

Retinoic	O
acid	O
-	O
induced	O
expression	O
of	O
CD38	B
antigen	I
in	O
myeloid	O
cells	O
is	O
mediated	O
through	O
retinoic	B
acid	I
receptor	I
-	I
alpha	I
.	O

CD38	B
is	O
a	O
leukocyte	B
differentiation	I
antigen	I
that	O
has	O
been	O
thought	O
to	O
be	O
a	O
phenotypic	O
marker	O
of	O
different	O
subpopulations	O
of	O
T	O
-	O
and	O
B	O
-	O
lymphocytes	O
.	O

In	O
myeloid	O
cells	O
,	O
CD38	B
is	O
expressed	O
during	O
early	O
stages	O
of	O
differentiation	O
.	O

Some	O
antioxidants	O
inhibit	O
,	O
in	O
a	O
co	O
-	O
ordinate	O
fashion	O
,	O
the	O
production	O
of	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
,	O
IL	B
-	I
beta	I
,	O
and	O
IL	B
-	I
6	I
by	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
.	O

Inhibition	O
of	O
cytokine	B
production	O
was	O
gene	O
selective	O
and	O
not	O
due	O
to	O
general	O
effects	O
on	O
protein	O
synthesis	O
.	O

Much	O
higher	O
concentrations	O
of	O
other	O
antioxidants	O
-	O
-	O
including	O
ascorbic	O
acid	O
,	O
trolox	O
,	O
alpha	O
-	O
tocopherol	O
,	O
butylated	O
hydroxytoluene	O
,	O
and	O
the	O
5	O
-	O
lipoxygenase	O
inhibitor	O
zileuton	O
-	O
-	O
did	O
not	O
affect	O
the	O
production	O
of	O
these	O
cytokines	B
.	O

Thus	O
antioxidants	O
vary	O
widely	O
in	O
potency	O
as	O
inhibitors	O
of	O
the	O
activation	O
of	O
transcription	B
factors	I
and	O
of	O
the	O
transcription	O
of	O
genes	B
for	O
pro	B
-	I
inflammatory	I
cytokines	I
.	O

This	O
protein	O
has	O
now	O
been	O
purified	O
and	O
its	O
encoding	O
gene	O
cloned	O
.	O

Examination	O
of	O
the	O
primary	O
amino	O
acid	O
sequence	O
of	O
this	O
protein	O
indicates	O
that	O
it	O
is	O
a	O
member	O
of	O
the	O
signal	B
transducers	I
and	I
activators	I
of	I
transcription	I
(	I
Stat	I
)	I
family	I
of	O
DNA	B
binding	I
proteins	I
,	O
hereby	O
designated	O
IL	B
-	I
4	I
Stat	I
.	O

Such	O
observations	O
indicate	O
that	O
IL	B
-	I
4	I
Stat	I
has	O
the	O
same	O
functional	B
domain	I
for	O
both	O
receptor	O
coupling	O
and	O
dimerization	O
.	O

Lung	O
disease	O
associated	O
with	O
disorders	O
such	O
as	O
cystic	O
fibrosis	O
(	O
CF	O
)	O
may	O
be	O
amenable	O
to	O
somatic	O
gene	O
therapy	O
in	O
which	O
there	O
is	O
delivery	O
of	O
the	O
normal	B
gene	I
directly	O
to	O
the	O
respiratory	O
epithelium	O
using	O
E1a	O
-	O
adenovirus	O
(	O
Ad	O
)	O
type	O
2	O
-	O
or	O
5	O
-	O
based	O
vectors	O
.	O

In	O
the	O
E1a	O
-	O
positive	O
samples	O
,	O
the	O
average	O
of	O
E1a	O
copy	O
number	O
was	O
55	O
+	O
/	O
-	O
18	O
/	O
10	O
(	O
3	O
)	O
recovered	O
cells	O
.	O

Tumor	O
cells	O
showed	O
an	O
overexpression	O
of	O
p53	B
protein	I
and	O
were	O
estrogen	B
receptor	I
-	O
positive	O
.	O

The	O
magnitude	O
and	O
time	O
kinetics	O
of	O
the	O
LIF	B
effects	O
were	O
similar	O
to	O
interleukin	B
1	I
(	O
IL	B
-	I
1	I
)	O
,	O
IL	B
-	I
6	I
,	O
and	O
tumor	B
necrosis	I
factor	I
(	O
TNF	B
)	O
,	O
other	O
cytokines	O
known	O
to	O
induce	O
HIV	O
replication	O
in	O
this	O
cell	O
line	O
.	O

To	O
characterize	O
mechanisms	O
responsible	O
for	O
these	O
LIF	B
effects	O
,	O
levels	O
of	O
HIV	B
mRNA	I
,	O
activation	O
of	O
the	O
DNA	B
binding	I
protein	I
nuclear	I
factor	I
(	B
NF	I
)	I
-	I
kB	I
,	O
signal	O
transduction	O
pathways	O
,	O
and	O
potential	O
interactions	O
with	O
other	O
cytokines	B
were	O
analyzed	O
.	O

In	O
both	O
cell	O
lines	O
LIF	B
increased	O
NF	B
-	I
kB	I
activity	O
.	O

Induction	O
of	O
NF	B
-	I
kB	I
and	O
HIV	O
replication	O
by	O
cytokines	B
are	O
at	O
least	O
in	O
part	O
dependent	O
on	O
reactive	O
oxygen	O
intermediates	O
.	O

The	O
mechanisms	O
involved	O
in	O
the	O
inhibition	O
of	O
growth	O
of	O
a	O
human	O
B	O
lymphoma	O
cell	O
line	O
,	O
B104	O
,	O
by	O
anti	B
-	I
MHC	I
class	I
II	I
antibodies	I
(	O
Ab	B
)	O
were	O
compared	O
with	O
those	O
in	O
anti	B
-	I
IgM	I
Ab	I
-	O
induced	O
B104	O
growth	O
inhibition	O
.	O

In	O
order	O
to	O
study	O
CD14	B
gene	I
regulation	O
,	O
the	O
human	B
CD14	I
gene	I
was	O
cloned	O
from	O
a	O
partial	O
EcoRI	B
digested	I
chromosome	I
5	I
library	I
.	O

Four	O
regions	O
in	O
this	O
DNA	B
fragment	I
interact	O
with	O
nuclear	B
proteins	I
isolated	O
from	O
monocytic	O
cells	O
.	O

The	O
Sp1	B
transcription	B
factor	I
bound	O
to	O
three	O
different	O
regions	O
in	O
the	O
CD14	B
promoter	I
.	O

Binding	O
data	O
were	O
derived	O
from	O
Scatchard	O
analysis	O
.	O

In	O
fertile	O
women	O
remarkable	O
changes	O
in	O
androgen	B
binding	I
sites	I
were	O
seen	O
in	O
the	O
course	O
of	O
the	O
menstrual	O
cycle	O
,	O
with	O
a	O
significant	O
increase	O
in	O
the	O
immediate	O
preovulatory	O
period	O
.	O

The	O
immunological	O
implications	O
of	O
these	O
results	O
are	O
discussed	O
.	O

Stimulation	O
of	O
the	O
CD28	B
cell	I
surface	I
molecule	I
delivers	O
costimulatory	O
signals	O
essential	O
for	O
lymphokine	B
production	O
in	O
activated	O
T	O
cells	O
via	O
a	O
conserved	B
sequence	I
element	I
found	O
in	O
the	O
promoter	B
of	O
several	O
lymphokine	B
genes	I
.	O

Diminished	O
glucocorticoid	B
receptors	I
do	O
not	O
result	O
in	O
glucocorticoid	O
resistance	O
.	O

Corticosteroid	B
Type	I
I	I
and	I
Type	I
II	I
receptors	I
are	O
inversely	O
correlated	O
with	O
age	O
.	O

All	O
-	O
trans	O
retinoic	O
acid	O
and	O
1	O
alpha	O
,	O
25	O
-	O
dihydroxyvitamin	O
D3	O
co	O
-	O
operate	O
to	O
promote	O
differentiation	O
of	O
the	O
human	O
promyeloid	O
leukemia	O
cell	O
line	O
HL60	O
to	O
monocytes	O
.	O

A	O
basis	O
for	O
differentiation	O
therapy	O
of	O
leukemias	O
is	O
provided	O
by	O
knowledge	O
of	O
agents	O
which	O
induce	O
specific	O
lineage	O
maturation	O
.	O

That	O
RA	O
promotes	O
both	O
neutrophil	O
and	O
monocyte	O
differentiation	O
has	O
implications	O
for	O
the	O
use	O
of	O
RA	O
and	O
D3	O
in	O
treatment	O
of	O
leukemias	O
and	O
provides	O
insight	O
into	O
mechanisms	O
whereby	O
RAR	O
,	O
VDR	B
and	O
RXR	B
facilitate	O
monocyte	O
differentiation	O
.	O

Thrombin	B
and	O
thrombin	B
receptor	I
agonist	O
peptide	O
induce	O
early	O
events	O
of	O
T	O
cell	O
activation	O
and	O
synergize	O
with	O
TCR	B
cross	O
-	O
linking	O
for	O
CD69	B
expression	O
and	O
interleukin	O
2	O
production	O
.	O

There	O
was	O
a	O
good	O
correlation	O
between	O
thrombin	B
-	O
induced	O
tyrosine	O
phosphorylation	O
of	O
the	O
latter	O
three	O
proteins	O
and	O
Ca2	O
+	O
mobilization	O
.	O

Stress	O
response	O
of	O
senescent	O
T	O
lymphocytes	O
:	O
reduced	O
hsp70	B
is	O
independent	O
of	O
the	O
proliferative	O
block	O
.	O

Senescent	O
human	O
T	O
lymphocyte	O
cultures	O
are	O
unable	O
to	O
undergo	O
proliferation	O
,	O
but	O
show	O
no	O
difference	O
from	O
early	O
passage	O
cells	O
in	O
cytotoxic	O
function	O
or	O
surface	O
antigenic	O
profile	O
.	O

Interestingly	O
,	O
the	O
progressive	O
decline	O
in	O
the	O
heat	O
shock	O
response	O
of	O
cultured	O
T	O
cells	O
correlates	O
with	O
the	O
percent	O
proliferative	O
life	O
span	O
completed	O
rather	O
than	O
with	O
the	O
actual	O
proliferative	O
activity	O
at	O
the	O
time	O
of	O
heat	O
shock	O
.	O

Wortmannin	O
,	O
an	O
inhibitor	O
of	O
receptor	O
-	O
coupled	O
PLD	B
activation	O
,	O
blocked	O
the	O
anti	B
-	I
CD3	I
-	O
induced	O
increases	O
in	O
both	O
PLD	B
activity	O
and	O
AP	B
-	I
1	I
enhancer	I
activity	O
.	O

We	O
found	O
a	O
good	O
correlation	O
in	O
the	O
transfected	O
cells	O
between	O
PLD	B
activation	O
and	O
induction	O
of	O
AP	B
-	I
1	I
enhancer	I
activity	O
under	O
different	O
experimental	O
conditions	O
.	O

We	O
therefore	O
reexamined	O
this	O
issue	O
by	O
using	O
two	O
different	O
experimental	O
approaches	O
that	O
allowed	O
LMP1	B
-	O
induced	O
effects	O
to	O
be	O
monitored	O
immediately	O
following	O
expression	O
of	O
the	O
viral	O
protein	O
and	O
in	O
the	O
absence	O
of	O
selective	O
pressures	O
;	O
activation	O
of	O
the	O
NF	B
-	I
kappa	I
B	I
transcription	B
factor	I
and	O
upregulation	O
of	O
the	O
cell	B
adhesion	I
molecule	I
ICAM	B
-	I
1	I
were	O
used	O
as	O
early	O
indices	O
of	O
LMP1	B
function	O
.	O

In	O
the	O
second	O
approach	O
,	O
we	O
tested	O
the	O
generality	O
of	O
this	O
phenomenon	O
by	O
transiently	O
expressing	O
LMP1	B
from	O
a	O
strong	O
constitutively	O
active	O
promoter	O
in	O
a	O
range	O
of	O
different	O
cell	O
types	O
.	O

In	O
the	O
same	O
experiments	O
,	O
all	O
three	O
non	O
-	O
B	O
-	O
cell	O
lines	O
showed	O
NF	B
-	I
kappa	I
B	I
activation	O
and	O
ICAM	B
-	I
1	I
upregulation	O
but	O
never	O
any	O
effect	O
upon	O
Bcl	B
-	I
2	I
.	O

We	O
found	O
that	O
tyrosine	B
kinase	I
activity	O
was	O
similar	O
for	O
both	O
mAbs	B
over	O
a	O
period	O
of	O
hours	O
.	O

However	O
,	O
the	O
inositol	O
phosphate	O
response	O
was	O
stronger	O
for	O
64	B
.	I
1	I
than	O
for	O
OKT3	B
.	O

To	O
tie	O
these	O
events	O
to	O
gene	O
activation	O
,	O
we	O
measured	O
NF	B
-	I
kappa	I
B	I
and	O
NF	B
-	I
AT	I
activity	O
in	O
the	O
nucleus	O
after	O
anti	B
-	I
CD3	I
stimulation	O
.	O

Both	O
stimuli	O
induced	O
the	O
appearance	O
of	O
the	O
NF	B
-	I
kappa	I
B	I
components	I
(	O
c	B
-	I
Rel	I
,	O
p65	B
(	O
RelA	B
)	O
,	O
and	O
p50	B
(	O
NF	B
-	I
kappa	I
B1	I
)	O
)	O
and	O
NF	B
-	I
kappa	I
B	I
DNA	O
binding	O
activity	O
in	O
the	O
nucleus	O
.	O

From	O
a	O
consecutive	O
series	O
of	O
350	O
cases	O
of	O
adult	O
de	O
novo	O
acute	O
myeloid	O
leukemia	O
(	O
AML	O
)	O
,	O
we	O
identified	O
20	O
cases	O
(	O
6	O
%	O
)	O
with	O
a	O
unique	O
immunophenotype	O
:	O
CD33	O
+	O
,	O
CD56	O
+	O
,	O
CD11a	O
+	O
,	O
CD13lo	O
,	O
CD15lo	O
,	O
CD34	O
+	O
/	O
-	O
,	O
HLA	B
-	I
DR	I
-	O
,	O
CD16	B
-	O
.	O

This	O
was	O
supported	O
by	O
the	O
observation	O
that	O
the	O
down	O
-	O
regulatory	O
capacity	O
of	O
IL	B
-	I
4	I
appeared	O
to	O
be	O
dependent	O
on	O
de	O
novo	O
protein	O
synthesis	O
.	O

Although	O
these	O
data	O
suggest	O
AP	B
-	I
1	I
regulated	O
cytokine	B
mRNA	O
expression	O
,	O
results	O
from	O
PBMo	O
are	O
not	O
in	O
accordance	O
with	O
this	O
notion	O
.	O

These	O
differences	O
may	O
represent	O
different	O
regulatory	O
pathways	O
of	O
the	O
two	O
cell	O
systems	O
.	O

Furthermore	O
,	O
the	O
present	O
results	O
demonstrate	O
clearly	O
that	O
mycoplasma	B
products	I
can	O
have	O
a	O
profound	O
impact	O
on	O
the	O
activation	O
status	O
of	O
eukaryotic	O
cells	O
.	O

Novel	B
membrane	I
receptors	I
for	O
aldosterone	O
in	O
human	O
lymphocytes	O
:	O
a	O
50	B
kDa	I
protein	I
on	O
SDS	O
-	O
PAGE	O
.	O

The	O
novel	O
aldosterone	O
membrane	O
receptor	O
was	O
analyzed	O
on	O
SDS	O
-	O
PAGE	O
after	O
labeling	O
of	O
microsomal	O
membranes	O
from	O
human	O
mononuclear	O
leukocytes	O
with	O
a	O
[	O
125I	O
]	O
-	O
aldosterone	O
-	O
derivative	O
by	O
use	O
of	O
BASED	O
as	O
a	O
photoactivatable	O
crosslinker	O
.	O

Binding	O
of	O
1	O
nM	O
[	O
125I	O
]	O
-	O
aldosterone	O
was	O
found	O
at	O
a	O
molecular	O
weight	O
of	O
approximately	O
50	O
kDa	O
which	O
was	O
absent	O
with	O
1	O
microM	O
cold	O
aldosterone	O
,	O
but	O
not	O
cortisol	O
in	O
the	O
binding	O
media	O
.	O

It	O
,	O
thus	O
,	O
appears	O
as	O
an	O
integral	B
membrane	I
protein	I
.	O

Analysis	O
of	O
the	O
chromatin	O
organization	O
of	O
the	O
integrated	O
human	B
immunodeficiency	I
virus	I
type	I
1	I
(	I
HIV	I
-	I
1	I
)	I
genome	I
has	O
previously	O
revealed	O
a	O
major	B
constitutive	I
DNase	I
I	I
-	I
hypersensitive	I
site	I
associated	O
with	O
the	O
pol	B
gene	I
(	O
E	O
.	O
Verdin	O
,	O
J	O
.	O
Virol	O
.	O
65	O
:	O
6790	O
-	O
6799	O
,	O
1991	O
)	O
.	O

Site	B
D	I
(	O
nt	B
4816	I
to	I
4851	I
)	O
specifically	O
bound	O
a	O
ubiquitously	B
expressed	I
factor	I
.	O

NF	B
-	I
kappa	I
B	I
is	O
a	O
rapidly	O
inducible	O
transcriptional	B
activator	I
that	O
responds	O
to	O
a	O
variety	O
of	O
signals	O
and	O
influences	O
the	O
expression	O
of	O
many	O
genes	O
involved	O
in	O
the	O
immune	O
response	O
.	O

Human	O
herpesvirus	O
6	O
(	O
HHV	O
-	O
6	O
)	O
is	O
a	O
lymphotropic	O
herpesvirus	O
,	O
and	O
in	O
vitro	O
,	O
it	O
can	O
productively	O
infect	O
human	O
CD4	O
+	O
T	O
cells	O
as	O
HIV	O
-	O
1	O
.	O

Sequence	O
analyses	O
show	O
that	O
this	O
protein	O
has	O
significant	O
homology	O
with	O
the	O
human	B
cytomegalovirus	I
UL44	I
gene	I
coding	O
for	O
the	O
ICP36	B
family	I
of	O
early	B
-	I
late	I
-	I
class	I
phosphoprotein	I
.	O

Sequence	O
analyses	O
of	O
pCD41	B
indicate	O
that	O
there	O
are	O
two	O
potential	O
open	B
reading	I
frames	I
(	O
ORFs	B
)	O
,	O
A	B
and	O
B	B
,	O
which	O
are	O
homologous	O
to	O
the	O
ORFs	B
found	O
in	O
the	O
genomic	O
clone	O
pGD41	B
.	O

CD14	B
-	O
mediated	O
translocation	O
of	O
nuclear	B
factor	I
-	I
kappa	I
B	I
induced	O
by	O
lipopolysaccharide	O
does	O
not	O
require	O
tyrosine	B
kinase	I
activity	O
.	O

Nuclear	O
translocation	O
of	O
cytosolic	O
NF	O
-	O
kappa	O
B	O
is	O
correlated	O
with	O
a	O
number	O
of	O
LPS	O
-	O
inducible	O
responses	O
.	O

LPS	O
-	O
stimulated	O
translocation	O
of	O
NF	B
-	I
kappa	I
B	I
in	O
CHO	O
/	O
CD14	O
cells	O
resembled	O
the	O
same	O
response	O
in	O
the	O
murine	O
macrophage	O
-	O
like	O
cell	O
line	O
RAW	O
264	O
.	O
7	O
.	O

The	O
stimulatory	O
effects	O
of	O
gp160	O
are	O
mediated	O
through	O
the	O
CD4	B
molecule	I
,	O
since	O
pretreatment	O
with	O
soluble	O
CD4	B
abrogates	O
its	O
activity	O
.	O

The	O
stimulatory	O
effect	O
of	O
gp160	O
on	O
NF	B
-	I
kappa	I
B	I
activation	O
is	O
protein	O
synthesis	O
independent	O
,	O
is	O
dependent	O
upon	O
protein	O
tyrosine	O
phosphorylation	O
,	O
and	O
abrogated	O
by	O
inhibitors	O
of	O
protein	B
kinase	I
C	I
.	O

No	O
evidence	O
for	O
the	O
expression	O
of	O
the	O
progesterone	B
receptor	I
on	O
peripheral	O
blood	O
lymphocytes	O
during	O
pregnancy	O
[	O
see	O
comments	O
]	O

A	O
role	O
for	O
the	O
progesterone	B
receptor	I
in	O
the	O
mechanism	O
of	O
the	O
known	O
effect	O
of	O
progesterone	O
on	O
peripheral	O
blood	O
lymphocytes	O
is	O
also	O
excluded	O
.	O

In	O
nuclear	O
run	O
-	O
on	O
analysis	O
,	O
such	O
tolerant	O
cells	O
show	O
only	O
a	O
low	O
degree	O
of	O
transcription	O
,	O
indicating	O
that	O
tolerance	O
operates	O
at	O
or	O
upstream	O
of	O
the	O
transcription	O
level	O
.	O

The	O
CD14	B
LPS	O
receptor	O
is	O
,	O
however	O
,	O
up	O
-	O
regulated	O
(	O
not	O
down	O
-	O
regulated	O
)	O
in	O
tolerant	O
cells	O
,	O
and	O
LPS	O
can	O
,	O
in	O
fact	O
,	O
still	O
lead	O
to	O
activation	O
of	O
tolerant	O
cells	O
as	O
evidenced	O
by	O
mobilization	O
of	O
the	O
transcription	B
factor	I
nuclear	B
factor	I
kappa	I
B	I
(	O
NF	B
-	I
kappa	I
B	I
)	O
.	O

Resolution	O
of	O
the	O
NF	B
-	I
kappa	I
B	I
complex	I
in	O
gel	O
shift	O
analysis	O
shows	O
that	O
the	O
binding	B
protein	I
,	O
mobilized	O
in	O
naive	O
Mono	O
Mac	O
6	O
cells	O
,	O
consists	O
mainly	O
of	O
p50	B
-	I
p65	I
heterodimers	I
,	O
while	O
in	O
tolerant	O
cells	O
,	O
the	O
p50	B
homodimer	I
is	O
predominant	O
.	O

This	O
increase	O
in	O
p50	B
homodimers	I
coincides	O
with	O
an	O
increase	O
in	O
p105	B
mRNA	I
,	O
suggestive	O
of	O
a	O
transcriptional	O
up	O
-	O
regulation	O
of	O
p50	B
.	O

Analysis	O
of	O
Oct2	B
-	I
isoform	I
expression	O
in	O
lipopolysaccharide	O
-	O
stimulated	O
B	O
lymphocytes	O
.	O

Oct2	B
-	I
isoform	I
expression	O
in	O
splenic	O
B	O
cells	O
stimulated	O
with	O
lipopolysaccharide	O
or	O
lipopolysaccharide	O
plus	O
phorbol	O
-	O
di	O
-	O
butyrate	O
was	O
analysed	O
by	O
cDNA	O
cloning	O
.	O

A	O
new	O
exon	B
containing	O
a	O
highly	O
basic	O
region	O
(	O
4c	O
)	O
was	O
characterized	O
,	O
between	B
exons	I
4	I
and	I
5	I
.	O

In	O
addition	O
,	O
a	O
new	O
combination	O
isoform	O
containing	O
Oct2a	B
'	I
s	I
amino	I
terminal	I
insert	I
(	O
exon	B
7a	I
)	O
and	O
Oct2b	B
'	I
s	I
carboxy	I
terminal	I
insert	I
(	O
exon	B
13	I
)	O
was	O
found	O
that	O
created	O
a	O
novel	O
large	O
isoform	O
,	O
Oct2ab	B
.	O

Positive	O
regulators	O
of	O
the	O
lineage	O
-	O
specific	O
transcription	B
factor	I
GATA	B
-	I
1	I
in	O
differentiating	O
erythroid	O
cells	O
.	O

Analyses	O
with	O
cultured	O
cells	O
and	O
cell	O
-	O
free	O
systems	O
have	O
provided	O
strong	O
evidence	O
that	O
GATA	B
-	I
1	I
is	O
involved	O
in	O
control	O
of	O
globin	B
gene	I
expression	O
during	O
erythroid	O
differentiation	O
.	O

The	O
role	O
of	O
the	O
human	B
immunodeficiency	I
virus	I
(	I
HIV	I
-	I
1	I
)	I
Nef	I
protein	I
in	O
T	O
cell	O
activation	O
pathways	O
was	O
investigated	O
using	O
a	O
Jurkat	O
CD4	O
+	O
cell	O
line	O
stably	O
transfected	O
with	O
a	O
Nef	O
expression	O
vector	O
.	O

The	O
response	O
of	O
mammalian	O
cells	O
to	O
stress	O
is	O
controlled	O
by	O
transcriptional	B
regulatory	I
proteins	I
such	O
as	O
nuclear	B
factor	I
kappa	I
B	I
(	O
NF	B
-	I
kappa	I
B	I
)	O
to	O
induce	O
a	O
wide	O
variety	O
of	O
early	B
response	I
genes	I
.	O

In	O
comparison	O
to	O
other	O
activators	O
of	O
NF	B
-	I
kappa	I
B	I
such	O
as	O
phorbol	O
myristate	O
acetate	O
or	O
tumor	B
necrosis	I
factor	I
,	O
we	O
did	O
not	O
detect	O
changes	O
in	O
the	O
tyrosine	O
phosphorylation	O
status	O
of	O
I	B
kappa	I
B	I
alpha	I
following	O
treatment	O
with	O
either	O
of	O
these	O
agents	O
.	O

Molecular	O
,	O
biochemical	O
and	O
epidemiological	O
evidence	O
implicate	O
HTLV	O
-	O
I	O
as	O
an	O
etiologic	O
agent	O
of	O
adult	O
T	O
cell	O
leukemia	O
(	O
ATL	O
)	O
.	O

Furthermore	O
,	O
the	O
NFKB2	B
precursor	O
is	O
physically	O
associated	O
with	O
c	B
-	I
Rel	I
and	O
with	O
Tax	B
in	O
HTLV	O
-	O
I	O
infected	O
cells	O
.	O

We	O
have	O
examined	O
the	O
effects	O
of	O
RA	O
on	O
normal	O
hematopoiesis	O
by	O
using	O
early	O
hematopoietic	O
progenitor	O
cells	O
(	O
HPC	O
)	O
stringently	O
purified	O
from	O
adult	O
peripheral	O
blood	O
.	O

This	O
phenomenon	O
is	O
correlated	O
with	O
inhibition	O
of	O
GATA1	B
induction	O
in	O
the	O
early	O
stages	O
of	O
erythropoietic	O
differentiation	O
.	O

We	O
have	O
previously	O
shown	O
that	O
a	O
human	O
B	O
lymphoma	O
cell	O
line	O
,	O
B104	O
,	O
expressed	O
surface	B
IgM	I
(	O
sIgM	B
)	O
and	O
surface	B
IgD	I
(	O
sIgD	B
)	O
,	O
and	O
that	O
crosslinking	O
of	O
sIgM	B
and	O
sIgD	B
by	O
anti	B
-	I
IgM	I
antibody	I
(	I
Ab	I
)	I
and	O
anti	B
-	I
IgD	I
Ab	I
,	O
respectively	O
,	O
induced	O
Ca2	O
+	O
influx	O
to	O
almost	O
the	O
same	O
degree	O
,	O
whereas	O
only	O
sIgM	B
-	O
crosslinking	O
caused	O
B104	O
cell	O
death	O
.	O

Phorbol	O
myristate	O
acetate	O
induced	O
Egr	B
-	I
1	I
mRNA	I
expression	O
but	O
forskolin	O
and	O
dibutyryl	O
cyclic	O
AMP	O
did	O
not	O
.	O

Treatment	O
of	O
human	O
erythrocytes	O
with	O
10	O
microM	O
sodium	O
orthovanadate	O
(	O
NaOV	O
)	O
,	O
an	O
inhibitor	O
of	O
plasma	B
membrane	I
Ca	I
-	I
ATPase	I
and	O
phosphotyrosine	B
phosphatase	I
,	O
decreased	O
parasitemia	O
by	O
30	O
%	O
.	O

Because	O
erythrocytes	O
are	O
anucleated	O
,	O
these	O
results	O
are	O
discussed	O
as	O
evidence	O
for	O
biochemical	O
changes	O
by	O
TCDD	O
without	O
requiring	O
the	O
activation	O
of	O
gene	B
products	I
.	O

Irrespective	O
of	O
the	O
human	O
cell	O
partner	O
used	O
for	O
fusion	O
,	O
a	O
certain	O
number	O
of	O
hybrids	O
lost	O
CD5	B
surface	O
expression	O
over	O
a	O
period	O
of	O
time	O
in	O
culture	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
indicate	O
that	O
MS	B
-	I
2beta	I
and	O
MS	B
-	I
2gamma	I
interact	O
with	O
nuclear	B
factors	I
that	O
are	O
induced	O
during	O
U937	O
differentiation	O
.	O

These	O
factors	O
are	O
detected	O
at	O
the	O
time	O
the	O
CD11b	B
promoter	I
is	O
activated	O
.	O

The	O
presence	O
of	O
multiple	O
potential	O
binding	O
sites	O
for	O
MS	B
-	I
2	I
in	O
the	O
promoter	O
regions	O
of	O
a	O
wide	O
range	O
of	O
genes	O
expressed	O
in	O
mature	O
myeloid	O
cells	O
suggests	O
this	O
factor	O
plays	O
a	O
general	O
role	O
in	O
myeloid	O
differentiation	O
.	O

Acetylsalicylic	O
acid	O
and	O
sodium	O
salicylate	O
inhibit	O
LPS	O
-	O
induced	O
NF	B
-	I
kappa	I
B	I
/	I
c	I
-	I
Rel	I
nuclear	O
translocation	O
,	O
and	O
synthesis	O
of	O
tissue	B
factor	I
(	O
TF	B
)	O
and	O
tumor	B
necrosis	I
factor	I
alfa	I
(	O
TNF	B
-	I
alpha	I
)	O
in	O
human	O
monocytes	O
.	O

Interferon	O
augments	O
PML	B
and	O
PML	B
/	I
RAR	I
alpha	I
expression	O
in	O
normal	O
myeloid	O
and	O
acute	O
promyelocytic	O
cells	O
and	O
cooperates	O
with	O
all	O
-	O
trans	O
retinoic	O
acid	O
to	O
induce	O
maturation	O
of	O
a	O
retinoid	O
-	O
resistant	O
promyelocytic	O
cell	O
line	O
.	O

PML	B
is	O
expressed	O
in	O
diverse	O
tissues	O
and	O
cell	O
lines	O
and	O
localized	O
in	O
the	O
nucleus	O
with	O
a	O
typical	O
speckled	O
pattern	O
.	O

Neutral	B
sphingomyelinase	I
(	O
SMase	B
)	O
can	O
be	O
activated	O
by	O
extracellular	O
signals	O
to	O
produce	O
ceramide	O
,	O
which	O
may	O
affect	O
mitogen	B
-	I
activated	I
protein	I
kinase	I
(	O
MAPK	B
)	O
activities	O
.	O

PMA	O
acted	O
synergistically	O
with	O
ionomycin	O
to	O
activate	O
JNK	B
MAPKs	I
in	O
Jurkat	O
and	O
EL4	O
within	O
10	O
minutes	O
.	O

Ara	O
-	O
C	O
activated	O
JNKs	B
only	O
after	O
prolonged	O
incubation	O
(	O
90	O
-	O
120	O
minutes	O
)	O
.	O

The	O
transmembrane	O
domains	O
are	O
well	O
conserved	O
,	O
but	O
there	O
is	O
striking	O
sequence	O
divergence	O
of	O
the	O
carboxy	B
-	I
terminal	I
cytoplasmic	I
domain	I
essential	O
for	O
B	O
-	O
cell	O
immortalization	O
and	O
interaction	O
with	O
the	O
tumor	B
necrosis	I
factor	I
receptor	I
signaling	O
pathway	O
.	O

Distinct	O
patterns	O
of	O
chromosome	B
1	I
abnormalities	O
were	O
found	O
among	O
the	O
histologic	O
types	O
of	O
breast	O
carcinoma	O
.	O

These	O
results	O
indicate	O
the	O
utility	O
of	O
this	O
FISH	O
technique	O
for	O
a	O
better	O
definition	O
of	O
the	O
biological	O
characteristics	O
of	O
ductal	O
carcinomas	O
.	O

Increased	O
proliferation	O
,	O
cytotoxicity	O
,	O
and	O
gene	O
expression	O
after	O
stimulation	O
of	O
human	O
peripheral	O
blood	O
T	O
lymphocytes	O
through	O
a	O
surface	O
ganglioside	O
(	O
GD3	O
)	O
[	O
published	O
erratum	O
appears	O
in	O
J	O
Immunol	O
1994	O
Jul	O
15	O
;	O
153	O
(	O
2	O
)	O
:	O
910	O
]	O

However	O
,	O
their	O
specific	O
function	O
in	O
these	O
processes	O
has	O
not	O
been	O
clearly	O
defined	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
investigated	O
the	O
mechanisms	O
by	O
which	O
the	O
R24	B
mAb	I
affects	O
T	O
cell	O
functions	O
.	O

We	O
have	O
observed	O
that	O
the	O
R24	B
mAb	I
stimulates	O
GD3	O
+	O
T	O
cell	O
proliferation	O
,	O
cytotoxicity	O
,	O
and	O
surface	O
marker	O
expression	O
of	O
IL	B
-	I
2R	I
alpha	I
-	I
chain	I
,	O
IL	B
-	I
2R	I
beta	I
-	I
chain	I
,	O
HLA	B
-	I
DR	I
,	O
CD11a	B
,	O
and	O
CD11c	B
.	O

R24	B
-	O
stimulated	O
increases	O
in	O
proliferation	O
,	O
cytotoxicity	O
,	O
and	O
cell	O
surface	O
protein	O
expression	O
could	O
be	O
blocked	O
by	O
cyclosporin	O
and	O
staurosporin	O
,	O
indicating	O
that	O
cyclophilin	B
/	I
calcineurin	I
and	O
protein	B
kinase	I
C	I
may	O
be	O
involved	O
in	O
the	O
R24	B
signaling	O
pathway	O
.	O

Additionally	O
,	O
herbimycin	O
A	O
,	O
a	O
tyrosine	B
kinase	I
inhibitor	O
,	O
blocked	O
the	O
R24	B
-	O
stimulated	O
increase	O
in	O
proliferation	O
but	O
not	O
cytotoxicity	O
at	O
concentrations	O
consistent	O
with	O
specificity	O
for	O
tyrosine	B
kinases	I
.	O

Using	O
fluorescence	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
,	O
we	O
show	O
here	O
that	O
the	O
genes	B
encoding	O
the	O
TATA	B
-	I
box	I
binding	I
protein	I
(	O
TBP	B
)	O
,	O
TFIIB	B
,	O
TFIIE	B
alpha	I
,	O
TFIIE	B
beta	I
,	O
RAP30	B
,	O
RAP74	B
and	O
the	O
62	B
kDa	I
subunit	I
,	O
of	O
TFIIH	B
are	O
located	O
at	O
the	O
human	B
chromosomal	I
bands	I
6q26	I
-	I
27	I
,	I
1p21	I
-	I
22	I
,	I
3q21	I
-	I
24	I
,	I
8p12	I
,	I
13q14	I
,	I
19p13	I
.	I
3	I
and	I
11p14	I
-	I
15	I
.	I
1	I
,	O
respectively	O
.	O

Although	O
no	O
proof	O
yet	O
exists	O
of	O
a	O
role	O
for	O
these	O
lesions	O
in	O
DLCL	O
pathogenesis	O
,	O
the	O
feature	O
of	O
the	O
BCL	B
-	I
6	I
gene	I
product	I
,	O
its	O
specific	O
pattern	O
of	O
expression	O
in	O
B	O
cells	O
,	O
and	O
the	O
clustering	O
of	O
lesions	O
disrupting	O
its	O
regulatory	O
domain	O
strongly	O
suggest	O
that	O
deregulation	O
of	O
BCL	B
-	I
6	I
expression	O
may	O
contribute	O
to	O
DLCL	O
development	O
.	O

DLCL	O
represent	O
a	O
heterogeneous	O
group	O
of	O
neoplasms	O
which	O
are	O
treated	O
homogeneously	O
despite	O
the	O
fact	O
that	O
only	O
50	O
%	O
of	O
patients	O
experience	O
long	O
-	O
term	O
disease	O
-	O
free	O
survival	O
(	O
Schneider	O
et	O
al	O
.	O
1990	O
)	O
.	O

It	O
is	O
thus	O
generally	O
believed	O
that	O
the	O
pancreatic	O
endocrine	O
-	O
lineage	O
possesses	O
the	O
ability	O
to	O
mature	O
along	O
a	O
differentiation	O
pathway	O
that	O
shares	O
many	O
characteristics	O
with	O
those	O
of	O
neuronal	O
differentiation	O
.	O

Octamer	O
independent	O
activation	O
of	O
transcription	O
from	O
the	O
kappa	B
immunoglobulin	I
germline	I
promoter	I
.	O

To	O
further	O
elucidate	O
the	O
role	O
of	O
this	O
variant	O
octamer	B
motif	I
in	O
the	O
regulation	O
of	O
germline	B
transcription	O
from	O
the	O
unrearranged	O
kappa	B
locus	I
,	O
we	O
have	O
quantitated	O
the	O
relative	O
binding	O
affinity	O
of	O
Oct	B
-	I
1	I
and	O
Oct	B
-	I
2	I
for	O
the	O
variant	O
octamer	B
motif	I
and	O
determined	O
the	O
functional	O
role	O
of	O
this	O
octamer	B
motif	I
in	O
transcriptional	O
activation	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
showed	O
that	O
CD14	O
+	O
adherent	O
human	O
monocytes	O
can	O
differentiate	O
into	O
CD1	O
+	O
relB	O
+	O
dendritic	O
cells	O
(	O
DC	O
)	O
by	O
the	O
combination	O
of	O
GM	B
-	I
CSF	I
plus	O
interleukin	B
-	I
4	I
(	O
IL	B
-	I
4	I
)	O
and	O
that	O
they	O
differentiate	O
into	O
tartrate	O
-	O
resistant	O
acid	O
phosphatase	O
(	O
TRAP	O
)	O
-	O
positive	O
osteoclast	O
-	O
like	O
multinucleated	O
giant	O
cells	O
(	O
MGC	O
)	O
by	O
the	O
combination	O
of	O
M	B
-	I
CSF	I
plus	O
IL	B
-	I
4	I
.	O

The	O
mechanism	O
of	O
inhibition	O
is	O
related	O
to	O
the	O
surface	O
expression	O
of	O
several	O
cell	O
adhesion	B
molecules	I
.	O

Flow	O
cytometry	O
analyses	O
on	O
cultured	O
cells	O
that	O
were	O
treated	O
with	O
tepoxalin	O
or	O
antisense	O
oligonucleotides	O
to	O
the	O
P65	B
/	I
p50	I
subunit	I
of	O
NF	B
-	I
kappa	I
B	I
,	O
and	O
then	O
stimulated	O
with	O
PMA	O
,	O
revealed	O
a	O
reduced	O
expression	O
of	O
CD11b	B
/	I
CD18	I
on	O
monocytic	O
HL60	O
cells	O
,	O
and	O
endothelial	B
adhesion	I
molecule	I
-	I
1	I
(	O
CD62E	B
)	O
and	O
vascular	B
adhesion	I
molecule	I
-	I
1	I
(	O
CD106	B
)	O
on	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
.	O

Tepoxalin	O
also	O
inhibited	O
the	O
secretion	O
of	O
a	O
NF	B
-	I
kappa	I
B	I
regulated	I
chemokine	I
,	O
IL	B
-	I
8	I
,	O
a	O
known	O
inducer	O
of	O
CD11b	B
/	I
CD18	I
expression	O
.	O

Thus	O
the	O
suppression	O
of	O
CD11b	B
/	I
CD18	I
expression	O
by	O
tepoxalin	O
may	O
involve	O
IL	B
-	I
8	I
.	O

Characterization	O
of	O
a	O
CD43	B
/	I
leukosialin	I
-	O
mediated	O
pathway	O
for	O
inducing	O
apoptosis	O
in	O
human	O
T	O
-	O
lymphoblastoid	O
cells	O
.	O

The	O
monoclonal	B
antibody	I
(	O
mAb	B
)	O
J393	B
induces	O
apoptosis	O
in	O
Jurkat	O
T	O
-	O
cells	O
.	O

NH2	B
-	O
terminal	O
amino	O
acid	O
sequence	O
analysis	O
identified	O
the	O
140	B
-	I
kDa	I
surface	I
antigen	I
for	O
mAb	B
J393	I
as	O
CD43	B
/	I
leukosialin	I
,	O
the	O
major	O
sialoglycoprotein	B
of	O
leukocytes	O
.	O

While	O
Jurkat	O
cells	O
co	O
-	O
expressed	O
two	O
discrete	O
cell	B
-	I
surface	I
isoforms	I
of	O
CD43	B
,	O
recognized	O
by	O
mAb	B
J393	I
and	O
mAb	B
G10	I
-	I
2	I
,	O
respectively	O
,	O
only	O
J393	B
/	I
CD43	I
signaled	O
apoptosis	O
.	O

Tyrosine	B
kinase	I
inhibition	O
by	O
herbimycin	O
A	O
diminished	O
J393	B
/	I
CD43	I
-	O
mediated	O
apoptosis	O
,	O
whereas	O
inhibition	O
of	O
phosphotyrosine	B
phosphatase	I
activity	O
by	O
bis	O
(	O
maltolato	O
)	O
oxovanadium	O
-	O
IV	O
enhanced	O
cell	O
death	O
.	O

Consequently	O
,	O
the	O
present	O
study	O
was	O
addressed	O
to	O
understand	O
this	O
phenomenon	O
and	O
revealed	O
the	O
existence	O
of	O
a	O
unique	B
47	I
kDa	I
protein	I
factor	I
having	O
affinity	O
for	O
this	O
SRE	B
sequence	I
in	O
lymphocytes	O
from	O
normal	O
subjects	O
as	O
well	O
as	O
its	O
absence	O
in	O
lymphocytes	O
from	O
untreated	O
CML	O
patients	O
.	O

To	O
understand	O
the	O
mechanism	O
by	O
which	O
PRL	B
regulates	O
the	O
biphasic	O
expression	O
of	O
IRF	B
-	I
1	I
,	O
we	O
cloned	O
the	O
rat	B
IRF	I
-	I
1	I
gene	I
and	O
functionally	O
characterized	O
the	O
IRF	B
-	I
1	I
promoter	I
.	O

Hence	O
,	O
the	O
PRL	B
-	O
induced	O
biphasic	O
expression	O
of	O
the	O
IRF	B
-	I
1	I
gene	I
appears	O
to	O
be	O
controlled	O
by	O
separate	O
PRL	B
-	I
responsive	I
elements	I
:	O
elements	O
in	O
the	O
first	O
0	O
.	O
2	O
kb	O
of	O
the	O
IRF	B
-	I
1	I
promoter	I
region	I
act	O
during	O
early	O
activation	O
,	O
and	O
elements	O
between	O
0	O
.	O
2	O
and	O
1	O
.	O
7	O
kb	O
act	O
in	O
concert	O
with	O
the	O
proximal	O
0	O
.	O
2	O
-	O
kb	O
region	O
during	O
S	O
phase	O
progression	O
.	O

The	O
SCL	B
protein	I
displays	O
cell	O
-	O
specific	O
heterogeneity	O
in	O
size	O
.	O

In	O
most	O
cell	O
lines	O
,	O
proteins	O
of	O
molecular	O
weight	O
49	O
and	O
44	O
kDa	O
were	O
found	O
,	O
however	O
two	O
myeloid	O
cell	O
lines	O
expressed	O
only	O
lower	O
molecular	B
weight	I
species	I
of	I
24	I
and	I
22	I
kDa	I
.	O

The	O
restricted	O
pattern	O
of	O
SCL	B
protein	I
synthesis	O
is	O
consistent	O
with	O
the	O
restricted	O
expression	O
of	O
SCL	B
mRNA	I
documented	O
previously	O
.	O

This	O
effect	O
required	O
surface	O
expression	O
of	O
the	O
CD45	B
PTPase	I
and	O
was	O
not	O
observed	O
in	O
CD45	O
-	O
deficient	O
variants	O
of	O
Jurkat	O
cells	O
.	O

Pervanadate	B
activated	I
NF	I
-	I
kappa	I
B	I
,	O
as	O
shown	O
by	O
an	O
increase	O
in	O
DNA	O
-	O
binding	O
activity	O
of	O
this	O
transcription	B
factor	I
.	O

Signals	O
transduced	O
via	O
the	O
TCR	B
activate	O
the	O
transcription	B
factor	I
nuclear	B
factor	I
-	I
kappaB	I
(	O
NF	B
-	I
kappaB	I
)	O
,	O
which	O
,	O
in	O
turn	O
,	O
is	O
critical	O
to	O
the	O
transcriptional	O
induction	O
of	O
many	O
genes	O
important	O
for	O
the	O
proliferation	O
and	O
expression	O
of	O
a	O
differentiated	O
phenotype	O
.	O

Here	O
we	O
identify	O
intracellular	O
signaling	O
components	O
involved	O
in	O
activation	O
of	O
NF	B
-	I
kappaB	I
following	O
TCR	B
stimulation	O
.	O

We	O
have	O
shown	O
elsewhere	O
that	O
both	O
the	O
major	B
immediate	I
-	I
early	I
gene	I
(	O
MIE	B
)	O
and	O
lytic	O
cycle	O
infectious	O
progeny	O
virus	O
expression	O
can	O
be	O
induced	O
in	O
otherwise	O
nonpermissive	O
monocyte	O
-	O
like	O
U	O
-	O
937	O
cell	O
cultures	O
infected	O
with	O
either	O
human	O
CMV	O
(	O
HCMV	O
)	O
or	O
simian	O
CMV	O
(	O
SCMV	O
)	O
by	O
treatment	O
with	O
the	O
phorbol	O
ester	O
12	O
-	O
O	O
-	O
tetradecanoylphorbol	O
-	O
13	O
-	O
acetate	O
(	O
TPA	O
)	O
.	O

Therefore	O
,	O
to	O
evaluate	O
the	O
mechanism	O
of	O
TPA	O
responsiveness	O
of	O
the	O
SNE	B
motifs	I
and	O
of	O
a	O
related	O
16	O
-	O
bp	O
SEE	B
(	O
SRF	B
/	I
ETS	I
element	I
)	O
motif	O
found	O
in	O
the	O
HCMV	B
and	I
chimpanzee	I
CMV	I
MIE	I
enhancers	I
,	O
we	O
have	O
examined	O
the	O
functional	O
responses	O
and	O
protein	O
binding	O
properties	O
of	O
multimerized	B
wild	I
-	I
type	I
and	I
mutant	I
elements	I
added	O
upstream	O
to	O
the	O
SCMV	B
MIE	I
or	O
simian	B
virus	I
40	I
minimal	I
promoter	I
regions	I
in	O
the	O
U	O
-	O
937	O
,	O
K	O
-	O
562	O
,	O
HL	O
-	O
60	O
,	O
THP	O
-	O
1	O
,	O
and	O
Jurkat	O
cell	O
lines	O
.	O

T	O
-	O
cell	O
-	O
directed	O
TAL	B
-	I
1	I
expression	O
induces	O
T	O
-	O
cell	O
malignancies	O
in	O
transgenic	O
mice	O
.	O

The	O
survival	O
rate	O
of	O
tal	B
-	I
1	I
transgenic	O
animals	O
was	O
much	O
lower	O
as	O
compared	O
with	O
control	O
mice	O
.	O

To	O
further	O
unravel	O
the	O
tal	B
-	I
1	I
oncogenic	O
potential	O
,	O
a	O
strain	O
of	O
tal	B
-	I
1	I
transgenic	O
mice	O
was	O
crossbred	O
with	O
p53	O
-	O
/	O
-	O
mice	O
;	O
the	O
survival	O
rate	O
in	O
these	O
animals	O
was	O
reduced	O
by	O
more	O
than	O
one	O
-	O
half	O
when	O
compared	O
with	O
that	O
of	O
tal	B
-	I
1	I
mice	O
,	O
and	O
histopathological	O
analysis	O
revealed	O
exclusively	O
T	O
-	O
cell	O
lymphomas	O
.	O

TSC2	B
is	O
a	O
gene	O
on	O
chromosome	B
16p13	I
.	I
3	I
associated	O
with	O
the	O
autosomal	O
dominant	O
neurocutaneous	O
disorder	O
,	O
tuberous	O
sclerosis	O
complex	O
(	O
TSC	O
)	O
.	O

TSC2	B
messenger	I
RNA	I
was	O
widely	O
expressed	O
in	O
various	O
cell	O
types	O
throughout	O
the	O
body	O
,	O
including	O
epithelia	O
,	O
lymphocytes	O
,	O
and	O
cells	O
with	O
endocrine	O
functions	O
,	O
e	O
.	O
g	O
.	O
,	O
adrenal	O
cortex	O
and	O
anterior	O
pituitary	O
.	O

Fas	B
-	O
mediated	O
apoptosis	O
plays	O
an	O
important	O
role	O
in	O
regulating	O
the	O
immune	O
response	O
in	O
peripheral	O
T	O
cells	O
.	O

In	O
contrast	O
,	O
interleukin	O
-	O
1beta	O
-	O
converting	O
enzyme	O
family	O
protease	O
inhibitors	O
Ac	O
-	O
DEVD	O
-	O
CHO	O
and	O
CrmA	O
blocked	O
Fas	B
-	O
mediated	O
apoptosis	O
.	O

These	O
results	O
suggest	O
that	O
peripheral	O
T	O
cells	O
use	O
distinct	O
apoptosis	O
signaling	O
pathways	O
with	O
differential	O
sensitivity	O
to	O
Bcl	B
-	I
2	I
and	O
interleukin	O
-	O
1beta	O
-	O
converting	O
enzyme	O
family	O
protease	O
inhibitors	O
.	O

However	O
,	O
in	O
contrast	O
to	O
human	O
lymphocytes	O
,	O
IFN	B
-	I
gamma	I
production	O
was	O
inhibited	O
and	O
IFN	B
-	I
gamma	I
mRNA	I
levels	O
were	O
unaffected	O
at	O
24	O
h	O
and	O
only	O
slightly	O
upregulated	O
at	O
48	O
and	O
72	O
h	O
of	O
culture	O
in	O
murine	O
splenocytes	O
incubated	O
with	O
cipro	O
(	O
20	O
micrograms	O
/	O
ml	O
)	O
.	O

Cipro	O
did	O
not	O
affect	O
the	O
nuclear	B
transcription	I
factors	I
AP	B
-	I
1	I
or	O
NFIL	B
-	I
2A	I
.	O

An	O
additional	O
distinguishing	O
characteristic	O
of	O
HTLV	O
-	O
I	O
infection	O
is	O
the	O
profound	O
state	O
of	O
viral	O
latency	O
that	O
is	O
present	O
in	O
circulating	O
primary	O
leukemic	O
T	O
cells	O
.	O

Furthermore	O
,	O
the	O
physical	O
interaction	O
of	O
Tax	B
with	O
p100	B
leads	O
to	O
the	O
inhibition	O
of	O
Tax	B
-	O
induced	O
activation	O
of	O
the	O
HTLV	O
-	O
I	O
and	O
human	B
immunodeficiency	I
virus	I
type	I
1	I
long	I
terminal	I
repeats	I
,	O
reflecting	O
p100	B
-	O
mediated	O
cytoplasmic	O
sequestration	O
of	O
the	O
normally	O
nuclearly	O
expressed	O
Tax	B
protein	I
.	O

Selection	O
against	O
such	O
mutations	O
may	O
be	O
the	O
result	O
of	O
functional	O
redundancy	O
of	O
these	O
myogenic	B
transcription	I
factors	I
.	O

In	O
vertebrates	O
,	O
five	O
distinct	O
DNA	B
binding	I
subunits	I
are	O
currently	O
known	O
which	O
might	O
extensively	O
heterodimerize	O
,	O
thereby	O
forming	O
complexes	O
with	O
distinct	O
transcriptional	O
activity	O
,	O
DNA	O
sequence	O
specificity	O
,	O
and	O
cell	O
type	O
-	O
and	O
cell	O
stage	O
-	O
specific	O
distribution	O
.	O

Other	O
I	B
kappa	I
B	I
proteins	I
are	O
rather	O
involved	O
in	O
terminating	O
NF	B
-	I
kappa	I
B	I
'	O
s	O
activity	O
in	O
the	O
nucleus	O
.	O

The	O
intracellular	O
events	O
that	O
lead	O
to	O
the	O
inactivation	O
of	O
I	B
kappa	I
B	I
,	O
i	O
.	O
e	O
.	O
the	O
activation	O
of	O
NF	B
-	I
kappa	I
B	I
,	O
are	O
complex	O
.	O

In	O
previous	O
studies	O
,	O
it	O
was	O
shown	O
that	O
the	O
fusion	O
region	O
of	O
the	O
pml	B
/	I
RAR	I
-	I
alpha	I
protein	I
,	O
expressed	O
by	O
acute	O
promyelocytic	O
leukemia	O
(	O
APL	O
)	O
cells	O
,	O
can	O
be	O
specifically	O
recognized	O
in	O
vitro	O
by	O
donor	O
(	O
D	O
.	O
E	O
.	O
)	O
CD4	O
T	O
cells	O
in	O
a	O
HLA	B
class	I
II	I
DR11	O
-	O
restricted	O
fashion	O
.	O

We	O
present	O
here	O
the	O
results	O
on	O
the	O
recognition	O
of	O
several	O
pml	O
/	O
RAR	O
-	O
alpha	O
peptides	O
by	O
APL	O
patients	O
expressing	O
HLA	B
DR11	I
.	O

These	O
clones	O
were	O
tested	O
for	O
their	O
recognition	O
of	O
BCR1	O
/	O
25	O
.	O

APL	O
blasts	O
,	O
available	O
only	O
from	O
patients	O
F	O
.	O
R	O
.	O
and	O
P	O
.	O
G	O
.	O
,	O
were	O
not	O
lysed	O
by	O
C3	O
/	O
5	O
and	O
were	O
unable	O
to	O
present	O
peptide	O
BCR1	O
/	O
25	O
.	O

No	O
peptide	O
-	O
specific	O
T	O
-	O
cell	O
line	O
or	O
clone	O
could	O
be	O
generated	O
from	O
both	O
donors	O
and	O
patients	O
.	O

Interferon	B
-	I
gamma	I
(	O
IFN	B
-	I
gamma	I
)	O
is	O
produced	O
by	O
natural	O
killer	O
cells	O
and	O
certain	O
subsets	O
of	O
T	O
cells	O
,	O
but	O
the	O
basis	O
for	O
its	O
selective	O
expression	O
is	O
unknown	O
.	O

The	O
proximal	O
element	O
is	O
a	O
composite	O
site	O
that	O
binds	O
members	O
of	O
the	O
CREB	B
/	I
ATF	I
,	O
AP	B
-	I
1	I
,	O
and	O
octamer	B
families	I
of	O
transcription	B
factors	I
.	O

S107	O
plasmacytoma	O
cells	O
,	O
which	O
express	O
CD40	B
but	O
are	O
defective	O
for	O
the	O
nuclear	O
appearance	O
of	O
p50	B
/	I
p65	I
-	I
NF	I
-	I
kappaB	I
,	O
do	O
not	O
express	O
RelB	B
after	O
CD40	B
stimulation	O
.	O

The	O
nuclear	O
body	O
(	O
NB	O
)	O
is	O
a	O
cellular	O
organelle	O
that	O
is	O
involved	O
in	O
the	O
pathogenesis	O
of	O
acute	O
promyelocytic	O
leukemia	O
and	O
viral	O
infection	O
.	O

The	O
predicted	O
amino	O
acid	O
sequence	O
of	O
the	O
amino	B
-	I
terminal	I
portion	I
of	O
Sp140	B
was	O
similar	O
to	O
Sp100	B
,	O
a	O
previously	O
identified	O
NB	B
protein	I
.	O

B	O
lymphocyte	O
stimulation	O
via	O
both	O
CD40	B
and	O
surface	B
Ig	I
(	I
sIg	I
)	I
receptors	I
substantially	O
induced	O
fra	B
-	I
1	I
expression	O
,	O
and	O
for	O
both	O
receptors	O
,	O
induction	O
was	O
protein	B
kinase	I
C	I
(	O
PKC	B
)	O
dependent	O
.	O

Induction	O
of	O
fra	B
-	I
1	I
following	O
engagement	O
of	O
CD40	B
did	O
not	O
require	O
protein	O
synthesis	O
,	O
suggesting	O
that	O
the	O
PKC	B
-	O
dependent	O
linkage	O
between	O
CD40	B
and	O
fra	B
-	I
1	I
is	O
direct	O
.	O

Pentoxifylline	O
for	O
the	O
treatment	O
of	O
infection	O
with	O
human	O
immunodeficiency	O
virus	O
.	O

Cytokine	O
dysregulation	O
in	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
infection	O
has	O
been	O
documented	O
in	O
numerous	O
studies	O
and	O
has	O
been	O
cited	O
as	O
an	O
important	O
component	O
in	O
the	O
pathogenesis	O
of	O
this	O
retroviral	O
infection	O
.	O

Pentoxifylline	O
,	O
a	O
trisubstituted	O
xanthine	O
derivative	O
,	O
has	O
been	O
used	O
to	O
decrease	O
blood	O
viscosity	O
and	O
is	O
reasonably	O
well	O
tolerated	O
by	O
most	O
recipients	O
of	O
the	O
drug	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

The	O
other	O
two	O
SR	O
patients	O
had	O
an	O
abnormally	O
low	O
GR	B
number	O
with	O
normal	O
binding	O
affinity	O
that	O
was	O
not	O
limited	O
to	O
T	O
cells	O
.	O

This	O
may	O
be	O
due	O
to	O
the	O
low	O
prevalence	O
of	O
overexpressed	O
ER	B
and	O
the	O
small	O
number	O
of	O
controls	O
.	O

A	O
large	O
prospective	O
trial	O
is	O
needed	O
to	O
determine	O
if	O
one	O
or	O
more	O
of	O
these	O
biomarkers	O
,	O
is	O
predictive	O
of	O
breast	O
cancer	O
development	O
.	O

Inhibition	O
of	O
RANTES	B
expression	O
did	O
not	O
appear	O
to	O
be	O
secondary	O
to	O
IL	B
-	I
2	I
inhibition	O
and	O
required	O
binding	O
to	O
the	O
intracellular	O
glucocorticoid	B
receptor	I
.	O

Association	O
of	O
TRAF1	B
,	O
TRAF2	B
,	O
and	O
TRAF3	B
with	O
an	O
Epstein	B
-	I
Barr	I
virus	I
LMP1	I
domain	I
important	O
for	O
B	O
-	O
lymphocyte	O
transformation	O
:	O
role	O
in	O
NF	B
-	I
kappaB	I
activation	O
.	O

The	O
Epstein	B
-	I
Barr	I
virus	I
(	I
EBV	I
)	I
transforming	I
protein	I
LMP1	I
appears	O
to	O
be	O
a	O
constitutively	B
activated	I
tumor	I
necrosis	I
factor	I
receptor	I
(	O
TNFR	B
)	O
on	O
the	O
basis	O
of	O
an	O
intrinsic	O
ability	O
to	O
aggregate	O
in	O
the	O
plasma	O
membrane	O
and	O
an	O
association	O
of	O
its	O
cytoplasmic	B
carboxyl	I
terminus	I
(	O
CT	B
)	O
with	O
TNFR	B
-	I
associated	I
factors	I
(	O
TRAFs	B
)	O
.	O

TRAF1	B
,	O
TRAF2	B
,	O
and	O
TRAF3	B
bind	O
to	O
a	O
single	O
site	O
in	O
the	O
LMP1	B
CT	I
corresponding	O
to	O
amino	O
acids	O
(	O
aa	O
)	O
199	O
to	O
214	O
,	O
within	O
a	O
domain	O
which	O
is	O
important	O
for	O
B	O
-	O
lymphocyte	O
growth	O
transformation	O
(	O
aa	O
187	O
to	O
231	O
)	O
.	O

NF	B
-	I
kappaB	I
activation	O
by	O
LMP1	B
(	O
1	O
-	O
231	O
)	O
is	O
likely	O
to	O
be	O
mediated	O
by	O
TRAF1	B
/	B
TRAF2	I
heteroaggregates	O
since	O
TRAF1	B
is	O
unique	O
among	O
the	O
TRAFs	B
in	O
coactivating	O
NF	B
-	I
kappaB	I
with	O
LMP1	B
(	O
1	O
-	O
231	O
)	O
,	O
a	O
TRAF2	B
dominant	O
-	O
negative	O
mutant	O
can	O
block	O
LMP1	B
(	O
1	O
-	O
231	O
)	O
-	O
mediated	O
NF	B
-	I
kappaB	I
activation	O
as	O
well	O
as	O
TRAF1	B
coactivation	O
,	O
and	O
30	O
%	O
of	O
TRAF2	B
is	O
associated	O
with	O
TRAF1	B
in	O
EBV	O
-	O
transformed	O
B	O
cells	O
.	O

The	O
gene	O
encoding	O
the	O
Epstein	B
-	I
Barr	I
virus	I
(	I
EBV	I
)	I
-	I
specific	I
dUTPase	I
was	O
amplified	O
from	O
virus	B
DNA	I
by	O
PCR	O
.	O

Preliminary	O
experiments	O
yielded	O
a	O
Km	O
value	O
of	O
about	O
0	O
.	O
8	O
microM	O
for	O
dUTP	O
.	O

This	O
indicated	O
that	O
the	O
dUTPase	O
is	O
expressed	O
during	O
EBV	O
replication	O
and	O
reactivation	O
.	O

Two	O
pp56	B
(	I
lck	I
)	I
mutants	I
lacking	O
either	O
the	O
entire	O
catalytic	B
domain	I
or	O
the	O
entire	O
NH2	B
regulatory	B
domain	I
were	O
generated	O
,	O
and	O
their	O
abilities	O
to	O
trigger	O
transactivation	O
of	O
the	O
TCR	B
-	I
regulated	I
nuclear	I
factor	I
of	I
activated	I
T	I
cells	I
(	I
NF	I
-	I
AT	I
)	I
region	I
of	O
the	O
IL	B
-	I
2	I
promoter	I
were	O
compared	O
.	O

The	O
results	O
showed	O
that	O
the	O
average	O
number	O
of	O
GCR	B
in	O
asthmatics	O
was	O
significantly	O
lower	O
than	O
that	O
in	O
healthy	O
subjects	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
,	O
and	O
there	O
was	O
a	O
linear	O
correlation	O
between	O
the	O
number	O
of	O
GCR	B
and	O
the	O
course	O
of	O
asthma	O
.	O

These	O
findings	O
suggest	O
that	O
there	O
is	O
no	O
primary	O
and	O
general	O
impairment	O
of	O
glucocorticoid	O
metabolism	O
in	O
the	O
asthmatics	O
,	O
but	O
the	O
number	O
of	O
GCR	B
in	O
the	O
asthmatics	O
is	O
lower	O
than	O
that	O
in	O
healthy	O
controls	O
.	O

Subsequently	O
binding	O
sites	O
have	O
been	O
demonstrated	O
in	O
the	O
plasma	O
membrane	O
of	O
human	O
lymphocytes	O
which	O
show	O
pharmacological	O
(	O
aldosterone	O
specificity	O
)	O
and	O
kinetic	O
(	O
high	O
turnover	O
)	O
properties	O
identical	O
with	O
those	O
of	O
the	O
rapid	O
aldosterone	O
effects	O
in	O
the	O
same	O
cells	O
.	O

The	O
macrophage	B
colony	I
-	I
stimulating	I
factor	I
(	I
M	I
-	I
CSF	I
)	I
receptor	I
is	O
expressed	O
in	O
a	O
tissue	O
-	O
specific	O
fashion	O
from	O
two	O
distinct	O
promoters	B
in	O
monocytes	O
/	O
macrophages	O
and	O
the	O
placenta	O
.	O

CONCLUSION	O
.	O

The	O
number	O
of	O
GCR	B
may	O
be	O
improved	O
by	O
inhalation	O
of	O
oxygen	O
.	O

Signaling	O
via	O
IL	B
-	I
2	I
and	O
IL	B
-	I
4	I
in	O
JAK3	O
-	O
deficient	O
severe	O
combined	O
immunodeficiency	O
lymphocytes	O
:	O
JAK3	B
-	O
dependent	O
and	O
independent	O
pathways	O
.	O

However	O
,	O
IL	B
-	I
4	I
-	O
induced	O
effects	O
were	O
clearly	O
improved	O
following	O
JAK3	B
expression	O
.	O

Interleukin	B
2	I
(	O
IL	B
-	I
2	I
)	O
stimulates	O
IL	B
-	I
2R	I
alpha	I
.	O

We	O
identified	O
an	O
86	O
-	O
nucleotide	O
fragment	O
that	O
is	O
90	O
%	O
identical	O
to	O
the	O
recently	O
characterized	O
murine	B
IL	I
-	I
2	I
-	I
responsive	I
element	I
(	O
mIL	B
-	I
2rE	I
)	O
.	O

Tumor	B
necrosis	I
factor	I
receptor	I
-	I
1	I
(	O
TNFR	B
-	I
1	I
)	O
and	O
CD95	B
(	O
also	O
called	O
Fas	B
or	O
APO	B
-	I
1	I
)	O
are	O
cytokine	B
receptors	I
that	O
engage	O
the	O
apoptosis	O
pathway	O
through	O
a	O
region	O
of	O
intracellular	O
homology	O
,	O
designated	O
the	O
`	O
`	O
death	B
domain	I
.	O
'	O
'	O
Another	O
death	B
domain	I
-	I
containing	I
member	I
of	O
the	O
TNFR	B
family	I
,	O
death	B
receptor	I
3	I
(	O
DR3	B
)	O
,	O
was	O
identified	O
and	O
was	O
shown	O
to	O
induce	O
both	O
apoptosis	O
and	O
activation	O
of	O
nuclear	B
factor	I
kappaB	I
.	O

Differential	O
nuclear	O
localization	O
of	O
p50	B
,	O
p52	B
,	O
and	O
RelB	B
proteins	O
in	O
human	O
accessory	O
cells	O
of	O
the	O
immune	O
response	O
in	O
situ	O
.	O

The	O
different	O
patterns	O
of	O
p50	B
,	O
p52	B
and	O
RelB	B
protein	O
nuclear	O
localization	O
may	O
provide	O
insight	O
into	O
their	O
different	O
roles	O
during	O
the	O
immune	O
response	O
in	O
vivo	O
.	O

Although	O
mutation	O
of	O
either	O
Y113	O
and	O
Y128	O
has	O
a	O
minimal	O
effect	O
on	O
SLP	B
-	I
76	I
function	O
,	O
mutation	O
of	O
both	O
residues	O
decreases	O
significantly	O
the	O
ability	O
of	O
SLP	B
-	I
76	I
to	O
promote	O
T	O
cell	O
activation	O
.	O

The	O
IRF	B
-	I
2	I
promoter	B
region	I
contains	O
a	O
CpG	O
island	O
,	O
with	O
several	O
GC	B
boxes	I
,	O
a	O
putative	O
NF	B
-	I
kappa	I
B	I
-	I
binding	I
site	I
,	O
and	O
a	O
CAAT	B
box	I
,	O
but	O
no	O
TATA	B
box	I
.	O

When	O
the	O
promoter	B
region	I
was	O
linked	O
with	O
a	O
heterologous	B
reporter	I
gene	I
,	O
we	O
found	O
that	O
the	O
promoter	B
region	I
is	O
inducible	O
by	O
both	O
interferons	B
(	O
interferon	B
-	I
alpha	I
and	I
-	I
gamma	I
)	O
and	O
interferon	B
regulatory	I
factor	I
1	I
.	O

Interferon	B
alpha	I
selectively	O
affects	O
expression	O
of	O
the	O
human	B
myeloid	I
cell	I
nuclear	I
differentiation	I
antigen	I
in	O
late	O
stage	O
cells	O
in	O
the	O
monocytic	O
but	O
not	O
the	O
granulocytic	O
lineage	O
.	O

Although	O
,	O
the	O
level	O
of	O
MNDA	B
mRNA	I
in	O
primary	O
monocytes	O
is	O
very	O
low	O
it	O
was	O
up	O
-	O
regulated	O
at	O
6	O
h	O
following	O
the	O
addition	O
of	O
interferon	B
alpha	I
.	O

This	O
reduced	O
level	O
of	O
mRNA	B
could	O
then	O
be	O
elevated	O
with	O
subsequent	O
interferon	B
alpha	I
treatment	O
.	O

We	O
identified	O
a	O
protein	O
,	O
p37	O
,	O
which	O
specifically	O
bound	O
to	O
DRE	B
1	I
.	O

Binding	O
of	O
the	O
cDNA	B
fusion	I
protein	I
,	O
similarly	O
to	O
the	O
results	O
obtained	O
with	O
purified	O
Jurkat	O
protein	O
,	O
was	O
decreased	O
by	O
introduction	O
of	O
site	O
-	O
specific	O
mutations	O
in	O
the	O
DRE	B
1	I
regulatory	I
sequence	I
.	O

Cotransfection	O
of	O
a	O
YB	B
-	I
1	I
expression	I
plasmid	I
increases	O
HTLV	O
-	O
I	O
basal	O
transcription	O
approximately	O
14	O
-	O
fold	O
in	O
Jurkat	O
T	O
lymphocytes	O
.	O

The	O
subjects	O
were	O
exposed	O
to	O
cold	O
air	O
(	O
4	O
degrees	O
C	O
)	O
twice	O
/	O
d	O
,	O
30	O
min	O
/	O
exposure	O
,	O
for	O
a	O
total	O
of	O
80	O
exposures	O
.	O

These	O
results	O
describe	O
for	O
the	O
first	O
time	O
the	O
rapid	O
modulation	O
of	O
the	O
NT3R	B
in	O
response	O
to	O
the	O
combined	O
influence	O
of	O
cold	O
exposure	O
and	O
reduced	O
circulating	O
T4	O
and	O
TSH	O
.	O

HIV	B
-	I
1	I
LTR	I
activity	O
in	O
human	O
CD40	O
-	O
activated	O
B	O
lymphocytes	O
is	O
dependent	O
on	O
NF	B
-	I
kappaB	I
.	O

In	O
these	O
cells	O
,	O
nuclear	B
factors	I
involved	O
in	O
activation	O
of	O
the	O
HIV	B
-	I
1	I
LTR	I
,	O
which	O
contains	O
the	O
transcriptional	B
control	I
elements	I
of	O
the	O
virus	O
,	O
are	O
unknown	O
.	O

In	O
preincubated	O
cells	O
,	O
the	O
cycloheximide	O
response	O
is	O
decreased	O
,	O
especially	O
in	O
the	O
case	O
of	O
FOSB	B
.	O

Regions	O
of	O
low	O
base	O
order	O
-	O
dependent	O
stem	O
-	O
loop	O
potential	O
in	O
the	O
region	O
of	O
the	O
gene	O
are	O
defined	O
.	O

Susceptibility	O
of	O
these	O
transformed	O
cell	O
lines	O
to	O
NK	O
cells	O
was	O
determined	O
by	O
cytolytic	O
assays	O
.	O

Cell	O
specific	O
expression	O
of	O
human	B
Bruton	I
'	I
s	I
agammaglobulinemia	I
tyrosine	I
kinase	I
gene	I
(	O
Btk	B
)	O
is	O
regulated	O
by	O
Sp1	B
-	I
and	O
Spi	B
-	I
1	I
/	I
PU	I
.	I
1	I
-	I
family	I
members	I
.	O

In	O
vitro	O
footprinting	O
analysis	O
within	O
this	O
part	O
of	O
the	O
promoter	B
revealed	O
two	O
Sp1	B
binding	I
sites	I
as	O
well	O
as	O
a	O
PU	B
-	I
box	I
.	O

In	O
addition	O
Spi	B
-	I
B	I
as	O
well	O
as	O
PU	B
.	I
1	I
were	O
able	O
to	O
transactivate	O
Btk	B
expression	O
.	O

They	O
also	O
demonstrate	O
for	O
the	O
first	O
time	O
the	O
occurrence	O
of	O
T	O
cell	O
responses	O
against	O
EBV	B
transactivating	I
factors	I
,	O
which	O
might	O
be	O
central	O
in	O
the	O
control	O
of	O
virus	O
reactivation	O
.	O

CD14	B
-	O
mediated	O
signal	O
pathway	O
of	O
Porphyromonas	O
gingivalis	O
lipopolysaccharide	O
in	O
human	O
gingival	O
fibroblasts	O
.	O

In	O
this	O
study	O
,	O
we	O
observed	O
unexpectedly	O
by	O
immunohistochemical	O
,	O
Western	O
blotting	O
(	O
immunoblotting	O
)	O
,	O
and	O
Northern	O
(	O
RNA	O
)	O
blotting	O
assays	O
that	O
CD14	B
is	O
expressed	O
at	O
high	O
density	O
in	O
human	O
gingival	O
fibroblasts	O
.	O

The	O
inhibitor	O
also	O
dramatically	O
inhibited	O
monocyte	O
chemotactic	O
activity	O
of	O
and	O
MCP	B
-	I
1	I
production	O
by	O
the	O
cells	O
.	O

Thus	O
,	O
the	O
tyrosine	B
kinase	I
activated	O
by	O
G	B
-	I
CSF	I
appears	O
to	O
directly	O
transduce	O
a	O
signal	O
to	O
a	O
protein	O
which	O
functions	O
as	O
a	O
transcriptional	B
regulator	I
.	O

Thus	O
,	O
we	O
focused	O
our	O
study	O
on	O
isolated	O
FDC	O
clusters	O
from	O
normal	O
tonsils	O
.	O

As	O
showed	O
on	O
tissue	O
sections	O
,	O
we	O
detected	O
the	O
p50	B
in	O
both	O
cytoplasm	O
and	O
nucleus	O
of	O
FDC	O
.	O

Now	O
that	O
these	O
proteins	O
are	O
purified	O
and	O
cloned	O
,	O
the	O
major	O
goals	O
will	O
be	O
to	O
understand	O
their	O
role	O
and	O
the	O
roles	O
of	O
other	O
family	O
members	O
in	O
thymic	O
development	O
.	O

This	O
effect	O
is	O
blocked	O
by	O
anti	B
-	I
VCAM	I
antibodies	I
.	O

This	O
activity	O
seems	O
to	O
be	O
due	O
to	O
increased	O
cAMP	O
levels	O
because	O
forskolin	O
and	O
IBMX	O
mimic	O
the	O
effects	O
of	O
PGE2	O
.	O

These	O
data	O
support	O
the	O
positive	O
role	O
for	O
PGE2	O
on	O
some	O
immune	O
functions	O
.	O

In	O
addition	O
,	O
analysis	O
of	O
EBV	O
protein	O
expression	O
by	O
IH	O
revealed	O
a	O
heterogeneous	O
pattern	O
of	O
EBV	B
gene	I
expression	O
at	O
the	O
single	O
-	O
cell	O
level	O
consisting	O
of	O
both	O
LMP1	O
+	O
and	O
LMP1	O
-	O
tumour	O
cells	O
,	O
suggesting	O
a	O
mixture	O
of	O
latency	O
I	O
and	O
II	O
.	O

This	O
made	O
the	O
need	O
for	O
VD	O
analogues	O
with	O
selectively	O
increased	O
cell	O
regulatory	O
properties	O
.	O

Studies	O
with	O
20	O
-	O
epi	O
analogues	O
pointed	O
out	O
the	O
importance	O
of	O
the	O
carbon	O
-	O
20	O
position	O
and	O
led	O
to	O
the	O
development	O
of	O
20	O
-	O
methyl	O
derivatives	O
of	O
VD	O
.	O

Moreover	O
,	O
ZK161422	O
,	O
but	O
not	O
ZK157202	O
,	O
showed	O
preference	O
for	O
gene	O
activation	O
from	O
a	O
promoter	B
carrying	O
a	O
VD	B
response	I
element	I
with	O
a	O
palindromic	O
arrangement	O
of	O
two	O
hexameric	B
receptor	I
binding	I
sites	I
spaced	O
by	O
9	O
nucleotides	O
(	O
IP9	O
)	O
rather	O
than	O
for	O
activation	O
from	O
a	O
response	B
element	I
formed	O
by	O
a	O
direct	O
repeat	O
spaced	O
by	O
3	O
nucleotides	O
(	O
DR3	O
)	O
.	O

This	O
observation	O
supports	O
a	O
model	O
,	O
in	O
which	O
promoter	O
selectivity	O
reflects	O
the	O
selectively	O
increased	O
antiproliferative	O
effect	O
of	O
VD	O
analogues	O
.	O

The	O
process	O
of	O
activation	O
involves	O
calcium	O
mobilization	O
,	O
activation	O
of	O
protein	B
kinase	I
C	I
(	O
PKC	B
)	O
,	O
and	O
phosphorylation	O
of	O
tyrosine	B
kinases	I
.	O

The	O
involvement	O
of	O
p21	B
(	I
ras	I
)	I
in	O
the	O
regulation	O
of	O
calcium	O
-	O
dependent	O
signals	O
has	O
been	O
suggested	O
through	O
analysis	O
of	O
its	O
role	O
in	O
the	O
activation	O
of	O
NF	B
-	I
AT	I
.	O

The	O
expression	O
of	O
activated	O
p21	B
(	I
ras	I
)	I
negatively	O
regulated	O
the	O
induction	O
of	O
IE	B
genes	I
by	O
calcium	O
ionophore	O
.	O

A	O
later	O
result	O
of	O
inhibition	O
of	O
this	O
activation	O
pathway	O
by	O
p21	B
(	I
ras	I
)	I
was	O
down	O
-	O
regulation	O
of	O
the	O
activity	O
of	O
the	O
transcription	B
factor	I
AP	B
-	I
1	I
and	O
subsequent	O
coordinate	O
reductions	O
in	O
IL	B
-	I
2	I
gene	I
expression	O
and	O
protein	O
production	O
.	O

Calcineurin	B
acts	O
in	O
synergy	O
with	O
PMA	O
to	O
inactivate	O
I	B
kappa	I
B	I
/	I
MAD3	I
,	O
an	O
inhibitor	O
of	O
NF	B
-	I
kappa	I
B	I
.	O

Calcineurin	B
stimulates	O
the	O
NF	B
-	I
kappa	I
B	I
element	I
by	O
enhancing	O
inactivation	O
of	O
I	B
kappa	I
B	I
/	I
MAD3	I
,	O
an	O
inhibitor	O
of	O
NF	B
-	I
kappa	I
B	I
,	O
thereby	O
increasing	O
the	O
amount	O
of	O
nuclear	O
NF	B
-	I
kappa	I
B	I
DNA	O
binding	O
activity	O
.	O

Inhibition	O
of	O
membrane	O
IL	B
-	I
2R	I
alpha	I
and	O
IL	B
-	I
2R	I
beta	I
expression	O
by	O
10	O
(	O
-	O
6	O
)	O
M	O
DM	O
was	O
partially	O
reversible	O
by	O
recombinant	B
human	I
IL	I
-	I
2	I
(	O
rhIL	B
-	I
2	I
)	O
.	O

The	O
mechanism	O
of	O
action	O
of	O
DM	O
on	O
IL	B
-	I
2R	I
alpha	I
transcription	O
was	O
examined	O
by	O
determining	O
the	O
mRNA	O
levels	O
of	O
the	O
p50	O
subunit	O
of	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF	B
-	I
kappa	I
B	I
)	O
,	O
a	O
transcription	B
factor	I
that	O
stimulates	O
IL	B
-	I
2R	I
alpha	I
gene	O
expression	O
.	O

However	O
,	O
simultaneous	O
incubation	O
of	O
RU	O
486	O
with	O
dexamethasone	O
caused	O
a	O
distinct	O
interference	O
of	O
RU	O
486	O
with	O
dexamethasone	O
.	O

The	O
protein	B
-	I
tyrosine	I
kinase	I
ZAP	B
-	I
70	I
is	O
implicated	O
,	O
together	O
with	O
the	O
Src	B
kinase	I
p56	B
(	I
lck	I
)	I
,	O
in	O
controlling	O
the	O
early	O
steps	O
of	O
the	O
T	O
-	O
cell	O
antigen	O
receptor	O
(	O
TCR	B
)	O
signaling	O
cascade	O
.	O

To	O
help	O
elucidate	O
further	O
the	O
mechanism	O
by	O
which	O
ZAP	B
-	I
70	I
regulates	O
these	O
initial	O
events	O
,	O
we	O
used	O
a	O
dominant	O
-	O
negative	O
mutant	O
approach	O
.	O

ZAP	B
-	I
70	I
will	O
then	O
be	O
able	O
to	O
effectively	O
control	O
phosphorylation	O
of	O
its	O
substrates	O
and	O
lead	O
to	O
gene	O
activation	O
.	O

Peripheral	O
blood	O
mononuclear	O
cell	O
GCR	B
binding	O
affinities	O
for	O
dexamethasone	O
and	O
budesonide	O
were	O
also	O
determined	O
for	O
both	O
patient	O
groups	O
by	O
using	O
a	O
radioligand	O
binding	O
assay	O
and	O
Scatchard	O
analysis	O
.	O

The	O
GCR	B
binding	O
affinity	O
for	O
budesonide	O
was	O
significantly	O
higher	O
in	O
both	O
groups	O
(	O
i	O
.	O
e	O
.	O
,	O
lower	O
dissociation	O
constant	O
)	O
than	O
that	O
obtained	O
for	O
dexamethasone	O
.	O

Characterization	O
of	O
the	O
murine	B
cyclin	I
-	I
dependent	I
kinase	I
inhibitor	I
gene	I
p27Kip1	B
.	O

The	O
gene	O
consists	O
of	O
at	O
least	O
three	O
exons	O
and	O
spans	O
more	O
than	O
5	B
.	I
6	I
kb	I
of	I
DNA	I
.	O

Primer	O
extension	O
and	O
nuclease	O
S1	O
protection	O
analysis	O
revealed	O
two	O
major	O
transcription	B
initiation	I
sites	I
.	O

The	O
-	B
326	I
to	I
-	I
615	I
region	I
contained	O
positive	B
regulatory	I
elements	I
.	O

Constitutive	O
nuclear	O
appearance	O
was	O
also	O
observed	O
for	O
NF	O
-	O
kB2	O
/	O
p52	O
.	O

These	O
findings	O
indicate	O
that	O
T	O
cells	O
representing	O
different	O
activation	O
and	O
/	O
or	O
differentiation	O
stages	O
can	O
be	O
differentially	O
responsive	O
to	O
ROI	O
-	O
mediated	O
signals	O
.	O

Furthermore	O
,	O
overexpression	O
and	O
constitutive	O
nuclear	O
localization	O
of	O
NF	B
-	I
AT	I
,	O
but	O
not	O
Jun	B
,	I
Fos	I
,	I
NF	I
-	I
kappaB	I
,	I
Oct	I
or	I
Ets	I
family	I
members	I
,	O
renders	O
the	O
interleukin	B
-	I
2	I
enhancer	I
in	O
Jurkat	O
T	O
lymphocytes	O
resistant	O
to	O
FK506	O
and	O
cyclosporin	O
A	O
.	O

These	O
findings	O
thus	O
reveal	O
the	O
presence	O
of	O
a	O
second	O
inducible	O
autoregulated	O
inhibitory	O
pathway	O
that	O
helps	O
ensure	O
the	O
rapid	O
but	O
transient	O
action	O
of	O
nuclear	B
NF	I
-	I
kappa	I
B	I
.	O

Implications	O
for	O
replication	O
of	O
HIV	O
-	O
1	O
.	O

First	O
,	O
anti	B
-	I
CD45	I
antibodies	I
did	O
not	O
affect	O
basal	O
but	O
decreased	O
activated	O
levels	O
of	O
expression	O
from	O
the	O
HIV	B
-	I
1	I
LTR	I
.	O

The	O
expression	O
of	O
GM	B
-	I
CSF	I
and	O
IL	B
-	I
2	I
is	O
inhibited	O
by	O
immunosuppressive	O
drugs	O
such	O
as	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
and	O
FK506	O
.	O

The	O
constitutively	O
active	O
type	O
of	O
the	O
CN	B
A	I
subunit	I
,	O
which	O
lacks	O
the	O
auto	B
-	I
inhibitory	I
and	O
calmodulin	B
-	I
binding	I
domains	I
,	O
acts	O
in	O
synergy	O
with	O
PMA	O
to	O
activate	O
transcription	O
from	O
the	O
GM	B
-	I
CSF	I
promoter	I
.	O

Alternate	O
immune	O
system	O
targets	O
for	O
TCDD	O
:	O
lymphocyte	O
stem	O
cells	O
and	O
extrathymic	O
T	O
-	O
cell	O
development	O
.	O

TCDD	O
mediates	O
atrophy	O
induction	O
through	O
its	O
specific	O
receptor	O
(	O
the	O
AhR	B
)	O
and	O
not	O
through	O
effects	O
on	O
the	O
estrogen	O
receptor	O
.	O

Both	O
TCDD	O
and	O
estradiol	O
induce	O
extrathymic	O
T	O
-	O
cell	O
differentiation	O
in	O
the	O
liver	O
.	O

It	O
predicts	O
for	O
two	O
open	B
reading	I
frames	I
(	O
ORFs	B
)	O
.	O

ORF1	B
consists	O
of	O
240	O
bp	O
that	O
would	O
encode	O
80	O
amino	O
acids	O
,	O
while	O
the	O
major	B
ORF2	I
consists	O
of	O
648	O
bp	O
capable	O
of	O
coding	O
for	O
216	O
amino	O
acids	O
.	O

To	O
investigate	O
the	O
mechanisms	O
of	O
transcriptional	O
activation	O
of	O
interleukin	B
-	I
1beta	I
(	O
IL	B
-	I
1beta	I
)	O
in	O
non	O
-	O
monocytic	O
cells	O
,	O
we	O
constructed	O
a	O
series	O
of	O
reporter	O
plasmids	O
with	O
the	O
bacterial	O
chloramphenicol	O
acetyltransferase	O
gene	O
linked	O
to	O
various	O
parts	O
of	O
the	O
human	B
IL	I
-	I
1beta	I
promoter	I
and	O
performed	O
transient	O
transfection	O
experiments	O
.	O

Egr	B
-	I
1	I
expression	O
correlates	O
with	O
the	O
cellular	O
phenotype	O
and	O
the	O
specific	O
pattern	O
of	O
viral	O
latency	O
established	O
within	O
the	O
individual	O
cell	O
lines	O
.	O

Several	O
forms	O
of	O
EGR	B
-	I
1	I
protein	I
are	O
found	O
within	O
the	O
different	O
groups	O
of	O
cell	O
lines	O
,	O
and	O
the	O
binding	O
activity	O
to	O
DNA	B
consensus	I
sequences	I
was	O
investigated	O
.	O

In	O
all	O
cells	O
tested	O
,	O
IL	B
-	I
10	I
activated	O
Stat1	B
and	O
Stat3	B
and	O
induced	O
the	O
formation	O
of	O
three	O
distinct	O
DNA	B
binding	I
complexes	I
that	O
contained	O
different	O
combinations	O
of	O
these	O
two	O
transcription	B
factors	I
.	O

Using	O
a	O
structure	O
-	O
function	O
mutagenesis	O
approach	O
,	O
two	O
tyrosine	O
residues	O
(	O
Tyr427	O
and	O
Tyr477	O
)	O
in	O
the	O
intracellular	B
domain	I
of	O
the	O
murine	O
IL	B
-	I
10	I
receptor	O
were	O
found	O
to	O
be	O
redundantly	O
required	O
for	O
receptor	O
function	O
and	O
for	O
activation	O
of	O
Stat3	B
but	O
not	O
for	O
Stat1	B
or	O
Stat5	B
.	O

This	O
study	O
thus	O
supports	O
the	O
concept	O
that	O
utilization	O
of	O
distinct	O
STAT	B
proteins	I
by	O
different	O
cytokine	B
receptors	I
is	O
dependent	O
on	O
the	O
expression	O
of	O
particular	O
ligand	O
-	O
activatable	O
,	O
tyrosine	B
-	I
containing	I
STAT	I
docking	I
sites	I
in	O
receptor	B
intracellular	I
domains	I
.	O

Silencing	O
of	O
human	O
fetal	O
globin	B
expression	O
is	O
impaired	O
in	O
the	O
absence	O
of	O
the	O
adult	B
beta	I
-	I
globin	I
gene	I
activator	I
protein	I
EKLF	B
.	O

Globin	B
genes	I
are	O
subject	O
to	O
tissue	O
-	O
specific	O
and	O
developmental	O
stage	O
-	O
specific	O
regulation	O
.	O

Stimulation	O
of	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
by	O
zinc	O
and	O
related	O
cations	O
.	O

Therefore	O
,	O
monokine	O
induction	O
is	O
a	O
zinc	O
-	O
specific	O
effect	O
influenced	O
by	O
the	O
physicochemical	O
properties	O
of	O
the	O
ion	O
.	O

Confirmation	O
of	O
the	O
unique	O
significance	O
of	O
zinc	O
for	O
immune	O
function	O
provides	O
a	O
better	O
understanding	O
of	O
the	O
mechanisms	O
of	O
specific	O
zinc	O
-	O
mediated	O
immune	O
modulation	O
.	O

E3	B
,	O
a	O
hematopoietic	B
-	I
specific	I
transcript	I
directly	O
regulated	O
by	O
the	O
retinoic	B
acid	I
receptor	I
alpha	I
.	O

E3	B
,	O
one	O
of	O
nine	O
sequences	O
identified	O
,	O
was	O
upregulated	O
in	O
an	O
immediate	O
-	O
early	O
manner	O
,	O
with	O
transcript	O
levels	O
peaking	O
after	O
60	O
minutes	O
exposure	O
to	O
RA	O
.	O

E3	B
transcripts	I
were	O
RA	O
-	O
inducible	O
in	O
HL60	O
cells	O
,	O
but	O
not	O
in	O
an	O
RA	O
-	O
resistant	O
subclone	O
,	O
HL60R	O
,	O
that	O
harbors	O
a	O
mutated	O
RAR	B
alpha	I
gene	I
.	O

These	O
results	O
indicate	O
that	O
E3	B
is	O
a	O
hematopoietic	B
-	I
specific	I
gene	I
that	O
is	O
an	O
immediate	O
target	O
for	O
the	O
activated	O
RAR	B
alpha	I
during	O
myelopoiesis	O
.	O

The	O
molecular	O
mechanism	O
underlying	O
IL	B
-	I
2	I
transcriptional	O
blockade	O
in	O
anergic	O
T	O
cell	O
clones	O
is	O
not	O
fully	O
understood	O
.	O

To	O
examine	O
whether	O
an	O
active	O
negative	O
regulatory	O
process	O
occurs	O
,	O
we	O
created	O
a	O
reporter	B
construct	I
containing	O
as	O
an	O
enhancer	B
four	O
copies	O
of	O
the	O
NF	B
-	I
AT	I
site	I
and	O
one	O
copy	O
of	O
the	O
octamer	B
site	I
(	O
4X	B
NF	I
-	I
AT	I
-	I
Oct	I
)	O
.	O

The	O
simplest	O
model	O
to	O
explain	O
these	O
results	O
is	O
that	O
anergy	O
is	O
mediated	O
by	O
a	O
complex	O
of	O
multiple	O
transcription	B
factors	I
that	O
exert	O
a	O
cis	O
-	O
acting	O
dominant	O
negative	O
regulatory	O
effect	O
on	O
the	O
trans	O
-	O
activation	O
of	O
the	O
IL	B
-	I
2	I
gene	I
.	O

In	O
contrast	O
,	O
expression	O
of	O
the	O
activation	B
-	I
dependent	I
cell	I
surface	I
markers	I
CD25	B
and	O
CD69	B
was	O
within	O
normal	O
limits	O
.	O

Whereas	O
AP	B
-	I
1	I
,	O
NF	O
-	O
kappa	O
B	O
,	O
Oct	B
,	O
CREB	B
and	O
SP1	B
displayed	O
normal	O
binding	O
activities	O
in	O
nuclear	O
extracts	O
,	O
the	O
binding	O
of	O
NF	B
-	I
AT	I
to	O
its	O
IL	B
-	I
2	I
promoter	O
response	O
element	O
was	O
barely	O
detectable	O
both	O
before	O
and	O
after	O
T	O
cell	O
stimulation	O
.	O

Our	O
results	O
strongly	O
suggest	O
that	O
this	O
NF	B
-	I
AT	I
/	O
DNA	O
binding	O
defect	O
is	O
responsible	O
for	O
the	O
multiple	O
cytokine	B
deficiency	O
and	O
the	O
SCID	O
phenotype	O
observed	O
in	O
the	O
two	O
infant	O
brothers	O
.	O

During	O
Epstein	O
-	O
Barr	O
virus	O
latent	O
infection	O
of	O
B	O
lymphocytes	O
in	O
vitro	O
,	O
six	O
viral	B
nuclear	I
antigens	I
(	O
EBNAs	B
)	O
are	O
expressed	O
from	O
one	O
of	O
two	O
promoters	B
,	O
Cp	B
or	O
Wp	B
,	O
whose	O
activities	O
are	O
mutually	O
exclusive	O
.	O

Deletion	O
of	O
the	O
EBNA2	B
-	I
dependent	I
enhancer	I
located	O
upstream	O
of	O
Cp	B
resulted	O
in	O
a	O
ca	O
.	O
two	O
-	O
to	O
fivefold	O
reduction	O
in	O
Cp	B
activity	O
in	O
the	O
LCLs	O
assayed	O
.	O

Deletion	O
of	O
the	O
glucocorticoid	O
response	O
elements	O
located	O
at	O
ca	B
.	I
bp	I
-	I
850	I
upstream	O
of	O
Cp	B
did	O
not	O
result	O
in	O
a	O
significant	O
loss	O
in	O
activity	O
.	O

The	O
identification	O
of	O
oriP	B
and	O
the	O
EBNA2	B
-	I
dependent	I
enhancer	I
as	O
the	O
major	O
positive	O
cis	B
elements	I
involved	O
in	O
regulating	O
Cp	B
activity	O
in	O
LCL	O
suggests	O
that	O
EBNA	B
gene	I
transcription	O
is	O
largely	O
autoregulated	O
by	O
EBNA	B
1	I
and	O
EBNA	B
2	I
.	O

Expression	O
of	O
interleukin	B
1beta	I
and	O
other	O
cytokines	B
,	O
such	O
as	O
interleukin	B
6	I
and	O
tumor	B
necrosis	I
factor	I
alpha	I
,	O
has	O
been	O
shown	O
to	O
be	O
dependent	O
on	O
the	O
activation	O
of	O
the	O
transcription	B
factor	I
,	O
NFkappaB	B
.	O

HIV	O
-	O
1	O
infection	O
resulted	O
in	O
constitutive	O
,	O
low	O
-	O
level	O
expression	O
of	O
type	B
1	I
interferon	I
(	O
IFN	B
)	O
at	O
the	O
mRNA	O
level	O
.	O

We	O
suggest	O
that	O
HIV	O
-	O
1	O
infection	O
of	O
myeloid	O
cells	O
induces	O
IFN	B
production	O
and	O
PKR	B
activity	O
,	O
which	O
in	O
turn	O
contribute	O
to	O
enhanced	O
IkappaBalpha	B
phosphorylation	O
and	O
subsequent	O
degradation	O
.	O

Nuclear	O
translocation	O
of	O
NF	B
-	I
kappaB	I
subunits	I
may	O
ultimately	O
increase	O
the	O
intracellular	O
pool	O
of	O
NF	B
-	I
kappaB	I
/	I
IkappaBalpha	I
by	O
an	O
autoregulatory	O
mechanism	O
.	O

The	O
transcription	O
and	O
transformation	O
activity	O
of	O
c	B
-	I
Jun	I
is	O
governed	O
by	O
a	O
27	B
-	I
amino	I
acid	I
regulatory	I
motif	I
,	O
labeled	O
the	O
delta	B
-	I
domain	I
,	O
which	O
is	O
deleted	O
in	O
v	B
-	I
Jun	I
.	O

Here	O
,	O
we	O
report	O
that	O
differentiated	O
B	O
cells	O
contain	O
a	O
novel	O
substoichiometric	O
TAF	B
of	O
105	O
kDa	O
not	O
found	O
associated	O
with	O
TFIID	B
isolated	O
from	O
other	O
cell	O
types	O
.	O

All	O
cells	O
tested	O
express	O
TAFII105	B
mRNA	I
,	O
but	O
only	O
B	O
cells	O
contain	O
significant	O
levels	O
of	O
protein	O
associated	O
with	O
TFIID	B
.	O

The	O
association	O
of	O
20q	B
deletions	I
with	O
myeloid	O
`	O
`	O
stem	O
cell	O
'	O
'	O
disorders	O
suggests	O
that	O
the	O
deletions	O
mark	O
the	O
site	O
of	O
one	O
or	O
more	O
genes	O
,	O
loss	O
or	O
inactivation	O
of	O
which	O
plays	O
a	O
role	O
in	O
the	O
regulation	O
of	O
normal	O
hematopoietic	O
progenitors	O
.	O

Seventeen	O
microsatellite	B
markers	I
that	O
span	O
the	O
common	O
deleted	O
region	O
were	O
used	O
to	O
search	O
for	O
loss	O
of	O
heterozygosity	O
in	O
granulocyte	B
DNA	I
.	O

Therefore	O
,	O
the	O
human	B
androgen	I
receptor	I
assay	O
(	O
HUMARA	O
)	O
was	O
used	O
to	O
determine	O
granulocyte	O
clonality	O
.	O

These	O
results	O
show	O
that	O
,	O
in	O
the	O
vast	O
majority	O
of	O
patients	O
presented	O
here	O
,	O
the	O
failure	O
to	O
detect	O
loss	O
of	O
heterozygosity	O
can	O
not	O
be	O
attributed	O
to	O
the	O
presence	O
of	O
normal	O
polyclonal	O
granulocytes	O
.	O

In	O
contrast	O
to	O
MM	O
cells	O
,	O
normal	O
splenic	O
B	O
cells	O
express	O
dephosphorylated	B
pRB	I
.	O

Although	O
CD40	B
ligand	I
(	O
CD40L	B
)	O
triggers	O
a	O
shift	O
from	O
dephosphorylated	O
to	O
phosphorylated	O
pRB	B
and	O
proliferation	O
of	O
B	O
cells	O
,	O
the	O
addition	O
of	O
exogenous	O
IL	B
-	I
6	I
to	O
CD40L	B
-	O
treated	O
B	O
cells	O
does	O
not	O
alter	O
either	O
pRB	B
or	O
proliferation	O
,	O
as	O
observed	O
in	O
MM	O
cells	O
.	O

Soluble	B
factors	I
secreted	O
by	O
activated	O
T	O
-	O
lymphocytes	O
modulate	O
the	O
transcription	O
of	O
the	O
immunosuppressive	B
cytokine	I
TGF	B
-	I
beta	I
2	I
in	O
glial	O
cells	O
.	O

These	O
data	O
along	O
with	O
previous	O
observations	O
demonstrating	O
the	O
potent	O
immunosuppressive	O
activity	O
of	O
TGF	B
-	I
beta	I
2	I
,	O
support	O
a	O
model	O
for	O
a	O
feedback	O
mechanism	O
between	O
the	O
activated	O
T	O
-	O
lymphocytes	O
and	O
astrocytes	O
via	O
TGF	B
-	I
beta	I
2	I
to	O
regulate	O
the	O
immune	O
response	O
.	O

The	O
transcriptionally	B
regulatory	I
regions	I
of	O
the	O
lymphomagenic	O
Akv	O
and	O
SL3	O
-	O
3	O
murine	O
leukemia	O
retroviruses	O
(	O
MLVs	O
)	O
contain	O
two	O
types	O
of	O
E	B
-	I
box	I
consensus	I
motifs	I
,	O
CAGATG	O
.	O

We	O
have	O
examined	O
the	O
requirements	O
of	O
the	O
individual	O
E	B
-	I
boxes	I
in	O
MLV	O
transcriptional	O
regulation	O
.	O

In	O
lymphoid	O
cell	O
lines	O
only	O
,	O
the	O
E	B
(	I
gre	I
)	I
-	I
binding	I
protein	I
complexes	I
included	O
ALF1	B
or	O
HEB	B
and	O
E2A	B
basic	I
helix	I
-	I
loop	I
-	I
helix	I
proteins	I
.	O

ALF1	B
transactivated	O
transcription	O
of	O
Akv	O
MLV	O
through	O
the	O
two	O
E	B
(	I
gre	I
)	I
motifs	I
equally	O
,	O
whereas	O
E2A	B
protein	I
required	O
the	O
promoter	O
-	O
proximal	O
E	B
(	I
gre	I
)	I
motif	O
.	O

Moreover	O
,	O
ectopic	B
Id1	I
repressed	O
E	B
(	I
gre	I
)	I
-	O
directed	O
but	O
not	O
EA	B
/	I
S	I
-	O
directed	O
MLV	O
transcription	O
in	O
lymphoid	O
cell	O
lines	O
.	O

In	O
conclusion	O
,	O
E	B
(	I
gre	I
)	I
motifs	O
and	O
interacting	O
basic	B
helix	I
-	I
loop	I
-	I
helix	I
proteins	I
are	O
important	O
determinants	O
for	O
MLV	O
transcriptional	O
activity	O
in	O
lymphocytic	O
cell	O
lines	O
.	O

Reversal	O
of	O
apoptosis	O
by	O
the	O
leukaemia	O
-	O
associated	O
E2A	B
-	I
HLF	I
chimaeric	I
transcription	I
factor	I
.	O

We	O
cloned	O
human	O
nur77	B
beta	I
cDNA	I
,	O
called	O
TINUR	B
.	O

Although	O
NGFI	B
-	I
B	I
/	I
nur77	I
is	O
essential	O
for	O
TCR	O
-	O
mediated	O
apoptosis	O
in	O
T	B
-	I
cell	I
hybridomas	I
,	O
the	O
reports	O
on	O
nur77	O
knock	O
-	O
out	O
mice	O
and	O
nur77	O
dominant	O
negative	O
transgenic	O
mice	O
suggest	O
that	O
there	O
is	O
a	O
functional	O
redundancy	O
among	O
NGFI	B
-	I
B	I
/	I
nur77	I
family	I
.	O

Correlations	O
were	O
found	O
between	O
plasma	B
IFN	I
alpha	I
and	O
receptor	O
Kd	O
on	O
monocytes	O
of	O
AIDS	O
-	O
GR	O
(	O
r	O
=	O
0	O
.	O
77	O
)	O
and	O
between	O
IFN	B
alpha	I
and	O
plasma	O
cortisol	O
in	O
the	O
same	O
group	O
(	O
r	O
=	O
0	O
.	O
74	O
)	O
.	O

By	O
contrast	O
,	O
glucocorticoids	O
failed	O
to	O
inhibit	O
IFNalpha	B
production	O
from	O
AIDS	O
-	O
GR	O
monocytes	O
(	O
approximately	O
20	O
%	O
inhibition	O
)	O
.	O

This	O
activation	O
differed	O
substantially	O
from	O
that	O
mediated	O
by	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
(	O
PMA	O
)	O
and	O
Ca2	O
+	O
ionophore	O
or	O
produced	O
by	O
costimulation	O
with	O
antibodies	B
against	O
the	O
T	B
cell	I
receptor	I
-	I
CD3	I
complex	I
and	O
to	O
CD28	B
.	O

The	O
age	O
-	O
associated	O
immune	O
dysfunction	O
may	O
be	O
implicated	O
to	O
some	O
degree	O
in	O
the	O
extreme	O
susceptibility	O
of	O
the	O
elderly	O
to	O
infection	O
and	O
neoplasia	O
and	O
may	O
even	O
participate	O
in	O
various	O
aspects	O
of	O
senescence	O
.	O

The	O
biochemical	O
modifications	O
responsible	O
for	O
the	O
defect	O
in	O
transduction	O
and	O
execution	O
of	O
the	O
proliferative	O
signal	O
are	O
analyzed	O
as	O
a	O
function	O
of	O
age	O
.	O

The	O
multiple	O
alterations	O
observed	O
on	O
the	O
various	O
biochemical	O
pathways	O
may	O
appear	O
as	O
a	O
consequence	O
of	O
a	O
unique	O
deleterious	O
mechanism	O
more	O
fundamentally	O
related	O
to	O
the	O
process	O
of	O
senescence	O
such	O
as	O
the	O
inability	O
to	O
cope	O
with	O
oxidative	O
stress	O
.	O

Induction	O
of	O
bcl	B
-	I
2	I
expression	O
by	O
phosphorylated	O
CREB	O
proteins	O
during	O
B	O
-	O
cell	O
activation	O
and	O
rescue	O
from	O
apoptosis	O
.	O

Engagement	O
of	O
surface	O
immunoglobulin	O
on	O
mature	O
B	O
cells	O
leads	O
to	O
rescue	O
from	O
apoptosis	O
and	O
to	O
proliferation	O
.	O

These	O
stimuli	O
result	O
in	O
phosphorylation	O
of	O
CREB	B
at	O
serine	O
133	O
.	O

It	O
is	O
possible	O
that	O
the	O
CRE	B
site	I
is	O
responsible	O
for	O
induction	O
of	O
bcl	B
-	I
2	I
expression	O
in	O
other	O
cell	O
types	O
,	O
particularly	O
those	O
in	O
which	O
protein	B
kinase	I
C	I
is	O
involved	O
.	O

MNDA	B
(	O
myeloid	B
cell	I
nuclear	I
differentiation	I
antigen	I
)	O
is	O
an	O
interferon	B
alpha	I
regulated	I
nuclear	I
protein	I
expressed	O
only	O
in	O
cells	O
of	O
the	O
human	O
myelomonocytic	O
lineage	O
.	O

In	O
addition	O
,	O
DNA	O
methylation	O
was	O
revealed	O
as	O
one	O
of	O
the	O
possible	O
factors	O
in	O
establishing	O
MNDA	B
expression	O
.	O

This	O
abnormality	O
was	O
not	O
seen	O
in	O
resting	O
T	O
cells	O
nor	O
T	O
cells	O
from	O
patients	O
with	O
systemic	O
lupus	O
erythematosus	O
,	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
,	O
or	O
SS	O
accompanied	O
by	O
RA	O
.	O

Characterization	O
of	O
a	O
new	O
isoform	O
of	O
the	O
NFAT	B
(	O
nuclear	B
factor	I
of	I
activated	I
T	I
cells	I
)	O
gene	O
family	O
member	O
NFATc	B
[	O
published	O
erratum	O
appears	O
in	O
J	O
Biol	O
Chem	O
1996	O
Dec	O
27	O
;	O
271	O
(	O
52	O
)	O
:	O
33705	O
]	O

The	O
amino	B
acid	I
sequence	I
of	O
NFATc	B
.	I
beta	I
differs	O
from	O
that	O
of	O
NFATc	B
.	O

Transient	O
expression	O
of	O
NFATc	B
.	I
beta	I
was	O
capable	O
of	O
activating	O
an	O
interleukin	B
-	I
2	I
NFAT	I
-	I
driven	I
reporter	I
gene	I
in	O
stimulated	O
Jurkat	O
cells	O
in	O
a	O
CsA	O
-	O
sensitive	O
manner	O
.	O

However	O
,	O
NFATc	B
.	I
beta	I
neither	O
bound	O
to	O
the	O
kappa3	B
element	I
(	O
an	O
NFAT	B
-	I
binding	I
site	I
)	O
in	O
the	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
promoter	I
nor	O
activated	O
the	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
promoter	I
in	O
cotransfection	O
assays	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
seven	O
EBV	O
-	O
positive	O
gastric	O
carcinoma	O
tissues	O
for	O
viral	O
gene	O
expression	O
at	O
the	O
mRNA	O
level	O
,	O
from	O
which	O
studies	O
on	O
the	O
EBV	O
oncogenicity	O
in	O
human	O
epithelial	O
cells	O
will	O
benefit	O
.	O

Both	O
are	O
located	O
in	O
the	O
particulate	O
fraction	O
following	O
platelet	O
activation	O
and	O
are	O
also	O
able	O
to	O
bind	O
to	O
a	O
GST	B
-	I
construct	I
containing	O
the	O
SH2	B
and	I
SH3	I
domains	I
of	O
phospholipase	B
C	I
gamma	I
1	I
.	O

Constitutive	O
expression	O
of	O
specific	O
interferon	B
isotypes	I
in	O
peripheral	O
blood	O
leukocytes	O
from	O
normal	O
individuals	O
and	O
in	O
promonocytic	O
U937	O
cells	O
.	O

Constitutive	O
expression	O
of	O
IFN	B
-	I
alpha5	I
and	O
IFN	B
-	I
beta	I
was	O
detected	O
in	O
different	O
lymphoid	O
cells	O
including	O
peripheral	O
blood	O
mononuclear	O
cells	O
from	O
normal	O
individuals	O
following	O
amplification	O
of	O
IFN	B
mRNA	I
by	O
reverse	B
transcriptase	I
-	O
polymerase	O
chain	O
reaction	O
and	O
direct	O
sequencing	O
of	O
the	O
amplified	B
product	I
.	O

These	O
results	O
suggest	O
that	O
IFN	B
-	I
alpha5	I
and	O
IFN	B
-	I
beta	I
are	O
produced	O
at	O
low	O
levels	O
in	O
normal	O
tissues	O
and	O
play	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
cell	O
function	O
and	O
in	O
the	O
maintenance	O
of	O
homeostasis	O
.	O

Thus	O
,	O
IL	B
-	I
2	I
-	O
induced	O
IL	B
-	I
2R	I
alpha	I
promoter	I
activity	O
requires	O
a	O
complex	B
upstream	I
element	I
,	O
which	O
appears	O
to	O
contain	O
binding	B
sites	I
for	O
both	O
positive	B
and	I
negative	I
regulatory	I
factors	I
.	O

Lymphocytes	O
from	O
CML	O
patients	O
lack	O
a	O
47	B
kDa	I
factor	I
having	O
affinity	O
for	O
a	O
genomic	B
sterol	I
regulatory	I
sequence	I
.	O

The	O
proximal	B
sequence	I
element	I
(	I
PSE	I
)	I
-	I
binding	I
transcription	I
factor	I
(	O
PTF	B
)	O
,	O
which	O
binds	O
the	O
PSE	B
of	O
both	O
RNA	B
polymerase	I
II	I
-	I
and	I
RNA	I
polymerase	I
III	I
-	I
transcribed	I
mammalian	I
small	I
nuclear	I
RNA	I
(	I
snRNA	I
)	I
genes	I
,	O
is	O
essential	O
for	O
their	O
transcription	O
.	O

Here	O
we	O
describe	O
the	O
isolation	O
and	O
expression	O
of	O
a	O
cDNA	B
encoding	O
PTF	B
beta	I
,	O
as	O
well	O
as	O
functional	O
studies	O
using	O
anti	B
-	I
PTF	I
beta	I
antibodies	I
.	O

We	O
report	O
here	O
on	O
the	O
identification	O
of	O
a	O
17	B
kDa	I
variant	I
of	O
the	O
14	B
kDa	I
Id	I
-	I
3	I
protein	O
termed	O
Id	B
-	I
3L	I
(	O
long	O
version	O
)	O
which	O
possesses	O
a	O
unique	O
60	B
amino	I
acid	I
carboxy	I
-	I
terminus	I
generated	O
by	O
read	O
through	O
of	O
a	O
'	O
coding	B
intron	I
'	O
and	O
alternative	O
splicing	O
.	O

Tyloxapol	O
inhibits	O
NF	B
-	I
kappa	I
B	I
and	O
cytokine	B
release	O
,	O
scavenges	O
HOCI	B
,	O
and	O
reduces	O
viscosity	O
of	O
cystic	O
fibrosis	O
sputum	O
.	O

In	O
the	O
search	O
for	O
a	O
potential	O
treatment	O
,	O
we	O
have	O
tested	O
tyloxapol	O
,	O
an	O
alkylaryl	O
polyether	O
alcohol	O
polymer	O
detergent	O
previously	O
used	O
as	O
a	O
mucolytic	O
agent	O
in	O
adult	O
chronic	O
bronchitis	O
.	O

Tyloxapol	O
inhibits	O
activation	O
of	O
the	O
transcription	B
factor	I
nuclear	I
factor	I
-	I
kappa	I
B	I
(	O
NK	B
-	I
kappa	I
B	I
)	O
,	O
reduces	O
resting	O
secretion	O
of	O
the	O
cytokine	B
interleukin	B
-	I
8	I
(	O
IL	B
-	I
8	I
)	O
in	O
cultured	O
human	O
monocytes	O
,	O
and	O
inhibits	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-	O
stimulated	O
release	O
of	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
(	O
TNF	B
-	I
alpha	I
)	O
,	O
IL	B
-	I
1	I
beta	I
,	O
IL	B
-	I
6	I
,	O
IL	B
-	I
8	I
,	O
granulocyte	B
-	I
macrophage	I
colony	I
-	I
stimulating	I
factor	I
(	O
GM	B
-	I
CSF	I
)	O
,	O
and	O
the	O
eiconsanoids	O
thromboxane	O
A2	O
and	O
leukotriene	O
B4	O
(	O
LTB4	O
)	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
the	O
molecular	O
mechanism	O
by	O
which	O
agents	O
that	O
elevate	O
intracellular	O
cAMP	O
inhibit	O
the	O
expression	O
of	O
the	O
tumor	B
necrosis	I
factor	I
alpha	I
(	O
TNFalpha	B
)	O
,	O
tissue	B
factor	I
,	O
endothelial	B
leukocyte	I
adhesion	I
molecule	I
-	I
1	I
,	O
and	O
vascular	B
cell	I
adhesion	I
molecule	I
-	I
1	I
genes	I
.	O

We	O
propose	O
that	O
direct	O
interaction	O
between	O
the	O
glucocorticoid	B
receptor	I
and	O
nuclear	B
factor	I
-	I
kappa	I
B	I
factors	I
is	O
at	O
least	O
a	O
partial	O
explanation	O
for	O
the	O
effects	O
of	O
this	O
hormone	O
in	O
inflammatory	O
diseases	O
.	O

Abnormalities	O
in	O
the	O
p16	B
,	I
p15	I
and	I
CDK4	I
genes	I
that	O
regulate	O
transition	O
through	O
the	O
G1	O
phase	O
of	O
the	O
cell	O
cycle	O
have	O
been	O
implicated	O
in	O
the	O
malignant	O
progression	O
of	O
astrocytomas	O
.	O

The	O
primary	O
and	O
recurrent	O
tumors	O
in	O
Group	O
A	O
did	O
not	O
show	O
structural	O
alterations	O
in	O
the	O
p16	B
,	I
p15	I
or	I
CDK4	I
genes	I
,	O
whereas	O
homozygous	O
codeletion	O
of	O
p16	B
and	O
p15	B
was	O
observed	O
in	O
both	O
primary	O
and	O
recurrent	O
tumors	O
in	O
Group	O
B	O
.	O

The	O
primary	O
tumors	O
in	O
Group	O
C	O
had	O
a	O
normal	O
profile	O
of	O
p16	B
,	O
p15	B
and	O
CDK4	B
at	O
presentation	O
.	O

Approximately	O
40	O
%	O
of	O
diffuse	O
large	O
cell	O
lymphoma	O
are	O
associated	O
with	O
chromosomal	O
translocations	O
that	O
deregulate	O
the	O
expression	O
of	O
the	O
BCL6	B
gene	I
by	O
juxtaposing	O
heterologous	B
promoters	I
to	O
the	O
BCL	B
-	I
6	I
coding	I
domain	I
.	O

In	O
transient	O
transfectin	O
experiments	O
,	O
BCL6	B
can	O
repress	O
transcription	O
from	O
promoters	B
linked	O
to	O
its	O
DNA	B
target	I
sequence	I
and	O
this	O
activity	O
is	O
dependent	O
upon	O
specific	O
DNA	O
-	O
binding	O
and	O
the	O
presence	O
of	O
an	O
intact	O
N	B
-	I
terminal	I
half	I
of	O
the	O
protein	O
.	O

As	O
the	O
NF	B
-	I
kappa	I
B	I
transcription	I
factor	I
has	O
a	O
central	O
role	O
in	O
the	O
control	O
of	O
transcription	O
of	O
several	O
genes	B
involved	O
in	O
immune	O
and	O
inflammatory	O
responses	O
,	O
the	O
authors	O
have	O
analysed	O
the	O
activation	O
of	O
NF	B
-	I
kappa	I
B	I
in	O
human	O
umbilical	O
cord	O
T	O
lymphocytes	O
.	O

The	O
key	O
role	O
of	O
erythropoietin	B
(	O
Epo	B
)	O
for	O
colony	O
formation	O
by	O
early	O
erythroid	O
progenitors	O
(	O
burst	O
-	O
forming	O
units	O
-	O
erythroid	O
[	O
BFU	O
-	O
E	O
]	O
)	O
has	O
been	O
confirmed	O
.	O

High	O
concentrations	O
of	O
either	O
compound	O
(	O
1	O
)	O
drastically	O
reduced	O
the	O
number	O
of	O
primary	O
HPP	O
-	O
CFC	O
colonies	O
and	O
totally	O
abolished	O
their	O
recloning	O
capacity	O
and	O
(	O
2	O
)	O
inhibited	O
HSC	O
proliferation	O
.	O

Altogether	O
,	O
these	O
results	O
suggest	O
that	O
ATRA	O
/	O
9	O
-	O
cis	O
RA	O
may	O
play	O
a	O
key	O
role	O
in	O
FL	O
hematopoiesis	O
via	O
a	O
dual	O
effect	O
hypothetically	O
mediated	O
by	O
interaction	O
with	O
the	O
RAR	B
/	I
RXR	I
heterodimer	I
,	O
ie	O
,	O
inhibition	O
of	O
HSC	O
/	O
primitive	O
HPC	O
proliferation	O
and	O
induction	O
of	O
CFU	O
-	O
GEMM	O
/	O
BFU	O
-	O
E	O
/	O
CFU	O
-	O
M	O
shift	O
from	O
the	O
multipotent	O
/	O
erythroid	O
/	O
monocytic	O
to	O
the	O
granulocytic	O
-	O
neutrophilic	O
differentiation	O
program	O
.	O

We	O
previously	O
suggested	O
that	O
the	O
measurement	O
of	O
corticosteroid	B
receptors	I
in	O
lymphocytes	O
is	O
an	O
index	O
of	O
an	O
analogous	O
pattern	O
in	O
brain	O
.	O

Receptors	O
were	O
measured	O
by	O
radioreceptor	O
assay	O
.	O

Analysis	O
of	O
the	O
ligand	B
-	I
binding	I
domain	I
of	O
human	B
retinoic	I
acid	I
receptor	I
alpha	I
by	O
site	O
-	O
directed	O
mutagenesis	O
.	O

Three	O
subtypes	O
of	O
retinoic	B
acid	I
receptors	I
(	O
RAR	B
)	O
,	O
termed	O
RAR	B
alpha	I
,	O
RAR	B
beta	I
,	O
and	O
RAR	B
gamma	I
,	O
have	O
been	O
described	O
.	O

RARs	B
specifically	O
bind	O
all	O
-	O
trans	O
-	O
retinoic	O
acid	O
(	O
RA	O
)	O
,	O
9	O
-	O
cis	O
-	O
RA	O
,	O
and	O
retinoid	O
analogs	O
.	O

Interestingly	O
,	O
residue	O
C	O
-	O
235	O
is	O
specifically	O
important	O
in	O
antagonist	O
binding	O
.	O

With	O
respect	O
to	O
arginine	O
residues	O
,	O
only	O
the	O
two	O
single	O
mutations	O
of	O
R	O
-	O
276	O
and	O
R	O
-	O
394	O
to	O
alanine	O
showed	O
a	O
dramatic	O
decrease	O
of	O
agonist	O
and	O
antagonist	O
binding	O
whereas	O
the	O
R272A	O
mutation	O
showed	O
only	O
a	O
slight	O
effect	O
.	O

For	O
all	O
other	O
arginine	O
mutations	O
,	O
no	O
differences	O
in	O
affinity	O
were	O
detectable	O
.	O

The	O
two	O
mutations	O
R217A	O
and	O
R294A	O
caused	O
an	O
increased	O
binding	O
efficiency	O
for	O
antagonists	O
but	O
no	O
change	O
in	O
agonist	O
binding	O
.	O

From	O
these	O
results	O
,	O
we	O
can	O
conclude	O
that	O
electrostatic	O
interactions	O
of	O
retinoids	O
with	O
the	O
RAR	B
alpha	I
-	I
LBD	I
play	O
a	O
significant	O
role	O
in	O
ligand	O
binding	O
.	O

In	O
spite	O
of	O
this	O
similar	O
downstream	O
signalling	O
,	O
IL4	B
and	O
IL13	B
used	O
a	O
different	O
set	O
of	O
Janus	B
kinases	I
:	O
IL13	B
is	O
unable	O
to	O
activate	O
JAK1	B
and	O
JAK3	B
.	O

Our	O
findings	O
support	O
the	O
recently	O
determined	O
calcineurin	B
X	O
-	O
ray	O
crystal	O
structure	O
,	O
provide	O
evidence	O
that	O
calcineurin	B
is	O
the	O
only	O
CsA	B
-	I
sensitive	I
component	I
limiting	O
signaling	O
from	O
the	O
T	B
cell	I
receptor	I
to	O
the	O
nucleus	O
,	O
and	O
suggest	O
a	O
means	O
to	O
render	O
cells	O
and	O
tissues	O
resistant	O
to	O
the	O
toxic	O
side	O
effects	O
of	O
CsA	O
and	O
FK506	O
.	O

Epstein	O
-	O
Barr	O
viral	O
latency	O
is	O
disrupted	O
by	O
the	O
immediate	B
-	I
early	I
BRLF1	I
protein	I
through	O
a	O
cell	O
-	O
specific	O
mechanism	O
.	O

Epithelial	O
cells	O
are	O
the	O
major	O
site	O
of	O
lytic	O
EBV	O
replication	O
within	O
the	O
human	O
host	O
,	O
and	O
viral	O
reactivation	O
occurs	O
in	O
EBV	O
-	O
associated	O
nasopharyngeal	O
carcinomas	O
.	O

Eosinophils	O
play	O
an	O
important	O
role	O
in	O
the	O
effector	O
phase	O
of	O
allergic	O
inflammation	O
.	O

The	O
extent	O
to	O
which	O
peptides	O
containing	O
chemically	O
and	O
post	O
-	O
translationally	O
modified	O
amino	B
acid	I
side	I
chains	I
are	O
recognized	O
by	O
primed	O
CTL	O
has	O
not	O
been	O
clearly	O
defined	O
.	O

The	O
CTL	O
specifically	O
recognized	O
the	O
succinimide	O
-	O
containing	O
peptide	O
showing	O
only	O
weak	O
cross	O
-	O
reactivity	O
at	O
high	O
concentrations	O
of	O
the	O
parent	O
peptide	O
containing	O
unmodified	O
asparagine	O
.	O

Moreover	O
,	O
since	O
succinimide	O
intermediates	O
of	O
deamidated	O
peptides	O
can	O
occasionally	O
be	O
very	O
stable	O
,	O
these	O
peptides	O
have	O
the	O
potential	O
to	O
act	O
as	O
altered	O
self	O
-	O
Ags	O
with	O
significant	O
implications	O
for	O
autoimmunity	O
.	O

A	O
3	O
'	O
-	O
-	O
>	O
5	O
'	O
XPB	B
helicase	I
defect	O
in	O
repair	B
/	I
transcription	I
factor	I
TFIIH	B
of	O
xeroderma	O
pigmentosum	O
group	O
B	O
affects	O
both	O
DNA	O
repair	O
and	O
transcription	O
.	O

Although	O
identical	O
in	O
composition	O
and	O
stoichiometry	O
to	O
TFIIHwt	B
,	O
TFIIHmut	B
shows	O
a	O
reduced	O
3	O
'	O
-	O
-	O
>	O
5	O
'	O
XPB	B
helicase	O
activity	O
.	O

The	O
XPB	B
mutation	O
causes	O
a	O
severe	O
NER	O
defect	O
.	O

The	O
latter	O
defect	O
may	O
provide	O
an	O
explanation	O
for	O
many	O
of	O
the	O
XP	O
and	O
CS	O
symptoms	O
that	O
are	O
difficult	O
to	O
rationalize	O
based	O
solely	O
on	O
an	O
NER	O
defect	O
.	O

PU	B
.	I
1	I
is	O
completely	O
absent	O
from	O
peripheral	O
T	O
cells	O
and	O
most	O
T	O
cell	O
lines	O
based	O
on	O
sensitive	O
RT	O
-	O
PCR	O
assays	O
.	O

In	O
contrast	O
,	O
Spi	B
-	I
B	I
is	O
expressed	O
exclusively	O
in	O
lymphoid	O
cells	O
and	O
can	O
be	O
detected	O
in	O
early	O
fetal	O
thymus	O
and	O
spleen	O
.	O

In	O
situ	O
hybridization	O
and	O
Northern	O
blot	O
analysis	O
suggest	O
that	O
Spi	B
-	I
B	I
gene	O
expression	O
increases	O
during	O
B	O
cell	O
maturation	O
and	O
decreases	O
during	O
T	O
cell	O
maturation	O
.	O

Taken	O
together	O
,	O
these	O
data	O
suggest	O
that	O
differences	O
in	O
patterns	O
of	O
expression	O
between	O
Spi	B
-	I
B	I
and	O
PU	B
.	I
1	I
distinguish	O
the	O
function	O
of	O
each	O
protein	O
during	O
development	O
of	O
the	O
immune	O
system	O
.	O

DNase	B
I	I
hypersensitive	I
site	I
(	O
DHS	B
)	O
mapping	O
revealed	O
that	O
the	O
perforin	B
locus	I
contained	O
six	O
DHS	B
within	O
7	O
.	O
0	O
kb	O
of	O
the	O
5	B
'	I
upstream	I
sequence	I
(	O
-	O
7	O
.	O
0	O
kb	O
)	O
and	O
two	O
DHS	B
in	O
intron	B
2	I
.	O

Chloramphenicol	B
acetyltransferase	I
(	O
CAT	B
)	O
activities	O
directed	O
by	O
5	B
'	I
upstream	I
promoter	I
were	O
detected	O
preferentially	O
in	O
perforin	O
-	O
expressing	O
cell	O
lines	O
.	O

When	O
single	O
-	O
point	O
mutation	O
was	O
introduced	O
to	O
each	O
GC	B
box	I
,	O
EBS	B
,	O
and	O
GT	B
box	I
in	O
PFP9a20	B
,	O
at	O
least	O
3	O
-	O
fold	O
less	O
CAT	B
activity	O
was	O
observed	O
in	O
CTLL	O
-	O
R8	O
cells	O
.	O

The	O
results	O
suggest	O
that	O
a	O
combination	O
of	O
the	O
three	O
proximal	O
cis	B
-	I
acting	I
elements	I
may	O
constitute	O
a	O
minimal	O
region	O
responsible	O
for	O
CTL	O
-	O
specific	O
expression	O
of	O
perforin	B
.	O

Thus	O
Oct	B
-	I
2	I
plays	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
cellular	O
gene	O
expression	O
in	O
both	O
B	O
cells	O
and	O
neuronal	O
cells	O
as	O
well	O
as	O
in	O
the	O
control	O
of	O
viral	O
latency	O
.	O

Instead	O
,	O
ATF	B
-	I
2	I
and	O
Jun	B
proteins	I
bind	O
to	O
the	O
composite	B
kappa	I
3	I
/	I
CRE	I
site	I
and	O
NFATp	B
binds	O
to	O
a	O
newly	O
identified	O
second	O
NFAT	B
site	I
centered	O
at	O
-	B
76	I
nucleotides	I
relative	O
to	O
the	O
TNF	B
-	I
alpha	I
transcription	I
start	I
site	I
.	O

Consistent	O
with	O
these	O
results	O
,	O
quantitative	O
DNase	B
footprinting	O
of	O
the	O
TNF	B
-	I
alpha	I
promoter	I
using	O
increasing	O
amounts	O
of	O
recombinant	O
NFATp	B
demonstrated	O
that	O
the	O
-	B
76	I
site	I
binds	O
to	O
NFATp	B
with	O
a	O
higher	O
affinity	O
than	O
the	O
kappa	B
3	I
site	I
.	O

Thus	O
,	O
through	O
the	O
differential	O
use	O
of	O
the	O
same	O
promoter	B
element	I
,	O
the	O
composite	B
kappa	I
3	I
/	I
CRE	I
site	I
,	O
the	O
TNF	B
-	I
alpha	I
gene	I
is	O
regulated	O
in	O
a	O
cell	O
-	O
type	O
-	O
specific	O
manner	O
in	O
response	O
to	O
the	O
same	O
extracellular	O
signal	O
.	O

To	O
address	O
possible	O
mechanisms	O
that	O
could	O
explain	O
this	O
selective	O
activity	O
of	O
c	B
-	I
ErbB	I
,	O
we	O
analyzed	O
the	O
ability	O
of	O
these	O
receptors	O
to	O
activate	O
the	O
different	O
members	O
of	O
the	O
Stat	B
transcription	I
factor	I
family	I
.	O

Ligand	O
activation	O
of	O
c	B
-	I
ErbB	I
induced	O
the	O
tyrosine	O
phosphorylation	O
,	O
DNA	O
-	O
binding	O
,	O
and	O
reporter	B
gene	I
transcription	O
of	O
Stat	B
5b	I
in	O
erythroblasts	O
.	O

In	O
contrast	O
,	O
ligand	O
activation	O
of	O
c	B
-	I
Kit	I
was	O
unable	O
to	O
induce	O
any	O
of	O
these	O
effects	O
in	O
the	O
same	O
cells	O
.	O

Sequence	O
-	O
specific	O
DNA	O
binding	O
of	O
the	O
B	B
-	I
cell	I
-	I
specific	I
coactivator	I
OCA	B
-	I
B	I
.	O

While	O
one	O
of	O
the	O
twins	O
was	O
clinically	O
affected	O
,	O
the	O
other	O
was	O
asymptomatic	O
.	O

This	O
is	O
the	O
first	O
documented	O
case	O
of	O
female	O
twins	O
discordant	O
for	O
Fabry	O
disease	O
.	O

Precise	O
alignment	B
of	I
sites	I
required	O
for	O
mu	B
enhancer	I
activation	O
in	O
B	O
cells	O
.	O

The	O
lymphocyte	B
-	I
specific	I
immunoglobulin	I
mu	I
heavy	I
-	I
chain	I
gene	I
intronic	I
enhancer	I
is	O
regulated	O
by	O
multiple	O
nuclear	B
factors	I
.	O

The	O
previously	O
defined	O
minimal	B
enhancer	I
containing	O
the	O
muA	B
,	I
muE3	I
,	I
and	I
muB	I
sites	I
is	O
transactivated	O
by	O
a	O
combination	O
of	O
the	O
ETS	B
-	I
domain	I
proteins	I
PU	B
.	I
1	I
and	O
Ets	B
-	I
1	I
in	O
nonlymphoid	O
cells	O
.	O

The	O
core	O
GGAAs	O
of	O
the	O
muA	B
and	I
muB	I
sites	I
are	O
separated	O
by	O
30	O
nucleotides	O
,	O
suggesting	O
that	O
ETS	B
proteins	I
bind	O
to	O
these	O
sites	O
from	O
these	O
same	O
side	O
of	O
the	O
DNA	O
helix	O
.	O

In	O
allergic	O
bronchial	O
asthma	O
,	O
inflammation	O
seems	O
to	O
be	O
orchestrated	O
predominantly	O
by	O
a	O
subset	O
of	O
T	O
lymphocytes	O
,	O
with	O
a	O
phenotype	O
similar	O
to	O
the	O
Th2	O
subset	O
able	O
to	O
produce	O
IL	B
-	I
4	I
and	O
IL	B
-	I
5	I
.	O

Some	O
criteria	O
which	O
can	O
be	O
used	O
to	O
define	O
steroid	O
-	O
resistant	O
bronchial	O
asthma	O
are	O
listed	O
here	O
.	O

Mechanisms	O
of	O
transactivation	O
by	O
nuclear	B
factor	I
of	I
activated	I
T	I
cells	I
-	I
1	I
.	O

Nuclear	B
factor	I
of	I
activated	I
T	I
cells	I
-	I
family	I
proteins	I
(	O
NFAT1	B
/	I
NFATp	I
,	O
NFATc	B
,	O
NFAT3	B
,	O
and	O
NFAT4	B
/	I
NFATx	I
/	I
NFATc3	I
)	O
play	O
a	O
key	O
role	O
in	O
the	O
transcription	O
of	O
cytokine	B
genes	I
and	O
other	O
genes	O
during	O
the	O
immune	O
response	O
.	O

Our	O
results	O
emphasize	O
the	O
multiple	O
levels	O
at	O
which	O
NFAT	O
-	O
dependent	O
transactivation	O
is	O
regulated	O
,	O
and	O
predict	O
significant	O
differences	O
in	O
the	O
architecture	O
of	O
cooperative	O
transcription	B
complexes	I
containing	O
different	O
NFAT	B
-	I
family	I
proteins	I
.	O

A	O
major	O
obstacle	O
in	O
understanding	O
the	O
signaling	O
events	O
that	O
follow	O
CD28	B
receptor	O
ligation	O
arises	O
from	O
the	O
fact	O
that	O
CD28	B
acts	O
as	O
a	O
costimulus	O
to	O
TCR	B
engagement	O
,	O
making	O
it	O
difficult	O
to	O
assess	O
the	O
relative	O
contribution	O
of	O
CD28	B
signals	O
as	O
distinct	O
from	O
those	O
of	O
the	O
TCR	B
.	O

This	O
revealed	O
that	O
NF	B
-	I
kappaB	I
generation	O
was	O
sensitive	O
to	O
chloroquine	O
,	O
an	O
inhibitor	O
of	O
acidic	B
sphingomyelinase	I
,	O
but	O
not	O
to	O
the	O
phosphatidylinositol	B
3	I
-	I
kinase	I
inhibitor	O
,	O
wortmannin	O
.	O

To	O
investigate	O
the	O
presence	O
of	O
various	O
isoforms	O
of	O
the	O
estrogen	B
receptor	I
(	O
ER	B
)	O
in	O
SLE	O
we	O
isolated	O
RNA	O
from	O
mononuclear	O
cells	O
of	O
lupus	O
patients	O
and	O
normal	O
controls	O
.	O

It	O
is	O
expressed	O
on	O
a	O
subpopulation	O
of	O
macrophages	O
in	O
lymphoid	O
tissues	O
and	O
in	O
chronic	O
inflammation	O
(	O
e	O
.	O
g	O
.	O
,	O
during	O
autoimmune	O
diseases	O
)	O
.	O

Sialoadhesin	B
expression	O
was	O
functional	O
as	O
shown	O
by	O
cell	O
adhesion	O
assays	O
with	O
human	O
RBCs	O
.	O

Northern	O
blotting	O
experiments	O
indicated	O
that	O
regulation	O
predominantly	O
occurred	O
at	O
the	O
mRNA	O
level	O
.	O

The	O
results	O
suggest	O
a	O
new	O
option	O
for	O
HIV	O
gene	O
therapy	O
;	O
bcl	B
-	I
2	I
muteins	I
that	O
have	O
noncleavable	B
alterations	I
surrounding	O
the	O
HIV	B
protease	I
cleavage	I
site	I
.	O

In	O
contrast	O
to	O
freshly	O
isolated	O
T	O
cells	O
,	O
in	O
vitro	O
-	O
cultured	O
T	O
cells	O
did	O
not	O
require	O
costimulation	O
for	O
cytokine	B
secretion	O
in	O
response	O
to	O
anti	B
-	I
CD3	I
alone	O
.	O

The	O
induction	O
of	O
T	O
cell	O
proliferation	O
requires	O
signals	O
from	O
the	O
TCR	B
and	O
a	O
co	B
-	I
receptor	I
molecule	I
,	O
such	O
as	O
CD28	B
,	O
that	O
activate	O
parallel	O
and	O
partially	O
cross	O
-	O
reactive	O
signaling	O
pathways	O
.	O

Our	O
results	O
suggest	O
that	O
PKA	B
inhibits	O
T	O
cell	O
activation	O
by	O
interfering	O
with	O
multiple	O
events	O
along	O
the	O
two	O
signaling	O
pathways	O
operating	O
downstream	O
of	O
the	O
TCR	B
and	O
the	O
CD28	B
co	I
-	I
receptor	I
molecules	I
.	O

This	O
pattern	O
of	O
STAT	B
activation	O
was	O
seen	O
in	O
all	O
BCP	O
-	O
ALL	O
cases	O
that	O
respond	O
to	O
IL	B
-	I
7	I
in	O
proliferation	O
assays	O
.	O

To	O
determine	O
the	O
contribution	O
of	O
the	O
cytoplasmic	B
domain	I
of	O
the	O
IL	B
-	I
7	I
receptor	I
alpha	I
chain	I
(	O
IL	B
-	I
7R	I
alpha	I
)	O
to	O
activation	O
of	O
STAT	B
proteins	I
,	O
transfectants	O
of	O
the	O
murine	O
pro	O
-	O
B	O
cell	O
line	O
BAF3	O
were	O
made	O
that	O
express	O
chimeric	B
receptors	I
consisting	O
of	O
the	O
extracellular	B
domain	I
of	O
human	B
granulocyte	I
colony	I
-	I
stimulating	I
factor	I
receptor	I
(	O
G	B
-	I
CSF	I
-	I
R	I
)	O
and	O
the	O
transmembrane	B
and	I
intracellular	I
domains	I
of	O
human	B
IL	I
-	I
7R	I
alpha	I
.	O

The	O
oligo	O
sequence	O
I	O
stimulated	O
proliferation	O
of	O
both	O
T	O
and	O
,	O
to	O
a	O
lesser	O
extent	O
,	O
B	O
cells	O
.	O

The	O
percentage	O
of	O
cells	O
expressing	O
CD40	B
in	O
T	O
and	O
B	O
cell	O
co	O
-	O
cultures	O
increased	O
from	O
4	O
.	O
2	O
%	O
to	O
13	O
.	O
8	O
%	O
after	O
oligo	O
stimulation	O
in	O
patients	O
,	O
while	O
it	O
increased	O
form	O
4	O
.	O
7	O
%	O
to	O
48	O
.	O
6	O
%	O
in	O
healthy	O
controls	O
.	O

We	O
demonstrate	O
that	O
CaMKIV	B
/	I
Gr	I
reconstitutes	O
the	O
capacity	O
of	O
the	O
cytosolic	O
component	O
of	O
NFAT	B
to	O
direct	O
transcription	O
from	O
NFAT	B
sites	I
in	O
non	O
-	O
T	O
cells	O
.	O

This	O
was	O
identified	O
as	O
the	O
mRNA	B
encoding	O
the	O
transcription	B
factor	I
egr	B
-	I
1	I
,	O
which	O
is	O
expressed	O
with	O
fast	O
kinetics	O
in	O
T	O
and	O
NK	O
cells	O
upon	O
IL	B
-	I
2	I
,	O
but	O
not	O
IL	B
-	I
12	I
,	O
stimulation	O
.	O

Increasing	O
the	O
levels	O
of	O
BCL	B
-	I
2	I
retarded	O
the	O
G0	O
-	O
-	O
>	O
S	O
transition	O
,	O
sustained	O
the	O
levels	O
of	O
cyclin	B
-	I
dependent	I
kinase	I
inhibitor	O
p27Kip1	O
,	O
and	O
repressed	O
postactivation	O
death	O
.	O

However	O
,	O
the	O
transcription	O
and	O
synthesis	O
of	O
interleukin	B
2	I
and	O
other	O
delayed	O
early	O
cytokines	B
were	O
markedly	O
attenuated	O
by	O
BCL	B
-	I
2	I
.	O

On	O
the	O
basis	O
of	O
several	O
independent	O
assays	O
,	O
we	O
now	O
report	O
a	O
physical	O
and	O
functional	O
interaction	O
between	O
Tax	B
and	O
the	O
transcription	B
factor	I
,	O
TFIIA	B
.	O

Finally	O
,	O
TFIIA	B
facilitates	O
Tax	B
transactivation	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Inhibition	O
of	O
transcription	B
factor	I
Stat1	B
activity	O
in	O
mononuclear	O
cell	O
cultures	O
and	O
T	O
cells	O
by	O
the	O
cyclic	O
AMP	O
signaling	O
pathway	O
.	O

Suppression	O
of	O
c	B
-	I
jun	I
by	O
antisense	O
oligonucleotides	O
inhibits	O
cell	O
adhesion	O
but	O
not	O
respiratory	O
burst	O
during	O
phorbol	O
ester	O
-	O
induced	O
differentiation	O
of	O
U937	O
human	O
monoblastic	O
cells	O
.	O

GM	B
-	I
CSF	I
gene	I
activation	O
in	O
T	O
cells	O
is	O
known	O
to	O
involve	O
the	O
transcription	B
factors	I
nuclear	B
factor	I
-	I
kappa	I
B	I
,	O
AP	B
-	I
1	I
,	O
NFAT	B
,	O
and	O
Sp1	O
.	O

A	O
2	B
-	I
bp	I
mutation	I
within	O
the	O
CBF	B
site	O
resulted	O
in	O
a	O
2	O
-	O
3	O
-	O
fold	O
decrease	O
in	O
the	O
activities	O
of	O
both	O
a	O
69	B
-	I
bp	I
proximal	I
promoter	I
fragment	I
and	O
a	O
627	B
-	I
bp	I
full	I
-	I
length	I
promoter	I
fragment	I
.	O

The	O
AML1	B
and	I
CBF	I
beta	I
genes	I
that	O
encode	O
CBF	B
each	O
have	O
the	O
ability	O
to	O
influence	O
cell	O
growth	O
and	O
differentiation	O
and	O
have	O
been	O
implicated	O
as	O
proto	B
-	I
oncogenes	I
in	O
acute	O
myeloid	O
leukemia	O
.	O

The	O
GM	B
-	I
CSF	I
locus	I
may	O
represent	O
one	O
of	O
several	O
target	O
genes	B
that	O
are	O
dysregulated	O
in	O
acute	O
myeloid	O
leukemia	O
.	O

The	O
preferential	O
induction	O
of	O
c	B
-	I
jun	I
by	O
H2O2	O
did	O
not	O
represent	O
redox	O
stabilization	O
of	O
mRNA	B
transcripts	I
,	O
and	O
oxidative	O
signals	O
closely	O
resembled	O
PHA	O
/	O
PMA	O
stimulation	O
by	O
effectively	O
transactivating	O
the	O
full	O
length	O
c	B
-	I
jun	I
promoter	O
via	O
the	O
proximal	B
jun1	I
tumor	I
promoter	I
-	I
responsive	I
element	I
(	I
TRE	I
)	I
-	I
like	I
promoter	I
element	I
.	O

Furthermore	O
,	O
sublethal	O
levels	O
of	O
H2O2	O
actively	O
suppressed	O
the	O
transcriptional	O
activation	O
of	O
NF	B
-	I
AT	I
and	O
IL	B
-	I
2	I
reporters	I
as	O
well	O
as	O
the	O
expression	O
of	O
IL	B
-	I
2	I
mRNA	I
in	O
cells	O
stimulated	O
with	O
PHA	O
/	O
PMA	O
.	O

These	O
results	O
suggest	O
that	O
oxidative	O
signals	O
can	O
positively	O
and	O
negatively	O
regulate	O
T	O
cell	O
transcriptional	O
events	O
and	O
that	O
changes	O
in	O
cellular	O
redox	O
can	O
uncouple	O
AP	B
-	I
1	I
regulation	O
of	O
c	B
-	I
jun	I
from	O
transcriptional	O
up	O
-	O
regulation	O
of	O
IL	B
-	I
2	I
via	O
NF	B
-	I
AT	I
.	O

Many	O
of	O
Pb	O
'	O
s	O
effects	O
on	O
the	O
immune	O
system	O
could	O
be	O
explained	O
through	O
activation	O
of	O
the	O
transcription	B
factor	I
,	O
NF	B
-	I
kappa	I
B	I
.	O

Tyrosine	B
kinase	I
and	O
cAMP	B
-	I
dependent	I
protein	I
kinase	I
activities	O
in	O
CD40	O
-	O
activated	O
human	O
B	O
lymphocytes	O
.	O

In	O
vitro	O
,	O
human	O
B	O
lymphocytes	O
undergo	O
long	O
-	O
term	O
proliferation	O
when	O
activated	O
through	O
CD40	B
,	O
a	O
protein	O
expressed	O
on	O
their	O
cell	O
surface	O
.	O

Rather	O
,	O
tyrosine	O
phosphorylation	O
was	O
shown	O
to	O
be	O
directly	O
involved	O
in	O
mediating	O
CD40	B
-	O
dependent	O
signals	O
.	O

To	O
examine	O
the	O
potential	O
effects	O
of	O
stress	O
on	O
TH1	O
/	O
TH2	O
balance	O
,	O
we	O
studied	O
the	O
ability	O
of	O
three	O
prototype	O
stress	O
hormones	O
-	O
dexamethasone	O
(	O
a	O
synthetic	O
glucocorticoid	O
)	O
and	O
the	O
catecholamines	O
norepinephrine	O
and	O
epinephrine	O
-	O
to	O
alter	O
the	O
production	O
of	O
IL	B
-	I
12	I
(	O
p70	B
)	O
and	O
IL	B
-	I
10	I
induced	O
by	O
bacterial	O
lipopolysaccharide	O
(	O
LPS	O
)	O
in	O
human	O
whole	O
blood	O
.	O

The	O
effects	O
of	O
either	O
catecholamine	O
on	O
IL	B
-	I
12	I
or	O
IL	B
-	I
10	I
secretion	O
were	O
blocked	O
completely	O
by	O
propranolol	O
,	O
a	O
beta	O
-	O
adrenoreceptor	O
antagonist	O
,	O
indicating	O
that	O
they	O
were	O
mediated	O
by	O
the	O
beta	B
-	I
adrenergic	I
receptor	I
.	O

These	O
findings	O
suggest	O
that	O
the	O
central	O
nervous	O
system	O
may	O
regulate	O
IL	O
-	O
12	O
and	O
IL	O
-	O
10	O
secretion	O
and	O
,	O
hence	O
,	O
TH1	O
/	O
TH2	O
balance	O
via	O
the	O
peripheral	O
end	O
-	O
effectors	O
of	O
the	O
stress	O
system	O
.	O

There	O
is	O
increasing	O
evidence	O
that	O
lipoproteins	B
of	O
Treponema	O
pallidum	O
and	O
Borrelia	O
burgdorferi	O
are	O
key	O
inflammatory	O
mediators	O
during	O
syphilis	O
and	O
Lyme	O
disease	O
.	O

Acylation	O
of	O
OspA	B
and	O
the	O
synthetic	O
peptides	O
was	O
requisite	O
for	O
cell	O
activation	O
.	O

Polymyxin	O
B	O
abrogated	O
only	O
the	O
response	O
to	O
LPS	O
.	O

Finally	O
,	O
the	O
biological	O
relevance	O
of	O
the	O
observation	O
that	O
T	B
.	I
pallidum	I
lipoproteins	I
-	O
lipopeptides	O
induce	O
both	O
NF	B
-	I
kappa	I
B	I
and	O
cytokine	B
production	O
in	O
monocytes	O
was	O
supported	O
by	O
the	O
ability	O
of	O
the	O
synthetic	O
analogs	O
to	O
promote	O
human	O
immunodeficiency	O
virus	O
replication	O
in	O
chronically	O
infected	O
U1	O
monocytoid	O
cells	O
;	O
these	O
observations	O
also	O
suggest	O
a	O
potential	O
mechanism	O
whereby	O
a	O
syphilitic	O
chancre	O
can	O
serve	O
as	O
a	O
cofactor	O
for	O
human	O
immunodeficiency	O
virus	O
transmission	O
.	O

The	O
present	O
study	O
describes	O
the	O
cloning	O
of	O
a	O
lymphoid	B
-	I
restricted	I
gene	I
,	O
LYSP100	B
,	O
that	O
is	O
homologous	O
to	O
another	O
protein	O
that	O
localizes	O
to	O
PML	O
NBs	O
,	O
SP100	B
.	O

We	O
term	O
the	O
LYSP100	B
structures	O
`	O
`	O
LANDs	O
,	O
'	O
'	O
for	O
LYSP100	B
-	O
associated	O
nuclear	O
domains	O
.	O

Immunoelectron	O
microscopy	O
revealed	O
LANDs	O
to	O
be	O
globular	O
,	O
electron	O
-	O
dense	O
structures	O
morphologically	O
distinct	O
from	O
the	O
annular	O
structures	O
characteristic	O
of	O
PML	O
NBs	O
.	O

Transcriptional	O
control	O
of	O
steroid	O
-	O
regulated	O
apoptosis	O
in	O
murine	O
thymoma	O
cells	O
.	O

Early	O
studies	O
in	O
murine	O
T	O
cell	O
lines	O
indicated	O
that	O
transcriptional	O
transactivation	O
functions	O
encoded	O
in	O
the	O
glucocorticoid	B
receptor	I
(	I
GR	I
)	I
N	I
-	I
terminal	I
domain	I
are	O
required	O
for	O
glucocorticoid	O
-	O
mediated	O
apoptosis	O
.	O

To	O
better	O
understand	O
the	O
contribution	O
of	O
the	O
GR	B
N	I
-	I
terminal	I
transactivation	I
domain	I
in	O
mediating	O
murine	O
thymocyte	O
apoptosis	O
,	O
we	O
stably	O
transfected	O
GR	B
,	O
GR	B
variants	I
,	O
and	O
the	O
androgen	B
receptor	I
(	O
AR	B
)	O
into	O
receptor	O
-	O
negative	O
S49	O
murine	O
thymoma	O
cells	O
.	O

One	O
p21ras	B
effector	O
pathway	O
involves	O
the	O
MAP	B
kinase	I
ERK	B
-	I
2	I
,	O
and	O
we	O
have	O
examined	O
its	O
role	O
in	O
NFAT	B
regulation	O
.	O

In	O
vivo	O
differentiation	O
therapy	O
with	O
retinoids	O
in	O
APL	O
patients	O
follows	O
strict	O
guidelines	O
related	O
both	O
to	O
the	O
APL	O
cell	O
and	O
the	O
biodisposal	O
of	O
all	O
-	O
trans	O
retinoic	O
acid	O
.	O

IL	O
-	O
2	O
-	O
,	O
IL	O
-	O
12	O
-	O
,	O
and	O
IFN	O
-	O
alpha	O
-	O
mediated	O
signaling	O
pathways	O
were	O
analyzed	O
in	O
primary	O
NK	O
cells	O
and	O
in	O
the	O
NK3	O
.	O
3	O
cell	O
line	O
.	O

Gel	O
mobility	O
shift	O
and	O
immunoprecipitation	O
analyses	O
revealed	O
that	O
in	O
addition	O
to	O
activating	O
STAT3	B
(	O
signal	B
transducer	I
and	I
activator	I
of	I
transcription	I
-	I
3	I
)	O
and	O
STAT5	B
,	O
IL	B
-	I
2	I
induced	O
tyrosine	O
and	O
serine	O
phosphorylation	O
of	O
STAT1	B
alpha	I
,	O
which	O
formed	O
IFN	B
-	I
gamma	I
-	I
activated	I
sequence	I
-	I
binding	I
complexes	I
by	O
itself	O
and	O
with	O
STAT3	B
.	O

Although	O
IL	B
-	I
2	I
and	O
IFN	B
-	I
alpha	I
activated	O
STAT1	B
alpha	I
and	O
STAT5	B
,	O
IL	B
-	I
2	I
predominantly	O
activated	O
STAT5	B
,	O
while	O
IFN	B
-	I
alpha	I
predominantly	O
activated	O
STAT1	B
alpha	I
.	O

STAT1	B
alpha	I
activation	O
by	O
IL	B
-	I
12	I
correlated	O
with	O
increased	O
phosphorylation	O
of	O
serine	O
,	O
but	O
not	O
tyrosine	O
.	O

Direct	O
evidence	O
that	O
N	O
-	O
acetylcysteine	O
(	O
NAC	O
)	O
enhances	O
the	O
immune	O
response	O
of	O
peripheral	O
blood	O
T	O
cells	O
at	O
the	O
level	O
of	O
NF	B
(	I
kappa	I
)	I
B	I
is	O
presented	O
.	O

In	O
addition	O
,	O
NAC	O
blocks	O
the	O
suppression	O
of	O
T	O
cell	O
mitogenesis	O
and	O
cytokine	B
production	O
by	O
protease	O
inhibitors	O
such	O
as	O
N	O
-	O
tosylphenylalanine	O
chloromethyl	O
ketone	O
(	O
TPCK	O
)	O
.	O

Strikingly	O
,	O
the	O
immunosuppressive	O
effects	O
of	O
TPCK	O
are	O
blocked	O
when	O
T	O
cells	O
are	O
pretreated	O
for	O
15	O
min	O
with	O
5	O
mM	O
NAC	O
.	O

Our	O
data	O
support	O
the	O
notion	O
that	O
NF	B
(	I
kappa	I
)	I
B	I
and	O
I	B
(	I
kappa	I
)	I
B	I
proteases	I
play	O
obligate	O
roles	O
in	O
T	O
cell	O
activation	O
and	O
mitogenesis	O
,	O
roles	O
that	O
are	O
enhanced	O
significantly	O
by	O
NAC	O
.	O

Recently	O
it	O
has	O
become	O
clear	O
that	O
these	O
cytokines	B
activate	O
a	O
number	O
of	O
important	O
intracellular	B
signaling	I
molecules	I
,	O
including	O
the	O
Janus	B
kinases	I
JAK1	B
and	O
JAK3	B
and	O
members	O
of	O
the	O
transcription	B
factor	I
family	I
of	O
signal	B
transducers	I
and	O
activators	B
of	I
transcription	I
(	O
STATs	B
)	O
.	O

In	O
this	O
review	O
we	O
examine	O
the	O
structure	O
and	O
function	O
of	O
cytokine	B
receptors	I
and	O
the	O
signaling	O
pathways	O
involved	O
in	O
their	O
regulation	O
of	O
gene	O
expression	O
.	O

Retinoic	O
acid	O
(	O
RA	O
)	O
and	O
1	O
,	O
25	O
alpha	O
-	O
dihydroxycholecalcif	O
(	O
VitD3	O
)	O
are	O
potent	O
regulators	O
of	O
hematopoletic	O
differentiation	O
.	O

Yet	O
,	O
little	O
is	O
known	O
as	O
to	O
how	O
the	O
RA	B
and	I
VitD3	I
receptor	I
network	I
operates	O
in	O
hematopoietic	O
cells	O
,	O
and	O
whether	O
receptor	O
interactions	O
can	O
explain	O
the	O
interplay	O
between	O
the	O
RA	O
-	O
and	O
VitD3	O
-	O
signaling	O
pathways	O
during	O
differentiation	O
.	O

Therefore	O
,	O
we	O
analyzed	O
the	O
expression	O
,	O
DNA	O
binding	O
,	O
and	O
transcriptional	O
activity	O
of	O
the	O
endogenous	B
RA	I
and	I
VitD3	I
receptors	I
[	O
retinoic	B
acid	I
receptors	I
(	O
RARs	B
)	O
,	O
retinoid	B
X	I
receptors	I
(	O
RXRs	B
)	O
,	O
and	O
VitD3	B
receptor	I
(	O
VDR	B
)	O
]	O
in	O
the	O
U	O
-	O
937	O
cell	O
line	O
,	O
in	O
which	O
RA	O
and	O
VitD3	O
induce	O
distinct	O
monocytic	O
differentiation	O
pathways	O
.	O

However	O
,	O
transcriptional	O
activation	O
was	O
only	O
observed	O
from	O
a	O
VitD3	B
response	I
element	I
-	I
driven	I
reporter	I
construct	I
.	O

Also	O
,	O
VitD3	O
inhibited	O
the	O
expression	O
of	O
CD23	B
and	O
CD49f	B
,	O
characteristic	O
markers	O
of	O
retinoid	O
-	O
induced	O
U	O
-	O
937	O
cell	O
differentiation	O
.	O

Freshly	O
isolated	O
monocytes	O
expressed	O
94	B
-	I
kD	I
STAT5A	I
,	O
92	O
-	O
kD	O
STAT5B	B
,	O
and	O
an	O
80	B
-	I
kD	I
STAT5A	I
molecule	I
.	O

STAT5A	B
-	I
STAT5A	I
homodimers	I
and	O
STAT5A	B
-	I
STAT5B	I
heterodimers	I
formed	O
in	O
response	O
to	O
GM	B
-	I
CSF	I
.	O

Translocation	B
(	I
3	I
;	I
14	I
)	I
(	I
q27	I
;	I
q11	I
)	I
:	O
a	O
new	O
variant	O
translocation	O
in	O
a	O
patient	O
with	O
non	O
-	O
Hodgkin	O
'	O
s	O
lymphoma	O
of	O
B	O
-	O
cell	O
type	O
with	O
BCL6	B
rearrangement	O
.	O

Southern	O
blot	O
analysis	O
showed	O
rearrangement	O
of	O
BCL6	B
,	O
JH	B
,	O
and	O
TCR	B
beta	I
but	O
not	O
of	O
TCR	B
delta	I
.	O

Basal	O
total	O
white	O
blood	O
cell	O
and	O
granulocyte	O
counts	O
did	O
not	O
appreciably	O
differ	O
between	O
PML	B
/	I
RARalpha	I
transgenic	O
and	O
control	O
mice	O
.	O

As	O
expected	O
,	O
nearly	O
all	O
control	O
mice	O
(	O
94	O
.	O
4	O
%	O
)	O
survived	O
irradiation	O
,	O
yet	O
this	O
irradiation	O
was	O
lethal	O
to	O
45	O
.	O
8	O
%	O
of	O
PML	B
/	I
RARalpha	I
transgenic	O
mice	O
.	O

B	O
-	O
cell	O
immortalization	O
by	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
is	O
dependent	O
on	O
permanent	O
control	O
of	O
the	O
cellular	O
processes	O
which	O
normally	O
regulate	O
cell	O
division	O
and	O
apoptosis	O
,	O
functions	O
possessed	O
by	O
p53	B
in	O
a	O
number	O
of	O
normal	O
cell	O
types	O
.	O

Latent	B
membrane	I
protein	I
1	I
and	O
,	O
to	O
a	O
lesser	O
extent	O
,	O
EBV	B
nuclear	I
antigen	I
2	I
mediated	O
the	O
increase	O
in	O
p53	B
levels	O
via	O
activation	O
of	O
the	O
NF	B
-	I
kappaB	I
transcription	B
factor	I
.	O

Tissue	O
-	O
specific	O
expression	O
of	O
interleukin	B
-	I
3	I
(	O
IL	B
-	I
3	I
)	O
is	O
mediated	O
via	O
cis	B
-	I
acting	I
elements	I
located	O
within	O
315	O
base	O
pairs	O
of	O
the	O
transcription	B
start	I
.	O

In	O
addition	O
to	O
the	O
already	O
identified	O
NIP	B
repressor	I
site	I
,	O
evidence	O
is	O
presented	O
for	O
a	O
second	B
repressor	I
region	I
that	O
restricts	O
promoter	O
activity	O
in	O
fibroblasts	O
.	O

In	O
the	O
current	O
studies	O
,	O
IL	B
-	I
2	I
production	O
by	O
T	O
cells	O
from	O
elderly	O
(	O
mean	O
78	O
years	O
)	O
and	O
young	O
(	O
mean	O
37	O
years	O
)	O
humans	O
was	O
measured	O
in	O
cultures	O
stimulated	O
with	O
PHA	B
,	O
PHA	B
plus	O
PMA	O
,	O
crosslinked	O
anti	O
-	O
CD3	O
mAB	O
OKT3	O
plus	O
PMA	O
,	O
or	O
PMA	O
plus	O
ionomycin	O
.	O

By	O
contrast	O
,	O
T	O
cells	O
from	O
elderly	O
subjects	O
with	O
normal	O
levels	O
of	O
IL	B
-	I
2	I
production	O
exhibited	O
normal	O
activation	O
of	O
AP	B
-	I
1	I
and	O
NF	B
-	I
AT	I
.	O

IL	B
-	I
13	I
caused	O
rapid	O
phosphorylation	O
of	O
the	O
three	O
out	O
of	O
four	O
members	O
of	O
the	O
known	O
Janus	B
family	I
of	I
kinases	I
(	O
JAKs	B
)	O
.	O

IL	B
-	I
4	I
also	O
stimulated	O
all	O
three	O
kinases	B
and	O
substrates	O
,	O
but	O
unlike	O
in	O
immune	O
cells	O
,	O
IL	B
-	I
4	I
did	O
not	O
involve	O
JAK3	B
activation	O
for	O
its	O
signaling	O
in	O
colon	O
cancer	O
cell	O
lines	O
.	O

Furthermore	O
,	O
JAK2	B
associated	O
with	O
the	O
IL	B
-	I
4R	I
p140	I
before	O
and	O
after	O
stimulation	O
with	O
IL	B
-	I
13	I
.	O

Differential	O
regulation	O
of	O
IL	B
-	I
6	I
gene	I
transcription	O
and	O
expression	O
by	O
IL	B
-	I
4	I
and	O
IL	B
-	I
10	I
in	O
human	O
monocytic	O
cell	O
lines	O
.	O

To	O
investigate	O
the	O
molecular	O
mechanism	O
of	O
the	O
inhibitory	O
effect	O
on	O
transcriptional	O
or	O
post	O
-	O
transcriptional	O
regulation	O
of	O
IL	B
-	I
6	I
gene	I
expression	O
by	O
IL	B
-	I
4	I
and	O
IL	B
-	I
10	I
,	O
we	O
studied	O
IL	B
-	I
6	I
production	O
,	O
expression	O
level	O
of	O
IL	B
-	I
6	I
mRNA	I
,	O
IL	B
-	I
6	I
promoter	O
activity	O
,	O
transcriptional	O
activity	O
of	O
NF	B
-	I
kappaB	I
and	O
NF	B
-	I
IL	I
-	I
6	I
,	O
and	O
IL	B
-	I
6	I
mRNA	I
stability	O
in	O
human	O
monocytic	O
cell	O
lines	O
,	O
THP	O
-	O
1	O
and	O
U937	O
,	O
stimulated	O
by	O
PMA	O
and	O
LPS	O
in	O
the	O
absence	O
or	O
the	O
presence	O
of	O
IL	B
-	I
4	I
or	O
IL	B
-	I
10	I
.	O

In	O
chloramphenicol	B
acetyltransferase	I
assays	O
,	O
utilizing	O
the	O
transient	O
transfection	O
of	O
a	O
chloramphenicol	B
acetyltransferase	I
reporter	I
plasmid	I
containing	O
the	O
IL	B
-	I
6	I
gene	I
promoter	I
,	O
IL	B
-	I
4	I
,	O
but	O
not	O
IL	B
-	I
10	I
,	O
suppressed	O
the	O
transcriptional	O
activity	O
of	O
the	O
IL	O
-	O
6	O
gene	O
promoter	O
stimulated	O
by	O
PMA	O
and	O
LPS	O
.	O

On	O
the	O
other	O
hand	O
,	O
IL	B
-	I
10	I
enhanced	O
the	O
degradation	O
of	O
IL	B
-	I
6	I
mRNA	I
in	O
a	O
mRNA	O
stability	O
assay	O
.	O

These	O
results	O
suggest	O
that	O
IL	B
-	I
4	I
may	O
inhibit	O
the	O
transcription	O
of	O
the	O
IL	B
-	I
6	I
gene	I
by	O
affecting	O
NF	B
-	I
kappaB	I
binding	O
activity	O
,	O
while	O
IL	B
-	I
10	I
may	O
inhibit	O
the	O
IL	B
-	I
6	I
mRNA	I
levels	O
post	O
-	O
transcriptionally	O
,	O
without	O
suppressing	O
promoter	O
activity	O
.	O

IL	B
-	I
2	I
production	O
by	O
CsA	O
-	O
treated	O
cells	O
is	O
therefore	O
dramatically	O
reduced	O
.	O

Electrophoretic	O
mobility	O
shift	O
assay	O
showed	O
the	O
induction	O
of	O
a	O
CsA	B
-	I
resistant	I
NFAT	I
complex	I
in	O
the	O
nuclear	O
extracts	O
of	O
peripheral	O
blood	O
T	O
cells	O
stimulated	O
with	O
PMA	O
plus	O
alphaCD28	B
.	O

Deactivation	O
of	O
mononuclear	O
phagocytes	O
is	O
critical	O
to	O
limit	O
the	O
inflammatory	O
response	O
but	O
can	O
be	O
detrimental	O
in	O
the	O
face	O
of	O
progressive	O
infection	O
.	O

We	O
compared	O
the	O
effects	O
of	O
the	O
deactivating	B
cytokine	I
interleukin	B
10	I
(	O
IL	B
-	I
10	I
)	O
on	O
human	O
peripheral	O
blood	O
mononuclear	O
cell	O
(	O
PBMC	O
)	O
responses	O
to	O
lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
Cryptococcus	O
neoformans	O
,	O
and	O
Candida	O
albicans	O
.	O

Characterization	O
and	O
purification	O
of	O
a	O
protein	B
kinase	I
C	I
substrate	I
in	O
human	O
B	O
cells	O
.	O

These	O
findings	O
,	O
therefore	O
,	O
could	O
have	O
clinical	O
significance	O
to	O
AIDS	O
patients	O
with	O
malignancies	O
who	O
are	O
undergoing	O
radiotherapy	O
and	O
chemotherapy	O
.	O

To	O
determine	O
whether	O
the	O
IL	B
-	I
10R	I
has	O
signaling	O
functions	O
similar	O
to	O
IL	B
-	I
6R	I
in	O
cells	O
normally	O
expressing	O
these	O
receptors	O
,	O
leukocytes	O
of	O
the	O
B	O
-	O
,	O
T	O
-	O
,	O
and	O
NK	O
-	O
cell	O
lineages	O
were	O
treated	O
with	O
either	O
cytokine	O
.	O

The	O
IL	B
-	I
10R	I
,	O
together	O
with	O
reporter	O
gene	O
constructs	O
containing	O
different	O
IL	B
-	I
6	I
-	I
responsive	I
gene	I
elements	I
,	O
reconstituted	O
in	O
hepatoma	O
cells	O
an	O
induction	O
of	O
transcription	O
by	O
IL	B
-	I
10	I
that	O
was	O
comparable	O
to	O
that	O
by	O
IL	B
-	I
6	I
.	O

These	O
receptor	O
functions	O
required	O
the	O
presence	O
of	O
the	O
box	B
3	I
motifs	I
,	O
as	O
shown	O
by	O
the	O
analysis	O
of	O
the	O
mouse	O
IL	B
-	I
10R	I
constructs	O
containing	O
progressively	B
truncated	I
cytoplasmic	I
domains	I
.	O

These	O
results	O
suggest	O
that	O
both	O
common	O
mechanisms	O
,	O
such	O
as	O
the	O
one	O
mediated	O
by	O
the	O
CIITA	B
trans	I
-	I
activator	I
,	O
and	O
distinct	O
tissue	O
-	O
specific	O
constraints	O
contribute	O
to	O
the	O
transcriptional	O
control	O
of	O
constitutive	O
and	O
IFN	B
-	I
gamma	I
-	O
induced	O
MHC	B
class	I
II	I
gene	I
expression	O
.	O

E3330	O
inhibited	O
this	O
induced	O
promoter	O
activity	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

There	O
are	O
four	O
putative	O
NF	B
-	I
kappa	I
B	I
binding	I
sites	I
(	O
kappa	B
B	I
-	I
1	I
,	O
kappa	B
B	I
-	I
2	I
,	O
kappa	B
B	I
-	I
3	I
,	O
kappa	B
B	I
-	I
4	I
)	O
in	O
human	B
TNF	I
-	I
alpha	I
promoter	I
.	O

In	O
this	O
study	O
we	O
have	O
analysed	O
the	O
structural	O
requirements	O
for	O
transcriptional	O
activation	O
by	O
BSAP	B
.	O

We	O
have	O
demonstrated	O
that	O
the	O
level	O
of	O
CRE	B
binding	I
protein	I
(	O
CREB	B
)	O
was	O
the	O
same	O
in	O
all	O
cell	O
lines	O
and	O
that	O
the	O
putative	O
AR	B
-	I
CRE	I
forms	O
specific	O
and	O
compatible	O
protein	O
interactions	O
with	O
CREB	B
.	O

Structural	O
and	O
functional	O
characterization	O
of	O
the	O
human	B
CD36	I
gene	I
promoter	I
:	O
identification	O
of	O
a	O
proximal	O
PEBP2	B
/	I
CBF	I
site	I
.	O

In	O
these	O
cells	O
,	O
CD36	B
is	O
involved	O
in	O
phagocytosis	O
of	O
apoptotic	O
cells	O
,	O
and	O
foam	O
cell	O
formation	O
by	O
uptake	O
of	O
oxidized	B
low	I
density	I
lipoprotein	I
.	O

Biochemical	O
analysis	O
of	O
the	O
region	O
-	B
158	I
/	I
-	I
90	I
revealed	O
a	O
binding	O
site	O
for	O
transcription	B
factors	I
of	O
the	O
polyomavirus	B
enhancer	I
-	I
binding	I
protein	I
2	I
/	I
core	I
-	I
binding	I
factor	I
(	I
PEBP2	I
/	I
CBF	I
)	I
family	I
at	O
position	B
-	I
103	I
.	O

Disruption	O
of	O
the	O
PEBP2	B
/	I
CBF	I
site	I
markedly	O
diminished	O
the	O
role	O
of	O
the	O
PEBP2	B
/	I
CBF	I
factors	I
in	O
the	O
constitutive	O
transcription	O
of	O
the	O
CD36	B
gene	I
.	O

The	O
association	O
of	O
specific	O
HLA	B
-	I
DQ	I
alleles	I
with	O
autoimmunity	O
is	O
correlated	O
with	O
discrete	O
polymorphisms	O
in	O
the	O
HLA	B
-	I
DQ	I
sequence	I
that	O
are	O
localized	O
within	O
sites	O
suitable	O
for	O
peptide	O
recognition	O
.	O

Appearance	O
of	O
the	O
STAT1	B
factor	O
is	O
significantly	O
reduced	O
in	O
the	O
presence	O
of	O
cyclosporin	O
A	O
,	O
and	O
blocked	O
by	O
cycloheximide	O
,	O
indicating	O
that	O
its	O
activation	O
is	O
dependent	O
upon	O
a	O
protein	O
(	O
s	O
)	O
synthesized	O
in	O
response	O
to	O
initial	O
signaling	O
events	O
.	O

Neutralizing	O
antiserum	O
against	O
IFN	B
-	I
gamma	I
,	O
but	O
not	O
other	O
cytokines	B
tested	O
,	O
blocked	O
activation	O
of	O
the	O
factor	O
almost	O
completely	O
,	O
and	O
IFN	B
-	I
gamma	I
was	O
found	O
in	O
the	O
culture	O
supernatants	O
of	O
stimulated	O
cells	O
at	O
levels	O
at	O
which	O
recombinant	O
IFN	B
-	I
gamma	I
could	O
activate	O
the	O
factor	O
in	O
naive	O
cells	O
.	O

Therefore	O
,	O
a	O
STAT1	B
transcription	B
factor	I
is	O
activated	O
by	O
IFN	B
-	I
gamma	I
synthesized	O
and	O
released	O
upon	O
stimulation	O
of	O
T	O
lymphocyte	O
populations	O
.	O

While	O
Jurkat	O
cells	O
both	O
secrete	O
and	O
respond	O
to	O
IFN	B
-	I
gamma	I
in	O
an	O
autocrine	O
loop	O
,	O
it	O
seems	O
likely	O
that	O
the	O
responding	O
cells	O
may	O
differ	O
from	O
those	O
synthesizing	O
this	O
cytokine	B
in	O
the	O
mononuclear	O
cell	O
cultures	O
in	O
the	O
light	O
of	O
the	O
recent	O
report	O
that	O
Th1	O
cells	O
lack	O
the	O
IFN	B
-	I
gamma	I
receptor	O
chain	O
necessary	O
for	O
activation	O
of	O
STAT1	B
(	O
Pernis	O
,	O
A	O
.	O
,	O
Gupta	O
,	O
S	O
.	O
,	O
Gollob	O
,	O
K	O
.	O
J	O
.	O
,	O
Garfein	O
,	O
E	O
.	O
,	O
Coffman	O
,	O
R	O
.	O
L	O
.	O
,	O
Schindler	O
,	O
C	O
.	O
,	O
and	O
Rothman	O
,	O
P	O
.	O
,	O
Science	O
1995	O
.	O
269	O
:	O
245	O
)	O
.	O

Based	O
on	O
the	O
presence	O
of	O
T	B
cell	I
receptor	I
-	I
beta	I
(	I
TcR	I
-	I
beta	I
)	I
gene	I
rearrangements	I
in	O
L428	O
and	O
HDLM	O
-	O
1	O
cells	O
,	O
the	O
expression	O
of	O
CD2	B
in	O
HDLM	O
-	O
1	O
cells	O
,	O
and	O
the	O
presence	O
of	O
immunoglobulin	B
heavy	I
-	I
chain	I
(	I
IgH	I
)	I
gene	I
rearrangement	I
in	O
KM	O
-	O
H2	O
cells	O
,	O
some	O
researchers	O
have	O
concluded	O
that	O
these	O
long	O
-	O
term	O
cell	O
lines	O
derived	O
from	O
patients	O
with	O
Hodgkin	O
'	O
s	O
disease	O
are	O
lymphoid	O
in	O
nature	O
.	O

Expression	O
of	O
the	O
MAP	B
kinase	I
-	I
specific	I
phosphatase	I
,	O
MKP	B
-	I
1	I
,	O
which	O
blocks	O
ERK	B
activation	O
,	O
inhibited	O
IL	B
-	I
2	I
promoter	I
and	O
NF	B
-	I
AT	I
-	O
driven	O
transcription	O
stimulated	O
by	O
a	O
calcium	O
ionophore	O
and	O
PMA	O
,	O
and	O
in	O
addition	O
,	O
MKP	B
-	I
1	I
neutralized	O
the	O
transcriptional	O
enhancement	O
caused	O
by	O
active	O
Raf	O
-	O
1	O
and	O
MEK1	O
expression	O
.	O

Although	O
GM	B
-	I
CSF	I
does	O
not	O
appear	O
to	O
be	O
essential	O
for	O
normal	O
hemopoiesis	O
,	O
overexpression	O
of	O
GM	O
-	O
CSF	O
has	O
been	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
some	O
diseases	O
such	O
as	O
myeloid	O
leukemia	O
and	O
chronic	O
inflammation	O
.	O

We	O
investigated	O
oligonucleotide	O
-	O
directed	O
triple	O
helix	O
formation	O
across	O
this	O
regulatory	B
sequence	I
as	O
a	O
potential	O
tool	O
to	O
inhibit	O
GM	B
-	I
CSF	I
gene	O
transcription	O
.	O

Triplex	O
formation	O
by	O
GM3	O
blocked	O
recombinant	B
and	I
nuclear	I
NF	I
-	I
kappaB	I
proteins	I
binding	O
to	O
the	O
GM	B
-	I
CSF	I
element	I
.	O

Finally	O
,	O
GM3	O
greatly	O
reduced	O
the	O
concentration	O
of	O
endogenous	O
GM	B
-	I
CSF	I
mRNA	I
induced	O
by	O
different	O
stimuli	O
in	O
Jurkat	O
T	O
cells	O
but	O
did	O
not	O
affect	O
interleukin	B
3	I
mRNA	I
levels	O
in	O
the	O
same	O
cells	O
.	O

We	O
conclude	O
that	O
the	O
kappaB	B
element	I
in	O
the	O
GM	B
-	I
CSF	I
promoter	I
plays	O
a	O
central	O
role	O
in	O
the	O
transcriptional	O
activation	O
of	O
the	O
endogenous	O
GM	B
-	I
CSF	I
gene	I
.	O

Colinear	O
triplex	O
formation	O
acts	O
as	O
a	O
selective	O
transcriptional	O
repressor	O
of	O
the	O
GM	B
-	I
CSF	I
gene	I
and	O
may	O
have	O
potential	O
therapeutic	O
application	O
in	O
cases	O
of	O
undesirable	O
overexpression	O
of	O
this	O
protein	O
.	O

ML	O
-	O
9	O
induced	O
nitroblue	O
tetrazolium	O
(	O
NBT	O
)	O
-	O
reducing	O
activity	O
of	O
U937	O
cell	O
more	O
rapidly	O
than	O
VD3	O
:	O
This	O
differentiation	O
marker	O
was	O
induced	O
significantly	O
after	O
incubation	O
with	O
ML	O
-	O
9	O
and	O
VD3	O
for	O
4	O
hours	O
and	O
1	O
day	O
,	O
respectively	O
.	O

These	O
results	O
suggest	O
that	O
ML	O
-	O
9	O
should	O
be	O
useful	O
for	O
studying	O
the	O
mechanisms	O
of	O
monocytic	O
differentiation	O
.	O

Modulation	O
of	O
endogenous	O
IL	B
-	I
1	I
beta	I
and	O
IL	B
-	I
1	I
receptor	I
antagonist	O
results	O
in	O
opposing	O
effects	O
on	O
HIV	O
expression	O
in	O
chronically	O
infected	O
monocytic	O
cells	O
.	O

The	O
present	O
study	O
examines	O
the	O
mechanisms	O
involved	O
in	O
LPS	O
-	O
mediated	O
induction	O
of	O
HIV	O
expression	O
in	O
U1	O
cells	O
,	O
a	O
promonocytic	O
cell	O
line	O
chronically	O
infected	O
with	O
HIV	O
.	O

Costimulation	O
of	O
U1	O
cells	O
with	O
LPS	O
plus	O
GM	B
-	I
CSF	I
resulted	O
in	O
the	O
accumulation	O
of	O
steady	O
-	O
state	O
levels	O
of	O
HIV	B
RNA	I
;	O
however	O
,	O
only	O
a	O
weak	O
induction	O
of	O
HIV	B
long	I
terminal	I
repeat	I
-	O
driven	O
transcription	O
,	O
which	O
was	O
not	O
associated	O
with	O
the	O
activation	O
of	O
the	O
cellular	B
transcription	I
factor	I
nuclear	B
factor	I
-	I
kappa	I
B	I
,	O
was	O
noted	O
.	O

IL	B
-	I
12	I
is	O
a	O
novel	O
heterodimeric	B
cytokine	I
important	O
for	O
the	O
regulation	O
and	O
differentiation	O
of	O
lymphocytes	O
and	O
NK	O
cells	O
.	O

Using	O
these	O
T	O
cells	O
as	O
a	O
model	O
of	O
IL	B
-	I
12	I
signal	O
transduction	O
,	O
we	O
confirmed	O
that	O
these	O
events	O
involve	O
members	O
of	O
the	O
Janus	B
kinase	I
family	I
of	O
nonreceptor	B
tyrosine	I
kinases	I
JAK2	B
,	O
TYK2	B
,	O
and	O
signal	B
transducer	I
and	I
activator	I
of	I
transcription	I
4	I
.	O

These	O
mechanisms	O
include	O
the	O
assembly	O
of	O
higher	B
order	I
nucleoprotein	I
complexes	I
and	O
other	O
protein	O
-	O
protein	O
interactions	O
that	O
enhance	O
the	O
functional	O
specificity	O
of	O
transcriptional	B
regulators	I
in	O
lymphocytes	O
.	O

Patients	O
with	O
HIV	O
infections	O
often	O
show	O
elevated	O
circulating	O
levels	O
of	O
cortisol	O
,	O
suggesting	O
some	O
misfunction	O
in	O
the	O
regulatory	O
systems	O
that	O
maintain	O
the	O
levels	O
of	O
this	O
critical	O
hormone	O
.	O

At	O
the	O
cellular	O
level	O
,	O
it	O
is	O
known	O
that	O
both	O
acute	O
HIV	O
infection	O
and	O
glucocorticoids	O
can	O
cause	O
apoptotic	O
cell	O
death	O
in	O
thymic	O
lymphocytes	O
.	O

In	O
vitro	O
,	O
chronically	O
HIV	O
-	O
infected	O
cells	O
of	O
the	O
lymphoid	O
CEM	O
line	O
displayed	O
resistance	O
to	O
glucocorticoid	O
-	O
induced	O
apoptosis	O
.	O

Thus	O
it	O
appears	O
that	O
there	O
may	O
often	O
be	O
malfunction	O
of	O
the	O
normal	O
glucocorticoid	O
response	O
in	O
HIV	O
-	O
infected	O
cells	O
probably	O
due	O
to	O
altered	O
interactions	O
between	O
the	O
glucocorticoid	B
receptor	I
and	O
its	O
hormone	O
.	O

Nuclei	O
of	O
unstimulated	O
PBL	O
from	O
different	O
donors	O
expressed	O
p62c	B
-	I
fos	I
and	O
p39c	B
-	I
jun	I
,	O
but	O
AP	B
-	I
1	I
was	O
not	O
detected	O
in	O
the	O
majority	O
of	O
samples	O
.	O

Following	O
PHA	B
stimulation	O
of	O
PBL	O
,	O
the	O
increase	O
in	O
AP	B
-	I
1	I
activity	O
was	O
delayed	O
with	O
respect	O
to	O
the	O
augmentation	O
of	O
p39c	B
-	I
jun	I
expression	O
.	O

However	O
,	O
no	O
cytoplasmic	B
p62c	I
-	I
fos	I
was	O
detected	O
in	O
unstimulated	O
PBL	O
,	O
although	O
in	O
some	O
cases	O
cytoplasmic	B
p39c	I
-	I
jun	I
was	O
detected	O
,	O
suggesting	O
that	O
subcellular	O
compartmentalization	O
of	O
these	O
proteins	B
may	O
occur	O
under	O
certain	O
circumstances	O
.	O

However	O
,	O
the	O
inducible	O
degradation	O
of	O
p105	B
is	O
not	O
coupled	O
with	O
the	O
generation	O
of	O
p50	B
.	O

Together	O
,	O
these	O
studies	O
demonstrate	O
that	O
the	O
processing	O
and	O
inducible	O
degradation	O
of	O
p105	B
are	O
differentially	O
regulated	O
.	O

However	O
,	O
synthesis	O
of	O
the	O
26	B
-	I
kDa	I
membrane	I
form	I
of	O
TNF	B
was	O
effectively	O
blocked	O
by	O
CNI	O
-	O
1493	O
.	O

r	B
-	I
hTBP	I
-	I
1	I
and	O
rhu	B
TNFR	I
:	I
Fc	I
also	O
decreased	O
p24	B
antigen	I
synthesized	O
by	O
U1	O
cells	O
in	O
response	O
to	O
other	O
stimuli	O
,	O
including	O
phytohemagglutinin	B
(	I
PHA	I
)	I
-	I
induced	I
supernatant	I
,	O
granulocyte	B
-	I
macrophage	I
colony	I
-	I
stimulating	I
factor	I
,	O
interleukin	B
-	I
6	I
,	O
and	O
TNF	B
.	O

Addition	O
of	O
r	B
-	I
hTBP	I
-	I
1	I
to	O
U1	O
cells	O
during	O
the	O
last	O
4	O
h	O
of	O
a	O
24	O
h	O
incubation	O
with	O
PMA	O
still	O
inhibited	O
p24	B
antigen	I
production	O
by	O
15	O
%	O
.	O

r	B
-	I
hTBP	I
-	I
1	I
also	O
partially	O
reversed	O
inhibition	O
of	O
U1	O
cellular	O
proliferation	O
caused	O
by	O
PMA	O
.	O

Transcriptional	O
activation	O
of	O
RNA	B
polymerase	I
III	I
-	I
dependent	I
genes	I
by	O
the	O
human	B
T	I
-	I
cell	I
leukemia	I
virus	I
type	I
1	I
tax	I
protein	I
.	O

The	O
viral	B
protein	I
Tax	I
was	O
likely	O
responsible	O
for	O
this	O
higher	O
level	O
of	O
class	B
II	I
gene	I
transcription	O
,	O
as	O
purified	B
Tax	I
was	O
found	O
to	O
stimulate	O
both	O
genes	O
when	O
added	O
to	O
the	O
uninfected	O
cell	O
extract	O
or	O
in	O
reconstituted	O
systems	O
.	O

Expression	O
of	O
Retinoid	B
X	I
Receptor	I
alpha	I
is	O
increased	O
upon	O
monocytic	O
cell	O
differentiation	O
.	O

Efficient	O
gene	O
activation	O
requires	O
the	O
heterodimerization	O
of	O
VDR	B
with	O
Retinoid	B
X	I
Receptors	I
(	O
RXR	B
)	O
.	O

Combinations	O
of	O
all	O
-	O
trans	O
retinoic	O
acid	O
(	O
RA	O
)	O
and	O
VD	O
,	O
in	O
some	O
cases	O
,	O
increased	O
this	O
effect	O
.	O

We	O
have	O
generated	O
rabbit	O
antisera	O
against	O
this	O
putative	O
p13MTCP1	B
protein	I
and	O
screened	O
for	O
expression	O
of	O
p13MTCP1	B
normal	O
lymphoid	O
tissues	O
and	O
33	O
cases	O
of	O
immature	O
and	O
mature	O
lymphoid	O
T	O
-	O
cell	O
proliferations	O
using	O
a	O
sensitive	O
Western	O
blot	O
assay	O
.	O

The	O
p13MTCP1	B
protein	I
was	O
detected	O
in	O
the	O
three	O
T	O
-	O
cell	O
proliferations	O
with	O
MTCP1	B
rearrangements	I
because	O
of	O
t	O
(	O
X	O
;	O
14	O
)	O
translocations	O
,	O
but	O
neither	O
in	O
normal	O
resting	O
and	O
activated	O
lymphocytes	O
nor	O
in	O
the	O
other	O
T	O
-	O
cell	O
leukemias	O
.	O

A	O
variety	O
of	O
cytokines	B
and	O
growth	B
factors	I
act	O
through	O
an	O
induction	O
of	O
gene	O
expression	O
mediated	O
by	O
a	O
family	O
of	O
latent	B
transcription	I
factors	I
called	O
STAT	B
(	I
signal	I
transducers	I
and	I
activators	I
of	I
transcription	I
)	I
proteins	I
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSAs	O
)	O
demonstrated	O
that	O
unstimulated	O
monocytes	O
predominantly	O
expressed	O
p50	B
NF	B
-	I
kappa	I
B	I
.	O

However	O
,	O
the	O
combined	O
stimulation	O
did	O
not	O
result	O
in	O
enhanced	O
p50	B
and	O
p65	B
protein	I
expression	O
.	O

The	O
effects	O
of	O
IFN	B
-	I
gamma	I
on	O
the	O
transcription	B
factors	I
were	O
specific	O
,	O
since	O
no	O
change	O
was	O
observed	O
in	O
the	O
expression	O
of	O
NF	B
-	I
IL	I
-	I
6	I
or	O
I	B
kappa	I
B	I
alpha	I
,	O
the	O
inhibitor	O
of	O
NF	B
-	I
kappa	I
B	I
.	O

We	O
conclude	O
that	O
the	O
effects	O
of	O
IFN	B
-	I
gamma	I
on	O
the	O
expression	O
of	O
the	O
transcription	B
factors	I
AP	B
-	I
1	I
and	O
NF	B
-	I
kappa	I
B	I
may	O
be	O
important	O
for	O
the	O
modulatory	O
effects	O
of	O
IFN	B
-	I
gamma	I
on	O
the	O
cytokine	B
expression	O
in	O
activated	O
human	O
monocytes	O
.	O

The	O
expression	O
of	O
MIP	B
-	I
1	I
alpha	I
is	O
induced	O
during	O
cellular	O
activation	O
of	O
CD4	O
+	O
T	O
-	O
cells	O
and	O
monocytes	O
.	O

It	O
is	O
also	O
expressed	O
in	O
transformed	O
B	O
-	O
cells	O
.	O

We	O
have	O
previously	O
identified	O
a	O
new	O
transcription	B
factor	I
family	I
(	O
the	O
MNP	B
family	I
)	O
whose	O
expression	O
is	O
crucial	O
for	O
the	O
induction	O
of	O
MIP	B
-	I
1	I
alpha	I
transcription	O
during	O
cellular	O
activation	O
and	O
in	O
transformed	O
B	O
cells	O
.	O

In	O
this	O
report	O
we	O
show	O
induction	O
of	O
MNP	B
-	I
1	I
in	O
Jurkat	O
T	O
-	O
cells	O
expressing	O
HIV	B
-	I
1	I
tat	I
.	O

Differentiation	O
of	O
T	O
-	O
helper	O
lymphocytes	O
:	O
selective	O
regulation	O
by	O
members	O
of	O
the	O
STAT	B
family	I
of	O
transcription	B
factors	I
.	O

Specific	O
docking	B
sites	I
within	O
individual	O
cytokine	B
receptors	I
have	O
been	O
identified	O
for	O
almost	O
all	O
Stat	B
proteins	I
.	O

The	O
direct	O
coupling	O
between	O
cytokine	B
receptor	I
and	O
transcription	B
factor	I
helps	O
to	O
explain	O
how	O
different	O
cytokines	B
elicit	O
distinct	O
patterns	O
of	O
gene	O
expression	O
.	O

Here	O
we	O
identify	O
the	O
gene	O
encoding	O
the	O
lymphocyte	B
homing	I
and	I
migration	I
protein	I
CD44	B
as	O
a	O
target	O
of	O
EGR1	B
regulation	O
in	O
B	O
cells	O
.	O

The	O
EGR1	B
binding	I
motif	I
was	O
shown	O
to	O
be	O
necessary	O
for	O
stimulus	O
-	O
induced	O
expression	O
of	O
a	O
CD44	B
promoter	B
-	I
chloramphenicol	I
acetyltransferase	I
reporter	I
construct	I
in	O
nontransformed	O
B	O
lymphocytes	O
and	O
was	O
required	O
for	O
transactivation	O
by	O
an	O
EGR1	B
expression	I
vector	I
in	O
a	O
B	O
-	O
cell	O
line	O
.	O

These	O
studies	O
identify	O
EGR1	B
as	O
an	O
intermediary	O
linking	O
BCR	B
-	O
derived	O
signals	O
to	O
the	O
induction	O
of	O
CD44	B
.	O

In	O
Jurkat	O
cells	O
that	O
are	O
not	O
sensitive	O
to	O
H2O2	O
-	O
induced	O
NF	B
-	I
kappaB	I
activation	O
,	O
H2O2	O
potentiated	O
NF	B
-	I
kappaB	I
activation	O
in	O
the	O
presence	O
of	O
sustained	O
high	O
[	O
Ca2	O
+	O
]	O
i	O
following	O
thapsigargin	O
treatment	O
.	O

A	O
mutant	O
Tax	B
protein	I
deficient	O
in	O
transactivation	O
of	O
genes	O
by	O
the	O
nuclear	B
factor	I
(	I
NF	I
)	I
-	I
kappaB	I
pathway	O
was	O
unable	O
to	O
induce	O
transcriptional	O
activity	O
of	O
IL	B
-	I
1alpha	I
promoter	I
-	I
CAT	I
constructs	I
,	O
but	O
was	O
rescued	O
by	O
exogenous	O
provision	O
of	O
p65	B
/	I
p50	I
NF	B
-	I
kappaB	I
.	O

mRNA	O
for	O
c	O
-	O
fes	O
has	O
been	O
detected	O
exclusively	O
in	O
myeloid	O
cells	O
and	O
vascular	O
endothelial	O
cells	O
in	O
adult	O
mammals	O
.	O

Although	O
a	O
13	B
-	I
kilobase	I
-	I
pair	I
(	I
kb	I
)	I
human	I
c	I
-	I
fes	I
transgene	I
exhibits	O
high	O
levels	O
of	O
expression	O
in	O
mice	O
,	O
the	O
sequences	O
that	O
confer	O
myeloid	O
-	O
cell	O
-	O
specific	O
expression	O
of	O
the	O
human	B
c	I
-	I
fes	I
gene	I
have	O
not	O
been	O
defined	O
.	O

However	O
,	O
the	O
first	O
two	O
footprints	O
resided	O
in	O
sequences	O
that	O
were	O
largely	O
dispensable	O
for	O
transient	O
activity	O
.	O

Electrophoretic	O
mobility	O
shift	O
analyses	O
demonstrated	O
that	O
the	O
151	B
-	I
bp	I
region	I
contains	O
nuclear	B
protein	I
binding	I
sites	I
for	O
Sp1	B
,	O
PU	B
.	I
1	I
,	O
and	O
/	O
or	O
Elf	B
-	I
1	I
,	O
and	O
a	O
novel	B
factor	I
.	O

IL	B
-	I
10	I
markedly	O
reduces	O
nuclear	O
factor	O
(	B
NF	I
)	I
-	I
kappa	I
B	I
/	I
Rel	I
nuclear	O
activity	O
induced	O
in	O
PBMC	O
by	O
stimulation	O
with	O
the	O
anti	B
-	I
CD3	I
mAb	I
OKT3	B
.	O

As	O
judged	O
by	O
supershifting	O
the	O
DNA	B
-	I
protein	I
complexes	I
with	O
Abs	B
recognizing	O
specific	O
components	O
of	O
the	O
NF	B
-	I
kappa	I
B	I
/	I
Rel	I
protein	I
family	I
,	O
the	O
p50	B
/	I
p65	I
(	O
Rel	B
A	I
)	O
heterodimeric	O
form	O
of	O
NF	B
-	I
kappa	I
B	I
is	O
primarily	O
affected	O
.	O

The	O
maximal	O
effect	O
is	O
observed	O
at	O
the	O
IL	B
-	I
10	I
concentration	O
of	O
20	O
U	O
/	O
ml	O
.	O

Our	O
results	O
demonstrate	O
that	O
IL	B
-	I
10	I
can	O
inhibit	O
the	O
induction	O
of	O
NF	B
-	I
kappa	I
B	I
/	I
Rel	I
nuclear	O
activity	O
in	O
CD3	O
-	O
stimulated	O
T	O
lymphocytes	O
.	O

In	O
a	O
panel	O
of	O
32	O
B	O
-	O
cell	O
lines	O
,	O
A	B
-	I
myb	I
was	O
very	O
strongly	O
expressed	O
in	O
most	O
Burkitt	O
'	O
s	O
lymphoma	O
(	O
BL	O
)	O
cell	O
lines	O
,	O
but	O
weak	O
or	O
negative	O
in	O
2	O
pre	O
-	O
B	O
acute	O
lymphoblastic	O
leukemia	O
(	O
ALL	O
)	O
,	O
4	O
non	O
-	O
Hodgkin	O
'	O
s	O
lymphoma	O
(	O
NHL	O
)	O
,	O
6	O
Epstein	O
-	O
Barr	O
virus	O
-	O
immortalized	O
lymphoblastoid	O
cell	O
lines	O
,	O
and	O
6	O
myeloma	O
lines	O
.	O

C	O
-	O
myb	O
and	O
B	B
-	I
myb	I
were	O
expressed	O
in	O
all	O
neoplastic	O
groups	O
,	O
except	O
in	O
CLL	O
cells	O
.	O

Thus	O
,	O
A	B
-	I
myb	I
expression	O
,	O
unlike	O
that	O
of	O
c	B
-	I
myb	I
and	O
B	B
-	I
myb	I
,	O
is	O
restricted	O
to	O
a	O
subset	O
of	O
B	O
-	O
cell	O
neoplasias	O
(	O
in	O
particular	O
BL	O
and	O
slg	O
+	O
B	O
-	O
ALL	O
)	O
representative	O
of	O
a	O
specific	O
stage	O
of	O
B	O
-	O
cell	O
differentiation	O
.	O

Here	O
we	O
provide	O
evidence	O
that	O
this	O
transformation	O
is	O
the	O
result	O
of	O
double	O
infection	O
of	O
a	O
cell	O
with	O
two	O
virions	O
,	O
the	O
P3HR1	B
virus	I
genome	I
and	O
a	O
mini	B
-	I
EBV	I
plasmid	I
carrying	O
the	O
chimeric	O
EBNA2	B
gene	I
.	O

It	O
remains	O
open	O
whether	O
the	O
growth	O
retarding	O
property	O
of	O
the	O
EBNA2	B
-	I
oestrogen	I
receptor	I
fusion	I
protein	I
in	O
B	O
cell	O
lymphoma	O
lines	O
is	O
due	O
to	O
unphysiologically	O
high	O
expression	O
of	O
the	O
chimeric	B
protein	I
or	O
to	O
interference	O
with	O
a	O
cellular	O
programme	O
driving	O
proliferation	O
in	O
these	O
cell	O
lines	O
.	O

These	O
results	O
indicate	O
that	O
,	O
as	O
already	O
reported	O
for	O
the	O
IL2Rbeta	B
promoter	I
,	O
GA	B
-	I
binding	I
protein	I
is	O
an	O
essential	O
component	O
of	O
gammac	O
basal	O
promoter	O
activity	O
.	O

Detection	O
of	O
intracellular	B
signal	I
transduction	I
molecules	I
in	O
PBMC	O
from	O
rhesus	O
macaques	O
and	O
sooty	O
mangabeys	O
.	O

The	O
molecular	O
mechanisms	O
associated	O
with	O
the	O
T	O
-	O
cell	O
dysfunction	O
remain	O
to	O
be	O
elucidated	O
.	O

Because	O
relatively	O
little	O
is	O
known	O
about	O
these	O
events	O
in	O
nonhuman	O
primates	O
,	O
our	O
laboratory	O
defined	O
optimal	O
conditions	O
,	O
reagents	O
,	O
and	O
assays	O
for	O
the	O
study	O
of	O
signal	O
transduction	O
events	O
in	O
cells	O
from	O
nonhuman	O
primates	O
.	O

The	O
protein	O
phosphorylation	O
patterns	O
in	O
the	O
two	O
monkeys	O
exhibited	O
quantitative	O
,	O
qualitative	O
,	O
and	O
kinetic	O
differences	O
.	O

Expression	O
of	O
ATF	B
-	I
2	I
in	O
S	O
.	O
cerevisiae	O
did	O
not	O
activate	O
TRE	B
-	I
1	I
in	O
the	O
presence	O
of	O
Tax	B
.	O

This	O
shows	O
that	O
in	O
a	O
eukaryotic	O
nucleus	O
,	O
Tax	B
specifically	O
interacts	O
with	O
the	O
basic	B
domain	I
-	I
leucine	I
zipper	I
region	I
of	O
ATF	B
-	I
1	I
,	O
CREB	B
,	O
and	O
CREM	B
.	O

Trapoxin	O
is	O
a	O
microbially	O
derived	O
cyclotetrapeptide	O
that	O
inhibits	O
histone	B
deacetylation	O
in	O
vivo	O
and	O
causes	O
mammalian	O
cells	O
to	O
arrest	O
in	O
the	O
cell	O
cycle	O
.	O

The	O
mechanisms	O
by	O
which	O
these	O
promoters	O
of	O
cell	O
growth	O
exert	O
their	O
inhibitory	O
effects	O
vary	O
,	O
but	O
in	O
most	O
instances	O
they	O
involve	O
a	O
disruption	O
of	O
the	O
IFN	O
-	O
alpha	O
/	O
beta	O
-	O
induced	O
transcription	O
complex	O
ISGF3	O
such	O
that	O
the	O
DNA	O
-	O
binding	O
component	O
of	O
this	O
complex	O
(	O
the	O
48	O
-	O
kDa	O
ISGF3gamma	O
protein	O
)	O
does	O
not	O
bind	O
to	O
the	O
interferon	O
-	O
stimulated	O
response	O
element	O
(	O
ISRE	O
)	O
.	O

Phorbol	O
ester	O
treatment	O
of	O
monocytes	O
inhibited	O
IFN	O
alpha	O
-	O
stimulated	O
tyrosine	O
phosphorylation	O
of	O
the	O
transcription	B
factors	I
Stat1alpha	B
,	O
Stat2	B
,	O
and	O
Stat3	B
and	O
of	O
the	O
tyrosine	B
kinase	I
Tyk2	B
but	O
had	O
no	O
effect	O
on	O
IFN	B
-	I
gamma	I
activation	O
of	O
Stat1alpha	B
.	O

Pretreatment	O
of	O
cells	O
with	O
vanadate	O
prevented	O
the	O
effects	O
of	O
PMA	O
with	O
regard	O
to	O
PMA	O
-	O
induced	O
Tyk2	B
dephosphorylation	O
.	O

Interleukin	B
-	I
2	I
(	I
IL	I
-	I
2	I
)	I
promoter	I
-	B
reporter	I
gene	I
behavior	O
closely	O
parallels	O
the	O
endogenous	B
gene	I
in	O
response	O
to	O
T	B
cell	I
receptor	I
and	O
costimulatory	O
signals	O
.	O

The	O
RAR	B
-	I
RXR	I
as	O
well	O
as	O
the	O
RXR	B
-	I
RXR	I
pathway	O
is	O
involved	O
in	O
signaling	O
growth	O
inhibition	O
of	O
human	O
CD34	O
+	O
erythroid	O
progenitor	O
cells	O
.	O

Previous	O
studies	O
have	O
shown	O
that	O
retinoic	O
acid	O
(	O
RA	O
)	O
,	O
similar	O
to	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
(	O
TNF	B
-	I
alpha	I
)	O
,	O
can	O
act	O
as	O
a	O
bifunctional	O
regulator	O
of	O
the	O
growth	O
of	O
bone	O
marrow	O
progenitors	O
,	O
in	O
that	O
it	O
can	O
stimulate	O
granulocyte	O
-	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
(	O
GM	O
-	O
CSF	O
)	O
-	O
or	O
interleukin	O
-	O
3	O
(	O
IL	O
-	O
3	O
)	O
-	O
induced	O
GM	O
colony	O
formation	O
,	O
but	O
potently	O
inhibit	O
G	B
-	I
CSF	I
-	O
induced	O
growth	O
.	O

Erythroid	O
colony	O
growth	O
was	O
also	O
inhibited	O
when	O
CD34	O
+	O
progenitors	O
were	O
seeded	O
at	O
one	O
cell	O
per	O
well	O
,	O
suggesting	O
a	O
direct	O
action	O
of	O
RA	O
.	O

At	O
this	O
concentration	O
,	O
Ro	O
13	O
-	O
7410	O
potently	O
inhibited	O
G	B
-	I
CSF	I
-	O
stimulated	O
myeloid	O
as	O
well	O
as	O
SCF	B
+	O
Epo	B
-	O
induced	O
erythroid	O
colony	O
growth	O
.	O

At	O
the	O
same	O
concentration	O
,	O
Ro	O
25	O
-	O
6603	O
and	O
Ro	O
25	O
-	O
7386	O
had	O
little	O
or	O
no	O
effect	O
on	O
G	B
-	I
CSF	I
-	O
induced	O
colony	O
formation	O
,	O
whereas	O
they	O
inhibited	O
75	O
%	O
and	O
53	O
%	O
,	O
respectively	O
,	O
of	O
SCF	B
+	O
Epo	B
-	O
stimulated	O
BFU	O
-	O
E	O
colony	O
growth	O
.	O

Thus	O
,	O
the	O
RAR	B
-	I
RXR	I
response	O
pathway	O
can	O
signal	O
growth	O
inhibition	O
of	O
normal	O
bone	O
marrow	O
myeloid	O
and	O
erythroid	O
progenitor	O
cells	O
.	O

After	O
treatment	O
of	O
APL	O
cells	O
with	O
AM580	O
either	O
alone	O
or	O
in	O
combination	O
with	O
granulocyte	B
colony	I
-	I
stimulating	I
factor	I
(	O
G	B
-	I
CSF	I
)	O
,	O
the	O
compound	O
induces	O
granulocytic	O
maturation	O
,	O
as	O
assessed	O
by	O
determination	O
of	O
the	O
levels	O
of	O
leukocyte	B
alkaline	I
phosphatase	I
,	I
CD11b	I
,	I
CD33	I
,	I
and	I
G	I
-	I
CSF	I
receptor	I
mRNA	I
,	O
at	O
concentrations	O
that	O
are	O
10	O
-	O
to	O
100	O
-	O
fold	O
lower	O
than	O
those	O
of	O
ATRA	O
necessary	O
to	O
produce	O
similar	O
effects	O
.	O

By	O
contrast	O
,	O
AM580	O
is	O
not	O
effective	O
as	O
ATRA	O
in	O
modulating	O
the	O
expression	O
of	O
these	O
differentiation	B
markers	I
in	O
the	O
HL	O
-	O
60	O
cell	O
line	O
and	O
in	O
freshly	O
isolated	O
granulocytes	O
obtained	O
from	O
the	O
peripheral	O
blood	O
of	O
chronic	O
myelogenous	O
leukemia	O
patients	O
during	O
the	O
stable	O
phase	O
of	O
the	O
disease	O
.	O

In	O
NB4	O
cells	O
,	O
two	O
other	O
synthetic	O
nonselective	O
RAR	O
ligands	O
are	O
capable	O
of	O
inducing	O
LAP	B
as	O
much	O
as	O
AM580	O
,	O
whereas	O
RAR	O
beta	O
-	O
or	O
RAR	O
gamma	O
-	O
specific	O
ligands	O
are	O
totally	O
ineffective	O
.	O

These	O
results	O
show	O
that	O
AM580	O
is	O
more	O
powerful	O
than	O
ATRA	O
in	O
modulating	O
the	O
expression	O
of	O
differentiation	O
antigens	O
only	O
in	O
cells	O
in	O
which	O
PML	B
-	I
RAR	I
is	O
present	O
.	O

Binding	O
experiments	O
,	O
using	O
COS	O
-	O
7	O
cells	O
transiently	O
transfected	O
with	O
PML	B
-	I
RAR	I
and	O
the	O
normal	O
RAR	B
alpha	I
,	O
show	O
that	O
AM580	O
has	O
a	O
lower	O
affinity	O
than	O
ATRA	O
for	O
both	O
receptors	O
.	O

Inhibition	O
of	O
vitamin	B
D	I
receptor	I
-	I
retinoid	I
X	I
receptor	I
-	I
vitamin	I
D	I
response	I
element	I
complex	I
formation	O
by	O
nuclear	O
extracts	O
of	O
vitamin	O
D	O
-	O
resistant	O
New	O
World	O
primate	O
cells	O
.	O

Nuclear	O
and	O
post	O
-	O
nuclear	O
extracts	O
were	O
prepared	O
from	O
two	O
B	O
-	O
lymphoblastoid	O
cell	O
lines	O
known	O
to	O
be	O
representative	O
of	O
the	O
vitamin	O
D	O
-	O
resistant	O
and	O
wild	O
type	O
phenotypes	O
,	O
respectively	O
.	O

In	O
addition	O
,	O
vitamin	O
D	O
-	O
resistant	O
cell	O
nuclear	O
extract	O
contained	O
a	O
protein	O
(	O
s	O
)	O
which	O
was	O
bound	O
specifically	O
to	O
the	O
VDRE	B
and	O
was	O
capable	O
of	O
completely	O
inhibiting	O
VDR	B
-	I
RXR	I
-	I
VDRE	I
complex	I
formation	O
;	O
these	O
effects	O
were	O
not	O
demonstrated	O
with	O
nuclear	O
extract	O
from	O
the	O
wild	O
type	O
cell	O
line	O
or	O
with	O
the	O
post	O
-	O
nuclear	O
extract	O
of	O
the	O
vitamin	O
D	O
-	O
resistant	O
cell	O
line	O
.	O

We	O
conclude	O
that	O
a	O
VDRE	B
-	I
binding	I
protein	I
(	O
s	O
)	O
,	O
distinct	O
from	O
IDBP	B
and	O
present	O
in	O
nuclear	O
extract	O
of	O
cells	O
from	O
a	O
prototypical	O
vitamin	O
D	O
-	O
resistant	O
NWP	O
,	O
is	O
capable	O
of	O
inhibiting	O
normal	O
VDR	B
-	I
RXR	I
heterodimer	O
binding	O
to	O
the	O
VDRE	B
.	O

Finally	O
,	O
the	O
activation	O
-	O
induced	O
changes	O
in	O
one	O
set	O
of	O
phosphoproteins	B
were	O
dramatically	O
inhibited	O
by	O
cyclosporin	O
A	O
.	O

Like	O
IkappaBalpha	B
,	O
Tax	B
-	O
mediated	O
breakdown	O
of	O
IkappaBbeta	B
in	O
transfected	O
T	O
lymphocytes	O
is	O
blocked	O
either	O
by	O
cell	O
-	O
permeable	O
proteasome	O
inhibitors	O
or	O
by	O
mutation	O
Of	O
IkappaBbeta	B
at	O
two	O
serine	O
residues	O
present	O
within	O
its	O
N	B
-	I
terminal	I
region	I
.	O

Although	O
a	O
role	O
of	O
p16	B
in	O
this	O
regulation	O
has	O
been	O
presumed	O
,	O
there	O
is	O
no	O
proof	O
so	O
far	O
that	O
loss	O
of	O
this	O
tumor	B
suppressor	I
gene	I
really	O
affects	O
E2F	B
-	O
mediated	O
regulations	O
.	O

Nuclear	B
factors	I
from	O
unstimulated	O
,	O
but	O
not	O
from	O
activated	O
cells	O
,	O
bound	O
a	O
site	O
,	O
META	B
(	I
D	I
-	I
)	I
,	O
adjacent	O
to	O
META	B
(	I
D	I
+	I
)	I
.	O

We	O
have	O
isolated	O
a	O
novel	B
cDNA	I
clone	I
encoding	O
interferon	B
(	I
IFN	I
)	I
consensus	I
sequence	I
-	I
binding	I
protein	I
in	O
adult	O
T	O
-	O
cell	O
leukemia	O
cell	O
line	O
or	O
activated	O
T	O
cells	O
(	O
ICSAT	B
)	O
;	O
this	O
protein	O
is	O
the	O
human	O
homolog	O
of	O
the	O
recently	O
cloned	O
Pip	B
/	I
LSIRF	I
.	O

Here	O
,	O
we	O
describe	O
the	O
effect	O
of	O
383	B
-	I
bp	I
(	I
delta383	I
)	I
and	I
99	I
-	I
bp	I
(	I
delta99	I
)	I
sequences	I
containing	O
the	O
PYBF	B
-	I
binding	I
site	I
on	O
transcription	O
from	O
various	O
globin	O
and	O
non	O
-	O
globin	O
promoters	O
,	O
using	O
a	O
transient	O
assay	O
with	O
the	O
cat	B
reporter	I
gene	I
in	O
murine	O
erythroleukemia	O
(	O
MEL	O
)	O
cells	O
,	O
a	O
cell	O
line	O
with	O
abundant	O
PYBF	B
activity	O
.	O

Translocation	B
breakpoints	I
in	O
three	O
patients	O
with	O
campomelic	O
dysplasia	O
and	O
autosomal	O
sex	O
reversal	O
map	O
more	O
than	O
130	O
kb	O
from	O
SOX9	B
.	O

Campomelic	O
dysplasia	O
(	O
CMPD1	O
)	O
and	O
autosomal	O
XY	O
sex	O
reversal	O
(	O
SRA1	O
)	O
are	O
caused	O
by	O
mutations	O
in	O
the	O
SRY	B
-	I
related	I
gene	I
SOX9	B
on	O
17q	B
.	O

Unexpectedly	O
,	O
the	O
17q	B
breakpoints	I
in	O
four	O
CMPD1	O
translocation	O
cases	O
previously	O
analyzed	O
by	O
us	O
and	O
others	O
map	O
50	O
kb	O
or	O
more	O
from	O
SOX9	B
.	O

DeltaSpi	B
-	I
B	I
product	O
was	O
not	O
able	O
to	O
bind	O
DNA	O
and	O
was	O
recovered	O
in	O
cytoplasmic	O
cellular	O
extracts	O
.	O

Both	O
CIITA	B
and	O
Bob1	B
increase	O
the	O
expression	O
from	O
the	O
DRA	B
promoter	I
,	O
which	O
is	O
a	O
prototypic	O
class	B
II	I
promoter	I
.	O

However	O
,	O
the	O
growth	O
of	O
most	O
mutated	O
viruses	O
was	O
suppressed	O
in	O
primary	O
rhesus	O
monkey	O
alveolar	O
macrophages	O
(	O
SIVmacMER	O
approximately	O
2xNFkappaB	B
approximately	O
substNFkappaB	B
>	O
deltaNFkappaB	B
>	O
deltaNFkappaB	B
deltaSpl234	B
approximately	O
deltaNFkappaBdeltaSp	B
>	O
deltaSpl234	B
approximately	O
substSpl2	B
>	O
substSp23	B
approximately	O
substSp34	B
approximately	O
substSpl234	B
>	O
or	O
=	O
SIVmac239	O
)	O
.	O

The	O
ability	O
of	O
T	O
cells	O
to	O
form	O
high	O
intracellular	O
levels	O
of	O
cAMP	O
is	O
acquired	O
during	O
development	O
in	O
the	O
human	O
thymus	O
and	O
is	O
retained	O
by	O
the	O
majority	O
of	O
mature	O
peripheral	O
T	O
lymphocytes	O
.	O

A	O
hydrophobic	O
domain	O
of	O
Ca2	B
+	I
-	I
modulating	I
cyclophilin	I
ligand	I
modulates	O
calcium	O
influx	O
signaling	O
in	O
T	O
lymphocytes	O
.	O

Ca2	B
+	I
-	I
modulating	I
cyclophilin	I
ligand	I
(	O
CAML	B
)	O
was	O
originally	O
described	O
as	O
a	O
cyclophilin	B
B	I
-	I
binding	I
protein	I
whose	O
overexpression	O
in	O
T	O
cells	O
causes	O
a	O
rise	O
in	O
intracellular	O
calcium	O
,	O
thus	O
activating	O
transcription	B
factors	I
responsible	O
for	O
the	O
early	O
immune	O
response	O
.	O

The	O
Epstein	B
-	I
Barr	I
virus	I
-	I
encoded	I
nuclear	I
antigen	I
EBNA	I
-	I
5	I
accumulates	O
in	O
PML	O
-	O
containing	O
bodies	O
.	O

The	O
chromosome	B
17	I
breakpoint	I
was	O
localized	O
to	O
intron	B
2	I
of	O
RARA	B
by	O
Southern	O
blotting	O
,	O
and	O
there	O
was	O
no	O
evidence	O
at	O
the	O
molecular	O
level	O
for	O
rearrangement	O
at	O
PML	B
locus	I
.	O

Immunocytochemistry	O
identified	O
the	O
cells	O
in	O
the	O
infiltrate	O
as	O
cytotoxic	O
T	O
cells	O
.	O

In	O
these	O
same	O
animals	O
,	O
E1A	B
protein	I
was	O
detected	O
20	O
days	O
after	O
infection	O
in	O
two	O
and	O
47	O
days	O
after	O
infection	O
in	O
one	O
while	O
persistent	O
bronchiolitis	O
was	O
observed	O
in	O
four	O
and	O
three	O
animals	O
20	O
and	O
47	O
days	O
after	O
infection	O
,	O
respectively	O
.	O

Cyclic	O
AMP	O
-	B
responsive	I
element	I
-	O
dependent	O
activation	O
of	O
Epstein	O
-	O
Barr	O
virus	O
zebra	B
promoter	I
by	O
human	O
herpesvirus	O
6	O
.	O

Mutation	O
of	O
the	O
consensus	B
AP	I
-	I
1	I
/	I
CRE	I
site	I
within	O
ZII	B
abolished	O
the	O
inducibility	O
of	O
Zp	B
by	O
HHV	O
-	O
6	O
,	O
whereas	O
positioning	O
of	O
the	O
ZII	B
domain	I
upstream	O
of	O
the	O
beta	B
-	I
globin	I
minimal	I
promoter	I
conferred	O
responsiveness	O
following	O
HHV	O
-	O
6	O
infection	O
.	O

Antibodies	O
against	O
CRE	B
-	I
binding	I
(	I
CREB	I
)	I
protein	I
but	O
not	O
against	O
c	B
-	I
Fos	I
or	O
c	B
-	I
Jun	I
were	O
able	O
to	O
supershift	O
the	O
DNA	B
-	I
protein	I
complex	I
,	O
identifying	O
the	O
nature	O
of	O
the	O
transcription	B
factor	I
which	O
binds	O
to	O
ZII	B
as	O
a	O
member	O
of	O
the	O
CREB	B
family	I
of	I
proteins	I
.	O

Regulation	O
of	O
the	O
nuclear	B
factor	I
of	I
activated	I
T	I
cells	I
in	O
stably	O
transfected	O
Jurkat	O
cell	O
clones	O
.	O

Glucocorticoids	O
induced	O
down	O
-	O
regulation	O
of	O
glucocorticoid	B
receptor	I
mRNA	O
expression	O
in	O
asthma	O
.	O

The	O
lymphoid	B
-	I
specific	I
transcription	I
factor	I
Oct	B
-	I
2a	I
is	O
implicated	O
in	O
B	O
cell	O
-	O
specific	O
transcriptional	O
activity	O
via	O
the	O
octamer	O
motif	O
.	O

Structure	O
/	O
function	O
analysis	O
of	O
various	O
Oct	B
-	I
2a	I
effector	I
regions	I
in	O
the	O
context	O
of	O
the	O
GAL4	B
DNA	I
-	I
binding	I
domain	I
revealed	O
that	O
Oct	B
-	I
2a	I
contains	O
two	O
functionally	O
different	O
activation	B
domains	I
at	O
the	O
N	B
and	I
the	I
C	I
termini	I
.	O

When	O
this	O
domain	O
was	O
transferred	O
to	O
a	O
potent	O
activator	O
,	O
transcription	O
was	O
strongly	O
inhibited	O
.	O

In	O
this	O
study	O
we	O
present	O
a	O
deletion	O
analysis	O
of	O
the	O
N	B
-	I
terminal	I
region	I
of	O
Oct	B
-	I
2a	I
to	O
determine	O
the	O
minimal	B
repression	I
domain	I
.	O

The	O
possibility	O
that	O
Oct	B
-	I
2a	I
can	O
act	O
as	O
an	O
activator	O
and	O
/	O
or	O
a	O
repressor	O
may	O
have	O
important	O
consequences	O
for	O
the	O
function	O
of	O
Oct	B
-	I
2a	I
in	O
B	O
cell	O
differentiation	O
and	O
other	O
developmental	O
processes	O
.	O

Although	O
there	O
have	O
been	O
a	O
number	O
of	O
reports	O
demonstrating	O
that	O
glucocorticoids	O
(	O
in	O
particular	O
dexamethasone	O
)	O
antagonize	O
the	O
eosinophil	O
life	O
-	O
prolonging	O
effects	O
of	O
hemopoietins	B
,	O
direct	O
effects	O
of	O
dexamethasone	O
on	O
eosinophil	O
apoptosis	O
have	O
not	O
been	O
documented	O
.	O

In	O
contrast	O
,	O
dexamethasone	O
was	O
a	O
potent	O
inhibitor	O
of	O
neutrophil	O
apoptosis	O
.	O

For	O
this	O
purpose	O
,	O
we	O
used	O
three	O
main	O
approaches	O
.	O

The	O
first	O
was	O
to	O
abruptly	O
terminate	O
tumor	O
necrosis	O
factor	O
-	O
induced	O
NF	B
-	I
kappaB	I
binding	O
to	O
the	O
enhancer	O
sequences	O
in	O
U1	O
monocytic	O
cells	O
,	O
using	O
a	O
short	O
pulse	O
of	O
exogenous	B
tumor	I
necrosis	I
factor	I
.	O

Together	O
,	O
our	O
results	O
indicate	O
that	O
occupancy	O
of	O
the	O
viral	B
enhancer	I
by	O
NF	B
-	I
kappaB	I
(	I
p50	I
/	I
p65	I
)	I
heterodimers	I
is	O
required	O
for	O
ongoing	O
transcription	O
of	O
integrated	O
HIV	O
provirus	O
in	O
monocytes	O
,	O
even	O
in	O
cells	O
chronically	O
infected	O
and	O
permanently	O
producing	O
functional	O
HIV	B
Tat	I
protein	I
.	O

In	O
an	O
attempt	O
to	O
identify	O
changes	O
in	O
gene	O
expression	O
that	O
accompany	O
the	O
T	O
-	O
cell	O
stimulation	O
defects	O
associated	O
with	O
the	O
loss	O
of	O
Rel	B
,	O
we	O
have	O
examined	O
the	O
expression	O
of	O
cell	B
surface	I
activation	I
markers	I
and	O
cytokine	O
production	O
in	O
mitogen	O
-	O
stimulated	O
Rel	O
-	O
/	O
-	O
T	O
cells	O
.	O

Exogenous	O
IL	B
-	I
2	I
,	O
which	O
restitutes	O
the	O
proliferative	O
response	O
of	O
the	O
anti	O
-	O
CD3	O
-	O
and	O
anti	O
-	O
CD28	O
-	O
treated	O
Rel	O
-	O
/	O
-	O
T	O
cells	O
,	O
restores	O
production	O
of	O
IL	O
-	O
5	O
,	O
TNF	B
-	I
alpha	I
,	O
and	O
IFN	B
-	I
gamma	I
,	O
but	O
not	O
IL	B
-	I
3	I
and	O
GM	B
-	I
CSF	I
expression	O
to	O
approximately	O
normal	O
levels	O
.	O

These	O
findings	O
establish	O
that	O
Rel	B
can	O
function	O
as	O
an	O
activator	O
or	O
repressor	O
of	O
gene	O
expression	O
and	O
is	O
required	O
by	O
T	O
lymphocytes	O
for	O
production	O
of	O
IL	B
-	I
3	I
and	O
GM	B
-	I
CSF	I
.	O

Nuclear	O
appearance	O
of	O
a	O
factor	O
that	O
binds	O
the	O
CD28	B
response	I
element	I
within	O
the	O
interleukin	B
-	I
2	I
enhancer	I
correlates	O
with	O
interleukin	B
-	I
2	I
production	O
.	O

These	O
results	O
indicate	O
that	O
mitogenic	O
combinations	O
of	O
T	O
cell	O
activation	O
signals	O
are	O
integrated	O
at	O
the	O
level	O
of	O
NF	B
-	I
MATp35	I
induction	O
.	O

Transcriptional	O
basis	O
for	O
hyporesponsiveness	O
of	O
the	O
human	B
inducible	I
nitric	I
oxide	I
synthase	I
gene	I
to	O
lipopolysaccharide	O
/	O
interferon	O
-	O
gamma	O
.	O

Two	O
explanations	O
for	O
hyporesponsiveness	O
of	O
the	O
human	B
iNOS	I
promoter	I
to	O
LPS	O
+	O
/	O
-	O
IFN	B
-	I
gamma	I
were	O
found	O
:	O
(	O
1	O
)	O
multiple	O
inactivating	O
nucleotide	O
substitutions	O
in	O
the	O
human	O
counterpart	O
of	O
the	O
enhancer	B
element	I
that	O
has	O
been	O
shown	O
to	O
regulate	O
LPS	O
/	O
IFN	B
-	I
gamma	I
induced	O
expression	O
of	O
the	O
mouse	B
iNOS	I
gene	I
;	O
and	O
(	O
2	O
)	O
and	O
absence	O
of	O
one	O
or	O
more	O
nuclear	B
factors	I
in	O
human	O
macrophages	O
(	O
e	O
.	O
g	O
.	O
,	O
an	O
LPS	B
-	I
inducible	I
nuclear	I
factor	I
-	I
kappa	I
B	I
/	I
Rel	I
complex	I
)	O
,	O
that	O
is	O
(	O
are	O
)	O
required	O
for	O
maximal	O
expression	O
of	O
the	O
gene	O
.	O

Severe	O
skewing	O
of	O
X	O
inactivation	O
resulting	O
in	O
inactivity	O
of	O
the	O
intact	O
X	B
was	O
found	O
in	O
blood	O
and	O
cultures	O
of	O
both	O
types	O
of	O
skin	O
,	O
but	O
analysis	O
of	O
DNA	O
prepared	O
directly	O
from	O
hypopigmented	O
skin	O
showed	O
significant	O
inactivation	O
of	O
the	O
translocated	O
X	B
,	O
inconsistent	O
with	O
the	O
usual	O
mechanism	O
of	O
phenotypic	O
expression	O
in	O
X	B
;	I
autosome	I
translocations	I
.	O

While	O
partial	O
variable	O
monosomy	O
of	O
loci	O
on	O
chromosome	B
17p	I
can	O
not	O
be	O
excluded	O
as	O
contributing	O
to	O
the	O
phenotype	O
in	O
this	O
patient	O
,	O
it	O
is	O
argued	O
that	O
the	O
major	O
likely	O
factor	O
is	O
partial	O
functional	O
disomy	O
of	O
sequences	O
on	O
Xp	B
in	O
cell	O
lineages	O
that	O
have	O
failed	O
to	O
inactivate	O
the	O
intact	O
X	B
chromosome	I
.	O

After	O
several	O
round	O
of	O
subcloning	O
followed	O
by	O
transfection	O
,	O
oriP	B
was	O
mapped	O
to	O
a	O
1	B
.	I
955	I
-	I
kb	I
viral	I
segment	I
.	O

Large	O
amounts	O
of	O
AP	B
-	I
1	I
and	O
NF	B
-	I
kappa	I
B	I
and	O
significant	O
quantities	O
of	O
NF	B
-	I
AT	I
were	O
induced	O
in	O
SEA	O
-	O
activated	O
CD4	O
+	O
spleen	O
T	O
cells	O
,	O
whereas	O
Oct	O
-	O
1	O
and	O
Oct	O
-	O
2	O
DNA	O
binding	O
activity	O
was	O
similar	O
in	O
both	O
resting	O
and	O
activated	O
T	O
cells	O
.	O

Fas	B
ligation	O
induces	O
apoptosis	O
and	O
Jun	B
kinase	I
activation	O
independently	O
of	O
CD45	B
and	O
Lck	B
in	O
human	O
T	O
cells	O
.	O

More	O
is	O
known	O
regarding	O
signal	O
transduction	O
events	O
that	O
occur	O
after	O
ligation	O
of	O
the	O
T	B
-	I
cell	I
antigen	I
receptor	I
(	O
TCR	B
)	O
.	O

Although	O
prior	O
studies	O
suggest	O
a	O
role	O
for	O
protein	B
tyrosine	I
kinases	I
and	O
phosphatases	O
in	O
Fas	B
signaling	O
,	O
we	O
report	O
here	O
that	O
Fas	O
ligation	O
induces	O
apoptosis	O
in	O
T	O
cells	O
deficient	O
in	O
either	O
CD45	B
or	O
Lck	B
.	O

Globin	O
gene	O
switching	O
.	O

In	O
contrast	O
,	O
in	O
vivo	O
footprints	O
on	O
GT	B
(	I
CACCC	I
)	I
motifs	I
differed	O
between	O
the	O
cells	O
expressing	O
the	O
fetal	O
or	O
the	O
adult	O
globin	O
program	O
.	O

The	O
active	O
vitamin	O
D3	O
metabolite	O
1	O
,	O
25	O
-	O
dihydroxycholecalcif	O
(	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
)	O
acts	O
as	O
an	O
antiproliferative	O
and	O
differentiating	O
agent	O
for	O
the	O
monoblastoid	O
cell	O
line	O
U937	O
and	O
as	O
an	O
important	O
immunologic	O
mediator	O
implicated	O
particularly	O
in	O
the	O
function	O
of	O
cells	O
belonging	O
to	O
the	O
monocyte	O
/	O
macrophage	O
lineage	O
.	O

Cell	O
cycle	O
analysis	O
showed	O
shifts	O
in	O
the	O
distribution	O
of	O
cells	O
from	O
G1	O
to	O
S	O
phase	O
,	O
which	O
were	O
more	O
pronounced	O
after	O
cadmium	O
treatment	O
.	O

These	O
data	O
indicate	O
that	O
,	O
in	O
contrast	O
to	O
most	O
LPS	O
effects	O
,	O
AP	B
-	I
1	I
,	O
but	O
not	O
nuclear	B
factor	I
-	I
kappaB	I
,	O
mediates	O
LPS	O
induction	O
of	O
collagenase	B
transcription	O
in	O
macrophagelike	O
cells	O
.	O

Activation	O
of	O
macrophages	O
by	O
bacterial	O
lipopolysaccharide	O
(	O
LPS	O
)	O
induces	O
transcription	O
of	O
genes	O
that	O
encode	O
for	O
proinflammatory	B
regulators	I
of	O
the	O
immune	O
response	O
.	O

LPS	O
treatment	O
of	O
RAW	O
264	O
.	O
7	O
cells	O
,	O
murine	O
bone	O
marrow	O
-	O
derived	O
macrophages	O
,	O
and	O
the	O
human	O
monocyte	O
cell	O
line	O
THP	O
-	O
1	O
resulted	O
in	O
rapid	O
activation	O
of	O
the	O
p46	B
and	I
p54	I
isoforms	I
of	O
JNK	B
.	O

These	O
results	O
suggest	O
that	O
LPS	O
activation	O
of	O
JNK	B
in	O
monocyte	O
/	O
macrophage	O
cells	O
is	O
a	O
CD14	O
-	O
and	O
protein	O
tyrosine	O
phosphorylation	O
-	O
dependent	O
event	O
that	O
may	O
mediate	O
the	O
early	O
activation	O
of	O
AP	B
-	I
1	I
in	O
regulating	O
LPS	O
-	O
triggered	O
gene	O
induction	O
.	O

A	O
cell	B
type	I
-	I
specific	I
enhancer	I
in	O
the	O
human	B
B7	I
.	I
1	I
gene	I
regulated	O
by	O
NF	B
-	I
kappaB	I
.	O

This	O
183	B
-	I
bp	I
region	I
was	O
both	O
cell	O
type	O
specific	O
and	O
responsive	O
to	O
two	O
distinct	O
stimuli	O
,	O
lipopolysaccharide	O
and	O
dibutyryl	O
cAMP	O
,	O
known	O
to	O
regulate	O
B7	B
.	I
1	I
expression	O
.	O

Deletional	O
and	O
site	O
-	O
directed	O
mutagenesis	O
revealed	O
the	O
presence	O
of	O
multiple	O
functionally	O
critical	O
cis	B
elements	I
within	O
this	O
region	O
,	O
one	O
of	O
which	O
was	O
a	O
nuclear	B
factor	I
(	I
NF	I
)	I
-	I
kappaB	I
consensus	I
sequence	I
.	O

This	O
is	O
the	O
first	O
description	O
,	O
to	O
our	O
knowledge	O
,	O
of	O
regulatory	B
elements	I
that	O
control	O
expression	O
of	O
a	O
gene	O
encoding	O
a	O
B7	B
costimulatory	I
molecule	I
.	O

Recombinant	O
c	B
-	I
Jun	I
and	O
c	B
-	I
Fos	I
were	O
ubiquitinylated	O
by	O
the	O
ubiquitin	B
carrier	I
enzymes	I
E214K	B
,	O
E220K	B
,	O
or	O
E232K	B
in	O
the	O
presence	O
of	O
the	O
ubiquitin	B
-	I
activating	I
enzyme	I
,	O
E1	B
.	O

We	O
have	O
also	O
characterized	O
the	O
genomic	B
mBob1	I
clone	I
.	O

Analysis	O
of	O
its	O
intron	O
-	O
exon	O
structure	O
has	O
allowed	O
identification	O
of	O
a	O
C	B
-	I
terminal	I
splice	I
variant	I
.	O

mBob1	B
interacts	O
with	O
the	O
octamer	B
transcription	I
factors	I
Oct	B
-	I
1	I
and	O
Oct	B
-	I
2	I
and	O
stimulates	O
transcription	O
mediated	O
by	O
these	O
factors	O
.	O

It	O
is	O
well	O
established	O
that	O
the	O
two	O
major	O
glial	O
cells	O
in	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
,	O
astrocytes	O
and	O
microglia	O
,	O
are	O
key	O
participants	O
in	O
mediating	O
the	O
neurologic	O
dysfunction	O
associated	O
with	O
HIV	O
infection	O
of	O
the	O
CNS	O
.	O

Moreover	O
,	O
gp120	B
induces	O
tyrosine	O
phosphorylation	O
of	O
signal	B
transducer	I
and	I
activator	I
of	I
transcription	I
(	O
STAT	B
-	I
1	I
alpha	I
)	O
as	O
well	O
as	O
the	O
Janus	B
kinase	I
(	O
JAK2	B
)	O
in	O
glial	O
cells	O
.	O

Northern	O
blot	O
analysis	O
as	O
well	O
as	O
Ab	O
blocking	O
and	O
cytokine	B
secretion	O
studies	O
indicated	O
that	O
the	O
induction	O
of	O
either	O
endogenous	B
TNF	I
-	I
alpha	I
or	O
IL	B
-	I
10	I
was	O
not	O
involved	O
in	O
the	O
cooperativity	O
,	O
nor	O
was	O
an	O
up	O
-	O
regulation	O
of	O
TNF	B
-	I
alpha	I
receptors	I
.	O

Interaction	O
of	O
HTLV	B
-	I
I	I
Tax	I
with	O
the	O
human	B
proteasome	I
:	O
implications	O
for	O
NF	B
-	I
kappa	I
B	I
induction	O
.	O

We	O
identified	O
a	O
physical	O
interaction	O
between	O
Tax	B
and	O
the	O
HsN3	B
subunit	I
of	O
the	O
human	B
proteasome	I
.	O

This	O
raises	O
the	O
intriguing	O
possibility	O
that	O
physical	O
association	O
of	O
the	O
HsN3	B
proteasome	I
subunit	I
with	O
HTLV	B
-	I
I	I
Tax	I
coupled	O
with	O
the	O
independent	O
interaction	O
of	O
Tax	B
with	O
either	O
p100	O
or	O
p65	O
-	O
I	B
kappa	I
B	I
alpha	I
targets	O
these	O
cytoplasmic	B
NF	I
-	I
kappa	I
B	I
/	I
Rel	I
complexes	I
to	O
the	O
proteasome	B
for	O
processing	O
.	O

Basement	O
membrane	O
immunoreactivity	O
for	O
type	B
IV	I
collagen	I
and	O
laminin	B
was	O
discontinuous	O
in	O
most	O
examples	O
of	O
IDC	O
regardless	O
of	O
type	O
,	O
with	O
a	O
trend	O
toward	O
more	O
intense	O
staining	O
in	O
comedo	O
than	O
in	O
noncomedo	O
carcinomas	O
.	O

Periductal	O
angiogenesis	O
was	O
not	O
significantly	O
related	O
to	O
the	O
type	O
of	O
IDC	O
but	O
was	O
more	O
pronounced	O
with	O
comedo	O
carcinomas	O
.	O

They	O
correlated	O
with	O
markers	O
of	O
tumor	O
aggressivity	O
(	O
axillary	O
node	O
involvement	O
and	O
especially	O
with	O
markers	O
of	O
high	O
mitotic	O
rate	O
as	O
Ki	O
-	O
67	O
staining	O
,	O
histological	O
grade	O
)	O
.	O

OBJECTIVE	O
:	O
We	O
sought	O
to	O
investigate	O
the	O
molecular	O
mechanisms	O
regulating	O
this	O
early	O
inflammatory	O
response	O
.	O

We	O
have	O
focused	O
on	O
the	O
study	O
of	O
the	O
signal	O
transduction	O
pathways	O
triggered	O
by	O
CD23	B
in	O
human	O
monocytes	O
and	O
the	O
promonocytic	O
cell	O
line	O
U937	O
.	O

IkappaBalpha	B
phosphorylation	O
and	O
degradation	O
was	O
analyzed	O
by	O
Western	O
blot	O
.	O

Paclitaxel	O
and	O
other	O
drugs	O
that	O
disturb	O
microtubule	B
dynamics	O
kill	O
cells	O
in	O
a	O
Fas	B
/	B
Fas	I
ligand	I
(	O
FasL	B
)	O
-	O
dependent	O
manner	O
;	O
antibody	O
to	O
FasL	B
inhibits	O
paclitaxel	O
-	O
induced	O
apoptosis	O
.	O

Without	O
NFAT	B
nuclear	O
translocation	O
,	O
the	O
FasL	B
gene	O
is	O
not	O
transcribed	O
.	O

The	O
effects	O
of	O
Bcl	B
-	I
2	I
can	O
be	O
overcome	O
,	O
at	O
least	O
partially	O
,	O
through	O
phosphorylation	O
of	O
Bcl	B
-	I
2	I
.	O

MHC	O
-	O
peptide	O
ligand	O
interactions	O
establish	O
a	O
functional	O
threshold	O
for	O
antigen	O
-	O
specific	O
T	O
cell	O
recognition	O
.	O

Regulatory	O
effects	O
of	O
interleukin	B
-	I
11	I
during	O
acute	O
lung	O
inflammatory	O
injury	O
.	O

IL	B
-	I
11	I
mRNA	I
and	O
protein	O
were	O
both	O
up	O
-	O
regulated	O
during	O
the	O
course	O
of	O
this	O
inflammatory	O
response	O
.	O

Recently	O
,	O
we	O
and	O
others	O
have	O
shown	O
that	O
thrombopoietin	B
induces	O
rapid	O
tyrosine	O
phosphorylation	O
of	O
Jak2	B
and	O
other	O
proteins	O
in	O
human	O
platelets	O
and	O
BaF3	O
cells	O
,	O
genetically	O
engineered	O
to	O
express	O
c	B
-	I
Mpl	I
,	O
a	O
receptor	O
for	O
thrombopoietin	B
.	O

Thus	O
,	O
our	O
data	O
indicate	O
that	O
Stat3	B
and	O
Stat5	B
may	O
be	O
involved	O
in	O
signal	O
transduction	O
after	O
ligand	O
binding	O
to	O
c	B
-	I
Mpl	I
and	O
that	O
this	O
event	O
may	O
have	O
a	O
role	O
in	O
megakaryopoiesis	O
/	O
thrombopoiesis	O
or	O
possibly	O
a	O
mature	O
platelet	O
function	O
such	O
as	O
aggregation	O
.	O

Damage	O
to	O
the	O
genes	O
encoding	O
proteins	O
that	O
function	O
in	O
intracellular	O
signaling	O
,	O
transcription	O
,	O
or	O
regulation	O
of	O
the	O
cell	O
cycle	O
has	O
been	O
identified	O
and	O
linked	O
at	O
varying	O
degrees	O
to	O
the	O
progression	O
of	O
certain	O
lymphoid	O
malignancies	O
.	O

One	O
such	O
example	O
is	O
the	O
excessive	O
expression	O
of	O
`	B
`	I
normal	I
'	I
'	I
lymphokines	I
of	O
cytokines	B
which	O
accompanies	O
many	O
lymphoproliferative	O
diseases	O
.	O

The	O
dysregulated	O
expression	O
of	O
cytokines	B
during	O
malignancy	O
can	O
result	O
in	O
the	O
augmentation	O
of	O
growth	O
of	O
transformed	O
lymphocytes	O
,	O
as	O
well	O
as	O
an	O
alteration	O
of	O
the	O
anti	O
-	O
tumor	O
immune	O
response	O
.	O

In	O
addition	O
to	O
its	O
role	O
as	O
a	O
precursor	O
for	O
other	O
steroid	O
hormones	O
,	O
DHEA	O
has	O
been	O
proposed	O
to	O
play	O
an	O
important	O
role	O
in	O
immunity	O
.	O

Monocytes	O
stimulated	O
with	O
LPS	O
concentrations	O
of	O
1	O
.	O
0	O
micrograms	O
/	O
ml	O
displayed	O
the	O
above	O
cytotoxic	O
markers	O
,	O
whereas	O
monocytes	O
stimulated	O
with	O
DHEA	O
alone	O
or	O
with	O
LPS	O
at	O
a	O
lower	O
concentration	O
of	O
0	O
.	O
2	O
ng	O
/	O
ml	O
did	O
not	O
.	O

Finally	O
,	O
Scatchard	O
plot	O
analysis	O
demonstrated	O
the	O
presence	O
of	O
a	O
DHEA	O
receptor	O
in	O
monocytes	O
,	O
suggesting	O
that	O
DHEA	O
effects	O
on	O
LPS	O
-	O
stimulated	O
monocytes	O
are	O
mediated	O
through	O
a	O
receptor	O
-	O
dependent	O
process	O
.	O

IL	B
-	I
4	I
activates	O
gene	O
expression	O
by	O
inducing	O
tyrosine	O
phosphorylation	O
,	O
homodimerization	O
,	O
and	O
nuclear	O
translocation	O
of	O
the	O
latent	B
transcription	I
factor	I
,	O
STAT6	B
(	O
signal	B
transducer	I
and	I
activator	I
of	I
transcription	I
-	I
6	I
)	O
.	O

Because	O
STAT6	B
activation	O
is	O
essential	O
for	O
IL	B
-	I
4	I
-	O
induced	O
gene	O
expression	O
,	O
we	O
examined	O
the	O
ability	O
of	O
type	O
I	O
and	O
type	O
II	O
IFNs	B
to	O
regulate	O
activation	O
of	O
STAT6	B
by	O
IL	B
-	I
4	I
in	O
primary	O
human	O
monocytes	O
.	O

The	O
shift	O
from	O
complex	B
I	I
to	O
complex	B
II	I
seen	O
only	O
in	O
SCM	O
-	O
1	O
-	O
producer	O
T	O
cell	O
lines	O
upon	O
activation	O
was	O
completely	O
suppressed	O
by	O
cyclosporin	O
A	O
.	O

One	O
-	O
hybrid	O
assays	O
in	O
yeast	B
isolated	I
NF	I
-	I
ATp	I
as	O
an	O
E1	B
binding	I
protein	I
,	O
and	O
transfection	O
of	O
NF	B
-	I
ATp	I
into	O
T	O
and	O
B	O
cell	O
lines	O
strongly	O
enhanced	O
the	O
activation	B
-	I
dependent	I
SCM	I
-	I
1	I
promoter	O
activity	O
.	O

Recent	O
studies	O
have	O
reported	O
that	O
lymphocytes	O
produce	O
,	O
transport	O
and	O
bind	O
dopamine	O
present	O
in	O
plasma	O
.	O

The	O
importance	O
of	O
NF	B
-	I
kappaB	I
sites	I
was	O
confirmed	O
by	O
using	O
vectors	O
containing	O
wild	B
-	I
type	I
or	I
mutant	I
kappaB	I
sites	I
in	O
a	O
heterologous	B
promoter	I
.	O

Consistent	O
with	O
the	O
role	O
of	O
NF	B
-	I
kappaB	I
in	O
mediating	O
dopamine	O
responsiveness	O
,	O
the	O
proteasome	O
inhibitor	O
MG132	O
abolished	O
dopamine	O
-	O
induced	O
transcriptional	O
activation	O
.	O

A	O
significant	O
correlation	O
between	O
high	O
lymphocytic	O
infiltration	O
(	O
2	O
.	O
5	O
points	O
)	O
,	O
low	O
body	O
mass	O
and	O
fat	O
was	O
identified	O
.	O

Moderate	O
body	O
mass	O
,	O
relatively	O
low	O
fat	O
level	O
and	O
positive	O
receptor	O
status	O
are	O
among	O
factors	O
of	O
good	O
prognosis	O
in	O
breast	O
cancer	O
of	O
early	O
stages	O
.	O

In	O
this	O
study	O
,	O
we	O
analyzed	O
the	O
binding	O
activity	O
of	O
IL	B
-	I
10	I
-	I
and	I
IFN	I
-	I
gamma	I
-	I
activated	I
STAT	I
molecules	I
to	O
two	O
kinds	O
of	O
GAS	B
-	O
motif	O
sequences	O
.	O

This	O
may	O
explain	O
the	O
difference	O
between	O
IL	B
-	I
10	I
and	O
IFN	B
-	I
gamma	I
in	O
biological	O
activity	O
,	O
and	O
the	O
inhibitory	O
effect	O
of	O
IL	B
-	I
10	I
on	O
IFN	B
-	I
gamma	I
activities	O
.	O

Peptides	O
derived	O
from	O
the	O
HSV	B
-	I
2	I
VP16	I
protein	I
were	O
utilized	O
for	O
studies	O
of	O
peptide	O
binding	O
to	O
DQ0302	O
molecules	O
and	O
T	O
cell	O
activation	O
at	O
both	O
neutral	O
and	O
acidic	O
pH	O
.	O

The	O
short	O
truncated	O
analog	O
433	O
-	O
442A	O
binds	O
very	O
poorly	O
at	O
both	O
acidic	O
and	O
neutral	O
pH	O
.	O

Much	O
higher	O
concentrations	O
of	O
wild	O
type	O
peptides	O
were	O
needed	O
to	O
activate	O
T	O
cells	O
at	O
neutral	O
pH	O
.	O

To	O
investigate	O
a	O
potential	O
role	O
of	O
E2F	B
-	I
1	I
in	O
differentiation	O
,	O
we	O
assayed	O
the	O
ability	O
of	O
megakaryocytes	O
to	O
form	O
platelets	O
in	O
an	O
in	O
vivo	O
transgenic	O
model	O
.	O

Administration	O
of	O
megakaryocyte	B
growth	I
and	I
development	I
factor	I
or	O
interleukin	B
6	I
could	O
not	O
overcome	O
the	O
differentiation	O
block	O
.	O

A	O
recent	O
sib	O
-	O
pair	O
analysis	O
revealed	O
a	O
tight	O
linkage	O
between	O
markers	O
on	O
5q31	B
.	I
1	I
and	O
a	O
major	B
susceptibility	I
gene	I
controlling	O
total	O
serum	O
IgE	B
levels	O
.	O

Evidence	O
for	O
lowered	O
induction	O
of	O
nuclear	B
factor	I
kappa	I
B	I
in	O
activated	O
human	O
T	O
lymphocytes	O
during	O
aging	O
.	O

Inhibition	O
of	O
lipopolysaccharide	O
-	O
induced	O
monocyte	B
interleukin	I
-	I
1	I
receptor	I
antagonist	O
synthesis	O
by	O
cortisol	O
:	O
involvement	O
of	O
the	O
mineralocorticoid	B
receptor	I
.	O

The	O
mineralocorticoid	O
aldosterone	O
exerted	O
a	O
significant	O
decrease	O
in	O
LPS	O
-	O
induced	O
monocyte	O
IL	B
-	I
1ra	I
secretion	O
in	O
vitro	O
,	O
which	O
was	O
blocked	O
by	O
coincubation	O
with	O
spironolactone	O
.	O

Moreover	O
,	O
we	O
provide	O
evidence	O
that	O
,	O
in	O
addition	O
to	O
a	O
glucocorticoid	B
receptor	I
-	O
mediated	O
effect	O
,	O
the	O
mineralocorticoid	B
receptor	I
is	O
involved	O
in	O
the	O
inhibition	O
of	O
monocyte	O
IL	B
-	I
1ra	I
secretion	O
by	O
cortisol	O
.	O

Cell	O
-	O
mediated	O
immunity	O
plays	O
an	O
essential	O
role	O
in	O
the	O
control	O
of	O
infection	O
with	O
the	O
human	O
cytomegalovirus	O
(	O
HCMV	O
)	O
.	O

Here	O
,	O
we	O
have	O
readdressed	O
the	O
issue	O
of	O
CD8	O
(	O
+	O
)	O
T	O
cells	O
specific	O
for	O
the	O
72	B
-	I
kDa	I
major	I
immediate	I
-	I
early	I
protein	I
(	O
IE	B
-	I
1	I
)	O
,	O
which	O
is	O
nonstructural	O
but	O
is	O
found	O
very	O
early	O
and	O
throughout	O
the	O
replicative	O
cycle	O
.	O

In	O
summary	O
,	O
our	O
results	O
suggest	O
that	O
IE	B
-	I
1	I
is	O
far	O
more	O
important	O
as	O
a	O
CD8	O
(	O
+	O
)	O
-	O
T	O
-	O
cell	O
target	O
than	O
current	O
opinion	O
suggests	O
.	O

E1A	B
oncogene	I
induction	O
of	O
cellular	O
susceptibility	O
to	O
killing	O
by	O
cytolytic	O
lymphocytes	O
through	O
target	O
cell	O
sensitization	O
to	O
apoptotic	O
injury	O
.	O

Since	O
CLs	O
can	O
induce	O
either	O
apoptotic	O
or	O
necrotic	O
cell	O
death	O
,	O
we	O
asked	O
whether	O
E1A	B
sensitization	O
to	O
injury	O
-	O
induced	O
apoptosis	O
is	O
sufficient	O
to	O
explain	O
E1A	B
-	O
induced	O
cytolytic	O
susceptibility	O
.	O

Copyright	O
1999	O
Academic	O
Press	O
.	O

TCL1	B
oncogene	I
expression	O
in	O
AIDS	O
-	O
related	O
lymphomas	O
and	O
lymphoid	O
tissues	O
.	O

We	O
find	O
that	O
TCL1	B
is	O
expressed	O
in	O
the	O
majority	O
of	O
AIDS	O
IBLP	O
tumors	O
examined	O
.	O

They	O
also	O
indicate	O
that	O
abundant	O
TCL1	B
expression	O
in	O
quiescent	O
mantle	O
zone	O
B	O
cells	O
is	O
down	O
-	O
regulated	O
in	O
activated	O
germinal	O
center	O
follicular	O
B	O
cells	O
in	O
parallel	O
to	O
the	O
known	O
expression	O
pattern	O
of	O
BCL	B
-	I
2	I
.	O

High	O
-	O
level	O
expression	O
in	O
nonproliferating	O
B	O
cells	O
suggests	O
that	O
TCL1	B
may	O
function	O
in	O
protecting	O
naive	O
preactivated	O
B	O
cells	O
from	O
apoptosis	O
.	O

Here	O
,	O
we	O
report	O
a	O
model	O
of	O
CD28	B
costimulation	O
using	O
PMA	O
plus	O
the	O
natural	B
ligand	I
CD80	I
that	O
resulted	O
in	O
very	O
limited	O
stimulation	O
of	O
IL	B
-	I
2	I
,	O
as	O
evidenced	O
by	O
both	O
cytokine	B
production	O
and	O
IL	B
-	I
2	I
promoter	I
stimulation	O
.	O

We	O
have	O
determined	O
that	O
the	O
JAK	B
/	B
STAT	I
pathway	O
positively	O
regulates	O
Qp	B
activity	O
.	O

In	O
transient	O
-	O
transfection	O
assays	O
,	O
a	O
Qp	B
-	I
CAT	I
reporter	I
was	O
activated	O
by	O
cotransfected	O
JAK	B
-	I
1	I
and	O
by	O
treatment	O
of	O
cells	O
with	O
the	O
cytokine	B
IL	B
-	I
6	I
.	O

Consistent	O
with	O
a	O
role	O
for	O
STATs	B
in	O
Qp	B
function	O
,	O
Qp	B
using	O
Burkitt	O
'	O
s	O
lymphoma	O
Rael	O
cells	O
and	O
cultured	O
nasopharyngeal	O
carcinoma	O
(	O
NPC	O
)	O
cells	O
contained	O
nuclear	O
STAT	B
protein	I
.	O

This	O
negative	O
regulation	O
required	O
Zta	B
DNA	O
-	O
binding	O
activity	O
.	O

We	O
provide	O
evidence	O
that	O
Zta	B
up	O
-	O
regulation	O
of	O
p53	B
leads	O
to	O
p53	B
-	O
mediated	O
interference	O
with	O
JAK	B
/	B
STAT	I
activation	O
of	O
Qp	B
.	O

Reactive	O
oxygen	O
intermediate	O
-	O
release	O
of	O
fibre	O
-	O
exposed	O
monocytes	O
increases	O
inflammatory	O
cytokine	B
-	I
mRNA	I
level	O
,	O
protein	B
tyrosine	I
kinase	I
and	O
NF	B
-	I
kappaB	I
activity	O
in	O
co	O
-	O
cultured	O
bronchial	O
epithelial	O
cells	O
(	O
BEAS	O
-	O
2B	O
)	O
.	O

We	O
show	O
here	O
that	O
the	O
response	O
of	O
the	O
HIV	O
-	O
1	O
long	O
terminal	O
repeat	O
(	O
LTR	B
)	O
to	O
mitogenic	O
or	O
Tat	B
-	O
mediated	O
activation	O
is	O
sensitive	O
to	O
the	O
suppressive	O
action	O
of	O
a	O
Herpesvirus	O
saimiri	O
(	O
HVS	O
)	O
-	O
transformed	O
CD8	O
+	O
T	O
cell	O
clone	O
from	O
an	O
HIV	O
-	O
infected	O
individual	O
and	O
supernatants	O
from	O
CD8	O
+	O
T	O
cells	O
of	O
HIV	O
-	O
1	O
-	O
infected	O
asymptomatic	O
subjects	O
(	O
CD4	B
+	I
>	O
350	O
/	O
microliters	O
)	O
.	O

Mutagenesis	O
of	O
NF	B
kappa	I
B	I
or	I
Sp	I
-	I
1	I
elements	I
within	O
the	O
LTR	B
resulted	O
in	O
no	O
change	O
in	O
the	O
ability	O
of	O
CD8	O
+	O
T	O
cell	O
supernatants	O
to	O
inhibit	O
Tat	O
-	O
or	O
mitogen	O
-	O
mediated	O
LTR	O
transcription	O
.	O

Taken	O
together	O
,	O
these	O
observations	O
suggest	O
that	O
mitogenic	O
activation	O
,	O
mediated	O
primarily	O
through	O
the	O
NF	B
kappa	I
B	I
enhancer	I
,	O
is	O
susceptible	O
to	O
CD8	B
-	O
mediated	O
inhibition	O
,	O
however	O
,	O
inhibition	O
of	O
Tat	B
-	O
mediated	O
activation	O
may	O
rely	O
upon	O
a	O
different	O
pathway	O
that	O
is	O
NFAT	B
-	I
1	I
dependent	O
.	O

Nuclear	B
factor	I
(	I
NF	I
)	I
-	I
kappa	I
B	I
is	O
a	O
redox	B
sensitive	I
cytosolic	I
transcription	I
factor	I
.	O

Induction	O
of	O
endothelial	B
adhesion	I
molecules	I
by	O
the	O
cytokine	B
tumor	B
necrosis	I
factor	I
-	I
alpha	I
(	O
TNF	B
)	O
can	O
occur	O
independently	O
of	O
protein	B
kinase	I
C	I
and	O
activation	O
of	O
a	O
protein	B
tyrosine	I
kinase	I
(	O
PTK	B
)	O
has	O
recently	O
been	O
implicated	O
in	O
the	O
upregulation	O
of	O
vascular	B
cell	I
adhesion	I
molecule	I
1	I
(	O
VCAM	B
-	I
1	I
)	O
by	O
interleukin	B
-	I
4	I
(	O
IL	B
-	I
4	I
)	O
on	O
endothelial	O
cells	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
constitutive	O
expression	O
of	O
bcl	B
-	I
xl	I
but	O
not	O
bcl	B
-	I
2	I
,	O
bcl	B
-	I
xs	I
,	O
bak	B
,	O
bad	B
,	O
or	O
bax	B
was	O
associated	O
with	O
apoptosis	O
resistance	O
after	O
IL	B
-	I
2	I
deprivation	O
in	O
CTLL	O
-	O
2	O
cells	O
that	O
expressed	O
Tax	B
.	O

Transient	O
-	O
transfection	O
assays	O
showed	O
that	O
bcl	B
-	I
x	I
promoter	I
was	O
transactivated	O
by	O
wild	B
-	I
type	I
Tax	I
.	O

We	O
find	O
that	O
recruitment	O
of	O
EKLF	B
to	O
5	B
'	I
HS2	I
requires	O
the	O
TATA	B
box	I
,	O
but	O
recruitment	O
to	O
5	B
'	I
HS3	I
depends	O
on	O
the	O
CACCC	O
and	O
TATA	B
boxes	I
of	O
the	O
beta	B
-	I
globin	I
promoter	I
.	O

We	O
have	O
found	O
that	O
the	O
recruitment	O
of	O
EKLF	B
to	O
5	B
'	I
HS3	I
depends	O
on	O
the	O
presence	O
of	O
5	B
'	I
HS2	I
in	O
cis	O
,	O
but	O
the	O
recruitment	O
to	O
5	B
'	I
HS2	I
does	O
not	O
depend	O
on	O
5	B
'	I
HS3	I
.	O

Based	O
on	O
these	O
results	O
,	O
we	O
present	O
a	O
model	O
that	O
illustrates	O
how	O
EKLF	B
may	O
be	O
recruited	O
to	O
the	O
beta	B
-	I
globin	I
locus	I
.	O

We	O
also	O
report	O
that	O
in	O
RAW	O
264	O
.	O
7	O
cells	O
,	O
an	O
E	O
(	O
2	O
)	O
receptor	O
-	O
positive	O
murine	O
monocytic	O
line	O
,	O
E	O
(	O
2	O
)	O
downregulates	O
cytokine	O
-	O
induced	O
TNF	B
gene	O
expression	O
by	O
decreasing	O
the	O
activity	O
of	O
the	O
Jun	B
NH	I
(	I
2	I
)	I
-	I
terminal	I
kinase	I
(	O
JNK	B
)	O
.	O

The	O
resulting	O
diminished	O
phosphorylation	O
of	O
c	B
-	I
Jun	I
and	O
JunD	B
at	O
their	O
NH	B
(	I
2	I
)	I
-	I
termini	I
decreases	O
the	O
ability	O
of	O
these	O
nuclear	O
proteins	O
to	O
autostimulate	O
the	O
expression	O
of	O
the	O
c	B
-	I
Jun	I
and	I
JunD	I
genes	I
,	O
thus	O
leading	O
to	O
lower	O
production	O
of	O
c	B
-	I
Jun	I
and	O
JunD	B
.	O

Recent	O
data	O
show	O
that	O
TCR	B
/	I
CD3	I
stimulation	O
induces	O
activation	O
of	O
Stat5	B
in	O
murine	O
T	O
cells	O
.	O

In	O
conclusion	O
,	O
we	O
show	O
that	O
CD3	B
ligation	O
by	O
mAb	B
and	O
SE	O
triggers	O
a	O
rapid	O
,	O
PP1	B
-	O
sensitive	O
tyrosine	O
and	O
serine	O
phosphorylation	O
of	O
Stat3	B
in	O
human	O
CD4	O
+	O
T	O
cells	O
.	O

Clusters	O
of	O
genes	B
expressed	O
by	O
stromal	O
cells	O
and	O
lymphocytes	O
in	O
the	O
breast	O
tumors	O
also	O
were	O
identified	O
in	O
this	O
analysis	O
.	O

Stimulation	O
of	O
T	O
cells	O
with	O
calcium	O
ionophore	O
induced	O
a	O
shift	O
in	O
the	O
molecular	O
weight	O
of	O
NFATp	B
that	O
is	O
due	O
to	O
its	O
dephosphorylation	O
.	O

This	O
dephosphorylation	O
was	O
inhibited	O
by	O
treatment	O
of	O
T	O
cells	O
with	O
cyclosporin	O
A	O
or	O
FK506	O
prior	O
to	O
stimulation	O
.	O

The	O
B	B
cell	I
-	I
associated	I
surface	I
molecule	I
CD40	B
plays	O
a	O
key	O
role	O
in	O
T	O
cell	O
-	O
dependent	O
B	O
cell	O
maturation	O
,	O
as	O
individuals	O
with	O
defects	O
in	O
either	O
CD40	B
or	O
its	O
ligand	O
are	O
impaired	O
in	O
immunoglobulin	B
isotype	O
class	O
switching	O
and	O
germinal	O
center	O
formation	O
.	O

CD40	B
signaling	O
activates	O
downstream	B
effectors	I
,	O
including	O
the	O
tyrosine	B
protein	I
kinase	I
,	O
Lyn	B
,	O
the	O
phosphatidylinositol	B
-	I
3	I
-	I
kinase	I
(	O
PI	B
-	I
3	I
kinase	I
)	O
,	O
and	O
the	O
transcription	O
factor	O
,	O
NF	B
-	I
kappa	I
B	I
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
stress	B
-	I
activated	I
protein	I
kinases	I
(	O
SAPK	B
)	O
are	O
activated	O
after	O
CD40	B
cross	O
-	O
linking	O
on	O
various	O
B	O
cell	O
lines	O
or	O
human	O
tonsillar	O
B	O
cells	O
.	O

In	O
summary	O
,	O
CD40	B
signaling	O
preferentially	O
induces	O
SAPK	B
but	O
not	O
MAPK	B
.	O

Using	O
CD45	O
-	O
or	O
CD3	O
-	O
negative	O
variants	O
of	O
the	O
Jurkat	O
leukemic	O
T	O
-	O
cell	O
line	O
we	O
show	O
that	O
the	O
different	O
biochemical	O
events	O
induced	O
by	O
pervanadate	O
appeared	O
to	O
be	O
dependent	O
on	O
the	O
presence	O
at	O
the	O
cell	O
surface	O
of	O
either	O
CD45	B
or	O
CD3	B
.	O

CD45	B
-	O
dependent	O
events	O
such	O
as	O
tyrosine	B
phosphorylation	I
of	O
Shc	B
,	O
activation	O
of	O
nuclear	B
factor	I
-	I
kappa	I
B	I
(	O
NF	B
-	I
kappa	I
B	I
)	O
,	O
activator	B
protein	I
-	I
1	I
(	O
AP	B
-	I
1	I
)	O
,	O
transcription	B
factors	I
,	O
and	O
stimulation	O
of	O
interleukin	B
-	I
2	I
(	I
IL	I
-	I
2	I
)	I
promoter	I
and	O
of	O
CD69	B
and	O
CD25	B
surface	O
expression	O
paralleled	O
activation	O
of	O
the	O
tyrosine	B
kinases	I
lck	B
and	O
fyn	B
.	O

Previously	O
,	O
the	O
action	O
of	O
MC903	O
and	O
KH1060	O
was	O
presumed	O
to	O
be	O
mediated	O
by	O
the	O
nuclear	B
vitamin	I
D	I
receptor	I
(	O
VDRnuc	B
)	O
.	O

These	O
data	O
suggest	O
that	O
although	O
MC903	O
and	O
KH1060	O
may	O
bind	O
the	O
VDRnuc	B
,	O
that	O
the	O
differentiative	O
activities	O
of	O
these	O
agents	O
requires	O
nongenomic	O
signaling	O
pathways	O
.	O

Here	O
we	O
show	O
that	O
1alpha	O
,	O
25	O
(	O
OH	O
)	O
2	O
-	O
d5	O
-	O
previtamin	O
D3	O
(	O
HF	O
)	O
,	O
JN	O
,	O
KH1060	O
,	O
and	O
MC903	O
induce	O
expression	O
of	O
PKC	B
alpha	I
and	O
PKC	B
delta	I
and	O
translocation	O
of	O
both	O
isoforms	O
to	O
the	O
particulate	O
fraction	O
,	O
and	O
PKC	B
alpha	I
to	O
the	O
nuclear	O
fraction	O
.	O

Retinoic	O
acid	O
can	O
directly	O
modulate	O
gene	O
expression	O
via	O
binding	O
to	O
its	O
nuclear	B
receptors	I
,	O
which	O
can	O
,	O
in	O
turn	O
,	O
activate	O
transcription	O
of	O
target	B
genes	I
.	O

Tax	B
has	O
been	O
shown	O
to	O
transactivate	O
several	O
cellular	B
genes	I
.	O

Induced	O
MIP	B
-	I
1alpha	I
expression	O
and	O
secretion	O
in	O
PMA	O
/	O
PHA	O
stimulated	O
tax	O
transfected	O
cells	O
correlate	O
with	O
the	O
noninduction	O
of	O
MNP	B
-	I
1	I
transcription	B
factor	I
,	O
which	O
is	O
intimately	O
involved	O
in	O
downmodulating	O
the	O
MIP	B
-	I
1alpha	I
gene	I
.	O

Copyright	O
1999	O
Academic	O
Press	O
.	O

Like	O
a	O
delayed	O
-	O
type	O
hypersensitivity	O
response	O
,	O
the	O
rheumatoid	O
synovium	O
represents	O
an	O
effector	O
site	O
.	O

The	O
other	O
major	O
subpopulation	O
expressing	O
the	O
CD4	B
receptor	I
,	O
namely	O
,	O
the	O
double	O
-	O
positive	O
(	O
DP	O
)	O
CD4	O
(	O
+	O
)	O
CD8	O
(	O
+	O
)	O
CD3	O
(	O
+	O
/	O
-	O
)	O
thymocytes	O
,	O
despite	O
the	O
entry	O
of	O
the	O
virus	O
,	O
do	O
not	O
produce	O
a	O
significant	O
level	O
of	O
virus	O
,	O
presumably	O
because	O
they	O
are	O
unresponsive	O
to	O
TNF	B
and	O
IL	B
-	I
7	I
.	O

Activation	O
of	O
CD40	B
is	O
essential	O
for	O
thymus	O
-	O
dependent	O
humoral	O
immune	O
responses	O
and	O
rescuing	O
B	O
cells	O
from	O
apoptosis	O
.	O

MBP	B
over	O
the	O
concentration	O
range	O
of	O
0	O
.	O
1	O
to	O
10	O
microM	O
stimulated	O
the	O
release	O
of	O
up	O
to	O
approximately	O
8	O
ng	O
/	O
ml	O
IL	B
-	I
8	I
.	O

MBP	B
also	O
induced	O
transient	O
increases	O
in	O
mRNA	B
for	O
macrophage	B
inflammatory	I
protein	I
(	I
MIP	I
)	I
-	I
1alpha	I
and	O
MIP	B
-	I
1beta	I
,	O
but	O
did	O
not	O
stimulate	O
the	O
release	O
of	O
either	O
chemokine	B
.	O

Patients	O
with	O
the	O
recessively	O
inherited	O
disorder	O
ataxia	O
telangiectasia	O
(	O
A	O
-	O
T	O
)	O
have	O
a	O
high	O
level	O
of	O
specific	O
chromosome	B
translocations	I
which	O
can	O
be	O
easily	O
observed	O
in	O
peripheral	O
T	O
cells	O
and	O
show	O
a	O
greatly	O
increased	O
predisposition	O
to	O
leukaemia	O
/	O
lymphoma	O
,	O
mainly	O
of	O
T	O
cell	O
origin	O
.	O

On	O
the	O
average	O
,	O
no	O
correlation	O
was	O
established	O
between	O
degree	O
of	O
lymphocyte	O
infiltration	O
in	O
breast	O
tumor	O
and	O
age	O
and	O
menopause	O
onset	O
.	O

A	O
high	O
-	O
affinity	O
calcineurin	B
-	O
binding	O
peptide	O
was	O
selected	O
from	O
combinatorial	O
peptide	O
libraries	O
based	O
on	O
the	O
calcineurin	B
docking	I
motif	I
of	O
NFAT	B
.	O

Substitution	O
of	O
the	O
optimized	O
peptide	O
sequence	O
into	O
the	O
natural	O
calcineurin	B
docking	I
site	I
increased	O
the	O
calcineurin	B
responsiveness	O
of	O
NFAT	B
.	O

Compounds	O
that	O
interfere	O
selectively	O
with	O
the	O
calcineurin	B
-	B
NFAT	I
interaction	O
without	O
affecting	O
calcineurin	B
phosphatase	B
activity	O
may	O
be	O
useful	O
as	O
therapeutic	O
agents	O
that	O
are	O
less	O
toxic	O
than	O
current	O
drugs	O
.	O

9	O
-	O
cis	O
retinoic	O
acid	O
induces	O
monocyte	B
chemoattractant	I
protein	I
-	I
1	I
secretion	O
in	O
human	O
monocytic	O
THP	O
-	O
1	O
cells	O
.	O

Thus	O
,	O
both	O
copies	O
of	O
BRCA1	B
were	O
retained	O
in	O
tumor	O
.	O

The	O
DNA	O
variation	O
,	O
233G	O
-	O
-	O
>	O
A	O
,	O
does	O
not	O
result	O
in	O
an	O
amino	O
acid	O
change	O
,	O
and	O
is	O
considered	O
a	O
benign	O
polymorphism	O
.	O

Therefore	O
,	O
we	O
investigated	O
whether	O
IVS1	O
-	O
10T	O
-	O
-	O
>	O
C	O
deleteriously	O
affected	O
BRCA1	B
splicing	O
or	O
expression	O
,	O
and	O
thereby	O
inactivated	O
the	O
other	O
BRCA1	B
allele	I
.	O

For	O
example	O
dendritic	O
cells	O
(	O
DC	O
)	O
can	O
be	O
found	O
in	O
colonies	O
of	O
GM	O
-	O
CSF	O
-	O
responsive	O
bone	O
marrow	O
cells	O
,	O
and	O
under	O
experimental	O
conditions	O
are	O
routinely	O
expanded	O
as	O
a	O
population	O
in	O
vitro	O
from	O
GM	O
-	O
CSF	O
-	O
responsive	O
progenitor	O
cells	O
.	O

We	O
have	O
used	O
this	O
MTHC	O
system	O
to	O
analyze	O
differences	O
in	O
gene	O
expression	O
as	O
the	O
cells	O
mature	O
along	O
the	O
DC	O
and	O
macrophage	O
pathways	O
.	O

We	O
have	O
investigated	O
mechanisms	O
and	O
consequences	O
of	O
STAT5	B
activation	O
through	O
the	O
human	B
IL	I
-	I
4	I
receptor	I
(	O
IL	B
-	I
4R	I
)	O
.	O

By	O
functionally	O
expressing	O
receptor	B
mutants	I
in	O
the	O
murine	O
pro	O
-	O
B	O
cell	O
line	O
Ba	O
/	O
F3	O
,	O
we	O
could	O
show	O
that	O
phosphorylated	O
tyrosine	O
residues	O
within	O
the	O
IL	B
-	I
4R	I
alpha	I
chain	I
are	O
dispensable	O
for	O
IL	B
-	I
4	I
-	O
induced	O
STAT5	B
activity	O
.	O

An	O
inhibitory	O
,	O
`	O
`	O
dominant	O
-	O
negative	O
,	O
'	O
'	O
form	O
of	O
the	O
calcineurin	B
catalytic	I
(	I
A	I
)	I
subunit	I
was	O
prepared	O
,	O
which	O
lacks	O
the	O
calmodulin	B
-	I
binding	I
domain	I
,	O
autoinhibitory	B
domain	I
and	O
most	O
of	O
its	O
catalytic	O
core	O
but	O
possesses	O
the	O
regulatory	B
(	I
B	I
)	I
subunit	I
binding	O
domain	O
.	O

Immunoprecipitation	O
of	O
epitope	B
-	I
labeled	I
BKO	I
demonstrated	O
for	O
the	O
formation	O
of	O
a	O
tight	O
complex	O
with	O
endogenous	B
B	I
subunit	I
in	O
Jurkat	O
cells	O
,	O
consistent	O
with	O
an	O
inhibitory	O
mechanism	O
that	O
involves	O
the	O
sequestration	O
of	O
the	O
B	B
subunit	I
.	O

Monoclonal	B
anti	I
-	I
D	I
antibodies	I
submitted	O
to	O
the	O
Third	O
Monoclonal	O
International	O
Workshop	O
were	O
evaluated	O
against	O
a	O
number	O
of	O
D	O
variant	O
cells	O
using	O
standard	O
serological	O
techniques	O
.	O

Cells	O
within	O
each	O
category	O
did	O
not	O
give	O
any	O
aberrant	O
results	O
.	O

B	O
cells	O
were	O
purified	O
from	O
buffy	O
coat	O
preparations	O
of	O
healthy	O
blood	O
donors	O
by	O
positive	O
selection	O
using	O
an	O
anti	B
CD20	I
monoclonal	I
antibody	I
and	O
a	O
MiniMACS	O
separation	O
unit	O
.	O

RNA	B
was	O
extracted	O
by	O
phenol	O
/	O
chloroform	O
and	O
c	B
-	I
fos	I
expression	O
was	O
analyzed	O
by	O
PCR	O
assisted	O
mRNA	O
assay	O
.	O

A	O
significant	O
2	O
-	O
4	O
fold	O
increase	O
of	O
c	B
-	I
fos	I
expression	O
was	O
observed	O
within	O
30	O
min	O
of	O
stimulation	O
with	O
IL	B
-	I
10	I
(	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

Since	O
this	O
is	O
the	O
first	O
report	O
on	O
IL	B
-	I
10	I
induced	O
signal	O
transduction	O
,	O
these	O
data	O
may	O
help	O
to	O
identify	O
the	O
intracellular	O
mechanisms	O
by	O
which	O
IL	B
-	I
10	I
stimulates	O
human	O
B	O
-	O
cells	O
.	O

MNDA	B
was	O
not	O
detected	O
in	O
normal	O
tissue	O
histiocytes	O
but	O
was	O
found	O
in	O
activated	O
macrophages	O
and	O
foreign	O
body	O
giant	O
cells	O
associated	O
with	O
inflammation	O
.	O

Flow	O
cytometric	O
cell	O
sorting	O
of	O
normal	O
bone	O
marrow	O
established	O
that	O
MNDA	B
is	O
initially	O
expressed	O
in	O
myeloid	O
blast	O
cells	O
.	O

Peroxisome	B
proliferator	I
-	I
activated	I
receptors	I
(	O
PPARs	B
)	O
,	O
members	O
of	O
the	O
nuclear	B
receptor	I
superfamily	I
of	O
transcription	B
factors	I
,	O
are	O
activated	O
by	O
fatty	O
acid	O
metabolites	O
,	O
peroxisome	O
proliferators	O
,	O
and	O
thiazolidinediones	O
and	O
are	O
now	O
recognized	O
as	O
important	O
mediators	O
in	O
the	O
inflammatory	O
response	O
.	O

Expression	O
of	O
wild	B
-	I
type	I
SHP1	I
had	O
a	O
very	O
small	O
effect	O
on	O
the	O
TCR	O
-	O
induced	O
tyrosine	O
phosphorylation	O
of	O
ZAP	B
-	I
70	I
and	O
Syk	B
,	O
even	O
when	O
SHP1	B
was	O
overexpressed	O
20	O
-	O
100	O
-	O
fold	O
over	O
endogenous	B
SHP1	I
.	O

However	O
,	O
the	O
two	O
SH2	B
domains	I
of	O
SHP1	B
did	O
not	O
facilitate	O
its	O
recognition	O
of	O
ZAP	B
-	I
70	I
and	O
Syk	B
as	O
substrates	O
in	O
intact	O
cells	O
.	O

Eosinophil	B
granule	I
major	I
basic	I
protein	I
(	O
MBP	B
)	O
is	O
expressed	O
exclusively	O
in	O
eosinophils	O
and	O
basophils	O
in	O
hematopoietic	O
cells	O
.	O

In	O
the	O
cell	O
line	O
HT93A	O
,	O
which	O
is	O
capable	O
of	O
differentiating	O
towards	O
both	O
the	O
eosinophil	O
and	O
neutrophil	O
lineages	O
in	O
response	O
to	O
retinoic	O
acid	O
(	O
RA	O
)	O
,	O
C	B
/	I
EBPalpha	I
mRNA	I
expression	O
decreased	O
significantly	O
concomitant	O
with	O
eosinophilic	O
and	O
neutrophilic	O
differentiation	O
,	O
whereas	O
C	B
/	I
EBPbeta	I
expression	O
was	O
markedly	O
increased	O
.	O

Furthermore	O
,	O
we	O
have	O
demonstrated	O
that	O
both	O
C	B
/	I
EBPbeta	I
and	O
GATA	B
-	I
1	I
can	O
bind	O
simultaneously	O
to	O
the	O
C	O
/	O
EBP	O
-	O
and	O
GATA	B
-	I
binding	I
sites	I
in	O
the	O
MBP	B
promoter	I
.	O

Role	O
of	O
the	O
camp	B
response	I
element	I
site	I
in	O
mediating	O
repression	O
by	O
the	O
upstream	B
regulatory	I
region	I
.	O

DNase	B
I	I
footprinting	O
identified	O
several	O
protected	O
areas	O
including	O
Sp1	B
,	I
Sp1	I
/	I
AP	I
-	I
2	I
,	I
and	I
cAMP	I
response	I
element	I
(	I
CRE	I
)	I
binding	I
sites	I
within	O
the	O
201	O
-	O
bp	O
core	O
promoter	O
region	O
and	O
Sp1	B
,	I
NRE	I
-	I
2a	I
,	I
TCF	I
-	I
1	I
/	I
LEF	I
-	I
1	I
,	I
and	I
Sp1	I
/	I
NF	I
-	I
AT	I
binding	I
sites	I
in	O
the	O
upstream	B
regulatory	I
region	I
.	O

Electrophoretic	O
mobility	O
shift	O
assay	O
analysis	O
of	O
proteins	O
binding	O
to	O
the	O
CRE	B
site	I
identified	O
both	O
ATF	B
-	I
1	I
and	O
ATF	B
-	I
2	I
in	O
Jurkat	O
cells	O
.	O

In	O
summary	O
,	O
we	O
have	O
identified	O
a	O
tissue	B
-	I
specific	I
regulatory	I
region	I
5	O
'	O
of	O
the	O
ecto	B
-	I
5	I
'	I
-	I
NT	I
core	I
promoter	I
that	O
requires	O
the	O
presence	O
of	O
a	O
functional	O
CRE	B
site	I
within	O
the	O
basal	B
promoter	I
for	O
its	O
suppressive	O
activity	O
.	O

Extracellular	O
signal	O
-	O
regulated	O
protein	O
kinase	O
(	O
ERK	O
)	O
-	O
dependent	O
and	O
ERK	O
-	O
independent	O
pathways	O
target	O
STAT3	B
on	O
serine	O
-	O
727	O
in	O
human	O
neutrophils	O
stimulated	O
by	O
chemotactic	B
factors	I
and	O
cytokines	B
.	O

(	O
2	O
-	O
Amino	O
-	O
3	O
'	O
-	O
methoxyphenyl	O
)	O
oxanaphthalen	O
-	O
4	O
-	O
one	O
(	O
PD	O
98059	O
)	O
,	O
an	O
inhibitor	O
of	O
extracellular	O
signal	B
-	I
regulated	I
protein	I
kinase	I
(	O
ERK	B
)	O
activation	O
,	O
blocked	O
the	O
serine	O
phosphorylation	O
of	O
STAT3	B
induced	O
by	O
chemotactic	B
factors	I
or	O
PMA	O
.	O

These	O
foci	O
,	O
which	O
were	O
preferentially	O
found	O
adjacent	O
to	O
nucleoli	O
or	O
at	O
the	O
nuclear	O
periphery	O
,	O
did	O
not	O
represent	O
sites	O
of	O
active	O
transcription	O
or	O
binding	O
of	O
GATA	B
-	I
1	I
to	O
consensus	B
sites	I
in	O
the	O
beta	B
-	I
globin	I
loci	I
.	O

After	O
exercise	O
following	O
placebo	O
administration	O
we	O
observed	O
increases	O
in	O
concentrations	O
of	O
blood	O
substrates	O
,	O
plasma	B
adrenocorticotropin	I
(	O
ACTH	B
)	O
,	O
growth	O
hormone	O
and	O
cortisol	O
and	O
in	O
the	O
number	O
of	O
glucocorticoid	B
receptors	I
in	O
lymphocytes	O
without	O
changes	O
in	O
the	O
dissociation	O
constant	O
.	O

Intravenous	O
PCr	O
injection	O
led	O
to	O
smaller	O
changes	O
in	O
ACTH	B
and	O
cortisol	O
concentrations	O
as	O
well	O
as	O
to	O
a	O
lower	O
activation	O
of	O
glucocorticoid	O
binding	O
in	O
lymphocytes	O
.	O

Putative	B
steroid	I
binding	I
domain	I
of	O
the	O
human	B
mineralocorticoid	I
receptor	I
,	O
expressed	O
in	O
E	O
.	O
coli	O
in	O
the	O
presence	O
of	O
heat	B
shock	I
proteins	I
shows	O
typical	O
native	O
receptor	O
characteristics	O
.	O

These	O
bacterially	B
-	I
produced	I
MR	I
constructs	I
had	O
no	O
steroid	O
binding	O
activity	O
per	O
se	O
.	O

The	O
Kd	O
value	O
for	O
aldosterone	O
was	O
0	O
.	O
3	O
nM	O
and	O
the	O
Bmax	O
=	O
32	O
pmol	O
/	O
mg	O
.	O

Renal	O
cell	O
carcinoma	O
-	O
derived	O
gangliosides	O
suppress	O
nuclear	B
factor	I
-	I
kappaB	I
activation	O
in	O
T	O
cells	O
.	O

Indeed	O
,	O
we	O
detected	O
gangliosides	O
in	O
supernatants	O
from	O
RCC	O
explants	O
and	O
not	O
from	O
adjacent	O
normal	O
kidney	O
tissue	O
.	O

In	O
this	O
study	O
,	O
we	O
investigate	O
the	O
role	O
of	O
TNFalpha	B
-	O
inducible	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
in	O
IL	B
-	I
8	I
expression	O
by	O
`	O
`	O
monocyte	O
-	O
like	O
'	O
'	O
U937	O
histiocytic	O
lymphoma	O
cells	O
.	O

These	O
data	O
indicate	O
that	O
TNFalpha	B
induces	O
a	O
delayed	O
ROS	O
-	O
dependent	O
signalling	O
pathway	O
that	O
is	O
required	O
for	O
NF	B
-	I
kappaB	I
transcriptional	O
activation	O
and	O
is	O
separable	O
from	O
that	O
required	O
for	O
its	O
nuclear	O
translocation	O
.	O

Estrogen	B
receptors	I
influence	O
non	O
-	O
genomic	O
events	O
,	O
which	O
are	O
rapid	O
in	O
onset	O
and	O
genomic	O
events	O
,	O
which	O
are	O
longer	O
acting	O
responses	O
.	O

Estrogens	O
also	O
influence	O
production	O
of	O
mitogens	O
which	O
,	O
when	O
released	O
at	O
sites	O
of	O
vascular	O
injury	O
,	O
affect	O
vascular	O
remodeling	O
.	O

Protein	B
kinase	I
C	I
and	O
calcineurin	B
synergize	O
to	O
activate	O
IkappaB	B
kinase	I
and	O
NF	B
-	I
kappaB	I
in	O
T	O
lymphocytes	O
.	O

We	O
also	O
demonstrate	O
that	O
the	O
IKK	B
complex	I
,	O
but	O
not	O
p90	B
(	I
rsk	I
)	I
,	O
is	O
responsible	O
for	O
the	O
in	O
vivo	O
phosphorylation	O
of	O
IkappaBalpha	B
mediated	O
by	O
the	O
co	O
-	O
activation	O
of	O
PKC	B
and	O
calcineurin	B
.	O

The	O
p53	B
paradox	O
in	O
the	O
pathogenesis	O
of	O
tumor	O
progression	O
.	O

Additional	O
upstream	O
gene	O
segments	O
dramatically	O
affected	O
B29	B
minimal	B
promoter	I
activity	O
.	O

These	O
findings	O
indicate	O
that	O
B29	B
gene	I
expression	O
is	O
controlled	O
by	O
the	O
complex	O
interplay	O
of	O
positive	O
and	O
negative	B
regulatory	I
elements	I
.	O

A	O
novel	O
immunosuppressive	B
factor	I
in	O
bovine	O
colostrum	O
blocks	O
activation	O
of	O
the	O
interleukin	B
2	I
gene	I
enhancer	I
at	O
the	O
NFAT	B
site	I
.	O

A	O
factor	O
in	O
bovine	O
colostrum	O
(	O
colostrum	B
inhibitory	I
factor	I
,	O
CIF	B
)	O
inhibits	O
interleukin	B
2	I
(	O
IL2	B
)	O
production	O
in	O
activated	O
T	O
helper	O
cells	O
by	O
blocking	O
the	O
accumulation	O
of	O
IL2	B
mRNA	I
.	O

To	O
determine	O
whether	O
CIF	B
blocks	O
at	O
the	O
level	O
of	O
IL2	B
transcription	O
,	O
we	O
introduced	O
reporter	O
plasmids	O
into	O
the	O
human	O
T	O
leukemia	O
cell	O
line	O
Jurkat	O
by	O
transient	O
transfection	O
.	O

The	O
NFAT	B
-	I
controlled	I
luciferase	I
gene	I
system	I
distinguishes	O
CIF	B
from	O
other	O
T	O
cell	O
inhibitory	O
activities	O
present	O
in	O
colostrum	O
,	O
in	O
particular	O
,	O
TGF	B
beta	I
1	I
and	O
TGF	B
beta	I
2	I
and	O
the	O
glucocorticoids	O
.	O

The	O
NFAT	B
-	O
luc	O
assay	O
is	O
a	O
useful	O
technique	O
for	O
the	O
rapid	O
,	O
sensitive	O
measurement	O
of	O
CIF	B
or	O
other	O
immunosuppressants	O
with	O
a	O
similar	O
mode	O
of	O
action	O
.	O

To	O
propel	O
itself	O
in	O
infected	O
cells	O
,	O
the	O
pathogen	O
Shigella	O
flexneri	O
subverts	O
the	O
Cdc42	B
-	O
controlled	O
machinery	O
responsible	O
for	O
actin	B
assembly	O
during	O
filopodia	O
formation	O
.	O

Using	O
a	O
combination	O
of	O
bacterial	O
motility	O
assays	O
in	O
platelet	O
extracts	O
with	O
Escherichia	O
coli	O
expressing	O
the	O
Shigella	B
IcsA	I
protein	I
and	O
in	O
vitro	O
analysis	O
of	O
reconstituted	O
systems	O
from	O
purified	B
proteins	I
,	O
we	O
show	O
here	O
that	O
the	O
bacterial	B
protein	I
IcsA	I
binds	O
N	B
-	I
WASP	I
and	O
activates	O
it	O
in	O
a	O
Cdc42	B
-	O
like	O
fashion	O
.	O

VASP	O
is	O
not	O
involved	O
in	O
Shigella	O
movement	O
,	O
and	O
the	O
function	O
of	O
profilin	B
does	O
not	O
require	O
its	O
binding	O
to	O
proline	B
-	I
rich	I
regions	I
.	O

c	B
-	I
Maf	I
induces	O
monocytic	O
differentiation	O
and	O
apoptosis	O
in	O
bipotent	O
myeloid	O
progenitors	O
.	O

We	O
have	O
shown	O
that	O
the	O
c	B
-	I
Maf	I
and	O
c	B
-	I
Myb	I
transcription	I
factors	I
physically	O
interact	O
in	O
myeloid	O
cells	O
to	O
form	O
inhibitory	O
complexes	O
that	O
hinder	O
transactivation	O
of	O
c	B
-	I
Myb	I
target	I
genes	I
through	O
direct	O
binding	O
to	O
Myb	B
consensus	I
sites	I
.	O

Elevated	O
levels	O
of	O
c	B
-	I
Maf	I
protein	I
led	O
to	O
marked	O
increases	O
in	O
Myb	B
:	I
Maf	I
complexes	I
and	O
the	O
accumulation	O
of	O
monocyte	O
/	O
macrophage	O
cells	O
,	O
followed	O
by	O
eventual	O
programmed	O
cell	O
death	O
.	O

Analysis	O
of	O
targets	O
that	O
could	O
mediate	O
these	O
phenotypic	O
changes	O
indicated	O
that	O
c	B
-	I
Maf	I
likely	O
plays	O
a	O
key	O
role	O
in	O
myeloid	O
cell	O
development	O
through	O
dual	O
mechanisms	O
;	O
inhibition	O
of	O
a	O
select	O
set	O
of	O
c	B
-	I
Myb	I
regulated	O
targets	O
,	O
such	O
as	O
Bcl	B
-	I
2	I
and	O
CD13	B
/	I
APN	I
,	O
coupled	O
with	O
the	O
activation	O
of	O
as	O
yet	O
undefined	O
differentiation	B
-	I
promoting	I
genes	I
.	O

We	O
have	O
examined	O
the	O
effect	O
of	O
Rb	B
expression	O
on	O
the	O
activation	O
of	O
the	O
promoter	O
for	O
HLA	B
-	I
DRA	I
,	O
the	O
prototype	B
class	I
II	I
gene	I
.	O

Different	O
glucocorticoid	O
hormones	O
(	O
GCH	O
)	O
show	O
differences	O
in	O
the	O
intensity	O
and	O
in	O
the	O
kinetics	O
of	O
their	O
immunomodulating	O
activity	O
.	O

The	O
mechanism	O
(	O
s	O
)	O
of	O
action	O
of	O
GCH	O
is	O
under	O
investigation	O
,	O
but	O
is	O
has	O
been	O
noted	O
that	O
they	O
exert	O
immune	O
activity	O
via	O
the	O
genomic	O
pathway	O
.	O

These	O
findings	O
suggest	O
that	O
BCL	B
-	I
6	I
may	O
play	O
a	O
role	O
in	O
regulating	O
differentiation	O
of	O
normal	O
germinal	O
center	O
B	O
cells	O
and	O
that	O
its	O
deregulated	O
expression	O
caused	O
by	O
rearrangements	O
may	O
contribute	O
to	O
lymphomagenesis	O
.	O

Activation	O
of	O
NF	B
-	I
kappa	I
B	I
is	O
induced	O
by	O
prooxidants	O
and	O
several	O
stimuli	O
eliciting	O
oxidative	O
stress	O
,	O
such	O
as	O
cytokines	B
,	O
lipopolysaccharide	O
,	O
UV	O
irradiation	O
and	O
other	O
mediators	O
.	O

To	O
better	O
understand	O
the	O
assembly	O
mechanism	O
for	O
the	O
progesterone	B
receptor	I
(	O
PR	B
)	O
,	O
we	O
have	O
developed	O
cell	O
-	O
free	O
systems	O
for	O
studying	O
interactions	O
of	O
PR	B
,	O
hsp90	B
,	O
and	O
other	O
associated	B
proteins	I
.	O

These	O
interactions	O
require	O
ATP	O
/	O
Mg2	O
+	O
and	O
when	O
ATP	O
is	O
limiting	O
the	O
PR	B
complex	O
is	O
altered	O
to	O
one	O
containing	O
the	O
proteins	O
p60	B
and	O
p48	B
,	O
but	O
lacking	O
immunophilins	B
and	O
p23	B
.	O

One	O
contains	O
hsp90	B
bound	O
to	O
hsp70	B
and	O
p60	B
and	O
this	O
complex	O
forms	O
spontaneously	O
in	O
the	O
absence	O
of	O
ATP	O
.	O

This	O
explains	O
,	O
in	O
part	O
,	O
the	O
known	O
effects	O
of	O
ATP	O
and	O
molybdate	O
on	O
assembly	O
of	O
PR	B
complexes	I
.	O

We	O
have	O
recently	O
demonstrated	O
that	O
hydrocortisone	O
and	O
other	O
glucocorticoids	O
inhibit	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
generation	O
by	O
mononuclear	O
(	O
MNC	O
)	O
and	O
polymorphonuclear	O
leucocytes	O
(	O
PMNL	O
)	O
.	O

Since	O
NF	O
-	O
kappaB	O
/	O
IkappaB	B
system	O
regulates	O
the	O
transcription	O
of	O
proinflammatory	B
genes	I
,	O
including	O
those	O
responsible	O
for	O
ROS	O
generation	O
,	O
we	O
tested	O
the	O
hypothesis	O
that	O
hydrocortisone	O
may	O
stimulate	O
IkappaB	B
production	O
thus	O
inhibiting	O
NF	B
-	I
kappaB	I
translocation	O
from	O
the	O
cytosol	O
into	O
the	O
nucleus	O
in	O
MNC	O
,	O
in	O
vivo	O
.	O

Blood	O
samples	O
were	O
obtained	O
prior	O
to	O
the	O
injection	O
and	O
at	O
1	O
,	O
2	O
,	O
4	O
,	O
8	O
and	O
24	O
hr	O
after	O
the	O
injection	O
.	O

The	O
total	O
protein	O
content	O
of	O
NF	B
-	I
kappaB	I
subunit	I
(	O
P65	B
)	O
in	O
MNC	O
lysates	O
also	O
showed	O
a	O
decrease	O
following	O
hydrocortisone	O
injection	O
.	O

This	O
decrease	O
was	O
observed	O
at	O
2	O
hr	O
,	O
reached	O
a	O
nadir	O
at	O
4	O
hr	O
,	O
and	O
returned	O
to	O
baseline	O
levels	O
at	O
24	O
hr	O
.	O

Our	O
data	O
demonstrate	O
that	O
hydrocortisone	O
induces	O
IkappaB	B
and	O
suppresses	O
NF	B
-	I
kappaB	I
expression	O
in	O
MNC	O
in	O
parallel	O
.	O

However	O
,	O
the	O
exact	O
cellular	O
mechanisms	O
underlying	O
this	O
anti	O
-	O
inflammatory	O
capacity	O
are	O
still	O
unknown	O
.	O

In	O
our	O
study	O
,	O
we	O
determined	O
the	O
induction	O
of	O
apoptosis	O
by	O
GC	O
in	O
human	O
monocytes	O
.	O

Monocyte	O
apoptosis	O
was	O
determined	O
by	O
four	O
independent	O
methods	O
,	O
including	O
annexin	O
-	O
V	O
staining	O
,	O
TUNEL	O
,	O
DNA	O
-	O
laddering	O
,	O
and	O
typical	O
morphology	O
by	O
means	O
of	O
transmission	O
electron	O
microscopy	O
.	O

Necrosis	O
was	O
excluded	O
by	O
propidium	O
iodide	O
staining	O
.	O

Proinflammatory	B
cytokines	I
such	O
as	O
IL	B
-	I
1beta	I
and	O
TNF	B
-	I
alpha	I
were	O
down	O
-	O
regulated	O
by	O
GC	O
treatment	O
.	O

Continuous	O
treatment	O
of	O
monocytes	O
with	O
IL	B
-	I
1beta	I
,	O
but	O
not	O
with	O
TNF	B
-	I
alpha	I
,	O
could	O
almost	O
completely	O
prevent	O
GC	O
-	O
induced	O
cell	O
death	O
.	O

The	O
addition	O
of	O
mifepristone	O
or	O
caspase	O
-	O
3	O
inhibitor	O
could	O
partially	O
abrogate	O
GC	O
-	O
induced	O
apoptosis	O
as	O
well	O
as	O
GC	O
-	O
induced	O
inhibition	O
of	O
IL	B
-	I
1beta	I
.	O

The	O
inflammatory	O
mediators	O
lipopolysaccharide	O
(	O
LPS	O
)	O
and	O
tumor	B
necrosis	I
factor	I
(	O
TNF	B
)	O
are	O
potent	O
activators	O
of	O
NF	B
-	I
kappaB	I
.	O

Kinase	O
assays	O
showed	O
that	O
TNF	B
elicited	O
a	O
rapid	O
but	O
short	O
-	O
lived	O
induction	O
of	O
IKK	B
activity	O
with	O
a	O
3	O
-	O
fold	O
greater	O
effect	O
on	O
IKK	B
-	I
alpha	I
than	O
on	O
IKK	B
-	I
beta	I
,	O
peaking	O
at	O
5	O
min	O
.	O

Furthermore	O
,	O
our	O
studies	O
showed	O
association	O
of	O
the	O
IKK	B
-	I
alpha	I
/	I
beta	I
heterodimer	I
with	O
NIK	B
,	O
IkappaB	B
-	I
alpha	I
and	O
-	B
epsilon	I
in	O
unstimulated	O
cells	O
.	O

The	O
understanding	O
of	O
LPS	O
-	O
and	O
TNF	O
-	O
induced	O
signaling	O
may	O
allow	O
the	O
development	O
of	O
specific	O
strategies	O
to	O
treat	O
sepsis	O
-	O
associated	O
disease	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
examine	O
the	O
ability	O
of	O
tumor	B
necrosis	I
factor	I
alpha	I
(	O
TNFalpha	B
,	O
a	O
proinflammatory	B
cytokine	I
)	O
and	O
interleukin	B
(	I
IL	I
)	I
-	I
10	I
(	O
an	O
anti	B
-	I
inflammatory	I
cytokine	I
)	O
to	O
differentially	O
regulate	O
the	O
sensitivity	O
of	O
human	O
monocytes	O
/	O
macrophages	O
to	O
glucocorticoids	O
.	O

Finally	O
,	O
we	O
investigated	O
whether	O
the	O
modulation	O
of	O
corticosensitivity	O
in	O
TNFalpha	O
-	O
and	O
IL	O
-	O
10	O
-	O
pretreated	O
U937	O
cells	O
was	O
related	O
to	O
a	O
change	O
of	O
the	O
glucocorticoid	B
receptor	I
concentration	O
and	O
affinity	O
.	O

TNFalpha	B
decreased	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
while	O
IL	B
-	I
10	I
increased	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
the	O
concentration	O
of	O
dexamethasone	O
binding	O
sites	O
in	O
these	O
cells	O
,	O
with	O
no	O
discernible	O
effect	O
on	O
their	O
binding	O
affinity	O
.	O

We	O
conclude	O
that	O
glucocorticoids	O
differentially	O
modulate	O
TNFalpha	B
and	O
IL	B
-	I
10	I
secretion	O
by	O
human	O
monocytes	O
in	O
a	O
LPS	O
dose	O
-	O
dependent	O
fashion	O
and	O
that	O
the	O
sensitivity	O
of	O
these	O
cells	O
to	O
glucocorticoids	O
is	O
altered	O
by	O
TNFalpha	B
or	O
IL	B
-	I
10	I
pretreatment	O
;	O
TNFalpha	B
blocks	O
their	O
effects	O
,	O
whereas	O
IL	B
-	I
10	I
acts	O
synergistically	O
with	O
glucocorticoids	O
.	O

Because	O
NF	B
-	I
kappa	I
B	I
contributes	O
to	O
the	O
transcription	O
of	O
numerous	O
inflammatory	B
genes	I
and	O
has	O
been	O
shown	O
to	O
be	O
a	O
molecular	O
target	O
of	O
antiinflammatory	O
drugs	O
,	O
we	O
sought	O
to	O
characterize	O
the	O
functional	O
role	O
of	O
the	O
NF	B
-	I
kappa	I
B	I
protein	I
complex	I
in	O
lupus	O
T	O
cells	O
.	O

Also	O
,	O
NF	B
-	I
kappa	I
B	I
activity	O
remained	O
absent	O
in	O
follow	O
-	O
up	O
studies	O
.	O

As	O
p65	B
complexes	I
are	O
transcriptionally	O
active	O
in	O
comparison	O
to	O
the	O
p50	O
homodimer	O
,	O
this	O
novel	O
finding	O
may	O
provide	O
insight	O
on	O
the	O
origin	O
of	O
abnormal	B
cytokine	I
or	O
other	O
gene	O
transcription	O
in	O
SLE	O
patients	O
.	O

Here	O
,	O
we	O
investigate	O
further	O
the	O
events	O
triggered	O
by	O
TLR2	B
in	O
response	O
to	O
LPS	O
.	O

Intracellular	O
deletion	O
variants	O
of	O
TLR2	B
lacking	O
C	O
-	O
terminal	O
13	O
or	O
141	O
aa	O
fail	O
to	O
recruit	O
IRAK	B
,	O
which	O
is	O
consistent	O
with	O
the	O
inability	O
of	O
these	O
mutants	O
to	O
transmit	O
LPS	O
cellular	O
signaling	O
.	O

Here	O
we	O
provide	O
novel	O
evidence	O
that	O
AG	O
-	O
490	O
potently	O
inhibits	O
the	O
autokinase	O
activity	O
of	O
JAK3	B
and	O
tyrosine	O
phosphorylation	O
and	O
DNA	O
binding	O
of	O
signal	B
transducer	I
and	I
activator	I
of	I
transcription	I
5a	I
and	I
5b	I
(	I
STAT5a	I
/	I
b	I
)	I
.	O

AG	O
-	O
490	O
also	O
inhibited	O
IL	B
-	I
2	I
-	O
mediated	O
proliferative	O
growth	O
in	O
human	O
T	O
cells	O
with	O
an	O
IC50	O
)	O
=	O
25	O
microM	O
that	O
was	O
partially	O
recoverable	O
.	O

Taken	O
together	O
,	O
these	O
findings	O
suggest	O
that	O
AG	O
-	O
490	O
inhibits	O
the	O
JAK3	B
-	O
mediated	O
Type	O
II	O
signaling	O
pathway	O
but	O
not	O
the	O
T	O
cell	O
receptor	O
-	O
derived	O
Type	O
I	O
pathway	O
and	O
possesses	O
therapeutic	O
potential	O
for	O
T	O
cell	O
-	O
derived	O
pathologies	O
such	O
as	O
graft	O
-	O
versus	O
-	O
host	O
disease	O
,	O
allergy	O
,	O
and	O
autoimmune	O
disorders	O
.	O

Two	O
-	O
color	O
immunohistochemistry	O
demonstrated	O
that	O
both	O
macrophages	O
and	O
fibroblast	O
-	O
like	O
synoviocytes	O
were	O
positive	O
for	O
nuclear	O
C	B
/	I
EBP	I
beta	I
.	O

PU	B
.	I
1	I
is	O
a	O
hematopoietic	B
-	I
specific	I
Ets	I
family	I
transcription	I
factor	I
that	O
is	O
required	O
for	O
development	O
of	O
some	O
lymphoid	O
and	O
myeloid	O
lineages	O
.	O

We	O
find	O
that	O
PU	B
.	I
1	I
interacts	O
directly	O
with	O
GATA	B
-	I
1	I
,	O
a	O
zinc	B
finger	I
transcription	I
factor	I
required	O
for	O
erythroid	O
differentiation	O
.	O

Both	O
the	O
DNA	B
binding	I
and	O
transactivation	B
domains	I
of	O
PU	B
.	I
1	I
are	O
required	O
for	O
repression	O
and	O
both	O
domains	O
are	O
also	O
needed	O
to	O
block	O
terminal	O
differentiation	O
in	O
MEL	O
cells	O
.	O

To	O
better	O
clarify	O
the	O
molecular	O
basis	O
of	O
IL	B
-	I
12	I
action	O
,	O
we	O
set	O
out	O
to	O
characterize	O
genes	O
up	O
-	O
regulated	O
by	O
IL	B
-	I
12	I
,	O
first	O
by	O
contrasting	O
IL	B
-	I
12	I
-	O
and	O
IFN	B
-	I
alpha	I
-	I
inducible	I
genes	I
.	O

We	O
identified	O
several	O
genes	O
up	O
-	O
regulated	O
by	O
IL	B
-	I
12	I
,	O
namely	O
,	O
MIP	B
-	I
1alpha	I
,	O
MIP	B
-	I
1beta	I
,	O
IL	B
-	I
1RA	I
,	O
and	O
IFN	B
regulatory	I
factor	I
-	I
1	I
(	I
IRF	I
-	I
1	I
)	I
.	O

Therefore	O
,	O
IRF	B
-	I
1	I
may	O
be	O
an	O
important	O
contributor	O
to	O
IL	B
-	I
12	I
signaling	O
,	O
and	O
we	O
speculate	O
that	O
the	O
defective	O
IL	B
-	I
12	I
responses	O
seen	O
in	O
IRF	B
-	O
1	O
-	O
/	O
-	O
mice	O
might	O
be	O
attributable	O
,	O
in	O
part	O
,	O
to	O
the	O
absence	O
of	O
this	O
transcription	B
factor	I
.	O

To	O
determine	O
whether	O
it	O
is	O
possible	O
to	O
artificially	O
enhance	O
the	O
opening	O
of	O
the	O
chromatin	O
structure	O
of	O
a	O
minimal	B
beta	I
-	I
globin	I
promoter	I
,	O
we	O
placed	O
a	O
101bp	O
,	O
erythroid	B
-	I
specific	I
DNase	I
1	I
hypersensitive	I
site	I
-	I
forming	I
element	I
(	O
HSFE	B
)	O
immediately	O
upstream	O
of	O
the	O
beta	B
-	I
globin	I
promoter	I
and	I
gene	I
.	O

This	O
remodeling	O
of	O
promoter	O
chromatin	O
structure	O
resulted	O
in	O
3	O
-	O
fold	O
increases	O
in	O
beta	B
-	I
globin	I
gene	I
transcription	O
and	O
induction	O
,	O
and	O
inhibited	O
long	O
-	O
term	O
beta	B
-	I
globin	I
gene	I
silencing	O
.	O

Regulation	O
of	O
low	O
shear	O
flow	O
-	O
induced	O
HAEC	O
VCAM	B
-	I
1	I
expression	O
and	O
monocyte	O
adhesion	O
.	O

Here	O
we	O
investigate	O
the	O
hypothesis	O
that	O
low	O
shear	O
-	O
induced	O
activation	O
of	O
NF	B
-	I
kappaB	I
is	O
responsible	O
for	O
enhanced	O
expression	O
of	O
vascular	B
cell	I
adhesion	I
molecule	I
(	O
VCAM	B
-	I
1	I
)	O
resulting	O
in	O
augmented	O
endothelial	O
cell	O
-	O
monocyte	O
(	O
EC	O
-	O
Mn	O
)	O
adhesion	O
and	O
that	O
this	O
activation	O
is	O
dependent	O
on	O
intracellular	O
oxidant	O
activity	O
.	O

These	O
data	O
suggest	O
that	O
NF	B
-	I
kappaB	I
plays	O
a	O
key	O
role	O
in	O
low	O
shear	O
-	O
induced	O
VCAM	B
-	I
1	I
expression	O
and	O
that	O
pathways	O
mediating	O
low	O
shear	O
-	O
and	O
cytokine	O
-	O
induced	O
EC	O
-	O
Mn	O
adhesion	O
may	O
be	O
differentially	O
regulated	O
.	O

Nuclear	B
factor	I
-	I
90	I
of	O
activated	O
T	O
-	O
cells	O
:	O
A	O
double	B
-	I
stranded	I
RNA	I
-	O
binding	O
protein	O
and	O
substrate	O
for	O
the	O
double	B
-	I
stranded	I
RNA	I
-	I
dependent	I
protein	I
kinase	I
,	O
PKR	B
.	O

Using	O
in	O
vitro	O
translated	O
polypeptides	O
,	O
we	O
have	O
demonstrated	O
that	O
NF90	B
specifically	O
binds	O
to	O
double	B
-	I
stranded	I
RNA	I
.	O

C5a	O
-	O
induced	O
reporter	B
gene	I
expression	O
was	O
abolished	O
by	O
introducing	O
mutations	O
into	O
the	O
kappaB	B
sites	I
and	O
by	O
coexpression	O
of	O
a	O
dominant	B
negative	I
IkappaBalpha	I
construct	I
resistant	O
to	O
agonist	O
-	O
induced	O
phosphorylation	O
.	O

Pertussis	O
toxin	O
,	O
which	O
ADP	O
-	O
ribosylates	O
the	O
Gi	B
proteins	I
known	O
to	O
couple	O
to	O
the	O
C5a	B
receptor	I
,	O
produced	O
minimal	O
inhibition	O
of	O
C5a	O
-	O
induced	O
IL	B
-	I
8	I
expression	O
and	O
had	O
little	O
effect	O
on	O
C5a	O
-	O
induced	O
calcium	O
mobilization	O
in	O
RAW264	O
.	O
7	O
cells	O
.	O

Patients	O
with	O
GC	O
-	O
insensitive	O
asthma	O
expressed	O
a	O
significantly	O
higher	O
number	O
of	O
GCRbeta	O
-	O
immunoreactive	O
cells	O
in	O
their	O
BAL	O
and	O
peripheral	O
blood	O
than	O
GC	O
-	O
sensitive	O
asthmatics	O
or	O
normal	O
control	O
subjects	O
.	O

CD40	B
/	B
CD40	I
ligand	O
interactions	O
play	O
a	O
key	O
role	O
in	O
the	O
immune	O
responses	O
of	O
B	O
lymphocytes	O
,	O
monocytes	O
,	O
and	O
dendritic	O
cells	O
.	O

However	O
,	O
the	O
components	O
of	O
the	O
NF	B
-	I
kappaB	I
complexes	I
were	O
different	O
in	O
monocytes	O
and	O
B	O
cells	O
,	O
because	O
p50	B
is	O
part	O
of	O
the	O
NF	B
-	I
kappaB	I
complex	I
induced	O
by	O
CD40	B
triggering	O
in	O
both	O
monocytes	O
and	O
B	O
cells	O
,	O
whereas	O
p65	B
was	O
only	O
induced	O
in	O
B	O
cells	O
.	O
In	O
contrast	O
,	O
although	O
the	O
Janus	B
kinase	I
3	I
tyrosine	I
kinase	I
was	O
associated	O
with	O
CD40	B
molecules	O
in	O
both	O
monocytes	O
and	O
resting	O
B	O
cells	O
,	O
Janus	B
kinase	I
3	I
phosphorylation	O
induction	O
was	O
observed	O
only	O
in	O
CD40	O
-	O
activated	O
monocytes	O
,	O
with	O
subsequent	O
induction	O
of	O
STAT5a	B
DNA	O
binding	O
activity	O
in	O
the	O
nucleus	O
.	O

Interestingly	O
,	O
when	O
we	O
fused	O
HT	O
-	O
2	O
cells	O
expressing	O
the	O
EPOR	B
with	O
Ba	O
/	O
F3	O
cells	O
in	O
a	O
complementation	O
assay	O
,	O
the	O
resulting	O
hybridomas	O
proliferated	O
and	O
potently	O
activated	O
STAT	B
-	I
5	I
and	O
MAPK	B
in	O
response	O
to	O
EPO	B
.	O

Moreover	O
,	O
Ba	O
/	O
F3	O
cells	O
apparently	O
express	O
this	O
factor	O
(	O
s	O
)	O
and	O
somatic	O
fusions	O
can	O
,	O
therefore	O
,	O
confer	O
EPO	B
-	O
responsiveness	O
to	O
HT	O
-	O
2	O
cells	O
that	O
lack	O
this	O
factor	O
.	O

When	O
a	O
drug	O
appears	O
to	O
be	O
less	O
effective	O
than	O
preclinical	O
models	O
suggest	O
,	O
can	O
failures	O
in	O
effectiveness	O
from	O
delivery	O
or	O
dosing	O
be	O
differentiated	O
?	O
The	O
disappointing	O
results	O
of	O
clinical	O
trials	O
with	O
IL	B
-	I
10	I
-	O
-	O
so	O
at	O
odds	O
with	O
the	O
prediction	O
of	O
benefit	O
from	O
animal	O
models	O
-	O
-	O
bring	O
into	O
question	O
the	O
validity	O
of	O
those	O
models	O
as	O
well	O
as	O
the	O
soundness	O
of	O
design	O
of	O
the	O
clinical	O
trials	O
on	O
which	O
efficacy	O
of	O
IL	B
-	I
10	I
is	O
judged	O
.	O

The	O
variability	O
of	O
response	O
even	O
to	O
the	O
most	O
narrowly	O
targeted	O
agents	O
suggests	O
that	O
these	O
diseases	O
are	O
far	O
more	O
heterogeneous	O
in	O
humans	O
than	O
in	O
their	O
murine	O
counterparts	O
.	O

Potent	O
and	O
stable	O
attenuation	O
of	O
live	O
-	O
HIV	O
-	O
1	O
by	O
gain	O
of	O
a	O
proteolysis	B
-	I
resistant	I
inhibitor	I
of	O
NF	B
-	I
kappaB	I
(	O
IkappaB	B
-	I
alphaS32	I
/	I
36A	I
)	O
and	O
the	O
implications	O
for	O
vaccine	O
development	O
.	O

These	O
findings	O
illustrate	O
gain	O
-	O
of	O
-	O
function	O
as	O
a	O
feasible	O
strategy	O
for	O
developing	O
safer	O
live	O
-	O
attenuated	O
HIVs	O
to	O
be	O
tested	O
as	O
candidates	O
for	O
AIDS	O
vaccine	O
.	O

Multiple	O
NF	B
-	I
ATc	I
isoforms	I
with	O
individual	O
transcriptional	O
properties	O
are	O
synthesized	O
in	O
T	O
lymphocytes	O
.	O

The	O
transcription	B
factor	I
NF	B
-	I
ATc	I
that	O
controls	O
gene	O
expression	O
in	O
T	O
lymphocytes	O
and	O
embryonic	O
cardiac	O
cells	O
is	O
expressed	O
in	O
three	O
prominent	O
isoforms	O
.	O

Various	O
stimuli	O
of	O
T	O
cells	O
that	O
induce	O
the	O
activity	O
of	O
TAD	B
-	I
A	I
also	O
enhance	O
the	O
activity	O
of	O
TAD	B
-	I
B	I
,	O
but	O
,	O
unlike	O
TAD	B
-	I
A	I
,	O
TAD	B
-	I
B	I
remains	O
unphosphorylated	O
by	O
protein	O
from	O
12	O
-	O
O	O
-	O
tetradecanoyl	O
12	O
-	O
phorbol	O
13	O
-	O
acetate	O
-	O
stimulated	O
T	O
cells	O
.	O

Selection	O
and	O
long	O
-	O
term	O
persistence	O
of	O
reactive	O
CTL	O
clones	O
during	O
an	O
EBV	O
chronic	O
response	O
are	O
determined	O
by	O
avidity	O
,	O
CD8	B
variable	O
contribution	O
compensating	O
for	O
differences	O
in	O
TCR	B
affinities	O
.	O

We	O
found	O
a	O
wide	O
range	O
of	O
TCR	B
affinities	O
among	O
the	O
different	O
clonotypes	O
that	O
segregated	O
with	O
Vbeta	O
usage	O
.	O

Nuclear	O
localization	O
and	O
formation	O
of	O
beta	B
-	I
catenin	I
-	I
lymphoid	I
enhancer	I
factor	I
1	I
complexes	I
are	O
not	O
sufficient	O
for	O
activation	O
of	O
gene	O
expression	O
.	O

Lymphoid	O
cell	O
differentiation	O
relies	O
on	O
precisely	O
orchestrated	O
gene	O
activation	O
and	O
repression	O
events	O
.	O

Packaging	O
of	O
viral	O
particles	O
,	O
integration	O
into	O
the	O
target	O
genome	O
,	O
and	O
stability	O
of	O
the	O
integrated	O
provirus	O
are	O
not	O
affected	O
by	O
the	O
LTR	B
modification	O
.	O

Enhancer	O
replacement	O
is	O
therefore	O
an	O
effective	O
strategy	O
to	O
target	O
expression	O
of	O
a	O
retroviral	B
transgene	I
to	O
a	O
specific	O
progeny	O
of	O
transduced	O
hematopoietic	O
stem	O
cells	O
.	O

Regulation	O
of	O
Fas	B
ligand	I
expression	O
and	O
cell	O
death	O
by	O
apoptosis	B
-	I
linked	I
gene	I
4	I
.	O

These	O
results	O
indicate	O
that	O
ALG	B
-	I
4	I
is	O
necessary	O
and	O
sufficient	O
for	O
FasL	B
expression	O
.	O

We	O
now	O
find	O
that	O
LMP1	B
signaling	O
through	O
TRADD	B
differs	O
from	O
TNFR1	B
signaling	O
through	O
TRADD	B
.	O

Inhibition	O
of	O
NF	B
-	I
kappa	I
B	I
resulted	O
in	O
the	O
externalization	O
of	O
phosphatidylserine	O
,	O
induction	O
of	O
DNA	O
breaks	O
,	O
and	O
morphological	O
changes	O
consistent	O
with	O
apoptosis	O
.	O

Among	O
upstream	B
signaling	I
molecules	I
of	O
ERK	B
,	O
Shc	B
was	O
constitutively	O
associated	O
with	O
Grb2	O
and	O
was	O
not	O
tyrosine	O
-	O
phosphorylated	O
by	O
GM	B
-	I
CSF	I
and	O
FMLP	O
,	O
and	O
Sos1	B
and	O
c	B
-	I
Raf	I
-	I
1	I
were	O
not	O
phosphorylated	O
by	O
GM	B
-	I
CSF	I
,	O
IL	O
-	O
3	O
,	O
TNF	O
,	O
and	O
FMLP	O
in	O
monocytes	O
,	O
whereas	O
all	O
these	O
signaling	O
molecules	O
were	O
affected	O
and	O
/	O
or	O
utilized	O
by	O
GM	B
-	I
CSF	I
in	O
MO7e	O
cells	O
.	O

In	O
contrast	O
to	O
neutrophils	O
,	O
p38	B
was	O
constitutively	O
phosphorylated	O
and	O
agonist	O
-	O
dependent	O
phosphorylation	O
and	O
activation	O
was	O
not	O
detected	O
in	O
human	O
monocytes	O
.	O

Functional	O
analysis	O
indicates	O
that	O
the	O
BRs	B
are	O
involved	O
in	O
control	O
of	O
hIL	B
-	I
5	I
promoter	I
activity	O
.	O

PNU156804	O
action	O
is	O
restricted	O
to	O
some	O
signaling	O
pathways	O
;	O
it	O
does	O
not	O
affect	O
NF	B
-	I
kappa	I
B	I
activation	O
by	O
PMA	O
in	O
T	O
cells	O
but	O
blocks	O
that	O
induced	O
by	O
CD40	B
cross	O
-	O
linking	O
in	O
B	O
lymphocytes	O
.	O

The	O
expression	O
of	O
STAT1	B
and	O
STAT5	B
in	O
a	O
human	O
T	O
-	O
cell	O
line	O
was	O
induced	O
by	O
Tax	B
.	O

Transcriptional	O
control	O
of	O
the	O
IL	B
-	I
5	I
gene	O
by	O
human	O
helper	O
T	O
cells	O
:	O
IL	B
-	I
5	I
synthesis	O
is	O
regulated	O
independently	O
from	O
IL	B
-	I
2	I
or	O
IL	B
-	I
4	I
synthesis	O
.	O

METHODS	O
:	O
Allergen	O
-	O
specific	O
T	O
-	O
cell	O
clones	O
and	O
T	O
-	O
cell	O
hybridomas	O
were	O
established	O
from	O
the	O
peripheral	O
blood	O
lymphocytes	O
of	O
patients	O
with	O
asthma	O
,	O
and	O
the	O
transcriptional	O
regulation	O
of	O
the	O
IL	B
-	I
5	I
gene	I
was	O
investigated	O
with	O
transient	O
transfection	O
and	O
electrophoretic	O
mobility	O
shift	O
analysis	O
.	O

RESULTS	O
:	O
A	O
human	O
IL	B
-	I
5	I
promoter	I
/	I
enhancer	I
-	I
luciferase	I
gene	I
construct	I
,	O
pIL	B
-	I
5	I
(	I
-	I
511	I
)	I
Luc	I
,	O
was	O
transcribed	O
on	O
activation	O
of	O
IL	O
-	O
5	O
-	O
producing	O
T	O
-	O
cell	O
clones	O
,	O
but	O
not	O
IL	O
-	O
5	O
-	O
nonproducing	O
clones	O
.	O

pIL	B
-	I
5	I
(	I
-	I
511	I
)	I
Luc	I
was	O
transcribed	O
by	O
T	O
-	O
cell	O
hybridomas	O
derived	O
from	O
fusion	O
between	O
IL	O
-	O
5	O
-	O
producing	O
T	O
-	O
cell	O
clones	O
and	O
an	O
IL	O
-	O
5	O
gene	O
-	O
nonexpressing	O
T	O
-	O
cell	O
line	O
,	O
but	O
not	O
by	O
hybridomas	O
derived	O
from	O
IL	O
-	O
5	O
-	O
nonproducing	O
T	O
-	O
cell	O
clones	O
.	O

CONCLUSION	O
:	O
IL	B
-	I
5	I
synthesis	O
by	O
human	O
helper	O
T	O
cells	O
is	O
regulated	O
at	O
the	O
transcriptional	O
level	O
.	O

We	O
used	O
an	O
adenoviral	O
technique	O
of	O
blocking	O
NF	B
-	I
kappaB	I
through	O
overexpression	O
of	O
the	O
inhibitory	B
subunit	I
IkappaBalpha	B
,	O
which	O
has	O
the	O
advantage	O
that	O
it	O
can	O
be	O
used	O
in	O
the	O
diseased	O
tissue	O
itself	O
,	O
with	O
>	O
90	O
%	O
of	O
the	O
synovial	O
macrophages	O
,	O
fibroblasts	O
,	O
and	O
T	O
cells	O
infected	O
.	O

Of	O
even	O
more	O
interest	O
,	O
IkappaBalpha	B
overexpression	O
inhibited	O
the	O
production	O
of	O
matrix	B
metalloproteinases	I
1	I
and	I
3	I
while	O
not	O
affecting	O
their	O
tissue	O
inhibitor	O
.	O

This	O
finding	O
may	O
provide	O
a	O
tool	O
to	O
improve	O
current	O
protocols	O
of	O
immunotherapy	O
and	O
insights	O
to	O
how	O
tumor	O
cells	O
are	O
or	O
are	O
not	O
killed	O
by	O
LAK	O
cells	O
.	O

Clonality	O
analysis	O
utilizing	O
X	B
-	I
chromosome	I
inactivation	O
has	O
been	O
used	O
in	O
the	O
study	O
of	O
various	O
diseases	O
,	O
including	O
hematological	O
malignancies	O
.	O

One	O
problem	O
in	O
using	O
these	O
clonality	O
analysis	O
methods	O
,	O
however	O
,	O
is	O
that	O
there	O
may	O
be	O
significant	O
variation	O
in	O
Lyonization	O
in	O
blood	O
cells	O
in	O
normal	O
individuals	O
.	O

We	O
also	O
found	O
that	O
the	O
deviation	O
of	O
methylation	O
in	O
granulocytes	O
and	O
T	O
cells	O
was	O
well	O
correlated	O
.	O

Thus	O
,	O
we	O
conclude	O
that	O
appropriate	O
controls	O
from	O
the	O
same	O
individuals	O
,	O
such	O
as	O
T	O
cells	O
in	O
the	O
case	O
of	O
stem	O
cell	O
disorders	O
,	O
should	O
always	O
be	O
employed	O
to	O
conclusively	O
determine	O
whether	O
certain	O
cells	O
of	O
hematopoietic	O
origin	O
are	O
clonal	O
.	O

A	O
high	O
expression	O
of	O
WT1	B
has	O
been	O
detected	O
in	O
a	O
range	O
of	O
acute	O
leukemias	O
,	O
and	O
WT1	B
is	O
downregulated	O
during	O
induced	O
differentiation	O
of	O
some	O
leukemic	O
cell	O
lines	O
.	O

K562	O
cells	O
express	O
endogenous	O
WT1	B
,	O
which	O
is	O
downregulated	O
as	O
a	O
response	O
to	O
induced	O
differentiation	O
along	O
the	O
erythroid	O
and	O
megakaryocytic	O
pathways	O
.	O

However	O
,	O
activation	O
of	O
STAT6	B
,	O
CD23	B
expression	O
,	O
and	O
IgE	B
synthesis	O
induced	O
by	O
IL	B
-	I
4	I
were	O
not	O
affected	O
in	O
p47phox	O
-	O
deficient	O
patients	O
,	O
which	O
raises	O
the	O
possibility	O
that	O
p47phox	O
may	O
be	O
important	O
in	O
other	O
signaling	O
activities	O
as	O
well	O
in	O
B	O
cells	O
.	O

METHODS	O
:	O
Protein	O
production	O
in	O
supernatants	O
was	O
assessed	O
by	O
ELISA	O
,	O
and	O
mRNA	B
expression	O
was	O
evaluated	O
by	O
semiquantitative	O
RT	O
-	O
PCR	O
.	O

On	O
the	O
contrary	O
,	O
the	O
release	O
of	O
MCP	B
-	I
1	I
was	O
significantly	O
inhibited	O
,	O
also	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

Messenger	B
RNA	I
production	O
coding	O
for	O
IL	B
-	I
8	I
,	O
RANTES	B
,	O
and	O
MCP	B
-	I
1	I
showed	O
parallel	O
variations	O
to	O
the	O
production	O
of	O
the	O
correspondent	B
proteins	I
.	O

Furthermore	O
,	O
SLP	B
-	I
76	I
and	O
Vav	B
have	O
a	O
synergistic	O
effect	O
on	O
interleukin	B
(	I
IL	I
)	I
-	I
2	I
promoter	I
activity	O
in	O
T	O
cells	O
.	O

Surprisingly	O
,	O
we	O
find	O
also	O
that	O
the	O
interaction	O
between	O
SLP	B
-	I
76	I
and	O
Vav	B
is	O
not	O
required	O
for	O
their	O
cooperation	O
in	O
augmenting	O
IL	B
-	I
2	I
promoter	I
activity	O
,	O
as	O
the	O
two	O
molecules	O
appear	O
to	O
function	O
in	O
different	O
signaling	O
pathways	O
upstream	O
of	O
IL	B
-	I
2	I
gene	I
expression	O
.	O

In	O
contrast	O
,	O
overexpression	O
of	O
Vav	B
leads	O
to	O
enhanced	O
nuclear	B
factor	I
of	I
activated	I
T	I
cells	I
activity	O
without	O
affecting	O
AP	B
-	I
1	I
.	O

Additionally	O
,	O
overexpression	O
of	O
Vav	B
,	O
but	O
not	O
SLP	B
-	I
76	I
,	O
augments	O
CD28	O
-	O
induced	O
IL	B
-	I
2	I
promoter	I
activity	O
.	O

Here	O
,	O
we	O
show	O
that	O
Jagged1	B
is	O
a	O
Rel	B
/	I
NF	I
-	I
kappaB	I
-	I
responsive	I
gene	I
.	O

This	O
correlated	O
with	O
the	O
initiation	O
of	O
signaling	O
downstream	O
of	O
Notch	O
,	O
as	O
evidenced	O
by	O
increased	O
levels	O
of	O
HES	B
-	I
1	I
transcripts	I
in	O
co	O
-	O
cultivated	O
T	O
cells	O
and	O
of	O
CD23	B
transcripts	I
in	O
co	O
-	O
cultivated	O
B	O
cells	O
.	O

Our	O
results	O
demonstrated	O
that	O
:	O
(	O
i	O
)	O
PGN	O
induced	O
phosphorylation	O
of	O
the	O
transcription	B
factors	I
ATF	B
-	I
1	I
and	O
CREB	B
;	O
(	O
ii	O
)	O
ATF	B
-	I
1	I
and	O
CREB	B
bound	O
DNA	O
as	O
a	O
dimer	O
and	O
induced	O
transcriptional	O
activation	O
of	O
a	O
CRE	B
reporter	I
plasmid	I
,	O
which	O
was	O
inhibited	O
by	O
dominant	O
negative	O
CREB	B
and	O
ATF	B
-	I
1	I
;	O
(	O
iii	O
)	O
PGN	O
induced	O
phosphorylation	O
of	O
c	B
-	I
Jun	I
,	O
protein	O
synthesis	O
of	O
JunB	B
and	O
c	B
-	I
Fos	I
,	O
and	O
transcriptional	O
activation	O
of	O
the	O
AP	B
-	I
1	I
reporter	I
plasmid	I
,	O
which	O
was	O
inhibited	O
by	O
dominant	O
negative	O
c	B
-	I
Fos	I
;	O
and	O
(	O
iv	O
)	O
PGN	O
-	O
induced	O
activation	O
of	O
CREB	B
/	I
ATF	I
and	O
AP	B
-	I
1	I
was	O
mediated	O
through	O
CD14	B
.	O

In	O
contrast	O
to	O
these	O
findings	O
,	O
mucosal	O
hGR	B
levels	O
were	O
significantly	O
decreased	O
in	O
both	O
steroid	O
-	O
treated	O
(	O
18	O
.	O
0	O
+	O
/	O
-	O
15	O
.	O
5	O
)	O
and	O
not	O
steroid	O
-	O
treated	O
(	O
37	O
.	O
8	O
+	O
/	O
-	O
30	O
.	O
5	O
)	O
patients	O
compared	O
with	O
control	O
subjects	O
(	O
125	O
.	O
6	O
+	O
/	O
-	O
97	O
.	O
1	O
;	O
P	O
=	O
0	O
.	O
00009	O
and	O
P	O
=	O
0	O
.	O
0008	O
respectively	O
)	O
.	O

In	O
this	O
study	O
,	O
we	O
created	O
transgenic	O
mice	O
overexpressing	O
ICSAT	B
in	O
lymphocytes	O
.	O

Altered	O
memory	O
T	O
cell	O
differentiation	O
in	O
patients	O
with	O
early	O
rheumatoid	O
arthritis	O
.	O

A	O
cell	O
culture	O
system	O
was	O
then	O
employed	O
that	O
permitted	O
the	O
differentiation	O
of	O
Th	B
effectors	I
from	O
resting	O
memory	O
T	O
cells	O
by	O
short	O
term	O
priming	O
.	O

Our	O
findings	O
offer	O
important	O
insights	O
into	O
parasite	O
survival	O
strategies	O
and	O
demonstrate	O
that	O
parasite	O
-	O
induced	O
constitutive	O
NF	B
-	I
kappaB	I
activation	O
is	O
an	O
essential	O
step	O
in	O
maintaining	O
the	O
transformed	O
phenotype	O
of	O
the	O
infected	O
cells	O
.	O

A	O
polymorphism	O
that	O
affects	O
OCT	B
-	I
1	I
binding	O
to	O
the	O
TNF	B
promoter	I
region	I
is	O
associated	O
with	O
severe	O
malaria	O
[	O
see	O
comments	O
]	O

The	O
results	O
show	O
that	O
the	O
CYP1A1	B
mRNA	I
level	O
induced	O
by	O
UV	O
in	O
the	O
presence	O
of	O
tryptophan	O
was	O
higher	O
than	O
that	O
induced	O
by	O
UV	O
alone	O
in	O
both	O
HaCaT	O
cells	O
and	O
lymphocytes	O
after	O
3	O
h	O
of	O
incubation	O
post	O
-	O
UV	O
irradiation	O
.	O

Wild	O
-	O
type	O
(	O
wt	O
)	O
cells	O
were	O
inducible	O
either	O
by	O
the	O
tryptophan	O
photoproduct	O
6	O
-	O
formylindolo	O
[	O
3	O
,	O
2	O
-	O
b	O
]	O
carbazole	O
(	O
FICZ	O
)	O
or	O
by	O
UV	O
-	O
irradiation	O
but	O
very	O
low	O
or	O
undetectable	O
levels	O
were	O
observed	O
in	O
the	O
c12	O
cells	O
.	O

This	O
shows	O
that	O
the	O
induction	O
of	O
gene	O
expression	O
by	O
FICZ	O
and	O
UV	O
is	O
Ah	B
receptor	I
dependent	O
.	O

Thus	O
,	O
the	O
photoproducts	O
of	O
tryptophan	O
are	O
suggested	O
to	O
be	O
mediators	O
of	O
light	O
via	O
binding	O
to	O
the	O
Ah	B
receptor	I
and	O
as	O
such	O
also	O
could	O
have	O
a	O
role	O
in	O
light	O
-	O
regulated	O
biological	O
rhythms	O
.	O

Repression	O
by	O
Ikaros	B
and	O
Aiolos	B
is	O
mediated	O
through	O
histone	B
deacetylase	I
complexes	I
.	O

To	O
better	O
understand	O
signals	O
controlling	O
proliferation	O
and	O
viability	O
,	O
erythroid	O
cells	O
that	O
resist	O
apoptosis	O
in	O
the	O
absence	O
of	O
EPO	B
were	O
subcloned	O
and	O
characterized	O
(	O
HCD57	O
-	O
SREI	O
cells	O
)	O
.	O

Enforced	O
expression	O
of	O
Id3	B
,	O
which	O
has	O
the	O
capacity	O
to	O
inhibit	O
many	O
basic	B
helix	I
-	I
loop	I
-	I
helix	I
(	I
bHLH	I
)	I
transcription	I
factors	I
,	O
in	O
human	O
CD34	O
(	O
+	O
)	O
hematopoietic	O
progenitor	O
cells	O
that	O
have	O
not	O
undergone	O
T	B
cell	I
receptor	I
(	I
TCR	I
)	I
gene	I
rearrangements	I
inhibits	O
development	O
of	O
the	O
transduced	O
cells	O
into	O
TCRalpha	O
beta	O
and	O
gamma	O
delta	O
cells	O
in	O
a	O
fetal	O
thymic	O
organ	O
culture	O
(	O
FTOC	O
)	O
.	O

These	O
cells	O
had	O
properties	O
of	O
both	O
natural	O
killer	O
(	O
NK	O
)	O
and	O
pre	O
-	O
T	O
cells	O
.	O

HIV	O
-	O
1	O
reactivation	O
in	O
resting	O
peripheral	O
blood	O
mononuclear	O
cells	O
of	O
infected	O
adults	O
upon	O
in	O
vitro	O
CD4	B
cross	O
-	O
linking	O
by	O
ligands	O
of	O
the	O
CDR2	B
-	I
loop	I
in	O
extracellular	B
domain	I
1	I
.	O

Additionally	O
,	O
virus	O
reactivation	O
in	O
resting	O
PBMCs	O
infected	O
in	O
vitro	O
with	O
HIV	O
-	O
1	O
was	O
found	O
to	O
be	O
specifically	O
induced	O
by	O
ligands	O
of	O
the	O
CDR2	B
-	I
loop	I
in	O
domain	B
1	I
(	O
D1	B
)	O
of	O
CD4	B
(	O
virus	B
envelope	I
and	I
anti	I
-	I
CD4	I
monoclonal	I
antibodies	I
)	O
.	O

In	O
contrast	O
,	O
virus	O
reactivation	O
was	O
not	O
observed	O
following	O
CD4	B
oligomerization	O
by	O
antibodies	B
that	O
bind	O
other	O
epitopes	O
in	O
D1	B
,	O
including	O
the	O
D1	B
/	I
CDR3	I
-	I
loop	I
.	O

Our	O
results	O
indicate	O
that	O
the	O
signaling	O
events	O
initiated	O
in	O
PBMCs	O
by	O
oligomerization	O
of	O
CD4	B
at	O
the	O
D1	B
/	I
CDR2	I
-	I
loop	I
can	O
trigger	O
HIV	O
-	O
1	O
upregulation	O
in	O
infected	O
individuals	O
.	O

Signaling	O
through	O
the	O
lymphotoxin	B
-	I
beta	I
receptor	I
stimulates	O
HIV	O
-	O
1	O
replication	O
alone	O
and	O
in	O
cooperation	O
with	O
soluble	O
or	O
membrane	B
-	I
bound	I
TNF	I
-	I
alpha	I
.	O

The	O
level	O
of	O
ongoing	O
HIV	O
-	O
1	O
replication	O
within	O
an	O
individual	O
is	O
critical	O
to	O
HIV	O
-	O
1	O
pathogenesis	O
.	O

Given	O
the	O
critical	O
role	O
that	O
LT	B
-	I
alpha1beta2	I
plays	O
in	O
lymphoid	O
architecture	O
,	O
we	O
speculate	O
that	O
LT	B
-	I
alpha1beta2	I
may	O
be	O
involved	O
in	O
HIV	O
-	O
associated	O
abnormalities	O
of	O
the	O
lymphoid	O
organs	O
.	O

The	O
secretion	O
levels	O
of	O
interleukin	B
-	I
6	I
(	O
IL	B
-	I
6	I
)	O
and	O
von	O
Willebrand	O
factor	O
(	O
vWF	O
)	O
were	O
determined	O
,	O
to	O
serve	O
as	O
markers	O
for	O
EC	O
activation	O
.	O

In	O
addition	O
,	O
nuclear	O
extracts	O
of	O
the	O
mAECA	O
-	O
treated	O
EC	O
were	O
analyzed	O
for	O
the	O
induction	O
of	O
translocation	O
of	O
nuclear	B
factor	I
kappaB	I
(	O
NF	B
-	I
kappaB	I
)	O
,	O
using	O
a	O
specific	O
NF	B
-	I
kappaB	I
oligoprobe	O
in	O
an	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O

The	O
mAECA	B
,	O
but	O
not	O
normal	B
human	I
IgG	I
,	O
had	O
anti	O
-	O
human	O
aortic	O
EC	O
activity	O
.	O

Four	O
of	O
the	O
6	O
mAECA	B
activated	O
EC	O
,	O
manifested	O
by	O
increased	O
IL	B
-	I
6	I
and	O
vWF	O
secretion	O
.	O

However	O
NF	B
-	I
ATs	I
appear	O
in	O
the	O
nuclei	O
of	O
IL	O
-	O
4	O
-	O
,	O
IL	O
-	O
5	O
-	O
,	O
or	O
ionomycin	O
-	O
stimulated	O
eosinophils	O
.	O

Both	O
PPARalpha	B
activators	O
decreased	O
cytokine	O
-	O
induced	O
VCAM	B
-	I
1	I
mRNA	O
expression	O
without	O
altering	O
its	O
mRNA	O
half	O
-	O
life	O
.	O

Such	O
findings	O
also	O
have	O
implications	O
regarding	O
the	O
clinical	O
use	O
of	O
lipid	O
-	O
lowering	O
agents	O
,	O
like	O
fibric	O
acids	O
,	O
which	O
can	O
activate	O
PPARalpha	B
.	O

CBP	B
/	I
p300	I
integrates	O
Raf	B
/	O
Rac	B
-	O
signaling	O
pathways	O
in	O
the	O
transcriptional	O
induction	O
of	O
NF	B
-	I
ATc	I
during	O
T	O
cell	O
activation	O
.	O

We	O
have	O
carried	O
out	O
a	O
detailed	O
analysis	O
of	O
the	O
cellular	O
immune	O
functions	O
of	O
breast	O
cancer	O
patients	O
in	O
comparison	O
with	O
healthy	O
controls	O
.	O

Inhibition	O
of	O
NF	B
-	I
kappaB	I
has	O
been	O
achieved	O
by	O
pharmacological	O
and	O
genetic	O
approaches	O
;	O
however	O
,	O
monocyte	O
interactions	O
with	O
activated	O
endothelium	O
in	O
shear	O
flow	O
following	O
gene	O
transfer	O
of	O
the	O
NF	B
-	I
kappaB	I
inhibitor	O
IkappaB	B
-	I
alpha	I
have	O
not	O
been	O
studied	O
.	O

This	O
was	O
associated	O
with	O
a	O
reduction	O
in	O
endothelial	O
MCP	B
-	I
1	I
secretion	O
and	O
GRO	B
-	I
alpha	I
immobilization	O
.	O

Adhesion	O
assays	O
under	O
physiological	O
shear	O
flow	O
conditions	O
showed	O
that	O
firm	O
arrest	O
,	O
spreading	O
,	O
and	O
transmigration	O
of	O
monocytes	O
on	O
TNF	B
-	I
alpha	I
-	O
activated	O
endothelium	O
was	O
markedly	O
inhibited	O
by	O
IkappaB	B
-	I
alpha	I
overexpression	O
.	O

In	O
contrast	O
,	O
rolling	O
of	O
monocytes	O
was	O
increased	O
by	O
IkappaB	B
-	I
alpha	I
transfer	O
and	O
was	O
partly	O
mediated	O
by	O
P	B
-	I
selectin	I
;	O
however	O
,	O
it	O
appeared	O
to	O
be	O
unaffected	O
by	O
the	O
inhibition	O
of	O
E	B
-	I
selectin	I
induction	O
.	O

Copyright	O
1999	O
Academic	O
Press	O
.	O

The	O
effect	O
of	O
oestrogens	O
on	O
oestrogen	O
-	O
receptive	O
organs	O
and	O
cells	O
is	O
mediated	O
via	O
intracellular	B
receptors	I
(	O
ERalpha	B
and	O
ERbeta	B
)	O
.	O

All	O
tissues	O
and	O
cells	O
studied	O
were	O
homozygous	O
for	O
the	O
wild	B
-	I
type	I
gene	I
,	O
and	O
were	O
heterozygous	O
as	O
well	O
as	O
homozygous	O
for	O
the	O
codon	B
-	I
10	I
-	I
variant	I
type	I
.	O

These	O
results	O
indicate	O
that	O
the	O
presence	O
of	O
the	O
codon	B
-	I
10	I
-	I
variant	I
type	I
is	O
not	O
a	O
characteristic	O
of	O
breast	O
cancer	O
.	O

USF	B
/	I
c	I
-	I
Myc	I
enhances	O
,	O
while	O
Yin	B
-	I
Yang	I
1	I
suppresses	O
,	O
the	O
promoter	O
activity	O
of	O
CXCR4	B
,	O
a	O
coreceptor	B
for	O
HIV	O
-	O
1	O
entry	O
.	O

We	O
have	O
identified	O
an	O
E	B
box	I
around	O
-	B
260	I
and	O
a	O
YY1	B
binding	I
site	I
around	O
-	B
300	I
relative	O
to	O
the	O
transcription	B
start	I
site	I
.	O

RCC	O
-	O
S	O
did	O
not	O
alter	O
the	O
cytoplasmic	O
levels	O
of	O
RelA	B
and	O
NF	B
-	I
kappaB1	I
but	O
did	O
suppress	O
their	O
nuclear	O
localization	O
and	O
inhibited	O
the	O
activation	O
of	O
RelA	B
/	I
NF	I
-	I
kappaB1	I
binding	I
complexes	I
.	O

These	O
results	O
show	O
that	O
RCC	O
-	O
S	O
can	O
induce	O
in	O
normal	O
T	O
cells	O
the	O
same	O
phenotype	O
of	O
impaired	O
NF	B
-	I
kappaB	I
activation	O
that	O
is	O
detected	O
in	O
T	O
cells	O
of	O
RCC	O
patient	O
.	O

Human	O
monocytes	O
isolated	O
from	O
peripheral	O
blood	O
of	O
healthy	O
donors	O
show	O
a	O
time	O
-	O
dependent	O
differentiation	O
into	O
macrophages	O
upon	O
in	O
vitro	O
cultivation	O
,	O
closely	O
mimicking	O
their	O
in	O
vivo	O
migration	O
and	O
maturation	O
into	O
extravascular	O
tissues	O
.	O

The	O
mediator	O
(	O
s	O
)	O
of	O
this	O
maturation	O
process	O
has	O
not	O
been	O
yet	O
defined	O
.	O

We	O
investigated	O
the	O
involvement	O
of	O
signal	B
transducers	I
and	I
activators	I
of	I
transcription	I
(	I
STAT	I
)	I
factors	I
in	O
this	O
phenomenon	O
and	O
reported	O
the	O
specific	O
,	O
time	O
-	O
dependent	O
,	O
activation	O
of	O
STAT1	B
protein	O
starting	O
at	O
day	O
0	O
/	O
1	O
of	O
cultivation	O
and	O
maximally	O
expressed	O
at	O
day	O
5	O
.	O

STAT1	B
activity	O
was	O
evident	O
on	O
the	O
STAT	B
binding	I
sequences	I
(	O
SBE	B
)	O
present	O
in	O
the	O
promoters	B
of	O
genes	O
which	O
are	O
up	O
-	O
regulated	O
during	O
monocyte	O
to	O
macrophage	O
maturation	O
such	O
as	O
FcgammaRI	B
and	O
ICAM	B
-	I
1	I
,	O
and	O
in	O
the	O
promoter	O
of	O
the	O
transcription	B
factor	I
IFN	I
regulatory	I
factor	I
-	I
1	I
.	O

Compared	O
with	O
monocytes	O
adherent	O
on	O
plastic	O
surfaces	O
,	O
freshly	O
isolated	O
cells	O
allowed	O
to	O
adhere	O
either	O
to	O
fibronectin	O
-	O
or	O
laminin	O
-	O
coated	O
flasks	O
exhibited	O
an	O
increased	O
STAT1	B
binding	O
activity	O
both	O
in	O
control	O
and	O
in	O
IFN	O
-	O
gamma	O
-	O
treated	O
cells	O
.	O

Thereafter	O
,	O
PML	B
is	O
downmodulated	O
in	O
late	O
granulocytic	O
maturation	O
,	O
whereas	O
it	O
is	O
sustainably	O
expressed	O
through	O
the	O
erythroid	O
pathway	O
.	O

Furthermore	O
,	O
PML	B
and	O
pRb	B
105	I
were	O
co	O
-	O
immunoprecipitated	O
in	O
cellular	O
lysates	O
derived	O
from	O
erythroid	O
precursors	O
indicating	O
that	O
this	O
functional	O
interaction	O
may	O
have	O
a	O
biochemical	O
basis	O
.	O

Endogenous	O
and	O
therapeutic	O
steroid	O
hormones	O
affect	O
the	O
immune	O
system	O
,	O
and	O
inflammatory	O
diseases	O
are	O
associated	O
with	O
activation	O
of	O
the	O
hypothalamic	O
-	O
pituitary	O
-	O
adrenal	O
axis	O
,	O
providing	O
evidence	O
of	O
an	O
immune	O
-	O
endocrine	O
interplay	O
.	O

No	O
effect	O
of	O
age	O
,	O
sex	O
,	O
course	O
,	O
duration	O
or	O
severity	O
of	O
disease	O
,	O
or	O
prior	O
steroid	O
treatments	O
was	O
detected	O
.	O

These	O
data	O
suggest	O
that	O
the	O
physiological	O
relationship	O
between	O
binding	O
and	O
function	O
of	O
the	O
glucocorticoid	B
receptor	I
is	O
disturbed	O
in	O
MS	O
.	O

Treatment	O
of	O
cells	O
with	O
PD98059	O
,	O
a	O
specific	O
inhibitor	O
of	O
mitogen	B
-	I
activated	I
protein	I
kinase	I
kinase	I
(	O
MEK	B
)	O
,	O
inhibited	O
TPA	O
-	O
induced	O
ERK2	B
activity	O
.	O

METHODS	O
:	O
Twenty	O
-	O
two	O
patients	O
with	O
severe	O
restrictive	O
anorexia	O
nervosa	O
,	O
10	O
patients	O
with	O
active	O
Cushing	O
'	O
s	O
disease	O
,	O
and	O
24	O
healthy	O
volunteers	O
without	O
psychiatric	O
disorders	O
or	O
mood	O
alterations	O
were	O
investigated	O
.	O

RESULTS	O
:	O
The	O
number	O
of	O
glucocorticoid	B
receptors	I
on	O
mononuclear	O
leukocytes	O
(	O
MNL	O
)	O
was	O
comparable	O
in	O
patients	O
with	O
anorexia	O
nervosa	O
,	O
patients	O
with	O
active	O
Cushing	O
'	O
s	O
disease	O
,	O
and	O
normal	O
subjects	O
(	O
binding	O
capacity	O
3	O
.	O
3	O
+	O
/	O
-	O
0	O
.	O
23	O
vs	O
.	O
3	O
.	O
7	O
+	O
/	O
-	O
0	O
.	O
30	O
and	O
3	O
.	O
5	O
+	O
/	O
-	O
0	O
.	O
20	O
fmol	O
/	O
10	O
(	O
6	O
)	O
cells	O
)	O
.	O

In	O
patients	O
with	O
anorexia	O
nervosa	O
,	O
the	O
incorporation	O
of	O
[	O
3H	O
]	O
thymidine	O
into	O
the	O
MNL	O
was	O
inversely	O
correlated	O
with	O
urinary	O
free	O
cortisol	O
levels	O
.	O

Different	O
sequence	O
requirements	O
for	O
expression	O
in	O
erythroid	O
and	O
megakaryocytic	O
cells	O
within	O
a	O
regulatory	B
element	I
upstream	O
of	O
the	O
GATA	B
-	I
1	I
gene	I
.	O

We	O
have	O
localized	O
a	O
317	O
base	O
pair	O
cis	B
-	I
acting	I
regulatory	I
element	I
,	O
HS	B
I	I
,	O
associated	O
with	O
a	O
hematopoietic	B
-	I
specific	I
DNase	I
I	I
hypersensitive	I
site	I
,	O
which	O
lies	O
approx	O
.	O

This	O
core	O
contains	O
a	O
GATA	B
site	I
separated	O
by	O
10	O
base	O
pairs	O
from	O
an	O
E	B
-	I
box	I
motif	I
.	O

In	O
addition	O
,	O
sodium	O
salicylate	O
and	O
additional	O
NSAIDs	O
used	O
at	O
concentrations	O
that	O
activate	O
HSF1	B
also	O
inhibited	O
the	O
expression	O
of	O
other	O
monocytic	B
genes	I
(	O
TNF	B
-	I
alpha	I
,	O
IL	B
-	I
1beta	I
,	O
IL	B
-	I
6	I
,	O
IL	B
-	I
8	I
,	O
IL	B
-	I
10	I
,	O
ICAM	B
-	I
1	I
)	O
activated	O
by	O
exposure	O
to	O
a	O
pro	O
-	O
inflammatory	O
stimulus	O
(	O
lipopolysaccharide	O
,	O
LPS	O
)	O
.	O

Copyright	O
1999	O
Academic	O
Press	O
.	O

Fibroblast	B
growth	I
factors	I
(	O
FGFs	B
)	O
are	O
heparin	B
-	I
binding	I
proteins	I
crucial	O
to	O
embryogenesis	O
,	O
angiogenesis	O
,	O
and	O
wound	O
healing	O
.	O

FGF	B
-	I
1	I
is	O
abundantly	O
expressed	O
in	O
the	O
synovium	O
in	O
rheumatoid	O
arthritis	O
and	O
in	O
rejecting	O
allografts	O
,	O
sites	O
of	O
chronic	O
immune	O
-	O
mediated	O
inflammation	O
.	O

In	O
this	O
paper	O
,	O
we	O
show	O
that	O
HCMV	O
down	O
regulates	O
gamma	O
interferon	O
(	O
IFN	B
-	I
gamma	I
)	O
-	O
induced	O
HLA	B
-	I
DR	I
expression	O
in	O
U373	O
MG	O
astrocytoma	O
cells	O
due	O
to	O
a	O
defect	O
downstream	O
of	O
STAT1	B
phosphorylation	O
and	O
nuclear	O
translocation	O
.	O

Inhibition	O
of	O
NF	B
-	I
kappaB	I
transcriptional	O
activity	O
and	O
promotion	O
of	O
IkappaBalpha	B
degradation	O
.	O

DZA	O
inhibits	O
the	O
transcriptional	O
activity	O
of	O
NF	B
-	I
kappaB	I
through	O
the	O
hindrance	O
of	O
p65	B
(	O
Rel	B
-	I
A	I
)	O
phosphorylation	O
without	O
reduction	O
of	O
its	O
nuclear	O
translocation	O
and	O
DNA	O
binding	O
activity	O
.	O

The	O
inhibitory	O
effect	O
of	O
DZA	O
on	O
NF	B
-	I
kappaB	I
transcriptional	O
activity	O
is	O
potentiated	O
by	O
the	O
addition	O
of	O
homocysteine	O
.	O

Decidual	O
gammadelta	O
T	O
cells	O
,	O
which	O
significantly	O
increase	O
in	O
number	O
during	O
pregnancy	O
,	O
might	O
play	O
a	O
role	O
in	O
recognition	O
of	O
fetal	B
antigens	I
and	O
also	O
in	O
determining	O
the	O
quality	O
of	O
the	O
response	O
to	O
these	O
antigens	B
.	O

Here	O
,	O
we	O
investigate	O
the	O
role	O
of	O
Rho	B
in	O
regulating	O
the	O
distribution	O
of	O
the	O
monocyte	B
-	I
binding	I
receptors	I
E	B
-	I
selectin	I
,	O
ICAM	B
-	I
1	I
,	O
and	O
VCAM	B
-	I
1	I
in	O
human	O
endothelial	O
cells	O
.	O

C3	O
transferase	O
and	O
cytochalasin	O
D	O
did	O
not	O
alter	O
the	O
expression	O
levels	O
of	O
monocyte	B
-	I
binding	I
receptors	I
on	O
endothelial	O
cells	O
,	O
but	O
did	O
inhibit	O
clustering	O
of	O
E	B
-	I
selectin	I
,	O
ICAM	B
-	I
1	I
,	O
and	O
VCAM	B
-	I
1	I
on	O
the	O
cell	O
surface	O
induced	O
by	O
monocyte	O
adhesion	O
or	O
cross	B
-	I
linking	I
antibodies	I
.	O

Similarly	O
,	O
N19RhoA	B
inhibited	O
receptor	O
clustering	O
.	O

Finally	O
,	O
receptor	O
clusters	O
colocalized	O
with	O
ezrin	B
/	I
moesin	I
/	I
radixin	I
proteins	I
.	O

Although	O
recognized	O
as	O
fundamental	O
aspects	O
of	O
T	O
lymphocyte	O
development	O
,	O
only	O
recently	O
have	O
the	O
mechanisms	O
governing	O
positive	O
and	O
negative	O
selection	O
been	O
examined	O
at	O
a	O
molecular	O
level	O
.	O

Negative	O
selection	O
refers	O
to	O
the	O
deletion	O
or	O
inactivation	O
of	O
potentially	O
autoreactive	O
thymocytes	O
.	O

CD28	B
costimulation	O
augments	O
IL	B
-	I
2	I
secretion	O
of	O
activated	O
lamina	O
propria	O
T	O
cells	O
by	O
increasing	O
mRNA	O
stability	O
without	O
enhancing	O
IL	B
-	I
2	I
gene	O
transactivation	O
.	O

Previous	O
studies	O
have	O
characterized	O
the	O
CD28	B
augmentation	O
of	O
TCR	B
-	O
mediated	O
signaling	O
in	O
peripheral	O
blood	O
T	O
cells	O
through	O
transcriptional	O
activation	O
of	O
an	O
IL	B
-	I
2	I
promoter	O
CD28	B
response	I
element	I
(	O
CD28RE	B
)	O
,	O
along	O
with	O
enhanced	O
mRNA	O
stability	O
.	O

LPMC	O
exhibited	O
increased	O
IL	B
-	I
2	I
production	O
in	O
response	O
to	O
CD28	B
costimulation	O
,	O
compared	O
with	O
cells	O
activated	O
through	O
CD2	B
alone	O
.	O

In	O
conclusion	O
,	O
production	O
of	O
a	O
Th1	B
cytokine	I
,	O
IFN	B
-	I
gamma	I
,	O
by	O
HBsAg	B
-	O
reactive	O
cells	O
was	O
associated	O
with	O
hepatocyte	O
damage	O
in	O
chronic	O
hepatitis	O
B	O
,	O
while	O
no	O
counteracting	O
effect	O
of	O
Th2	B
cytokines	I
produced	O
by	O
those	O
cells	O
was	O
observed	O
.	O

BACKGROUND	O
:	O
Arsenic	O
trioxide	O
(	O
As2O3	O
)	O
can	O
induce	O
clinical	O
remission	O
in	O
patients	O
with	O
acute	O
promyelocytic	O
leukemia	O
via	O
induction	O
of	O
differentiation	O
and	O
programmed	O
cell	O
death	O
(	O
apoptosis	O
)	O
.	O

We	O
investigated	O
the	O
effects	O
of	O
As2O3	O
on	O
a	O
panel	O
of	O
malignant	O
lymphocytes	O
to	O
determine	O
whether	O
growth	O
-	O
inhibitory	O
and	O
apoptotic	O
effects	O
of	O
As2O3	O
can	O
be	O
observed	O
in	O
these	O
cells	O
at	O
clinically	O
achievable	O
concentrations	O
.	O

Caspase	B
-	I
3	I
activation	O
,	O
usually	O
resulting	O
from	O
delta	O
psi	O
(	O
m	O
)	O
collapse	O
,	O
was	O
not	O
always	O
associated	O
with	O
As2O3	O
-	O
induced	O
apoptosis	O
.	O

As2O3	O
induced	O
PML	O
(	O
promyelocytic	O
leukemia	O
)	O
protein	O
degradation	O
but	O
did	O
not	O
modulate	O
expression	O
of	O
cell	B
cycle	I
-	I
related	I
proteins	I
,	O
including	O
c	B
-	I
myc	I
,	O
retinoblastoma	B
protein	I
,	O
cyclin	B
-	I
dependent	I
kinase	I
4	I
,	O
cyclin	B
D1	I
,	O
and	O
p53	B
,	O
or	O
expression	O
of	O
differentiation	B
-	I
related	I
antigens	I
.	O

A20	O
can	O
be	O
regulated	O
by	O
the	O
NF	B
-	I
kappaB	I
transcription	B
factor	I
,	O
which	O
is	O
known	O
to	O
be	O
activated	O
by	O
the	O
EBV	B
LMP	I
-	I
1	I
protein	I
.	O

CTLA	B
-	I
4	I
ligation	O
inhibited	O
CD3	O
/	O
CD28	B
-	O
induced	O
IL	B
-	I
2	I
mRNA	I
accumulation	O
by	O
inhibiting	O
IL	B
-	I
2	I
transcription	O
,	O
which	O
appears	O
to	O
be	O
mediated	O
in	O
part	O
through	O
decreasing	O
NF	B
-	I
AT	I
accumulation	O
in	O
the	O
nuclei	O
.	O

Further	O
,	O
CTLA	B
-	I
4	I
engagement	O
inhibited	O
progression	O
through	O
the	O
cell	O
cycle	O
by	O
inhibiting	O
the	O
production	O
of	O
cyclin	B
D3	I
,	O
cyclin	B
-	I
dependent	I
kinase	I
(	B
cdk	I
)	I
4	I
,	O
and	O
cdk6	B
when	O
the	O
T	O
cells	O
were	O
stimulated	O
with	O
anti	B
-	I
CD3	I
/	I
CD28	I
and	O
with	O
anti	B
-	I
CD3	I
alone	O
.	O

Dexamethasone	O
(	O
Dex	O
)	O
,	O
a	O
synthetic	O
glucocorticoid	O
hormone	O
,	O
cooperated	O
with	O
Epo	B
and	O
stem	B
cell	I
factor	I
to	O
induce	O
erythroid	O
progenitors	O
to	O
undergo	O
15	O
to	O
22	O
cell	O
divisions	O
,	O
corresponding	O
to	O
a	O
10	O
(	O
5	O
)	O
-	O
to	O
10	O
(	O
6	O
)	O
-	O
fold	O
amplification	O
of	O
erythroid	O
cells	O
.	O

Sustained	O
proliferation	O
of	O
erythroid	O
progenitors	O
could	O
be	O
induced	O
equally	O
well	O
from	O
purified	O
erythroid	O
burst	O
-	O
forming	O
units	O
(	O
BFU	O
-	O
E	O
)	O
,	O
from	O
CD34	O
(	O
+	O
)	O
blast	O
cells	O
,	O
and	O
from	O
bone	O
marrow	O
depleted	O
from	O
CD34	O
(	O
+	O
)	O
cells	O
.	O

We	O
conclude	O
that	O
NF	B
-	I
kappaB	I
is	O
a	O
context	O
-	O
dependent	O
apoptosis	O
regulator	O
.	O

SOCS	B
-	I
3	I
protein	O
was	O
detectable	O
as	O
early	O
as	O
30	O
min	O
following	O
IL	B
-	I
2	I
stimulation	O
,	O
while	O
CIS	B
was	O
seen	O
only	O
at	O
low	O
levels	O
after	O
2	O
h	O
.	O

Tyrosine	O
phosphorylation	O
of	O
SOCS	B
-	I
3	I
was	O
observed	O
upon	O
coexpression	O
with	O
Jak1	B
and	O
Jak2	B
but	O
only	O
weakly	O
with	O
Jak3	B
.	O

Finally	O
,	O
proliferation	O
induced	O
by	O
both	O
IL	B
-	I
2	I
-	O
and	O
IL	B
-	I
3	I
was	O
significantly	O
inhibited	O
in	O
the	O
presence	O
of	O
SOCS	B
-	I
3	I
.	O

There	O
was	O
,	O
however	O
,	O
a	O
significant	O
difference	O
in	O
the	O
amounts	O
of	O
the	O
nuclear	B
protein	I
,	O
REF	B
-	I
1	I
(	O
which	O
regulates	O
AP	B
-	I
1	I
DNA	O
binding	O
by	O
altering	O
the	O
redox	O
status	O
of	O
FOS	B
and	O
JUN	B
proteins	I
)	O
,	O
in	O
alveolar	O
macrophages	O
compared	O
with	O
monocytes	O
.	O

Finally	O
,	O
addition	O
of	O
REF	B
-	I
1	I
from	O
activated	O
monocytes	O
to	O
alveolar	O
macrophage	O
nuclear	O
proteins	O
resulted	O
in	O
a	O
marked	O
increase	O
in	O
AP	B
-	I
1	I
DNA	O
binding	O
.	O

Studies	O
over	O
the	O
past	O
few	O
years	O
have	O
identified	O
lymphotoxin	O
as	O
a	O
critical	O
signaling	O
molecule	O
not	O
only	O
for	O
the	O
organogenesis	O
of	O
secondary	O
lymphoid	O
tissues	O
but	O
for	O
the	O
maintenance	O
of	O
aspects	O
of	O
their	O
microarchitecture	O
as	O
well	O
.	O

This	O
review	O
focuses	O
on	O
studies	O
defining	O
recently	O
identified	O
crucial	O
signals	O
for	O
the	O
biogenesis	O
of	O
secondary	O
lymphoid	O
organs	O
and	O
for	O
the	O
maintenance	O
of	O
their	O
proper	O
microarchitecture	O
.	O

The	O
costimulatory	B
molecule	I
CD28	B
has	O
a	O
restricted	O
tissue	O
distribution	O
and	O
is	O
expressed	O
on	O
T	O
cells	O
and	O
some	O
plasmacytoma	O
cells	O
.	O

In	O
vivo	O
,	O
CD8	O
+	O
T	O
cells	O
and	O
,	O
less	O
frequently	O
,	O
CD4	O
+	O
T	O
cells	O
may	O
completely	O
lose	O
CD28	B
surface	O
expression	O
during	O
chronic	O
infections	O
and	O
with	O
aging	O
.	O

Both	O
alpha	O
-	O
and	O
beta	O
-	O
bound	O
complexes	O
are	O
found	O
only	O
in	O
lymphoid	O
tissues	O
,	O
in	O
CD28	O
+	O
T	O
cells	O
,	O
and	O
in	O
some	O
transformed	O
B	O
cells	O
.	O

A	O
role	O
for	O
RanBP1	B
in	O
the	O
release	O
of	O
CRM1	B
from	O
the	O
nuclear	B
pore	I
complex	I
in	O
a	O
terminal	O
step	O
of	O
nuclear	O
export	O
.	O

It	O
also	O
stimulates	O
nuclear	O
export	O
in	O
cells	O
that	O
have	O
not	O
been	O
preincubated	O
with	O
RanQ69L	B
.	O

In	O
a	O
model	O
where	O
foreign	O
cells	O
(	O
rat	O
fibroblasts	O
)	O
were	O
cocultured	O
with	O
human	O
IL	O
-	O
2	O
activated	O
NK	O
cells	O
,	O
we	O
observed	O
that	O
NK	O
cells	O
were	O
capable	O
of	O
efficiently	O
killing	O
their	O
targets	O
only	O
if	O
the	O
cells	O
overexpressed	O
the	O
oncogene	O
c	B
-	I
Myc	I
or	O
E1A	B
.	O

These	O
results	O
provided	O
evidence	O
that	O
c	B
-	I
Myc	I
and	O
E1A	B
activated	O
the	O
NK	O
cell	O
induced	O
cytolysis	O
at	O
a	O
post	O
-	O
triggering	O
stage	O
of	O
NK	O
cell	O
-	O
target	O
cell	O
interaction	O
.	O

Unicellular	O
-	O
unilineage	O
erythropoietic	O
cultures	O
:	O
molecular	O
analysis	O
of	O
regulatory	O
gene	O
expression	O
at	O
sibling	O
cell	O
level	O
.	O

In	O
the	O
culture	O
system	O
reported	O
here	O
,	O
(	O
1	O
)	O
the	O
growth	B
factor	I
(	O
GF	B
)	O
stimulus	O
induces	O
cord	O
blood	O
(	O
CB	O
)	O
progenitor	O
cells	O
to	O
proliferate	O
and	O
differentiate	O
/	O
mature	O
exclusively	O
along	O
the	O
erythroid	O
lineage	O
;	O
(	O
2	O
)	O
this	O
erythropoietic	O
wave	O
is	O
characterized	O
by	O
less	O
than	O
4	O
%	O
apoptotic	O
cells	O
;	O
(	O
3	O
)	O
asymmetric	O
divisions	O
are	O
virtually	O
absent	O
,	O
ie	O
,	O
nonresponsive	O
hematopoietic	O
progenitors	O
with	O
no	O
erythropoietic	O
potential	O
are	O
forced	O
into	O
apoptosis	O
;	O
(	O
4	O
)	O
the	O
system	O
is	O
cell	O
division	O
controlled	O
(	O
cdc	O
)	O
,	O
ie	O
,	O
the	O
number	O
of	O
divisions	O
performed	O
by	O
each	O
cell	O
is	O
monitored	O
.	O

Single	O
-	O
cell	O
reverse	B
transcriptase	I
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
analysis	O
was	O
applied	O
to	O
this	O
culture	O
system	O
to	O
investigate	O
gene	O
expression	O
of	O
diverse	O
receptors	B
,	O
markers	B
of	I
differentiation	I
,	O
and	O
transcription	B
factors	I
(	O
EKLF	B
,	O
GATA	B
-	I
1	I
,	O
GATA	B
-	I
2	I
,	O
p45	B
NF	I
-	I
E2	I
,	O
PU	B
.	I
1	I
,	O
and	O
SCL	B
/	I
Tal1	I
)	O
at	O
discrete	O
stages	O
of	O
erythropoietic	O
development	O
.	O

However	O
,	O
stimulation	O
with	O
IL	B
-	I
2	I
resulted	O
in	O
Jak3	B
and	O
STAT5	B
phosphorylation	O
in	O
both	O
leukemic	O
ATLL	O
cells	O
and	O
IL	O
-	O
2	O
-	O
dependent	O
lines	O
.	O

A	O
skewed	O
XCI	O
pattern	O
with	O
greater	O
than	O
75	O
%	O
amplification	O
of	O
1	O
allele	B
(	O
allele	B
ratio	O
>	O
3	O
:	O
1	O
)	O
was	O
found	O
in	O
22	O
(	O
9	O
.	O
1	O
%	O
)	O
of	O
242	O
control	O
subjects	O
.	O

Although	O
statistical	O
evaluation	O
of	O
the	O
data	O
showed	O
a	O
significant	O
difference	O
between	O
patients	O
with	O
a	O
chronic	O
MPD	O
and	O
control	O
subjects	O
,	O
proof	O
of	O
clonality	O
in	O
individual	O
,	O
especially	O
elderly	O
,	O
patients	O
is	O
difficult	O
.	O

Here	O
we	O
report	O
that	O
in	O
erythroid	O
cells	O
,	O
GATA	B
-	I
1	I
strongly	O
induces	O
the	O
expression	O
of	O
the	O
anti	B
-	I
apoptotic	I
protein	I
bcl	B
-	I
xL	I
,	O
but	O
not	O
the	O
related	O
proteins	O
bcl	B
-	I
2	I
and	O
mcl	B
-	I
1	I
.	O

In	O
T	O
lymphocytes	O
,	O
the	O
hematopoietic	B
cytokine	I
interleukin	B
-	I
2	I
(	O
IL	B
-	I
2	I
)	O
uses	O
phosphatidylinositol	B
3	I
-	I
kinase	I
(	O
PI	B
3	I
-	I
kinase	I
)	O
-	O
induced	O
signaling	O
pathways	O
to	O
regulate	O
E2F	B
transcriptional	O
activity	O
,	O
a	O
critical	O
cell	O
cycle	O
checkpoint	O
.	O

PI	B
3	I
-	I
kinase	I
also	O
regulates	O
the	O
activity	O
of	O
p70	B
(	I
s6k	I
)	I
,	O
the	O
40S	B
ribosomal	I
protein	I
S6	I
kinase	I
,	O
a	O
response	O
that	O
is	O
abrogated	O
by	O
the	O
macrolide	O
rapamycin	O
.	O

Moreover	O
,	O
the	O
effects	O
of	O
rapamycin	O
on	O
,	O
and	O
the	O
role	O
of	O
p70	B
(	I
s6k	I
)	I
in	O
,	O
IL	B
-	I
2	I
and	O
PI	B
3	I
-	I
kinase	I
activation	O
of	O
E2Fs	B
have	O
not	O
been	O
characterized	O
.	O

Our	O
present	O
results	O
show	O
that	O
IL	B
-	I
2	I
-	O
and	O
PI	B
3	I
-	I
kinase	I
-	O
induced	O
pathways	O
for	O
the	O
regulation	O
of	O
E2F	B
transcriptional	O
activity	O
include	O
both	O
rapamycin	O
-	O
resistant	O
and	O
rapamycin	O
-	O
sensitive	O
components	O
.	O

Thus	O
,	O
the	O
rapamycin	O
-	O
controlled	O
processes	O
involved	O
in	O
E2F	B
regulation	O
appear	O
to	O
be	O
mediated	O
by	O
p70	B
(	I
s6k	I
)	I
.	O

Since	O
1988	O
,	O
several	O
families	O
of	O
functionally	O
important	O
T	B
cell	I
transcription	I
factors	I
have	O
been	O
identified	O
.	O

These	O
include	O
the	O
Ikaros	B
,	O
LKLF	B
,	O
and	O
GATA3	B
zinc	I
-	I
finger	I
proteins	I
;	O
the	O
Ets	B
,	O
CREB	B
/	I
ATF	I
,	O
and	O
NF	B
-	I
kappa	I
B	I
/	I
Rel	I
/	I
NFAT	I
transcription	I
factors	I
;	O
the	O
Stat	B
proteins	I
;	O
and	O
HMG	B
box	I
transcription	I
factors	I
such	O
as	O
LEF1	B
,	O
TCF1	B
,	O
and	O
Sox4	B
.	O

The	O
proliferative	O
deficiency	O
of	O
the	O
transgenic	O
T	O
cells	O
was	O
associated	O
with	O
an	O
increased	O
apoptosis	O
.	O

Paradoxical	O
priming	O
effects	O
of	O
IL	B
-	I
10	I
on	O
cytokine	B
production	O
.	O

Interestingly	O
,	O
an	O
enhanced	O
frequency	O
of	O
CD16	B
and	O
CD68	O
(	O
+	O
)	O
cells	O
among	O
the	O
CD14	O
(	O
+	O
)	O
cells	O
was	O
observed	O
in	O
the	O
presence	O
of	O
IL	B
-	I
10	I
,	O
independently	O
of	O
the	O
pre	O
-	O
culture	O
conditions	O
of	O
the	O
PBMC	O
.	O

Transcription	B
factors	I
Sp1	B
and	O
AP	B
-	I
2	I
mediate	O
induction	O
of	O
acid	B
sphingomyelinase	I
during	O
monocytic	O
differentiation	O
.	O

Cells	O
from	O
the	O
human	O
monocytic	O
leukemia	O
cell	O
line	O
THP	O
-	O
1	O
differentiate	O
towards	O
a	O
macrophage	O
-	O
like	O
phenotype	O
when	O
stimulated	O
with	O
phorbol	O
12	O
-	O
myristate	O
-	O
13	O
-	O
acetate	O
(	O
PMA	O
)	O
,	O
1	O
,	O
25	O
-	O
dihydroxy	O
-	O
vitamin	O
D3	O
,	O
and	O
various	O
other	O
agents	O
.	O

A	O
PMA	B
responsive	I
element	I
was	O
localized	O
to	O
a	O
region	O
between	O
-	B
319	I
and	I
-	I
219	I
bp	I
upstream	I
of	O
the	O
initiation	O
codon	O
and	O
co	O
-	O
transfections	O
with	O
transcription	B
factor	I
expression	I
plasmids	I
for	O
AP	B
-	I
2	I
and	O
Sp1	B
resulted	O
in	O
augmented	O
ASM	O
promoter	O
activity	O
,	O
which	O
was	O
abolished	O
when	O
the	O
binding	B
sites	I
for	O
these	O
two	O
factors	O
were	O
deleted	O
.	O

However	O
,	O
the	O
intensity	O
of	O
the	O
complex	O
formed	O
appeared	O
to	O
increase	O
when	O
nuclear	O
extracts	O
from	O
PMA	O
-	O
treated	O
cells	O
were	O
used	O
.	O

NF	B
-	I
kappaB	I
DNA	O
binding	O
was	O
evaluated	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O

Direct	O
activation	O
of	O
PKC	B
with	O
PMA	O
induced	O
both	O
NF	B
-	I
kappaB	I
activation	O
and	O
TNF	B
-	I
alpha	I
production	O
by	O
human	O
monocytes	O
.	O

Furthermore	O
,	O
our	O
results	O
provide	O
evidence	O
that	O
PTK	B
plays	O
a	O
role	O
in	O
LPS	O
-	O
induced	O
NF	B
-	I
kappaB	I
activation	O
and	O
TNF	B
-	I
alpha	I
release	O
in	O
human	O
monocytes	O
and	O
thus	O
could	O
be	O
a	O
potential	O
therapeutic	O
target	O
in	O
inflammatory	O
states	O
.	O

The	O
effects	O
of	O
GDSP	O
on	O
pancreatic	O
weight	O
,	O
serum	B
amylase	I
and	I
lipase	I
,	O
morphologic	O
changes	O
in	O
the	O
pancreas	O
,	O
neutrophil	O
infiltration	O
,	O
and	O
nuclear	B
factor	I
KB	I
(	O
NF	B
-	I
KB	I
)	O
activation	O
were	O
measured	O
in	O
rats	O
infused	O
with	O
supramaximal	O
dose	O
of	O
cerulein	O
(	O
5	O
(	O
g	O
/	O
kg	O
/	O
h	O
)	O
for	O
6	O
h	O
.	O

Elastatinal	O
had	O
some	O
of	O
the	O
same	O
effects	O
as	O
GDSP	O
but	O
was	O
less	O
potent	O
and	O
effective	O
.	O

The	O
nature	O
of	O
the	O
nuclear	B
factor	I
(	O
s	O
)	O
that	O
control	O
TNF	B
-	I
alpha	I
gene	O
transcription	O
in	O
humans	O
remains	O
obscure	O
,	O
although	O
NF	B
-	I
kappaB	I
has	O
been	O
suggested	O
.	O

Our	O
previous	O
studies	O
pertaining	O
to	O
macrophage	O
response	O
to	O
LPS	O
identified	O
a	O
novel	O
DNA	B
-	I
binding	I
domain	I
located	O
from	O
-	O
550	O
to	O
-	O
487	O
in	O
the	O
human	B
TNF	I
-	I
alpha	I
promoter	I
that	O
contains	O
transcriptional	O
activity	O
,	O
but	O
lacks	O
any	O
known	O
NF	B
-	I
kappaB	I
-	B
binding	I
sites	I
.	O

Inhibition	O
of	O
LITAF	B
mRNA	I
expression	O
in	O
THP	O
-	O
1	O
cells	O
resulted	O
in	O
a	O
reduction	O
of	O
TNF	B
-	I
alpha	I
transcripts	O
.	O

In	O
addition	O
,	O
high	O
level	O
of	O
expression	O
of	O
LITAF	B
mRNA	I
was	O
observed	O
predominantly	O
in	O
the	O
placenta	O
,	O
peripheral	O
blood	O
leukocytes	O
,	O
lymph	O
nodes	O
,	O
and	O
the	O
spleen	O
.	O

A	O
human	B
IFNGR1	I
small	I
deletion	I
hotspot	I
associated	O
with	O
dominant	O
susceptibility	O
to	O
mycobacterial	O
infection	O
[	O
see	O
comments	O
]	O

Characterization	O
of	O
expression	O
of	O
the	O
gene	O
for	O
human	B
pterin	I
carbinolamine	I
dehydratase	I
/	I
dimerization	I
cofactor	I
of	O
HNF1	B
.	O

In	O
the	O
nucleus	O
,	O
it	O
functions	O
as	O
a	O
dimerization	B
cofactor	I
of	O
HNF1	B
and	O
increases	O
the	O
transcriptional	O
activity	O
of	O
HNF1	B
.	O

Transfection	O
of	O
Jurkat	O
cells	O
with	O
the	O
NF	B
-	I
kappaB	I
subunits	I
p50	B
and	O
p65	B
confers	O
resistance	O
against	O
Fas	O
-	O
mediated	O
apoptosis	O
.	O

Capacitance	O
would	O
simply	O
involve	O
expression	O
of	O
IL	B
-	I
12R	I
beta	I
1	I
and	I
beta	I
2	I
subunits	I
,	O
regulated	O
by	O
TCR	O
,	O
IL	B
-	I
4	I
and	O
IFNs	B
.	O

The	O
activation	O
of	O
STAT3	B
was	O
not	O
found	O
in	O
human	O
eosinophils	O
,	O
monocytes	O
,	O
and	O
HL	O
-	O
60	O
cells	O
,	O
although	O
the	O
STAT3	B
protein	I
was	O
expressed	O
in	O
these	O
cells	O
.	O

The	O
transcription	B
factor	I
NF	B
-	I
ATc	I
is	O
synthesized	O
in	O
three	O
prominent	O
isoforms	B
.	O

These	O
differ	O
in	O
the	O
length	O
of	O
their	O
C	O
terminal	O
peptides	O
and	O
mode	O
of	O
synthesis	O
.	O

Together	O
,	O
these	O
results	O
demonstrate	O
that	O
ER	B
and	O
PR	B
can	O
be	O
activated	O
by	O
endogenous	O
or	O
exogenous	O
ligands	O
to	O
induce	O
a	O
genetic	O
response	O
that	O
impairs	O
TNF	B
-	I
alpha	I
-	O
induced	O
apoptosis	O
in	O
U937	O
cells	O
.	O

Retinoidal	O
antagonists	O
and	O
potential	O
agonists	O
.	O

Inhibition	O
of	O
T	O
cell	O
signaling	O
by	O
mitogen	B
-	I
activated	I
protein	I
kinase	I
-	I
targeted	I
hematopoietic	I
tyrosine	I
phosphatase	I
(	O
HePTP	B
)	O
.	O

Activation	O
of	O
T	O
lymphocytes	O
to	O
produce	O
cytokines	B
is	O
regulated	O
by	O
the	O
counterbalance	O
of	O
protein	B
-	I
tyrosine	I
kinases	I
and	O
protein	O
-	O
tyrosine	O
phosphatases	O
,	O
many	O
of	O
which	O
have	O
a	O
high	O
degree	O
of	O
substrate	O
specificity	O
because	O
of	O
physical	O
association	O
with	O
their	O
targets	O
.	O

In	O
contrast	O
,	O
HePTP	B
had	O
no	O
effects	O
on	O
N	B
-	I
terminal	I
c	I
-	I
Jun	I
kinase	I
or	O
on	O
events	O
upstream	O
of	O
the	O
MAP	O
kinases	O
.	O

However	O
,	O
p38	B
MAPK	I
is	O
activated	O
strongly	O
and	O
synergistically	O
by	O
either	O
CD3	B
/	I
CD28	I
coligation	O
or	O
PMA	O
/	O
Ca2	O
+	O
ionophore	O
stimulation	O
,	O
which	O
mimics	O
TCR	B
-	O
CD3	B
/	I
CD28	I
-	O
mediated	O
signaling	O
.	O

We	O
have	O
compared	O
the	O
effects	O
of	O
Epo	B
and	O
the	O
chemical	O
inducers	O
,	O
delta	O
-	O
aminolaevulinic	O
acid	O
(	O
delta	O
-	O
ALA	O
)	O
and	O
haemin	O
on	O
the	O
differentiation	O
capacity	O
of	O
UT	O
-	O
7	O
cells	O
.	O

Epo	B
alone	O
promoted	O
relatively	O
early	O
events	O
in	O
erythroid	O
maturation	O
,	O
without	O
significant	O
changes	O
in	O
haemoglobin	O
production	O
or	O
morphology	O
.	O

Epo	B
caused	O
an	O
increase	O
in	O
the	O
proportion	O
of	O
cells	O
expressing	O
cell	O
surface	O
glycophorin	B
A	I
(	O
GPA	B
)	O
and	O
up	O
-	O
regulated	O
beta	B
-	I
and	I
gamma	I
-	I
globin	I
by	O
several	O
fold	O
.	O

There	O
is	O
little	O
direct	O
evidence	O
regarding	O
the	O
role	O
of	O
alveolar	O
macrophages	O
in	O
these	O
activation	O
events	O
.	O

These	O
data	O
suggest	O
that	O
,	O
in	O
this	O
inflammatory	O
model	O
,	O
initial	O
activation	O
of	O
NF	B
-	I
kappaB	I
occurs	O
in	O
alveolar	O
macrophages	O
and	O
the	O
ensuing	O
production	O
of	O
TNF	B
-	I
alpha	I
may	O
propagate	O
NF	B
-	I
kappaB	I
activation	O
to	O
other	O
cell	O
types	O
in	O
the	O
lung	O
.	O

Interferon	B
-	I
beta	I
mediates	O
stromal	O
cell	O
rescue	O
of	O
T	O
cells	O
from	O
apoptosis	O
.	O

Interferon	B
-	I
alpha	I
and	I
-	I
beta	I
promote	O
the	O
reversion	O
of	O
blast	O
Tcells	O
to	O
a	O
resting	O
G0	O
/	O
G1	O
configuration	O
with	O
all	O
the	O
characteristic	O
features	O
of	O
stromal	O
cell	O
rescue	O
;	O
such	O
as	O
high	O
Bcl	B
-	I
XL	I
expression	O
and	O
low	O
Bcl	B
-	I
2	I
.	O

We	O
also	O
show	O
that	O
DFX	O
treatment	O
limits	O
the	O
in	O
vivo	O
activation	O
of	O
NF	B
-	I
kappaB	I
,	O
a	O
transcription	B
factor	I
involved	O
in	O
both	O
TNF	B
-	I
alpha	I
gene	O
transcription	O
and	O
TNF	B
-	I
alpha	I
signalling	O
(	O
P	O
<	O
0	O
.	O
005	O
)	O
.	O

In	O
this	O
study	O
,	O
the	O
influence	O
of	O
the	O
sequences	O
located	O
between	B
-	I
3134	I
and	I
-	I
2987	I
on	O
the	O
transcriptional	O
activity	O
of	O
the	O
proIL	B
-	I
1beta	I
gene	I
in	O
LPS	O
-	O
stimulated	O
Raw	O
264	O
.	O
7	O
cells	O
was	O
examined	O
in	O
detail	O
.	O

These	O
specific	O
bindings	O
were	O
time	O
and	O
LPS	O
dose	O
dependent	O
.	O

These	O
data	O
indicated	O
that	O
two	O
NF	B
-	I
kappaB	I
-	I
binding	I
sites	I
,	O
which	O
are	O
located	O
between	O
-	B
3134	I
and	I
-	I
3059	I
,	O
are	O
critical	O
for	O
the	O
activation	O
of	O
proIL	B
-	I
1beta	I
gene	I
transcription	O
.	O

N	O
-	O
acetyl	O
-	O
L	O
-	O
cysteine	O
inhibits	O
primary	O
human	O
T	O
cell	O
responses	O
at	O
the	O
dendritic	O
cell	O
level	O
:	O
association	O
with	O
NF	B
-	I
kappaB	I
inhibition	O
.	O

Altogether	O
,	O
our	O
results	O
suggest	O
that	O
NAC	O
might	O
impair	O
the	O
generation	O
of	O
primary	O
immune	O
responses	O
in	O
humans	O
through	O
its	O
inhibitory	O
action	O
on	O
DC	O
.	O

Gel	O
supershift	O
assays	O
demonstrated	O
that	O
thrombin	B
induced	O
binding	O
of	O
NF	B
-	I
kappa	I
Bp65	I
(	O
Rel	B
A	I
)	O
to	O
downstream	O
NF	B
-	I
kappa	I
B	I
site	I
of	O
the	O
ICAM	B
-	I
1	I
promoter	I
.	O

Thrombin	B
receptor	O
activation	O
peptide	O
,	O
a	O
14	O
-	O
amino	O
-	O
acid	O
peptide	O
representing	O
the	O
new	O
NH2	B
terminus	I
of	O
proteolytically	O
activated	O
receptor	B
-	I
1	I
,	O
mimicked	O
thrombin	B
'	O
s	O
action	O
in	O
inducing	O
ICAM	B
-	I
1	I
expression	O
.	O

These	O
data	O
indicate	O
that	O
thrombin	B
activates	O
endothelial	O
ICAM	B
-	I
1	I
expression	O
and	O
polymorphonuclear	O
leukocyte	O
adhesion	O
by	O
NF	B
-	I
kappa	I
Bp65	I
binding	O
to	O
the	O
downstream	O
NF	B
-	I
kappa	I
B	I
site	I
of	O
ICAM	B
-	I
1	I
promoter	I
after	O
proteolytically	O
activated	O
receptor	O
-	O
1	O
activation	O
.	O

Here	O
we	O
demonstrate	O
that	O
both	O
Smad6	B
and	O
Smad7	B
are	O
human	B
bone	I
morphogenetic	I
protein	I
-	I
2	I
(	O
hBMP	B
-	I
2	I
)	O
-	O
inducible	O
antagonists	O
of	O
hBMP	B
-	I
2	I
-	O
induced	O
growth	O
arrest	O
and	O
apoptosis	O
in	O
mouse	O
B	O
cell	O
hybridoma	O
HS	O
-	O
72	O
cells	O
.	O

The	O
effect	O
was	O
dose	O
dependent	O
and	O
appeared	O
relatively	O
late	O
.	O

Significant	O
differences	O
were	O
observed	O
from	O
day	O
4	O
onward	O
.	O

RA	O
previously	O
was	O
found	O
to	O
inhibit	O
granulocyte	B
colony	I
-	I
stimulating	I
factor	I
-	O
-	O
and	O
not	O
granulocyte	B
-	I
macrophage	I
colony	I
-	I
stimulating	I
factor	I
-	O
-	O
stimulated	O
proliferation	O
of	O
CD34	O
+	O
cells	O
.	O

Interestingly	O
,	O
CyA	O
and	O
indomethacin	O
did	O
not	O
suppress	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
(	O
TNF	B
-	I
alpha	I
)	O
-	O
induced	O
adhesion	O
molecule	O
expression	O
on	O
HUVECs	O
,	O
whereas	O
aspirin	O
had	O
an	O
inhibitory	O
effect	O
.	O

CONCLUSION	O
:	O
Our	O
results	O
show	O
that	O
the	O
tested	O
agents	O
(	O
except	O
indomethacin	O
)	O
are	O
inhibitors	O
of	O
the	O
T	O
cell	O
-	O
mediated	O
immune	O
response	O
,	O
as	O
expected	O
,	O
that	O
aspirin	O
is	O
an	O
effective	O
suppressor	O
of	O
adhesion	B
molecule	I
expression	O
,	O
and	O
that	O
all	O
three	O
agents	O
can	O
induce	O
Hsp60	B
in	O
HUVECs	O
.	O

METHODS	O
:	O
Ten	O
atopic	O
asthmatic	O
subjects	O
were	O
treated	O
with	O
FP	O
250	O
microg	O
twice	O
daily	O
for	O
4	O
weeks	O
.	O

In	O
addition	O
,	O
a	O
24	O
-	O
hour	O
urinary	O
cortisol	O
excretion	O
and	O
an	O
adrenocorticotropic	O
hormone	O
test	O
before	O
and	O
after	O
treatment	O
with	O
FP	O
were	O
performed	O
.	O

However	O
,	O
we	O
detected	O
a	O
significant	O
reduction	O
of	O
the	O
GR	B
mRNA	I
levels	O
in	O
the	O
endobronchial	O
biopsy	O
specimens	O
after	O
FP	O
treatment	O
(	O
36	O
.	O
6	O
+	O
/	O
-	O
23	O
.	O
1	O
and	O
25	O
.	O
0	O
+	O
/	O
-	O
10	O
.	O
9	O
amol	O
GR	B
mRNA	I
/	O
microg	O
RNA	O
,	O
respectively	O
;	O
P	O
<	O
.	O
01	O
)	O
.	O

In	O
the	O
peripheral	O
blood	O
lymphocytes	O
an	O
even	O
more	O
striking	O
downregulation	O
of	O
the	O
GR	O
by	O
its	O
cognate	O
ligand	O
was	O
documented	O
(	O
30	O
.	O
3	O
+	O
/	O
-	O
26	O
.	O
5	O
and	O
8	O
.	O
8	O
+	O
/	O
-	O
5	O
amol	O
GR	B
mRNA	I
/	O
microg	O
RNA	O
,	O
respectively	O
;	O
P	O
<	O
.	O
001	O
)	O
,	O
possibly	O
reflecting	O
differences	O
in	O
glucocorticoid	O
sensitivity	O
between	O
tissues	O
.	O

Inflammation	O
is	O
constantly	O
observed	O
in	O
allergic	O
reactions	O
.	O

The	O
action	O
of	O
glucocorticosteroids	O
is	O
mediated	O
through	O
glucocorticoid	B
receptors	I
present	O
in	O
the	O
cellular	O
cytoplasm	O
.	O

Interaction	O
to	O
DNA	O
induces	O
changes	O
in	O
the	O
transcription	O
rate	O
,	O
leading	O
to	O
either	O
gene	O
induction	O
or	O
gene	O
repression	O
.	O

RESULTS	O
:	O
Phorbol	O
-	O
myristate	O
-	O
acetate	O
and	O
ionomycine	O
strongly	O
increase	O
the	O
percent	O
-	O
age	O
of	O
IL	O
-	O
2	O
+	O
cells	O
;	O
an	O
additional	O
50	O
%	O
HCSs	O
significantly	O
suppresses	O
the	O
percentage	O
to	O
,	O
or	O
below	O
the	O
level	O
of	O
unstimulated	O
cells	O
.	O

50	O
%	O
HCS	O
downregulates	O
the	O
alpha	B
-	I
chain	I
and	O
slightly	O
upregulates	O
the	O
beta	B
-	I
chain	I
.	O

Inhibition	O
of	O
IL	B
-	I
4	I
-	O
inducible	O
gene	O
expression	O
in	O
human	O
monocytes	O
by	O
type	B
I	I
and	I
type	I
II	I
interferons	I
.	O

However	O
,	O
the	O
mechanism	O
by	O
which	O
IFNs	B
mediate	O
this	O
inhibition	O
has	O
not	O
been	O
defined	O
.	O

Because	O
STAT6	B
activation	O
plays	O
an	O
essential	O
role	O
in	O
IL	B
-	I
4	I
/	O
IL	B
-	I
13	I
-	O
induced	O
gene	O
expression	O
,	O
the	O
ability	O
of	O
IFN	B
-	I
beta	I
and	O
IFN	B
-	I
gamma	I
to	O
inhibit	O
STAT6	B
activity	O
provides	O
an	O
explanation	O
for	O
how	O
IFNs	B
can	O
suppress	O
IL	B
-	I
4	I
/	O
IL	B
-	I
13	I
-	O
inducible	O
gene	O
expression	O
.	O

HLA	B
class	I
I	I
Ags	I
have	O
been	O
implicated	O
to	O
play	O
a	O
major	O
role	O
in	O
this	O
process	O
,	O
since	O
signaling	O
via	O
HLA	B
class	I
I	I
molecules	I
can	O
induce	O
the	O
proliferation	O
of	O
aortic	O
endothelial	O
as	O
well	O
as	O
smooth	O
muscle	O
cells	O
.	O

A	O
cdk2	O
inhibitor	O
,	O
Olomoucine	O
,	O
as	O
well	O
as	O
a	O
dominant	B
-	I
negative	I
cdk2	I
construct	I
prevented	O
HLA	B
class	I
I	I
-	O
mediated	O
inactivation	O
of	O
Rb	B
;	O
in	O
contrast	O
,	O
dominant	B
-	I
negative	I
cdk4	I
and	I
cdk6	I
constructs	I
had	O
no	O
effect	O
.	O

PG490	O
inhibits	O
interleukin	B
(	I
IL	I
)	I
-	I
2	I
expression	O
by	O
normal	O
human	O
peripheral	O
blood	O
lymphocytes	O
stimulated	O
with	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
(	O
PMA	O
)	O
and	O
antibody	O
to	O
CD3	B
(	O
IC50	O
of	O
10	O
ng	O
/	O
ml	O
)	O
,	O
and	O
with	O
PMA	O
and	O
ionomycin	O
(	O
Iono	O
,	O
IC50	O
of	O
40	O
ng	O
/	O
ml	O
)	O
.	O

In	O
Jurkat	O
T	O
-	O
cells	O
,	O
PG490	O
inhibits	O
PMA	O
/	O
Iono	O
-	O
stimulated	O
IL	B
-	I
2	I
transcription	O
.	O

PG490	O
can	O
completely	O
inhibit	O
transcriptional	O
activation	O
at	O
the	O
purine	B
-	I
box	I
/	I
ARRE	I
/	I
NF	I
-	I
AT	I
and	I
NF	I
-	I
kappaB	I
target	I
DNA	I
sequences	I
triggered	O
by	O
all	O
stimuli	O
examined	O
(	O
PMA	O
,	O
PMA	O
/	O
Iono	O
,	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
)	O
.	O

PG490	O
also	O
inhibits	O
PMA	O
-	O
stimulated	O
activation	O
of	O
a	O
chimeric	B
transcription	I
factor	I
in	O
which	O
the	O
C	B
-	I
terminal	I
TA1	I
transactivation	I
domain	I
of	O
NF	B
-	I
kappaB	I
p65	I
is	O
fused	O
to	O
the	O
DNA	B
binding	I
domain	I
of	O
GAL4	B
.	O

Unexpected	O
and	O
coordinated	O
expression	O
of	O
Spi	B
-	I
1	I
,	O
Fli	B
-	I
1	I
,	O
and	O
megakaryocytic	B
genes	I
in	O
four	O
Epo	O
-	O
dependent	O
cell	O
lines	O
established	O
from	O
transgenic	O
mice	O
displaying	O
erythroid	O
-	O
specific	O
expression	O
of	O
a	O
thermosensitive	B
SV40	I
T	I
antigen	I
.	O

Most	O
erythroleukemic	O
cell	O
lines	O
established	O
in	O
vitro	O
coexpress	O
erythrocytic	B
and	I
megakaryocytic	I
markers	I
that	O
often	O
are	O
associated	O
with	O
expression	O
of	O
Spi	B
-	I
1	I
and	O
/	O
or	O
Fli	B
-	I
1	I
transcription	I
factors	I
known	O
as	O
transactivators	B
of	I
megakaryocyte	I
-	I
specific	I
promoters	I
.	O

In	O
the	O
present	O
study	O
,	O
we	O
examined	O
the	O
possibility	O
of	O
establishing	O
new	O
cell	O
lines	O
keeping	O
strictly	O
erythroid	O
-	O
specific	O
properties	O
in	O
vitro	O
through	O
the	O
targeted	O
and	O
conditional	O
immortalization	O
of	O
erythrocytic	O
progenitors	O
.	O

However	O
,	O
like	O
normal	O
Ter	O
119	O
erythroid	O
cells	O
,	O
these	O
Ter	O
119	O
positive	O
cells	O
from	O
transgenic	O
mice	O
still	O
expressed	O
high	O
levels	O
of	O
beta	B
-	I
globin	I
and	O
very	O
low	O
or	O
undetectable	O
glycoprotein	B
IIb	I
and	O
platelet	B
factor	I
4	I
megakaryocytic	I
transcripts	I
.	O

Taken	O
together	O
,	O
these	O
data	O
indicate	O
that	O
the	O
unexpected	O
expression	O
of	O
megakaryocytic	B
genes	I
is	O
a	O
specific	O
property	O
of	O
immortalized	O
cells	O
that	O
can	O
not	O
be	O
explained	O
only	O
by	O
enhanced	O
expression	O
of	O
Spi	B
-	I
1	I
and	I
/	I
or	I
Fli	I
-	I
1	I
genes	I
.	O

Fludarabine	O
-	O
induced	O
immunosuppression	O
is	O
associated	O
with	O
inhibition	O
of	O
STAT1	B
signaling	O
.	O

Fludarabine	O
is	O
a	O
nucleoside	O
analog	O
used	O
in	O
the	O
treatment	O
of	O
hematologic	O
malignancies	O
that	O
can	O
induce	O
severe	O
and	O
prolonged	O
immunosuppression	O
.	O

STAT1	B
,	O
which	O
is	O
activated	O
in	O
response	O
to	O
many	O
lymphocyte	B
-	I
activating	I
cytokines	I
including	O
the	O
interferons	B
,	O
is	O
essential	O
for	O
cell	O
-	O
mediated	O
immunity	O
,	O
as	O
the	O
absence	O
of	O
this	O
protein	O
is	O
associated	O
with	O
prominent	O
defects	O
in	O
the	O
ability	O
to	O
control	O
viral	O
infections	O
.	O

Here	O
we	O
show	O
that	O
fludarabine	O
,	O
but	O
not	O
the	O
immunosuppressant	O
cyclosporine	O
A	O
,	O
inhibits	O
the	O
cytokine	B
-	O
induced	O
activation	O
of	O
STAT1	B
and	O
STAT1	B
-	O
dependent	O
gene	O
transcription	O
in	O
normal	O
resting	O
or	O
activated	O
lymphocytes	O
.	O

Fludarabine	O
caused	O
a	O
specific	O
depletion	O
of	O
STAT1	B
protein	I
(	O
and	O
mRNA	O
)	O
but	O
not	O
of	O
other	O
STATs	B
.	O

This	O
loss	O
of	O
STAT1	B
was	O
also	O
seen	O
in	O
cells	O
from	O
patients	O
treated	O
with	O
fludarabine	O
in	O
vivo	O
.	O

Thus	O
,	O
STAT1	B
may	O
be	O
a	O
useful	O
target	O
in	O
the	O
development	O
of	O
new	O
immunosuppressive	O
and	O
antineoplastic	O
agents	O
.	O

Furthermore	O
,	O
it	O
demonstrates	O
that	O
aging	O
does	O
not	O
influence	O
the	O
sensitivity	O
of	O
this	O
phosphatase	B
.	O

Spi	B
-	I
C	I
,	O
a	O
novel	O
Ets	B
protein	I
that	O
is	O
temporally	O
regulated	O
during	O
B	O
lymphocyte	O
development	O
.	O

Spi	B
-	I
C	I
interacted	O
with	O
DNA	O
similarly	O
to	O
PU	B
.	I
1	I
as	O
judged	O
by	O
methylation	O
interference	O
,	O
band	O
-	O
shift	O
and	O
site	O
selection	O
analysis	O
,	O
and	O
activated	O
transcription	O
of	O
a	O
kappaY	B
element	I
reporter	I
gene	I
upon	O
co	O
-	O
transfection	O
of	O
HeLa	O
cells	O
.	O

Spi	B
-	I
C	I
RNA	I
was	O
expressed	O
in	O
mature	O
B	O
lymphocytes	O
and	O
at	O
lower	O
levels	O
in	O
macrophages	O
.	O

Under	O
these	O
conditions	O
,	O
dexamethasone	O
had	O
a	O
minimal	O
effect	O
on	O
cell	O
growth	O
,	O
elicited	O
little	O
internucleosomal	O
DNA	O
fragmentation	O
,	O
and	O
induced	O
no	O
cell	O
cycle	O
perturbation	O
.	O

Human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV	O
-	O
I	O
)	O
is	O
an	O
etiologic	O
agent	O
of	O
adult	O
T	O
-	O
cell	O
leukemia	O
(	O
ATL	O
)	O
.	O

The	O
viral	B
protein	I
Tax	B
induces	O
the	O
activation	O
and	O
nuclear	O
translocalization	O
of	O
transcription	B
factor	I
NF	B
-	I
kappaB	I
,	O
which	O
is	O
proposed	O
to	O
play	O
a	O
crucial	O
role	O
in	O
the	O
transformation	O
of	O
T	O
cells	O
by	O
HTLV	O
-	O
I	O
.	O

However	O
,	O
the	O
HTLV	B
-	I
I	I
genes	I
including	O
Tax	B
are	O
not	O
expressed	O
significantly	O
in	O
primary	O
leukemic	O
cells	O
from	O
ATL	O
patients	O
.	O

We	O
found	O
that	O
leukemic	O
cells	O
from	O
ATL	O
patients	O
,	O
like	O
HTLV	O
-	O
I	O
-	O
infected	O
T	O
-	O
cell	O
lines	O
,	O
display	O
constitutive	O
NF	B
-	I
kappaB	I
DNA	O
binding	O
activity	O
and	O
increased	O
degradation	O
of	O
IkappaBalpha	B
(	O
an	O
inhibitor	O
of	O
NF	B
-	I
kappaB	I
)	O
.	O

One	O
T	O
-	O
cell	O
line	O
derived	O
from	O
ATL	O
leukemic	O
cells	O
,	O
TL	O
-	O
Om1	O
,	O
displayed	O
constitutive	O
NF	B
-	I
kappaB	I
activity	O
,	O
as	O
well	O
as	O
enhanced	O
degradation	O
of	O
IkappaBalpha	B
,	O
despite	O
the	O
lack	O
of	O
detectable	O
Tax	B
expression	O
.	O

Interestingly	O
,	O
the	O
NF	B
-	I
kappaB	I
in	O
TL	O
-	O
Om1	O
consists	O
of	O
p50	B
/	I
p50	I
and	O
p50	B
/	I
p65	I
like	O
that	O
in	O
fresh	O
primary	O
leukemic	O
cells	O
.	O

The	O
most	O
characterized	O
pathway	O
is	O
via	O
JAK	B
-	B
STAT	I
signaling	O
.	O

Therefore	O
,	O
this	O
study	O
was	O
designed	O
to	O
analyze	O
the	O
role	O
of	O
Lck	B
in	O
IFN	B
-	I
alpha	I
signaling	O
by	O
using	O
the	O
Jurkat	O
,	O
JCam	O
(	O
an	O
Lck	O
-	O
defective	O
cell	O
line	O
derived	O
from	O
Jurkat	O
)	O
,	O
and	O
JCam	O
/	O
Lck	O
(	O
JCam	O
cells	O
with	O
Lck	B
restored	O
)	O
.	O

Finally	O
,	O
the	O
results	O
demonstrate	O
that	O
IFN	B
-	I
alpha	I
exerts	O
an	O
antiproliferative	O
effect	O
in	O
all	O
three	O
cell	O
lines	O
.	O

We	O
investigated	O
the	O
MAPk	B
kinase	I
(	O
MKK	B
)	O
that	O
activates	O
p38	B
MAPk	I
in	O
response	O
to	O
LPS	O
,	O
the	O
p38	B
MAPk	I
isoforms	I
that	O
are	O
activated	O
as	O
part	O
of	O
this	O
pathway	O
,	O
and	O
the	O
functional	O
responses	O
affected	O
by	O
p38	B
MAPk	I
activation	O
.	O

Although	O
MKK3	B
,	O
MKK4	B
,	O
and	O
MKK6	B
all	O
activated	O
p38	B
MAPk	I
in	O
experimental	O
models	O
,	O
only	O
MKK3	B
was	O
found	O
to	O
activate	O
recombinant	O
p38	B
MAPk	I
in	O
LPS	O
-	O
treated	O
neutrophils	O
.	O

The	O
I	B
gamma	I
3	I
ECS	B
lies	O
upstream	O
of	O
the	O
major	B
I	I
gamma	I
3	I
transcription	I
initiation	I
site	I
and	O
displays	O
more	O
than	O
90	O
%	O
identity	O
with	O
the	O
corresponding	O
human	B
I	I
gamma	I
1	I
,	O
I	B
gamma	I
2	I
,	O
and	O
I	B
gamma	I
4	I
regions	O
.	O

In	O
these	O
transfected	O
CL	O
-	O
01	O
cells	O
,	O
CD40	O
:	O
CD40L	B
engagement	O
and	O
exposure	O
to	O
IL	B
-	I
4	I
synergistically	O
induced	O
gamma	O
3	O
ECS	O
-	O
dependent	O
luciferase	B
reporter	I
gene	I
activation	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
showed	O
that	O
p50	B
/	I
p65	I
/	I
c	I
-	I
Rel	I
and	O
STAT	B
-	I
6	I
are	O
effectively	O
induced	O
by	O
CD40L	B
and	O
IL	B
-	I
4	I
,	O
respectively	O
,	O
and	O
bind	O
to	O
specific	O
DNA	B
motifs	I
within	O
the	O
ECS	B
.	O

CIITA	B
-	O
induced	O
occupation	O
of	O
MHC	B
class	I
II	I
promoters	I
is	O
independent	O
of	O
the	O
cooperative	O
stabilization	O
of	O
the	O
promoter	B
-	I
bound	I
multi	I
-	I
protein	I
complexes	I
.	O

Activation	O
of	O
MHC	B
class	I
II	I
promoters	I
requires	O
binding	O
of	O
at	O
least	O
three	O
distinct	O
multi	B
-	I
protein	I
complexes	I
(	O
RFX	B
,	O
X2BP	B
and	O
NF	B
-	I
Y	I
)	O
.	O

We	O
show	O
,	O
however	O
,	O
that	O
the	O
presence	O
of	O
CIITA	B
does	O
not	O
affect	O
the	O
stability	O
of	O
the	O
higher	O
-	O
order	O
protein	O
complex	O
formed	O
on	O
DNA	O
by	O
RFX	B
,	O
X2BP	B
and	O
NF	B
-	I
Y	I
.	O

Finally	O
,	O
we	O
conclude	O
that	O
this	O
effect	O
of	O
CIITA	B
is	O
cell	O
-	O
type	O
specific	O
,	O
since	O
expression	O
of	O
CIITA	B
is	O
not	O
required	O
for	O
normal	O
occupation	O
of	O
MHC	B
class	I
II	I
promoters	I
in	O
B	O
lymphocytes	O
.	O

SH2	B
domain	I
-	I
containing	I
protein	I
76	I
(	O
SLP	B
-	I
76	I
)	O
interacts	O
with	O
the	O
guanine	B
nucleotide	I
exchange	I
factor	I
Vav	B
to	O
activate	O
the	O
nuclear	B
factor	I
of	I
activated	I
cells	I
(	O
NF	B
-	I
AT	I
)	O
,	O
and	O
its	O
expression	O
is	O
required	O
for	O
normal	O
T	O
cell	O
development	O
.	O

In	O
contrast	O
,	O
another	O
inducible	O
gene	O
expression	O
of	O
monocyte	B
chemotactic	I
protein	I
-	I
1	I
(	O
a	O
CC	B
chemokine	I
)	O
and	O
the	O
activation	O
of	O
the	O
transcriptional	B
factor	I
(	O
FcRFgamma	B
)	O
bound	O
to	O
the	O
gamma	B
response	I
region	I
were	O
similarly	O
or	O
less	O
abundantly	O
induced	O
by	O
IFNgamma	B
treatment	O
in	O
PMA	O
-	O
or	O
RA	O
-	O
differentiated	O
U937	O
cells	O
,	O
indicating	O
that	O
increased	O
IP	B
-	I
10	I
mRNA	I
induction	O
was	O
not	O
due	O
to	O
the	O
augmented	O
ability	O
of	O
the	O
cells	O
to	O
respond	O
to	O
the	O
presence	O
of	O
IFNgamma	B
.	O

Role	O
of	O
cellular	B
tumor	I
necrosis	I
factor	I
receptor	I
-	I
associated	I
factors	I
in	O
NF	B
-	I
kappaB	I
activation	O
and	O
lymphocyte	O
transformation	O
by	O
herpesvirus	O
Saimiri	O
STP	B
.	O

In	O
addition	O
,	O
a	O
somewhat	O
divergent	O
region	O
of	O
STP	B
-	I
C488	I
is	O
critical	O
for	O
TRAF	B
association	O
.	O

In	O
contrast	O
,	O
caspase	O
1	O
(	O
ICE	O
)	O
did	O
not	O
cleave	O
SP1	B
in	O
vitro	O
.	O

Comparison	O
of	O
tumor	O
specimen	O
from	O
MM	O
precursor	O
lesions	O
,	O
primary	O
tumors	O
,	O
and	O
metastases	O
revealed	O
that	O
CD40	B
surface	O
expression	O
is	O
down	O
-	O
regulated	O
during	O
tumor	O
progression	O
.	O

CD40	B
expression	O
was	O
confirmed	O
in	O
7	O
human	O
MM	O
cell	O
lines	O
established	O
from	O
immunogenic	O
primary	O
tumors	O
or	O
metastases	O
,	O
whereas	O
11	O
cell	O
lines	O
established	O
from	O
advanced	O
stages	O
were	O
CD40	B
negative	O
.	O

Furthermore	O
,	O
CD40	B
ligation	O
of	O
a	O
HLA	O
-	O
A2	O
+	O
,	O
MelanA	O
/	O
MART1	O
+	O
MM	O
cell	O
line	O
enhanced	O
its	O
susceptibility	O
to	O
specific	O
lysis	O
by	O
a	O
HLA	O
-	O
A2	O
-	O
restricted	O
,	O
MelanA	O
/	O
MART	O
-	O
1	O
-	O
specific	O
CTL	O
clone	O
.	O

Human	O
immunodeficiency	O
virus	O
-	O
associated	O
Hodgkin	O
'	O
s	O
disease	O
derives	O
from	O
post	O
-	O
germinal	O
center	O
B	O
cells	O
.	O

Human	O
immunodeficiency	O
virus	O
-	O
associated	O
Hodgkin	O
'	O
s	O
disease	O
(	O
HIV	O
-	O
HD	O
)	O
displays	O
several	O
peculiarities	O
when	O
compared	O
with	O
HD	O
of	O
the	O
general	O
population	O
.	O

MDS1	B
/	I
EVI1	I
is	O
inappropriately	O
activated	O
in	O
myeloid	O
leukemias	O
following	O
chromosomal	O
rearrangements	O
involving	O
band	B
3q26	I
.	O

This	O
fusion	O
protein	O
contains	O
the	O
DNA	B
-	I
binding	I
domain	I
of	O
the	O
transcription	B
factor	I
AML1	B
fused	O
in	O
-	O
frame	O
to	O
the	O
entire	O
MDS1	B
/	I
EVI1	I
with	O
the	O
exclusion	O
of	O
its	O
first	O
12	O
amino	O
acids	O
.	O

In	O
this	O
report	O
,	O
we	O
have	O
analyzed	O
the	O
response	O
of	O
the	O
hematopoietic	O
precursor	O
cell	O
line	O
32Dcl3	O
,	O
expressing	O
either	O
the	O
normal	B
protein	I
MDS1	I
/	I
EVI1	I
or	O
the	O
fusion	B
protein	I
AML1	I
/	I
MDS1	I
/	I
EVI1	I
,	O
to	O
factors	O
that	O
control	O
cell	O
differentiation	O
or	O
cell	O
replication	O
.	O

This	O
effect	O
is	O
similar	O
to	O
that	O
previously	O
described	O
by	O
others	O
for	O
32Dcl3	O
cells	O
that	O
express	O
transgenic	B
Evil	I
.	O

By	O
using	O
the	O
yeast	O
two	O
-	O
hybrid	O
system	O
,	O
we	O
also	O
show	O
that	O
EVI1	B
(	O
contained	O
in	O
its	O
entirety	O
in	O
MDS1	B
/	I
EVI1	I
and	O
AML1	B
/	I
MDS1	I
/	I
EVI1	I
)	O
physically	O
interacts	O
with	O
SMAD3	B
,	O
which	O
is	O
an	O
intracellular	O
mediator	O
of	O
TGF	B
-	I
beta1	I
signaling	O
.	O

The	O
levels	O
of	O
cAMP	B
-	I
dependent	I
protein	I
kinase	I
and	O
Rap1	B
were	O
assessed	O
by	O
Western	O
blot	O
analysis	O
,	O
immunostaining	O
,	O
and	O
computer	O
-	O
assisted	O
imaging	O
.	O

In	O
many	O
pathological	O
situations	O
,	O
the	O
balance	O
between	O
Th1	O
and	O
Th2	O
immune	O
responses	O
determines	O
the	O
outcome	O
of	O
diverse	O
immunologically	O
mediated	O
clinical	O
syndromes	O
including	O
infectious	O
,	O
autoimmune	O
,	O
and	O
allergic	O
diseases	O
.	O

Tcf	B
-	I
1	I
-	O
mediated	O
transcription	O
in	O
T	O
lymphocytes	O
:	O
differential	O
role	O
for	O
glycogen	B
synthase	I
kinase	I
-	I
3	I
in	O
fibroblasts	O
and	O
T	O
cells	O
.	O

Beta	O
-	O
catenin	O
is	O
the	O
vertebrate	O
homolog	O
of	O
the	O
Drosophila	B
segment	I
polarity	I
gene	I
Armadillo	B
and	O
plays	O
roles	O
in	O
both	O
cell	O
-	O
cell	O
adhesion	O
and	O
transduction	O
of	O
the	O
Wnt	O
signaling	O
cascade	O
.	O

Recently	O
,	O
members	O
of	O
the	O
Lef	B
/	I
Tcf	I
transcription	I
factor	I
family	I
have	O
been	O
identified	O
as	O
protein	O
partners	O
of	O
beta	B
-	I
catenin	I
,	O
explaining	O
how	O
beta	B
-	I
catenin	I
alters	O
gene	O
expression	O
.	O

In	O
contrast	O
,	O
in	O
C57MG	O
fibroblast	O
cells	O
,	O
lithium	O
inactivates	O
GSK	B
-	I
3beta	I
and	O
induces	O
Tcf	O
-	O
controlled	O
transcription	O
.	O

Overexpression	O
of	O
SIT	B
in	O
Jurkat	O
cells	O
downmodulates	O
T	O
cell	O
receptor	O
-	O
and	O
phytohemagglutinin	O
-	O
mediated	O
activation	O
of	O
the	O
nuclear	B
factor	I
of	I
activated	I
T	I
cells	I
(	O
NF	B
-	I
AT	I
)	O
by	O
interfering	O
with	O
signaling	O
processes	O
that	O
are	O
probably	O
located	O
upstream	O
of	O
activation	O
of	O
phospholipase	B
C	I
.	O

However	O
,	O
binding	O
of	O
SHP2	B
to	O
SIT	B
is	O
not	O
required	O
for	O
inhibition	O
of	O
NF	B
-	I
AT	I
induction	O
,	O
suggesting	O
that	O
SIT	B
not	O
only	O
regulates	O
NF	B
-	I
AT	I
activity	O
but	O
also	O
controls	O
NF	B
-	I
AT	I
unrelated	O
pathways	O
of	O
T	O
cell	O
activation	O
involving	O
SHP2	B
.	O

We	O
investigated	O
the	O
function	O
of	O
conditionally	O
expressed	O
EBNA2	B
in	O
the	O
context	O
of	O
the	O
IFN	B
response	O
in	O
Burkitt	O
'	O
s	O
lymphoma	O
cell	O
lines	O
.	O

Expression	O
of	O
EBNA2	B
led	O
to	O
the	O
transcriptional	O
activation	O
of	O
both	O
endogenous	O
or	O
transfected	O
IFN	B
-	I
stimulated	I
genes	I
(	O
ISGs	B
)	O
,	O
genes	O
which	O
contain	O
within	O
their	O
promoters	B
either	O
the	O
interferon	B
-	I
stimulated	I
response	I
element	I
(	O
ISRE	B
)	O
or	O
the	O
gamma	B
interferon	I
activation	I
site	I
(	O
GAS	B
)	O
.	O

PGG	O
-	O
Glucan	O
,	O
a	O
soluble	O
beta	O
-	O
(	O
1	O
,	O
6	O
)	O
-	O
branched	O
beta	O
-	O
(	O
1	O
,	O
3	O
)	O
-	O
linked	O
glucose	O
homopolymer	O
derived	O
from	O
the	O
cell	O
wall	O
of	O
the	O
yeast	O
Saccharomyces	O
cerevisiae	O
,	O
is	O
an	O
immunomodulator	O
which	O
enhances	O
leukocyte	O
anti	O
-	O
infective	O
activity	O
and	O
enhances	O
myeloid	O
and	O
megakaryocyte	O
progenitor	O
proliferation	O
.	O

The	O
binding	O
of	O
3H	O
-	O
PGG	O
-	O
Glucan	O
to	O
human	O
leukocyte	O
membranes	O
was	O
specific	O
,	O
concentration	O
-	O
dependent	O
,	O
saturable	O
,	O
and	O
high	O
affinity	O
(	O
Kd	O
approximately	O
6	O
nM	O
)	O
.	O

We	O
conclude	O
that	O
potentiation	O
of	O
nonphlogistic	O
clearance	O
of	O
apoptotic	O
leukocytes	O
by	O
phagocytes	O
is	O
a	O
hitherto	O
unrecognized	O
property	O
of	O
glucocorticoids	O
that	O
has	O
potential	O
implications	O
for	O
therapies	O
aimed	O
at	O
promoting	O
the	O
resolution	O
of	O
inflammatory	O
diseases	O
.	O

However	O
,	O
the	O
mechanisms	O
and	O
strategies	O
to	O
overcome	O
RA	O
resistance	O
by	O
APL	O
cells	O
are	O
still	O
unclear	O
.	O

Also	O
,	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
(	O
10	O
(	O
-	O
10	O
)	O
to	O
10	O
(	O
-	O
7	O
)	O
mol	O
/	O
L	O
)	O
in	O
combination	O
with	O
RA	O
markedly	O
inhibits	O
cellular	O
proliferation	O
in	O
a	O
dose	O
-	O
and	O
time	O
-	O
dependent	O
manner	O
.	O

Interestingly	O
,	O
the	O
combination	O
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
and	O
RA	O
markedly	O
enhanced	O
the	O
levels	O
of	O
p27	B
(	I
KIP1	I
)	I
transcript	O
and	O
protein	O
as	O
compared	O
with	O
levels	O
induced	O
by	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
alone	O
.	O

Molecular	O
mechanisms	O
of	O
neutrophil	O
-	O
endothelial	O
cell	O
adhesion	O
induced	O
by	O
redox	O
imbalance	O
.	O

Previous	O
studies	O
have	O
implicated	O
a	O
role	O
for	O
intracellular	O
thiols	O
in	O
the	O
activation	O
of	O
nuclear	B
factor	I
-	I
kappaB	I
and	O
transcriptional	O
regulation	O
of	O
endothelial	B
cell	I
adhesion	I
molecules	I
.	O

This	O
study	O
was	O
designed	O
to	O
determine	O
whether	O
changes	O
in	O
endothelial	O
cell	O
glutathione	O
(	O
GSH	O
)	O
or	O
oxidized	O
glutathione	O
(	O
GSSG	O
)	O
can	O
alter	O
neutrophil	O
adhesivity	O
and	O
to	O
define	O
the	O
molecular	O
mechanism	O
that	O
underlies	O
this	O
GSSG	O
/	O
GSH	O
-	O
induced	O
adhesion	O
response	O
.	O

Diamide	O
plus	O
BSO	O
-	O
induced	O
thiol	O
/	O
disulfide	O
imbalance	O
was	O
associated	O
with	O
a	O
biphasic	O
increase	O
in	O
neutrophil	O
adhesion	O
to	O
HUVECs	O
with	O
peak	O
responses	O
observed	O
at	O
15	O
minutes	O
(	O
phase	O
1	O
)	O
and	O
240	O
minutes	O
(	O
phase	O
2	O
)	O
.	O

This	O
study	O
demonstrates	O
that	O
changes	O
in	O
endothelial	O
cell	O
GSSG	O
/	O
GSH	O
cause	O
transcription	O
-	O
independent	O
and	O
transcription	O
-	O
dependent	O
surface	O
expression	O
of	O
different	O
endothelial	B
cell	I
adhesion	I
molecules	I
,	O
which	O
leads	O
to	O
a	O
2	O
-	O
phase	O
neutrophil	O
-	O
endothelial	O
adhesion	O
response	O
.	O

In	O
-	O
situ	O
detection	O
of	O
fragmented	O
DNA	O
was	O
performed	O
to	O
identify	O
apoptotic	O
cells	O
.	O

Angiotensin	B
II	I
activates	O
the	O
proinflammatory	B
transcription	I
factor	I
nuclear	B
factor	I
-	I
kappaB	I
in	O
human	O
monocytes	O
.	O

ANG	B
II	I
,	O
like	O
TNFalpha	B
,	O
caused	O
rapid	O
activation	O
of	O
NF	B
-	I
kappaB	I
in	O
human	O
mononuclear	O
cells	O
isolated	O
from	O
peripheral	O
blood	O
by	O
Ficoll	O
density	O
gradient	O
.	O

Recently	O
,	O
its	O
presence	O
has	O
been	O
demonstrated	O
in	O
atherosclerotic	O
lesions	O
.	O

Increased	O
mRNA	B
and	O
surface	O
expression	O
of	O
E	B
-	I
selectin	I
,	O
ICAM	B
-	I
1	I
,	O
and	O
VCAM	B
-	I
1	I
were	O
noted	O
within	O
hours	O
.	O

Transient	O
pseudo	O
-	O
hypoaldosteronism	O
following	O
resection	O
of	O
the	O
ileum	O
:	O
normal	O
level	O
of	O
lymphocytic	B
aldosterone	I
receptors	I
outside	O
the	O
acute	O
phase	O
.	O

A	O
urinary	O
steroidogram	O
resulted	O
in	O
highly	O
elevated	O
tetrahydrocortisol	O
(	O
THF	O
:	O
13	O
.	O
3	O
mg	O
/	O
24h	O
;	O
N	O
:	O
1	O
.	O
4	O
+	O
/	O
-	O
0	O
.	O
8	O
)	O
with	O
no	O
increase	O
in	O
tetrahydrocortisone	O
(	O
THE	O
:	O
3	O
.	O
16	O
mg	O
/	O
24h	O
;	O
N	O
:	O
2	O
.	O
7	O
+	O
/	O
-	O
2	O
.	O
0	O
)	O
excretion	O
,	O
and	O
with	O
low	O
THE	O
/	O
THF	O
(	O
0	O
.	O
24	O
;	O
N	O
:	O
1	O
.	O
87	O
+	O
/	O
-	O
0	O
.	O
36	O
)	O
and	O
alpha	O
THF	O
/	O
THF	O
(	O
0	O
.	O
35	O
;	O
N	O
:	O
0	O
.	O
92	O
+	O
/	O
-	O
0	O
.	O
42	O
)	O
ratios	O
.	O

Small	O
-	O
bowel	O
resection	O
in	O
ileostomized	O
patients	O
causes	O
excessive	O
fecal	O
sodium	O
losses	O
and	O
results	O
in	O
chronic	O
sodium	O
depletion	O
with	O
contraction	O
of	O
the	O
plasma	O
volume	O
and	O
severe	O
secondary	O
hyperaldosteronism	O
.	O

A	O
decrease	O
in	O
the	O
translation	O
rate	O
is	O
observed	O
when	O
the	O
cells	O
are	O
induced	O
to	O
differentiate	O
along	O
the	O
monocytic	O
/	O
macrophage	O
pathway	O
or	O
along	O
the	O
granulocytic	O
pathway	O
.	O

In	O
contrast	O
,	O
treatment	O
of	O
HL	O
-	O
60	O
cells	O
with	O
retinoic	O
acid	O
or	O
DMSO	O
,	O
which	O
results	O
in	O
a	O
granulocytic	O
differentiation	O
of	O
these	O
cells	O
,	O
decreases	O
4E	B
-	I
BP1	I
amount	O
without	O
affecting	O
its	O
phosphorylation	O
and	O
strongly	O
increases	O
4E	B
-	I
BP2	I
amount	O
.	O

We	O
found	O
frequent	O
hypermutation	O
in	O
follicular	O
lymphoma	O
(	O
25	O
of	O
59	O
=	O
42	O
%	O
)	O
(	O
germinal	O
center	O
cell	O
origin	O
)	O
and	O
mucosa	O
-	O
associated	O
lymphoid	O
tissue	O
(	O
MALT	O
)	O
lymphoma	O
(	O
19	O
of	O
45	O
=	O
42	O
%	O
)	O
(	O
postgerminal	O
center	O
)	O
,	O
but	O
only	O
occasionally	O
in	O
mantle	O
cell	O
lymphoma	O
(	O
1	O
of	O
21	O
=	O
4	O
.	O
8	O
%	O
)	O
(	O
pregerminal	O
center	O
)	O
.	O

Most	O
mutations	O
were	O
outside	O
the	O
motifs	O
potentially	O
important	O
for	O
transcription	O
,	O
suggesting	O
they	O
were	O
not	O
important	O
in	O
lymphomagenesis	O
but	O
may	O
,	O
like	O
Ig	O
mutation	O
,	O
represent	O
an	O
inherent	O
feature	O
of	O
the	O
lymphoma	O
precursor	O
cells	O
.	O

Markedly	O
impaired	O
binding	O
was	O
observed	O
,	O
consistent	O
with	O
both	O
the	O
use	O
of	O
different	O
anchor	O
residues	O
and	O
with	O
changes	O
in	O
levels	O
of	O
DQ	O
cis	O
-	O
dimer	B
availability	O
for	O
peptide	O
binding	O
interactions	O
.	O

Detection	O
of	O
intracellular	B
phosphorylated	I
STAT	I
-	I
1	I
by	O
flow	O
cytometry	O
.	O

In	O
addition	O
,	O
this	O
technique	O
should	O
permit	O
dissection	O
of	O
a	O
full	O
range	O
of	O
cellular	O
signaling	O
pathways	O
at	O
the	O
protein	O
level	O
.	O

Consequently	O
,	O
cytosolic	O
activation	O
,	O
nuclear	O
translocation	O
and	O
DNA	O
-	O
binding	O
of	O
nuclear	B
factor	I
-	I
kappaB	I
were	O
decreased	O
.	O

5	O
.	O
Neutrophil	O
apoptosis	O
and	O
inhibition	O
of	O
neutrophil	O
function	O
were	O
induced	O
at	O
lower	O
concentrations	O
of	O
SMX	O
-	O
NHOH	O
and	O
SMX	O
-	O
NO	O
than	O
those	O
inducing	O
loss	O
of	O
membrane	O
viability	O
,	O
with	O
SMX	O
having	O
no	O
effect	O
.	O

7	O
.	O
Our	O
results	O
suggest	O
that	O
the	O
balance	O
between	O
oxidation	O
of	O
SMX	O
to	O
its	O
toxic	O
metabolites	O
and	O
their	O
reduction	O
is	O
an	O
important	O
protective	O
cellular	O
mechanism	O
.	O

Recently	O
,	O
we	O
reported	O
cases	O
of	O
angioimmunoblastic	O
T	O
-	O
cell	O
lymphoma	O
(	O
AITL	O
)	O
with	O
hyperplastic	O
GCs	O
(	O
AITL	O
/	O
GC	O
)	O
,	O
and	O
observed	O
that	O
borders	O
of	O
enlarged	O
GCs	O
were	O
ill	O
defined	O
,	O
with	O
features	O
suggestive	O
of	O
an	O
outward	O
migration	O
of	O
GC	O
cells	O
to	O
surrounding	O
interfollicular	O
zones	O
.	O

In	O
FL	O
,	O
follicles	O
were	O
densely	O
populated	O
,	O
and	O
their	O
borders	O
were	O
irregular	O
,	O
with	O
some	O
Bcl	O
-	O
6	O
+	O
cells	O
in	O
the	O
interfollicular	O
zones	O
.	O

Double	O
staining	O
revealed	O
that	O
these	O
interfollicular	O
Bcl	O
-	O
6	O
+	O
cells	O
in	O
AITL	O
/	O
GC	O
were	O
Bcl6	O
+	O
/	O
CD3	O
+	O
/	O
CD20	O
-	O
/	O
CD57	O
-	O
T	O
cells	O
.	O

In	O
typical	O
AITL	O
,	O
some	O
neoplastic	O
cells	O
were	O
positive	O
for	O
Bcl	B
-	I
6	I
,	O
showing	O
variable	O
degrees	O
of	O
staining	O
.	O

(	O
2	O
)	O
Intrafollicular	O
CD3	O
+	O
T	O
cells	O
,	O
many	O
of	O
which	O
were	O
also	O
positive	O
for	O
Bcl	B
-	I
6	I
,	O
were	O
markedly	O
depleted	O
in	O
AITL	O
/	O
GC	O
,	O
with	O
increased	O
interfollicular	O
Bcl	O
-	O
6	O
+	O
/	O
CD3	O
+	O
cells	O
,	O
suggesting	O
an	O
outward	O
migration	O
of	O
intrafollicular	O
T	O
cells	O
in	O
this	O
condition	O
.	O

(	O
5	O
)	O
Some	O
neoplastic	O
cells	O
in	O
AITL	O
stained	O
for	O
Bcl	B
-	I
6	I
,	O
suggesting	O
up	O
-	O
regulation	O
of	O
Bcl	B
-	I
6	I
expression	O
in	O
this	O
tumor	O
.	O

To	O
continue	O
our	O
investigation	O
of	O
the	O
cellular	O
events	O
that	O
occur	O
following	O
human	O
CMV	O
(	O
HCMV	O
)	O
infection	O
,	O
we	O
focused	O
on	O
the	O
regulation	O
of	O
cellular	O
activation	O
following	O
viral	O
binding	O
to	O
human	O
monocytes	O
.	O

Because	O
these	O
induced	O
gene	O
products	O
have	O
NF	B
-	I
kappaB	I
sites	I
in	O
their	O
promoter	B
regions	I
,	O
we	O
next	O
examined	O
whether	O
there	O
was	O
an	O
up	O
-	O
regulation	O
of	O
nuclear	O
NF	B
-	I
kappaB	I
levels	O
.	O

These	O
results	O
support	O
our	O
hypothesis	O
that	O
HCMV	O
initiates	O
a	O
signal	O
transduction	O
pathway	O
that	O
leads	O
to	O
monocyte	O
activation	O
and	O
pinpoints	O
a	O
potential	O
mechanism	O
whereby	O
HCMV	O
infection	O
of	O
monocytes	O
can	O
result	O
in	O
profound	O
pathogenesis	O
,	O
especially	O
in	O
chronic	O
inflammatory	O
-	O
type	O
conditions	O
.	O

Glycoprotein	B
(	I
GP	I
)	I
IX	I
is	O
a	O
subunit	O
of	O
the	O
von	B
Willebrand	I
receptor	I
,	O
GPIb	B
-	I
V	I
-	I
IX	I
,	O
which	O
mediates	O
adhesion	O
of	O
platelets	O
to	O
the	O
subendothelium	O
of	O
damaged	O
blood	O
vessels	O
.	O

Previous	O
characterization	O
of	O
the	O
GPIX	B
promoter	I
identified	O
a	O
functional	O
Ets	O
site	O
that	O
,	O
when	O
disrupted	O
,	O
reduced	O
promoter	O
activity	O
.	O

These	O
results	O
suggest	O
that	O
Fli	B
-	I
1	I
is	O
likely	O
to	O
regulate	O
lineage	B
-	I
specific	I
genes	I
during	O
megakaryocytopoiesis	O
.	O

However	O
,	O
I	B
(	I
kappa	I
)	I
B	I
(	I
alpha	I
)	I
has	O
also	O
been	O
detected	O
in	O
the	O
nucleus	O
of	O
cell	O
lines	O
and	O
when	O
overexpressed	O
by	O
transient	O
transfection	O
.	O

Immunoprecipitation	O
experiments	O
failed	O
to	O
demonstrate	O
an	O
association	O
between	O
nuclear	O
I	B
(	I
kappa	I
)	I
B	I
(	I
alpha	I
)	I
and	O
NF	B
-	I
kappaB	I
proteins	O
.	O

SERCA	B
activity	O
was	O
measured	O
as	O
the	O
thapsigargin	O
sensitive	O
,	O
Ca2	O
+	O
dependent	O
and	O
ouabain	O
resistant	O
,	O
ATP	O
hydrolyses	O
in	O
platelet	O
membranes	O
.	O

Cobalt	O
chloride	O
-	O
induced	O
signaling	O
in	O
endothelium	O
leading	O
to	O
the	O
augmented	O
adherence	O
of	O
sickle	O
red	O
blood	O
cells	O
and	O
transendothelial	O
migration	O
of	O
monocyte	O
-	O
like	O
HL	O
-	O
60	O
cells	O
is	O
blocked	O
by	O
PAF	O
-	O
receptor	O
antagonist	O
.	O

In	O
response	O
to	O
hypoxia	O
,	O
sickle	O
red	O
blood	O
cells	O
(	O
SS	O
RBC	O
)	O
and	O
leukocytes	O
exhibit	O
increased	O
adherence	O
to	O
the	O
vascular	O
endothelium	O
,	O
while	O
diapedesis	O
of	O
leukocytes	O
through	O
the	O
blood	O
vessel	O
increases	O
.	O

We	O
utilized	O
CoCl2	O
as	O
a	O
mimetic	O
molecule	O
for	O
hypoxia	O
to	O
study	O
cellular	O
signaling	O
pathways	O
.	O

Additionally	O
,	O
CoCl2	O
caused	O
a	O
two	O
-	O
to	O
threefold	O
increase	O
in	O
the	O
rate	O
of	O
transendothelial	O
migration	O
of	O
monocyte	O
-	O
like	O
HL	O
-	O
60	O
cells	O
and	O
a	O
twentyfold	O
increase	O
in	O
phosphorylation	O
of	O
platelet	B
endothelial	I
cell	I
adhesion	I
molecules	I
(	O
PECAM	B
-	I
1	I
)	O
.	O

Activation	O
of	O
NF	B
-	I
kappaB	I
is	O
thought	O
to	O
be	O
required	O
for	O
cytokine	O
release	O
from	O
LPS	O
-	O
responsive	O
cells	O
,	O
a	O
critical	O
step	O
for	O
endotoxic	O
effects	O
.	O

LPS	O
-	O
induced	O
NF	B
-	I
kappaB	I
activation	O
was	O
not	O
inhibited	O
by	O
a	O
dominant	O
negative	O
mutant	O
of	O
TRAF2	B
that	O
is	O
involved	O
in	O
TNF	B
signaling	O
.	O

Tyrosine	O
phosphorylation	O
of	O
IFN	B
-	I
gammaR	I
,	O
Jak1	B
,	O
Jak2	B
,	O
and	O
Stat1alpha	B
was	O
examined	O
by	O
immunoblotting	O
.	O

In	O
addition	O
,	O
IFN	B
-	I
gamma	I
enhanced	O
the	O
DNA	O
-	O
binding	O
activity	O
of	O
Stat1alpha	B
.	O

Moreover	O
,	O
several	O
transgenic	O
mice	O
developed	O
acute	O
leukemia	O
,	O
classified	O
as	O
T	O
-	O
ALL	O
based	O
on	O
the	O
surface	O
marker	O
analysis	O
and	O
DNA	O
rearrangements	O
,	O
suggesting	O
that	O
an	O
additional	O
event	O
is	O
required	O
for	O
malignant	O
transformation	O
of	O
lymphoid	O
cells	O
expressing	O
E2A	B
-	I
HLF	I
.	O

Our	O
findings	O
provide	O
insight	O
into	O
the	O
biological	O
function	O
of	O
E2A	B
-	I
HLF	I
in	O
lymphoid	O
development	O
and	O
also	O
its	O
role	O
in	O
leukemogenesis	O
.	O

This	O
RXR	B
agonist	O
activity	O
is	O
blocked	O
by	O
RAR	B
-	O
specific	O
antagonists	O
,	O
suggesting	O
extensive	O
cross	O
-	O
talk	O
between	O
the	O
partners	O
of	O
the	O
RXR	B
-	I
RARalpha403	I
heterodimer	I
.	O

We	O
found	O
IL	B
-	I
2Ralpha	I
expression	O
to	O
be	O
increased	O
in	O
BAL	O
cells	O
from	O
involved	O
sites	O
of	O
active	O
pulmonary	O
tuberculosis	O
.	O

Expression	O
of	O
the	O
alpha	B
-	I
chain	I
of	O
IL	B
-	I
2Ralpha	I
on	O
peripheral	O
blood	O
monocytes	O
(	O
PBM	O
)	O
was	O
induced	O
by	O
M	O
.	O
tuberculosis	O
by	O
flow	O
cytometry	O
evaluation	O
.	O

Furthermore	O
,	O
the	O
two	O
VDR	B
3	I
'	I
-	I
UTR	I
haplotypes	O
conferred	O
an	O
identical	O
half	O
-	O
life	O
on	O
a	O
heterologous	B
beta	I
-	I
globin	I
reporter	I
gene	I
,	O
in	O
an	O
in	O
vitro	O
assay	O
.	O

The	O
IL	B
-	I
2	I
growth	O
hormone	O
is	O
the	O
major	O
growth	O
factor	O
of	O
activated	O
T	O
lymphocytes	O
during	O
a	O
developing	O
immune	O
response	O
.	O

In	O
several	O
cell	O
types	O
,	O
activation	O
of	O
NF	B
-	I
kappa	I
B	I
and	O
/	O
or	O
activating	B
protein	I
-	I
1	I
(	O
AP	B
-	I
1	I
)	O
has	O
been	O
demonstrated	O
to	O
be	O
extremely	O
important	O
in	O
blocking	O
apoptosis	O
.	O

Similarly	O
,	O
IL	B
-	I
2	I
neither	O
activates	O
JNK	B
nor	O
increases	O
AP	B
-	I
1	I
binding	O
activity	O
to	O
a	O
consensus	O
o	B
-	I
tetradecanoylphorbol	I
13	I
-	I
acetate	I
(	I
TPA	I
)	I
response	I
element	I
.	O

In	O
particular	O
,	O
our	O
findings	O
suggest	O
that	O
local	O
metabolism	O
of	O
steroids	O
by	O
normal	O
as	O
well	O
as	O
leukemic	O
myeloid	O
cells	O
influences	O
their	O
responsiveness	O
to	O
D3	O
and	O
retinoids	O
.	O

The	O
phosphorylation	O
appears	O
to	O
be	O
related	O
to	O
the	O
signaling	O
events	O
that	O
are	O
activated	O
by	O
TRAF2	B
under	O
these	O
circumstances	O
,	O
since	O
two	O
nonfunctional	O
mutants	O
were	O
found	O
to	O
be	O
phosphorylated	O
significantly	O
less	O
than	O
the	O
wild	B
-	I
type	I
protein	I
.	O

We	O
conclude	O
from	O
these	O
studies	O
that	O
the	O
phosphorylation	O
of	O
TRAF2	B
is	O
likely	O
to	O
play	O
an	O
important	O
role	O
in	O
regulating	O
signaling	O
by	O
virtue	O
of	O
its	O
ability	O
to	O
influence	O
the	O
CD40	B
-	B
TRAF2	I
interaction	O
.	O

Unlike	O
the	O
proposed	O
role	O
of	O
Cbl	B
as	O
a	O
negative	O
regulator	O
,	O
our	O
results	O
suggest	O
that	O
the	O
Cbl	B
homologue	O
Cbl	B
-	I
b	I
has	O
a	O
positive	O
role	O
in	O
T	O
-	O
cell	O
signaling	O
,	O
most	O
likely	O
via	O
a	O
direct	O
interaction	O
with	O
the	O
upstream	B
kinase	I
Zap	B
-	I
70	I
.	O

Grf40	B
,	O
A	O
novel	O
Grb2	B
family	I
member	I
,	O
is	O
involved	O
in	O
T	O
cell	O
signaling	O
through	O
interaction	O
with	O
SLP	B
-	I
76	I
and	O
LAT	B
.	O

As	O
a	O
result	O
of	O
its	O
transforming	O
abilities	O
,	O
activated	B
Ras	I
is	O
expressed	O
in	O
a	O
great	O
number	O
of	O
cancers	O
.	O

This	O
review	O
will	O
discuss	O
the	O
mechanisms	O
by	O
which	O
Ras	B
expressing	O
tumors	O
are	O
able	O
to	O
evade	O
destruction	O
by	O
the	O
immune	O
system	O
and	O
enhance	O
their	O
growth	O
and	O
metastatic	O
potential	O
.	O

Though	O
the	O
levels	O
of	O
DP1	B
and	I
-	I
2	I
increase	O
when	O
cells	O
progress	O
from	O
G0	O
to	O
S	O
,	O
the	O
proportion	O
of	O
DP1	B
to	O
DP2	B
remains	O
relatively	O
constant	O
during	O
the	O
cell	O
cycle	O
.	O

We	O
also	O
observed	O
an	O
increase	O
in	O
electrophoretic	O
mobility	O
of	O
the	O
predominant	O
E2F	B
components	I
,	O
DP1	B
and	O
E2F4	B
,	O
as	O
B	O
-	O
lymphocytes	O
progressed	O
from	O
G0	O
into	O
early	O
G1	O
.	O

In	O
addition	O
,	O
DNA	O
-	O
binding	O
activities	O
of	O
Jun	B
-	I
Fos	I
heterodimers	I
were	O
observed	O
by	O
electrophoretic	O
mobility	O
shift	O
assays	O
during	O
the	O
course	O
of	O
natural	O
cytotoxicity	O
.	O

The	O
therapeutic	O
potential	O
of	O
drugs	O
that	O
block	O
the	O
induction	O
of	O
cyclooxygenase	B
-	I
2	I
has	O
been	O
emphasized	O
.	O

When	O
two	O
4	O
-	O
trifluoromethyl	O
salicylate	O
derivatives	O
[	O
2	O
-	O
acetoxy	O
-	O
4	O
-	O
trifluoromethyl	O
-	O
benzoic	O
acid	O
(	O
triflusal	O
)	O
and	O
its	O
deacetylated	O
metabolite	O
2	O
-	O
hydroxy	O
-	O
4	O
-	O
trifluoromethylbenzo	O
acid	O
(	O
HTB	O
)	O
]	O
were	O
compared	O
with	O
aspirin	O
and	O
sodium	O
salicylate	O
as	O
cyclooxygenase	B
-	I
2	I
(	O
COX	O
-	O
2	O
)	O
inhibitors	O
,	O
we	O
observed	O
that	O
in	O
bacterial	O
lipopolysaccharide	O
-	O
activated	O
human	O
blood	O
,	O
triflusal	O
,	O
aspirin	O
,	O
and	O
HTB	O
,	O
but	O
not	O
sodium	O
salicylate	O
,	O
inhibited	O
COX	O
-	O
2	O
-	O
mediated	O
prostaglandin	O
E2	O
(	O
PGE2	O
)	O
production	O
(	O
IC50	O
=	O
0	O
.	O
16	O
,	O
0	O
.	O
18	O
,	O
0	O
.	O
39	O
,	O
and	O
>	O
10	O
mM	O
,	O
respectively	O
)	O
.	O

Intracellular	O
signals	O
that	O
mediate	O
differentiation	O
of	O
pluripotent	O
hemopoietic	O
progenitors	O
to	O
dendritic	O
cells	O
(	O
DC	O
)	O
are	O
largely	O
undefined	O
.	O

The	O
CD34	O
+	O
myelomonocytic	O
cell	O
line	O
KG1	O
differentiates	O
into	O
dendritic	O
-	O
like	O
cells	O
in	O
response	O
to	O
granulocyte	B
-	I
macrophage	I
CSF	I
plus	O
TNF	B
-	I
alpha	I
,	O
or	O
PMA	O
(	O
with	O
or	O
without	O
the	O
calcium	O
ionophore	O
ionomycin	O
,	O
or	O
TNF	B
-	I
alpha	I
)	O
,	O
with	O
different	O
stimuli	O
mediating	O
different	O
aspects	O
of	O
the	O
process	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
whether	O
gp41	B
-	O
induced	O
IL	B
-	I
10	I
up	O
-	O
regulation	O
is	O
mediated	O
by	O
the	O
previously	O
described	O
synergistic	O
activation	O
of	O
cAMP	O
and	O
NF	B
-	I
kappaB	I
pathways	O
.	O

Analysis	O
of	O
the	O
modulation	O
of	O
transcriptional	O
activity	O
in	O
myelopoiesis	O
and	O
leukemogenesis	O
.	O

The	O
transcription	B
factors	I
PU	B
.	I
1	I
and	O
C	B
/	I
EBPalpha	I
are	O
responsible	O
for	O
normal	O
myeloid	O
differentiation	O
from	O
stem	O
cells	O
to	O
monocytes	O
or	O
granulocytes	O
.	O

However	O
,	O
the	O
phenotypic	O
analysis	O
of	O
NF	B
-	I
AT	I
-	O
deficient	O
mice	O
supports	O
the	O
idea	O
that	O
there	O
are	O
tissue	O
-	O
and	O
gene	O
-	O
specific	O
functions	O
as	O
well	O
.	O

Despite	O
minimal	O
discrepancies	O
in	O
the	O
coding	B
region	I
,	O
there	O
are	O
striking	O
tissue	O
-	O
and	O
cell	O
type	O
-	O
specific	O
differences	O
in	O
isoform	O
expression	O
patterns	O
.	O

Thus	O
CTL	O
clones	O
that	O
recognized	O
the	O
viral	O
,	O
self	O
,	O
and	O
bacterial	O
peptides	O
expressed	O
a	O
highly	O
restricted	O
alphabeta	O
TCR	B
phenotype	O
.	O

RFLAT	B
-	I
1	I
:	O
a	O
new	O
zinc	B
finger	I
transcription	I
factor	I
that	O
activates	O
RANTES	B
gene	I
expression	O
in	O
T	O
lymphocytes	O
.	O

Furthermore	O
,	O
these	O
oxidative	O
stresses	O
inhibited	O
activity	O
of	O
calcineurin	O
,	O
a	O
serine	O
/	O
threonine	B
phosphatase	I
that	O
regulates	O
NFAT	B
activation	O
.	O

Several	O
intracellular	O
signaling	B
proteins	I
,	O
such	O
as	O
CBL	B
and	O
VAV	B
,	O
were	O
phosphorylated	O
on	O
tyrosine	O
in	O
response	O
to	O
CD80	B
,	O
CD86	B
,	O
and	O
anti	B
-	I
CD28	I
mAb	I
.	O

In	O
addition	O
,	O
the	O
association	O
of	O
phosphoinositide	B
3	I
-	I
kinase	I
with	O
CD28	B
and	O
enhanced	O
tyrosine	O
phosphorylation	O
of	O
phospholipase	O
Cgamma	O
were	O
seen	O
after	O
anti	O
-	O
CD28	O
mAb	O
and	O
CHO	O
-	O
CD80	O
stimulation	O
but	O
to	O
a	O
much	O
lesser	O
extent	O
after	O
CHO	B
-	I
CD86	I
stimulation	O
.	O

However	O
,	O
CD80	B
and	O
CD86	B
also	O
induce	O
distinct	O
signal	O
transduction	O
pathways	O
including	O
the	O
tyrosine	O
phosphorylation	O
of	O
CD28	B
and	O
phospholipase	B
Cgamma1	I
and	O
the	O
SH2	B
-	O
dependent	O
association	O
of	O
phosphoinositide	B
3	I
-	I
kinase	I
with	O
CD28	B
.	O

Binding	O
of	O
HMG	B
-	I
I	I
(	I
Y	I
)	I
elicits	O
structural	O
changes	O
in	O
a	O
silencer	O
of	O
the	O
human	B
beta	I
-	I
globin	I
gene	I
.	O

If	O
there	O
is	O
a	O
reciprocal	O
elevation	O
of	O
gamma	B
-	I
globin	I
expression	O
upon	O
repression	O
,	O
this	O
approach	O
could	O
be	O
useful	O
in	O
additional	O
hemoglobinopathies	O
.	O

We	O
demonstrate	O
that	O
binding	O
of	O
HMG	B
-	I
I	I
(	I
Y	I
)	I
to	O
this	O
oligonucleotide	O
causes	O
bending	O
/	O
flexure	O
of	O
the	O
DNA	O
.	O

The	O
master	O
switch	O
for	O
the	O
expression	O
of	O
these	O
genes	O
is	O
the	O
class	B
II	I
transactivator	I
(	O
CIITA	B
)	O
.	O

In	O
contrast	O
,	O
overexpression	O
of	O
CREB	B
inhibited	O
GAL4	B
-	O
p65	O
(	O
286	O
-	O
551	O
)	O
-	O
mediated	O
transcription	O
.	O

Glucocorticoid	B
receptors	I
in	O
cord	O
blood	O
lymphocytes	O
of	O
healthy	O
neonates	O
and	O
of	O
preterms	O
suffering	O
from	O
respiratory	O
distress	O
syndrome	O
.	O

We	O
measured	O
the	O
number	O
of	O
glucocorticoid	B
receptors	I
(	O
GR	B
)	O
in	O
cord	O
blood	O
lymphocytes	O
and	O
the	O
binding	O
affinity	O
(	O
Kd	O
)	O
in	O
15	O
term	O
and	O
in	O
20	O
preterm	O
babies	O
.	O

Thirteen	O
preterms	O
of	O
the	O
latter	O
group	O
received	O
prenatal	O
steroid	O
treatment	O
.	O

The	O
number	O
of	O
GR	B
and	O
the	O
Kd	O
were	O
similar	O
in	O
the	O
term	O
and	O
preterm	O
(	O
with	O
and	O
without	O
NRDS	O
)	O
babies	O
.	O

In	O
order	O
to	O
elucidate	O
the	O
role	O
of	O
NF	B
-	I
ATp	I
,	O
one	O
of	O
the	O
most	O
prominent	O
members	O
of	O
family	O
of	O
NF	B
-	I
AT	I
transcription	I
factors	I
in	O
peripheral	O
T	O
lymphocytes	O
,	O
in	O
T	O
cell	O
activation	O
and	O
differentiation	O
we	O
created	O
NF	B
-	I
ATp	I
-	O
deficient	O
mice	O
by	O
gene	O
targeting	O
.	O

Apart	O
from	O
clear	O
-	O
cut	O
defects	O
in	O
the	O
synthesis	O
of	O
mRNAs	B
for	O
Th2	B
-	I
type	I
lymphokines	I
,	O
such	O
as	O
IL	B
-	I
4	I
,	O
IL	B
-	I
5	I
,	O
IL	B
-	I
10	I
and	O
IL	B
-	I
13	I
,	O
in	O
primary	O
and	O
secondary	O
stimulations	O
of	O
spleen	O
cells	O
in	O
vitro	O
,	O
of	O
a	O
distinct	O
impaired	O
deletion	O
of	O
V	O
beta	O
11	O
+	O
/	O
CD4	O
+	O
T	O
lymphocytes	O
from	O
these	O
mice	O
was	O
detected	O
after	O
superantigen	O
injection	O
.	O

Moreover	O
,	O
NF	B
-	I
ATp	I
-	O
/	O
-	O
mice	O
older	O
than	O
6	O
weeks	O
show	O
an	O
2	O
-	O
5	O
fold	O
increase	O
in	O
number	O
of	O
lymphocytes	O
.	O

Our	O
data	O
constitute	O
a	O
starting	O
point	O
for	O
studies	O
to	O
elucidate	O
the	O
molecular	O
mechanism	O
by	O
which	O
TGF	B
-	I
beta	I
regulates	O
IgA	B
production	O
.	O

Daidzein	O
and	O
genistein	O
glucuronides	O
in	O
vitro	O
are	O
weakly	O
estrogenic	O
and	O
activate	O
human	O
natural	O
killer	O
cells	O
at	O
nutritionally	O
relevant	O
concentrations	O
.	O

Daidzein	O
and	O
genistein	O
glucuronides	O
(	O
DG	O
and	O
GG	O
)	O
,	O
major	O
isoflavone	O
metabolites	O
,	O
may	O
be	O
partly	O
responsible	O
for	O
biological	O
effects	O
of	O
isoflavones	O
,	O
such	O
as	O
estrogen	O
receptor	O
binding	O
and	O
natural	O
killer	O
cell	O
(	O
NK	O
)	O
activation	O
or	O
inhibition	O
.	O

DG	O
and	O
GG	O
were	O
synthesized	O
using	O
3	O
-	O
methylcholanthrene	O
-	O
induced	O
rat	O
liver	O
microsomes	O
.	O

DG	O
and	O
GG	O
were	O
further	O
purified	O
by	O
a	O
Sephadex	O
LH	O
-	O
20	O
column	O
.	O

In	O
this	O
study	O
,	O
we	O
propose	O
a	O
novel	O
function	O
for	O
CD44	O
.	O

Using	O
synovial	O
cells	O
from	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
patients	O
,	O
we	O
demonstrated	O
that	O
CD44	O
cross	O
-	O
linking	O
and	O
binding	O
to	O
hyaluronan	O
augmented	O
VCAM	B
-	I
1	I
expression	O
and	O
subsequently	O
VCAM	B
-	I
1	I
-	O
mediated	O
cell	O
adhesion	O
.	O

In	O
neutrophils	O
,	O
TNF	B
-	I
alpha	I
caused	O
a	O
gliotoxin	O
-	O
inhibitable	O
activation	O
of	O
an	O
inducible	O
form	O
of	O
NF	B
-	I
kappaB	I
,	O
a	O
response	O
that	O
may	O
underlie	O
the	O
ability	O
of	O
TNF	B
-	I
alpha	I
to	O
delay	O
apoptosis	O
at	O
later	O
times	O
(	O
12	O
-	O
24	O
h	O
)	O
and	O
limit	O
its	O
early	O
killing	O
effect	O
.	O

We	O
previously	O
identified	O
a	O
Fas	B
ligand	I
regulatory	I
element	I
(	O
FLRE	B
)	O
in	O
the	O
Fas	B
ligand	I
(	I
fasL	I
)	I
promoter	I
that	O
binds	O
Egr	B
family	I
proteins	I
and	O
demonstrated	O
that	O
Egr	B
-	I
3	I
(	O
PILOT	B
)	O
but	O
not	O
Egr	B
-	I
1	I
(	O
NGFI	B
-	I
A	I
,	O
Krox	B
-	I
24	I
,	O
Tis	B
-	I
8	I
,	O
and	O
Zif	B
-	I
268	I
)	O
induces	O
transcription	O
of	O
fasL	B
.	O

The	O
aberrant	O
CD4	O
(	O
-	O
)	O
CD8	O
(	O
-	O
)	O
T	O
cells	O
from	O
lpr	O
/	O
lpr	O
and	O
gld	O
/	O
gld	O
mice	O
,	O
which	O
have	O
mutations	O
in	O
the	O
genes	O
encoding	O
Fas	B
and	O
FasL	B
,	O
respectively	O
,	O
have	O
an	O
activated	O
phenotype	O
and	O
constitutively	O
express	O
high	O
levels	O
of	O
fasL	B
mRNA	I
,	O
prompting	O
us	O
to	O
ask	O
what	O
role	O
if	O
any	O
the	O
FLRE	B
and	O
Egr	B
family	I
proteins	I
have	O
in	O
this	O
aberrant	O
expression	O
of	O
fasL	B
.	O

Although	O
overexpressed	O
Egr	B
-	I
1	I
was	O
ineffective	O
,	O
overexpressed	O
Egr	B
-	I
2	I
was	O
as	O
potent	O
as	O
Egr	B
-	I
3	I
in	O
inducing	O
fasL	B
promoter	I
-	I
dependent	I
reporter	I
constructs	I
in	O
T	O
cell	O
hybridomas	O
and	O
HeLa	O
cells	O
,	O
and	O
both	O
up	O
-	O
regulated	O
endogenous	O
fasL	B
mRNA	I
in	O
HeLa	O
cells	O
.	O

FasL	B
-	I
dependent	I
reporter	I
constructs	I
in	O
MRL	O
-	O
lpr	O
/	O
lpr	O
and	O
C3H	O
-	O
gld	O
/	O
gld	O
CD4	O
(	O
-	O
)	O
CD8	O
(	O
-	O
)	O
T	O
cells	O
were	O
constitutively	O
active	O
,	O
and	O
this	O
activity	O
was	O
largely	O
prevented	O
by	O
mutation	O
of	O
the	O
critical	O
Egr	B
family	I
binding	I
element	I
.	O

The	O
activity	O
of	O
the	O
CCAAT	B
-	I
box	I
binding	I
factor	I
NF	I
-	I
Y	I
is	O
modulated	O
through	O
the	O
regulated	O
expression	O
of	O
its	O
A	B
subunit	I
during	O
monocyte	O
to	O
macrophage	O
differentiation	O
:	O
regulation	O
of	O
tissue	B
-	I
specific	I
genes	I
through	O
a	O
ubiquitous	O
transcription	B
factor	I
.	O

Recent	O
studies	O
have	O
suggested	O
that	O
Y319	O
also	O
positively	O
regulate	O
ZAP	B
-	I
70	I
function	O
.	O

Deletion	O
of	O
interdomain	B
B	I
did	O
not	O
affect	O
the	O
ability	O
of	O
ZAP	B
-	I
70	I
to	O
bind	O
to	O
the	O
receptor	O
.	O

Differential	O
induction	O
of	O
DNA	B
-	I
binding	I
activities	I
following	O
CD19	B
cross	O
-	O
linking	O
in	O
human	O
B	O
lineage	O
cells	O
.	O

The	O
B	B
cell	I
-	I
specific	I
cell	I
surface	I
molecule	I
CD19	B
is	O
expressed	O
at	O
all	O
stages	O
of	O
B	O
cell	O
development	O
,	O
including	O
normal	O
plasma	O
cells	O
,	O
and	O
mediates	O
signal	O
transduction	O
via	O
interaction	O
with	O
cytoplasmic	B
effector	I
proteins	I
.	O

Oxidants	O
,	O
transcription	B
factors	I
,	O
and	O
intestinal	O
inflammation	O
.	O

It	O
is	O
now	O
well	O
appreciated	O
that	O
chronic	O
gut	O
inflammation	O
is	O
characterized	O
by	O
enhanced	O
production	O
of	O
reactive	O
metabolites	O
of	O
oxygen	O
and	O
nitrogen	O
.	O

Finally	O
,	O
oxidants	O
are	O
believed	O
to	O
promote	O
intestinal	O
epithelial	O
cell	O
apoptosis	O
,	O
and	O
the	O
B	B
-	I
cell	I
lymphoma	I
/	I
leukemia	I
-	I
2	I
gene	I
product	I
is	O
believed	O
to	O
inhibit	O
this	O
phenomenon	O
in	O
an	O
antioxidant	O
-	O
dependent	O
manner	O
.	O

The	O
regulatory	B
regions	I
of	O
several	O
genes	O
specifically	O
expressed	O
in	O
B	O
cells	O
contain	O
functional	B
binding	I
sites	I
for	O
Oct2	B
.	O

These	O
target	B
genes	I
show	O
quite	O
distinct	O
expression	O
patterns	O
demonstrating	O
that	O
transcription	B
factors	I
in	O
addition	O
to	O
Oct2	B
are	O
involved	O
in	O
their	O
regulation	O
.	O

The	O
protein	O
has	O
no	O
known	O
DNA	B
-	I
binding	I
domain	I
but	O
does	O
contain	O
three	O
ankyrin	O
repeats	O
that	O
are	O
likely	O
to	O
be	O
important	O
in	O
protein	O
-	O
protein	O
interactions	O
.	O

Binding	O
of	O
c	B
-	I
Rel	I
to	O
STAT5	B
target	I
sequences	I
in	O
HTLV	O
-	O
I	O
-	O
transformed	O
T	O
cells	O
.	O

Fas	B
(	O
CD95	B
)	O
and	O
Fas	B
ligand	I
(	O
CD95L	B
)	O
are	O
an	O
interacting	O
receptor	O
-	O
ligand	O
pair	O
required	O
for	O
immune	O
homeostasis	O
.	O

Although	O
resting	O
Jurkat	O
cells	O
express	O
Fas	B
,	O
Fas	B
mRNA	I
was	O
induced	O
approximately	O
10	O
-	O
fold	O
in	O
2	O
h	O
upon	O
P	O
/	O
I	O
stimulation	O
.	O

The	O
functional	O
contribution	O
of	O
the	O
kappaB	B
-	I
Sp1	I
composite	I
site	I
in	O
P	B
/	I
I	I
-	I
inducible	I
fas	I
promoter	I
activation	O
was	O
verified	O
by	O
using	O
kappaB	O
-	O
Sp1	B
concatamers	O
(	O
-	B
295	I
to	I
-	I
286	I
)	O
in	O
a	O
thymidine	B
kinase	I
promoter	I
-	I
driven	I
reporter	I
construct	I
and	O
native	B
promoter	I
constructs	I
in	O
Jurkat	O
cells	O
overexpressing	O
IkappaB	B
-	I
alpha	I
.	O

The	O
induction	O
of	O
clonal	O
anergy	O
in	O
a	O
T	O
cell	O
inhibits	O
IL	B
-	I
2	I
secretion	O
because	O
of	O
the	O
development	O
of	O
a	O
proximal	O
signal	O
transduction	O
defect	O
.	O

Members	O
of	O
the	O
cyclic	B
adenosine	I
monophosphate	I
(	I
cAMP	I
)	I
response	I
element	I
binding	I
(	I
CREB	I
)	I
/	I
activating	I
transcription	I
factor	I
1	I
(	I
ATF	I
-	I
1	I
)	I
family	I
of	O
transcription	B
factors	I
bind	O
three	O
21	B
-	I
bp	I
repeats	I
(	O
Tax	B
-	I
responsive	I
element	I
-	I
1	I
,	O
or	O
TRE	B
-	I
1	I
)	O
within	O
the	O
viral	B
promoter	I
and	O
are	O
important	O
for	O
basal	O
and	O
Tax	O
-	O
mediated	O
transcription	O
.	O

Exposing	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
(	O
HUVECs	O
)	O
to	O
anoxia	O
/	O
reoxygenation	O
(	O
A	O
/	O
R	O
)	O
results	O
in	O
an	O
increase	O
in	O
polymorphonuclear	O
leukocyte	O
(	O
PMN	O
)	O
adhesion	O
to	O
HUVECs	O
.	O

NO	O
production	O
by	O
HUVECs	O
is	O
increased	O
after	O
the	O
second	O
A	O
/	O
R	O
challenge	O
,	O
but	O
not	O
after	O
the	O
first	O
A	O
/	O
R	O
challenge	O
.	O

However	O
,	O
while	O
HUVECs	O
contained	O
endothelial	O
NOS	B
protein	I
,	O
no	O
inducible	O
NOS	B
was	O
detected	O
in	O
either	O
tolerant	O
or	O
nontolerant	O
cells	O
.	O

The	O
inhibition	O
of	O
IL	B
-	I
2	I
production	O
was	O
observed	O
in	O
the	O
CD3	B
(	O
+	O
)	O
T	O
-	O
lymphocyte	O
cytoplasm	O
as	O
early	O
as	O
4	O
h	O
after	O
activation	O
by	O
PMA	O
+	O
ionomycin	O
.	O

Delta	O
-	O
opioid	O
receptors	O
expressed	O
by	O
Jurkat	O
T	O
cells	O
enhance	O
IL	B
-	I
2	I
secretion	O
by	O
increasing	O
AP	B
-	I
1	I
complexes	I
and	O
activity	O
of	O
the	O
NF	B
-	I
AT	I
/	I
AP	I
-	I
1	I
-	I
binding	I
promoter	I
element	I
.	O

Reporter	O
gene	O
constructs	O
were	O
used	O
to	O
map	O
this	O
effect	O
of	O
deltorphin	O
to	O
the	O
AP	B
-	I
1	I
-	I
and	I
NF	I
-	I
AT	I
/	I
AP	I
-	I
1	I
-	I
binding	I
sites	I
of	O
the	O
IL	B
-	I
2	I
promoter	I
.	O

These	O
cells	O
,	O
stimulated	O
by	O
an	O
agonistic	O
monoclonal	O
antibody	O
against	O
CD40	B
or	O
by	O
transfection	O
with	O
a	O
CD40L	B
expression	I
vector	I
,	O
secreted	O
p40	B
and	O
showed	O
enhanced	O
p40	B
mRNA	I
expression	O
.	O

No	O
mutation	O
was	O
identified	O
in	O
either	O
of	O
the	O
genes	O
in	O
the	O
gynecomastias	O
.	O

We	O
have	O
mapped	O
the	O
DNase	B
-	I
I	I
-	I
hypersensitive	I
(	I
HS	I
)	I
regions	I
of	O
the	O
human	B
GATA	I
-	I
3	I
gene	I
in	O
T	O
-	O
cells	O
and	O
non	O
-	O
T	O
-	O
cells	O
and	O
studied	O
their	O
transcriptional	O
activities	O
.	O

HS	B
I	I
-	I
III	I
,	O
located	O
5	O
'	O
from	O
the	O
transcriptional	B
initiation	I
site	I
,	O
were	O
found	O
in	O
hematopoietic	O
and	O
non	O
-	O
hematopoietic	O
cells	O
,	O
whereas	O
HS	B
IV	I
-	I
VII	I
,	O
located	O
3	O
'	O
from	O
the	O
transcriptional	B
start	I
site	I
,	O
were	O
exclusively	O
observed	O
in	O
T	O
-	O
cells	O
.	O

Among	O
these	O
hypersensitive	B
sites	I
,	O
two	O
transcriptional	B
control	I
elements	I
were	O
found	O
,	O
one	O
in	O
the	O
first	B
intron	I
of	O
the	O
GATA	B
-	I
3	I
gene	I
and	O
the	O
other	O
between	B
8	I
.	I
3	I
and	I
5	I
.	I
9	I
kilobases	I
5	O
'	O
from	O
the	O
GATA	B
-	I
3	I
transcriptional	I
initiation	I
site	I
.	O

Two	O
CAGGTG	O
E	O
-	O
boxes	O
,	O
located	O
at	O
the	O
5	B
'	I
-	I
and	I
3	I
'	I
-	I
ends	I
of	O
the	O
silencer	O
,	O
were	O
necessary	O
for	O
this	O
silencer	O
activity	O
.	O

The	O
3	B
'	I
-	I
CAGGTG	I
E	I
-	I
box	I
could	O
bind	O
USF	B
proteins	I
,	O
the	O
ubiquitous	B
repressor	I
ZEB	B
,	O
or	O
the	O
basic	B
helix	I
-	I
loop	I
-	I
helix	I
proteins	I
E2A	B
and	O
HEB	B
,	O
and	O
we	O
showed	O
that	O
a	O
competition	O
between	O
ZEB	B
and	O
E2A	B
/	I
HEB	I
proteins	I
is	O
involved	O
in	O
the	O
silencer	O
activity	O
.	O

Reactive	O
oxygen	O
intermediate	O
-	O
dependent	O
NF	B
-	I
kappaB	I
activation	O
by	O
interleukin	B
-	I
1beta	I
requires	O
5	B
-	I
lipoxygenase	I
or	O
NADPH	O
oxidase	O
activity	O
.	O

However	O
,	O
the	O
sources	O
for	O
ROIs	O
in	O
various	O
cell	O
types	O
are	O
yet	O
to	O
be	O
determined	O
and	O
might	O
include	O
5	B
-	I
lipoxygenase	I
(	O
5	B
-	I
LOX	I
)	O
and	O
NADPH	O
oxidase	O
.	O

Stimulation	O
of	O
lymphoid	O
cells	O
with	O
interleukin	B
-	I
1beta	I
(	O
IL	B
-	I
1beta	I
)	O
led	O
to	O
ROI	O
production	O
and	O
NF	B
-	I
kappaB	I
activation	O
,	O
which	O
could	O
both	O
be	O
blocked	O
by	O
antioxidants	O
or	O
FLAP	B
inhibitors	O
,	O
confirming	O
that	O
5	B
-	I
LOX	I
was	O
the	O
source	O
of	O
ROIs	O
and	O
was	O
required	O
for	O
NF	B
-	I
kappaB	I
activation	O
in	O
these	O
cells	O
.	O

Cutting	O
edge	O
:	O
dominant	O
effect	O
of	O
Ile50Val	B
variant	I
of	O
the	O
human	B
IL	I
-	I
4	I
receptor	I
alpha	I
-	I
chain	I
in	O
IgE	B
synthesis	O
.	O

Constitutive	O
expression	O
of	O
human	B
colony	I
-	I
stimulating	I
factor	I
-	I
1	I
receptor	I
(	O
CSF	B
-	I
1R	I
)	O
confers	O
long	O
-	O
lasting	O
CSF	B
-	I
1	I
-	O
dependent	O
proliferation	O
to	O
mouse	O
myeloid	O
cell	O
lines	O
.	O

Morphologic	O
and	O
cytofluorometry	O
analysis	O
established	O
that	O
most	O
47	O
.	O
10	O
cells	O
are	O
immature	O
myelomonocytic	O
cells	O
.	O

In	O
agar	O
cultures	O
,	O
47	O
.	O
10	O
cells	O
form	O
7	O
-	O
and	O
14	O
-	O
day	O
colonies	O
in	O
response	O
to	O
a	O
cocktail	O
of	O
granulocyte	B
/	I
macrophage	I
colony	I
-	I
stimulating	I
factor	I
(	O
2	O
.	O
5	O
ng	O
/	O
mL	O
)	O
,	O
interleukin	B
-	I
3	I
(	O
1	O
ng	O
/	O
mL	O
)	O
,	O
and	O
mouse	O
CSF	B
-	I
1	I
(	O
10	O
ng	O
/	O
mL	O
)	O
.	O

In	O
conclusion	O
,	O
we	O
have	O
characterized	O
a	O
novel	O
continuous	O
myeloid	O
cell	O
line	O
presenting	O
a	O
hierarchical	O
structure	O
similar	O
to	O
that	O
of	O
the	O
bone	O
marrow	O
progenitor	O
cell	O
compartment	O
.	O

Regulation	O
of	O
IL	B
-	I
4	I
expression	O
by	O
the	O
transcription	B
factor	I
JunB	B
during	O
T	O
helper	O
cell	O
differentiation	O
.	O

Here	O
we	O
show	O
that	O
JunB	B
,	O
but	O
not	O
the	O
other	O
Jun	B
family	I
members	I
,	O
was	O
selectively	O
induced	O
in	O
Th2	O
cells	O
and	O
not	O
in	O
Th1	O
cells	O
during	O
differentiation	O
.	O

The	O
finding	O
of	O
Tax	B
mutants	O
segregating	O
these	O
two	O
pathways	O
suggested	O
that	O
the	O
NF	B
-	I
kappaB	I
pathway	O
was	O
essential	O
for	O
IL	B
-	I
2	I
-	O
independent	O
growth	O
of	O
CTLL	O
-	O
2	O
cells	O
while	O
the	O
CRE	B
pathway	O
was	O
unnecessary	O
.	O

However	O
,	O
both	O
pathways	O
were	O
necessary	O
for	O
another	O
transformation	O
-	O
related	O
activity	O
(	O
colony	O
formation	O
in	O
soft	O
agar	O
)	O
of	O
CTLL	B
-	I
2	I
/	I
Tax	I
.	O

Our	O
results	O
show	O
that	O
Tax	B
has	O
at	O
least	O
two	O
distinct	O
activities	O
on	O
T	O
cells	O
,	O
and	O
suggest	O
that	O
Tax	B
plays	O
a	O
crucial	O
role	O
in	O
IL	B
-	I
2	I
-	O
independent	O
T	O
-	O
cell	O
transformation	O
induced	O
by	O
HTLV	O
-	O
1	O
,	O
in	O
addition	O
to	O
its	O
well	O
-	O
known	O
IL	B
-	I
2	I
-	O
dependent	O
cell	O
transformation	O
.	O

First	O
,	O
it	O
gives	O
no	O
information	O
on	O
memory	O
to	O
lytic	B
cycle	I
antigens	I
;	O
second	O
,	O
it	O
preferentially	O
amplifies	O
the	O
dominant	O
components	O
of	O
latent	O
antigen	O
-	O
specific	O
memory	O
at	O
the	O
expense	O
of	O
key	O
subdominant	O
reactivities	O
.	O

Here	O
we	O
describe	O
an	O
alternative	O
approach	O
,	O
based	O
on	O
in	O
vitro	O
stimulation	O
with	O
epitope	O
peptide	O
-	O
loaded	O
dendritic	O
cells	O
(	O
DCs	O
)	O
,	O
which	O
allows	O
one	O
to	O
probe	O
the	O
CTL	O
repertoire	O
for	O
any	O
individual	O
reactivity	O
of	O
choice	O
;	O
this	O
method	O
proved	O
significantly	O
more	O
efficient	O
than	O
stimulation	O
with	O
peptide	O
alone	O
.	O

The	O
present	O
study	O
was	O
designed	O
to	O
analyze	O
the	O
roles	O
of	O
the	O
two	O
GR	B
isoforms	I
on	O
glucocorticoid	O
-	O
mediated	O
transrepression	O
of	O
the	O
IL	B
-	I
2	I
gene	I
.	O

Furthermore	O
,	O
GRbeta	B
did	O
not	O
antagonize	O
the	O
repressive	O
effects	O
of	O
GRalpha	B
on	O
IL	B
-	I
2	I
promoter	I
activity	O
.	O

Surprisingly	O
,	O
overexpression	O
of	O
GRbeta	B
in	O
Jurkat	O
cells	O
did	O
not	O
cause	O
significant	O
inhibition	O
of	O
GRalpha	B
-	O
induced	O
transactivation	O
of	O
a	O
GRE	B
-	I
dependent	I
luciferase	I
reporter	I
gene	I
either	O
.	O

Extinction	O
of	O
immunoglobulin	B
gene	I
expression	O
in	O
B	O
cells	O
upon	O
fusion	O
with	O
HeLa	O
cells	O
is	O
preceded	O
by	O
rapid	O
nuclear	O
depletion	O
of	O
essential	B
transcription	I
factors	I
and	O
is	O
accompanied	O
by	O
widespread	O
inactivation	O
of	O
genes	O
expressed	O
in	O
a	O
B	O
cell	O
-	O
specific	O
manner	O
.	O

Evidence	O
for	O
suppressed	O
activity	O
of	O
the	O
transcription	B
factor	I
NFAT1	B
at	O
its	O
proximal	B
binding	I
element	I
P0	B
in	O
the	O
IL	B
-	I
4	I
promoter	I
associated	O
with	O
enhanced	O
IL	B
-	I
4	I
gene	I
transcription	O
in	O
T	O
cells	O
of	O
atopic	O
patients	O
.	O

In	O
a	O
series	O
of	O
electrophoretic	O
mobility	O
shift	O
assays	O
with	O
protein	O
extracts	O
of	O
highly	O
polarized	O
Th2	O
clones	O
from	O
atopics	O
and	O
Th1	O
clones	O
from	O
controls	O
we	O
compared	O
DNA	O
-	O
binding	O
activities	O
at	O
the	O
two	O
NFAT	B
-	I
binding	I
elements	I
P0	B
and	O
P1	B
of	O
the	O
crucial	O
proximal	O
human	O
IL	B
-	I
4	I
promoter	I
.	O

At	O
the	O
most	O
proximal	O
P0	B
site	O
,	O
NFAT	O
-	O
containing	O
complexes	O
devoid	O
of	O
NFAT2	B
were	O
readily	O
inducible	O
in	O
the	O
Th1	O
clones	O
,	O
but	O
hardly	O
or	O
not	O
in	O
the	O
Th2	O
clones	O
.	O

These	O
findings	O
suggest	O
that	O
high	O
-	O
level	O
IL	B
-	I
4	I
production	O
in	O
atopic	O
Th2	O
cells	O
is	O
associated	O
with	O
selective	O
reduction	O
of	O
suppressive	O
NFAT1	B
activity	O
at	O
the	O
IL	B
-	I
4	I
P0	I
element	I
and	O
that	O
some	O
patients	O
with	O
this	O
multifactorial	O
disease	O
may	O
have	O
a	O
putative	O
systemic	O
disorder	O
at	O
this	O
level	O
.	O

Rather	O
,	O
squirrel	O
monkeys	O
express	O
a	O
soluble	O
factor	O
that	O
,	O
in	O
mixing	O
studies	O
of	O
cytosol	O
from	O
squirrel	O
monkey	O
lymphocytes	O
(	O
SML	O
)	O
and	O
mouse	O
L929	O
cells	O
,	O
reduced	O
GR	O
binding	O
affinity	O
by	O
11	O
-	O
fold	O
.	O

A	O
role	O
for	O
changes	O
in	O
immunophilins	B
,	O
causing	O
glucocorticoid	O
resistance	O
in	O
neotropical	O
primates	O
,	O
is	O
supported	O
by	O
the	O
following	O
:	O
the	O
changes	O
in	O
FKBP51	B
and	O
FKBP52	B
were	O
observed	O
in	O
cells	O
from	O
other	O
neotropical	O
primates	O
with	O
glucocorticoid	O
resistance	O
;	O
the	O
elevated	O
level	O
of	O
FKBP51	B
was	O
reflected	O
in	O
an	O
abundance	O
of	O
FKBP51	B
in	O
heat	B
shock	I
protein	I
90	I
complexes	I
in	O
SML	O
;	O
when	O
cytosols	O
of	O
SML	O
and	O
L929	O
cells	O
were	O
mixed	O
,	O
the	O
decrease	O
in	O
GR	O
binding	O
was	O
associated	O
with	O
incorporation	O
of	O
FKBP51	B
into	O
GR	B
heterocomplexes	I
;	O
the	O
effect	O
of	O
SML	O
cytosol	O
on	O
GR	O
binding	O
was	O
reproduced	O
with	O
cytosol	O
from	O
COS	O
cells	O
expressing	O
squirrel	O
monkey	O
FKBP51	B
;	O
and	O
both	O
the	O
effect	O
of	O
SML	O
cytosol	O
on	O
GR	O
binding	O
and	O
the	O
incorporation	O
of	O
FKBP51	B
into	O
GR	B
heterocomplexes	I
were	O
blocked	O
by	O
FK506	O
.	O

The	O
prevalent	O
complex	O
is	O
the	O
heterodimer	B
p50	I
-	I
p65	I
.	O

NF	B
-	I
kappaB	I
activity	O
is	O
tightly	O
correlated	O
with	O
the	O
transcriptional	O
activity	O
of	O
a	O
long	B
terminal	I
repeat	I
(	O
LTR	B
)	O
of	O
HIV	O
-	O
1	O
transfected	O
in	O
thymocytes	O
.	O

GCs	O
induce	O
apoptosis	O
in	O
neoplastic	O
lymphoid	O
cells	O
;	O
and	O
,	O
defective	O
apoptosis	O
is	O
implicated	O
in	O
the	O
genesis	O
of	O
chronic	O
lymphocytic	O
leukemia	O
(	O
CLL	O
)	O
.	O

These	O
findings	O
indicate	O
that	O
imbalanced	O
expression	O
of	O
the	O
GR	B
isoforms	I
may	O
be	O
a	O
mechanism	O
of	O
GC	O
resistance	O
,	O
and	O
may	O
have	O
implications	O
for	O
tumorigenesis	O
by	O
enhancing	O
cell	O
survival	O
.	O

A	O
second	O
hypersensitive	O
site	O
(	O
HS	O
2	O
)	O
was	O
identified	O
within	O
the	O
first	O
intron	O
in	O
pre	O
-	O
monocytic	O
cells	O
,	O
which	O
express	O
Elk	O
-	O
1	O
only	O
when	O
differentiating	O
to	O
monocytes	O
.	O

Twenty	O
-	O
seven	O
patients	O
with	O
tumors	O
of	O
the	O
oral	O
cavity	O
,	O
oropharynx	O
,	O
and	O
maxillary	O
sinus	O
were	O
examined	O
,	O
all	O
of	O
which	O
were	O
confirmed	O
as	O
squamous	O
cell	O
carcinomas	O
.	O

Serial	O
sectioning	O
of	O
6	O
micrometer	O
was	O
performed	O
using	O
a	O
cryostat	O
,	O
and	O
samples	O
were	O
immunohistochemicall	O
stained	O
using	O
the	O
streptoavidin	B
-	B
biotin	I
peroxidase	I
method	O
and	O
a	O
monoclonal	O
antibody	O
against	O
c	O
-	O
fos	O
.	O

Three	O
of	O
the	O
27	O
patients	O
with	O
squamous	O
cell	O
carcinoma	O
showed	O
slight	O
expression	O
of	O
c	O
-	O
fos	O
in	O
their	O
tumor	O
cells	O
before	O
and	O
/	O
or	O
at	O
4	O
or	O
10	O
Gy	O
of	O
radiotherapy	O
.	O

In	O
patients	O
whose	O
infiltration	O
of	O
c	B
-	I
fos	I
-	I
positive	I
lymphocytes	I
into	O
tumor	O
tissues	O
were	O
moderate	O
or	O
remarkable	O
at	O
4	O
Gy	O
of	O
radiotherapy	O
,	O
the	O
tumors	O
responded	O
significantly	O
well	O
to	O
radiation	O
therapy	O
(	O
P	O
<	O
0	O
.	O
025	O
,	O
chi2	O
test	O
)	O
,	O
and	O
the	O
patients	O
took	O
a	O
significantly	O
favorable	O
clinical	O
course	O
(	O
P	O
<	O
0	O
.	O
05	O
,	O
chi2	O
test	O
)	O
.	O

The	O
allele	O
-	O
specific	O
expression	O
profiles	O
of	O
other	O
imprinted	B
genes	I
,	O
IGF2	B
and	O
H19	B
,	O
on	O
human	B
chromosome	I
11	I
were	O
constant	O
and	O
consistent	O
with	O
those	O
in	O
other	O
tissues	O
.	O

Our	O
unexpected	O
observations	O
of	O
paternal	O
or	O
biallelic	O
expression	O
of	O
WT1	B
in	O
fibroblasts	O
and	O
lymphocytes	O
,	O
together	O
with	O
the	O
previous	O
findings	O
of	O
maternal	O
or	O
biallelic	O
expression	O
in	O
placentae	O
and	O
brains	O
,	O
suggest	O
that	O
the	O
allele	O
-	O
specific	O
regulatory	O
system	O
of	O
WT1	B
is	O
unique	O
and	O
may	O
be	O
controlled	O
by	O
a	O
putative	O
tissue	O
-	O
and	O
individual	O
-	O
specific	O
modifier	O
.	O

T	O
cell	O
responses	O
to	O
some	O
nuclear	O
antigens	O
,	O
particularly	O
U1RNP	B
,	O
have	O
been	O
detected	O
in	O
patients	O
with	O
systemic	O
lupus	O
erythematosus	O
(	O
SLE	O
)	O
and	O
in	O
healthy	O
subjects	O
.	O

METHODS	O
.	O

HLA	O
-	O
DR	O
typing	O
was	O
by	O
polymerase	O
chain	O
reaction	O
and	O
sequence	O
specific	O
oligonucleotide	O
typing	O
.	O

RESULTS	O
.	O

Six	O
of	O
20	O
patients	O
with	O
SS	O
and	O
10	O
/	O
19	O
controls	O
proliferated	O
to	O
La	O
(	O
rSSB	B
)	O
.	O

Tumor	B
necrosis	I
factor	I
(	I
TNF	I
)	I
-	I
alpha	I
-	O
induced	O
HIV	O
-	O
1	O
replication	O
in	O
OM10	O
.	O
1	O
or	O
Ach2	O
cells	O
was	O
significantly	O
inhibited	O
by	O
non	O
-	O
cytotoxic	O
doses	O
of	O
AuTG	O
(	O
>	O
10	O
microM	O
in	O
OM10	O
.	O
1	O
cells	O
and	O
>	O
25	O
F	O
.	O
M	O
in	O
Ach2	O
cells	O
)	O
,	O
while	O
25	O
microM	O
of	O
the	O
counter	B
-	I
anion	I
thioglucose	I
(	O
TG	B
)	O
or	O
gold	O
compound	O
containing	O
divalent	O
gold	O
ion	O
,	O
HAuCl3	O
,	O
had	O
no	O
effect	O
.	O

Specific	O
staining	O
as	O
well	O
as	O
electron	O
microscopic	O
examinations	O
revealed	O
the	O
accumulation	O
of	O
metal	O
gold	O
in	O
the	O
cells	O
,	O
supporting	O
our	O
previous	O
hypothesis	O
that	O
gold	O
ions	O
could	O
block	O
NF	B
-	I
kappaB	I
-	O
DNA	O
binding	O
by	O
a	O
redox	O
mechanism	O
.	O

In	O
the	O
absence	O
of	O
karyotypic	O
abnormalities	O
,	O
there	O
is	O
no	O
specific	O
test	O
to	O
detect	O
clonal	O
eosinophilia	O
in	O
IHES	O
.	O

Peripheral	O
blood	O
eosinophils	O
were	O
isolated	O
by	O
their	O
autofluoresence	O
using	O
flow	O
cytometric	O
sorting	O
.	O

After	O
corticosteroid	O
suppression	O
of	O
her	O
blood	O
eosinophilia	O
,	O
a	O
clonal	O
population	O
of	O
eosinophils	O
could	O
no	O
longer	O
be	O
detected	O
in	O
purified	O
eosinophils	O
.	O

This	O
pro	B
-	I
IL	I
-	I
16	I
is	O
subsequently	O
processed	O
to	O
the	O
mature	O
cytokine	O
of	O
13	B
kDa	I
.	O

The	O
5	B
'	I
sequences	I
up	O
to	O
nucleotide	O
-	O
120	O
of	O
the	O
human	O
and	O
murine	O
IL	B
-	I
16	I
genes	O
share	O
>	O
84	O
%	O
sequence	O
homology	O
and	O
harbor	B
promoter	I
elements	I
for	O
constitutive	O
and	O
inducible	O
transcription	O
in	O
T	O
cells	O
.	O

Therefore	O
,	O
this	O
genetic	O
variant	O
,	O
which	O
predisposes	O
to	O
low	O
bone	O
mineral	O
density	O
in	O
many	O
populations	O
,	O
may	O
confer	O
resistance	O
to	O
certain	O
infectious	O
diseases	O
.	O

Indeed	O
,	O
the	O
availability	O
of	O
selective	O
and	O
orally	O
active	O
proteasome	O
inhibitors	O
should	O
prove	O
useful	O
in	O
delineating	O
the	O
roles	O
of	O
the	O
proteasome	O
and	O
NF	B
-	I
kappa	I
B	I
in	O
other	O
pathophysiological	O
conditions	O
such	O
as	O
cancer	O
and	O
heart	O
disease	O
.	O

Lysophosphatidyletha	O
(	O
lysoPE	O
)	O
and	O
other	O
lysophospholipids	O
did	O
not	O
affect	O
LPS	O
-	O
induced	O
TF	O
activity	O
of	O
human	O
monocytes	O
.	O

TF	O
antigen	O
expression	O
as	O
elicited	O
by	O
LPS	O
was	O
also	O
lowered	O
by	O
lysoPC	O
.	O

LysoPC	O
inhibited	O
the	O
TF	O
activity	O
of	O
Mono	O
Mac	O
-	O
6	O
cells	O
to	O
a	O
similar	O
extent	O
as	O
in	O
the	O
monocytes	O
.	O

A	O
Taq	B
I	I
polymorphism	I
was	O
identified	O
which	O
enabled	O
chicken	O
IL2	B
to	O
be	O
mapped	O
to	O
chromosome	B
4	I
,	O
linked	O
to	O
ANX5	B
,	O
with	O
synteny	O
with	O
mouse	B
chromosome	I
3	I
and	O
human	B
chromosome	I
4	I
.	O

There	O
is	O
increasing	O
evidence	O
that	O
IFN	B
-	I
alpha	I
has	O
an	O
important	O
role	O
in	O
T	O
-	O
cell	O
biology	O
.	O

The	O
induction	O
of	O
these	O
genes	O
is	O
associated	O
with	O
interleukin	B
-	I
2	I
(	O
IL	B
-	I
2	I
)	O
-	O
induced	O
T	O
-	O
cell	O
proliferation	O
.	O

Taken	O
together	O
,	O
our	O
results	O
suggest	O
that	O
IFN	B
-	I
alpha	I
,	O
IL	B
-	I
2	I
,	O
IL	B
-	I
12	I
,	O
and	O
IL	B
-	I
15	I
have	O
overlapping	O
activities	O
on	O
human	O
T	O
cells	O
.	O

The	O
Megakaryocyte	B
/	I
Platelet	I
-	I
specific	I
enhancer	I
of	O
the	O
alpha2beta1	B
integrin	I
gene	I
:	O
two	O
tandem	O
AP1	B
sites	I
and	O
the	O
mitogen	B
-	I
activated	I
protein	I
kinase	I
signaling	O
cascade	O
.	O

Transcriptional	O
regulation	O
of	O
the	O
alpha2	B
integrin	I
gene	I
in	O
cells	O
undergoing	O
megakaryocytic	O
differentiation	O
requires	O
a	O
core	B
promoter	I
between	O
bp	O
-	O
30	O
and	O
-	O
92	O
,	O
a	O
silencer	B
between	O
bp	O
-	O
92	O
and	O
-	O
351	O
,	O
and	O
megakaryocytic	B
enhancers	I
in	O
the	O
distal	B
5	I
'	I
flank	I
.	O

Therefore	O
,	O
our	O
data	O
not	O
only	O
reveal	O
that	O
Nmi	B
can	O
potentiate	O
STAT	B
-	O
dependent	O
transcription	O
,	O
but	O
also	O
suggest	O
that	O
it	O
can	O
augment	O
coactivator	O
protein	O
recruitment	O
to	O
at	O
least	O
some	O
members	O
of	O
a	O
group	O
of	O
sequence	B
-	I
specific	I
transcription	I
factors	I
.	O

In	O
contrast	O
,	O
activation	O
in	O
THP	B
-	I
1	I
cells	I
occurred	O
in	O
the	O
absence	O
of	O
vanadate	O
and	O
was	O
unaffected	O
by	O
catalase	B
.	O

These	O
findings	O
suggest	O
the	O
presence	O
in	O
vaginal	O
fluid	O
of	O
agent	O
(	O
s	O
)	O
derived	O
from	O
indigenous	O
bacteria	O
that	O
can	O
activate	O
the	O
HIV	B
-	I
1	I
LTR	I
,	O
cytokine	B
production	O
,	O
and	O
NF	B
-	I
kappaB	I
in	O
cells	O
of	O
macrophage	O
lineage	O
,	O
with	O
possible	O
influence	O
on	O
vaginal	O
physiology	O
and	O
host	O
defense	O
.	O

Activated	O
primed	O
CD4	O
T	O
cells	O
contain	O
more	O
NFAT1	B
and	O
support	O
greater	O
NFAT	B
-	O
directed	O
transcription	O
than	O
unprimed	O
CD4	O
T	O
cells	O
,	O
while	O
activator	B
protein	I
1	I
binding	O
and	O
activator	B
protein	I
1	I
-	O
mediated	O
transcription	O
by	O
both	O
cell	O
types	O
is	O
similar	O
.	O

These	O
agents	O
also	O
significantly	O
decreased	O
TNF	B
-	O
and	O
LPS	O
-	O
stimulated	O
increases	O
in	O
HUVEC	B
surface	I
VCAM	I
-	I
1	I
.	O

TNF	B
stimulated	O
expression	O
of	O
both	O
intercellular	B
adhesion	I
molecule	I
-	I
1	I
and	O
E	B
-	I
selectin	I
in	O
HUVECs	O
,	O
but	O
in	O
HUAECs	O
,	O
only	O
intercellular	B
adhesion	I
molecule	I
-	I
1	I
was	O
increased	O
.	O

Functional	O
testosterone	B
receptors	I
in	O
plasma	O
membranes	O
of	O
T	O
cells	O
.	O

AR	B
can	O
be	O
visualized	O
with	O
the	O
anti	B
-	I
AR	I
antibodies	I
in	O
the	O
cytoplasm	O
of	O
permeabilized	O
T	O
cells	O
by	O
using	O
CLSM	O
,	O
though	O
AR	B
are	O
not	O
detectable	O
in	O
cytosol	O
fractions	O
when	O
using	O
the	O
charcoal	O
binding	O
assay	O
with	O
3H	O
-	O
R1881	O
as	O
ligand	O
.	O

Cytoplasmic	B
AR	I
do	O
not	O
translocate	O
to	O
the	O
nucleus	O
of	O
T	O
cells	O
in	O
the	O
presence	O
of	O
testosterone	O
,	O
in	O
contrast	O
to	O
cytoplasmic	B
AR	I
in	O
human	O
cancer	O
LNCaP	O
cells	O
.	O

By	O
contrast	O
,	O
the	O
cell	B
surface	I
receptors	I
for	O
testosterone	O
are	O
in	O
a	O
functionally	O
active	O
state	O
,	O
enabling	O
T	O
cells	O
a	O
nongenomic	O
response	O
to	O
testosterone	O
.	O

Limited	O
proteolysis	O
for	O
assaying	O
ligand	O
binding	O
affinities	O
of	O
nuclear	B
receptors	I
.	O

Using	O
the	O
wild	B
-	I
type	I
or	I
mutated	I
human	I
retinoic	I
acid	I
receptor	I
alpha	I
as	O
a	O
model	O
,	O
kDa	O
values	O
determined	O
by	O
classical	O
competition	O
binding	O
assays	O
using	O
tritiated	O
ligands	O
are	O
in	O
agreement	O
with	O
those	O
measured	O
by	O
the	O
proteolytic	O
assay	O
.	O

B	O
lymphocytes	O
from	O
patients	O
with	O
chronic	O
lymphocytic	O
leukemia	O
contain	O
signal	B
transducer	I
and	I
activator	I
of	I
transcription	I
(	I
STAT	I
)	I
1	I
and	O
STAT3	B
constitutively	O
phosphorylated	O
on	O
serine	O
residues	O
.	O

In	O
summary	O
,	O
the	O
constitutive	O
serine	O
phosphorylation	O
of	O
STAT1	B
and	O
STAT3	B
is	O
present	O
in	O
all	O
CLL	O
samples	O
tested	O
to	O
date	O
,	O
although	O
the	O
physiologic	O
significance	O
of	O
this	O
modification	O
remains	O
to	O
be	O
determined	O
.	O

G	O
.	O
vaginalis	O
lysates	O
also	O
activated	O
HIV	O
expression	O
in	O
certain	O
T	O
cell	O
lines	O
.	O

Highly	O
purified	O
monocytes	O
were	O
incubated	O
with	O
IL	B
-	I
10	I
for	O
60	O
to	O
90	O
minutes	O
before	O
the	O
addition	O
of	O
IFNgamma	B
or	O
IFNalpha	B
.	O

IL	B
-	I
10	I
preincubation	O
resulted	O
in	O
the	O
inhibition	O
of	O
gene	O
expression	O
for	O
several	O
IFN	B
-	I
induced	I
genes	I
,	O
such	O
as	O
IP	B
-	I
10	I
,	O
ISG54	B
,	O
and	O
intercellular	B
adhesion	I
molecule	I
-	I
1	I
.	O

The	O
development	O
of	O
ringed	O
sideroblasts	O
in	O
erythroid	O
colonies	O
by	O
iron	O
staining	O
and	O
their	O
X	O
-	O
inactivation	O
pattern	O
were	O
also	O
examined	O
.	O

Granulosa	O
cell	O
tumor	O
of	O
the	O
ovary	O
.	O

All	O
of	O
the	O
tumors	O
exhibited	O
typical	O
morphology	O
,	O
were	O
limited	O
to	O
the	O
ovary	O
(	O
stage	O
I	O
)	O
,	O
and	O
7	O
cases	O
followed	O
a	O
benign	O
clinical	O
course	O
.	O

Comparison	O
of	O
primary	O
sensitization	O
of	O
naive	O
human	O
T	O
cells	O
to	O
varicella	O
-	O
zoster	O
virus	O
peptides	O
by	O
dendritic	O
cells	O
in	O
vitro	O
with	O
responses	O
elicited	O
in	O
vivo	O
by	O
varicella	O
vaccination	O
.	O

Dendritic	O
cells	O
(	O
DC	O
)	O
are	O
potent	O
APC	O
during	O
primary	O
and	O
secondary	O
immune	O
responses	O
.	O

Monocytes	O
were	O
effective	O
APC	O
for	O
VZV	O
peptides	O
only	O
after	O
immunization	O
.	O

IL	B
-	I
10	I
treatment	O
prevented	O
the	O
downregulation	O
of	O
p27	B
(	I
Kip1	I
)	O
,	O
an	O
inhibitory	B
protein	I
that	O
controls	O
progression	O
out	O
of	O
the	O
G0	O
phase	O
of	O
the	O
cell	O
cycle	O
.	O

Associated	O
with	O
the	O
inhibition	O
of	O
the	O
cell	O
cycle	O
,	O
IL	B
-	I
10	I
suppressed	O
SEB	B
induction	O
of	O
interleukin	B
-	I
2	I
(	O
IL	B
-	I
2	I
)	O
.	O

Although	O
this	O
reversal	O
by	O
IL	B
-	I
2	I
was	O
pronounced	O
,	O
it	O
was	O
not	O
complete	O
,	O
suggesting	O
that	O
IL	B
-	I
10	I
may	O
have	O
some	O
effects	O
not	O
directly	O
related	O
to	O
the	O
suppression	O
of	O
IL	B
-	I
2	I
production	O
.	O

IL	B
-	I
4	I
and	O
IL	B
-	I
13	I
induced	O
dose	O
-	O
and	O
time	O
-	O
dependent	O
increases	O
in	O
IL	O
-	O
1RI	O
and	O
IL	O
-	O
1RII	O
mRNA	O
levels	O
.	O

IFN	B
-	I
gamma	I
decreased	O
basal	O
expression	O
as	O
well	O
as	O
the	O
induction	O
of	O
these	O
genes	O
by	O
IL	B
-	I
4	I
and	O
IL	B
-	I
13	I
.	O

Inhibition	O
of	O
IL	B
-	I
1RI	I
and	O
IL	O
-	O
1RII	O
mRNA	O
levels	O
by	O
IFN	B
-	I
gamma	I
was	O
transcriptionally	O
mediated	O
,	O
and	O
correlated	O
directly	O
with	O
decreased	O
production	O
of	O
soluble	O
IL	B
-	I
1RII	I
.	O

In	O
both	O
cell	O
types	O
,	O
the	O
cytokine	B
that	O
inhibits	O
the	O
induction	O
of	O
IkappaBalpha	B
by	O
DEX	O
,	O
also	O
rescues	O
these	O
cells	O
from	O
DEX	O
-	O
induced	O
apoptosis	O
,	O
although	O
the	O
rescue	O
cytokine	O
is	O
different	O
in	O
Th1	O
and	O
Th2	O
cells	O
.	O

Infection	O
of	O
human	O
monocytes	O
with	O
influenza	O
A	O
virus	O
induces	O
a	O
broad	O
range	O
of	O
proinflammatory	B
cytokines	I
and	O
mononuclear	O
cell	O
attracting	O
chemokines	B
before	O
the	O
infected	O
cells	O
undergo	O
apoptosis	O
.	O

In	O
conclusion	O
,	O
the	O
long	O
-	O
term	O
regulation	O
of	O
transcription	B
factor	I
gene	O
expression	O
in	O
non	O
-	O
proliferating	O
cells	O
seems	O
to	O
be	O
of	O
minor	O
importance	O
after	O
influenza	O
infection	O
since	O
in	O
apoptosisprone	O
cells	O
an	O
immediate	O
availability	O
of	O
transcription	B
factor	I
proteins	I
is	O
required	O
.	O

Patients	O
with	O
diabetic	O
nephropathy	O
showed	O
higher	O
NF	B
-	I
kappaB	I
binding	O
activity	O
in	O
Electrophoretic	O
Mobility	O
Shift	O
Assays	O
and	O
stronger	O
immunohistological	O
staining	O
for	O
activated	O
NF	B
-	I
kappaBp65	I
than	O
patients	O
without	O
renal	O
complications	O
.	O

Resorption	O
lacunae	O
can	O
be	O
observed	O
by	O
day	O
22	O
.	O

We	O
incubated	O
sodium	O
oleate	O
with	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
for	O
0	O
to	O
72	O
hours	O
,	O
followed	O
by	O
coincubation	O
of	O
oleate	O
with	O
human	B
recombinant	I
tumor	I
necrosis	I
factor	I
,	O
interleukin	B
(	I
IL	I
)	I
-	I
1alpha	I
,	O
IL	B
-	I
1beta	I
,	O
IL	B
-	I
4	I
,	O
Escherichia	O
coli	O
lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
or	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
for	O
a	O
further	O
6	O
to	O
24	O
hours	O
.	O

The	O
endothelial	O
expression	O
of	O
vascular	B
cell	I
adhesion	I
molecule	I
-	I
1	I
(	O
VCAM	B
-	I
1	I
)	O
,	O
E	B
-	I
selectin	I
,	O
and	O
intercellular	B
adhesion	I
molecule	I
-	I
1	I
was	O
monitored	O
by	O
cell	O
surface	O
enzyme	O
immunoassays	O
or	O
flow	O
cytometry	O
,	O
and	O
steady	O
-	O
state	O
levels	O
of	O
VCAM	B
-	I
1	I
mRNA	I
were	O
assessed	O
by	O
Northern	O
blot	O
analysis	O
.	O

Incubation	O
of	O
endothelial	O
cells	O
with	O
oleate	O
for	O
72	O
hours	O
decreased	O
the	O
relative	O
proportions	O
of	O
saturated	O
(	O
palmitic	O
and	O
stearic	O
)	O
acids	O
in	O
total	O
cell	O
lipids	O
and	O
increased	O
the	O
proportions	O
of	O
oleate	O
in	O
total	O
cell	O
lipids	O
without	O
significantly	O
changing	O
the	O
relative	O
proportions	O
of	O
polyunsaturated	O
fatty	O
acids	O
.	O

The	O
importance	O
of	O
BCL2	B
and	O
Stat3	B
on	O
IL	B
-	I
6	I
-	O
induced	O
macrophage	O
-	O
differentiation	O
and	O
apoptosis	O
was	O
studied	O
with	O
1A9	O
-	O
M	O
cells	O
expressing	O
human	B
BCL2	I
or	O
a	O
dominant	O
-	O
negative	O
form	O
of	O
Stat3	B
,	O
respectively	O
.	O

IL	B
-	I
6	I
-	O
induced	O
apoptosis	O
,	O
but	O
not	O
macrophage	O
-	O
differentiation	O
,	O
was	O
blocked	O
by	O
continuously	O
expressed	O
BCL2	B
.	O

Interleukin	B
-	I
8	I
(	O
IL	B
-	I
8	I
)	O
is	O
a	O
chemokine	B
that	O
belongs	O
to	O
the	O
alpha	B
-	I
chemokine	I
or	O
CXC	B
subfamily	I
and	O
is	O
produced	O
by	O
a	O
wide	O
variety	O
of	O
human	O
cells	O
,	O
including	O
monocytes	O
and	O
polymorphonuclear	O
cells	O
(	O
PMN	O
)	O
.	O

IL	B
-	I
8	I
is	O
secreted	O
in	O
response	O
to	O
inflammatory	O
stimuli	O
,	O
notably	O
bacterial	O
products	O
such	O
as	O
lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
but	O
little	O
is	O
known	O
about	O
the	O
mechanisms	O
by	O
which	O
these	O
agents	O
mediate	O
IL	B
-	I
8	I
induction	O
.	O

In	O
this	O
report	O
,	O
we	O
show	O
that	O
Mycoplasma	B
fermentans	I
lipid	I
-	I
associated	I
membrane	I
proteins	I
(	O
LAMPf	B
)	O
induce	O
the	O
production	O
of	O
high	O
levels	O
of	O
IL	B
-	I
8	I
by	O
THP	O
-	O
1	O
(	O
human	O
monocyte	O
)	O
cells	O
and	O
PMN	O
at	O
the	O
same	O
extent	O
as	O
LPS	O
.	O

In	O
this	O
study	O
we	O
investigated	O
the	O
effects	O
of	O
C3a	B
and	O
C3a	B
(	I
desArg	I
)	I
on	O
gene	O
expression	O
and	O
protein	O
secretion	O
of	O
IL	B
-	I
6	I
in	O
human	O
PBMCs	O
,	O
either	O
alone	O
or	O
in	O
combination	O
with	O
LPS	O
or	O
IL	B
-	I
1beta	I
.	O

Furthermore	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
C3a	B
and	O
C3a	B
(	I
desArg	I
)	I
on	O
induction	O
of	O
NF	B
-	I
kappaB	I
and	O
activating	B
protein	I
-	I
1	I
binding	O
.	O

These	O
results	O
demonstrate	O
the	O
capacity	O
of	O
intact	O
C3a	B
and	O
its	O
circulating	O
des	B
-	I
Arg	I
form	I
to	O
exert	O
immunmodulatory	O
effects	O
in	O
vitro	O
.	O

Phenylarsine	O
oxide	O
inhibits	O
ex	O
vivo	O
HIV	O
-	O
1	O
expression	O
.	O

Pharmacological	O
control	O
of	O
antigen	O
responsiveness	O
in	O
genetically	O
modified	O
T	O
lymphocytes	O
.	O

Recently	O
,	O
fibromyalgia	O
(	O
FMS	O
)	O
was	O
shown	O
to	O
be	O
a	O
disorder	O
associated	O
with	O
an	O
altered	O
functioning	O
of	O
the	O
stress	O
response	O
system	O
.	O

FMS	O
patients	O
display	O
a	O
hyperreactive	O
pituitary	O
adrenocorticotropic	O
hormone	O
(	O
ACTH	O
)	O
release	O
in	O
response	O
to	O
corticotropin	O
-	O
releasing	O
hormone	O
(	O
CRH	O
)	O
and	O
to	O
insulin	O
-	O
induced	O
hypoglycemia	O
.	O

Therefore	O
we	O
investigated	O
the	O
properties	O
and	O
function	O
of	O
the	O
glucocorticoid	B
receptors	I
(	O
GR	B
)	O
in	O
FMS	O
patients	O
and	O
compared	O
the	O
results	O
with	O
those	O
of	O
healthy	O
persons	O
and	O
patients	O
with	O
chronic	O
low	O
back	O
pain	O
(	O
LBP	O
a	O
localized	O
pain	O
condition	O
)	O
.	O

Forty	O
primary	O
FMS	O
patients	O
(	O
F	O
:	O
M	O
=	O
36	O
:	O
4	O
)	O
,	O
28	O
LBP	O
patients	O
(	O
25	O
:	O
3	O
)	O
and	O
14	O
(	O
12	O
:	O
2	O
)	O
healthy	O
,	O
sedentary	O
control	O
persons	O
were	O
recruited	O
for	O
the	O
study	O
.	O

Urinary	O
free	O
cortisol	O
excretion	O
in	O
FMS	O
and	O
LBP	O
patients	O
was	O
lower	O
compared	O
to	O
controls	O
.	O

We	O
conclude	O
that	O
FMS	O
patients	O
have	O
a	O
mild	O
hypocortisolemia	O
,	O
increased	O
cortisol	O
feedback	O
resistance	O
in	O
combination	O
probably	O
with	O
a	O
reduced	O
CRH	O
synthesis	O
or	O
release	O
in	O
the	O
hypothalamus	O
.	O

The	O
suggested	O
roles	O
of	O
the	O
downstream	B
3	I
'	I
regions	I
acting	O
as	O
a	O
Locus	B
Control	I
Region	I
(	O
LCR	B
)	O
,	O
have	O
allowed	O
comparisons	O
to	O
be	O
made	O
between	O
the	O
regulation	O
of	O
the	O
IgH	B
locus	I
with	O
other	O
model	O
systems	O
whose	O
gene	O
expression	O
is	O
governed	O
by	O
LCR	B
activity	O
.	O

T	O
lymphocytes	O
recognize	O
antigens	O
in	O
the	O
form	O
of	O
peptides	O
bound	O
to	O
HLA	B
-	I
molecules	I
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
Peptides	O
derived	O
from	O
oncogenic	B
proteins	I
were	O
screened	O
for	O
the	O
presence	O
of	O
HLA	B
binding	I
motifs	I
;	O
actual	O
binding	O
were	O
evaluated	O
by	O
HLA	O
stabilization	O
experiments	O
using	O
transfectants	O
and	O
specific	O
anti	B
-	I
HLA	I
antibodies	I
.	O

Specific	O
lymphocytes	O
were	O
induced	O
by	O
in	O
vitro	O
peptide	O
sensitization	O
and	O
screened	O
by	O
thymidine	O
uptake	O
or	O
cellular	O
cytotoxic	O
assays	O
.	O

RESULTS	O
:	O
We	O
identified	O
peptides	O
derived	O
from	O
EWS	B
/	I
FLI	I
-	I
1	I
fusion	I
protein	I
and	O
from	O
mutated	B
K	I
-	I
RAS	I
protein	I
(	O
encompassing	O
respectively	O
the	O
fusion	B
point	I
and	O
the	O
mutation	O
at	O
position	B
12	I
)	O
that	O
showed	O
binding	B
motif	I
for	O
HLA	B
-	I
Cw	I
*	I
0702	I
and	O
HLA	B
-	I
A3	I
respectively	O
.	O

OCA	B
-	I
B	I
is	O
a	O
functional	O
analog	O
of	O
VP16	B
but	O
targets	O
a	O
separate	O
surface	O
of	O
the	O
Oct	B
-	I
1	I
POU	I
domain	I
[	O
published	O
erratum	O
appears	O
in	O
Mol	O
Cell	O
Biol	O
1998	O
Apr	O
;	O
18	O
(	O
4	O
)	O
:	O
2430	O
]	O

Here	O
,	O
we	O
show	O
that	O
OCA	B
-	I
B	I
alters	O
the	O
activity	O
of	O
Oct	B
-	I
1	I
in	O
two	O
ways	O
.	O

These	O
results	O
emphasize	O
the	O
structural	O
versatility	O
of	O
the	O
Oct	B
-	I
1	I
POU	I
domain	I
in	O
its	O
interaction	O
with	O
coregulators	O
.	O

Phosphatidylinositol	B
3	I
-	I
kinase	I
couples	O
the	O
interleukin	B
-	I
2	I
receptor	I
to	O
the	O
cell	B
cycle	I
regulator	I
E2F	B
.	O

We	O
eliminate	O
both	O
Stat5	B
and	O
Raf	B
/	B
MEK	I
pathways	O
from	O
E2F	B
regulation	O
.	O

TRADD	B
was	O
the	O
only	O
protein	O
that	O
interacted	O
with	O
wild	B
-	I
type	I
TES2	I
and	O
not	O
with	O
isoleucine	B
-	I
mutated	I
TES2	I
.	O

In	O
transfection	O
assays	O
,	O
TRADD	B
and	O
TES2	B
synergistically	O
mediated	O
high	O
-	O
level	O
NF	B
-	I
kappaB	I
activation	O
.	O

Bipotential	O
T	O
/	O
natural	O
killer	O
(	O
NK	O
)	O
progenitor	O
cells	O
are	O
present	O
in	O
the	O
human	O
thymus	O
.	O

Although	O
experimental	O
evidence	O
is	O
lacking	O
,	O
lytic	O
viral	O
DNA	O
replication	O
is	O
believed	O
to	O
remove	O
modifications	O
or	O
binding	B
factors	I
from	O
the	O
genome	O
which	O
serve	O
to	O
repress	O
late	O
gene	O
expression	O
during	O
latency	O
or	O
the	O
early	O
lytic	O
cycle	O
.	O

Thus	O
,	O
replication	O
of	O
the	O
transcriptional	B
template	I
is	O
not	O
a	O
prerequisite	O
for	O
expression	O
with	O
late	O
kinetics	O
,	O
a	O
finding	O
inconsistent	O
with	O
the	O
current	O
models	O
which	O
posit	O
a	O
cis	O
-	O
active	O
relationship	O
between	O
lytic	O
EBV	O
DNA	O
replication	O
and	O
late	O
gene	O
expression	O
.	O

This	O
induction	O
of	O
C	B
/	I
EBP	I
epsilon	I
mRNA	I
expression	O
is	O
transcriptionally	O
mediated	O
and	O
occurs	O
in	O
the	O
absence	O
of	O
synthesis	O
of	O
additional	O
protein	B
factors	I
.	O

We	O
suspect	O
that	O
the	O
C	B
/	I
EBP	I
epsilon	I
promoter	I
/	I
enhancer	I
contains	O
a	O
retinoic	B
acid	I
-	I
response	I
element	I
that	O
is	O
directly	O
stimulated	O
by	O
retinoids	O
.	O

Core	B
-	I
specific	I
mAb	I
inhibited	O
mCD14	B
-	O
mediated	O
uptake	O
of	O
homologous	O
and	O
heterologous	O
LPS	O
,	O
while	O
producing	O
less	O
concurrent	O
enhancement	O
of	O
non	O
-	O
mCD14	B
-	O
mediated	O
LPS	O
uptake	O
.	O

Transfection	O
of	O
EL	O
-	O
4	O
cells	O
with	O
the	O
IL	B
-	I
4	I
promoter	I
-	I
reporter	I
constructs	I
carrying	O
mutated	B
P	I
-	I
like	I
elements	I
showed	O
that	O
four	O
P	B
-	I
like	I
elements	I
,	O
CLE0	B
,	O
P	B
,	O
P2	B
and	O
P4	B
,	O
but	O
not	O
P3	B
,	O
were	O
required	O
for	O
optimal	O
activation	O
of	O
the	O
IL	B
-	I
4	I
promoter	I
.	O

The	O
initiating	O
event	O
is	O
still	O
uncertain	O
,	O
but	O
activation	O
of	O
a	O
recently	O
described	O
receptor	B
-	I
associated	I
protein	I
kinase	I
is	O
one	O
of	O
the	O
earliest	O
events	O
detectable	O
(	O
Martin	O
et	O
al	O
.	O
,	O
Eur	O
.	O
J	O
.	O
Immunol	O
.	O
1994	O
.	O
24	O
:	O
1566	O
)	O
.	O

From	O
these	O
observations	O
we	O
conclude	O
that	O
free	O
thiols	O
in	O
the	O
IL	B
-	I
1RI	I
complex	I
are	O
essential	O
for	O
the	O
activation	O
of	O
the	O
IL	B
-	I
1RI	I
-	I
associated	I
protein	I
kinase	I
and	O
that	O
this	O
process	O
is	O
mandatory	O
for	O
IL	B
-	I
1	I
signaling	O
leading	O
to	O
NF	B
-	I
kappa	I
B	I
activation	O
.	O

Strikingly	O
,	O
Western	O
blotting	O
and	O
immunocytochemical	O
experiments	O
indicated	O
that	O
PDTC	O
promoted	O
a	O
transient	O
and	O
rapid	O
shuttling	O
of	O
NFATp	B
and	O
NFATc	B
,	O
leading	O
to	O
their	O
accelerated	O
export	O
from	O
the	O
nucleus	O
of	O
activated	O
T	O
cells	O
.	O

The	O
A	B
-	I
myb	I
transcription	I
factor	I
in	O
neoplastic	O
and	O
normal	O
B	O
cells	O
.	O

Its	O
normal	O
cellular	O
equivalent	O
c	B
-	I
myb	I
,	O
has	O
been	O
shown	O
to	O
promote	O
the	O
proliferation	O
and	O
block	O
the	O
differentiation	O
of	O
haematopoietic	O
cells	O
in	O
several	O
experimental	O
models	O
and	O
is	O
required	O
for	O
fetal	O
haematopoiesis	O
.	O

Both	O
have	O
been	O
shown	O
to	O
be	O
transcription	B
factors	I
.	O

These	O
studies	O
indicate	O
that	O
A	B
-	I
myb	I
plays	O
a	O
role	O
during	O
a	O
narrow	O
window	O
of	O
normal	O
B	O
cell	O
differentiation	O
.	O

Expression	O
of	O
bcl	B
-	I
6	I
protein	I
in	O
normal	O
skin	O
and	O
epidermal	O
neoplasms	O
.	O

It	O
was	O
recently	O
shown	O
by	O
us	O
that	O
the	O
protein	O
is	O
located	O
in	O
germinal	O
center	O
B	O
cells	O
and	O
their	O
neoplastic	O
counterparts	O
.	O

Squamous	O
cell	O
carcinomas	O
showed	O
a	O
variety	O
of	O
expression	O
levels	O
,	O
while	O
two	O
undifferentiated	O
spindle	O
-	O
shaped	O
carcinomas	O
and	O
one	O
undifferentiated	O
SCC	O
cell	O
line	O
remained	O
unstained	O
.	O

We	O
recently	O
identified	O
the	O
winged	B
-	I
helix	I
transcription	I
factor	I
Trident	B
and	O
described	O
its	O
expression	O
pattern	O
in	O
synchronized	O
fibroblasts	O
.	O

During	O
T	O
cell	O
differentiation	O
,	O
expression	O
peaked	O
in	O
the	O
actively	O
dividing	O
immature	O
single	O
positive	O
cells	O
.	O

The	O
estrogen	B
receptor	I
(	O
ER	B
)	O
repressed	O
erythroid	O
differentiation	O
and	O
erythroid	B
-	I
specific	I
gene	I
expression	O
.	O

These	O
bHLH	B
antagonists	I
are	O
induced	O
during	O
a	O
mitogenic	O
signalling	O
response	O
,	O
and	O
they	O
function	O
by	O
sequestering	O
their	O
bHLH	B
targets	I
in	O
inactive	B
heterodimers	I
that	O
are	O
unable	O
to	O
bind	O
to	O
specific	O
gene	B
regulatory	I
(	I
E	I
box	I
)	I
sequences	I
.	O

Recently	O
,	O
cyclin	O
E	O
-	O
Cdk2	O
-	O
and	O
cyclin	O
A	O
-	O
Cdk2	O
-	O
dependent	O
phosphorylation	O
of	O
a	O
single	O
conserved	O
serine	O
residue	O
(	O
Ser5	O
)	O
in	O
Id2	B
has	O
been	O
shown	O
to	O
occur	O
during	O
late	O
G1	O
-	O
to	O
-	O
S	O
phase	O
transition	O
of	O
the	O
cell	O
cycle	O
,	O
and	O
this	O
neutralizes	O
the	O
function	O
of	O
Id2	B
in	O
abrogating	O
E	B
-	I
box	I
-	I
dependent	I
bHLH	I
homo	O
-	O
or	O
heterodimer	O
complex	O
formation	O
in	O
vitro	O
(	O
E	O
.	O
Hara	O
,	O
M	O
.	O
Hall	O
,	O
and	O
G	O
.	O
Peters	O
,	O
EMBO	O
J	O
.	O
16	O
:	O
332	O
-	O
342	O
,	O
1997	O
)	O
.	O

Furthermore	O
,	O
compared	O
with	O
wild	B
-	I
type	I
Id3	I
,	O
an	O
Id3	B
Asp5	I
mutant	I
(	O
mimicking	O
phosphorylation	O
)	O
is	O
unable	O
to	O
promote	O
cell	O
cycle	O
S	O
phase	O
entry	O
in	O
transfected	O
fibroblasts	O
,	O
whereas	O
an	O
Id3	B
Ala5	I
mutant	I
(	O
ablating	O
phosphorylation	O
)	O
displays	O
an	O
activity	O
significantly	O
greater	O
than	O
that	O
of	O
wild	B
-	I
type	I
Id3	I
protein	I
.	O

Here	O
we	O
describe	O
cloning	O
and	O
characterization	O
of	O
full	O
-	O
length	O
cDNA	B
encoding	I
murine	I
(	I
m	I
)	I
NFATc	I
which	O
predicts	O
that	O
the	O
protein	O
has	O
all	O
the	O
conserved	B
structural	I
motifs	I
of	O
NFAT	B
family	I
members	I
,	O
including	O
the	O
rel	O
homology	O
domain	O
,	O
the	O
NFAT	B
homology	I
domain	I
and	O
the	O
nuclear	O
translocation	O
signals	O
.	O

In	O
the	O
mouse	O
embryo	O
,	O
mNFATc	B
transcript	I
was	O
strongly	O
expressed	O
in	O
thymus	O
,	O
lung	O
and	O
submandibular	O
gland	O
and	O
weakly	O
in	O
skeletal	O
muscle	O
and	O
heart	O
suggesting	O
that	O
mNFATc	B
may	O
have	O
a	O
role	O
both	O
in	O
embryogenesis	O
and	O
in	O
mature	O
T	O
cells	O
.	O

These	O
data	O
indicate	O
that	O
the	O
TRE	B
-	I
like	I
cAMP	I
-	I
responsive	I
DSE	I
sites	I
within	O
the	O
5	B
'	I
-	I
untranslated	I
leader	I
can	O
mediate	O
the	O
transcriptional	O
cooperativity	O
between	O
TNFalpha	B
and	O
the	O
cAMP	O
/	B
PKA	I
pathway	O
.	O

Copyright	O
1997	O
Academic	O
Press	O
.	O

In	O
many	O
chronic	O
inflammatory	O
disorders	O
,	O
glucocorticoid	O
(	O
GC	O
)	O
insensitivity	O
is	O
a	O
challenging	O
clinical	O
problem	O
associated	O
with	O
life	O
-	O
threatening	O
disease	O
progression	O
.	O

Furthermore	O
,	O
we	O
show	O
that	O
patients	O
with	O
GC	O
-	O
insensitive	O
asthma	O
have	O
cytokine	O
-	O
induced	O
abnormalities	O
in	O
the	O
DNA	O
binding	O
capability	O
of	O
the	O
GCR	B
.	O

Mutation	O
of	O
the	O
CBF1	B
/	I
RBP	I
-	I
Jkappa	I
binding	I
site	I
in	O
EBNA3C	B
abrogated	O
repression	O
,	O
strongly	O
suggesting	O
that	O
CBF1	B
/	I
RBP	I
-	I
Jkappa	I
is	O
necessary	O
for	O
targeting	O
the	O
viral	O
protein	O
to	O
Cp	B
.	O

PURPOSE	O
:	O
To	O
clarify	O
the	O
relationship	O
between	O
the	O
glucocorticoid	B
receptor	I
and	O
the	O
effectiveness	O
of	O
glucocorticoid	O
therapy	O
in	O
patients	O
with	O
ulcerative	O
colitis	O
,	O
we	O
investigated	O
the	O
number	O
and	O
apparent	O
dissociation	O
constant	O
of	O
glucocorticoid	B
receptor	I
in	O
peripheral	O
blood	O
mononuclear	O
leukocytes	O
of	O
patients	O
with	O
ulcerative	O
colitis	O
.	O

The	O
apparent	O
dissociation	O
constant	O
of	O
the	O
glucocorticoid	B
receptors	I
from	O
the	O
nonresponders	O
,	O
responders	O
,	O
and	O
healthy	O
controls	O
were	O
7	O
.	O
03	O
(	O
range	O
,	O
5	O
.	O
66	O
-	O
10	O
)	O
,	O
4	O
.	O
27	O
(	O
range	O
,	O
4	O
-	O
5	O
.	O
13	O
)	O
,	O
and	O
6	O
.	O
18	O
(	O
range	O
,	O
5	O
.	O
86	O
-	O
6	O
.	O
74	O
)	O
nM	O
,	O
respectively	O
.	O

Nonresponders	O
had	O
a	O
significant	O
increase	O
both	O
in	O
the	O
number	O
of	O
binding	B
sites	I
and	O
in	O
the	O
apparent	O
dissociation	O
constant	O
compared	O
with	O
responders	O
(	O
P	O
=	O
0	O
.	O
045	O
;	O
P	O
=	O
0	O
.	O
029	O
)	O
.	O

Cooperation	O
of	O
binding	B
sites	I
for	O
STAT6	B
and	O
NF	B
kappa	I
B	I
/	I
rel	I
in	O
the	O
IL	B
-	I
4	I
-	O
induced	O
up	O
-	O
regulation	O
of	O
the	O
human	B
IgE	I
germline	I
promoter	I
.	O

In	O
contrast	O
,	O
lipopolysaccharide	O
stimulation	O
primarily	O
induced	O
the	O
p65	B
/	I
p50	I
heterodimer	I
that	O
has	O
been	O
shown	O
to	O
result	O
in	O
gene	O
activation	O
.	O

Cyclosporin	O
A	O
inhibits	O
early	O
mRNA	O
expression	O
of	O
G0	B
/	I
G1	I
switch	I
gene	I
2	I
(	O
G0S2	B
)	O
in	O
cultured	O
human	O
blood	O
mononuclear	O
cells	O
.	O

In	O
cells	O
that	O
have	O
been	O
preincubated	O
to	O
lower	O
mRNA	O
levels	O
,	O
there	O
is	O
a	O
transient	O
increase	O
in	O
G0S2	B
mRNA	I
,	O
peaking	O
between	O
1	O
-	O
2	O
h	O
,	O
in	O
response	O
to	O
Concanavalin	O
-	O
A	O
(	O
ConA	O
)	O
,	O
or	O
to	O
the	O
combination	O
of	O
phorbol	O
ester	O
(	O
TPA	O
)	O
,	O
and	O
the	O
calcium	O
ionophore	O
,	O
ionomycin	O
.	O

YY1	B
,	O
a	O
widely	O
distributed	O
human	B
transcription	I
factor	I
,	O
is	O
known	O
to	O
inhibit	O
HIV	B
-	I
1	I
long	I
terminal	I
repeat	I
(	O
LTR	B
)	O
transcription	O
and	O
virus	O
production	O
.	O

LSF	B
(	O
also	O
known	O
as	O
LBP	B
-	I
1	I
,	O
UBP	B
,	O
and	O
CP	B
-	I
2	I
)	O
has	O
been	O
shown	O
to	O
repress	O
LTR	O
transcription	O
in	O
vitro	O
,	O
but	O
transient	O
expression	O
of	O
LSF	B
has	O
no	O
effect	O
on	O
LTR	B
activity	O
in	O
vivo	O
.	O

Relative	O
affinities	O
of	O
transcriptional	B
regulatory	I
elements	I
for	O
their	O
respective	O
factor	O
have	O
been	O
essentially	O
studied	O
by	O
bandshift	O
analysis	O
.	O

Here	O
we	O
report	O
a	O
real	O
-	O
time	O
study	O
of	O
factor	O
/	O
DNA	O
interactions	O
using	O
a	O
surface	O
plasmon	O
resonance	O
approach	O
and	O
further	O
characterization	O
of	O
recovered	B
proteins	I
involved	O
in	O
this	O
interaction	O
.	O

This	O
result	O
,	O
confirmed	O
by	O
competitions	O
with	O
each	O
GATA	B
site	I
,	O
demonstrated	O
the	O
higher	O
relative	O
affinity	O
(	O
at	O
least	O
sevenfold	O
)	O
of	O
site	O
3	O
.	O

Stable	O
transfection	O
of	O
U937	O
cells	O
with	O
sense	O
or	O
antisense	B
RXR	I
-	I
alpha	I
cDNA	I
suggests	O
a	O
role	O
for	O
RXR	B
-	I
alpha	I
in	O
the	O
control	O
of	O
monoblastic	O
differentiation	O
induced	O
by	O
retinoic	O
acid	O
and	O
vitamin	O
D	O
.	O

The	O
role	O
of	O
the	O
viral	B
trans	I
-	I
activator	I
Tax	I
protein	I
in	O
the	O
induction	O
of	O
VCAM	B
-	I
1	I
was	O
first	O
indicated	O
by	O
the	O
detection	O
of	O
this	O
adhesion	B
molecule	I
on	O
Jurkat	O
T	O
-	O
cell	O
clones	O
stably	O
expressing	O
the	O
tax	O
gene	O
.	O

The	O
effect	O
of	O
Tax	B
on	O
VCAM	B
-	I
1	I
gene	O
transcription	O
was	O
next	O
confirmed	O
in	O
JPX	O
-	O
9	O
cells	O
,	O
a	O
subclone	O
of	O
Jurkat	O
cells	O
,	O
carrying	O
the	O
tax	B
sequences	I
under	O
the	O
control	O
of	O
an	O
inducible	B
promoter	I
.	O

Furthermore	O
,	O
deletion	O
and	O
mutation	O
analyses	O
of	O
the	O
VCAM	B
-	I
1	I
promoter	I
performed	O
with	O
chloramphenicol	B
acetyltransferase	I
constructs	I
revealed	O
that	O
Tax	B
was	O
trans	O
activating	O
the	O
VCAM	B
-	I
1	I
promoter	I
via	O
two	O
NF	B
-	I
kappaB	I
sites	I
present	O
at	O
bp	O
-	O
72	O
and	O
-	O
57	O
in	O
the	O
VCAM	B
-	I
1	I
gene	I
promoter	I
,	O
with	O
both	O
of	O
them	O
being	O
required	O
for	O
the	O
Tax	B
-	O
induced	O
expression	O
of	O
this	O
adhesion	B
molecule	I
.	O

We	O
have	O
investigated	O
the	O
effects	O
of	O
Vpr	B
on	O
host	O
cell	O
activation	O
and	O
confirm	O
that	O
it	O
influences	O
cellular	O
proliferation	O
.	O

In	O
the	O
absence	O
of	O
TCR	B
-	O
mediated	O
activation	O
,	O
Vpr	B
induces	O
apoptosis	O
whereas	O
in	O
its	O
presence	O
,	O
Vpr	B
interrupts	O
the	O
expected	O
induction	O
of	O
apoptosis	O
.	O

Our	O
finding	O
that	O
Vpr	B
can	O
regulate	O
NF	B
-	I
kappa	I
B	I
supports	O
the	O
hypothesis	O
that	O
some	O
aspects	O
of	O
viral	O
pathogenesis	O
are	O
the	O
consequence	O
of	O
cell	O
dysregulation	O
by	O
Vpr	B
.	O

In	O
fact	O
,	O
by	O
employing	O
a	O
novel	O
haptenized	O
lysis	O
synthetic	O
substrate	O
which	O
allows	O
the	O
isolation	O
of	O
glutaminyl	O
-	O
tTG	O
substrates	O
in	O
vivo	O
,	O
we	O
identified	O
pRB	B
as	O
a	O
potential	O
tTG	O
substrate	O
in	O
U937	O
cells	O
undergoing	O
apoptosis	O
.	O

Interleukin	B
2	I
(	O
IL	B
-	I
2	I
)	O
induces	O
tyrosine	O
phosphorylation	O
of	O
STATs	B
3	I
and	I
5	I
(	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
)	O
.	O

IL	B
-	I
2	I
and	O
T	B
cell	I
antigen	I
receptor	I
complex	I
induction	O
of	O
STAT3alpha	B
serine	O
727	O
phosphorylation	O
is	O
dependent	O
on	O
the	O
activity	O
of	O
the	O
MEK	B
/	B
ERK	I
pathway	O
.	O

These	O
results	O
thus	O
show	O
that	O
STAT3	B
proteins	I
are	O
targets	O
for	O
multiple	O
kinase	O
pathways	O
in	O
T	O
cells	O
and	O
can	O
integrate	O
signals	O
from	O
both	O
cytokine	B
receptors	I
and	O
antigen	B
receptors	I
.	O

In	O
addition	O
,	O
both	O
RelA	B
and	O
c	B
-	I
Rel	I
,	O
but	O
not	O
NF	B
-	I
kappa	I
B1	I
,	O
were	O
shown	O
to	O
transactivate	O
an	O
ICAM	B
-	I
1	I
kappa	I
B	I
-	I
reporter	I
construct	I
.	O

Competent	O
transcription	O
initiation	O
by	O
RNA	B
polymerase	I
II	I
in	O
cell	O
-	O
free	O
extracts	O
from	O
xeroderma	O
pigmentosum	O
groups	O
B	O
and	O
D	O
in	O
an	O
optimized	O
RNA	O
transcription	O
assay	O
.	O

We	O
have	O
employed	O
an	O
optimized	O
cell	O
-	O
free	O
RNA	O
transcription	O
assay	O
to	O
analyze	O
transcription	O
activity	O
of	O
XP	O
-	O
B	O
and	O
XP	O
-	O
D	O
.	O

Binding	O
capacity	O
(	O
4978	O
+	O
/	O
-	O
391	O
versus	O
4131	O
+	O
/	O
-	O
321	O
sites	O
/	O
cell	O
)	O
,	O
Kd	O
values	O
for	O
dexamethasone	O
(	O
6	O
.	O
7	O
+	O
/	O
-	O
0	O
.	O
5	O
versus	O
5	O
.	O
7	O
+	O
/	O
-	O
0	O
.	O
3	O
nmol	O
/	O
L	O
)	O
,	O
and	O
IC50	O
values	O
for	O
dexamethasone	O
(	O
3	O
.	O
4	O
+	O
/	O
-	O
0	O
.	O
3	O
versus	O
3	O
.	O
1	O
+	O
/	O
-	O
0	O
.	O
2	O
nmol	O
/	O
L	O
)	O
and	O
cortisol	O
(	O
12	O
.	O
2	O
+	O
/	O
-	O
1	O
.	O
6	O
versus	O
9	O
.	O
5	O
+	O
/	O
-	O
0	O
.	O
3	O
nmol	O
/	O
L	O
)	O
were	O
not	O
significantly	O
different	O
.	O

Patients	O
with	O
renin	B
values	O
less	O
than	O
0	O
.	O
13	O
ng	O
angiotensin	O
I	O
/	O
L	O
per	O
second	O
were	O
markedly	O
less	O
sensitive	O
to	O
cortisol	O
than	O
those	O
with	O
higher	O
values	O
.	O

The	O
composite	B
PU	I
.	I
1	I
and	I
Pip	I
site	I
likely	O
accounts	O
for	O
both	O
lineage	O
and	O
stage	O
-	O
specific	O
expression	O
of	O
CD20	B
whereas	O
the	O
CD20	B
E	I
box	I
binding	I
proteins	I
enhance	O
overall	O
promoter	O
activity	O
and	O
may	O
link	O
the	O
promoter	O
to	O
a	O
distant	B
enhancer	I
.	O

HIV	O
infection	O
is	O
also	O
associated	O
with	O
activation	O
of	O
the	O
hypothalamo	O
-	O
pituitary	O
-	O
adrenal	O
axis	O
function	O
and	O
increased	O
plasma	O
and	O
urinary	O
cortisol	O
concentrations	O
.	O

After	O
DMSO	O
treatment	O
,	O
HL	O
-	O
60	O
cells	O
eventually	O
died	O
via	O
apoptosis	O
,	O
whereas	O
the	O
viability	O
of	O
PDBu	O
-	O
treated	O
cells	O
was	O
not	O
affected	O
during	O
the	O
same	O
interval	O
.	O

The	O
generality	O
of	O
this	O
finding	O
was	O
confirmed	O
by	O
the	O
induction	O
of	O
Bcl	B
-	I
xL	I
in	O
human	O
myeloid	O
U	O
-	O
937	O
cells	O
,	O
human	O
peripheral	O
blood	O
monocytes	O
exposed	O
to	O
phorbol	O
ester	O
,	O
and	O
mouse	O
thioglycollate	O
-	O
activated	O
and	O
resident	O
peritoneal	O
macrophages	O
.	O

Monochloramine	O
derivatives	O
are	O
long	O
lived	O
physiological	O
oxidants	O
produced	O
by	O
neutrophils	O
during	O
the	O
respiratory	O
burst	O
.	O

Cyclosporine	O
(	O
CsA	O
)	O
is	O
both	O
a	O
clinical	O
immunosuppressive	O
drug	O
and	O
a	O
probe	O
to	O
dissect	O
intracellular	O
signaling	O
pathways	O
.	O

Furthermore	O
,	O
the	O
degree	O
of	O
CN	B
inhibition	O
was	O
reflected	O
by	O
a	O
similar	O
degree	O
of	O
reduction	O
in	O
lymphocyte	O
proliferation	O
and	O
IFN	B
-	I
gamma	I
production	O
in	O
the	O
allogeneic	O
mixed	O
lymphocyte	O
cultures	O
.	O

Thus	O
,	O
the	O
reduction	O
of	O
CN	B
activity	O
observed	O
in	O
CsA	O
-	O
treated	O
patients	O
is	O
accompanied	O
by	O
a	O
similar	O
degree	O
of	O
reduction	O
in	O
lymphocyte	B
gene	I
activation	O
,	O
and	O
accounts	O
for	O
the	O
immunosuppression	O
observed	O
.	O

Control	O
of	O
NF	B
-	I
kappa	I
B	I
activity	O
by	O
the	O
I	B
kappa	I
B	I
beta	I
inhibitor	I
.	O

The	O
transcription	B
factor	I
NF	B
-	I
kappa	I
B	I
is	O
maintained	O
in	O
an	O
inactive	O
cytoplasmic	O
state	O
by	O
I	B
kappa	I
B	I
inhibitors	I
.	O

G28	B
-	I
5	I
sFv	I
was	O
a	O
more	O
potent	O
agonist	O
than	O
G28	B
-	I
5	I
IgG	I
and	O
was	O
able	O
to	O
stimulate	O
CD40	B
responses	O
by	O
B	O
cells	O
and	O
monocytes	O
.	O

Increased	O
CRH	B
promoter	O
activity	O
following	O
phorbol	O
ester	O
treatment	O
was	O
inhibited	O
by	O
a	O
dominant	O
negative	O
NF	B
-	I
IL6	I
mutant	I
,	O
showing	O
that	O
the	O
effects	O
of	O
phorbol	O
ester	O
were	O
principally	O
mediated	O
by	O
C	B
/	I
EBP	I
.	O

We	O
screened	O
TSG101	B
for	O
somatic	O
mutations	O
in	O
DNA	O
and	O
RNA	O
samples	O
isolated	O
from	O
a	O
variety	O
of	O
common	O
human	O
malignancies	O
,	O
EBV	O
-	O
immortalised	O
B	O
-	O
cells	O
,	O
and	O
normal	O
lung	O
parenchyma	O
.	O

Intragenic	O
TSG101	B
deletions	O
in	O
RNA	B
transcripts	I
were	O
frequently	O
found	O
in	O
all	O
types	O
of	O
samples	O
.	O

A	O
similar	O
spectrum	O
of	O
transcript	O
deletions	O
has	O
previously	O
been	O
described	O
in	O
the	O
putative	B
tumour	I
suppressor	I
gene	I
FHIT	B
.	O

Interleukin	B
-	I
7	I
upregulates	O
the	O
interleukin	B
-	I
2	I
-	I
gene	I
expression	O
in	O
activated	O
human	O
T	O
lymphocytes	O
at	O
the	O
transcriptional	O
level	O
by	O
enhancing	O
the	O
DNA	O
binding	O
activities	O
of	O
both	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
and	O
activator	B
protein	I
-	I
1	I
.	O

Production	O
of	O
IL	B
-	I
2	I
requires	O
the	O
formation	O
of	O
transcription	B
factors	I
involved	O
in	O
the	O
IL	B
-	I
2	I
-	I
gene	I
regulation	O
.	O

The	O
three	O
-	O
dimensional	O
positioning	O
of	O
immunoglobulin	B
(	I
Ig	I
)	I
genes	I
within	O
the	O
nucleus	O
of	O
human	O
cells	O
was	O
investigated	O
using	O
in	O
situ	O
hybridization	O
and	O
confocal	O
microscopy	O
.	O

The	O
visualization	O
of	O
heavy	B
and	I
light	I
chain	I
genes	I
in	O
B	O
-	O
lymphoid	O
cells	O
showed	O
that	O
the	O
three	O
Ig	B
genes	I
are	O
differentially	O
and	O
nonrandomly	O
distributed	O
in	O
different	O
nuclear	O
subvolumes	O
:	O
the	O
kappa	B
genes	I
were	O
found	O
to	O
be	O
preferentially	O
confined	O
to	O
an	O
outer	O
nuclear	O
volume	O
,	O
whereas	O
the	O
gamma	B
and	I
lambda	I
genes	I
consistently	O
occupied	O
more	O
central	O
positions	O
within	O
the	O
nucleus	O
,	O
the	O
lambda	B
genes	I
being	O
more	O
interior	O
when	O
compared	O
with	O
the	O
gamma	B
genes	I
.	O

These	O
findings	O
show	O
that	O
healthy	O
virus	O
carriers	O
maintain	O
a	O
high	O
frequency	O
of	O
BZLF1	O
-	O
specific	O
memory	O
T	O
cells	O
,	O
potentially	O
to	O
control	O
virus	O
spread	O
from	O
lytically	O
infected	O
cells	O
.	O

We	O
have	O
therefore	O
investigated	O
the	O
transcriptional	O
activity	O
of	O
A	B
-	I
MYB	I
and	O
its	O
regulation	O
in	O
several	O
human	O
lymphoid	O
cell	O
lines	O
using	O
co	O
-	O
transfection	O
assays	O
and	O
show	O
that	O
A	B
-	I
MYB	I
is	O
transcriptionally	O
active	O
in	O
all	O
the	O
B	O
cell	O
lines	O
studied	O
,	O
but	O
not	O
in	O
T	O
cells	O
.	O

Transcription	O
factor	O
Egr	B
-	I
1	I
activity	O
down	O
-	O
regulates	O
Fas	O
and	O
CD23	O
expression	O
in	O
B	O
cells	O
.	O

Transcription	B
factor	I
NF	B
-	I
kappa	I
B	I
must	O
be	O
released	O
from	O
cytoplasmic	B
inhibitory	I
molecules	I
(	O
I	B
kappa	I
Bs	I
)	O
in	O
order	O
to	O
move	O
to	O
the	O
nucleus	O
and	O
to	O
activate	O
its	O
target	B
genes	I
.	O

The	O
half	O
-	O
life	O
of	O
both	O
inhibitors	O
is	O
increased	O
in	O
HeLa	O
cells	O
.	O

PCR	O
analysis	O
of	O
spontaneous	O
EBV	O
-	O
transformed	O
lymphoblastoid	O
cell	O
lines	O
(	O
LCL	O
)	O
from	O
three	O
individuals	O
with	O
primary	O
infection	O
showed	O
that	O
two	O
were	O
infected	O
with	O
type	O
A	O
and	O
one	O
with	O
type	O
B	O
EBV	O
.	O

TCR	B
beta	I
analysis	O
showed	O
that	O
while	O
there	O
was	O
loop	O
length	O
restriction	O
in	O
the	O
putative	O
peptide	O
contact	O
site	O
of	O
all	O
responding	O
beta	B
chains	I
,	O
diverse	O
and	O
unique	O
(	O
non	O
-	O
recurrent	O
)	O
TCR	O
beta	O
clonotypes	O
were	O
selected	O
in	O
individuals	O
during	O
primary	O
infection	O
and	O
continued	O
to	O
emerge	O
after	O
long	O
-	O
term	O
virus	O
exposure	O
.	O

CD40	B
ligation	O
leads	O
to	O
B	O
cell	O
activation	O
events	O
such	O
as	O
proliferation	O
,	O
Ig	O
secretion	O
,	O
isotype	O
switching	O
,	O
and	O
up	O
-	O
regulation	O
of	O
cell	B
surface	I
molecules	I
,	O
as	O
well	O
as	O
the	O
generation	O
of	O
memory	O
B	O
cells	O
.	O

Many	O
of	O
these	O
events	O
are	O
dependent	O
upon	O
the	O
ability	O
of	O
CD40	B
to	O
activate	O
the	O
transcription	O
factor	O
NF	B
-	I
kappa	I
B	I
(	O
NF	B
-	I
kappa	I
B	I
)	O
.	O

To	O
define	O
the	O
CD40	B
signaling	O
components	O
upstream	O
of	O
NF	B
-	I
kappa	I
B	I
activation	O
and	O
the	O
functional	O
consequences	O
downstream	O
of	O
NF	B
-	I
kappa	I
B	I
activation	O
,	O
we	O
examined	O
mouse	O
B	O
cell	O
transfectants	O
expressing	O
wild	B
-	I
type	I
or	I
mutant	I
human	I
CD40	I
.	O

A	O
threonine	O
residue	O
at	O
position	B
234	I
,	O
previously	O
shown	O
to	O
be	O
important	O
for	O
CD40	B
association	O
with	O
TNF	B
receptor	I
-	I
associated	I
factor	I
2	I
(	O
TRAF2	B
)	O
,	O
TRAF3	B
,	O
and	O
TRAF5	B
,	O
was	O
not	O
required	O
for	O
NF	B
-	I
kappa	I
B	I
activation	O
.	O

NF	B
-	I
kappa	I
B	I
activation	O
was	O
independent	O
of	O
the	O
transmembrane	B
domain	I
of	O
CD40	B
,	O
suggesting	O
that	O
it	O
is	O
independent	O
of	O
p23	B
,	O
a	O
molecule	O
that	O
associates	O
with	O
CD40	B
in	O
a	O
region	O
other	O
than	O
the	O
cytoplasmic	B
domain	I
.	O

CD40	O
-	O
or	O
pervanadate	O
-	O
mediated	O
I	O
kappa	O
B	O
tyrosine	O
phosphorylation	O
was	O
not	O
detected	O
.	O

NF	B
-	I
kappa	I
B	I
activation	O
correlated	O
with	O
the	O
ability	O
of	O
CD40	B
to	O
induce	O
Ab	O
secretion	O
and	O
the	O
up	O
-	O
regulation	O
of	O
ICAM	B
-	I
1	I
and	O
LFA	B
-	I
1	I
.	O

The	O
M	B
-	I
CSF	I
receptor	I
was	O
first	O
detectable	O
in	O
the	O
myeloid	O
-	O
committed	O
CD34	O
+	O
Thy	O
-	O
l	O
-	O
CD45RA	O
+	O
subset	O
.	O

All	O
other	O
molecules	O
studied	O
were	O
found	O
to	O
be	O
expressed	O
at	O
this	O
stage	O
of	O
differentiation	O
.	O

Addition	O
of	O
GM	B
-	I
CSF	I
to	O
this	O
basic	O
cocktail	O
consistently	O
increased	O
the	O
clonogenic	O
capacity	O
of	O
single	O
CD34	O
+	O
Thy	O
-	O
1	O
+	O
cells	O
,	O
and	O
this	O
effect	O
was	O
further	O
enhanced	O
(	O
up	O
to	O
72	O
.	O
3	O
+	O
/	O
-	O
4	O
.	O
3	O
%	O
on	O
day	O
7	O
)	O
by	O
the	O
inclusion	O
of	O
TNF	B
-	I
alpha	I
.	O

Induction	O
of	O
endothelial	B
cell	I
surface	I
adhesion	I
molecules	I
by	O
tumor	B
necrosis	I
factor	I
is	O
blocked	O
by	O
protein	O
tyrosine	O
phosphatase	O
inhibitors	O
:	O
role	O
of	O
the	O
nuclear	B
transcription	I
factor	I
NF	I
-	I
kappa	I
B	I
.	O

The	O
induction	O
of	O
ICAM	B
-	I
1	I
,	O
VCAM	B
-	I
1	I
,	O
and	O
ELAM	B
-	I
1	I
by	O
TNF	B
in	O
MVEC	O
occurred	O
within	O
6	O
h	O
and	O
was	O
also	O
completely	O
down	O
-	O
regulated	O
by	O
PAO	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

Further	O
,	O
monocytes	O
from	O
patients	O
demonstrate	O
an	O
augmented	O
susceptibility	O
to	O
a	O
productive	O
infection	O
with	O
HIV	O
-	O
1	O
in	O
vitro	O
.	O

In	O
contrast	O
,	O
I	B
kappa	I
B	I
-	I
alpha	I
levels	O
in	O
PBMC	O
and	O
monocytes	O
from	O
healthy	O
subjects	O
or	O
from	O
patients	O
with	O
nontuberculous	O
pulmonary	O
conditions	O
were	O
intact	O
.	O

Further	O
,	O
M	O
.	O
tuberculosis	O
and	O
its	O
tuberculin	B
,	O
purified	B
protein	I
derivative	I
,	O
induced	O
the	O
degradation	O
of	O
I	B
kappa	I
B	I
-	I
alpha	I
and	O
the	O
expression	O
of	O
I	B
kappa	I
B	I
-	I
alpha	I
mRNA	I
,	O
and	O
purified	O
protein	O
derivative	O
induced	O
the	O
activation	O
of	O
NF	B
-	I
kappa	I
B	I
in	O
monocytes	O
.	O

Spi	B
-	I
1	I
/	I
PU	I
.	I
1	I
is	O
a	O
myeloid	B
-	I
and	I
B	I
-	I
cell	I
specific	I
transcription	I
factor	I
which	O
is	O
also	O
involved	O
in	O
Friend	O
virus	O
-	O
induced	O
murine	O
erythroleukemia	O
.	O

We	O
developed	O
a	O
heterologous	O
system	O
to	O
analyze	O
the	O
contribution	O
of	O
these	O
alterations	O
to	O
the	O
induction	O
of	O
primary	O
erythroblast	O
transformation	O
.	O

These	O
results	O
show	O
that	O
Spi	O
-	O
1	O
/	O
PU	B
.	I
1	I
requires	O
signals	O
emanating	O
from	O
specific	O
cytokine	O
and	O
growth	O
factor	O
receptors	O
to	O
affect	O
the	O
survival	O
,	O
proliferation	O
and	O
differentiation	O
control	O
of	O
primary	O
erythroblasts	O
.	O

They	O
also	O
suggest	O
that	O
the	O
function	O
of	O
Spi	B
-	I
1	I
/	I
PU	I
.	I
1	I
in	O
the	O
late	O
phase	O
of	O
Friend	O
leukemia	O
requires	O
specific	O
signaling	O
from	O
the	O
gp55	B
-	I
modified	I
EpoR	I
generated	O
during	O
the	O
early	O
phase	O
of	O
the	O
disease	O
.	O

METHODS	O
:	O
Allergen	O
-	O
specific	O
T	O
cell	O
clones	O
and	O
T	O
cell	O
hybridomas	O
were	O
established	O
from	O
the	O
peripheral	O
blood	O
lymphocytes	O
of	O
patients	O
with	O
asthma	O
,	O
and	O
the	O
responses	O
to	O
various	O
stimuli	O
were	O
determined	O
.	O

BACKGROUND	O
:	O
Fibrin	O
deposition	O
and	O
thrombosis	O
have	O
been	O
implicated	O
in	O
both	O
allograft	O
rejection	O
and	O
vasculopathy	O
after	O
cardiac	O
transplantation	O
.	O

Inhibition	O
of	O
TF	B
induction	O
in	O
the	O
presence	O
of	O
high	O
CsA	O
blood	O
concentrations	O
was	O
also	O
observed	O
when	O
stimulation	O
of	O
cells	O
was	O
performed	O
with	O
interferon	B
-	I
gamma	I
or	O
interleukin	B
-	I
1beta	I
.	O

As	O
shown	O
by	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
and	O
electrophoretic	O
mobility	O
shift	O
assay	O
,	O
respectively	O
,	O
treatment	O
with	O
CsA	O
leads	O
to	O
decreased	O
TF	B
mRNA	I
expression	O
and	O
reduced	O
activation	O
of	O
the	O
NF	B
-	I
kappaB	I
transcription	I
factor	I
,	O
which	O
is	O
known	O
to	O
contribute	O
to	O
the	O
induction	O
of	O
the	O
TF	B
promotor	I
in	O
human	O
monocytes	O
.	O

Inhibition	O
of	O
monocyte	O
TF	B
induction	O
by	O
CsA	O
may	O
contribute	O
to	O
its	O
successful	O
use	O
in	O
cardiac	O
transplant	O
medicine	O
and	O
might	O
be	O
useful	O
in	O
managing	O
further	O
settings	O
of	O
vascular	O
pathology	O
also	O
known	O
to	O
involve	O
TF	B
expression	O
and	O
NF	B
-	I
kappaB	I
activation	O
.	O

Both	O
cytokines	B
induced	O
assembly	O
of	O
STAT5A	B
and	O
STAT5B	B
containing	O
complexes	O
capable	O
of	O
binding	O
to	O
the	O
interferon	B
-	I
gamma	I
activation	I
sequence	I
(	O
GAS	B
)	O
,	O
and	O
these	O
complexes	O
rapidly	O
translocated	O
(	O
within	O
1	O
min	O
)	O
into	O
the	O
nucleus	O
of	O
IL	O
-	O
2	O
-	O
or	O
IL	O
-	O
7	O
-	O
treated	O
cells	O
.	O

IL	B
-	I
2	I
and	O
IL	B
-	I
7	I
were	O
equivalent	O
in	O
their	O
ability	O
to	O
induce	O
tyrosine	O
phosphorylation	O
of	O
STAT5A	B
and	O
STAT5B	B
and	O
to	O
facilitate	O
binding	O
of	O
these	O
STATs	B
to	O
an	O
immobilized	B
GAS	I
element	I
.	O

These	O
data	O
suggest	O
that	O
IL	B
-	I
2	I
and	O
IL	B
-	I
7	I
induce	O
assembly	O
of	O
STAT	B
heterodimers	I
in	O
a	O
similar	O
manner	O
and	O
that	O
subsequent	O
cellular	O
responses	O
may	O
be	O
driven	O
by	O
induction	O
of	O
similar	O
sets	O
of	O
genes	B
.	O

The	O
POU	B
transcription	I
factors	I
Oct	B
-	I
1	I
and	O
Oct	B
-	I
2	I
regulate	O
the	O
activity	O
of	O
octamer	B
-	I
dependent	I
promoters	I
,	O
including	O
those	O
that	O
direct	O
transcription	O
from	O
rearranged	O
immunoglobulin	B
genes	I
.	O

The	O
class	B
II	I
trans	I
-	I
activator	I
(	O
CIITA	B
)	O
is	O
a	O
bi	B
-	I
or	I
multi	I
-	I
functional	I
domain	I
protein	I
which	O
plays	O
a	O
critical	O
role	O
in	O
the	O
expression	O
of	O
MHC	B
class	I
II	I
genes	I
.	O

Transient	O
transfection	O
of	O
a	O
B	O
lymphoma	O
line	O
resulted	O
in	O
up	O
to	O
89	O
%	O
reduction	O
of	O
constitutive	O
MHC	B
class	I
II	I
expression	O
within	O
5	O
days	O
and	O
suppression	O
of	O
HLA	B
-	I
DRA	I
mRNA	I
synthesis	O
.	O

The	O
active	O
ingredients	O
mediating	O
the	O
pharmacological	O
effect	O
are	O
mainly	O
sesquiterpene	O
lactones	O
,	O
such	O
as	O
helenalin	O
,	O
11alpha	O
,	O
13	O
-	O
dihydrohelenalin	O
,	O
chamissonolid	O
and	O
their	O
ester	O
derivatives	O
.	O

We	O
show	O
here	O
that	O
helenalin	O
,	O
and	O
,	O
to	O
a	O
much	O
lesser	O
degree	O
,	O
11alpha	O
,	O
13	O
-	O
dihydrohelenalin	O
and	O
chamissonolid	O
,	O
inhibit	O
activation	O
of	O
transcription	B
factor	I
NF	B
-	I
kappaB	I
.	O

Rather	O
,	O
helenalin	O
modifies	O
the	O
NF	B
-	I
kappaB	I
/	I
IkappaB	I
complex	I
,	O
preventing	O
the	O
release	O
of	O
IkappaB	B
.	O

The	O
tax	B
protein	I
of	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
1	O
mediates	O
the	O
transactivation	O
of	O
the	O
c	B
-	I
sis	I
/	I
platelet	I
-	I
derived	I
growth	I
factor	I
-	I
B	I
promoter	I
through	O
interactions	O
with	O
the	O
zinc	B
finger	I
transcription	I
factors	I
Sp1	B
and	O
NGFI	B
-	I
A	I
/	I
Egr	I
-	I
1	I
.	O

In	O
the	O
present	O
work	O
,	O
we	O
have	O
investigated	O
the	O
mechanism	O
(	O
s	O
)	O
whereby	O
Tax	B
transactivates	O
the	O
c	B
-	I
sis	I
/	I
PDGF	I
-	I
B	I
proto	I
-	I
oncogene	I
.	O

Interestingly	O
,	O
co	O
-	O
immunoprecipitation	O
analysis	O
also	O
revealed	O
that	O
Tax	B
mutant	O
IEXC29S	B
is	O
unable	O
to	O
interact	O
with	O
NGFI	B
-	I
A	I
/	I
Egr	I
-	I
1	I
,	O
whereas	O
Tax	B
mutant	O
IEXL320G	B
is	O
able	O
to	O
interact	O
with	O
NGFI	B
-	I
A	I
/	I
Egr	I
-	I
1	I
.	O

Dendritic	O
cells	O
(	O
DC	O
)	O
are	O
potent	O
APCs	O
that	O
enter	O
resting	O
tissues	O
as	O
precursors	O
and	O
,	O
after	O
Ag	O
exposure	O
,	O
differentiate	O
and	O
migrate	O
to	O
draining	O
lymph	O
nodes	O
.	O

Immunohistochemical	O
staining	O
demonstrated	O
RelB	B
within	O
the	O
differentiated	O
lymph	O
node	O
interdigitating	O
DC	O
and	O
follicular	O
DC	O
,	O
but	O
not	O
undifferentiated	O
DC	O
in	O
normal	O
skin	O
.	O

NF	B
-	I
AT	I
activation	O
induced	O
by	O
a	O
CAML	B
-	O
interacting	O
member	O
of	O
the	O
tumor	B
necrosis	I
factor	I
receptor	I
superfamily	I
.	O

The	O
CAML	B
(	I
calcium	I
-	I
modulator	I
and	I
cyclophilin	I
ligand	I
)	I
protein	I
is	O
a	O
coinducer	O
of	O
NF	B
-	I
AT	I
activation	O
when	O
overexpressed	O
in	O
Jurkat	O
T	O
cells	O
.	O

In	O
most	O
cells	O
,	O
Rel	B
/	I
NF	I
-	I
kappa	I
B	I
transcription	B
factors	I
appear	O
to	O
mediate	O
survival	O
signals	O
that	O
protect	O
cells	O
from	O
apoptosis	O
;	O
however	O
,	O
under	O
some	O
circumstances	O
,	O
activation	O
of	O
these	O
factors	O
may	O
also	O
promote	O
apoptosis	O
.	O

These	O
results	O
suggest	O
that	O
coordination	O
of	O
NF	B
-	I
kappaB	I
and	O
STAT6	B
may	O
be	O
required	O
for	O
induction	O
of	O
germline	B
Cepsilon	O
transcription	O
by	O
IL	B
-	I
4	I
,	O
and	O
that	O
CD40	B
-	O
mediated	O
NF	B
-	I
kappaB	I
activation	O
may	O
be	O
important	O
in	O
regulating	O
both	O
enhancement	O
of	O
germline	B
Cepsilon	O
transcription	O
and	O
class	O
switching	O
to	O
IgE	B
.	O

There	O
are	O
many	O
hypotheses	O
concerning	O
the	O
pathogenesis	O
of	O
endometriosis	O
,	O
though	O
no	O
single	O
theory	O
can	O
explain	O
all	O
cases	O
.	O

This	O
review	O
considers	O
the	O
evidence	O
for	O
different	O
theories	O
of	O
the	O
histogenesis	O
of	O
endometriosis	O
and	O
discusses	O
possible	O
immune	O
factors	O
that	O
may	O
be	O
involved	O
in	O
the	O
pathophysiology	O
of	O
the	O
disease	O
.	O

Proteins	O
of	O
the	O
ATF	O
/	O
CREB	B
class	O
of	O
transcription	B
factors	I
stimulate	O
gene	O
expression	O
of	O
several	O
cell	B
growth	I
-	I
related	I
genes	I
through	O
protein	B
kinase	I
A	I
-	I
related	I
cAMP	I
response	I
elements	I
.	O

One	O
ATF	B
/	I
CRE	I
motif	I
is	O
located	O
in	O
the	O
distal	B
promoter	I
at	O
the	O
nuclear	B
matrix	I
-	I
associated	I
Site	I
IV	I
,	O
and	O
the	O
second	O
motif	O
is	O
present	O
in	O
the	O
proximal	B
promoter	I
at	O
Site	B
I	I
.	O

Site	O
-	O
directed	O
mutational	O
studies	O
demonstrate	O
that	O
Site	B
I	I
and	O
Site	B
IV	I
together	O
support	O
ATF1	O
-	O
and	O
CREB	O
-	O
induced	O
trans	O
-	O
activation	O
of	O
the	O
H4	B
promoter	I
.	O

Thus	O
,	O
our	O
data	O
establish	O
that	O
ATF	B
/	I
CREB	I
factors	I
functionally	O
modulate	O
histone	B
H4	I
gene	I
transcription	O
at	O
distal	B
and	I
proximal	I
promoter	I
elements	I
.	O

Abnormal	O
apoptosis	O
and	O
cell	O
cycle	O
progression	O
in	O
humans	O
exposed	O
to	O
methyl	O
tertiary	O
-	O
butyl	O
ether	O
and	O
benzene	O
contaminating	O
water	O
.	O

Because	O
cell	O
cycle	O
analysis	O
showed	O
that	O
in	O
PBL	O
from	O
chemically	O
-	O
exposed	O
individuals	O
,	O
between	O
20	O
-	O
50	O
%	O
of	O
cells	O
were	O
accumulated	O
at	O
the	O
S	O
-	O
G2	O
/	O
M	O
boundaries	O
.	O

Indeed	O
,	O
addition	O
of	O
inhibitors	O
of	O
NF	B
-	I
kappa	I
B	I
activation	O
pyrrolidine	O
dithiocarbamate	O
(	O
PDTC	O
)	O
,	O
to	O
the	O
lymphocytes	O
of	O
the	O
chemically	O
-	O
exposed	O
group	O
was	O
capable	O
of	O
inhibiting	O
programmed	O
cell	O
death	O
by	O
40	O
%	O
.	O

This	O
reversal	O
of	O
apoptosis	O
almost	O
to	O
the	O
control	O
level	O
by	O
inhibitor	O
of	O
NF	B
-	I
kappa	I
B	I
activation	O
may	O
indicate	O
involvement	O
of	O
this	O
signaling	B
molecule	I
in	O
MTBE	O
and	O
benzene	O
induction	O
of	O
programmed	O
cell	O
death	O
.	O

Purification	O
and	O
characterization	O
of	O
the	O
human	B
SR	I
31747A	I
-	I
binding	I
protein	I
.	O

A	O
nuclear	B
membrane	I
protein	I
related	O
to	O
yeast	B
sterol	I
isomerase	I
.	O

SR	O
31747A	O
,	O
defined	O
as	O
a	O
sigma	O
ligand	O
,	O
is	O
a	O
novel	O
immunosuppressive	O
agent	O
that	O
blocks	O
proliferation	O
of	O
human	O
and	O
mouse	O
lymphocytes	O
.	O

Using	O
a	O
radiolabeled	O
chemical	O
probe	O
,	O
we	O
here	O
purified	O
a	O
target	O
of	O
SR	O
31747A	O
and	O
called	O
it	O
SR	B
31747A	I
-	I
binding	I
protein	I
(	O
SR	B
-	I
BP	I
)	O
.	O

Purified	B
SR	I
-	I
BP	I
retained	O
its	O
binding	O
properties	O
and	O
migrated	O
on	O
SDS	O
-	O
polyacrylamide	O
gel	O
as	O
a	O
Mr	B
28	I
,	I
000	I
protein	I
.	O

Northern	O
blot	O
analysis	O
of	O
SR	B
-	I
BP	I
gene	O
expression	O
revealed	O
a	O
single	O
transcript	O
of	O
2	B
kilobases	I
which	O
was	O
widely	O
expressed	O
among	O
organs	O
,	O
with	O
the	O
highest	O
abundance	O
in	O
liver	O
and	O
the	O
lowest	O
abundance	O
in	O
brain	O
.	O

Here	O
we	O
report	O
the	O
induction	O
of	O
the	O
synthesis	O
and	O
of	O
the	O
hydrolytic	O
activity	O
of	O
phospholipase	B
C	I
gamma	I
1	I
(	O
PLC	B
gamma	I
1	I
)	O
in	O
human	O
T	O
lymphocytes	O
by	O
IFN	B
-	I
beta	I
.	O

The	O
increased	O
level	O
of	O
PLC	B
gamma	I
1	I
becomes	O
evident	O
after	O
90	O
min	O
of	O
IFN	B
-	I
beta	I
treatment	O
and	O
is	O
still	O
detectable	O
after	O
24	O
h	O
.	O

Neither	O
the	O
PLC	B
gamma	I
1	I
overexpression	O
induced	O
by	O
IFN	B
nor	O
the	O
increased	O
hydrolytic	O
activity	O
of	O
the	O
enzyme	B
appear	O
to	O
be	O
affected	O
by	O
pretreatment	O
of	O
the	O
cells	O
with	O
the	O
protein	O
tyrosine	B
kinase	I
inhibitor	O
genistein	O
,	O
which	O
is	O
known	O
to	O
prevent	O
the	O
association	O
of	O
ISGF3	B
components	O
.	O

These	O
results	O
suggest	O
that	O
in	O
human	O
T	O
lymphocytes	O
IFN	B
-	I
beta	I
can	O
activate	O
other	O
transcription	B
factor	I
(	O
s	O
)	O
distinct	O
from	O
ISGF3	B
to	O
regulate	O
PLC	B
gamma	I
1	I
expression	O
.	O

In	O
this	O
study	O
,	O
we	O
used	O
a	O
RT	O
-	O
PCR	O
based	O
approach	O
to	O
compare	O
the	O
stability	O
of	O
the	O
big	B
T	I
and	I
small	I
t	I
allele	I
in	O
normal	O
heterozygous	O
lymphocytes	O
and	O
the	O
heterozygous	O
cell	O
lines	O
NB4	O
(	O
myeloid	O
leukemia	O
)	O
and	O
PC	O
-	O
3	O
and	O
DU	O
145	O
(	O
prostate	O
cancers	O
)	O
.	O

Interestingly	O
,	O
we	O
consistently	O
observed	O
30	O
%	O
less	O
RT	B
-	I
PCR	I
product	I
derived	O
from	O
the	O
small	B
t	I
allele	I
mRNA	I
in	O
steady	O
state	O
,	O
a	O
finding	O
which	O
also	O
speaks	O
against	O
a	O
higher	O
stability	O
of	O
the	O
small	B
t	I
allele	I
mRNA	I
.	O

Moreover	O
,	O
anti	B
-	I
TNF	I
-	I
alpha	I
inhibited	O
HIV	B
-	I
1	I
long	I
terminal	I
repeat	I
(	O
LTR	B
)	O
-	O
driven	O
transcription	O
of	O
a	O
reporter	B
gene	I
in	O
primary	O
T	O
cells	O
in	O
response	O
to	O
activation	O
,	O
either	O
in	O
the	O
presence	O
or	O
the	O
absence	O
of	O
HIV	B
-	I
1	I
Tat	I
.	O

Our	O
results	O
support	O
an	O
important	O
role	O
for	O
autocrine	O
TNF	B
-	I
alpha	I
secretion	O
in	O
controlling	O
HIV	O
replication	O
in	O
primary	O
T	O
cells	O
because	O
of	O
its	O
ability	O
to	O
maintain	O
NF	B
-	I
kappa	I
B	I
elevated	O
in	O
the	O
nucleus	O
of	O
T	O
cells	O
.	O

Intercellular	B
adhesion	I
molecule	I
1	I
(	O
ICAM	B
-	I
1	I
)	O
is	O
an	O
important	O
molecule	O
in	O
promotion	O
of	O
polymorphonuclear	O
neutrophil	O
transendothelial	O
migration	O
during	O
inflammation	O
.	O

The	O
compound	O
induced	O
G1	O
arrest	O
and	O
granulocytic	O
differentiation	O
of	O
HL	O
-	O
60	O
cells	O
,	O
although	O
the	O
differentiation	O
-	O
inducing	O
effect	O
was	O
modest	O
.	O

These	O
results	O
indicate	O
that	O
JAK2	B
/	B
STAT5	I
activation	O
is	O
a	O
common	O
JAK	B
/	B
STAT	I
pathway	O
for	O
hIL	B
-	I
5	I
-	O
mediated	O
signal	O
in	O
these	O
cells	O
.	O

Nuclear	B
factor	I
-	I
kappa	I
B	I
(	I
NF	I
-	I
kappa	I
B	I
)	I
/	I
Rel	I
transcription	I
factors	I
may	O
be	O
involved	O
in	O
atherosclerosis	O
,	O
as	O
is	O
suggested	O
by	O
the	O
presence	O
of	O
activated	O
NF	B
-	I
kappa	I
B	I
in	O
human	O
atherosclerotic	O
lesions	O
.	O

Our	O
results	O
demonstrate	O
that	O
short	O
-	O
term	O
incubation	O
of	O
these	O
cells	O
with	O
oxLDL	B
activated	I
p50	I
/	I
p65	I
containing	O
NF	B
-	I
kappa	I
B	I
dimers	I
and	O
induced	O
the	O
expression	O
of	O
the	O
target	B
gene	I
IL	I
-	I
8	I
.	O

This	O
activation	O
of	O
NF	B
-	I
kappa	I
B	I
was	O
inhibited	O
by	O
the	O
antioxidant	O
and	O
H2O2	O
scavenger	O
pyrrolidine	O
dithiocarbamate	O
and	O
the	O
proteasome	B
inhibitor	O
PSI	O
.	O

The	O
oxLDL	B
-	O
induced	O
NF	B
-	I
kappa	I
B	I
activation	O
was	O
accompanied	O
by	O
an	O
initial	O
depletion	O
of	O
I	B
kappa	I
B	I
-	I
alpha	I
followed	O
by	O
a	O
slight	O
transient	O
increase	O
in	O
the	O
level	O
of	O
this	O
inhibitor	O
protein	O
.	O

These	O
observations	O
provide	O
additional	O
evidence	O
that	O
oxLDL	B
is	O
a	O
potent	O
modulator	O
of	O
gene	O
expression	O
and	O
suggest	O
that	O
(	O
dys	O
)	O
regulation	O
of	O
NF	B
-	I
kappa	I
B	I
/	I
Rel	I
is	O
likely	O
to	O
play	O
an	O
important	O
role	O
in	O
atherogenesis	O
.	O

PURPOSE	O
:	O
To	O
demonstrate	O
that	O
leukocyte	O
adhesion	O
to	O
cultured	O
corneal	O
endothelial	O
cells	O
is	O
mediated	O
by	O
the	O
CD18	B
antigen	I
,	O
and	O
to	O
determine	O
whether	O
dexamethasone	O
directly	O
suppresses	O
adhesion	O
by	O
inhibiting	O
activation	O
of	O
nuclear	B
factor	I
kappa	I
B	I
(	O
NFkappaB	B
)	O
.	O

Nonadherent	O
neutrophils	O
were	O
removed	O
by	O
sealing	O
and	O
inverting	O
the	O
culture	O
well	O
.	O

RESULTS	O
:	O
Neutrophil	O
adhesion	O
to	O
cultured	O
corneal	O
endothelial	O
cells	O
increased	O
significantly	O
on	O
exposure	O
to	O
TNFalpha	B
(	O
451	O
.	O
4	O
+	O
/	O
-	O
45	O
.	O
4	O
cells	O
/	O
mm2	O
,	O
n	O
=	O
16	O
)	O
compared	O
to	O
control	O
(	O
156	O
.	O
7	O
+	O
/	O
-	O
27	O
.	O
3	O
cells	O
/	O
mm2	O
,	O
n	O
=	O
16	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

The	O
transcriptional	B
start	I
sites	I
were	O
identified	O
by	O
an	O
RNase	B
protection	O
assay	O
.	O

Since	O
GH	B
stimulates	O
the	O
development	O
and	O
function	O
of	O
granulocytes	O
,	O
we	O
investigated	O
the	O
expression	O
of	O
GH	B
in	O
granulocyte	O
subsets	O
.	O

Restriction	O
analysis	O
revealed	O
that	O
neutrophils	O
express	O
the	O
GH	B
-	I
N	I
gene	I
but	O
not	O
the	O
GH	B
-	I
V	I
gene	I
.	O

In	O
addition	O
,	O
BHRF1	B
protected	O
these	O
cells	O
from	O
monocyte	O
-	O
mediated	O
killing	O
but	O
failed	O
to	O
protect	O
them	O
from	O
killing	O
mediated	O
by	O
lymphokine	O
-	O
activated	O
killer	O
cells	O
.	O

Genomic	O
organization	O
,	O
sequence	O
,	O
and	O
transcriptional	O
regulation	O
of	O
the	O
human	B
eotaxin	I
gene	I
.	O

Eotaxin	B
is	O
an	O
eosinophil	B
specific	I
beta	I
-	I
chemokine	I
assumed	O
to	O
be	O
involved	O
in	O
eosinophilic	O
inflammatory	O
diseases	O
such	O
as	O
atopic	O
dermatitis	O
,	O
allergic	O
rhinitis	O
,	O
asthma	O
and	O
parasitic	O
infections	O
.	O

Here	O
we	O
describe	O
the	O
functional	O
characterization	O
of	O
this	O
promoter	O
and	O
identification	O
of	O
the	O
factors	O
in	O
B	O
and	O
T	O
cells	O
that	O
regulate	O
its	O
activity	O
.	O

The	O
pp52	B
promoter	I
contains	O
an	O
initiator	O
specifying	O
the	O
unique	O
5	B
'	I
terminus	I
of	O
pp52	B
mRNA	I
,	O
tandem	O
pairs	O
of	O
Ets	B
and	I
SP1	I
motifs	I
,	O
and	O
a	O
lone	B
C	I
/	I
EBP	I
motif	I
.	O

BACKGROUND	O
:	O
Recent	O
studies	O
have	O
raised	O
the	O
hypothesis	O
that	O
glucocorticoids	O
could	O
diminish	O
the	O
ability	O
of	O
endothelial	O
cells	O
to	O
direct	O
leukocyte	O
traffic	O
into	O
inflamed	O
tissues	O
by	O
inhibiting	O
expression	O
of	O
the	O
adhesion	B
molecules	I
endothelial	B
-	I
leukocyte	I
adhesion	I
molecule	I
-	I
1	I
and	O
intercellular	B
adhesion	I
molecule	I
-	I
1	I
.	O

The	O
immediate	O
-	O
early	O
gene	O
product	O
Egr	B
-	I
1	I
regulates	O
the	O
human	B
interleukin	I
-	I
2	I
receptor	I
beta	I
-	I
chain	I
promoter	I
through	O
noncanonical	B
Egr	I
and	I
Sp1	I
binding	I
sites	I
.	O

In	O
Jurkat	O
cells	O
,	O
both	O
sites	O
were	O
required	O
for	O
maximal	O
IL	B
-	I
2Rbeta	I
promoter	O
activity	O
,	O
and	O
in	O
HeLaS3	O
cells	O
,	O
transfection	O
of	O
Egr	B
-	I
1	I
could	O
drive	O
activity	O
of	O
a	O
reporter	O
construct	O
containing	O
both	O
sites	O
.	O

Acquisition	O
of	O
heat	O
shock	O
factor	O
2	O
(	O
HSF2	O
)	O
DNA	O
binding	O
activity	O
is	O
accompanied	O
by	O
induced	O
transcription	O
of	O
heat	B
shock	I
genes	I
in	O
hemin	O
-	O
treated	O
K562	O
cells	O
undergoing	O
erythroid	O
differentiation	O
.	O

Sequential	O
development	O
of	O
structural	O
and	O
functional	O
alterations	O
in	O
T	O
cells	O
from	O
tumor	O
-	O
bearing	O
mice	O
.	O

These	O
defects	O
are	O
paralleled	O
by	O
an	O
impaired	O
ability	O
to	O
produce	O
Th1	B
cytokines	I
(	O
IL	B
-	I
2	I
and	O
IFN	B
-	I
gamma	I
)	O
.	O

Like	O
the	O
class	B
II	I
genes	I
,	O
the	O
HLA	B
-	I
DM	I
genes	I
contain	O
upstream	O
regulatory	O
sequences	O
similar	O
to	O
the	O
S	B
-	I
X	I
-	I
Y	I
regulatory	I
region	I
as	O
well	O
as	O
additional	O
putative	O
regulatory	O
sites	O
.	O

The	O
class	B
II	I
-	I
specific	I
transcription	I
factors	I
RFX	B
and	O
CIITA	B
are	O
also	O
required	O
for	O
expression	O
,	O
as	O
cell	O
lines	O
deficient	O
in	O
these	O
factors	O
failed	O
to	O
allow	O
transcription	O
from	O
the	O
DM	B
promoters	I
.	O

In	O
addition	O
,	O
in	O
vivo	O
footprint	O
analysis	O
showed	O
the	O
putative	O
X	B
and	I
Y	I
boxes	I
to	O
be	O
occupied	O
by	O
transcription	B
factors	I
in	O
wild	O
-	O
type	O
B	O
cells	O
,	O
but	O
not	O
in	O
RFX	O
-	O
deficient	O
B	O
cells	O
.	O

None	O
of	O
the	O
other	O
putative	O
regulatory	O
sites	O
was	O
occupied	O
in	O
vivo	O
,	O
indicating	O
that	O
they	O
may	O
not	O
be	O
functional	O
.	O

On	O
the	O
other	O
hand	O
,	O
Ad2	O
was	O
internalized	O
by	O
macrophages	O
.	O

Critical	O
cytoplasmic	B
domains	I
of	O
human	B
interleukin	I
-	I
9	I
receptor	I
alpha	I
chain	I
in	O
interleukin	B
-	O
9	O
-	O
mediated	O
cell	O
proliferation	O
and	O
signal	O
transduction	O
.	O

In	O
a	O
previous	O
study	O
,	O
we	O
demonstrated	O
that	O
bufalin	O
,	O
which	O
is	O
an	O
active	O
principle	O
of	O
Chinese	O
medicine	O
,	O
chan	O
'	O
su	O
,	O
caused	O
apoptosis	O
in	O
human	O
leukemia	O
U937	O
cells	O
by	O
anomalous	O
activation	O
of	O
mitogen	B
-	I
activated	I
protein	I
kinase	I
(	O
MAPK	B
)	O
via	O
the	O
signaling	O
pathway	O
of	O
Ras	B
,	O
Raf	B
-	I
1	I
,	O
and	O
MAPK	B
kinase	I
-	I
1	I
.	O

Here	O
,	O
we	O
report	O
the	O
effect	O
of	O
overexpression	O
of	O
bcl	B
-	I
2	I
in	O
U937	O
cells	O
on	O
the	O
signaling	O
pathway	O
of	O
apoptosis	O
that	O
is	O
induced	O
by	O
bufalin	O
.	O

The	O
genes	O
encoding	O
the	O
functionally	O
related	O
hepatocyte	B
nuclear	I
factors	I
HNF	B
-	I
1alpha	I
and	O
HNF	B
-	I
4alpha	I
play	O
a	O
critical	O
role	O
in	O
normal	O
pancreatic	O
beta	O
-	O
cell	O
function	O
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
HNF	B
-	I
3alpha	I
,	I
-	I
3beta	I
,	I
-	I
3gamma	I
,	I
-	I
4gamma	I
,	I
and	I
-	I
6	I
are	O
expressed	O
in	O
pancreatic	O
beta	O
-	O
cells	O
.	O

We	O
report	O
the	O
identification	O
and	O
characterization	O
of	O
simple	B
tandem	I
repeat	I
DNA	I
polymorphisms	I
in	O
the	O
genes	O
encoding	O
HNF	B
-	I
3alpha	I
,	O
-	B
3beta	I
,	O
-	B
3gamma	I
,	O
-	B
4gamma	I
,	O
and	O
-	B
6	I
and	O
the	O
mapping	O
of	O
HNF	B
-	I
6	I
to	O
chromosome	B
bands	I
15q21	B
.	I
1	I
-	I
21	I
.	I
2	I
by	O
fluorescence	O
in	O
situ	O
hybridization	O
.	O

Anti	B
-	I
E	I
.	I
chaffeensis	I
antibody	I
complexed	O
with	O
E	O
.	O
chaffeensis	O
significantly	O
enhanced	O
mRNA	O
expression	O
of	O
IL	B
-	I
1beta	I
in	O
THP	O
-	O
1	O
cells	O
.	O

Decreased	O
transcriptional	O
activation	O
by	O
N	B
-	I
terminal	I
deletions	I
of	O
CIITA	B
is	O
correlated	O
directly	O
with	O
their	O
reduced	O
binding	O
to	O
TAFII32	B
.	O

Ligand	O
binding	O
and	O
activation	O
of	O
the	O
IL	B
-	I
10	I
receptor	I
expressed	O
on	O
B	O
-	O
CLL	O
cells	O
results	O
in	O
the	O
phosphorylation	O
of	O
signal	B
transducer	I
and	I
activator	I
of	I
transcription	I
1	I
(	O
STAT1	B
)	O
and	O
STAT3	B
proteins	O
.	O

When	O
18C7	B
was	O
incubated	O
with	O
MR	B
before	O
aldosterone	O
or	O
progesterone	O
,	O
the	O
antibody	O
inhibited	O
75	O
-	O
80	O
%	O
of	O
the	O
binding	O
.	O

Molecular	O
cloning	O
of	O
SLAP	B
-	I
130	I
,	O
an	O
SLP	B
-	I
76	I
-	I
associated	I
substrate	I
of	O
the	O
T	B
cell	I
antigen	I
receptor	I
-	I
stimulated	I
protein	I
tyrosine	I
kinases	I
.	O

These	O
data	O
suggest	O
that	O
SLP	B
-	I
76	I
recruits	O
a	O
negative	O
regulator	O
,	O
SLAP	B
-	I
130	I
,	O
as	O
well	O
as	O
positive	O
regulators	O
of	O
signal	O
transduction	O
in	O
T	O
cells	O
.	O

This	O
review	O
focuses	O
on	O
the	O
molecular	O
actions	O
of	O
prolactin	O
in	O
the	O
immune	O
system	O
.	O

From	O
analyses	O
of	O
mice	O
deficient	O
in	O
transcription	B
factor	I
genes	I
and	O
from	O
the	O
characterizations	O
of	O
chromosome	B
breakpoints	I
in	O
human	O
leukemias	O
,	O
it	O
has	O
become	O
evident	O
that	O
transcription	B
factors	I
are	O
important	O
regulators	O
of	O
hematopoiesis	O
.	O

Induction	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
expression	O
in	O
monocytic	O
cells	O
by	O
Cryptococcus	O
neoformans	O
and	O
Candida	O
albicans	O
.	O

Because	O
candidiasis	O
and	O
cryptococcosis	O
are	O
common	O
in	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
-	O
infected	O
persons	O
,	O
the	O
effect	O
of	O
Cryptococcus	O
neoformans	O
and	O
Candida	O
albicans	O
on	O
HIV	O
expression	O
in	O
monocytic	O
cells	O
was	O
examined	O
.	O

Stimulation	O
of	O
the	O
latently	O
HIV	O
-	O
infected	O
myelomonocytic	O
cell	O
line	O
OM	O
-	O
10	O
.	O
1	O
with	O
C	O
.	O
neoformans	O
and	O
C	O
.	O
albicans	O
in	O
the	O
presence	O
of	O
pooled	O
human	O
serum	O
caused	O
a	O
ratio	O
-	O
dependent	O
increase	O
in	O
HIV	O
production	O
.	O

In	O
THP	O
-	O
1	O
cells	O
transfected	O
with	O
HIV	B
plasmid	I
constructs	I
,	O
both	O
organisms	O
induced	O
transcription	O
from	O
the	O
HIV	B
long	I
terminal	I
repeat	I
that	O
was	O
dependent	O
on	O
intact	O
NF	B
-	I
kappaB	I
binding	I
sequences	I
.	O

Thus	O
,	O
C	O
.	O
neoformans	O
and	O
C	O
.	O
albicans	O
enhance	O
HIV	O
expression	O
in	O
monocytic	O
cells	O
through	O
a	O
TNF	O
-	O
alpha	O
-	O
and	O
NF	O
-	O
kappaB	O
-	O
dependent	O
mechanism	O
.	O

In	O
this	O
report	O
we	O
present	O
the	O
characterisation	O
of	O
NF	B
-	I
kappaB	I
subunits	I
engaged	O
in	O
complexes	O
binding	O
to	O
the	O
HIV	B
-	I
1	I
NF	I
-	I
kappaB	I
site	I
in	O
human	O
8e51	O
T	O
-	O
cells	O
,	O
that	O
harbour	O
a	O
defective	O
HIV	O
-	O
1	O
.	O

With	O
the	O
use	O
of	O
specific	B
antibodies	I
we	O
have	O
determined	O
the	O
composition	O
of	O
each	O
complex	O
using	O
electrophoretic	O
mobility	O
shift	O
assays	O
.	O

c	B
-	I
Myb	I
and	O
Ets	B
proteins	I
synergize	O
to	O
overcome	O
transcriptional	O
repression	O
by	O
ZEB	B
.	O

IL	B
-	I
4	I
-	O
dependent	O
activation	O
of	O
Stat6	B
was	O
also	O
observed	O
in	O
HC11	O
mammary	O
epithelial	O
cells	O
.	O

In	O
these	O
cells	O
,	O
Stat6	B
activation	O
led	O
to	O
the	O
induction	O
of	O
the	O
beta	B
-	I
casein	I
gene	I
promoter	I
.	O

In	O
pre	O
-	O
B	O
cells	O
(	O
Ba	O
/	O
F3	O
)	O
,	O
the	O
transactivation	O
domain	O
of	O
Stat6	B
was	O
IL	B
-	I
4	I
regulated	O
,	O
independently	O
from	O
its	O
DNA	O
binding	O
function	O
.	O

Activation	O
of	O
helper	O
T	O
cells	O
results	O
in	O
coordinate	O
expression	O
of	O
a	O
number	O
of	O
cytokines	B
involved	O
in	O
differentiation	O
,	O
proliferation	O
and	O
activation	O
of	O
the	O
haematopoietic	O
system	O
.	O

Granulocyte	B
-	I
macrophage	I
colony	I
stimulating	I
factor	I
(	O
GM	B
-	I
CSF	I
)	O
is	O
one	O
such	O
cytokine	B
,	O
whose	O
increased	O
expression	O
results	O
mostly	O
from	O
increases	O
in	O
transcription	O
.	O

ETS1	B
is	O
a	O
transcription	B
factor	I
of	O
the	O
ETS	B
family	I
that	O
is	O
expressed	O
in	O
T	O
cells	O
.	O

We	O
have	O
previously	O
shown	O
that	O
ETS1	B
can	O
transactivate	O
GM	B
-	I
CSF	I
in	O
Jurkat	O
T	O
cells	O
,	O
but	O
only	O
after	O
the	O
cells	O
have	O
been	O
stimulated	O
by	O
treatment	O
with	O
PMA	O
and	O
ionomycin	O
,	O
agents	O
that	O
mimic	O
T	O
cell	O
activation	O
.	O

This	O
defect	O
in	O
maturation	O
resulted	O
in	O
a	O
transgene	O
dose	O
-	O
dependent	O
reduction	O
in	O
peripheral	O
T	O
lymphocytes	O
,	O
with	O
the	O
CD8	O
lineage	O
being	O
more	O
severely	O
affected	O
.	O

CD40	B
is	O
an	O
important	O
signaling	O
and	O
activation	O
Ag	O
found	O
on	O
certain	O
bone	O
marrow	O
-	O
derived	O
cells	O
.	O

Recently	O
,	O
CD40	B
also	O
has	O
been	O
shown	O
to	O
be	O
expressed	O
by	O
mesenchymal	O
cells	O
,	O
including	O
human	O
fibroblasts	O
.	O

Little	O
is	O
known	O
about	O
the	O
role	O
of	O
CD40	B
in	O
fibroblasts	O
.	O

The	O
current	O
study	O
investigates	O
the	O
hypothesis	O
that	O
CD40	B
expressed	O
on	O
lung	O
fibroblasts	O
is	O
an	O
activation	O
structure	O
and	O
mechanism	O
for	O
interaction	O
with	O
hemopoietic	O
cells	O
.	O

Signaling	O
through	O
CD40	B
with	O
soluble	O
CD40	B
ligand	O
stimulated	O
fibroblast	O
activation	O
,	O
as	O
evidenced	O
by	O
mobilization	O
of	O
nuclear	O
factor	O
-	O
kappaB	O
and	O
by	O
induction	O
of	O
the	O
proinflammatory	O
and	O
chemoattractant	O
cytokines	B
IL	B
-	I
6	I
and	O
IL	B
-	I
8	I
.	O

In	O
contrast	O
,	O
it	O
was	O
found	O
to	O
be	O
TNF	B
-	I
alpha	I
independent	O
in	O
the	O
early	O
time	O
point	O
.	O

In	O
fact	O
,	O
mAb	B
L243	I
but	O
not	O
the	O
staphylococcal	B
superantigens	I
,	O
staphylococcal	B
exotoxin	I
toxic	I
shock	I
syndrome	I
toxin	I
-	I
I	I
or	O
staphylococcal	B
enterotoxin	I
B	I
,	O
regulate	O
the	O
NF	B
-	I
kappa	I
B	I
binding	O
activity	O
.	O

Regulation	O
of	O
inosine	B
-	I
5	I
'	I
-	I
monophosphate	I
dehydrogenase	I
type	I
II	I
gene	O
expression	O
in	O
human	O
T	O
cells	O
.	O

Additional	O
major	O
protein	O
-	O
DNA	O
interactions	O
do	O
not	O
occur	O
within	O
the	O
promoter	O
region	O
after	O
T	O
lymphocyte	O
activation	O
,	O
indicating	O
a	O
requirement	O
for	O
additional	O
protein	O
-	O
protein	O
interactions	O
and	O
/	O
or	O
post	O
-	O
translational	O
modifications	O
of	O
pre	B
-	I
bound	I
transcription	I
factors	I
to	O
account	O
for	O
the	O
observed	O
increase	O
in	O
IMPDH	O
type	O
II	O
gene	O
expression	O
.	O

NAC	O
had	O
no	O
effect	O
on	O
the	O
half	O
-	O
life	O
of	O
E	B
-	I
selectin	I
or	I
VCAM	I
-	I
1	I
mRNA	I
.	O

Fusion	O
proteins	O
involving	O
the	O
retinoic	O
acid	O
receptor	B
alpha	I
(	O
RAR	B
alpha	I
)	O
and	O
the	O
PML	B
or	O
PLZF	B
nuclear	I
protein	I
are	O
the	O
genetic	O
markers	O
of	O
acute	O
promyelocytic	O
leukemias	O
(	O
APLs	O
)	O
.	O

Cytomegalovirus	O
(	O
CMV	O
)	O
infection	O
induced	O
interleukin	B
-	I
8	I
(	O
IL	B
-	I
8	I
)	O
gene	O
transcription	O
in	O
a	O
human	O
monocytic	O
cell	O
line	O
,	O
THP	O
-	O
1	O
cells	O
,	O
leading	O
to	O
IL	B
-	I
8	I
secretion	O
.	O

Moreover	O
,	O
electrophoretic	O
mobility	O
shift	O
assays	O
demonstrated	O
that	O
CMV	O
induced	O
the	O
formation	O
of	O
NF	B
-	I
kappaB	I
and	O
AP	B
-	I
1	I
complexes	I
.	O

Interleukin	B
-	I
12	I
(	O
IL	B
-	I
12	I
)	O
is	O
a	O
cytokine	B
that	O
exhibits	O
pleiotropic	O
effects	O
on	O
lymphocytes	O
and	O
natural	O
killer	O
cells	O
and	O
has	O
been	O
shown	O
to	O
have	O
promise	O
for	O
the	O
immunotherapy	O
of	O
cancer	O
.	O

This	O
presents	O
several	O
problems	O
in	O
vectors	O
,	O
particularly	O
those	O
in	O
which	O
additional	O
genes	O
,	O
either	O
a	O
co	B
-	I
stimulatory	I
gene	I
or	O
a	O
selectable	O
marker	O
,	O
are	O
inserted	O
.	O

Direct	O
analysis	O
of	O
these	O
modified	O
cells	O
acting	O
as	O
tumor	O
vaccines	O
is	O
underway	O
.	O

Plasma	O
sialyltransferase	B
levels	O
in	O
psychiatric	O
disorders	O
as	O
a	O
possible	O
indicator	O
of	O
HPA	O
axis	O
function	O
.	O

While	O
there	O
was	O
a	O
significant	O
increase	O
in	O
plasma	O
cortisol	O
levels	O
in	O
the	O
depressed	O
group	O
,	O
there	O
were	O
no	O
changes	O
in	O
the	O
lymphocyte	O
GR	B
binding	O
parameters	O
(	O
K	O
(	O
m	O
)	O
and	O
Bmax	O
)	O
.	O

There	O
was	O
,	O
however	O
,	O
a	O
significant	O
decrease	O
in	O
the	O
plasma	B
sialyltransferase	I
:	I
cortisol	O
ratio	O
in	O
the	O
depressed	O
group	O
suggesting	O
an	O
inability	O
of	O
the	O
raised	O
cortisol	O
levels	O
to	O
induce	O
enzyme	O
expression	O
and	O
this	O
ratio	O
may	O
provide	O
a	O
useful	O
biochemical	O
marker	O
of	O
cortisol	O
receptor	O
function	O
.	O

Therefore	O
,	O
while	O
the	O
total	O
plasma	B
sialyltransferase	I
:	O
cortisol	O
ratio	O
reflects	O
HPA	O
axis	O
function	O
,	O
alterations	O
in	O
specific	O
isozyme	O
activity	O
may	O
also	O
be	O
associated	O
with	O
other	O
CNS	O
disease	O
states	O
.	O

Using	O
a	O
previously	O
described	O
mutant	O
of	O
the	O
Jurkat	O
T	O
cell	O
line	O
,	O
we	O
show	O
that	O
proximal	O
signaling	O
events	O
dependent	O
on	O
the	O
presence	O
of	O
the	O
CD45	B
tyrosine	I
phosphatase	I
are	O
required	O
for	O
TCR	B
-	O
stimulated	O
CD95	B
ligand	I
expression	O
.	O

Together	O
,	O
these	O
studies	O
begin	O
a	O
dissection	O
of	O
the	O
biochemical	O
events	O
that	O
lead	O
to	O
expression	O
of	O
CD95	B
ligand	I
,	O
a	O
required	O
step	O
for	O
TCR	B
-	O
induced	O
apoptosis	O
.	O

This	O
paper	O
aims	O
to	O
review	O
the	O
role	O
of	O
free	O
radical	O
-	O
induced	O
tissue	O
damage	O
and	O
antioxidant	O
defence	O
mechanisms	O
in	O
inflammatory	O
diseases	O
that	O
involve	O
pathogenic	O
processes	O
similar	O
to	O
the	O
periodontal	O
diseases	O
.	O

There	O
is	O
a	O
clearly	O
defined	O
and	O
substantial	O
role	O
for	O
free	O
radicals	O
or	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
in	O
periodontitis	O
,	O
but	O
little	O
research	O
has	O
been	O
performed	O
in	O
this	O
area	O
.	O

Large	O
germline	O
deletions	O
of	O
TSC2	B
occur	O
in	O
<	O
5	O
%	O
of	O
cases	O
,	O
and	O
a	O
number	O
of	O
small	O
intragenic	O
mutations	O
have	O
been	O
described	O
.	O

TCP	O
succinate	O
(	O
200	O
microM	O
,	O
24	O
h	O
)	O
reduced	O
TNF	B
-	I
induced	I
VCAM	I
-	I
1	I
and	O
E	B
-	I
selectin	I
expression	O
from	O
a	O
specific	O
mean	O
fluorescence	O
intensity	O
of	O
151	O
+	O
/	O
-	O
28	O
to	O
12	O
+	O
/	O
-	O
4	O
channels	O
and	O
from	O
225	O
+	O
/	O
-	O
38	O
to	O
79	O
+	O
/	O
-	O
21	O
channels	O
,	O
respectively	O
.	O

The	O
Eed	B
-	O
mediated	O
transcriptional	O
effects	O
are	O
likely	O
to	O
reflect	O
the	O
interaction	O
of	O
Eed	B
with	O
multiple	O
molecular	O
partners	O
,	O
including	O
K	B
protein	I
.	O

When	O
macrophages	O
were	O
pretreated	O
with	O
low	O
doses	O
of	O
IFN	B
-	I
gamma	I
and	O
then	O
stimulated	O
with	O
IFN	B
-	I
alpha	I
,	O
clearly	O
enhanced	O
formation	O
of	O
specific	O
transcription	B
factor	I
complexes	O
was	O
detected	O
.	O

Activation	O
and	O
regulation	O
of	O
NF	B
-	I
kappa	I
B	I
are	O
tightly	O
controlled	O
by	O
a	O
group	O
of	O
inhibitory	B
proteins	I
(	O
I	B
kappa	I
B	I
)	O
that	O
sequester	O
NF	B
-	I
kappa	I
B	I
in	O
the	O
cytoplasm	O
of	O
immune	O
/	O
inflammatory	O
effector	O
cells	O
.	O

Liberated	O
NF	B
-	I
kappa	I
B	I
migrates	O
to	O
the	O
nucleus	O
,	O
where	O
it	O
binds	O
to	O
specific	B
promoter	I
sites	I
and	O
activates	O
gene	O
transcription	O
.	O

Constitutive	O
expression	O
of	O
E2a	B
-	I
Pbx1	I
did	O
not	O
induce	O
apoptosis	O
or	O
continued	O
cycling	O
of	O
Rat	O
-	O
1	O
fibroblasts	O
in	O
low	O
serum	O
conditions	O
.	O

The	O
human	B
C	I
/	I
EBPepsilon	I
gene	I
is	O
transcribed	O
by	O
two	O
alternative	O
promoters	B
,	O
Palpha	B
and	O
Pbeta	B
.	O

A	O
combination	O
of	O
differential	O
splicing	O
and	O
alternative	O
use	O
of	O
promoters	B
generates	O
four	O
mRNA	B
isoforms	I
,	O
of	O
2	O
.	O
6	O
kb	O
and	O
1	O
.	O
3	O
-	O
1	O
.	O
5	O
kb	O
in	O
size	O
.	O

C	B
/	I
EBPepsilon	I
mRNA	I
was	O
greatly	O
induced	O
during	O
in	O
vitro	O
granulocytic	O
differentiation	O
of	O
human	O
primary	O
CD34	O
(	O
+	O
)	O
cells	O
.	O

Thus	O
,	O
C	B
/	I
EBPepsilon	I
is	O
regulated	O
in	O
a	O
complex	O
fashion	O
and	O
may	O
play	O
a	O
role	O
in	O
the	O
regulation	O
of	O
genes	O
involved	O
in	O
myeloid	O
differentiation	O
.	O

We	O
now	O
report	O
that	O
PO	B
-	I
B	I
DNA	O
-	O
binding	O
in	O
HL	O
-	O
60	O
cells	O
is	O
similarly	O
induced	O
during	O
differentiation	O
to	O
the	O
granulocytic	O
lineage	O
(	O
with	O
either	O
retinoic	O
acid	O
or	O
dimethylsulfoxide	O
)	O
.	O

Recent	O
studies	O
have	O
revealed	O
that	O
interactions	O
between	O
transcription	B
factors	I
play	O
an	O
important	O
role	O
in	O
regulation	O
of	O
gene	O
expression	O
in	O
eukaryotic	O
cells	O
.	O

Oct	B
-	I
2	I
expressed	O
in	O
this	O
tester	O
strain	O
represses	O
the	O
expression	O
of	O
the	O
reporter	O
gene	O
and	O
changes	O
the	O
phenotype	O
of	O
the	O
cell	O
from	O
Lac	O
+	O
to	O
Lac	O
-	O
.	O

One	O
of	O
them	O
,	O
hT86	O
,	O
encoding	O
a	O
putative	B
zinc	I
finger	I
protein	I
was	O
found	O
to	O
derepress	O
beta	B
-	I
galactosidase	I
activity	O
in	O
the	O
Oct	B
-	I
2	I
-	O
harboring	O
tester	O
strain	O
at	O
the	O
transcriptional	O
level	O
.	O

Thus	O
,	O
Tap	B
is	O
likely	O
to	O
be	O
an	O
important	O
cellular	O
mediator	O
of	O
Tip	B
function	O
in	O
T	O
cell	O
transformation	O
by	O
herpesvirus	O
saimiri	O
.	O

Triggering	O
of	O
the	O
T	B
-	I
cell	I
receptor	I
-	I
CD3	I
complex	I
activates	O
two	O
major	O
signal	O
cascades	O
in	O
T	O
lymphocytes	O
,	O
(	O
i	O
)	O
Ca2	O
+	O
-	O
dependent	O
signal	O
cascades	O
and	O
(	O
ii	O
)	O
protein	B
kinase	I
cascades	O
.	O

Both	O
signal	O
cascades	O
contribute	O
to	O
the	O
induction	O
of	O
the	O
interleukin	B
2	I
(	I
IL	I
-	I
2	I
)	I
gene	I
during	O
T	O
-	O
cell	O
activation	O
.	O

Functional	O
analysis	O
of	O
monocytic	O
THP	O
-	O
1	O
cells	O
transfected	O
with	O
plasmids	B
containing	O
various	O
lengths	O
of	O
TNF	B
-	I
alpha	I
promoter	I
localized	O
enhancer	B
elements	I
in	O
a	O
region	O
(	O
-	B
182	I
to	I
-	I
37	I
base	I
pairs	I
(	O
bp	O
)	O
)	O
that	O
were	O
required	O
for	O
optimal	O
transcription	O
of	O
the	O
TNF	B
-	I
alpha	I
gene	I
in	O
response	O
to	O
LPS	O
.	O

In	O
unstimulated	O
THP	O
-	O
1	O
,	O
CRE	B
-	I
binding	I
protein	I
and	O
,	O
to	O
a	O
lesser	O
extent	O
,	O
c	B
-	I
Jun	I
complexes	I
were	O
found	O
to	O
bind	O
to	O
the	O
CRE	B
site	I
.	O

The	O
CRE	B
and	I
kappaB3	I
sites	I
in	O
region	B
II	I
together	O
conferred	O
strong	O
LPS	O
responsiveness	O
to	O
a	O
heterologous	B
promoter	I
,	O
whereas	O
individually	O
they	O
failed	O
to	O
provide	O
transcriptional	O
activation	O
.	O

Furthermore	O
,	O
increasing	O
the	O
spacing	O
between	O
the	O
CRE	B
and	I
the	I
kappaB3	I
sites	I
completely	O
abolished	O
LPS	O
induction	O
,	O
suggesting	O
a	O
cooperative	O
interaction	O
between	O
c	B
-	I
Jun	I
complexes	I
and	O
p50	B
/	I
p65	I
.	O

IFN	B
-	I
alpha	I
/	I
beta	I
specifically	O
induced	O
tyrosine	O
phosphorylation	O
and	O
translocation	O
into	O
nucleus	O
of	O
signal	B
transducers	I
and	I
activators	I
of	I
transcription	I
(	I
STAT	I
)	I
2	I
protein	I
in	O
the	O
T	O
cell	O
clones	O
.	O

IL	B
-	I
10	I
inhibition	O
of	O
IFN	B
-	I
gamma	I
-	O
induced	O
ICAM	B
-	I
1	I
expression	O
was	O
apparent	O
as	O
early	O
as	O
3	O
hours	O
and	O
was	O
blocked	O
by	O
an	O
anti	B
-	I
IL	I
-	I
10	I
antibody	I
but	O
not	O
by	O
an	O
isotype	B
-	I
matched	I
control	I
antibody	I
.	O

The	O
other	O
,	O
CIITA	B
,	O
encodes	O
a	O
large	O
protein	O
with	O
a	O
defined	O
acidic	B
transcriptional	I
activation	I
domain	I
;	O
this	O
protein	O
does	O
not	O
interact	O
with	O
DNA	O
.	O

However	O
,	O
these	O
plasmids	B
produced	O
transcriptional	O
activity	O
in	O
HeLa	O
cells	O
only	O
in	O
conjunction	O
with	O
interferon	B
gamma	I
stimulation	O
,	O
a	O
condition	O
in	O
which	O
expression	O
of	O
both	O
CIITA	B
and	O
class	B
II	I
major	I
histocompatibility	I
complex	I
surface	I
proteins	I
are	O
induced	O
.	O

Thus	O
,	O
RFX5	B
can	O
activate	O
transcription	O
only	O
in	O
cooperation	O
with	O
CIITA	B
.	O

Phosphatidylinositol	B
3	I
-	I
kinase	I
(	O
PI3	B
-	I
K	I
)	O
has	O
been	O
implicated	O
in	O
the	O
regulation	O
of	O
cell	O
proliferation	O
in	O
many	O
cell	O
types	O
.	O

Acute	O
promyelocytic	O
leukemia	O
(	O
APL	O
)	O
is	O
associated	O
with	O
reciprocal	O
chromosomal	O
translocations	O
involving	O
the	O
retinoic	B
acid	I
receptor	I
alpha	I
(	I
RARalpha	I
)	I
locus	I
on	O
chromosome	B
17	I
.	O

The	O
resulting	O
fusion	B
genes	I
encode	O
the	O
two	O
structurally	O
unique	O
PML	B
/	I
RARalpha	I
and	O
RARalpha	B
/	I
PML	I
fusion	I
proteins	I
as	O
well	O
as	O
aberrant	B
PML	I
gene	I
products	I
,	O
the	O
respective	O
pathogenetic	O
roles	O
of	O
which	O
have	O
not	O
been	O
elucidated	O
.	O

Interferon	O
-	O
gamma	O
(	O
IFN	B
-	I
gamma	I
)	O
is	O
a	O
key	O
cytokine	O
of	O
T	O
lymphocytes	O
with	O
major	O
regulatory	O
functions	O
in	O
the	O
immune	O
system	O
.	O

This	O
novel	B
target	I
site	I
,	O
denoted	O
the	O
C	B
-	I
site	I
,	O
was	O
shown	O
by	O
several	O
criteria	O
,	O
including	O
cell	O
distribution	O
studies	O
,	O
stimulation	O
experiments	O
,	O
supershift	O
assays	O
,	O
and	O
cross	O
-	O
competition	O
electrophoretic	O
mobility	O
shift	O
assays	O
to	O
bind	O
the	O
transcription	B
factor	I
AP	I
-	I
1	I
.	O

Mutation	O
of	O
the	O
C	B
-	I
site	I
that	O
prevented	O
AP	B
-	I
1	I
binding	O
to	O
this	O
site	O
was	O
sufficient	O
strikingly	O
to	O
reduce	O
inducible	O
promoter	O
activity	O
in	O
primary	O
CD45R0	O
T	O
cells	O
.	O

Latent	O
infection	O
of	O
B	O
lymphocytes	O
by	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
can	O
be	O
disrupted	O
by	O
expression	O
of	O
the	O
EBV	B
ZEBRA	I
protein	I
.	O

The	O
studies	O
described	O
herein	O
demonstrate	O
that	O
the	O
activation	O
domain	O
.	O

The	O
involvement	O
of	O
the	O
CCK	B
(	I
B	I
)	I
receptor	I
in	O
such	O
a	O
stimulation	O
was	O
demonstrated	O
by	O
the	O
inhibiting	O
effect	O
of	O
the	O
selective	O
CCK	B
(	I
B	I
)	I
receptor	I
antagonist	O
PD	O
-	O
135	O
,	O
158	O
.	O

To	O
better	O
understand	O
the	O
AP	B
-	I
1	I
-	O
dependent	O
luciferase	B
expression	O
in	O
Jurkat	O
T	O
cells	O
,	O
we	O
tested	O
two	O
specific	O
inhibitors	O
of	O
serine	B
/	I
threonine	I
phosphatases	I
-	I
1	I
and	I
-	I
2A	I
:	O
okadaic	O
acid	O
and	O
calyculin	O
A	O
.	O

In	O
Jurkat	O
T	O
cells	O
activated	O
by	O
phorbol	O
-	O
12	O
-	O
myristate	O
-	O
13	O
-	O
acetate	O
and	O
phytohemagglutinin	B
,	O
CCK	O
-	O
8	O
induced	O
IL	O
-	O
2	O
expression	O
.	O

Our	O
results	O
indicate	O
that	O
CCK	O
-	O
8	O
exerts	O
a	O
trophic	O
effect	O
in	O
Jurkat	O
T	O
cells	O
through	O
stimulation	O
of	O
CCK	B
(	I
B	I
)	I
receptors	I
by	O
modulation	O
of	O
expression	O
of	O
AP	B
-	I
1	I
-	I
regulated	I
genes	I
.	O

Binding	B
sites	I
at	O
the	O
core	O
region	O
show	O
little	O
conservation	O
with	O
consensus	B
sites	I
.	O

While	O
the	O
activation	O
of	O
JAK2	B
,	O
Shc	B
,	O
Erk	B
,	O
and	O
STAT5	B
proteins	I
correlated	O
with	O
hGM	B
-	I
CSF	I
-	O
mediated	O
cell	O
growth	O
,	O
cellular	O
differentiation	O
occurred	O
in	O
the	O
absence	O
of	O
activation	O
of	O
these	O
signal	O
transduction	O
pathways	O
.	O

We	O
utilized	O
THP	O
-	O
1	O
cells	O
to	O
examine	O
the	O
response	O
to	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
with	O
macrophage	O
activation	O
.	O

Molecular	O
cloning	O
and	O
characterization	O
of	O
a	O
cDNA	B
,	O
CHEMR1	B
,	O
encoding	O
a	O
chemokine	B
receptor	I
with	O
a	O
homology	O
to	O
the	O
human	B
C	I
-	I
C	I
chemokine	I
receptor	I
,	O
CCR	B
-	I
4	I
.	O

Chemokines	B
refer	O
to	O
a	O
rapidly	O
expanding	O
family	O
of	O
small	O
cytokines	B
whose	O
primary	O
function	O
is	O
recruitment	O
of	O
leukocytes	O
to	O
inflammatory	O
sites	O
.	O

These	O
are	O
known	O
to	O
bind	O
to	O
seven	B
-	I
transmembrane	I
-	I
domain	I
containing	I
receptors	I
.	O

Northern	O
blot	O
analysis	O
in	O
mouse	O
cell	O
lines	O
suggests	O
that	O
its	O
expression	O
is	O
found	O
in	O
a	O
variety	O
of	O
cells	O
,	O
including	O
T	O
cells	O
,	O
B	O
cells	O
,	O
and	O
macrophages	O
.	O

This	O
suggests	O
that	O
CHEMR1	B
may	O
be	O
a	O
receptor	O
for	O
unidentified	O
C	B
-	I
C	I
chemokine	I
or	O
a	O
low	O
-	O
affinity	O
receptor	O
for	O
MIP	B
-	I
1alpha	I
.	O

Its	O
N	B
-	I
terminal	I
region	I
is	O
capable	O
of	O
activating	O
transcription	O
from	O
a	O
reporter	O
gene	O
when	O
fused	O
to	O
a	O
DNA	B
binding	I
domain	I
.	O

To	O
understand	O
the	O
mechanisms	O
underlined	O
in	O
this	O
regulation	O
in	O
normal	O
human	O
cells	O
,	O
we	O
have	O
analysed	O
in	O
vivo	O
protein	O
-	O
DNA	O
interactions	O
at	O
the	O
Cyclin	B
A	I
locus	O
in	O
primary	O
T	O
lymphocytes	O
.	O

The	O
third	O
site	O
was	O
occupied	O
in	O
quiescent	O
cells	O
or	O
in	O
cells	O
stimulated	O
by	O
anti	B
CD2	I
or	O
anti	B
CD28	I
alone	O
.	O

We	O
have	O
recently	O
reported	O
a	O
series	O
(	O
A	O
)	O
of	O
1	O
,	O
25D3	O
-	O
resistant	O
variants	O
of	O
HL60	O
cells	O
which	O
proliferate	O
in	O
the	O
presence	O
of	O
1	O
,	O
25D3	O
and	O
do	O
not	O
express	O
differentiation	O
markers	O
(	O
Exp	O
.	O
Cell	O
Res	O
.	O
224	O
,	O
312	O
,	O
1996	O
)	O
.	O

Human	B
immunodeficiency	I
virus	I
type	I
1	I
(	I
HIV	I
-	I
1	I
)	I
Tat	I
,	O
an	O
early	O
regulatory	B
protein	I
that	O
is	O
critical	O
for	O
viral	O
gene	O
expression	O
and	O
replication	O
,	O
transactivates	O
the	O
HIV	B
-	I
1	I
long	I
terminal	I
repeat	I
(	O
LTR	B
)	O
via	O
its	O
binding	O
to	O
the	O
transactivation	B
response	I
element	I
(	O
TAR	B
)	O
and	O
,	O
along	O
with	O
other	O
cellular	O
factors	O
,	O
increases	O
viral	O
transcription	O
initiation	O
and	O
elongation	O
.	O

In	O
this	O
study	O
,	O
a	O
combined	O
pharmacologic	O
and	O
genetic	O
strategy	O
using	O
two	O
PKC	B
(	O
NF	B
-	I
kappa	I
B	I
)	O
inhibitors	O
,	O
pentoxifylline	O
(	O
PTX	O
)	O
and	O
Go	O
-	O
6976	O
,	O
and	O
a	O
stably	O
expressed	O
anti	B
-	I
Tat	I
single	I
-	I
chain	I
intracellular	I
antibody	I
(	O
sFv	B
intrabody	I
)	O
was	O
employed	O
to	O
obtain	O
cooperative	O
inhibition	O
of	O
both	O
HIV	O
-	O
1	O
LTR	B
-	O
driven	O
gene	O
expression	O
and	O
HIV	O
-	O
1	O
replication	O
.	O

Treatment	O
of	O
cells	O
with	O
PTX	O
and	O
Go	O
-	O
6976	O
resulted	O
in	O
cooperative	O
inhibition	O
of	O
both	O
HIV	B
-	I
1	I
LTR	I
-	O
driven	O
gene	O
expression	O
and	O
HIV	O
-	O
1	O
replication	O
.	O

The	O
combined	O
treatment	O
resulted	O
in	O
more	O
durable	O
inhibition	O
of	O
HIV	O
-	O
1	O
replication	O
than	O
was	O
seen	O
with	O
the	O
NF	B
-	I
kappa	I
B	I
inhibitors	O
alone	O
or	O
the	O
anti	O
-	O
Tat	B
sFv	I
intrabodies	I
alone	O
.	O

CD28	B
is	O
an	O
important	O
costimulatory	B
molecule	I
in	O
the	O
activation	O
of	O
human	O
T	O
cells	O
.	O

Also	O
in	O
the	O
current	O
study	O
,	O
binding	O
activity	O
to	O
the	O
CD28RE	B
/	I
AP	I
-	I
1	I
sequence	I
of	O
the	O
IL	B
-	I
2	I
promoter	I
is	O
evaluated	O
.	O

These	O
data	O
indicate	O
that	O
functional	O
complexes	O
encompassing	O
both	O
the	O
CD28RE	B
and	O
the	O
AP	B
-	I
1	I
-	I
binding	I
sites	I
influence	O
IL	B
-	I
2	I
promoter	I
activity	O
in	O
CD28	B
-	O
costimulated	O
T	O
cells	O
.	O

Inducible	O
expression	O
and	O
phosphorylation	O
of	O
coactivator	B
BOB	I
.	I
1	I
/	I
OBF	I
.	I
1	I
in	O
T	O
cells	O
[	O
see	O
comments	O
]	O

Upon	O
activation	O
of	O
Jurkat	O
T	O
cells	O
and	O
primary	O
murine	O
thymocytes	O
with	O
phorbol	O
esters	O
and	O
ionomycin	O
,	O
BOB	B
.	I
1	I
/	I
OBF	I
.	I
1	I
expression	O
and	O
transactivation	O
function	O
were	O
induced	O
.	O

Mutation	O
of	O
Ser184	O
also	O
diminished	O
transactivation	O
function	O
in	O
B	O
cells	O
,	O
suggesting	O
that	O
the	O
activating	O
phosphorylation	O
that	O
is	O
inducible	O
in	O
T	O
cells	O
is	O
constitutively	O
present	O
in	O
B	O
cells	O
.	O

In	O
fact	O
,	O
the	O
offspring	O
of	O
alcoholics	O
have	O
higher	O
levels	O
of	O
G	B
(	I
S	I
)	I
alpha	I
expression	O
in	O
certain	O
tissues	O
compared	O
with	O
the	O
offspring	O
of	O
nonalcoholics	O
.	O

The	O
aim	O
of	O
this	O
research	O
was	O
to	O
test	O
the	O
hypothesis	O
that	O
a	O
causal	O
relationship	O
exists	O
between	O
the	O
level	O
of	O
expression	O
of	O
G	B
(	I
S	I
)	I
alpha	I
and	O
induction	O
of	O
the	O
adenylyl	B
cyclase	I
(	O
AC	O
)	O
cascade	O
.	O

The	O
methodology	O
employed	O
transient	O
transfection	O
of	O
HEK	O
293	O
cells	O
with	O
a	O
cDNA	O
for	O
the	O
52	O
-	O
kDa	O
form	O
of	O
G	B
(	I
S	I
)	I
alpha	I
under	O
regulation	O
by	O
inducible	B
metallothionein	I
promoters	I
.	O

VSMCs	O
derived	O
from	O
human	O
coronary	O
atherosclerotic	O
plaques	O
that	O
apoptose	O
even	O
in	O
serum	O
also	O
generated	O
thrombin	B
(	O
AUC	O
of	O
260	O
+	O
/	O
-	O
2	O
nmol	O
x	O
min	O
/	O
L	O
;	O
PT	O
of	O
128	O
+	O
/	O
-	O
4	O
nmol	O
/	O
L	O
)	O
.	O

Patients	O
with	O
one	O
type	O
of	O
major	B
histocompatibility	I
complex	I
class	I
II	I
combined	O
immunodeficiency	O
have	O
mutations	O
in	O
a	O
gene	O
termed	O
class	B
II	I
transactivator	I
(	O
CIITA	B
)	O
,	O
which	O
coordinately	O
controls	O
the	O
transcription	O
of	O
the	O
three	O
major	O
human	B
class	I
II	I
genes	I
,	O
HLA	B
-	I
DR	I
,	I
-	I
DQ	I
,	I
and	I
-	I
DP	I
.	O

We	O
report	O
here	O
that	O
ectopic	O
expression	O
of	O
CIITA	B
cDNAs	I
derived	O
by	O
reverse	O
transcriptase	O
polymerase	O
chain	O
reaction	O
from	O
clone	O
13	O
do	O
not	O
restore	O
expression	O
of	O
HLA	B
-	I
DQ	I
in	O
another	O
CIITA	O
-	O
deficient	O
cell	O
line	O
,	O
RJ2	O
.	O
2	O
.	O
5	O
.	O

In	O
contrast	O
,	O
somatic	O
cell	O
fusion	O
between	O
clone	O
13	O
and	O
RJ2	O
.	O
2	O
.	O
5	O
restored	O
expression	O
of	O
the	O
HLA	B
-	I
DQ	I
haplotype	O
encoded	O
by	O
the	O
RJ2	B
.	I
2	I
.	I
5	I
DQB	I
gene	I
.	O

The	O
cytokines	B
interleukin	B
(	I
IL	I
)	I
-	I
4	I
and	O
IL	B
-	I
13	I
play	O
a	O
critical	O
role	O
in	O
inducing	O
Cepsilon	B
germline	I
transcripts	I
and	O
IgE	B
isotype	I
switching	O
in	O
human	O
B	O
cells	O
.	O

We	O
show	O
that	O
ligand	O
-	O
induced	O
homodimerization	O
of	O
chimeric	B
surface	I
receptors	I
consisting	O
of	O
the	O
extracellular	B
and	I
transmembrane	I
domains	I
of	O
the	O
erythropoietin	B
receptor	I
and	O
of	O
the	O
intracellular	B
domain	I
of	O
IL	B
-	I
4Ralpha	I
induces	O
Janus	B
kinase	I
1	I
(	O
Jak1	B
)	O
activation	O
,	O
STAT6	B
activation	O
,	O
and	O
Cepsilon	B
germline	I
transcripts	I
in	O
human	O
B	O
cell	O
line	O
BJAB	O
.	O

Characterization	O
of	O
peripheral	O
blood	O
T	O
-	O
lymphocytes	O
transduced	O
with	O
HTLV	B
-	I
I	I
Tax	I
mutants	I
with	O
different	O
trans	O
-	O
activating	O
phenotypes	O
.	O

Analysis	O
of	O
these	O
PBLs	O
revealed	O
that	O
activation	O
of	O
the	O
NF	B
-	I
kappaB	I
pathway	O
is	O
sufficient	O
to	O
promote	O
the	O
growth	O
response	O
to	O
IL	B
-	I
2	I
.	O

Some	O
of	O
the	O
most	O
potent	O
antiinflammatory	O
and	O
immunosuppressive	O
agents	O
are	O
synthetic	O
glucocorticoids	O
.	O

The	O
development	O
of	O
improved	O
glucocorticoid	O
-	O
based	O
drugs	O
will	O
require	O
the	O
separation	O
of	O
beneficial	O
from	O
deleterious	O
effects	O
.	O

One	O
possibility	O
toward	O
this	O
goal	O
is	O
to	O
try	O
to	O
dissociate	O
two	O
main	O
activities	O
of	O
glucocorticoids	O
,	O
i	O
.	O
e	O
.	O
transactivation	O
and	O
transrepression	O
.	O

To	O
understand	O
the	O
molecular	O
mechanisms	O
controlling	O
CD19	B
gene	O
expression	O
,	O
we	O
isolated	O
and	O
functionally	O
characterized	O
the	O
CD19	B
promoter	I
using	O
in	O
vivo	O
footprinting	O
,	O
gel	O
shift	O
assays	O
,	O
and	O
transfection	O
studies	O
.	O

EBF	B
and	O
E47	B
collaborate	O
to	O
induce	O
expression	O
of	O
the	O
endogenous	B
immunoglobulin	I
surrogate	I
light	I
chain	I
genes	I
.	O

Taken	O
together	O
,	O
these	O
data	O
suggest	O
that	O
EBF	B
and	O
E47	B
synergize	O
to	O
activate	O
expression	O
of	O
a	O
subset	O
of	O
genes	O
that	O
define	O
an	O
early	O
stage	O
of	O
the	O
B	O
cell	O
lineage	O
.	O

Treatment	O
of	O
cells	O
expressing	O
the	O
chimeric	B
receptor	I
kit	B
/	I
IL	I
-	I
4R	I
alpha	I
with	O
SCF	B
induces	O
activation	O
of	O
the	O
IL	B
-	I
4R	I
alpha	I
-	I
associated	I
kinase	I
JAK	B
-	I
1	I
and	O
the	O
transcription	B
factor	I
STAT6	B
.	O

Dose	O
-	O
dependence	O
studies	O
using	O
histamine	O
and	O
dimaprit	O
showed	O
that	O
the	O
EC50	O
values	O
for	O
cAMP	O
production	O
and	O
c	B
-	I
fos	I
increase	O
were	O
similar	O
,	O
suggesting	O
that	O
cAMP	O
might	O
be	O
involved	O
in	O
c	B
-	I
fos	I
induction	O
via	O
H2	B
receptors	I
.	O

BACKGROUND	O
:	O
Activated	O
platelets	O
tether	O
and	O
activate	O
myeloid	O
leukocytes	O
.	O

Throughout	O
the	O
study	O
period	O
,	O
CD41	O
immunofluorescence	O
of	O
leukocytes	O
(	O
flow	O
cytometry	O
)	O
revealed	O
increased	O
leukocyte	O
-	O
platelet	O
adhesion	O
in	O
patients	O
with	O
AMI	O
compared	O
with	O
control	O
patients	O
(	O
mean	O
+	O
/	O
-	O
SE	O
of	O
fluorescence	O
[	O
channels	O
]	O
before	O
PTCA	O
:	O
77	O
+	O
/	O
-	O
16	O
versus	O
35	O
+	O
/	O
-	O
9	O
;	O
P	O
=	O
.	O
003	O
)	O
.	O

After	O
4	O
hours	O
,	O
IL	B
-	I
1	I
beta	I
and	O
IL	B
-	I
8	I
concentration	O
of	O
the	O
cell	O
-	O
free	O
supernatant	O
had	O
increased	O
by	O
268	O
+	O
/	O
-	O
36	O
%	O
and	O
210	O
+	O
/	O
-	O
7	O
%	O
,	O
respectively	O
,	O
and	O
cellular	O
MCP	B
-	I
1	I
content	O
had	O
increased	O
by	O
170	O
+	O
/	O
-	O
8	O
%	O
.	O

The	O
present	O
work	O
shows	O
that	O
the	O
primary	O
CD8	O
+	O
CTL	O
response	O
to	O
EBV	O
in	O
infectious	O
mononucleosis	O
patients	O
contains	O
multiple	O
lytic	O
antigen	O
-	O
specific	O
reactivities	O
at	O
levels	O
at	O
least	O
as	O
high	O
as	O
those	O
seen	O
against	O
latent	B
antigens	I
;	O
similar	O
reactivities	O
are	O
also	O
detectable	O
in	O
CTL	O
memory	O
.	O

Clonal	O
analysis	O
revealed	O
individual	O
responses	O
to	O
the	O
two	O
immediate	B
early	I
proteins	I
BZLF1	B
and	O
BRLF1	B
,	O
and	O
to	O
three	O
(	O
BMLF1	B
,	O
BMRF1	B
,	O
and	O
BALF2	B
)	O
of	O
the	O
six	O
early	B
proteins	I
tested	O
.	O

The	O
unique	O
capacity	O
of	O
gamma	O
-	O
herpesvirus	O
to	O
amplify	O
the	O
viral	O
load	O
in	O
vivo	O
through	O
a	O
latent	O
growth	O
-	O
transforming	O
infection	O
may	O
have	O
rendered	O
these	O
agents	O
less	O
dependent	O
upon	O
viral	O
replication	O
as	O
a	O
means	O
of	O
successfully	O
colonizing	O
their	O
hosts	O
.	O

Triggering	O
of	O
HLA	B
class	I
II	I
antigens	I
by	O
the	O
anti	B
-	I
HLA	I
-	I
DR	I
monoclonal	I
antibody	I
(	I
mAb	I
)	I
L243	I
significantly	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
and	O
differentially	O
enhanced	O
the	O
release	O
of	O
tumor	B
necrosis	I
factor	I
alpha	I
(	O
TNF	B
-	I
alpha	I
)	O
by	O
the	O
non	O
-	O
Hodgkin	O
'	O
s	O
lymphoma	O
cells	O
Ri	O
-	O
I	O
,	O
Ci	O
-	O
I	O
,	O
and	O
Sc	O
-	O
I	O
,	O
which	O
are	O
at	O
a	O
distinct	O
stage	O
of	O
B	O
-	O
cell	O
differentiation	O
,	O
and	O
by	O
the	O
more	O
mature	O
Burkitt	O
lymphoma	O
cell	O
Raji	O
;	O
in	O
contrast	O
,	O
it	O
did	O
not	O
induce	O
TNF	B
-	I
alpha	I
release	O
by	O
the	O
pre	O
-	O
B	O
leukemia	O
cells	O
Nalm	O
-	O
6	O
and	O
BV173	O
.	O

Altogether	O
,	O
our	O
data	O
demonstrate	O
that	O
:	O
(	O
a	O
)	O
the	O
ability	O
of	O
B	O
cells	O
to	O
release	O
TNF	B
-	I
alpha	I
after	O
triggering	O
of	O
HLA	B
-	I
DR	I
antigens	I
depends	O
on	O
their	O
stage	O
of	O
differentiation	O
;	O
(	O
b	O
)	O
levels	O
of	O
released	O
TNF	B
-	I
alpha	I
seem	O
to	O
correlate	O
with	O
the	O
stage	O
of	O
B	O
-	O
cell	O
maturation	O
but	O
do	O
not	O
correlate	O
with	O
the	O
amounts	O
of	O
cell	B
surface	I
HLA	I
-	I
DR	I
antigens	I
;	O
(	O
c	O
)	O
secreted	O
TNF	B
-	I
alpha	I
regulates	O
the	O
levels	O
of	O
expression	O
of	O
NF	B
-	I
kappa	I
B	I
and	O
AP	B
-	I
1	I
by	O
an	O
autocrine	O
loop	O
;	O
and	O
(	O
d	O
)	O
intracellular	O
signals	O
mediating	O
TNF	B
-	I
alpha	I
release	O
by	O
B	O
cells	O
are	O
distinct	O
from	O
those	O
regulating	O
homotypic	O
aggregation	O
and	O
proliferation	O
.	O

To	O
identify	O
genes	O
that	O
are	O
expressed	O
in	O
T	O
cells	O
after	O
stimulation	O
,	O
mRNA	O
from	O
T	O
lymphocytes	O
that	O
had	O
been	O
activated	O
by	O
the	O
simultaneous	O
stimulation	O
of	O
the	O
CD3	B
and	O
CD28	B
trigger	O
molecules	O
was	O
transcribed	O
for	O
a	O
differential	O
mRNA	O
display	O
analysis	O
into	O
cDNA	O
and	O
was	O
compared	O
with	O
cDNA	O
from	O
CD28	B
-	O
or	O
CD3	B
-	O
activated	O
or	O
resting	O
lymphocytes	O
.	O

The	O
predictive	B
protein	I
-	I
coding	I
region	I
of	O
RP1	B
had	O
a	O
significant	O
homology	O
to	O
members	O
of	O
the	O
recently	O
found	O
adenomatous	B
polyposis	I
coli	I
(	I
APC	I
)	I
protein	I
-	I
binding	I
EB1	I
gene	I
family	I
,	O
which	O
codes	O
for	O
yet	O
unknown	O
protein	O
(	O
s	O
)	O
.	O

Bacterially	O
expressed	O
RP1	B
protein	I
revealed	O
specific	O
binding	O
to	O
wild	B
-	I
type	I
but	O
not	O
to	O
mutated	B
APC	I
protein	I
.	O

Cyclosporin	O
A	O
interferes	O
with	O
the	O
inducible	O
degradation	O
of	O
NF	B
-	I
kappa	I
B	I
inhibitors	O
,	O
but	O
not	O
with	O
the	O
processing	O
of	O
p105	O
/	O
NF	B
-	I
kappa	I
B1	I
in	O
T	O
cells	O
.	O

We	O
show	O
for	O
human	O
Jurkat	O
T	O
leukemia	O
cells	O
,	O
as	O
well	O
as	O
human	O
and	O
mouse	O
primary	O
T	O
lymphocytes	O
,	O
that	O
this	O
inhibitory	O
effect	O
is	O
accompanied	O
by	O
an	O
impaired	O
nuclear	O
translocation	O
of	O
the	O
Rel	B
proteins	I
c	B
-	I
Rel	I
,	O
RelA	B
/	I
p65	I
and	O
NF	B
-	I
kappa	I
B1	I
/	I
p50	I
,	O
whereas	O
the	O
nuclear	O
appearance	O
of	O
RelB	B
remains	O
unaffected	O
.	O

Accordingly	O
,	O
immunoblot	O
experiments	O
showed	O
that	O
amongst	O
NF	B
-	I
kappa	I
B	I
/	B
Rel	I
proteins	I
,	O
RelA	B
and	O
p50	B
are	O
mobilized	O
to	O
the	O
nucleus	O
following	O
microglial	O
cell	O
stimulation	O
with	O
A	O
beta	O
(	O
25	O
-	O
35	O
)	O
plus	O
IFN	B
gamma	I
.	O

Higher	O
concentrations	O
of	O
A	O
beta	O
(	O
25	O
-	O
35	O
)	O
were	O
effective	O
by	O
themselves	O
in	O
inducing	O
NF	B
-	I
kappa	I
B	I
activation	O
,	O
both	O
in	O
the	O
N9	O
microglial	O
cell	O
line	O
and	O
in	O
rat	O
primary	O
microglia	O
,	O
as	O
well	O
as	O
in	O
human	O
monocytes	O
.	O

For	O
purposes	O
of	O
comparison	O
,	O
microglia	O
were	O
also	O
stimulated	O
with	O
bacterial	O
LPS	O
,	O
a	O
known	O
NF	B
-	I
kappa	I
B	I
inducer	O
.	O

As	O
expected	O
,	O
LPS	O
strongly	O
induced	O
the	O
formation	O
of	O
two	O
NF	B
-	I
kappa	I
B	I
DNA	O
-	O
binding	O
activities	O
,	O
one	O
of	O
which	O
was	O
identified	O
as	O
RelA	B
/	I
p50	I
.	O

Collectively	O
,	O
these	O
findings	O
indicate	O
that	O
NF	B
-	I
kappa	I
B	I
activation	O
might	O
constitute	O
one	O
of	O
the	O
mechanisms	O
underlying	O
the	O
inducible	O
expression	O
of	O
kappa	B
B	I
-	I
dependent	I
genes	I
in	O
microglia	O
stimulated	O
by	O
A	O
beta	O
peptides	O
and	O
IFN	B
gamma	I
,	O
or	O
by	O
LPS	O
.	O

The	O
persistence	O
of	O
TGF	O
-	O
beta1	O
-	O
transcribing	O
macrophages	O
,	O
despite	O
paralysis	O
of	O
T	O
cell	O
function	O
,	O
may	O
provide	O
an	O
explanation	O
for	O
the	O
chronicity	O
of	O
the	O
disease	O
,	O
and	O
may	O
identify	O
a	O
novel	O
therapeutic	O
target	O
in	O
this	O
inflammatory	O
vasculopathy	O
.	O

We	O
have	O
generated	O
transgenic	O
mice	O
that	O
express	O
a	O
catalytically	B
inactive	I
form	I
of	O
Ca2	B
+	I
/	I
calmodulin	I
-	I
dependent	I
protein	I
kinase	I
IV	I
(	O
CaMKIV	B
)	O
specifically	O
in	O
thymic	O
T	O
cells	O
.	O

We	O
isolated	O
a	O
new	O
mouse	B
gene	I
that	O
is	O
highly	O
expressed	O
in	O
thymocytes	O
,	O
testis	O
,	O
and	O
brain	O
.	O

Rabbit	O
antiserum	O
raised	O
against	O
a	O
COOH	O
-	O
terminal	O
polypeptide	O
of	O
the	O
SRG3	B
recognized	O
a	O
protein	O
with	O
an	O
apparent	O
molecular	O
mass	O
of	O
155	O
kD	O
.	O

The	O
serum	O
also	O
detected	O
a	O
170	B
-	I
kD	I
protein	I
that	O
seems	O
to	O
be	O
a	O
mouse	O
homologue	O
of	O
human	B
BAF170	I
.	O

Transcriptional	O
induction	O
of	O
collagenase	B
-	I
1	I
in	O
differentiated	O
monocyte	O
-	O
like	O
(	O
U937	O
)	O
cells	O
is	O
regulated	O
by	O
AP	B
-	I
1	I
and	O
an	O
upstream	B
C	I
/	I
EBP	I
-	I
beta	I
site	I
.	O

Chloramphenicol	B
acetyltransferase	I
expression	I
constructs	I
containing	O
regions	O
of	O
the	O
human	B
collagenase	I
-	I
1	I
promoter	I
were	O
stably	O
or	O
transiently	O
transfected	O
into	O
U937	O
cells	O
,	O
and	O
reporter	O
activity	O
was	O
assessed	O
at	O
various	O
times	O
after	O
the	O
onset	O
of	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
(	O
PMA	O
)	O
-	O
mediated	O
differentiation	O
.	O

In	O
particular	O
,	O
Western	O
,	O
supershift	O
,	O
and	O
promoter	O
deletion	O
analyses	O
suggested	O
a	O
role	O
for	O
CCAAT	B
/	I
enhancer	I
-	I
binding	I
protein	I
-	I
beta	I
(	I
C	I
/	I
EBP	I
-	I
beta	I
)	I
binding	I
site	I
between	O
-	B
2010	I
and	I
-	I
1954	I
in	O
regulating	O
transcription	O
of	O
collagenase	B
-	I
1	I
in	O
monocytic	O
cells	O
.	O

It	O
has	O
been	O
recently	O
claimed	O
that	O
polymorphism	O
for	O
the	O
vitamin	B
D	I
receptor	I
(	O
VDR	B
)	O
influences	O
several	O
aspects	O
of	O
calcium	O
and	O
bone	O
metabolism	O
.	O

To	O
evaluate	O
the	O
physiologic	O
plausibility	O
of	O
these	O
claims	O
,	O
we	O
compared	O
the	O
abundance	O
of	O
the	O
VDR	B
mRNA	I
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMCs	O
)	O
between	O
different	O
VDR	B
genotypes	I
using	O
a	O
quantitative	O
reverse	O
transcribed	O
polymerase	O
chain	O
reaction	O
-	O
based	O
method	O
.	O

The	O
concentration	O
of	O
the	O
VDR	B
mRNA	I
,	O
corrected	O
for	O
the	O
number	O
of	O
monocytes	O
,	O
was	O
similar	O
among	O
the	O
three	O
genotype	O
groups	O
,	O
as	O
were	O
the	O
other	O
variables	O
examined	O
:	O
serum	B
calcitriol	I
,	O
serum	B
osteocalcin	I
,	O
and	O
vertebral	O
and	O
hip	O
bone	O
density	O
.	O

Both	O
truncated	O
forms	O
also	O
bound	O
to	O
the	O
transcription	B
factor	I
RBP	I
-	I
Jkappa	I
in	O
extracts	O
prepared	O
from	O
human	O
and	O
murine	O
T	O
-	O
ALL	O
cell	O
lines	O
.	O

Unexpectedly	O
,	O
a	O
second	O
,	O
stronger	O
RBP	B
-	I
Jkappa	I
-	I
binding	I
site	I
,	O
which	O
lies	O
within	O
the	O
intracellular	B
domain	I
close	O
to	O
the	O
transmembrane	O
region	O
and	O
significantly	O
augments	O
association	O
with	O
RBP	B
-	I
Jkappa	I
,	O
was	O
not	O
needed	O
for	O
oncogenesis	O
or	O
for	O
transcriptional	O
activation	O
.	O

In	O
support	O
of	O
this	O
interpretation	O
,	O
mutation	O
of	O
putative	O
nuclear	B
localization	I
sequences	I
decreased	O
nuclear	O
localization	O
and	O
increased	O
transcriptional	O
activation	O
by	O
membrane	B
-	I
bound	I
DeltaE	I
.	O

These	O
studies	O
have	O
indicated	O
that	O
the	O
individual	O
repeats	O
are	O
not	O
identical	O
with	O
respect	O
to	O
the	O
cellular	B
factors	I
with	O
which	O
they	O
interact	O
.	O

EMS	O
analyses	O
utilizing	O
a	O
series	O
of	O
mutated	B
pp	I
repeat	I
elements	I
demonstrate	O
that	O
the	O
nucleotide	O
sequence	O
requirements	O
for	O
U1	B
(	O
U1A	B
/	I
U1B	I
)	O
and	O
U2	B
formation	O
are	O
separable	O
from	O
those	O
required	O
for	O
C1	B
-	I
C3	I
formation	O
.	O

EMS	O
supershift	O
analyses	O
have	O
demonstrated	O
that	O
Sp1	B
is	O
involved	O
in	O
U1A	O
formation	O
while	O
Sp3	B
is	O
involved	O
in	O
U1B	O
and	O
U2	O
formation	O
.	O

In	O
the	O
adult	O
bone	O
marrow	O
,	O
we	O
found	O
expression	O
of	O
runt	O
polypeptides	O
in	O
differentiating	O
myeloid	O
cells	O
and	O
in	O
B	O
lymphocytes	O
.	O

Signal	B
transducer	I
and	I
activator	I
of	I
transcription	I
-	I
3	I
(	O
STAT3	B
)	O
is	O
constitutively	O
activated	O
in	O
normal	O
,	O
self	O
-	O
renewing	O
B	O
-	O
1	O
cells	O
but	O
only	O
inducibly	O
expressed	O
in	O
conventional	O
B	O
lymphocytes	O
[	O
see	O
comments	O
]	O

Cytokine	B
and	O
growth	B
factor	I
receptor	I
engagement	O
leads	O
to	O
the	O
rapid	O
phosphorylation	O
and	O
activation	O
of	O
latent	O
,	O
cytosolic	B
signal	I
transducers	I
and	I
activators	I
of	I
transcription	I
(	I
STAT	I
)	I
proteins	I
,	O
which	O
then	O
translocate	O
to	O
the	O
nucleus	O
where	O
they	O
regulate	O
transcriptional	O
events	O
from	O
specific	B
promoter	I
sequences	I
.	O

B	O
-	O
1	O
lymphocytes	O
are	O
self	O
-	O
renewing	O
,	O
CD5	O
+	O
B	O
cells	O
that	O
display	O
a	O
propensity	O
for	O
malignant	O
transformation	O
and	O
are	O
the	O
normal	O
counterpart	O
to	O
human	O
chronic	O
lymphocytic	O
leukemias	O
.	O

Further	O
,	O
B	O
-	O
1	O
cells	O
are	O
characterized	O
by	O
aberrant	O
intracellular	O
signaling	O
,	O
including	O
hyperresponsiveness	O
to	O
phorbol	O
ester	O
PKC	O
agonists	O
.	O

Induction	O
of	O
STAT3	B
is	O
inhibited	O
by	O
both	O
the	O
serine	O
/	O
threonine	O
protein	O
kinase	O
inhibitor	O
H	O
-	O
7	O
and	O
the	O
immunosuppressive	O
drug	O
rapamycin	O
and	O
requires	O
de	O
novo	O
protein	O
synthesis	O
,	O
demonstrating	O
novel	O
coupling	O
between	O
sIg	B
and	O
STAT	B
proteins	I
that	O
differs	O
from	O
the	O
classical	O
paradigm	O
for	O
STAT	B
induction	O
by	O
cytokine	B
receptors	I
.	O

One	O
of	O
the	O
potential	O
advantages	O
of	O
autologous	O
PBSCT	O
is	O
the	O
possibility	O
that	O
peripheral	O
blood	O
stem	O
cells	O
(	O
PBSC	O
)	O
are	O
less	O
likely	O
to	O
be	O
contaminated	O
by	O
leukemic	O
cells	O
than	O
bone	O
marrow	O
grafts	O
.	O

This	O
effect	O
was	O
specifically	O
due	O
to	O
Tat	B
,	O
since	O
Jurkat	O
and	O
U937	O
cells	O
cotransfected	O
either	O
with	O
tat	B
cDNA	I
in	O
antisense	O
orientation	O
(	O
tat	B
/	I
AS	I
)	O
,	O
tat	B
carrying	O
a	O
mutation	O
in	O
the	O
aminoacid	B
cys22	I
-	I
gly22	I
(	O
tat	B
22	I
/	I
S	I
)	O
or	O
with	O
the	O
backbone	B
vector	I
alone	I
(	O
pRPneo	B
-	I
SL3	I
)	O
did	O
not	O
show	O
any	O
significant	O
difference	O
in	O
c	B
-	I
fos	I
promoter	I
activity	O
as	O
compared	O
to	O
cells	O
transfected	O
with	O
FC3	B
plasmid	I
alone	O
.	O

c	B
-	I
Fos	I
protein	O
was	O
shown	O
essential	O
for	O
an	O
optimal	O
transactivation	O
of	O
the	O
HIV	O
-	O
1	O
long	B
terminal	I
repeat	I
(	O
LTR	B
)	O
by	O
Tat	B
:	O
incubation	O
of	O
Jurkat	O
cells	O
with	O
antisense	O
,	O
but	O
not	O
sense	O
,	O
c	O
-	O
fos	O
oligonucleotides	O
significantly	O
reduced	O
either	O
the	O
Tat	B
-	O
enhanced	O
expression	O
of	O
an	O
LTR	B
-	I
CAT	I
reporter	I
construct	I
or	O
the	O
levels	O
of	O
gag	B
p24	I
in	O
the	O
culture	O
supernatants	O
of	O
Jurkat	O
cells	O
and	O
PBMC	O
acutely	O
infected	O
with	O
HIV	O
-	O
1	O
.	O

Regulation	O
of	O
the	O
tissue	B
factor	I
gene	I
in	O
human	O
monocytic	O
cells	O
.	O

Role	O
of	O
AP	B
-	I
1	I
,	O
NF	B
-	I
kappa	I
B	I
/	I
Rel	I
,	O
and	O
Sp1	B
proteins	O
in	O
uninduced	O
and	O
lipopolysaccharide	O
-	O
induced	O
expression	O
.	O

The	O
human	B
TF	I
promoter	I
contains	O
binding	O
sites	O
for	O
the	O
transcription	O
factors	O
AP	B
-	I
1	I
,	O
c	B
-	I
Rel	I
/	I
p65	I
,	O
Egr	B
-	I
1	I
,	O
and	O
Sp1	B
.	O

The	O
two	O
AP	B
-	I
1	I
sites	I
bound	O
c	B
-	I
Fos	I
/	I
c	I
-	I
Jun	I
heterodimers	I
in	O
both	O
unstimulated	O
and	O
LPS	O
-	O
stimulated	O
cells	O
.	O

Inhibitory	O
effect	O
of	O
growth	O
hormone	O
on	O
TNF	B
-	I
alpha	I
secretion	O
and	O
nuclear	B
factor	I
-	I
kappaB	I
translocation	O
in	O
lipopolysaccharide	O
-	O
stimulated	O
human	O
monocytes	O
.	O

The	O
present	O
study	O
demonstrates	O
that	O
human	O
THP	O
-	O
1	O
promonocytic	O
cells	O
,	O
engineered	O
by	O
gene	O
transfer	O
to	O
constitutively	O
produce	O
human	O
growth	O
hormone	O
(	O
hGH	O
)	O
,	O
secreted	O
depressed	O
amounts	O
of	O
TNF	B
-	I
alpha	I
in	O
response	O
to	O
challenge	O
by	O
LPS	O
.	O

Previously	O
,	O
we	O
showed	O
that	O
fibroblast	O
conditioned	O
medium	O
(	O
FCM	O
)	O
is	O
able	O
to	O
inhibit	O
both	O
TNF	B
mRNA	I
accumulation	O
and	O
protein	O
release	O
in	O
peripheral	O
blood	O
-	O
derived	O
human	O
monocytes	O
(	O
PBM	O
)	O
stimulated	O
with	O
lipopolysaccharide	O
(	O
LPS	O
)	O
.	O

Furthermore	O
,	O
we	O
show	O
that	O
exogenous	O
PGE2	O
mimics	O
the	O
NF	B
-	I
kappaB	I
inhibitory	O
effect	O
of	O
FCM	O
.	O

Two	O
main	O
pieces	O
of	O
data	O
prompted	O
us	O
to	O
focus	O
on	O
the	O
activation	O
of	O
the	O
platelet	B
fibrinogen	I
receptor	I
,	O
the	O
alphaIIbbeta3	B
integrin	I
.	O

Immunoblot	O
and	O
flow	O
cytometry	O
analysis	O
revealed	O
a	O
limited	O
proteolysis	O
of	O
the	O
carboxyl	B
terminus	I
of	O
the	O
alphaIIb	B
subunit	I
heavy	I
chain	I
(	O
alphaIIbH	B
)	O
,	O
as	O
judged	O
by	O
the	O
disappearance	O
of	O
the	O
epitope	O
for	O
the	O
monoclonal	B
antibody	I
PMI	I
-	I
1	I
.	O

Treatment	O
by	O
NE	B
of	O
ATP	O
-	O
depleted	O
platelets	O
or	O
Chinese	O
hamster	O
ovary	O
cells	O
expressing	O
human	B
recombinant	I
alphaIIbbeta3	I
clearly	O
established	O
that	O
activation	O
of	O
the	O
integrin	B
was	O
independent	O
of	O
signal	O
transduction	O
events	O
and	O
was	O
concomitant	O
with	O
the	O
proteolysis	O
of	O
alphaIIbH	B
.	O

In	O
contrast	O
,	O
LAI	O
replicates	O
well	O
in	O
memory	O
CD4	O
T	O
cells	O
stimulated	O
in	O
the	O
same	O
way	O
.	O

These	O
studies	O
were	O
conducted	O
with	O
highly	O
purified	O
(	O
FACS	O
-	O
isolated	O
)	O
subsets	O
of	O
CD4	O
T	O
cells	O
identified	O
by	O
expression	O
of	O
both	O
CD45RA	B
and	O
CD62L	B
.	O

The	O
suppression	O
of	O
productive	O
LAI	O
replication	O
in	O
naive	O
T	O
cells	O
is	O
not	O
due	O
to	O
differential	O
expression	O
of	O
viral	B
coreceptors	I
,	O
nor	O
is	O
it	O
due	O
to	O
inhibition	O
of	O
activation	O
of	O
the	O
important	O
HIV	O
transcription	B
factors	I
,	O
nuclear	B
factor	I
-	I
kappaB	I
and	O
activator	B
protein	I
-	I
1	I
.	O

To	O
test	O
the	O
hypothesis	O
that	O
the	O
chimera	B
PMLRAR	I
alpha	I
plays	O
a	O
role	O
in	O
leukemogenesis	O
,	O
we	O
expressed	O
a	O
PMLRAR	B
alpha	I
cDNA	I
in	O
myeloid	O
cells	O
of	O
transgenic	O
mice	O
.	O

Retinoic	O
acid	O
caused	O
the	O
leukemic	O
cells	O
to	O
differentiate	O
in	O
vitro	O
and	O
in	O
vivo	O
,	O
eliciting	O
remissions	O
of	O
both	O
the	O
preleukemic	O
state	O
and	O
APL	O
in	O
mice	O
.	O

Our	O
results	O
demonstrate	O
that	O
PMLRAR	B
alpha	I
impairs	O
neutrophil	O
differentiation	O
and	O
initiates	O
the	O
development	O
of	O
APL	O
.	O

The	O
transgenic	O
mice	O
described	O
here	O
provide	O
an	O
apparently	O
accurate	O
model	O
for	O
human	O
APL	O
that	O
includes	O
clear	O
evidence	O
of	O
tumor	O
progression	O
.	O

Such	O
hypermethylation	O
-	O
associated	O
silencing	O
of	O
gene	O
expression	O
has	O
been	O
shown	O
for	O
several	O
genes	O
regulating	O
the	O
growth	O
and	O
differentiation	O
of	O
hematopoietic	O
cells	O
,	O
including	O
the	O
estrogen	B
receptor	I
(	I
ER	I
)	I
gene	I
,	O
P15	O
,	O
P16	O
and	O
others	O
.	O

The	O
high	O
prevalence	O
of	O
promoter	O
methylation	O
suggests	O
that	O
this	O
molecular	O
abnormality	O
can	O
be	O
used	O
to	O
monitor	O
disease	O
activity	O
during	O
therapy	O
.	O

Finally	O
,	O
reactivation	O
of	O
tumor	O
-	O
suppressor	O
gene	O
expression	O
through	O
pharmacologic	O
inhibition	O
of	O
DNA	B
methyltransferase	I
and	O
resultant	O
DNA	O
demethylation	O
appears	O
to	O
be	O
a	O
promising	O
new	O
avenue	O
of	O
therapy	O
in	O
acute	O
leukemia	O
.	O

Redox	O
regulation	O
of	O
the	O
mitogen	B
-	I
activated	I
protein	I
kinase	I
pathway	O
during	O
lymphocyte	O
activation	O
.	O

In	O
earlier	O
studies	O
,	O
we	O
have	O
identified	O
the	O
transcription	B
factors	I
NF	B
-	I
kappa	I
B	I
and	O
AP	B
-	I
1	I
as	O
molecular	O
targets	O
for	O
oxidative	O
signalling	O
processes	O
during	O
cell	O
cycle	O
entry	O
,	O
and	O
have	O
shown	O
that	O
oxidative	O
signalling	O
is	O
involved	O
in	O
the	O
regulation	O
of	O
early	O
changes	O
in	O
gene	O
expression	O
during	O
the	O
G0	O
to	O
G1	O
phase	O
transition	O
.	O

Using	O
the	O
yeast	O
two	O
-	O
hybrid	O
system	O
to	O
screen	O
for	O
proteins	O
which	O
interact	O
with	O
Tax1	B
,	O
we	O
isolated	O
the	O
B	B
subunit	I
of	O
the	O
CCAAT	B
binding	I
protein	I
NF	B
-	I
Y	I
from	O
a	O
HeLa	B
cDNA	I
library	I
.	O

The	O
interaction	O
of	O
Tax1	B
with	O
NF	B
-	I
YB	I
was	O
specific	O
in	O
that	O
NF	B
-	I
YB	I
did	O
not	O
interact	O
with	O
a	O
variety	O
of	O
other	O
transcription	B
factors	I
,	O
including	O
human	B
immunodeficiency	I
virus	I
Tat	I
,	O
human	B
papillomavirus	I
E6	I
,	O
and	O
Bicoid	B
,	O
or	O
with	O
the	O
M7	B
(	I
amino	I
acids	I
29CP	I
-	I
AS	I
)	I
Tax1	I
mutant	I
.	O

However	O
,	O
NF	B
-	I
YB	I
did	O
interact	O
with	O
the	O
C	B
-	I
terminal	I
Tax1	I
mutants	I
M22	B
(	O
130TL	B
-	I
AS	I
)	O
and	O
M47	B
(	O
319LL	B
-	I
RS	I
)	O
.	O

Through	O
activation	O
of	O
this	O
and	O
other	O
NF	B
-	I
Y	I
driven	O
promoters	B
,	O
the	O
Tax1	B
-	B
NF	I
-	I
Y	I
interaction	O
may	O
play	O
a	O
critical	O
role	O
in	O
causing	O
cellular	O
transformation	O
and	O
HTLV	O
-	O
1	O
pathogenesis	O
.	O

In	O
murine	O
Ba	O
/	O
F3	O
cells	O
transfected	O
with	O
the	O
human	B
G	I
-	I
CSFR	I
and	O
NFS	O
-	O
60	O
cells	O
constitutively	O
expressing	O
the	O
murine	B
G	I
-	I
CSFR	I
,	O
G	B
-	I
CSF	I
induced	O
tyrosine	O
phosphorylation	O
and	O
activation	O
of	O
Jak1	B
,	O
Jak2	B
,	O
and	O
Tyk2	B
.	O

Using	O
a	O
mitogenically	B
incompetent	I
human	I
G	I
-	I
CSFR	I
mutant	I
in	O
which	O
Pro639	O
and	O
Pro641	O
were	O
substituted	O
by	O
alanine	O
,	O
the	O
box	B
1	I
PDP	I
motif	I
was	O
found	O
to	O
be	O
required	O
for	O
activation	O
of	O
Jak	B
kinases	I
,	O
tyrosine	O
phosphorylation	O
of	O
the	O
G	B
-	I
CSFR	I
,	O
and	O
recruitment	O
of	O
Stat	B
proteins	I
.	O

Activation	O
of	O
the	O
Jak	B
-	B
Stat	I
pathway	O
correlates	O
with	O
proliferative	O
signaling	O
by	O
the	O
G	B
-	I
CSFR	I
and	O
requires	O
the	O
membrane	B
-	I
proximal	I
box	I
1	I
PXP	I
motif	I
,	O
which	O
is	O
conserved	O
in	O
members	O
of	O
the	O
cytokine	B
receptor	I
superfamily	I
.	O

Impaired	O
induction	O
of	O
c	B
-	I
fos	I
/	I
c	I
-	I
jun	I
genes	I
and	O
of	O
transcriptional	B
regulatory	I
proteins	I
binding	O
distinct	O
c	B
-	I
fos	I
/	I
c	I
-	I
jun	I
promoter	I
elements	I
in	O
activated	O
human	O
T	O
cells	O
during	O
aging	O
.	O

In	O
addition	O
,	O
RNase	B
protection	O
assays	O
revealed	O
that	O
anti	O
-	O
CD3	O
/	O
PMA	O
-	O
stimulated	O
T	O
cells	O
from	O
a	O
substantial	O
proportion	O
of	O
elderly	O
subjects	O
exhibited	O
decreased	O
levels	O
of	O
c	B
-	I
fos	I
and	I
/	I
or	I
c	I
-	I
jun	I
mRNA	I
compared	O
to	O
T	O
cells	O
from	O
young	O
subjects	O
.	O

BACKGROUND	O
:	O
Retinoic	O
acid	O
(	O
RA	O
)	O
has	O
important	O
immune	O
-	O
modulating	O
effects	O
on	O
both	O
T	O
and	O
B	O
cell	O
function	O
.	O

CONCLUSION	O
:	O
These	O
studies	O
suggest	O
that	O
RA	O
can	O
augment	O
IL	B
-	I
2	I
mRNA	I
production	O
by	O
T	O
cells	O
with	O
a	O
possible	O
paracrine	O
effect	O
on	O
IL	B
-	I
2R	I
-	I
alpha	I
expression	O
.	O

Interleukin	B
-	I
6	I
levels	O
are	O
increased	O
in	O
lung	O
transplant	O
patients	O
clinically	O
diagnosed	O
with	O
CMV	O
pneumonitis	O
.	O

In	O
contrast	O
,	O
the	O
RelA	B
(	I
p65	I
)	I
subunit	I
was	O
barely	O
detectable	O
in	O
monocytes	O
,	O
but	O
its	O
level	O
increased	O
markedly	O
in	O
MDMs	O
.	O

In	O
MDMs	O
,	O
an	O
upregulation	O
of	O
I	B
kappa	I
B	I
alpha	I
synthesis	O
as	O
well	O
as	O
the	O
appearance	O
of	O
a	O
novel	O
M	O
(	O
r	O
)	O
40	O
,	O
000	O
form	O
of	O
I	B
kappa	I
B	I
alpha	I
were	O
also	O
observed	O
.	O

However	O
,	O
the	O
intensity	O
of	O
p65	B
labeling	O
was	O
much	O
higher	O
in	O
several	O
thymocytes	O
from	O
the	O
medulla	O
.	O

p65	O
,	O
p50	O
,	O
and	O
c	O
-	O
Rel	O
activities	O
were	O
found	O
in	O
both	O
CD4	O
-	O
and	O
CD8	O
-	O
positive	O
thymocytes	O
.	O

These	O
observations	O
suggest	O
that	O
p65	B
and	I
c	I
-	I
Rel	I
complexes	I
play	O
distinct	O
roles	O
in	O
gene	O
expression	O
and	O
that	O
both	O
forms	O
of	O
NF	B
-	I
kappa	I
B	I
play	O
critical	O
roles	O
during	O
late	O
stages	O
of	O
the	O
intrathymic	O
maturation	O
of	O
T	O
cells	O
.	O

The	O
function	O
of	O
LEF	B
-	I
1	I
is	O
dependent	O
,	O
in	O
part	O
,	O
on	O
the	O
HMG	B
domain	I
that	O
induces	O
a	O
sharp	O
bend	O
in	O
the	O
DNA	O
helix	O
,	O
and	O
on	O
an	O
activation	B
domain	I
that	O
stimulates	O
transcription	O
only	O
in	O
a	O
specific	O
context	O
of	O
other	O
enhancer	B
-	I
binding	I
proteins	I
.	O

Overexpression	O
of	O
ALY	B
stimulates	O
the	O
activity	O
of	O
the	O
TCR	B
alpha	I
enhancer	I
complex	I
reconstituted	O
in	O
transfected	O
nonlymphoid	O
HeLa	O
cells	O
,	O
whereas	O
down	O
-	O
regulation	O
of	O
ALY	B
by	O
anti	O
-	O
sense	O
oligonucleotides	O
virtually	O
eliminates	O
TCR	B
alpha	I
enhancer	I
activity	O
in	O
T	O
cells	O
.	O

AML1	B
may	O
play	O
a	O
role	O
in	O
growth	O
and	O
differentiation	O
of	O
cells	O
along	O
erythroid	O
and	O
/	O
or	O
megakaryocytic	O
lineages	O
,	O
because	O
a	O
significant	O
level	O
of	O
the	O
AML1	B
gene	O
is	O
expressed	O
in	O
these	O
cells	O
.	O

We	O
overexpressed	O
AML1a	B
(	O
without	O
the	O
transcription	B
-	I
activating	I
domain	I
)	O
and	O
AML1b	B
(	O
with	O
the	O
domain	O
)	O
proteins	O
in	O
K562	O
leukemia	O
cells	O
,	O
which	O
can	O
be	O
induced	O
to	O
differentiate	O
into	O
hemoglobin	O
-	O
producing	O
cells	O
and	O
megakaryocytes	O
.	O

The	O
AML1a	O
-	O
transfected	O
K562	O
cells	O
had	O
a	O
reduced	O
capacity	O
to	O
differentiate	O
in	O
the	O
presence	O
of	O
sodium	O
n	O
-	O
butyrate	O
but	O
not	O
in	O
the	O
presence	O
of	O
other	O
inducers	O
,	O
such	O
as	O
hemin	O
,	O
1	O
-	O
beta	O
-	O
D	O
-	O
arabinofuranosylcyto	O
,	O
and	O
herbimycin	O
A	O
.	O

We	O
have	O
cloned	O
and	O
sequenced	O
a	O
portion	O
of	O
the	O
ER	B
upstream	B
regulatory	I
region	I
from	O
the	O
ER	O
-	O
positive	O
MCF	O
-	O
7	O
and	O
the	O
ER	O
-	O
negative	O
MDA	O
-	O
MB	O
-	O
231	O
breast	O
cancer	O
cell	O
lines	O
to	O
determine	O
if	O
sequence	O
alterations	O
in	O
this	O
region	O
account	O
for	O
the	O
ER	B
-	O
negative	O
phenotype	O
of	O
some	O
tumors	O
.	O

The	O
influence	O
of	O
the	O
anti	O
-	O
allergy	O
agent	O
azelastine	O
hydrochloride	O
(	O
Azeptin	O
)	O
on	O
NF	B
-	I
kappa	I
B	I
activation	O
associated	O
with	O
the	O
generation	O
of	O
cytokines	B
and	O
nitric	O
oxide	O
(	O
NO	O
)	O
was	O
investigated	O
in	O
various	O
kinds	O
of	O
human	O
and	O
mouse	O
cells	O
.	O

In	O
parallel	O
with	O
the	O
decreased	O
cytokine	B
generation	O
,	O
each	O
cytokine	B
mRNA	I
was	O
less	O
expressed	O
in	O
the	O
presence	O
of	O
10	O
(	O
-	O
5	O
)	O
M	O
Azeptin	O
.	O

In	O
addition	O
,	O
both	O
inducible	O
nitric	B
oxide	I
synthase	I
-	O
mRNA	O
level	O
and	O
NO	O
generation	O
in	O
mouse	O
peritoneal	O
macrophages	O
were	O
suppressed	O
by	O
10	O
(	O
-	O
5	O
)	O
M	O
Azeptin	O
.	O

Using	O
anti	B
-	I
C	I
/	I
EBPbeta	I
(	O
NF	B
-	I
IL6	I
)	O
,	O
anti	B
-	I
C	I
/	I
EBPdelta	I
(	O
NF	B
-	I
IL6beta	I
)	O
,	O
anti	B
-	I
NF	I
-	I
ATc	I
,	O
anti	B
-	I
NF	I
-	I
ATp	I
,	O
anti	B
-	I
Fos	I
,	O
and	O
anti	B
-	I
Jun	I
Abs	I
we	O
demonstrate	O
that	O
the	O
previously	O
identified	O
PRE	B
-	I
I	I
binding	I
factor	I
POS	B
-	I
1	I
is	O
composed	O
of	O
different	O
transcription	B
factors	I
in	O
different	O
Th	O
cell	O
subsets	O
.	O

Different	O
cytokines	B
activate	O
transcription	O
at	O
the	O
appropriate	O
germline	B
promoter	I
.	O

Experimental	O
expression	O
in	O
mice	O
and	O
spontaneous	O
expression	O
in	O
human	O
SLE	O
of	O
polyomavirus	B
T	I
-	I
antigen	I
.	O

A	O
molecular	O
basis	O
for	O
induction	O
of	O
antibodies	B
to	O
DNA	O
and	O
eukaryotic	B
transcription	I
factors	I
.	O

We	O
have	O
previously	O
demonstrated	O
that	O
experimental	O
expression	O
of	O
the	O
polyomavirus	B
transcription	I
factor	I
T	I
-	I
antigen	I
has	O
the	O
potential	O
to	O
induce	O
anti	B
-	I
DNA	I
antibodies	I
in	O
mice	O
.	O

Two	O
sets	O
of	O
independent	O
evidences	O
are	O
presented	O
here	O
that	O
demonstrate	O
a	O
biological	O
relevance	O
for	O
this	O
model	O
.	O

Secondly	O
,	O
we	O
investigated	O
whether	O
polyomavirus	O
reactivation	O
occurs	O
in	O
SLE	O
patients	O
,	O
and	O
whether	O
antibodies	B
to	O
T	B
-	I
antigen	I
,	O
DNA	O
,	O
and	O
to	O
TBP	B
and	O
CREB	B
are	O
linked	O
to	O
such	O
events	O
.	O

Both	O
within	O
and	O
among	O
these	O
SLE	O
patients	O
,	O
frequent	O
polyomavirus	O
reactivations	O
were	O
observed	O
that	O
could	O
not	O
be	O
explained	O
by	O
certain	O
rearrangements	O
of	O
the	O
noncoding	O
control	O
regions	O
,	O
nor	O
by	O
corticosteroid	O
treatment	O
.	O

Antibodies	O
recognizing	O
double	O
-	O
stranded	O
DNA	O
were	O
confined	O
to	O
patients	O
with	O
frequent	O
polyomavirus	O
reactivations	O
.	O

The	O
results	O
described	O
here	O
indicate	O
that	O
cognate	O
interaction	O
of	O
B	O
cells	O
recognizing	O
DNA	O
or	O
DNA	B
-	I
associated	I
proteins	I
and	O
T	O
cells	O
recognizing	O
T	B
antigen	I
had	O
taken	O
place	O
as	O
a	O
consequence	O
of	O
complex	O
formation	O
between	O
T	B
ag	I
and	O
DNA	O
in	O
vivo	O
in	O
the	O
context	O
of	O
polyomavirus	O
reactivations	O
.	O

Intimate	O
interactions	O
between	O
multipotential	O
hemopoietic	O
stem	O
cells	O
and	O
their	O
microenvironment	O
work	O
towards	O
redefining	O
the	O
identity	O
and	O
the	O
differentiative	O
fate	O
of	O
these	O
primitive	O
cells	O
.	O

Thus	O
,	O
gammac	B
is	O
not	O
necessary	O
to	O
trigger	O
IL	B
-	I
4	I
-	O
mediated	O
responses	O
in	O
B	O
cells	O
,	O
but	O
its	O
presence	O
is	O
important	O
for	O
optimal	O
IL	B
-	I
4	I
-	O
signaling	O
.	O

Cell	O
-	O
to	O
-	O
cell	O
contact	O
activates	O
the	O
long	B
terminal	I
repeat	I
of	O
human	O
immunodeficiency	O
virus	O
1	O
through	O
its	O
kappaB	B
motif	I
.	O

Cell	O
-	O
to	O
-	O
cell	O
contact	O
between	O
peripheral	O
blood	O
lymphocytes	O
and	O
transfected	O
human	O
colonic	O
carcinoma	O
cell	O
line	O
HT29	O
activates	O
transcription	O
of	O
the	O
long	B
terminal	I
repeats	I
(	O
LTR	B
)	O
of	O
human	O
immunodeficiency	O
virus	O
.	O

HIV	B
-	I
1	I
LTR	I
transcription	O
is	O
controlled	O
by	O
a	O
complex	O
array	O
of	O
virus	B
-	I
encoded	I
and	I
cellular	I
proteins	I
.	O

Identification	O
of	O
nucleotide	B
sequences	I
that	O
regulate	O
transcription	O
of	O
the	O
MCF13	O
murine	O
leukemia	O
virus	O
long	B
terminal	I
repeat	I
in	O
activated	O
T	O
cells	O
.	O

Differentiation	O
of	O
U	O
-	O
937	O
promonocytic	O
cells	O
by	O
etoposide	O
and	O
ICRF	O
-	O
193	O
,	O
two	O
antitumour	O
DNA	B
topoisomerase	I
II	I
inhibitors	O
with	O
different	O
mechanisms	O
of	O
action	O
.	O

By	O
contrast	O
,	O
these	O
effects	O
were	O
not	O
observed	O
upon	O
pulse	O
-	O
treatment	O
with	O
6	O
microM	O
ICRF	O
-	O
193	O
.	O

By	O
contrast	O
,	O
ICRF	O
-	O
193	O
only	O
provoked	O
a	O
late	O
activation	O
(	O
from	O
hours	O
72	O
to	O
96	O
)	O
of	O
the	O
total	O
enzyme	O
.	O

By	O
contrast	O
,	O
the	O
binding	O
activity	O
of	O
the	O
NF	B
-	I
kappa	I
(	I
B	I
)	I
and	O
EGR	B
-	I
1	I
transcription	B
factors	I
was	O
little	O
affected	O
.	O

GATA	B
-	I
1	I
DNA	O
binding	O
activity	O
is	O
down	O
-	O
regulated	O
in	O
late	O
S	O
phase	O
in	O
erythroid	O
cells	O
.	O

These	O
results	O
may	O
also	O
relate	O
to	O
recent	O
data	O
implicating	O
GATA	B
-	I
1	I
function	O
in	O
apoptosis	O
and	O
cell	O
cycle	O
progression	O

Activated	O
neutrophils	O
have	O
the	O
ability	O
to	O
upregulate	O
the	O
expression	O
of	O
many	O
genes	O
,	O
in	O
particular	O
those	O
encoding	O
cytokines	B
and	O
chemokines	B
,	O
and	O
to	O
subsequently	O
release	O
the	O
corresponding	O
proteins	O
.	O

Following	O
neutrophil	O
stimulation	O
with	O
proinflammatory	O
agonists	O
(	O
such	O
as	O
lipopolysaccharide	O
[	O
LPS	O
]	O
,	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
[	O
TNF	B
-	I
alpha	I
]	O
,	O
and	O
fMet	O
-	O
Leu	O
-	O
Phe	O
)	O
that	O
induce	O
the	O
production	O
of	O
cytokines	B
and	O
chemokines	B
in	O
these	O
cells	O
,	O
NF	B
-	I
kappaB	I
/	I
Rel	I
proteins	I
translocated	O
to	O
nuclear	O
fractions	O
,	O
resulting	O
in	O
a	O
transient	O
induction	O
of	O
NF	B
-	I
kappaB	I
DNA	O
binding	O
activity	O
,	O
as	O
determined	O
in	O
gel	O
mobility	O
shift	O
assays	O
.	O

The	O
onset	O
of	O
both	O
processes	O
was	O
found	O
to	O
be	O
closely	O
paralleled	O
by	O
,	O
and	O
dependent	O
on	O
,	O
IkappaB	B
-	I
alpha	I
degradation	O
.	O

Two	O
distinct	O
pathways	O
of	O
interleukin	B
-	I
5	I
synthesis	O
in	O
allergen	O
-	O
specific	O
human	O
T	O
-	O
cell	O
clones	O
are	O
suppressed	O
by	O
glucocorticoids	O
.	O

Glucocorticoids	O
(	O
GC	O
)	O
have	O
long	O
been	O
used	O
as	O
the	O
most	O
effective	O
agents	O
for	O
the	O
treatment	O
of	O
allergic	O
diseases	O
accompanied	O
by	O
eosinophilia	O
such	O
as	O
chronic	O
asthma	O
and	O
atopic	O
dermatitis	O
.	O

GC	O
efficiently	O
suppressed	O
IL	B
-	I
5	I
synthesis	O
of	O
T	O
-	O
cell	O
clones	O
activated	O
via	O
either	O
T	B
-	I
cell	I
receptor	I
(	O
TCR	B
)	O
or	O
IL	B
-	I
2	I
receptor	I
(	O
IL	B
-	I
2R	I
)	O
.	O

Stimulation	O
of	O
CD2	B
or	O
TCR	B
/	I
CD3	I
induced	O
activation	O
of	O
the	O
nuclear	B
factor	I
of	I
activated	I
T	I
cells	I
(	O
NFAT	B
)	O
,	O
the	O
binding	B
site	I
of	O
which	O
is	O
included	O
in	O
the	O
IL	B
-	I
2	I
gene	I
promoter	I
.	O

The	O
LAZ3	B
/	I
BCL6	I
transcript	I
was	O
found	O
in	O
a	O
variety	O
of	O
tissues	O
,	O
including	O
skeletal	O
muscle	O
,	O
peripheral	O
blood	O
leukocytes	O
,	O
and	O
weakly	O
in	O
normal	O
lymph	O
nodes	O
.	O

IL	O
-	O
4	O
treatment	O
rapidly	O
induced	O
tyrosine	O
phosphorylation	O
of	O
insulin	B
receptor	I
substrate	I
(	I
IRS	I
)	I
-	I
1	I
and	O
IRS	B
-	I
2	I
in	O
1D4	O
but	O
not	O
in	O
E1C3	O
cells	O
.	O

Nuclear	B
transcription	I
factor	I
kB	I
(	O
NF	B
-	I
kappa	I
B	I
)	O
is	O
a	O
ubiquitous	B
transcription	I
factor	I
and	O
pleiotropic	B
regulator	I
of	O
numerous	O
genes	O
involved	O
in	O
the	O
immune	O
and	O
inflammatory	O
responses	O
.	O

This	O
transcription	B
factor	I
is	O
activated	O
via	O
the	O
selective	O
phosphorylation	O
,	O
ubiquination	O
and	O
degradation	O
of	O
its	O
inhibitor	B
protein	I
I	I
-	I
kB	I
thereby	O
allowing	O
translocation	O
of	O
NF	B
-	I
kappa	I
B	I
into	O
the	O
nucleus	O
where	O
it	O
upregulates	O
the	O
transcription	O
of	O
a	O
variety	O
of	O
adhesion	B
molecules	I
(	O
e	O
.	O
g	O
.	O
ICAM	B
-	I
1	I
,	O
VCAM	B
-	I
1	I
)	O
,	O
cytokines	B
(	O
TNF	B
,	O
IL	B
-	I
1	I
,	O
IL	B
-	I
6	I
)	O
and	O
enzymes	B
(	O
iNOS	B
)	O
.	O

Based	O
upon	O
work	O
from	O
our	O
laboratory	O
,	O
we	O
propose	O
that	O
inhibition	O
of	O
NF	B
-	I
kappa	I
B	I
activation	O
produces	O
significant	O
anti	O
inflammatory	O
activity	O
which	O
may	O
be	O
mediated	O
by	O
the	O
inhibition	O
of	O
transcription	O
of	O
certain	O
pro	B
-	I
inflammatory	I
mediators	I
and	O
adhesion	B
molecules	I
.	O

Generation	O
of	O
cytotoxic	O
T	O
lymphocytes	O
against	O
immunorecessive	B
epitopes	I
after	O
multiple	O
immunizations	O
with	O
adenovirus	O
vectors	O
is	O
dependent	O
on	O
haplotype	O
.	O

However	O
,	O
the	O
cytotoxic	O
T	O
lymphocyte	O
(	O
CTL	O
)	O
response	O
to	O
Ad	O
could	O
limit	O
the	O
effectiveness	O
of	O
such	O
approaches	O
.	O

The	O
immune	O
response	O
to	O
Ad	O
in	O
BALB	O
/	O
c	O
mice	O
was	O
more	O
complex	O
.	O

Understanding	O
the	O
cis	B
-	I
and	I
transacting	I
factors	I
that	O
regulate	O
the	O
tissue	O
-	O
specific	O
expression	O
of	O
PECAM	B
-	I
1	I
should	O
increase	O
our	O
understanding	O
of	O
the	O
mechanisms	O
by	O
which	O
vascular	O
-	O
specific	O
gene	O
expression	O
is	O
achieved	O
.	O

However	O
,	O
little	O
is	O
known	O
about	O
negative	O
regulation	O
of	O
IL	B
-	I
1beta	I
expression	O
at	O
the	O
transcriptional	O
level	O
,	O
which	O
may	O
play	O
an	O
important	O
role	O
in	O
anti	O
-	O
inflammatory	O
and	O
immunosuppressive	O
effects	O
.	O

Interaction	O
of	O
transcription	B
factors	I
RFX1	B
and	O
MIBP1	B
with	O
the	O
gamma	B
motif	I
of	O
the	O
negative	B
regulatory	I
element	I
of	O
the	O
hepatitis	B
B	I
virus	I
core	I
promoter	I
.	O

The	O
negative	B
regulatory	I
element	I
(	O
NRE	B
)	O
of	O
the	O
hepatitis	B
B	I
virus	I
(	I
HBV	I
)	I
core	I
promoter	I
contains	O
three	O
subregions	O
which	O
act	O
synergistically	O
to	O
suppress	O
core	O
promoter	O
activity	O
.	O

In	O
addition	O
,	O
RFX1	B
can	O
bind	O
simultaneously	O
,	O
most	O
likely	O
as	O
a	O
heterodimer	B
,	O
with	O
the	O
transcription	B
factor	I
MIBP1	B
to	O
NRE	B
gamma	I
.	O

Use	O
of	O
arsenic	O
trioxide	O
(	O
As2O3	O
)	O
in	O
the	O
treatment	O
of	O
acute	O
promyelocytic	O
leukemia	O
(	O
APL	O
)	O
:	O
II	O
.	O

Pharmacokinetic	O
studies	O
,	O
which	O
were	O
performed	O
in	O
eight	O
patients	O
,	O
showed	O
that	O
after	O
a	O
peak	O
level	O
of	O
5	O
.	O
54	O
micromol	O
/	O
L	O
to	O
7	O
.	O
30	O
micromol	O
/	O
L	O
,	O
plasma	O
arsenic	O
was	O
rapidly	O
eliminated	O
,	O
and	O
the	O
continuous	O
administration	O
of	O
As2O3	O
did	O
not	O
alter	O
its	O
pharmacokinetic	O
behaviors	O
.	O

We	O
conclude	O
that	O
As2O3	O
treatment	O
is	O
an	O
effective	O
and	O
relatively	O
safe	O
drug	O
in	O
APL	O
patients	O
refractory	O
to	O
ATRA	O
and	O
conventional	O
chemotherapy	O
.	O

LR1	B
also	O
binds	O
Ig	B
heavy	I
chain	I
switch	O
region	O
sequences	O
and	O
may	O
function	O
in	O
class	O
switch	O
recombination	O
.	O

Both	O
of	O
these	O
parameters	O
,	O
however	O
,	O
did	O
not	O
change	O
significantly	O
after	O
mitogen	B
stimulation	O
.	O

There	O
was	O
a	O
significant	O
negative	O
correlation	O
between	O
IC50S	O
of	O
prednisolone	O
and	O
increase	O
-	O
ratios	O
(	O
post	O
/	O
pre	O
ratio	O
)	O
of	O
Bmax	O
after	O
mitogen	B
stimulation	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

The	O
Bmax	O
and	O
Kd	O
were	O
not	O
significantly	O
changed	O
after	O
mitogen	B
stimulation	O
in	O
both	O
subgroups	O
of	O
CRF	O
.	O

The	O
ZEBRA	B
protein	I
from	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
activates	O
a	O
switch	O
from	O
the	O
latent	O
to	O
the	O
lytic	O
expression	O
program	O
of	O
the	O
virus	O
.	O

The	O
additional	O
function	O
that	O
is	O
required	O
for	O
initiation	O
of	O
the	O
lytic	O
viral	O
life	O
cycle	O
is	O
likely	O
to	O
require	O
phosphorylation	O
of	O
serine	O
186	O
of	O
the	O
ZEBRA	B
protein	I
,	O
which	O
may	O
influence	O
either	O
DNA	O
recognition	O
or	O
transcriptional	O
activation	O
of	O
lytic	B
viral	I
promoters	I
in	O
a	O
chromatinized	B
viral	I
episome	I
.	O

Immune	O
hyperactivation	O
of	O
HIV	O
-	O
1	O
-	O
infected	O
T	O
cells	O
mediated	O
by	O
Tat	B
and	O
the	O
CD28	B
pathway	O
.	O

CONCLUSIONS	O
:	O
The	O
reduction	O
of	O
symptoms	O
due	O
to	O
topical	O
fluticasone	O
propionate	O
in	O
patients	O
with	O
rhinitis	O
and	O
allergy	O
to	O
house	O
dust	O
mite	O
is	O
not	O
correlated	O
with	O
the	O
characteristics	O
of	O
the	O
glucocorticoid	B
receptor	I
.	O

Human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
replicates	O
more	O
efficiently	O
in	O
vitro	O
in	O
differentiated	O
macrophages	O
than	O
in	O
freshly	O
isolated	O
monocytes	O
.	O

We	O
demonstrated	O
that	O
constitutive	O
expression	O
of	O
NF	B
-	I
kappaB	I
in	O
primary	O
human	O
monocytes	O
changed	O
significantly	O
with	O
differentiation	O
in	O
vitro	O
to	O
monocyte	O
-	O
derived	O
macrophages	O
(	O
MDMs	O
)	O
and	O
differentiation	O
in	O
vivo	O
to	O
alveolar	O
macrophages	O
(	O
AMs	O
)	O
.	O

NF	B
-	I
kappa	I
B	I
-	O
independent	O
suppression	O
of	O
HIV	O
expression	O
by	O
ascorbic	O
acid	O
.	O

Pretreatment	O
of	O
ACH	O
-	O
2	O
T	O
cells	O
by	O
NAC	O
followed	O
by	O
stimulation	O
with	O
PMA	O
,	O
TNF	B
-	I
alpha	I
,	O
or	O
hydrogen	O
peroxide	O
(	O
H2O2	O
)	O
resulted	O
in	O
strong	O
suppression	O
of	O
NF	B
-	I
kappa	I
B	I
activation	O
.	O

These	O
results	O
suggest	O
that	O
the	O
molecular	O
mechanism	O
of	O
HIV	O
inhibition	O
by	O
ascorbate	O
is	O
not	O
mediated	O
via	O
NF	B
-	I
kappa	I
B	I
inhibition	O
,	O
unlike	O
that	O
seen	O
with	O
other	O
antioxidants	O
.	O

A	O
T	B
cell	I
-	I
specific	I
enhancer	I
in	O
the	O
interleukin	B
-	I
3	I
locus	I
is	O
activated	O
cooperatively	O
by	O
Oct	B
and	I
NFAT	I
elements	I
within	O
a	O
DNase	B
I	I
-	I
hypersensitive	I
site	I
.	O

Interleukin	B
-	I
3	I
(	O
IL	B
-	I
3	I
)	O
is	O
a	O
cytokine	B
that	O
is	O
expressed	O
primarily	O
in	O
activated	O
T	O
cells	O
.	O

We	O
suggest	O
that	O
the	O
T	O
cell	O
-	O
specific	O
expression	O
of	O
the	O
IL	B
-	I
3	I
gene	I
is	O
partly	O
controlled	O
through	O
the	O
enhancer	O
by	O
cooperation	O
between	O
Oct	B
and	I
NFAT	I
family	I
proteins	I
.	O

The	O
adenovirus	B
E1B	I
19K	I
gene	I
plays	O
an	O
essential	O
role	O
in	O
transformation	O
of	O
primary	O
rodent	O
cells	O
in	O
cooperation	O
with	O
E1A	B
and	O
in	O
the	O
inhibition	O
of	O
apoptosis	O
during	O
lytic	O
infection	O
.	O

It	O
has	O
been	O
shown	O
that	O
this	O
E1B	B
19K	I
protein	I
is	O
not	O
necessary	O
for	O
viral	O
DNA	O
replication	O
in	O
human	O
cell	O
lines	O
,	O
such	O
as	O
HeLa	O
and	O
KB	O
.	O

Activation	O
of	O
Ras	O
and	O
mitogen	B
-	I
activated	I
protein	I
kinase	I
pathway	O
by	O
terminal	B
complement	I
complexes	I
is	O
G	B
protein	I
dependent	O
.	O

Spontaneous	O
occurrence	O
of	O
early	O
region	O
1A	O
reiteration	O
mutants	O
of	O
type	O
5	O
adenovirus	O
in	O
persistently	O
infected	O
human	O
T	O
-	O
lymphocytes	O
.	O

Mutants	O
of	O
type	O
5	O
adenovirus	O
(	O
Ad5	O
)	O
with	O
reiterated	B
DNA	I
sequences	I
in	O
the	O
E1a	B
region	I
appeared	O
in	O
a	O
human	O
T	O
-	O
lymphocyte	O
cell	O
line	O
,	O
Molt	O
-	O
4	O
,	O
persistently	O
infected	O
with	O
H5sub304	O
,	O
a	O
deletion	O
/	O
substitution	O
mutant	O
that	O
has	O
a	O
wild	O
-	O
type	O
phenotype	O
in	O
viral	O
replication	O
.	O

There	O
was	O
not	O
any	O
DNA	O
homology	O
between	O
the	O
breakpoints	O
in	O
the	O
second	O
exon	B
and	O
the	O
inserting	B
sequences	I
(	O
starting	O
at	O
nt	O
532	O
,	O
710	O
,	O
or	O
792	O
)	O
.	O

The	O
observed	O
E1a	B
reiterations	I
provide	O
a	O
model	O
to	O
gain	O
insight	O
into	O
understanding	O
the	O
evolutionary	O
events	O
of	O
some	O
,	O
if	O
not	O
all	O
,	O
adenovirus	O
types	O
during	O
many	O
years	O
of	O
symbiotic	O
,	O
persistent	O
relationship	O
in	O
human	O
tonsils	O
and	O
adenoids	O
and	O
possibly	O
other	O
lymphoid	O
organs	O
.	O

Residues	O
432	O
,	O
435	O
,	O
437	O
,	O
438	O
,	O
and	O
440	O
(	O
position	B
P1	I
,	I
P4	I
,	I
P6	I
,	I
P7	I
,	I
and	I
P9	I
)	O
contributed	O
to	O
DQ2	B
binding	O
,	O
whereas	O
residues	O
431	O
,	O
433	O
,	O
434	O
,	O
and	O
436	O
(	O
positions	B
P	I
1	I
,	I
P2	I
,	I
P3	I
,	I
and	I
P5	I
)	O
contributed	O
to	O
TCR	B
contact	O
.	O

The	O
hypothesis	O
that	O
the	O
nuclear	B
factor	I
of	I
activated	I
T	I
cells	I
(	O
NF	B
-	I
AT	I
)	O
may	O
influence	O
HIV	O
-	O
1	O
replication	O
is	O
therefore	O
compelling	O
given	O
the	O
tight	O
correlation	O
of	O
HIV	O
-	O
1	O
transcriptional	O
induction	O
to	O
T	O
cell	O
activation	O
.	O

These	O
results	O
link	O
regulatory	B
factors	I
critical	O
to	O
T	O
cell	O
commitment	O
directly	O
to	O
HIV	O
-	O
1	O
replication	O
.	O

eTh2	O
cells	O
are	O
the	O
major	O
source	O
of	O
IL	B
-	I
4	I
,	O
while	O
gamma	B
interferon	I
is	O
produced	O
by	O
eTh1	O
cells	O
.	O

However	O
,	O
although	O
NFAT	B
DNA	O
binding	O
is	O
similarly	O
induced	O
in	O
both	O
eTh1	O
and	O
eTh2	O
cells	O
upon	O
antigen	O
stimulation	O
,	O
only	O
the	O
NFAT	B
complexes	I
present	O
in	O
eTh2	O
cells	O
are	O
able	O
to	O
mediate	O
high	O
-	O
level	O
transcription	O
,	O
and	O
relatively	O
little	O
NFAT	B
transcriptional	O
activity	O
was	O
induced	O
in	O
eTh1	O
cells	O
.	O

The	O
greater	O
selectivity	O
of	O
PF	O
,	O
compared	O
with	O
FK506	O
,	O
at	O
both	O
the	O
molecular	O
and	O
cellular	O
levels	O
may	O
prove	O
advantageous	O
in	O
manipulating	O
T	O
cell	O
responses	O
in	O
vivo	O
.	O

V3	B
loop	I
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
suppresses	O
interleukin	B
2	I
-	O
induced	O
T	O
cell	O
growth	O
[	O
published	O
erratum	O
appears	O
in	O
AIDS	O
Res	O
Hum	O
Retroviruses	O
1997	O
May	O
1	O
;	O
13	O
(	O
7	O
)	O
:	O
633	O
]	O

V3	B
-	I
BH10	I
neither	O
blocked	O
radiolabeled	O
IL	B
-	I
2	I
binding	O
to	O
IL	B
-	I
2	I
receptors	I
nor	O
affected	O
tyrosyl	O
phosphorylation	O
of	O
several	O
cellular	B
proteins	I
(	O
p120	B
,	O
p98	B
,	O
p96	B
,	O
p54	B
,	O
and	O
p38	B
)	O
,	O
which	O
is	O
immediately	O
induced	O
by	O
IL	B
-	I
2	I
stimulation	O
.	O

However	O
,	O
V3	B
-	I
BH10	I
enhanced	O
IL	B
-	I
2	I
-	B
induced	I
mRNA	I
expression	O
of	O
c	B
-	I
fos	I
but	O
not	O
c	B
-	I
myc	I
or	O
junB	B
.	O

CONCLUSIONS	O
:	O
Our	O
results	O
establish	O
that	O
PI	B
3	I
-	I
kinase	I
can	O
both	O
positively	O
and	O
negatively	O
regulate	O
T	O
-	O
cell	O
function	O
,	O
and	O
uncover	O
a	O
previously	O
unrecognized	O
function	O
for	O
PI	B
3	I
-	I
kinase	I
in	O
T	O
cells	O
as	O
a	O
selective	O
negative	O
regulator	O
of	O
TCR	B
-	O
signalling	O
events	O
and	O
therefore	O
as	O
a	O
determinant	O
of	O
T	O
-	O
cell	O
homeostasis	O
.	O

Pax	B
-	I
5a	I
was	O
detectable	O
in	O
pro	O
-	O
,	O
pre	O
-	O
,	O
and	O
mature	O
B	O
-	O
cell	O
lines	O
,	O
but	O
not	O
in	O
two	O
plasmacytomas	O
;	O
Pax	B
-	I
5b	I
was	O
shown	O
to	O
be	O
present	O
at	O
low	O
levels	O
in	O
mature	O
B	O
-	O
cell	O
lines	O
and	O
,	O
unexpectedly	O
,	O
in	O
one	O
plasma	O
cell	O
line	O
,	O
but	O
not	O
in	O
pro	O
-	O
B	O
-	O
cell	O
or	O
T	O
-	O
cell	O
lines	O
.	O

The	O
two	O
related	O
protein	B
-	I
tyrosine	I
kinases	I
Syk	B
and	O
Zap	B
are	O
rapidly	O
phosphorylated	O
on	O
tyrosine	O
residues	O
and	O
enzymatically	O
activated	O
upon	O
crosslinking	O
of	O
the	O
T	B
cell	I
antigen	I
receptor	I
.	O

One	O
means	O
of	O
understanding	O
the	O
role	O
of	O
p38	B
in	O
these	O
responses	O
is	O
to	O
identify	O
proteins	O
with	O
functions	O
regulated	O
by	O
p38	B
-	O
catalysed	O
phosphorylation	O
.	O

Altogether	O
,	O
these	O
results	O
support	O
the	O
hypothesis	O
that	O
the	O
activation	O
of	O
NK	O
cells	O
involved	O
transcriptional	O
and	O
post	O
-	O
transcriptional	O
events	O
,	O
and	O
that	O
reactive	O
intermediates	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
molecular	O
processes	O
related	O
with	O
the	O
generation	O
of	O
a	O
cytotoxic	O
response	O
by	O
NK	O
cells	O
.	O

The	O
predominant	O
E2F	B
complex	I
in	O
human	O
primary	O
haemopoietic	O
cells	O
and	O
in	O
AML	O
blasts	O
contains	O
E2F	B
-	I
4	I
,	O
DP	B
-	I
1	I
and	O
p130	B
.	O

We	O
also	O
studied	O
blasts	O
from	O
18	O
patients	O
with	O
acute	O
myeloid	O
leukaemia	O
(	O
AML	O
)	O
.	O

An	O
E2F	B
-	I
4	I
/	I
p130	I
complex	I
was	O
detected	O
in	O
representative	O
samples	O
of	O
all	O
FAB	B
types	O
analysed	O
.	O

Associated	O
with	O
its	O
inhibitor	O
,	O
I	B
kappaB	I
,	O
NF	B
-	I
kappaB	I
resides	O
as	O
an	O
inactive	O
form	O
in	O
the	O
cytoplasm	O
.	O

The	O
transduction	O
pathways	O
that	O
lead	O
to	O
I	B
kappaB	I
inactivation	O
remain	O
poorly	O
understood	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
characterized	O
a	O
cellular	O
mutant	O
,	O
the	O
70	O
/	O
Z3	O
-	O
derived	O
1	O
.	O
3E2	O
murine	O
pre	O
-	O
B	O
cell	O
line	O
,	O
that	O
does	O
not	O
activate	O
NF	B
-	I
kappaB	I
in	O
response	O
to	O
several	O
stimuli	O
.	O

Our	O
results	O
demonstrate	O
that	O
1	O
.	O
3E2	O
is	O
a	O
cellular	B
transduction	I
mutant	I
exhibiting	O
a	O
defect	O
in	O
a	O
step	O
that	O
is	O
required	O
by	O
several	O
different	O
stimuli	O
to	O
activate	O
NF	B
-	I
kappaB	I
.	O

In	O
order	O
to	O
evaluate	O
the	O
conditions	O
for	O
optimal	O
expression	O
and	O
immunogenicity	O
of	O
varicella	B
-	I
zoster	I
virus	I
(	I
VZV	I
)	I
proteins	I
in	O
a	O
herpes	O
simplex	O
virus	O
-	O
1	O
(	O
HSV	O
-	O
1	O
)	O
vector	O
,	O
we	O
selected	O
the	O
VZV	B
glycoprotein	I
E	I
(	O
gE	B
)	O
,	O
encoded	O
by	O
ORF	B
68	I
and	O
the	O
VZV	B
product	I
of	O
ORF	B
62	I
,	O
an	O
immediate	B
-	I
early	I
major	I
tegument	I
protein	I
(	O
IE62	B
)	O
.	O

Immunoblot	O
analysis	O
and	O
immunoperoxidase	O
staining	O
of	O
infected	O
cell	O
monolayers	O
demonstrated	O
vector	O
expression	O
of	O
VZV	B
proteins	I
.	O

When	O
tested	O
in	O
cytotoxicity	O
assays	O
using	O
T	O
-	O
lymphocytes	O
from	O
VZV	O
immune	O
human	O
donors	O
,	O
the	O
range	O
of	O
precursor	O
frequencies	O
for	O
T	O
-	O
lymphocytes	O
that	O
recognized	O
VZV	B
gE	I
or	O
VZV	B
IE62	I
was	O
similar	O
whether	O
these	O
proteins	O
were	O
expressed	O
by	O
HSV	O
-	O
1	O
or	O
a	O
vaccinia	O
vector	O
.	O

In	O
this	O
report	O
,	O
we	O
demonstrate	O
that	O
the	O
active	O
form	O
of	O
NF	B
-	I
AT1	I
is	O
also	O
present	O
in	O
the	O
nuclei	O
of	O
HTLV	O
-	O
I	O
-	O
transformed	O
T	O
cells	O
that	O
express	O
the	O
Tax	B
protein	I
.	O

Interestingly	O
,	O
the	O
constitutive	O
activation	O
of	O
NF	B
-	I
AT1	I
in	O
these	O
T	O
cells	O
is	O
associated	O
with	O
its	O
dephosphorylation	O
.	O

Expression	O
of	O
NFAT	B
-	I
family	I
proteins	I
in	O
normal	O
human	O
T	O
cells	O
.	O

Higher	B
-	I
molecular	I
-	I
weight	I
species	I
of	O
NFATc	B
(	O
of	O
110	O
and	O
140	O
kDa	O
)	O
were	O
also	O
detected	O
.	O

In	O
contrast	O
to	O
ionomycin	O
treatment	O
,	O
exposure	O
of	O
cells	O
to	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
plus	O
anti	B
-	I
CD28	I
did	O
not	O
induce	O
NFATc	B
,	O
indicating	O
that	O
under	O
these	O
conditions	O
,	O
interleukin	B
-	I
2	I
synthesis	O
by	O
these	O
cells	O
is	O
apparently	O
independent	O
of	O
NFATc	B
.	O

Cotransfection	O
experiments	O
revealed	O
that	O
both	O
hGATA	B
-	I
4	I
and	O
PMA	O
/	O
A23187	O
stimulation	O
are	O
necessary	O
for	O
the	O
IL	B
-	I
5	I
promoter	I
activation	O
.	O

The	O
requirement	O
of	O
another	O
regulatory	B
element	I
called	O
CLE0	B
,	O
which	O
lies	O
downstream	O
of	O
the	O
-	B
70	I
GATA	I
site	I
,	O
was	O
also	O
demonstrated	O
.	O

The	O
electrophoretic	O
mobility	O
shift	O
assay	O
with	O
extracts	O
of	O
COS	O
cells	O
expressing	O
GATA	B
-	I
binding	I
proteins	I
showed	O
that	O
GATA	B
-	I
4	I
has	O
the	O
highest	O
binding	O
affinity	O
to	O
the	O
-	B
70	I
GATA	I
site	I
among	O
the	O
three	O
GATA	B
-	I
binding	I
proteins	I
.	O

These	O
results	O
demonstrate	O
the	O
selective	O
role	O
of	O
GATA	B
-	I
4	I
in	O
the	O
transcriptional	O
regulation	O
of	O
the	O
IL	B
-	I
5	I
gene	I
in	O
a	O
circumstance	O
where	O
multiple	O
members	O
of	O
the	O
GATA	B
-	I
binding	I
proteins	I
are	O
expressed	O
.	O

We	O
found	O
that	O
NFATx1	B
DNA	O
binding	O
activity	O
and	O
interaction	O
with	O
AP	O
-	O
1	O
polypeptides	O
were	O
dependent	O
on	O
its	O
central	B
Rel	I
similarity	I
region	I
and	O
that	O
transcriptional	O
activation	O
was	O
reduced	O
by	O
deletions	O
of	O
either	O
its	O
N	B
-	I
terminal	I
domain	I
or	O
its	O
C	B
-	I
terminal	I
domain	I
,	O
suggesting	O
the	O
presence	O
of	O
intrinsic	B
transcriptional	I
activation	I
motifs	I
in	O
both	O
regions	O
.	O

NO	O
is	O
produced	O
from	O
at	O
least	O
three	O
different	O
NO	B
synthase	I
(	I
NOS	I
)	I
isoforms	I
:	O
neuronal	B
NOS	I
(	O
nNOS	B
)	O
,	O
endothelial	B
NOS	I
,	O
and	O
immunologic	B
NOS	I
(	O
iNOS	B
)	O
.	O

Pyrrolidine	O
dithiocarbamate	O
(	O
PDTC	O
)	O
is	O
an	O
inhibitor	O
of	O
NF	B
kappaB	I
in	O
most	O
cells	O
;	O
however	O
,	O
we	O
show	O
that	O
PDTC	O
is	O
also	O
a	O
potent	O
scavenger	O
of	O
NO	O
through	O
formation	O
of	O
mononitrosyl	O
iron	O
complexes	O
with	O
PDTC	O
.	O

Contrary	O
to	O
the	O
results	O
in	O
Jurkat	O
cells	O
,	O
PDTC	O
did	O
not	O
inhibit	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
-	O
induced	O
NF	B
kappaB	I
activation	O
in	O
astrocytes	O
;	O
instead	O
PDTC	O
itself	O
induces	O
NF	B
kappaB	I
activation	O
in	O
astrocytes	O
,	O
and	O
this	O
may	O
be	O
related	O
to	O
scavenging	O
of	O
endogenously	O
produced	O
NO	O
by	O
the	O
PDTC	O
iron	O
complex	O
.	O

In	O
astrocytes	O
PDTC	O
also	O
dramatically	O
induces	O
the	O
NF	B
kappaB	I
-	I
dependent	I
enzyme	I
,	O
iNOS	B
,	O
supporting	O
the	O
physiologic	O
relevance	O
of	O
endogenous	O
NO	O
regulation	O
of	O
NF	B
kappaB	I
.	O

Involvement	O
of	O
Stat3	B
in	O
interleukin	B
-	I
6	I
-	O
induced	O
IgM	B
production	O
in	O
a	O
human	O
B	O
-	O
cell	O
line	O
.	O

EGF	O
treatment	O
induced	O
IgM	B
production	O
in	O
cells	O
transfected	O
with	O
an	O
intact	O
gp130	B
cytoplasmic	I
tail	I
,	O
but	O
not	O
in	O
untransfected	O
cells	O
or	O
cells	O
transfected	O
with	O
a	O
cytoplasmic	B
tail	I
lacking	O
all	O
four	O
signal	B
transducers	I
and	I
activators	I
of	I
transcription	I
(	I
Stat	I
)	I
binding	I
sites	I
.	O

Moreover	O
,	O
EGF	O
treatment	O
induced	O
Stat3	B
phosphorylation	O
in	O
cells	O
transfected	O
with	O
the	O
intact	O
chimeric	B
EGF	I
-	I
gp130	I
receptor	I
along	O
with	O
induction	O
of	O
DNA	O
-	O
mobility	O
shift	O
of	O
a	O
classical	B
interferon	I
-	I
gamma	I
-	I
activated	I
site	I
.	O

The	O
in	O
vitro	O
transendothelial	O
migration	O
of	O
circulating	O
filarial	O
antigen	O
-	O
specific	O
T	O
-	O
cells	O
was	O
examined	O
in	O
Wuchereria	O
banerofti	O
infection	O
.	O

This	O
cis	B
element	I
binds	O
a	O
protein	O
complex	O
referred	O
to	O
as	O
HRF	B
(	O
heme	B
-	I
responsive	I
factor	I
)	O
,	O
which	O
is	O
greatly	O
enhanced	O
both	O
in	O
heme	O
-	O
treated	O
FLCs	O
and	O
during	O
monocyte	O
-	O
to	O
-	O
macrophage	O
differentiation	O
.	O

One	O
of	O
the	O
latter	O
elements	O
,	O
the	O
IgH	B
3	I
'	I
enhancer	I
,	O
is	O
of	O
particular	O
interest	O
:	O
(	O
1	O
)	O
it	O
is	O
B	O
cell	O
-	O
specific	O
and	O
active	O
only	O
in	O
late	O
B	O
cell	O
development	O
;	O
(	O
2	O
)	O
in	O
rodent	O
plasmacytomas	O
and	O
in	O
some	O
human	O
Burkitt	O
'	O
s	O
lymphomas	O
it	O
is	O
part	O
of	O
a	O
locus	B
control	I
region	I
(	O
LCR	B
)	O
that	O
is	O
involved	O
in	O
deregulation	O
of	O
the	O
c	B
-	I
myc	I
oncogene	I
as	O
a	O
result	O
of	O
translocation	O
into	O
the	O
IgH	B
locus	I
;	O
and	O
(	O
3	O
)	O
it	O
has	O
been	O
implicated	O
in	O
the	O
mechanisms	O
that	O
control	O
Ig	B
gene	I
class	I
switch	O
recombination	O
.	O

Reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
such	O
as	O
hydrogen	O
peroxide	O
serve	O
as	O
second	O
messengers	O
in	O
the	O
induction	O
of	O
the	O
transcription	B
factor	I
NF	B
-	I
kappaB	I
,	O
and	O
hence	O
in	O
the	O
activation	O
and	O
replication	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
in	O
human	O
cells	O
.	O

NF	B
-	I
kappaB	I
activation	O
was	O
very	O
effective	O
when	O
cells	O
were	O
subjected	O
to	O
hyperthermia	O
before	O
being	O
treated	O
with	O
HOCl	O
.	O

Collectively	O
,	O
these	O
results	O
suggest	O
that	O
HOCl	O
should	O
be	O
considered	O
as	O
an	O
oxidative	O
species	O
capable	O
of	O
inducing	O
NF	B
-	I
kappaB	I
in	O
a	O
T	O
-	O
lymphocytic	O
cell	O
line	O
through	O
a	O
transduction	O
mechanism	O
involving	O
ROS	O
,	O
and	O
having	O
a	O
long	O
-	O
distance	O
effect	O
through	O
subsequent	O
TNF	B
-	I
alpha	I
release	O
.	O

Rap1	B
is	O
a	O
small	O
,	O
Ras	B
-	I
like	I
GTPase	I
whose	O
function	O
and	O
regulation	O
are	O
still	O
largely	O
unknown	O
.	O

Stimulation	O
of	O
blood	O
platelets	O
with	O
alpha	B
-	I
thrombin	I
or	O
other	O
platelet	O
activators	O
caused	O
a	O
rapid	O
and	O
strong	O
induction	O
of	O
Rap1	B
that	O
associated	O
with	O
RBD	B
in	O
vitro	O
.	O

From	O
our	O
results	O
,	O
we	O
conclude	O
that	O
Rap1	B
activation	O
in	O
platelets	O
is	O
an	O
important	O
common	O
event	O
in	O
early	O
agonist	O
-	O
induced	O
signalling	O
,	O
and	O
that	O
this	O
activation	O
is	O
mediated	O
by	O
an	O
increased	O
intracellular	O
Ca2	O
+	O
concentration	O

The	O
transcriptional	B
regulatory	I
elements	I
of	O
many	O
inducible	B
T	I
-	I
cell	I
genes	I
contain	O
adjacent	O
or	O
overlapping	B
binding	I
sites	I
for	O
the	O
Ets	B
and	I
NF	I
-	I
kappaB	I
/	I
NFAT	I
families	I
of	O
transcription	B
factors	I
.	O

From	O
AML1	B
gene	I
,	O
two	O
representative	O
forms	O
of	O
proteins	O
,	O
AML1a	B
and	O
AML1b	B
,	O
are	O
produced	O
by	O
an	O
alternative	O
splicing	O
.	O

These	O
data	O
strongly	O
suggest	O
that	O
a	O
transcriptionally	O
active	O
form	O
of	O
AML1	B
is	O
essential	O
for	O
the	O
myeloid	O
cell	O
differentiation	O
.	O

When	O
introduced	O
into	O
interleukin	B
3	I
(	O
IL	B
-	I
3	I
)	O
-	O
dependent	O
mouse	O
pro	O
-	O
B	O
lymphocytes	O
,	O
E2A	B
-	I
HLF	I
prevents	O
apoptosis	O
induced	O
by	O
growth	B
factor	I
deprivation	O
,	O
suggesting	O
that	O
IL	B
-	I
3	I
mediates	O
cell	O
survival	O
through	O
activation	O
of	O
a	O
transcription	B
factor	I
whose	O
activity	O
can	O
be	O
constitutively	O
replaced	O
by	O
the	O
chimeric	B
oncoprotein	I
.	O

The	O
expression	O
and	O
binding	O
activity	O
of	O
the	O
Nfil3	B
protein	I
(	O
also	O
called	O
E4bp4	B
)	O
,	O
but	O
not	O
of	O
Hlf	B
,	O
Dbp	B
,	O
or	O
Tef	B
,	O
was	O
found	O
to	O
be	O
regulated	O
by	O
IL	B
-	I
3	I
in	O
mouse	O
pro	O
-	O
B	O
cell	O
lines	O
(	O
Baf	O
-	O
3	O
and	O
FL5	O
.	O
12	O
)	O
.	O

Detection	O
of	O
adenovirus	O
DNA	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
by	O
polymerase	O
chain	O
reaction	O
assay	O
.	O

The	O
E1A	B
and	I
hexon	I
primers	I
amplified	O
DNA	O
from	O
representative	O
adenoviral	O
serotypes	O
in	O
all	O
six	O
adenoviral	O
groups	O
(	O
A	O
-	O
F	O
)	O
.	O

In	O
addition	O
,	O
assay	O
of	O
PBMC	O
by	O
the	O
adenovirus	O
-	O
specific	O
PCR	O
may	O
help	O
detect	O
early	O
invasive	O
disease	O
and	O
warrants	O
further	O
evaluation	O
.	O

Common	O
and	O
distinct	O
intracellular	O
signaling	O
pathways	O
in	O
human	O
neutrophils	O
utilized	O
by	O
platelet	B
activating	I
factor	I
and	O
FMLP	B
.	O

Stimulation	O
of	O
human	O
neutrophils	O
with	O
chemoattractants	B
FMLP	B
or	O
platelet	B
activating	I
factor	I
(	O
PAF	B
)	O
results	O
in	O
different	O
but	O
overlapping	O
functional	O
responses	O
.	O

We	O
questioned	O
whether	O
these	O
differences	O
might	O
reflect	O
patterns	O
of	O
intracellular	O
signal	O
transduction	O
.	O

Stimulation	O
with	O
either	O
PAF	B
or	O
FMLP	B
resulted	O
in	O
equivalent	O
phosphorylation	O
and	O
activation	O
of	O
the	O
mitogen	B
-	I
activated	I
protein	I
kinase	I
(	I
MAPk	I
)	I
homologue	I
38	B
-	I
kD	I
murine	I
MAP	I
kinase	I
homologous	O
to	O
HOG	B
-	I
1	I
(	I
p38	I
)	I
MAPk	I
.	O

A	O
specific	O
p38	B
MAPk	I
inhibitor	O
(	O
SK	O
&	O
F	O
86002	O
)	O
blocked	O
superoxide	O
anion	O
production	O
in	O
response	O
to	O
FMLP	B
and	O
reduced	O
adhesion	O
and	O
chemotaxis	O
in	O
response	O
to	O
PAF	B
or	O
FMLP	B
.	O

Chicken	B
NF	I
-	I
M	I
transcription	I
factor	I
,	O
in	O
cooperation	O
with	O
either	O
c	B
-	I
Myb	I
or	O
v	B
-	I
Myb	I
,	O
is	O
active	O
in	O
the	O
combinatorial	O
activation	O
of	O
myeloid	B
-	I
cell	I
-	I
specific	I
genes	I
in	O
heterologous	O
cell	O
types	O
,	O
such	O
as	O
embryonic	O
fibroblasts	O
.	O

In	O
the	O
present	O
report	O
,	O
we	O
show	O
that	O
A6H	B
costimulated	O
cell	O
proliferation	O
and	O
cytokine	B
production	O
in	O
purified	O
CD4	O
+	O
T	O
cells	O
.	O

Co	O
-	O
ligation	O
of	O
the	O
A6H	B
antigen	O
and	O
the	O
CD3	B
complex	I
induced	O
expression	O
of	O
the	O
transcription	B
factor	I
AP	B
-	I
1	I
in	O
CD4	O
+	O
T	O
cells	O
,	O
whereas	O
no	O
increase	O
in	O
NF	B
-	I
kappa	I
B	I
and	O
octamer	B
-	I
binding	I
(	I
Oct	I
)	I
proteins	I
was	O
seen	O
compared	O
to	O
T	O
cells	O
stimulated	O
with	O
anti	B
-	I
CD3	I
alone	O
.	O

Molecular	O
differences	O
of	O
the	O
A6H	B
molecule	I
or	O
distinct	O
regulation	O
of	O
the	O
A6H	B
transduced	O
AP	B
-	I
1	I
activation	O
pathway	O
may	O
exist	O
in	O
CD4	O
+	O
and	O
CD8	O
+	O
T	O
cell	O
subpopulations	O
.	O

The	O
DNA	B
-	I
binding	I
domain	I
(	O
amino	B
acids	I
421	I
-	I
486	I
)	O
is	O
completely	O
conserved	O
among	O
human	B
,	I
squirrel	I
monkey	I
,	I
owl	I
monkey	I
,	I
and	I
cotton	I
-	I
top	I
tamarin	I
receptors	I
.	O

Expressions	O
of	O
human	O
and	O
squirrel	O
monkey	O
glucocorticoid	B
receptors	I
and	O
a	O
squirrel	B
monkey	I
receptor	I
in	O
which	O
Phe774	O
was	O
mutated	O
to	O
Leu	O
(	O
F774L	O
)	O
were	O
similar	O
.	O

Shared	O
gamma	B
(	I
c	I
)	I
subunit	I
within	O
the	O
human	B
interleukin	I
-	I
7	I
receptor	I
complex	I
.	O

The	O
gamma	B
(	I
c	I
)	I
subunit	I
can	O
be	O
employed	O
in	O
receptor	B
complexes	I
for	O
IL	B
-	I
2	I
,	I
-	I
4	I
,	I
-	I
7	I
,	I
-	I
9	I
,	I
and	I
-	I
15	I
,	O
and	O
the	O
multiple	O
signaling	O
defects	O
that	O
would	O
result	O
from	O
a	O
defective	O
gamma	B
(	I
c	I
)	I
chain	I
in	O
these	O
receptors	O
are	O
proposed	O
to	O
cause	O
the	O
severe	O
phenotype	O
of	O
X	O
-	O
SCID	O
patients	O
.	O

These	O
observations	O
suggest	O
the	O
functional	O
importance	O
of	O
gamma	B
(	I
c	I
)	I
in	O
the	O
IL	B
-	I
7R	I
complex	I
.	O

In	O
this	O
study	O
we	O
determined	O
the	O
effects	O
of	O
SAC	O
on	O
NF	B
-	I
kappa	I
B	I
activation	O
in	O
human	O
T	O
lymphocytes	O
(	O
Jurkat	O
cells	O
)	O
induced	O
by	O
tumor	B
necrosis	I
factor	I
alpha	I
(	O
TNF	B
-	I
alpha	I
)	O
and	O
H2O2	O
.	O

Elf	B
-	I
2	I
,	O
a	O
rhombotin	B
-	I
2	I
binding	I
ets	I
transcription	I
factor	I
:	O
discovery	O
and	O
potential	O
role	O
in	O
T	O
cell	O
leukemia	O
.	O

By	O
screening	O
a	O
T	O
cell	O
cDNA	B
library	I
,	O
we	O
identified	O
a	O
novel	B
ets	I
transcription	I
factor	I
that	O
binds	O
RBTN	B
-	I
2	I
.	O

Thymocytes	O
expressed	O
four	O
-	O
to	O
10	O
-	O
fold	O
greater	O
amounts	O
of	O
the	O
3	B
.	I
5	I
kb	I
transcript	I
than	O
other	O
tissues	O
.	O

The	O
expression	O
patterns	O
suggest	O
that	O
RBTN	B
-	I
2	I
normally	O
interacts	O
equally	O
with	O
elf	B
-	I
2a	I
and	O
elf	B
-	I
2b	I
.	O

In	O
contrast	O
,	O
when	O
RBTN	B
-	I
2	I
is	O
inappropriately	O
expressed	O
in	O
T	O
cells	O
,	O
RBTN	B
-	I
2	I
would	O
interact	O
predominantly	O
with	O
elf	B
-	I
2b	I
;	O
this	O
interaction	O
may	O
lead	O
to	O
T	O
cell	O
proliferation	O
.	O

When	O
immunoglobulin	O
(	O
Ig	O
)	O
-	O
secreting	O
plasmacytomas	O
are	O
fused	O
to	O
a	O
T	O
-	O
cell	O
lymphoma	O
,	O
Ig	B
gene	I
expression	O
ceases	O
in	O
greater	O
than	O
95	O
%	O
of	O
the	O
resulting	O
hybrids	O
.	O

In	O
the	O
rare	O
hybrids	O
that	O
continue	O
to	O
express	O
Ig	O
,	O
all	O
other	O
tested	O
B	B
lymphocyte	I
-	I
specific	I
genes	I
also	O
remain	O
active	O
.	O

The	O
low	O
frequency	O
with	O
which	O
these	O
Ig	O
-	O
expressing	O
hybrids	O
are	O
recovered	O
,	O
along	O
with	O
the	O
fact	O
that	O
cell	O
fusions	O
can	O
lead	O
to	O
chromosome	O
loss	O
,	O
led	O
us	O
to	O
propose	O
that	O
this	O
rare	O
phenotype	O
was	O
due	O
to	O
loss	O
of	O
a	O
T	B
-	I
cell	I
-	I
derived	I
chromosome	I
encoding	I
a	I
factor	I
or	O
factors	O
with	O
gene	O
silencing	O
activity	O
.	O

To	O
identify	O
the	O
relevant	O
chromosome	O
,	O
we	O
have	O
used	O
a	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
-	O
assisted	O
method	O
of	O
chromosome	O
mapping	O
to	O
analyze	O
both	O
Ig	O
-	O
silenced	O
(	O
common	O
)	O
and	O
Ig	O
-	O
expressing	O
(	O
rare	O
)	O
hybrids	O
.	O

Kaposi	O
'	O
s	O
sarcoma	O
(	O
KS	O
)	O
-	O
associated	O
herpesvirus	O
(	O
KSHV	O
)	O
,	O
or	O
human	O
herpesvirus	O
8	O
,	O
is	O
a	O
lymphotropic	O
virus	O
strongly	O
linked	O
to	O
several	O
AIDS	O
-	O
related	O
neoplasms	O
.	O

Nuclear	B
factor	I
of	I
activated	I
T	I
cells	I
and	O
AP	B
-	I
1	I
are	O
insufficient	O
for	O
IL	B
-	I
2	I
promoter	I
activation	O
:	O
requirement	O
for	O
CD28	B
up	O
-	O
regulation	O
of	O
RE	B
/	I
AP	I
.	O

Uncontrolled	O
replication	O
of	O
a	O
virus	O
,	O
which	O
is	O
harmful	O
to	O
the	O
host	O
is	O
also	O
disadvantageous	O
to	O
the	O
virus	O
.	O

Therefore	O
,	O
only	O
the	O
time	O
between	O
infection	O
and	O
eradication	O
remains	O
for	O
these	O
viruses	O
to	O
proliferate	O
.	O

Both	O
are	O
true	O
for	O
the	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
.	O

Disturbance	O
of	O
both	O
the	O
immune	O
surveillance	O
as	O
well	O
as	O
viral	B
gene	I
regulation	O
may	O
result	O
in	O
EBV	O
-	O
associated	O
disease	O
.	O

3BP2	B
was	O
selectively	O
expressed	O
in	O
hematopoietic	O
/	O
lymphoid	O
tissues	O
and	O
bound	O
via	O
its	O
SH2	B
domain	I
activated	I
Syk	I
-	I
family	I
kinases	I
in	O
mammalian	O
cells	O
,	O
including	O
in	O
antigen	O
receptor	O
-	O
stimulated	O
T	O
cells	O
.	O

In	O
this	O
study	O
,	O
a	O
series	O
of	O
Burkitt	O
'	O
s	O
lymphoma	O
(	O
BL	O
)	O
cell	O
lines	O
were	O
assayed	O
for	O
their	O
expression	O
of	O
tissue	B
inhibitor	I
of	I
metalloproteinases	I
(	I
TIMP	I
)	I
-	I
1	I
.	O

Results	O
indicate	O
that	O
TIMP	O
-	O
1	O
-	O
positive	O
BL	O
lines	O
show	O
resistance	O
to	O
cold	O
-	O
shock	O
-	O
induced	O
apoptosis	O
.	O

Furthermore	O
,	O
recombinant	O
TIMP	B
-	I
1	I
,	O
but	O
not	O
TIMP	B
-	I
2	I
or	O
a	O
synthetic	O
metalloproteinase	O
inhibitor	O
(	O
BB	O
-	O
94	O
)	O
,	O
confers	O
resistance	O
to	O
apoptosis	O
induced	O
by	O
both	O
CD95	O
-	O
dependent	O
and	O
-	O
independent	O
(	O
cold	O
shock	O
,	O
serum	O
deprivation	O
,	O
and	O
gamma	O
-	O
radiation	O
)	O
pathways	O
in	O
TIMP	O
-	O
1	O
-	O
negative	O
BL	O
lines	O
.	O

The	O
spi	O
-	O
1	O
transfected	O
cells	O
showed	O
reduced	O
growth	O
rates	O
and	O
reduced	O
clonogenic	O
cell	O
growth	O
.	O

To	O
investigate	O
in	O
vivo	O
regulatory	O
mechanisms	O
that	O
control	O
the	O
population	O
of	O
type	O
2	O
T	O
cells	O
and	O
disease	O
susceptibility	O
,	O
we	O
have	O
created	O
lines	O
of	O
transgenic	O
mice	O
in	O
which	O
expression	O
of	O
a	O
chimeric	B
cytokine	I
receptor	I
(	O
the	O
mouse	B
interleukin	I
2	I
receptor	I
beta	I
chain	I
[	I
IL	I
-	I
2Rbeta	I
]	I
extracellular	I
domain	I
fused	O
to	O
the	O
cytoplasmic	B
tail	I
of	O
IL	B
-	I
4Ralpha	I
)	O
is	O
targeted	O
to	O
the	O
T	O
lymphoid	O
lineage	O
using	O
the	O
proximal	B
lck	I
promoter	I
.	O

We	O
have	O
recently	O
cloned	O
the	O
carboxylesterase	B
upstream	I
sequence	I
and	O
showed	O
its	O
basal	B
promoter	I
activity	O
in	O
CHO	O
cells	O
.	O

The	O
role	O
of	O
the	O
Ikaros	B
gene	I
in	O
lymphocyte	O
development	O
and	O
homeostasis	O
.	O

In	O
the	O
adult	O
,	O
however	O
,	O
lymphoid	O
lineages	O
rely	O
on	O
Ikaros	B
at	O
distinct	O
phases	O
of	O
their	O
development	O
.	O

Its	O
activity	O
is	O
essential	O
for	O
the	O
generation	O
of	O
B	O
cell	O
but	O
not	O
of	O
T	O
cell	O
precursors	O
,	O
although	O
the	O
differentiation	O
of	O
the	O
latter	O
is	O
not	O
normal	O
.	O

A	O
significant	O
increase	O
in	O
CD4	O
thymocytes	O
and	O
their	O
immediate	O
precursors	O
is	O
detected	O
,	O
and	O
because	O
these	O
cells	O
lack	O
markers	O
that	O
correlate	O
with	O
positive	O
selection	O
,	O
a	O
deregulation	O
in	O
their	O
maturation	O
process	O
is	O
suggested	O
.	O

Furthermore	O
,	O
Ikaros	O
-	O
null	O
thymocytes	O
hyperproliferate	O
in	O
response	O
to	O
T	B
cell	I
receptor	I
(	O
TCR	B
)	O
signaling	O
;	O
within	O
days	O
after	O
their	O
appearance	O
in	O
the	O
thymus	O
,	O
clonally	O
expanding	O
populations	O
are	O
detected	O
.	O

Deregulated	O
TCR	B
-	O
mediated	O
responses	O
and	O
the	O
fast	O
kinetics	O
of	O
tumor	O
development	O
in	O
these	O
mutant	O
thymocytes	O
implicate	O
Ikaros	O
as	O
a	O
central	B
tumor	I
suppressor	I
gene	I
for	O
the	O
T	O
cell	O
lineage	O
.	O

The	O
role	O
of	O
Aiolos	B
,	O
a	O
lymphoid	B
-	I
restricted	I
and	I
structurally	I
related	I
gene	I
,	O
in	O
lymphoid	O
differentiation	O
is	O
discussed	O
.	O

Changes	O
in	O
this	O
regulatory	O
network	O
may	O
reflect	O
differentiation	O
and	O
proliferation	O
adjustments	O
made	O
in	O
hemo	O
-	O
lymphoid	O
progenitors	O
and	O
precursors	O
as	O
they	O
give	O
rise	O
to	O
the	O
cells	O
of	O
our	O
immune	O
system	O
.	O

STAT1	B
pathway	O
is	O
involved	O
in	O
activation	O
of	O
caprine	O
arthritis	B
-	I
encephalitis	I
virus	I
long	I
terminal	I
repeat	I
in	O
monocytes	O
.	O

Substitution	O
mutations	O
in	O
this	O
consensus	B
sequence	I
eliminate	O
binding	O
of	O
the	O
inducible	B
factor	I
.	O

1	B
,	I
25	I
-	I
Dihydroxyvitamin	I
D3	I
receptors	I
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
from	O
patients	O
with	O
renal	O
insufficiency	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
have	O
investigated	O
the	O
specific	O
uptake	O
of	O
[	O
3H	O
]	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
by	O
PBMC	O
of	O
11	O
women	O
with	O
advanced	O
chronic	O
renal	O
failure	O
(	O
A	O
-	O
CRF	O
)	O
,	O
6	O
women	O
with	O
mild	O
-	O
moderate	O
renal	O
insufficiency	O
(	O
M	O
-	O
CRF	O
)	O
,	O
and	O
23	O
healthy	O
women	O
.	O

The	O
mean	O
dissociation	O
constant	O
(	O
KD	O
)	O
was	O
similar	O
in	O
both	O
groups	O
of	O
patients	O
and	O
in	O
healthy	O
women	O
(	O
A	O
-	O
CRF	O
:	O
0	O
.	O
7	O
+	O
/	O
-	O
0	O
.	O
5	O
x	O
10	O
(	O
-	O
10	O
)	O
M	O
;	O
M	O
-	O
CRF	O
:	O
1	O
.	O
1	O
+	O
/	O
-	O
0	O
.	O
9	O
x	O
10	O
(	O
-	O
10	O
)	O
M	O
;	O
controls	O
:	O
1	O
.	O
0	O
+	O
/	O
-	O
0	O
.	O
6	O
x	O
10	O
(	O
-	O
10	O
)	O
M	O
)	O
.	O

No	O
correlation	O
was	O
seen	O
between	O
VDR	B
and	O
serum	O
calcitriol	O
or	O
PTH	O
levels	O
,	O
when	O
considering	O
both	O
groups	O
of	O
patients	O
together	O
or	O
separately	O
.	O

Conversely	O
,	O
a	O
significant	O
negative	O
correlation	O
was	O
found	O
between	O
VDR	B
and	O
serum	O
creatinine	O
values	O
when	O
A	O
-	O
CRF	O
and	O
M	O
-	O
CRF	O
were	O
considered	O
altogether	O
(	O
r	O
=	O
-	O
0	O
.	O
63	O
;	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

These	O
data	O
are	O
well	O
in	O
line	O
with	O
the	O
long	O
-	O
standing	O
notion	O
that	O
interindividual	O
differences	O
in	O
platelet	B
monoamine	I
oxidase	I
may	O
represent	O
differences	O
in	O
expression	O
of	O
the	O
enzyme	O
rather	O
than	O
genotypic	O
variation	O
.	O

Ciprofibrate	O
,	O
an	O
hypolipidaemic	O
peroxisome	O
proliferator	O
,	O
induced	O
differentiation	O
of	O
HL	O
-	O
60	O
cells	O
.	O

In	O
particular	O
,	O
TRAF6	B
interacted	O
with	O
membrane	B
-	I
proximal	I
determinants	I
distinct	O
from	O
those	O
binding	O
TRAFs	B
1	I
,	I
2	I
,	I
3	I
,	I
and	I
5	I
.	O

The	O
molecular	O
mechanisms	O
by	O
which	O
IL	B
-	I
4	I
induces	O
expression	O
of	O
the	O
IL	B
-	I
4	I
gene	I
are	O
not	O
known	O
,	O
although	O
the	O
IL	B
-	I
4	I
-	I
activated	I
transcription	I
factor	I
signal	I
transducer	I
and	I
activator	I
of	I
transcription	I
6	I
(	O
Stat6	B
)	O
is	O
required	O
for	O
this	O
effect	O
.	O

CONCLUSIONS	O
:	O
Intestinal	O
epithelial	O
cells	O
initiate	O
an	O
inflammatory	O
response	O
with	O
resulting	O
neutrophil	O
-	O
mediated	O
tissue	O
damage	O
in	O
response	O
to	O
E	O
.	O
histolytica	O
infection	O
;	O
this	O
inflammatory	O
cascade	O
can	O
be	O
blocked	O
by	O
inhibiting	O
the	O
transcription	O
of	O
genes	O
regulated	O
by	O
nuclear	B
factor	I
kappaB	I
.	O

The	O
triptolide	O
-	O
induced	O
apoptosis	O
is	O
accompanied	O
by	O
increase	O
of	O
DEVD	O
-	O
cleavable	O
caspases	B
activity	O
and	O
degradation	O
of	O
caspase	B
substrate	I
poly	I
(	I
ADP	I
-	I
ribose	I
)	I
polymerase	I
(	O
PARP	B
)	O
.	O

A	O
specific	O
inhibitor	O
of	O
caspases	B
,	O
zVAD	O
-	O
FMK	O
,	O
prevents	O
triptolide	O
-	O
induced	O
PARP	B
degradation	O
and	O
DNA	O
fragmentation	O
but	O
not	O
growth	O
arrest	O
.	O

A	O
novel	O
transcription	B
factor	I
regulates	O
expression	O
of	O
the	O
vacuolar	B
H	I
+	I
-	I
ATPase	I
B2	I
subunit	I
through	O
AP	B
-	I
2	I
sites	I
during	O
monocytic	O
differentiation	O
.	O

In	O
mobility	O
shift	O
assays	O
,	O
a	O
nuclear	B
factor	I
from	O
THP	O
-	O
1	O
and	O
U	O
-	O
937	O
cells	O
was	O
identified	O
that	O
binds	O
to	O
several	O
AP	B
-	I
2	I
response	I
elements	I
within	O
the	O
B2	B
promoter	I
,	O
but	O
does	O
not	O
react	O
with	O
AP	B
-	I
2	I
antibodies	I
,	O
and	O
has	O
a	O
DNA	B
sequence	I
binding	O
affinity	O
profile	O
that	O
differs	O
from	O
AP	B
-	I
2	I
.	O

These	O
findings	O
suggest	O
that	O
a	O
novel	O
AP	B
-	I
2	I
-	I
like	I
transcription	I
factor	I
is	O
responsible	O
for	O
V	B
-	I
ATPase	I
B	I
subunit	I
amplification	O
during	O
monocyte	O
differentiation	O
.	O

c	O
-	O
Jun	O
and	O
GST	O
-	O
pi	O
expression	O
in	O
human	O
plasma	O
cells	O
.	O

The	O
expression	O
of	O
these	O
two	O
proteins	O
was	O
not	O
related	O
to	O
clinical	O
or	O
laboratory	O
data	O
.	O

It	O
has	O
been	O
shown	O
that	O
eosinophil	O
stimulation	O
by	O
these	O
cytokines	B
is	O
associated	O
with	O
increases	O
in	O
tyrosine	O
phosphorylation	O
of	O
several	O
cellular	O
substrates	O
.	O

This	O
review	O
will	O
concentrate	O
on	O
this	O
topic	O
and	O
on	O
its	O
role	O
for	O
the	O
regulation	O
of	O
eosinophil	O
apoptosis	O
.	O

Time	O
-	O
course	O
experiments	O
showed	O
that	O
nuclear	O
levels	O
of	O
GATA	B
-	I
1	I
and	O
p45	B
NF	I
-	I
E2	I
proteins	O
increased	O
during	O
BA	O
treatment	O
.	O

The	O
upstream	O
regions	O
UAS3	B
(	O
-	B
1168	I
to	I
-	I
440	I
)	O
and	O
UAS2	B
(	O
-	B
352	I
to	I
-	I
264	I
)	O
both	O
functioned	O
in	O
a	O
cell	O
lineage	O
-	O
independent	O
manner	O
and	O
were	O
together	O
responsible	O
for	O
the	O
bulk	O
of	O
Wp	O
activity	O
in	O
non	O
-	O
B	O
cells	O
;	O
mutational	O
analysis	O
indicated	O
the	O
importance	O
of	O
a	O
YY1	B
binding	I
site	I
in	O
UAS2	B
in	O
that	O
context	O
.	O

By	O
contrast	O
,	O
UAS1	B
(	O
-	B
140	I
to	I
-	I
87	I
)	O
was	O
B	O
cell	O
specific	O
and	O
was	O
the	O
key	O
determinant	O
of	O
the	O
promoter	O
'	O
s	O
increased	O
activity	O
in	O
B	O
cell	O
lines	O
.	O

When	O
mutations	O
that	O
abolished	O
factor	O
binding	O
in	O
bandshift	O
assays	O
were	O
introduced	O
into	O
a	O
Wp	B
reporter	I
construct	I
,	O
the	O
loss	O
of	O
any	O
one	O
of	O
the	O
three	O
UAS1	B
binding	I
sites	I
was	O
sufficient	O
to	O
reduce	O
promoter	O
activity	O
by	O
10	O
-	O
to	O
30	O
-	O
fold	O
in	O
B	O
cells	O
.	O

Both	O
BZLF1	B
and	I
BRLF1	I
immediate	I
-	I
early	I
transcripts	I
,	O
but	O
not	O
BMLF1	B
transcript	I
,	O
could	O
be	O
detected	O
in	O
individual	O
CD4	O
+	O
and	O
CD8	O
+	O
T	O
cells	O
infected	O
with	O
EBV	O
.	O

T	O
-	O
lineage	O
precursor	O
populations	O
from	O
the	O
adult	O
mouse	O
thymus	O
,	O
prior	O
to	O
T	O
-	O
cell	O
receptor	O
gene	O
rearrangement	O
,	O
display	O
a	O
capacity	O
to	O
produce	O
DC	O
as	O
well	O
as	O
T	O
cells	O
in	O
the	O
thymus	O
,	O
and	O
are	O
very	O
efficient	O
precursors	O
of	O
DC	O
in	O
culture	O
.	O

These	O
lymphoid	O
/	O
DC	O
precursors	O
have	O
little	O
capacity	O
to	O
form	O
myeloid	O
cells	O
,	O
indicating	O
that	O
thymic	O
DC	O
are	O
a	O
lymphoid	O
-	O
related	O
rather	O
than	O
myeloid	O
-	O
related	O
lineage	O
.	O

Pharmacologic	O
blockade	O
of	O
endogenous	B
NFAT	I
activity	O
by	O
FK506	O
or	O
CsA	O
inhibited	O
synthesis	O
of	O
reverse	O
transcription	O
and	O
also	O
potently	O
blocked	O
HIV	O
-	O
1	O
replication	O
.	O

The	O
first	O
step	O
in	O
the	O
nuclear	O
import	O
process	O
is	O
recognition	O
of	O
a	O
nuclear	B
localization	I
sequence	I
(	O
NLS	B
)	O
within	O
the	O
karyophilic	B
protein	I
by	O
a	O
cytoplasmic	B
receptor	I
such	O
as	O
the	O
importin	B
(	I
karyopherin	I
)	I
-	I
alpha	I
subunit	I
.	O

NLS	B
peptide	O
-	O
mediated	O
disruption	O
of	O
the	O
nuclear	O
import	O
of	O
these	O
transcription	B
factors	I
results	O
in	O
inhibition	O
of	O
I	O
kappa	O
B	O
alpha	O
and	O
IL	O
-	O
2	O
gene	O
expression	O
,	O
processes	O
dependent	O
on	O
NF	B
-	I
kappa	I
B	I
or	O
the	O
combination	O
of	O
NF	B
-	I
kappa	I
B	I
,	O
AP	B
-	I
1	I
,	O
and	O
NFAT	B
.	O

Further	O
,	O
we	O
show	O
that	O
inhibitory	O
NLS	B
peptide	O
interacts	O
in	O
vitro	O
with	O
a	O
cytoplasmic	B
NLS	I
receptor	I
complex	I
comprised	O
of	O
the	O
Rch1	B
/	I
importin	I
(	I
karyopherin	I
)	I
-	I
beta	I
heterodimer	I
expressed	O
in	O
Jurkat	O
T	O
cells	O
.	O

Forty	O
-	O
eight	O
hours	O
after	O
transfection	O
,	O
EC	O
were	O
stimulated	O
with	O
NK	O
cells	O
or	O
NK	O
cell	O
membrane	O
extracts	O
for	O
7	O
hr	O
and	O
activation	O
was	O
measured	O
by	O
a	O
luciferase	B
assay	O
.	O

CONCLUSIONS	O
:	O
Human	O
NK	O
cell	O
membrane	O
-	O
bound	O
LT	O
signals	O
across	O
species	O
via	O
TNFRI	B
,	O
leading	O
to	O
NF	B
-	I
kappaB	I
nuclear	O
translocation	O
and	O
transcription	O
of	O
E	B
-	I
selectin	I
and	O
IL	B
-	I
8	I
,	O
which	O
results	O
in	O
EC	O
activation	O
.	O

The	O
discrepancy	O
in	O
the	O
degree	O
of	O
inhibition	O
by	O
membrane	O
extracts	O
and	O
NK	O
cells	O
with	O
mutant	B
TNFRI	I
suggests	O
that	O
additional	O
pathways	O
are	O
utilized	O
by	O
NK	O
cells	O
to	O
activate	O
EC	O

Ras	B
-	O
dependent	O
,	O
Ca2	O
+	O
-	O
stimulated	O
activation	O
of	O
nuclear	B
factor	I
of	I
activated	I
T	I
cells	I
by	O
a	O
constitutively	O
active	O
Cbl	B
mutant	I
in	O
T	O
cells	O
.	O

Blood	O
monocytes	O
spontaneously	O
activate	O
endothelial	O
cells	O
in	O
culture	O
,	O
leading	O
to	O
adhesion	O
of	O
monocytic	O
cells	O
onto	O
the	O
endothelial	O
surface	O
and	O
overproduction	O
of	O
endothelial	O
proteins	O
such	O
as	O
von	B
Willebrand	I
factor	I
(	O
vWf	B
)	O
and	O
plasminogen	B
activator	I
inhibitor	I
type	I
1	I
(	O
PAI	B
-	I
1	I
)	O
.	O

Addition	O
of	O
untreated	O
THP	O
-	O
1	O
cells	O
had	O
little	O
effect	O
on	O
HUVEC	O
adhesiveness	O
.	O

Under	O
these	O
conditions	O
HUVEC	B
adhesion	I
molecules	I
,	O
E	B
-	I
selectin	I
,	O
VCAM	B
-	I
1	I
and	O
ICAM	B
-	I
1	I
,	O
were	O
increased	O
at	O
3	O
h	O
with	O
only	O
ICAM	B
-	I
1	I
remaining	O
overexpressed	O
at	O
24	O
h	O
.	O

Quantitative	O
reverse	B
transcriptase	I
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
showed	O
an	O
increase	O
in	O
steady	O
-	O
state	O
TNF	B
-	I
alpha	I
mRNA	I
after	O
3	O
to	O
4	O
hours	O
of	O
cross	O
-	O
linking	O
.	O

CD2	B
cross	O
-	O
linking	O
concurrently	O
increased	O
phosphorylation	O
of	O
CREB	B
detected	O
by	O
immunoblot	O
assay	O
eightfold	O
.	O

These	O
data	O
indicate	O
specific	O
modulation	O
of	O
the	O
CREB	B
/	I
ATF	I
-	I
1	I
family	I
of	O
transcription	B
factors	I
by	O
the	O
CD2	B
signalling	O
pathway	O
and	O
suggest	O
CD2	B
receptor	O
modulation	O
of	O
CRE	B
-	O
mediated	O
transcription	O
following	O
ligand	O
engagement	O
(	O
e	O
.	O
g	O
.	O
cell	O
-	O
to	O
-	O
cell	O
contact	O
)	O
.	O

In	O
the	O
present	O
report	O
we	O
show	O
that	O
in	O
various	O
transiently	O
or	O
stably	O
transfected	O
cell	O
lines	O
,	O
X	O
-	O
ray	O
irradiation	O
up	O
-	O
regulates	O
HIV	B
-	I
1	I
LTR	I
transcription	O
through	O
the	O
kappaB	B
regulatory	I
elements	I
.	O

In	O
addition	O
,	O
X	O
-	O
ray	O
activation	O
of	O
HIV	B
-	I
1	I
LTR	I
in	O
transiently	O
or	O
stably	O
transfected	O
cell	O
lines	O
is	O
inhibited	O
by	O
a	O
potent	O
antioxidant	O
drug	O
,	O
pyrrolidine	O
dithiocarbamate	O
and	O
by	O
another	O
drug	O
,	O
known	O
for	O
its	O
role	O
in	O
the	O
trapping	O
of	O
growth	B
factors	I
,	O
suramin	O
.	O

The	O
importance	O
of	O
these	O
observations	O
in	O
the	O
pathophysiology	O
of	O
patients	O
with	O
AIDS	O
-	O
related	O
cancers	O
treated	O
by	O
radiotherapy	O
remains	O
to	O
be	O
established	O
.	O

Restoration	O
of	O
the	O
CCAAT	B
box	I
at	O
-	B
70	I
bp	I
,	O
or	O
insertion	O
of	O
an	O
EKLF	B
binding	I
site	I
at	O
-	B
85	I
bp	I
or	O
-	B
95	I
bp	I
in	O
the	O
promoter	B
significantly	O
increased	O
delta	O
globin	O
gene	O
expression	O
in	O
hAEC	O
.	O

Constitutive	O
association	O
of	O
JAK1	B
and	O
STAT5	B
in	O
pro	O
-	O
B	O
cells	O
is	O
dissolved	O
by	O
interleukin	B
-	I
4	I
-	O
induced	O
tyrosine	O
phosphorylation	O
of	O
both	O
proteins	O
.	O

Nuclear	B
factor	I
-	I
kappaB	I
was	O
found	O
to	O
be	O
activated	O
in	O
ventilated	O
macrophages	O
.	O

To	O
determine	O
the	O
mechanisms	O
responsible	O
for	O
these	O
differences	O
,	O
we	O
turned	O
to	O
human	O
U937	O
promonocytic	O
cells	O
.	O

Based	O
on	O
the	O
high	O
specificity	O
of	O
this	O
compound	O
for	O
PKC	B
,	O
we	O
conclude	O
that	O
PKC	B
is	O
necessary	O
for	O
FN	B
-	O
induced	O
IL	B
-	I
1beta	I
protein	O
production	O
.	O

A	O
novel	O
member	O
of	O
the	O
tumor	B
necrosis	I
factor	I
(	I
TNF	I
)	I
receptor	I
family	I
,	O
designated	O
TRAMP	B
,	O
has	O
been	O
identified	O
.	O

Overexpression	O
of	O
TRAMP	B
leads	O
to	O
two	O
major	O
responses	O
,	O
NF	B
-	I
kappaB	I
activation	O
and	O
apoptosis	O
.	O

Using	O
a	O
nuclear	O
run	O
-	O
on	O
assay	O
,	O
IL	B
-	I
4	I
stimulation	O
was	O
shown	O
to	O
enhance	O
transcription	O
by	O
two	O
-	O
to	O
threefold	O
.	O

Conversely	O
,	O
IL	B
-	I
4	I
and	O
IL	B
-	I
13	I
markedly	O
and	O
significantly	O
inhibited	O
HIV	O
replication	O
at	O
the	O
transcriptional	O
level	O
in	O
monocyte	O
-	O
derived	O
macrophages	O
,	O
and	O
this	O
occurred	O
whether	O
these	O
cytokines	B
were	O
added	O
before	O
or	O
after	O
HIV	O
infection	O
.	O

Interleukin	B
-	I
10	I
(	O
IL	B
-	I
10	I
)	O
protects	O
animals	O
from	O
lethal	O
endotoxemia	O
.	O

Evidence	O
suggests	O
that	O
IL	B
-	I
10	I
may	O
inhibit	O
activation	O
of	O
the	O
transcription	B
factor	I
nuclear	B
factor	I
-	I
kappaB	I
(	O
NF	B
-	I
kappaB	I
)	O
through	O
an	O
unknown	O
mechanism	O
.	O

We	O
hypothesized	O
that	O
IL	B
-	I
10	I
prevents	O
human	O
monocyte	O
NF	B
-	I
kappaB	I
activation	O
and	O
resultant	O
TNF	B
-	I
alpha	I
production	O
by	O
stabilization	O
of	O
IkappaB	B
-	I
alpha	I
.	O

Cells	O
were	O
stimulated	O
with	O
endotoxin	B
(	O
LPS	O
,	O
100	O
ng	O
/	O
mL	O
)	O
with	O
and	O
without	O
human	O
IL	B
-	I
10	I
(	O
10	O
ng	O
/	O
mL	O
)	O
.	O

IL	B
-	I
10	I
attenuated	O
LPS	O
-	O
stimulated	O
TNF	B
-	I
alpha	I
production	O
(	O
297	O
+	O
/	O
-	O
54	O
;	O
p	O
<	O
.	O
001	O
versus	O
LPS	O
alone	O
)	O
.	O

IL	B
-	I
10	I
appears	O
to	O
prevent	O
activation	O
of	O
NF	B
-	I
kappaB	I
by	O
preserving	O
IkappaB	B
-	I
alpha	I
protein	O
levels	O
,	O
leading	O
to	O
a	O
reduction	O
in	O
TNF	B
-	I
alpha	I
release	O
.	O

Down	O
-	O
regulation	O
of	O
human	O
granzyme	B
B	I
expression	O
by	O
glucocorticoids	O
.	O

These	O
results	O
indicate	O
that	O
dexamethasone	O
is	O
able	O
to	O
abrogate	O
the	O
transcriptional	O
activity	O
of	O
the	O
human	B
granzyme	I
B	I
gene	I
promoter	I
by	O
inhibiting	O
the	O
binding	O
of	O
nuclear	B
factors	I
at	O
the	O
AP	B
-	I
1	I
and	I
Ikaros	I
sites	I
.	O

Therefore	O
in	O
this	O
study	O
,	O
we	O
have	O
examined	O
the	O
role	O
of	O
glucocorticoid	B
receptor	I
/	I
s	I
(	O
GR	B
)	O
characteristics	O
in	O
the	O
developing	O
of	O
these	O
abnormalities	O
in	O
patients	O
with	O
PCOS	O
.	O

ngal	O
gene	O
expression	O
was	O
found	O
at	O
moderate	O
levels	O
in	O
only	O
2	O
of	O
17	O
human	O
tissues	O
examined	O
,	O
breast	O
and	O
lung	O
.	O

Immuno	O
-	O
histochemical	O
analysis	O
confirmed	O
the	O
presence	O
of	O
NGAL	B
within	O
breast	O
carcinoma	O
cells	O
but	O
detected	O
only	O
low	O
levels	O
of	O
this	O
protein	O
in	O
normal	O
ductal	O
epithelium	O
.	O

In	O
contrast	O
,	O
a	O
significant	O
correlation	O
between	O
NGAL	B
expression	O
in	O
breast	O
cancer	O
was	O
found	O
with	O
several	O
other	O
markers	O
of	O
poor	O
prognosis	O
,	O
including	O
estrogen	O
and	O
progesterone	B
receptor	I
-	O
negative	O
status	O
and	O
high	O
proliferation	O
(	O
S	O
-	O
phase	O
fraction	O
)	O
.	O

BASH	B
,	O
a	O
novel	B
signaling	I
molecule	I
preferentially	O
expressed	O
in	O
B	O
cells	O
of	O
the	O
bursa	O
of	O
Fabricius	O
.	O

The	O
gene	O
encodes	O
an	O
85	B
-	I
kDa	I
protein	I
,	O
designated	O
BASH	B
(	O
B	B
cell	I
adaptor	I
containing	I
SH2	I
domain	I
)	O
,	O
that	O
contains	O
N	B
-	I
terminal	I
acidic	I
domains	I
with	O
SH2	B
domain	I
-	I
binding	I
phosphotyrosine	I
-	I
based	I
motifs	I
,	O
a	O
proline	B
-	I
rich	I
domain	I
,	O
and	O
a	O
C	B
-	I
terminal	I
SH2	I
domain	I
.	O

These	O
studies	O
revealed	O
that	O
the	O
major	B
protein	I
in	O
extracts	O
of	O
PMN	O
activated	O
by	O
G	B
-	I
CSF	I
to	O
bind	O
the	O
high	B
-	I
affinity	I
serum	I
-	I
inducible	I
element	I
(	O
hSIE	B
)	O
is	O
a	O
72	B
-	I
kDa	I
protein	I
that	O
cross	O
-	O
reacts	O
with	O
Stat3	B
monoclonal	I
antibody	I
,	O
which	O
we	O
have	O
designated	O
Stat3gamma	B
.	O

In	O
order	O
to	O
investigate	O
the	O
factors	O
that	O
influence	O
the	O
induction	O
of	O
ICAM	B
-	I
1	I
molecules	O
,	O
Northern	O
blot	O
analysis	O
to	O
measure	O
the	O
expression	O
level	O
of	O
ICAM	B
-	I
1	I
mRNAs	I
and	O
Southern	O
blot	O
hybridization	O
to	O
analyze	O
the	O
integration	O
of	O
human	O
T	O
-	O
cell	O
-	O
leukemia	O
virus	O
type	O
1	O
(	O
HTLV	O
-	O
1	O
)	O
provirus	O
were	O
done	O
.	O

These	O
sequences	O
were	O
chosen	O
for	O
study	O
because	O
mass	O
-	O
spectrometric	O
analysis	O
(	O
MS	O
)	O
of	O
a	O
CTL	O
active	O
HPLC	O
peptide	O
fraction	O
eluted	O
from	O
immunoaffinity	B
precipitated	I
HLA	I
-	I
A2	I
molecule	I
,	O
revealed	O
:	O
(	O
a	O
)	O
the	O
presence	O
of	O
an	O
ion	O
with	O
a	O
mass	O
-	O
to	O
-	O
charge	O
ratio	O
(	O
m	O
/	O
z	O
)	O
of	O
793	O
which	O
was	O
more	O
abundant	O
than	O
other	O
ions	O
of	O
similar	O
masses	O
;	O
(	O
b	O
)	O
the	O
tentatively	O
reconstituted	O
sequence	O
of	O
the	O
ion	O
793	O
matched	O
the	O
sequence	O
of	O
peptide	O
G76	O
.	O

These	O
concentrations	O
are	O
lower	O
than	O
concentrations	O
reported	O
to	O
activate	O
effector	O
function	O
of	O
CTL	O
recognizing	O
other	O
epithelial	B
tumor	I
Ag	I
.	O

Furthermore	O
,	O
analysis	O
with	O
cloned	O
CD8	O
+	O
T	O
cells	O
indicated	O
that	O
G75	O
and	O
G76	O
were	O
not	O
cross	O
-	O
reactive	O
specificities	O
,	O
suggesting	O
a	O
key	O
role	O
for	O
the	O
N	B
-	I
terminal	I
residues	I
of	O
the	O
variant	O
peptide	O
in	O
dictating	O
specificities	O
.	O

Since	O
the	O
AES	B
proteins	I
are	O
part	O
of	O
a	O
set	O
of	O
transcriptional	O
repressors	O
encoded	O
by	O
the	O
Enhancer	B
of	I
split	I
[	I
E	I
(	I
spl	I
)	I
]	I
genes	I
,	O
and	O
since	O
these	O
repressors	O
are	O
activated	O
to	O
suppress	O
cell	O
differentiation	O
in	O
response	O
to	O
Notch	B
receptors	I
signalling	O
,	O
the	O
AES	O
peptides	O
may	O
represent	O
a	O
novel	O
class	O
of	O
self	B
-	I
antigens	I
that	O
deserve	O
further	O
consideration	O
as	O
tumor	B
Ag	I
in	O
epithelial	O
cancers	O
.	O

Our	O
data	O
show	O
that	O
IFNs	B
and	O
IL	B
-	I
1	I
upregulate	O
PML	O
transcript	O
and	O
protein	O
expression	O
in	O
a	O
time	O
and	O
dose	O
-	O
dependent	O
manner	O
.	O

Glucocorticoid	B
receptors	I
(	O
GR	B
)	O
and	O
3	O
-	O
O	O
-	O
methyl	O
-	O
D	O
glucose	O
(	O
3	O
-	O
O	O
-	O
MG	O
)	O
transport	O
were	O
determined	O
in	O
mononuclear	O
leukocytes	O
(	O
MNL	O
)	O
from	O
11	O
abdominal	O
obese	O
subjects	O
,	O
10	O
pituitary	O
-	O
dependent	O
Cushing	O
'	O
s	O
syndrome	O
(	O
Cushing	O
'	O
s	O
disease	O
)	O
and	O
10	O
healthy	O
controls	O
.	O

Interleukin	B
-	I
10	I
(	O
IL	B
-	I
10	I
)	O
and	O
transforming	B
growth	I
factor	I
beta	I
(	O
TGF	B
-	I
beta	I
)	O
are	O
inhibitory	O
for	O
B	O
and	O
T	O
cells	O
,	O
IgE	B
production	O
,	O
and	O
mast	O
cell	O
proliferation	O
,	O
and	O
they	O
induce	O
apoptosis	O
in	O
eosinophils	O
.	O

The	O
IL	B
-	I
10	I
gene	O
polymorphism	O
was	O
a	O
C	O
-	O
to	O
-	O
A	O
exchange	O
571	B
base	I
pairs	I
upstream	I
from	O
the	O
translation	B
start	I
site	I
and	O
was	O
present	O
between	O
consensus	B
binding	I
sequences	I
for	O
Sp1	B
and	O
elevated	O
total	O
serum	O
.	O

This	O
polymorphism	O
was	O
associated	O
with	O
elevated	O
total	B
serum	I
IgE	I
in	O
subjects	O
heterozygotic	O
or	O
homozygotic	O
for	O
this	O
base	O
exchange	O
(	O
p	O
<	O
0	O
.	O
009	O
)	O
.	O

This	O
polymorphism	O
represented	O
a	O
C	O
-	O
to	O
-	O
T	O
base	O
exchange	O
which	O
induced	O
a	O
YY1	B
consensus	I
sequence	I
and	O
is	O
present	O
in	O
a	O
region	O
of	O
the	O
promoter	O
associated	O
with	O
negative	O
transcription	O
regulation	O
.	O

However	O
,	O
it	O
was	O
only	O
the	O
IL	B
-	I
2	I
promoter	I
whose	O
activation	O
by	O
Tpl	B
-	I
2	I
was	O
fully	O
blocked	O
by	O
the	O
dominant	B
negative	I
mutant	I
MEK1S218	I
/	I
222A	I
and	O
the	O
MEK1	O
/	O
MEK2	O
inhibitor	O
PD098059	O
.	O

Since	O
the	O
protein	O
has	O
a	O
homeodomain	B
and	O
can	O
activate	O
transcription	O
,	O
it	O
probably	O
exerts	O
at	O
least	O
some	O
of	O
its	O
effects	O
in	O
vivo	O
by	O
regulation	O
of	O
target	B
genes	I
.	O

We	O
investigated	O
the	O
function	O
of	O
the	O
evolutionary	O
conserved	O
X2	B
box	I
in	O
the	O
promoter	B
of	O
the	O
HLA	B
-	I
DRA	I
gene	I
from	O
the	O
human	B
major	I
histocompatibility	I
complex	I
(	O
MHC	B
)	O
in	O
resting	O
and	O
activated	O
B	O
cells	O
.	O

Thymocytes	O
control	O
the	O
CD4	B
gene	I
differently	O
from	O
mature	O
T	O
lymphocytes	O
.	O

Glucocorticoids	O
are	O
physiological	O
molecules	O
that	O
are	O
also	O
extensively	O
used	O
in	O
clinics	O
as	O
anti	O
-	O
inflammatory	O
,	O
immunosuppressive	O
or	O
anti	O
-	O
tumoral	O
agents	O
.	O

The	O
action	O
of	O
adenoviral	B
E1A	I
oncoprotein	I
on	O
host	B
immune	I
-	I
response	I
genes	I
has	O
been	O
attributed	O
to	O
interaction	O
with	O
p300	B
/	I
CBP	I
-	I
type	I
transcriptional	I
coactivators	I
in	O
competition	O
with	O
endogenous	B
transcription	I
factors	I
such	O
as	O
signal	B
transducer	I
and	I
activator	I
of	I
transcription	I
(	I
STAT	I
)	I
proteins	I
.	O

Effect	O
of	O
environmental	O
estrogens	O
on	O
IL	B
-	I
1beta	I
promoter	I
activity	O
in	O
a	O
macrophage	O
cell	O
line	O
.	O

17beta	O
-	O
estradiol	O
(	O
E2	O
)	O
markedly	O
enhanced	O
lipopolysaccharide	O
-	O
(	O
LPS	O
)	O
induced	O
IL	B
-	I
1beta	I
promoter	I
-	O
driven	O
CAT	B
activity	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

Unlike	O
the	O
mycoestrogens	O
,	O
none	O
of	O
the	O
compounds	O
,	O
with	O
the	O
exception	O
of	O
genistein	O
,	O
synergized	O
with	O
LPS	O
to	O
enhance	O
IL	B
-	I
1beta	I
promoter	I
activity	O
.	O

Naringenin	O
,	O
a	O
plant	O
flavonoid	O
,	O
showed	O
little	O
or	O
no	O
ability	O
to	O
antagonize	O
the	O
response	O
to	O
E2	O
.	O

Isolation	O
and	O
utilization	O
of	O
human	O
dendritic	O
cells	O
from	O
peripheral	O
blood	O
to	O
assay	O
an	O
in	O
vitro	O
primary	O
immune	O
response	O
to	O
varicella	O
-	O
zoster	O
virus	O
peptides	O
.	O

Here	O
we	O
evaluated	O
whether	O
xenogeneic	O
serum	O
,	O
as	O
a	O
source	O
of	O
xenoreactive	B
natural	I
antibodies	I
and	O
complement	O
,	O
induced	O
endothelial	O
cell	O
activation	O
with	O
consequent	O
leukocyte	O
adhesion	O
under	O
flow	O
conditions	O
.	O

Adherent	O
cells	O
were	O
counted	O
by	O
digital	O
image	O
analysis	O
.	O

In	O
order	O
to	O
elucidate	O
possible	O
mechanisms	O
underlying	O
endothelial	O
cell	O
activation	O
by	O
xenogeneic	O
serum	O
,	O
we	O
focussed	O
on	O
transcription	B
factor	I
NF	I
-	I
kappa	I
B	I
,	O
a	O
central	O
regulator	O
for	O
the	O
induction	O
of	O
different	O
genes	O
,	O
including	O
adhesive	B
molecules	I
and	O
chemoattractants	B
.	O

Anaphylatoxins	B
C5a	B
and	O
C3a	B
induce	O
nuclear	B
factor	I
kappaB	I
activation	O
in	O
human	O
peripheral	O
blood	O
monocytes	O
.	O

These	O
results	O
imply	O
a	O
potential	O
role	O
of	O
the	O
anaphylatoxins	B
C5a	B
and	O
C3a	B
in	O
regulating	O
leukocytes	O
gene	O
expression	O
through	O
G	O
protein	O
-	O
coupled	O
transcription	O
factor	O
activation	O
.	O

Plasma	O
TPO	B
levels	O
are	O
regulated	O
by	O
the	O
platelet	O
and	O
megakaryocyte	O
mass	O
through	O
Mpl	B
receptor	I
binding	O
,	O
internalization	O
and	O
degradation	O
.	O

The	O
Mpl	B
receptor	I
is	O
a	O
member	O
of	O
the	O
hematopoietin	B
receptor	I
superfamily	I
lacking	O
intrinsic	O
kinase	O
activity	O
.	O

Promoter	O
analysis	O
revealed	O
that	O
a	O
GATA	B
site	I
in	O
a	O
cryptic	B
promoter	I
in	O
the	O
second	B
intron	I
was	O
essential	O
and	O
sufficient	O
for	O
the	O
TAL1	O
-	O
and	O
LMO	O
-	O
dependent	O
transcriptional	O
activation	O
,	O
and	O
GATA3	B
binds	O
to	O
this	O
site	O
.	O

Glucocorticoids	O
are	O
important	O
for	O
maintaining	O
cellular	O
and	O
humoral	O
homeostasis	O
and	O
are	O
key	O
mediators	O
of	O
neuroendocrine	O
-	O
immune	O
regulatory	O
interactions	O
.	O

Several	O
neuroendocrine	O
-	O
immune	O
interactions	O
could	O
be	O
responsible	O
for	O
reduced	O
GR	B
levels	O
with	O
age	O
and	O
sport	O
activity	O
in	O
man	O
.	O

Glycation	O
-	O
dependent	O
,	O
reactive	O
oxygen	O
species	O
-	O
mediated	O
suppression	O
of	O
the	O
insulin	O
gene	O
promoter	O
activity	O
in	O
HIT	O
cells	O
.	O

In	O
non	O
-	O
rheumatoid	O
arthritis	O
,	O
binding	O
of	O
NF	B
-	I
kappa	I
B	I
in	O
synovial	O
T	O
cells	O
was	O
exclusively	O
mediated	O
by	O
p50	B
/	I
p50	I
homodimers	I
.	O

X	B
chromosome	I
inactivation	O
patterns	O
in	O
normal	O
females	O
.	O

Since	O
one	O
of	O
the	O
two	O
X	B
chromosomes	I
is	O
randomly	O
inactivated	O
at	O
an	O
early	O
stage	O
of	O
female	O
embryonic	O
development	O
,	O
X	B
-	I
linked	I
markers	I
have	O
been	O
used	O
to	O
study	O
the	O
origin	O
and	O
development	O
of	O
various	O
neoplastic	O
disorders	O
in	O
affected	O
heterozygous	O
women	O
;	O
clonality	O
assays	O
have	O
provided	O
a	O
useful	O
tool	O
to	O
the	O
understanding	O
of	O
the	O
mechanisms	O
underlying	O
the	O
development	O
of	O
neoplasia	O
.	O

Recently	O
,	O
a	O
technique	O
of	O
clonal	O
analysis	O
has	O
been	O
devised	O
that	O
takes	O
advantage	O
of	O
a	O
highly	O
polymorphic	O
short	B
tandem	I
repeat	I
within	O
the	O
X	B
-	I
linked	I
human	I
androgen	I
receptor	I
(	I
AR	I
)	I
gene	I
,	O
resulting	O
in	O
a	O
heterozygosity	O
rate	O
approaching	O
90	O
%	O
.	O

The	O
rapid	O
expansion	O
of	O
the	O
number	O
of	O
women	O
now	O
suitable	O
for	O
X	O
inactivation	O
analysis	O
has	O
however	O
given	O
rise	O
to	O
new	O
controversies	O
,	O
one	O
of	O
the	O
more	O
troublesome	O
being	O
the	O
possibility	O
of	O
a	O
modification	O
of	O
the	O
pattern	O
of	O
X	B
-	I
chromosome	I
inactivation	O
pattern	O
in	O
blood	O
cells	O
of	O
elderly	O
women	O
.	O

In	O
the	O
present	O
study	O
we	O
analyze	O
with	O
the	O
AR	O
assay	O
a	O
group	O
of	O
166	O
healthy	O
females	O
aged	O
between	O
8	O
and	O
94	O
years	O
,	O
with	O
no	O
history	O
of	O
genetic	O
or	O
neoplastic	O
familial	O
disorders	O
.	O

We	O
show	O
here	O
that	O
IFN	B
-	I
alpha	I
/	I
beta	I
act	O
directly	O
on	O
human	O
T	O
cells	O
to	O
drive	O
Th1	O
development	O
,	O
bypassing	O
the	O
need	O
for	O
IL	B
-	I
12	I
-	O
induced	O
signaling	O
,	O
whereas	O
IFN	B
-	I
alpha	I
can	O
not	O
substitute	O
IL	B
-	I
12	I
for	O
mouse	O
Th1	O
development	O
.	O

Unlike	O
IL	B
-	I
12	I
,	O
which	O
acts	O
only	O
on	O
Th1	O
cells	O
,	O
IFN	B
-	I
alpha	I
/	I
beta	I
can	O
activate	O
Stat4	B
not	O
only	O
in	O
human	O
Th1	O
,	O
but	O
also	O
in	O
Th2	O
cells	O
.	O

We	O
have	O
generated	O
antibodies	O
that	O
specifically	O
immunoprecipitated	O
the	O
in	B
-	I
vitro	I
-	I
translated	I
20	I
-	I
kDa	I
protein	I
.	O

The	O
mRNA	O
levels	O
for	O
fkhrl1	B
is	O
elevated	O
in	O
T	O
helper	O
-	O
induced	O
lymphocytes	O
in	O
comparison	O
to	O
PHA	O
-	O
stimulated	O
T	O
lymphocytes	O
.	O

Further	O
characterization	O
of	O
FKHRL1	B
and	O
its	O
related	O
family	O
members	O
should	O
shed	O
light	O
on	O
the	O
transcriptional	O
mechanisms	O
of	O
this	O
fork	B
head	I
gene	I
subfamily	I
and	O
their	O
role	O
in	O
T	O
helper	O
cell	O
differentiation	O
and	O
regulation	O
of	O
cell	O
growth	O
.	O

Inhibition	O
of	O
Th1	O
development	O
mediated	O
by	O
GATA	B
-	I
3	I
through	O
an	O
IL	O
-	O
4	O
-	O
independent	O
mechanism	O
.	O

These	O
motifs	O
are	O
regulatory	B
sequences	I
within	O
the	O
so	O
-	O
called	O
AU	B
-	I
rich	I
elements	I
(	O
AREs	B
)	O
often	O
found	O
in	O
3	B
'	I
untranslated	I
regions	I
of	O
genes	O
such	O
as	O
cytokines	B
,	O
proto	B
-	I
oncogenes	I
,	O
and	O
transcription	B
factors	I
.	O

Copyright	O
1998	O
Academic	O
Press	O
.	O

Transcription	O
factor	O
NF	B
-	I
kappaB	I
regulation	O
of	O
renal	O
fibrosis	O
during	O
ureteral	O
obstruction	O
.	O

Irrespective	O
of	O
the	O
etiology	O
,	O
many	O
kidney	O
diseases	O
result	O
in	O
inflammation	O
and	O
fibrosis	O
of	O
the	O
tubulointerstitium	O
,	O
with	O
the	O
subsequent	O
loss	O
of	O
renal	O
function	O
.	O

The	O
nuclear	B
factor	I
-	I
kappa	I
B	I
(	I
NF	I
-	I
kappaB	I
)	I
family	I
of	O
transcription	B
factors	I
regulates	O
genes	O
involved	O
in	O
inflammation	O
,	O
cell	O
proliferation	O
,	O
and	O
cell	O
differentiation	O
.	O

Morphological	O
studies	O
demonstrated	O
characteristic	O
features	O
of	O
erythroid	O
differentiation	O
and	O
maturation	O
.	O

At	O
the	O
same	O
time	O
there	O
was	O
no	O
change	O
in	O
the	O
level	O
of	O
expression	O
of	O
the	O
cell	B
surface	I
antigenes	I
CD33	B
,	O
CD34	B
,	O
CD45	B
,	O
CD71	B
and	O
glycophorin	B
A	I
.	O

The	O
class	B
II	I
transactivator	I
(	O
CIITA	B
)	O
is	O
essential	O
for	O
the	O
expression	O
of	O
major	B
histocompatibility	I
complex	I
(	I
MHC	I
)	I
class	I
II	I
antigens	I
.	O

In	O
contrast	O
,	O
luciferase	B
expression	O
was	O
not	O
stimulated	O
after	O
IFN	B
-	I
gamma	I
treatment	O
when	O
the	O
construct	O
was	O
transfected	O
in	O
macrophage	O
or	O
in	O
epithelial	O
cell	O
lines	O
.	O

These	O
studies	O
investigate	O
the	O
relationship	O
between	O
leukocyte	O
populations	O
,	O
steroid	B
hormone	I
receptor	I
expression	O
,	O
proliferative	O
activity	O
,	O
bcl	B
-	I
2	I
expression	O
and	O
apoptosis	O
in	O
eutopic	O
and	O
ectopic	O
endometrium	O
from	O
women	O
with	O
endometriosis	O
or	O
adenomyosis	O
at	O
different	O
phases	O
of	O
the	O
menstrual	O
cycle	O
.	O

Here	O
,	O
we	O
demonstrate	O
through	O
the	O
use	O
of	O
intracellular	O
staining	O
that	O
interleukin	B
-	I
1beta	I
(	O
IL	B
-	I
1beta	I
)	O
is	O
expressed	O
in	O
LCLs	O
and	O
investigate	O
the	O
influence	O
of	O
the	O
individual	O
latent	B
proteins	I
on	O
the	O
expression	O
of	O
IL	B
-	I
1beta	I
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSAs	O
)	O
demonstrated	O
that	O
the	O
-	O
300	O
region	O
of	O
the	O
IL	B
-	I
1beta	I
promoter	O
,	O
which	O
contains	O
a	O
nuclear	B
factor	I
-	I
kappaB	I
(	I
NF	I
-	I
kappaB	I
)	I
binding	I
site	I
,	O
contained	O
a	O
functional	B
RBP	I
binding	I
site	I
.	O

CD27	B
/	O
CD70	O
interaction	O
augments	O
IgE	B
secretion	O
by	O
promoting	O
the	O
differentiation	O
of	O
memory	O
B	O
cells	O
into	O
plasma	O
cells	O
.	O

The	O
induction	O
of	O
IgE	B
switching	O
in	O
B	O
cells	O
requires	O
several	O
signals	O
given	O
by	O
cytokines	B
and	O
cell	O
contact	O
-	O
delivered	O
signals	O
.	O

Here	O
,	O
we	O
investigated	O
the	O
role	O
of	O
CD27	B
/	O
CD70	O
interaction	O
in	O
B	O
cell	O
IgE	B
synthesis	O
.	O

The	O
effect	O
of	O
CD70	O
transfectants	O
was	O
dose	O
dependent	O
and	O
was	O
completely	O
blocked	O
by	O
anti	B
-	I
CD70	I
mAb	I
.	I

CD27	B
/	O
CD70	O
interaction	O
enhanced	O
B	O
cell	O
proliferation	O
in	O
the	O
presence	O
of	O
IL	B
-	I
4	I
or	O
IL	B
-	I
4	I
plus	O
anti	B
-	I
CD40	I
.	O

Recent	O
studies	O
,	O
however	O
,	O
demonstrate	O
that	O
the	O
transcribed	O
5	B
'	I
-	I
untranslated	I
leader	I
region	I
(	O
5	B
'	I
-	I
UTR	I
)	O
also	O
contains	O
important	O
transcriptional	B
elements	I
.	O

These	O
regulatory	B
elements	I
situated	O
downstream	O
of	O
transcription	O
interact	O
with	O
constitutive	O
and	O
inducible	O
transcription	B
factors	I
,	O
mediate	O
transmission	O
of	O
cellular	O
activation	O
signals	O
,	O
and	O
are	O
important	O
for	O
efficient	O
HIV	O
-	O
1	O
transcription	O
and	O
replication	O
.	O

Regulation	O
of	O
PAK	O
activation	O
and	O
the	O
T	O
cell	O
cytoskeleton	O
by	O
the	O
linker	B
protein	I
SLP	B
-	I
76	I
.	O

In	O
turn	O
,	O
assembly	O
of	O
this	O
complex	O
mediates	O
the	O
enzymatic	O
activation	O
of	O
the	O
p21	B
-	I
activated	I
protein	I
kinase	I
1	I
and	O
facilitates	O
actin	B
polymerization	O
.	O

Copyright	O
1998	O
Academic	O
Press	O
.	O

LOX	B
-	I
1	I
is	O
an	O
endothelial	B
receptor	I
for	O
oxidized	B
low	I
-	I
density	I
lipoprotein	I
that	O
plays	O
essential	O
roles	O
in	O
atherogenesis	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
cloned	O
and	O
characterized	O
the	O
human	B
LOX	I
-	I
1	I
gene	I
(	O
HGMW	B
-	I
approved	I
symbol	I
OLR1	I
)	O
.	O

In	O
contrast	O
,	O
the	O
expression	O
pattern	O
of	O
LOX	B
-	I
1	I
is	O
different	O
from	O
that	O
of	O
the	O
natural	B
killer	I
cell	I
receptors	I
;	O
LOX	B
-	I
1	I
is	O
expressed	O
in	O
vascular	O
-	O
rich	O
organs	O
,	O
but	O
not	O
in	O
lymphocytes	O
.	O

These	O
results	O
demonstrate	O
that	O
the	O
human	B
LOX	I
-	I
1	I
gene	I
is	O
a	O
new	O
member	O
of	O
the	O
natural	B
killer	I
gene	I
complex	I
with	O
a	O
unique	O
expression	O
profile	O
.	O

In	O
this	O
report	O
,	O
we	O
describe	O
the	O
transcriptional	O
regulation	O
of	O
the	O
beta	B
-	I
casein	I
gene	I
by	O
cytokines	B
in	O
T	O
cells	O
.	O

Coincidentally	O
,	O
a	O
deletion	O
of	O
this	O
region	O
enhanced	O
the	O
IL	B
-	I
2	I
-	O
induced	O
expression	O
of	O
beta	B
-	I
casein	I
.	O

In	O
addition	O
,	O
Ras	B
(	I
G12V	I
)	I
complemented	O
signaling	O
by	O
an	O
erythropoietin	B
receptor	I
mutant	I
defective	O
in	O
Ras	B
activation	O
and	O
augmented	O
the	O
activation	O
of	O
the	O
beta	B
-	I
casein	I
promoter	I
by	O
the	O
mutant	B
erythropoietin	I
receptor	I
signaling	O
,	O
suggesting	O
a	O
possible	O
role	O
of	O
Ras	B
in	O
Stat5	B
-	O
mediated	O
gene	O
expression	O
.	O

GATA	B
-	I
3	I
represses	O
gp91phox	B
gene	I
expression	O
in	O
eosinophil	O
-	O
committed	O
HL	O
-	O
60	O
-	O
C15	O
cells	O
.	O

An	O
81	O
%	O
increment	O
in	O
promoter	O
activity	O
was	O
obtained	O
when	O
a	O
mutation	O
was	O
introduced	O
in	O
the	O
GATA	B
-	I
3	I
binding	I
site	I
of	O
the	O
bp	B
-	I
267	I
to	I
+	I
12	I
construct	I
,	O
which	O
is	O
comparable	O
to	O
that	O
of	O
the	O
bp	B
-	I
245	I
to	I
+	I
12	I
construct	I
.	O

Ligation	O
of	O
CD3	B
also	O
induces	O
the	O
tyrosine	O
phosphorylation	O
of	O
HS1	B
,	O
a	O
75	B
-	I
kDa	I
hematopoietic	I
cell	I
-	I
specific	I
intracellular	I
signaling	I
protein	I
of	O
unknown	O
function	O
.	O

Costimulation	O
through	O
CD28	B
and	O
/	O
or	O
CD2	B
did	O
not	O
modulate	O
the	O
CD3	B
-	O
dependent	O
phosphorylation	O
of	O
HS1	B
.	O

c	O
-	O
fos	O
and	O
c	O
-	O
jun	O
mRNA	O
expression	O
in	O
activated	O
cord	O
and	O
adult	O
lymphocytes	O
:	O
an	O
analysis	O
by	O
Northern	O
hybridization	O
.	O

In	O
addition	O
,	O
Northern	O
blot	O
analysis	O
of	O
cord	O
and	O
adult	O
samples	O
revealed	O
similar	O
maximal	O
increases	O
in	O
c	B
-	I
fos	I
(	O
99	O
+	O
/	O
-	O
15	O
and	O
126	O
+	O
/	O
-	O
11	O
%	O
,	O
p	O
=	O
0	O
.	O
0126	O
)	O
and	O
c	B
-	I
jun	I
(	I
123	I
+	I
/	I
-	I
9	I
and	I
185	I
+	I
/	I
-	I
38	I
%	I
,	I
p	I
=	I
0	I
.	I
0291	I
)	I
mRNA	I
expression	O
,	O
respectively	O
,	O
as	O
early	O
as	O
15	O
min	O
post	O
-	O
alphaCD3	B
stimulation	O
.	O

Receptors	O
for	O
the	O
Fc	B
portion	I
of	O
immunoglobulin	B
molecules	I
(	O
FcR	B
)	O
present	O
on	O
leukocyte	O
cell	O
membranes	O
mediate	O
a	O
large	O
number	O
of	O
cellular	O
responses	O
that	O
are	O
very	O
important	O
in	O
host	O
defense	O
,	O
including	O
phagocytosis	O
,	O
cell	O
cytotoxicity	O
,	O
production	O
and	O
secretion	O
of	O
inflammatory	B
mediators	I
,	O
and	O
modulation	O
of	O
the	O
immune	O
response	O
.	O

Cross	O
-	O
linking	O
of	O
FcR	B
,	O
on	O
the	O
THP	O
-	O
1	O
monocytic	O
cell	O
line	O
,	O
by	O
immune	B
complexes	I
resulted	O
in	O
both	O
activation	O
of	O
the	O
transcription	B
factor	I
NF	B
-	I
kappaB	I
and	O
interleukin	B
1	I
production	O
.	O

BCL	B
-	I
6	I
mutations	O
in	O
normal	O
germinal	O
center	O
B	O
cells	O
:	O
evidence	O
of	O
somatic	O
hypermutation	O
acting	O
outside	O
Ig	B
loci	I
.	O

Thirty	O
percent	O
of	O
GC	O
B	O
cells	O
,	O
but	O
not	O
naive	O
B	O
cells	O
,	O
displayed	O
mutations	O
in	O
the	O
742	B
bp	I
region	I
analyzed	O
within	O
the	O
first	O
intron	O
of	O
BCL	B
-	I
6	I
(	O
overall	O
frequency	O
:	O
5	O
x	O
10	O
(	O
-	O
4	O
)	O
/	O
bp	O
)	O
.	O

The	O
ability	O
of	O
E2A	B
-	I
HLF	I
to	O
prolong	O
the	O
survival	O
of	O
interleukin	O
-	O
3	O
(	O
IL	O
-	O
3	O
)	O
-	O
dependent	O
murine	O
pro	O
-	O
B	O
cells	O
after	O
IL	B
-	I
3	I
withdrawal	O
suggests	O
that	O
it	O
disrupts	O
signaling	O
pathways	O
normally	O
responsible	O
for	O
cell	O
suicide	O
,	O
allowing	O
the	O
cells	O
to	O
accumulate	O
as	O
transformed	O
lymphoblasts	O
.	O

Neither	O
the	O
E12	B
nor	O
the	O
E47	B
product	O
of	O
the	O
E2A	B
gene	I
nor	O
the	O
wild	B
-	I
type	I
HLF	I
protein	I
was	O
able	O
to	O
protect	O
the	O
cells	O
from	O
apoptosis	O
induced	O
by	O
IL	B
-	I
3	I
deprivation	O
.	O

Surprisingly	O
,	O
different	O
combinations	O
of	O
disabling	O
mutations	O
within	O
the	O
HLF	B
bZIP	I
domain	I
had	O
little	O
effect	O
on	O
the	O
antiapoptotic	O
property	O
of	O
the	O
chimeric	B
protein	I
,	O
so	O
long	O
as	O
the	O
amino	O
-	O
terminal	O
portion	O
of	O
E2A	B
remained	O
intact	O
.	O

These	O
results	O
suggest	O
that	O
1	O
)	O
lipid	O
A	O
myristoyl	O
fatty	O
acid	O
,	O
although	O
it	O
is	O
important	O
for	O
the	O
induction	O
of	O
inflammatory	B
cytokine	I
production	O
by	O
human	O
monocytes	O
,	O
is	O
not	O
necessary	O
for	O
the	O
induction	O
of	O
Mn	B
SOD	I
,	O
2	O
)	O
endotoxin	B
-	O
mediated	O
induction	O
of	O
Mn	B
SOD	I
and	O
inflammatory	O
cytokines	B
are	O
regulated	O
,	O
at	O
least	O
in	O
part	O
,	O
through	O
different	O
signal	O
transduction	O
pathways	O
,	O
and	O
3	O
)	O
failure	O
of	O
the	O
mutant	B
endotoxin	I
to	O
induce	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
production	O
is	O
,	O
at	O
least	O
in	O
part	O
,	O
due	O
to	O
its	O
inability	O
to	O
activate	O
mitogen	B
-	I
activated	I
protein	I
kinase	I
.	O

Characterization	O
of	O
cytokine	B
differential	O
induction	O
of	O
STAT	B
complexes	I
in	O
primary	O
human	O
T	O
and	O
NK	O
cells	O
.	O

Finally	O
,	O
we	O
observed	O
that	O
activated	O
STAT5a	B
and	O
STAT5b	B
proteins	O
form	O
distinct	O
Fc	O
gamma	O
RI	O
GAS	O
binding	O
patterns	O
in	O
T	O
and	O
NK	O
cells	O
,	O
suggesting	O
that	O
they	O
might	O
have	O
different	O
roles	O
in	O
gene	O
regulation	O
.	O

A	O
regulatory	B
element	I
in	O
the	O
CD95	B
(	I
APO	I
-	I
1	I
/	I
Fas	I
)	I
ligand	I
promoter	I
is	O
essential	O
for	O
responsiveness	O
to	O
TCR	B
-	O
mediated	O
activation	O
.	O

The	O
DNA	O
sequence	O
at	O
-	B
120	I
also	O
contains	O
two	O
DNA	B
motifs	I
homologous	O
to	O
the	O
binding	O
site	O
for	O
NF	B
-	I
AT	I
.	O

NF	B
-	I
AT	I
does	O
not	O
directly	O
bind	O
to	O
this	O
element	O
.	O

Progesterone	O
acts	O
distally	O
to	O
the	O
initial	O
steps	O
of	O
T	B
cell	I
receptor	I
(	O
TCR	B
)	O
-	O
mediated	O
signal	O
transduction	O
,	O
since	O
it	O
blocks	O
sustained	O
Ca2	O
+	O
signals	O
after	O
thapsigargin	O
stimulation	O
,	O
as	O
well	O
as	O
oscillatory	O
Ca2	O
+	O
signals	O
,	O
but	O
not	O
the	O
Ca2	O
+	O
transient	O
after	O
TCR	B
stimulation	O
.	O

Progesterone	O
effectively	O
blocked	O
a	O
broad	O
spectrum	O
of	O
K	B
+	I
channels	I
,	O
reducing	O
both	O
Kv1	B
.	I
3	I
and	O
charybdotoxin	B
-	I
resistant	I
components	I
of	O
KV	B
current	O
and	O
KCa	B
current	O
in	O
T	O
cells	O
,	O
as	O
well	O
as	O
blocking	O
several	O
cloned	B
KV	I
channels	I
expressed	O
in	O
cell	O
lines	O
.	O

A	O
mouse	O
carrying	O
genetic	O
defect	O
in	O
the	O
choice	O
between	O
T	O
and	O
B	O
lymphocytes	O
.	O

The	O
present	O
study	O
shows	O
that	O
,	O
instead	O
of	O
T	O
cells	O
,	O
B	O
cells	O
are	O
generated	O
in	O
the	O
thymus	O
of	O
a	O
line	O
,	O
tg	O
epsilon26	O
,	O
of	O
the	O
human	O
CD3epsilon	O
transgenic	O
mice	O
.	O

The	O
accumulation	O
of	O
mature	O
B	O
cells	O
in	O
the	O
thymus	O
was	O
found	O
only	O
in	O
tg	O
epsilon26	O
mice	O
,	O
not	O
in	O
other	O
human	O
CD3epsilon	O
transgenic	O
mouse	O
lines	O
or	O
other	O
T	O
cell	O
-	O
deficient	O
mice	O
,	O
including	O
CD3	O
-	O
epsilon	O
knockout	O
mice	O
and	O
TCR	O
-	O
beta	O
/	O
TCR	O
-	O
delta	O
double	O
knockout	O
mice	O
.	O

The	O
chemokine	B
receptor	I
,	O
BLR1	B
,	O
is	O
a	O
major	O
regulator	O
of	O
the	O
microenvironmental	O
homing	O
of	O
B	O
cells	O
in	O
lymphoid	O
organs	O
.	O

Activation	O
of	O
the	O
CD4	B
promoter	I
occurs	O
in	O
the	O
presence	O
of	O
the	O
viral	O
DNA	O
polymerase	O
inhibitor	O
phosphonoformic	O
acid	O
,	O
which	O
limits	O
expression	O
to	O
the	O
immediate	B
-	I
early	I
and	I
early	I
classes	I
of	I
viral	I
genes	I
.	O

Both	O
Tax	B
-	O
mediated	O
apoptosis	O
and	O
oxidative	O
stress	O
can	O
be	O
potently	O
suppressed	O
by	O
antioxidants	O
,	O
as	O
is	O
seen	O
with	O
the	O
administration	O
of	O
recombinant	B
thioredoxin	I
(	O
adult	B
T	I
cell	I
leukemia	I
-	I
derived	I
factor	I
)	O
or	O
pyrrolidine	O
dithiocarbamate	O
.	O

The	O
efficacy	O
of	O
o	O
,	O
o	O
'	O
-	O
bismyristoyl	O
thiamine	O
disulfide	O
(	O
BMT	O
)	O
was	O
examined	O
in	O
detail	O
against	O
HIV	O
-	O
1	O
laboratory	O
isolates	O
(	O
HTLV	O
-	O
IIIB	O
,	O
JRFL	O
,	O
and	O
MN	O
)	O
,	O
primary	O
isolates	O
(	O
KMT	O
and	O
KMO	O
)	O
,	O
and	O
simian	O
immunodeficiency	O
virus	O
(	O
SIVmac251	O
)	O
in	O
vitro	O
.	O

In	O
addition	O
,	O
BMT	O
exhibited	O
antiviral	O
activity	O
against	O
SIVmac251	O
.	O

Minimizing	O
energy	O
studies	O
of	O
BMT	O
structure	O
reveal	O
that	O
a	O
trans	O
-	O
disulfide	O
of	O
thiamine	O
(	O
holo	O
drug	O
)	O
disulfide	O
(	O
TDS	O
,	O
protodrug	O
)	O
is	O
allosterically	O
transited	O
to	O
the	O
reactive	O
twisted	O
disulfide	O
of	O
BMT	O
(	O
allo	O
drug	O
)	O
by	O
o	O
,	O
o	O
'	O
-	O
bismyristoyl	O
esterification	O
of	O
TDS	O
.	O

Nor	O
was	O
fragmentation	O
observed	O
after	O
treatment	O
with	O
RU38486	O
,	O
indicating	O
that	O
repression	O
of	O
AP	B
-	I
1	I
activity	O
is	O
not	O
involved	O
.	O

Dexamethasone	O
treatment	O
completely	O
blocked	O
12	O
-	O
O	O
-	O
tetradecanoylphorbol	O
13	O
-	O
acetate	O
induction	O
of	O
nuclear	B
factor	I
-	I
kappaB	I
(	O
NF	B
-	I
kappaB	I
)	O
activity	O
and	O
elicited	O
an	O
increase	O
in	O
the	O
amount	O
of	O
immunoreactive	B
IkappaB	I
alpha	I
in	O
sensitive	O
6TG1	O
.	O
1	O
cells	O
but	O
not	O
in	O
resistant	O
ICR27TK	O
.	O
3	O
cells	O
.	O

It	O
was	O
proposed	O
that	O
the	O
mechanism	O
of	O
antiviral	O
action	O
of	O
S9a	O
was	O
on	O
the	O
host	O
cell	O
,	O
by	O
blocking	O
TNF	B
-	I
alpha	I
transcription	O
via	O
a	O
Tat	B
-	O
induced	O
tar	O
-	O
independent	O
loop	O
,	O
which	O
decreases	O
downstream	O
NF	B
-	I
kappaB	I
activation	O
of	O
HIV	B
-	I
1	I
long	I
terminal	I
repeat	I
(	O
LTR	B
)	O
.	O

S9a	O
was	O
superior	O
to	O
the	O
first	O
generation	O
compound	O
Canventol	O
,	O
which	O
was	O
superior	O
to	O
the	O
natural	O
compound	O
sarcophytol	O
A	O
,	O
demonstrating	O
that	O
further	O
structure	O
-	O
based	O
enhancement	O
of	O
potency	O
of	O
these	O
compounds	O
is	O
feasible	O
.	O

Intestinal	O
epithelial	O
cells	O
can	O
express	O
HLA	B
class	I
II	I
antigens	I
and	O
may	O
function	O
as	O
antigen	O
-	O
presenting	O
cells	O
to	O
CD4	O
(	O
+	O
)	O
T	O
cells	O
within	O
the	O
intestinal	O
mucosa	O
.	O

These	O
data	O
indicate	O
a	O
highly	O
polarized	O
functional	O
architecture	O
for	O
antigen	O
processing	O
and	O
presentation	O
by	O
intestinal	O
epithelial	O
cells	O
,	O
and	O
suggest	O
that	O
the	O
functional	O
outcome	O
of	O
antigen	O
processing	O
by	O
the	O
intestinal	O
epithelium	O
is	O
both	O
dependent	O
on	O
the	O
cellular	O
surface	O
at	O
which	O
the	O
foreign	O
antigen	O
is	O
internalized	O
and	O
by	O
the	O
underlying	O
degree	O
of	O
mucosal	O
inflammation	O

We	O
determined	O
whether	O
Hsp70	B
induction	O
by	O
TS	O
was	O
mediated	O
by	O
the	O
activation	O
of	O
the	O
HS	B
transcription	I
factor	I
,	O
HSF	B
.	O

Thus	O
,	O
we	O
also	O
determined	O
the	O
effects	O
of	O
TS	O
on	O
NFkappaB	B
.	O

TS	O
activated	O
HSF	B
,	O
which	O
was	O
associated	O
with	O
Hsp70	B
overexpression	O
and	O
inhibition	O
of	O
NFkappaB	B
binding	O
activity	O
and	O
TNFalpha	B
release	O
.	O

[	O
Molecular	O
mechanism	O
of	O
cytokine	B
gene	I
expression	O
in	O
Th1	O
and	O
Th2	O
]	O

Among	O
them	O
,	O
both	O
the	O
activation	O
of	O
PKC	O
/	O
Ras	O
-	O
and	O
CaM	O
/	O
CN	O
-	O
mediated	O
pathways	O
play	O
a	O
central	O
role	O
in	O
the	O
signal	O
transduction	O
of	O
cytokine	B
gene	I
expression	O
.	O

Activation	O
of	O
T	O
cells	O
results	O
in	O
the	O
rapid	O
calcineurin	B
-	O
dependent	O
translocation	O
of	O
NFAT	B
transcription	B
factors	I
from	O
the	O
cytoplasm	O
to	O
the	O
nucleus	O
.	O

Replication	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
-	O
1	O
(	O
HIV	O
-	O
1	O
)	O
is	O
highly	O
dependent	O
on	O
the	O
state	O
of	O
activation	O
of	O
the	O
infected	O
cells	O
and	O
is	O
modulated	O
by	O
interactions	O
between	O
viral	B
and	I
host	I
cellular	I
factors	I
.	O

These	O
results	O
suggest	O
that	O
secretion	O
of	O
PGE2	O
by	O
macrophages	O
in	O
response	O
to	O
infection	O
or	O
inflammatory	O
activators	O
could	O
induce	O
signaling	O
events	O
resulting	O
in	O
activation	O
of	O
proviral	O
DNA	O
present	O
into	O
T	O
cells	O
latently	O
infected	O
with	O
HIV	O
-	O
1	O
.	O

Unexpectedly	O
,	O
we	O
found	O
that	O
conventional	O
procedures	O
employed	O
to	O
prepare	O
cellular	O
extracts	O
cause	O
the	O
release	O
of	O
proteolytic	O
activities	O
that	O
are	O
normally	O
stored	O
in	O
intracellular	O
granules	O
,	O
resulting	O
in	O
the	O
degradation	O
of	O
various	O
NF	B
-	I
kappaB	I
/	I
Rel	I
and	O
STAT	B
proteins	I
.	O

In	O
addition	O
,	O
the	O
procedure	O
described	O
herein	O
could	O
prove	O
useful	O
in	O
other	O
cell	O
types	O
that	O
express	O
high	O
levels	O
of	O
endogenous	B
proteases	I
.	O

The	O
capacity	O
of	O
neonatal	O
T	O
cells	O
to	O
secrete	O
interleukin	B
-	I
2	I
(	O
IL	B
-	I
2	I
)	O
has	O
been	O
reported	O
to	O
be	O
variable	O
.	O

PDBu	O
+	O
iono	O
induced	O
equally	O
high	O
IL	B
-	I
2	I
levels	O
in	O
both	O
groups	O
and	O
,	O
when	O
stimulated	O
with	O
plate	O
-	O
bound	O
anti	B
-	I
CD3	I
monoclonal	I
antibody	I
(	O
mAb	B
)	O
,	O
the	O
IL	B
-	I
2	I
secretion	O
by	O
neonatal	O
cells	O
was	O
undetectable	O
and	O
adult	O
cells	O
produced	O
low	O
amounts	O
of	O
IL	B
-	I
2	I
(	O
mean	O
331	O
+	O
/	O
-	O
86	O
pg	O
/	O
ml	O
)	O
.	O

As	O
NF	B
-	I
kappa	I
B	I
is	O
a	O
critical	O
transcription	B
factor	I
in	O
the	O
control	O
of	O
IL	B
-	I
2	I
expression	O
,	O
we	O
next	O
analysed	O
its	O
nuclear	O
translocation	O
in	O
neonatal	O
and	O
adult	O
T	O
cells	O
using	O
the	O
electrophoretic	O
mobility	O
shift	O
assay	O
and	O
,	O
because	O
induction	O
of	O
reactive	O
oxygen	O
intermediates	O
(	O
ROI	O
)	O
is	O
required	O
for	O
the	O
activation	O
of	O
NF	B
-	I
kappa	I
B	I
,	O
we	O
also	O
analysed	O
levels	O
of	O
intracellular	O
ROI	O
in	O
these	O
cells	O
using	O
the	O
ROI	O
-	O
reactive	O
fluorochrome	O
DCFH	O
-	O
DA	O
and	O
flow	O
cytometry	O
.	O

Our	O
results	O
suggest	O
that	O
reduced	O
IL	B
-	I
2	I
production	O
by	O
neonatal	O
T	O
cells	O
is	O
specific	O
for	O
anti	B
-	I
CD3	I
and	O
anti	B
-	I
CD3	I
+	O
anti	B
-	I
CD28	I
-	O
mediated	O
stimulation	O
and	O
that	O
these	O
activators	O
can	O
not	O
effectively	O
activate	O
the	O
ROI	O
-	B
NF	I
-	I
kappa	I
B	I
signalling	O
pathway	O
in	O
neonatal	O
T	O
cells	O
.	O

CL	O
-	O
01	O
cells	O
are	O
IgM	B
+	O
IgD	B
+	O
CD30	B
+	O
and	O
switch	O
to	O
IgG	B
,	O
IgA	B
,	O
and	O
IgE	B
when	O
exposed	O
to	O
CD40L	B
and	O
IL	B
-	I
4	I
.	O

Switching	O
is	O
hampered	O
by	O
CD30	B
coengagement	O
,	O
possibly	O
through	O
interference	O
with	O
the	O
CD40	B
-	O
mediated	O
NF	B
-	I
kappaB	I
-	O
dependent	O
transcriptional	O
activation	O
of	O
downstream	B
C	I
(	I
H	I
)	I
genes	I
.	O

Are	O
there	O
effects	O
of	O
CyA	O
and	O
FK	O
506	O
all	O
attributable	O
to	O
CN	O
inhibition	O
,	O
and	O
how	O
much	O
of	O
them	O
are	O
mediated	O
through	O
the	O
NFATC	B
family	I
of	O
transcription	B
factors	I
?	O

To	O
investigate	O
processes	O
related	O
to	O
B	O
and	O
T	O
cell	O
activation	O
,	O
the	O
gene	O
expression	O
of	O
stimulated	O
and	O
nonstimulated	O
Ramos	O
and	O
Jurkat	O
cells	O
was	O
studied	O
using	O
cDNA	O
microarray	O
technology	O
.	O

Simultaneous	O
analysis	O
of	O
close	O
to	O
600	B
genes	I
indicated	O
highest	O
increase	O
in	O
the	O
expression	O
of	O
certain	O
transcription	B
,	I
differentiation	I
and	I
proliferation	I
factors	I
.	O

Also	O
genes	O
encoding	O
proteins	O
involved	O
in	O
DNA	O
replication	O
,	O
binding	O
,	O
transcription	O
and	O
translation	O
were	O
induced	O
.	O

Signal	B
transducer	I
and	I
activator	I
of	I
transcription	I
3	I
(	O
Stat3	B
)	O
has	O
recently	O
been	O
shown	O
to	O
exist	O
in	O
two	O
alternatively	O
spliced	O
isoforms	O
,	O
a	O
short	O
form	O
,	O
Stat3beta	B
,	O
and	O
a	O
longer	O
form	O
,	O
Stat3alpha	B
,	O
displaying	O
differences	O
in	O
transcriptional	O
activity	O
.	O

It	O
is	O
unknown	O
which	O
Stat3	B
isoform	I
(	O
s	O
)	O
is	O
activated	O
in	O
response	O
to	O
interleukin	B
(	I
IL	I
)	I
-	I
2	I
and	O
IL	B
-	I
15	I
.	O

It	O
is	O
shown	O
here	O
that	O
during	O
monocyte	O
to	O
macrophage	O
differentiation	O
,	O
the	O
expression	O
of	O
LAL	B
-	I
mRNA	I
is	O
induced	O
.	O

Relationship	O
between	O
IkappaBalpha	B
constitutive	O
expression	O
,	O
TNFalpha	B
synthesis	O
,	O
and	O
apoptosis	O
in	O
EBV	O
-	O
infected	O
lymphoblastoid	O
cells	O
.	O

In	O
order	O
to	O
understand	O
the	O
role	O
of	O
NF	B
-	I
kappaB	I
in	O
EBV	O
transformation	O
we	O
have	O
established	O
stably	O
transfected	O
IkappaBalpha	B
into	O
lymphoblastoid	O
cells	O
.	O

Protein	O
latency	O
expression	O
was	O
determined	O
by	O
immunocytochemistry	O
.	O

Our	O
results	O
suggest	O
that	O
the	O
TNFalpha	B
gene	I
could	O
be	O
one	O
of	O
the	O
targets	O
of	O
NF	B
-	I
kappaB	I
in	O
EBV	O
infected	O
cells	O
and	O
that	O
NF	O
-	O
kappaB	O
protects	O
EBV	O
-	O
infected	O
cells	O
from	O
apoptosis	O
induced	O
by	O
TNFalpha	B
,	O
which	O
may	O
favour	O
the	O
proliferative	O
effect	O
of	O
this	O
cytokine	B
.	O

We	O
report	O
an	O
unusual	O
case	O
of	O
a	O
55	O
year	O
old	O
Japanese	O
woman	O
with	O
a	O
seminoma	O
but	O
relatively	O
normal	O
menses	O
.	O

A	O
typical	O
seminoma	O
was	O
removed	O
from	O
the	O
left	O
adnexal	O
region	O
and	O
an	O
immature	O
testis	O
was	O
identified	O
separately	O
as	O
an	O
associated	O
right	O
adnexal	O
mass	O
.	O

Repeated	O
karyotypic	O
studies	O
on	O
peripheral	O
blood	O
lymphocyte	O
cultures	O
showed	O
only	O
46	O
,	O
X	O
,	O
-	O
Y	O
,	O
t	O
(	O
Y	O
;	O
15	O
)	O
(	O
q12	O
;	O
p13	O
)	O
.	O

Two	O
chronically	O
HIV	O
-	O
1	O
-	O
infected	O
cell	O
lines	O
,	O
U1	O
(	O
monocytic	O
)	O
and	O
ACH	O
-	O
2	O
(	O
T	O
lymphocytic	O
)	O
,	O
were	O
stimulated	O
with	O
TNF	B
-	I
alpha	I
or	O
PMA	O
and	O
cultured	O
in	O
the	O
presence	O
of	O
various	O
concentrations	O
of	O
the	O
compound	O
.	O

Its	O
50	O
%	O
effective	O
and	O
cytotoxic	O
concentrations	O
were	O
0	O
.	O
016	O
and	O
2	O
.	O
2	O
microg	O
/	O
ml	O
in	O
PMA	O
-	O
stimulated	O
U1	O
cells	O
,	O
respectively	O
.	O

These	O
results	O
indicate	O
that	O
cepharanthine	O
is	O
a	O
highly	O
potent	O
inhibitor	O
of	O
HIV	O
-	O
1	O
replication	O
in	O
a	O
chronically	O
infected	O
monocytic	O
cell	O
line	O
.	O

This	O
study	O
shows	O
that	O
expression	O
of	O
LMP1	B
activates	O
transcription	O
from	O
p50	B
/	I
p65	I
-	I
and	I
c	I
-	I
Rel	I
-	I
responsive	I
promoters	I
,	O
and	O
that	O
this	O
activity	O
can	O
be	O
completely	O
inhibited	O
by	O
expression	O
of	O
a	O
dominant	O
inhibitory	B
IkappaB	I
mutant	I
.	O

Furthermore	O
,	O
LMP1	B
-	O
induced	O
cell	O
size	O
increase	O
of	O
primary	O
B	O
cells	O
was	O
unaffected	O
by	O
IkappaB	B
expression	O
.	O

When	O
cultured	O
in	O
RPMI	O
1640	O
medium	O
containing	O
10	O
%	O
fetal	O
bovine	O
serum	O
,	O
most	O
YJ	O
cells	O
were	O
myeloblastoid	O
with	O
a	O
small	O
number	O
of	O
the	O
cells	O
having	O
eosinophilic	O
granules	O
.	O

The	O
eosinophilic	O
characteristics	O
of	O
YJ	O
cells	O
were	O
confirmed	O
by	O
histochemical	O
staining	O
with	O
Fast	O
-	O
Green	O
/	O
Neutral	O
-	O
Red	O
and	O
by	O
the	O
expression	O
of	O
mRNAs	B
for	O
eosinophil	B
-	I
associated	I
granule	I
proteins	I
,	O
eosinophil	B
cationic	I
protein	I
(	O
ECP	B
)	O
,	O
eosinophil	B
-	I
derived	I
neurotoxin	I
(	O
EDN	B
)	O
,	O
eosinophil	B
peroxidase	I
(	O
EPO	B
)	O
,	O
and	O
major	B
basic	I
protein	I
(	O
MBP	B
)	O
,	O
and	O
for	O
the	O
Charcot	B
-	I
Leyden	I
crystal	I
(	I
CLC	I
)	I
protein	I
.	O

The	O
expression	O
of	O
genes	O
for	O
transcription	B
factors	I
involved	O
in	O
myeloid	O
differentiation	O
was	O
evaluated	O
by	O
Northern	O
blot	O
analysis	O
.	O

The	O
YJ	O
cell	O
line	O
should	O
be	O
useful	O
for	O
elucidating	O
the	O
molecular	O
mechanisms	O
governing	O
lineage	O
switching	O
from	O
the	O
eosinophil	O
to	O
monocytic	O
or	O
neutrophil	O
lineages	O
.	O

To	O
examine	O
the	O
hypothesis	O
that	O
interleukin	B
-	I
6	I
(	O
IL	B
-	I
6	I
)	O
contributes	O
to	O
PMN	O
infiltration	O
and	O
lung	O
damage	O
in	O
HS	O
,	O
we	O
examined	O
the	O
lungs	O
of	O
rats	O
subjected	O
to	O
unresuscitated	O
and	O
resuscitated	O
HS	O
for	O
the	O
production	O
of	O
IL	B
-	I
6	I
and	O
activation	O
of	O
Stat3	B
.	O

Electrophoretic	O
mobility	O
shift	O
assay	O
of	O
protein	O
extracts	O
from	O
shock	O
lungs	O
exhibited	O
an	O
increase	O
in	O
Stat3	B
activation	O
with	O
kinetics	O
similar	O
to	O
IL	B
-	I
6	I
mRNA	I
.	O

The	O
MHC	B
class	I
II	I
transactivator	I
(	O
CIITA	B
)	O
requires	O
conserved	O
leucine	B
charged	I
domains	I
for	O
interactions	O
with	O
the	O
conserved	O
W	B
box	I
promoter	I
element	I
.	O

The	O
ability	O
of	O
mutants	O
to	O
activate	O
a	O
reporter	O
gene	O
under	O
the	O
control	O
of	O
MHC	B
class	I
II	I
conserved	O
W	B
-	I
X	I
-	I
Y	I
or	I
X	I
-	I
Y	I
regulatory	I
elements	I
was	O
determined	O
.	O

Two	O
mutants	O
displayed	O
differential	O
activity	O
between	O
the	O
two	O
promoters	B
,	O
activating	O
transcription	O
with	O
the	O
W	B
-	I
X	I
-	I
Y	I
but	I
not	I
the	I
X	I
-	I
Y	I
elements	I
.	O

All	O
mutants	O
were	O
tested	O
for	O
their	O
ability	O
to	O
interfere	O
with	O
wild	O
-	O
type	O
CIITA	B
activity	O
.	O

The	O
characterization	O
of	O
CIITA	B
mutants	I
that	O
are	O
able	O
to	O
discriminate	O
between	O
promoters	O
with	O
or	O
without	O
the	O
W	B
box	I
strongly	O
suggests	O
that	O
CIITA	B
requires	O
such	O
interactions	O
for	O
function	O
.	O

Recently	O
,	O
it	O
was	O
suggested	O
that	O
activation	O
of	O
the	O
alpha	B
isoform	I
of	O
PPAR	B
by	O
the	O
potent	O
proinflammatory	O
mediator	O
leukotriene	O
B4	O
(	O
LTB4	O
)	O
enhanced	O
degradation	O
of	O
this	O
eicosanoid	O
,	O
offersuggesting	O
a	O
new	O
aspect	O
of	O
down	O
-	O
regulation	O
of	O
inflammation	O
.	O

Thus	O
,	O
this	O
study	O
provides	O
no	O
evidence	O
indicating	O
a	O
regulatory	O
function	O
of	O
PPARalpha	B
in	O
LTB4	O
induced	O
adhesive	O
interactions	O
between	O
endothelial	O
cells	O
and	O
neutrophils	O

We	O
determined	O
whether	O
the	O
interaction	O
of	O
SS	O
RBC	O
with	O
cultured	O
endothelial	O
cells	O
induced	O
cellular	O
oxidant	O
stress	O
that	O
would	O
culminate	O
in	O
expression	O
of	O
cell	B
adhesion	I
molecules	I
(	O
CAMs	B
)	O
involved	O
in	O
the	O
adhesion	O
and	O
diapedesis	O
of	O
monocytes	O
and	O
the	O
adherence	O
of	O
SS	O
reticulocytes	O
.	O

These	O
results	O
suggest	O
that	O
the	O
adherence	O
/	O
contact	O
of	O
SS	O
RBC	O
to	O
endothelial	O
cells	O
in	O
large	O
vessel	O
can	O
generate	O
enhanced	O
oxidant	O
stress	O
leading	O
to	O
increased	O
adhesion	O
and	O
diapedesis	O
of	O
monocytes	O
,	O
as	O
well	O
as	O
heightened	O
adherence	O
of	O
SS	O
reticulocytes	O
,	O
indicating	O
that	O
injury	O
/	O
activation	O
of	O
endothelium	O
can	O
contribute	O
to	O
vaso	O
-	O
occlusion	O
in	O
SCD	O
.	O

Relative	O
levels	O
were	O
then	O
correlated	O
with	O
a	O
series	O
of	O
clinical	O
variables	O
including	O
response	O
to	O
therapy	O
,	O
performance	O
status	O
,	O
survival	O
,	O
disease	O
sites	O
,	O
age	O
,	O
and	O
others	O
.	O

Changes	O
in	O
these	O
signaling	O
molecules	O
during	O
cytokine	B
treatment	O
were	O
also	O
investigated	O
.	O

Correlations	O
of	O
TCRzeta	B
or	O
p56	B
(	I
lck	I
)	I
levels	O
with	O
response	O
or	O
disease	O
variables	O
,	O
except	O
for	O
lower	O
TCRzeta	B
levels	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
in	O
the	O
presence	O
of	O
bone	O
metastases	O
,	O
were	O
not	O
found	O
.	O

In	O
the	O
majority	O
of	O
patients	O
with	O
advanced	O
RCC	O
,	O
peripheral	O
blood	O
T	O
cells	O
express	O
TCRzeta	B
and	O
p56	B
(	I
lck	I
)	I
,	O
and	O
in	O
a	O
subset	O
,	O
reduced	O
levels	O
of	O
these	O
TCRzeta	B
associated	I
molecules	I
are	O
seen	O
that	O
may	O
increase	O
during	O
cytokine	B
-	O
based	O
therapy	O
.	O

Identification	O
of	O
transcription	B
factors	I
expressed	O
during	O
ATRA	O
-	O
induced	O
neutrophil	O
differentiation	O
of	O
HL60	O
cells	O
.	O

In	O
order	O
to	O
understand	O
this	O
block	O
the	O
cascade	O
of	O
molecular	O
events	O
needs	O
to	O
be	O
characterized	O
.	O

CD38	O
+	O
cells	O
committed	O
towards	O
this	O
lineage	O
were	O
enriched	O
and	O
a	O
population	O
of	O
these	O
cells	O
treated	O
with	O
dihydroxyvitamin	O
D3	O
to	O
induce	O
neutrophil	O
maturation	O
.	O

The	O
differential	O
expression	O
of	O
the	O
genes	O
in	O
the	O
zinc	B
finger	I
and	I
POU	I
families	I
will	O
lead	O
to	O
a	O
better	O
understanding	O
of	O
the	O
cascade	O
of	O
gene	O
expression	O
which	O
occurs	O
following	O
ATRA	O
-	O
induced	O
differentiation	O
.	O

Interleukin	B
-	I
4	I
and	I
-	I
13	I
induce	O
upregulation	O
of	O
the	O
murine	O
macrophage	O
12	B
/	I
15	I
-	I
lipoxygenase	I
activity	I
:	O
evidence	O
for	O
the	O
involvement	O
of	O
transcription	B
factor	I
STAT6	B
.	O

Moreover	O
,	O
a	O
strong	O
induction	O
of	O
the	O
enzyme	O
was	O
observed	O
in	O
red	O
cells	O
during	O
experimental	O
anemia	O
in	O
mice	O
.	O

The	O
cytokine	B
-	O
dependent	O
upregulation	O
of	O
the	O
murine	B
macrophage	I
12	I
-	I
lipoxygenase	I
and	O
its	O
induction	O
during	O
experimental	O
anemia	O
suggests	O
its	O
close	O
relatedness	O
with	O
the	O
human	B
reticulocyte	I
-	I
type	I
15	I
-	I
lipoxygenase	I
despite	O
their	O
differences	O
in	O
the	O
positional	O
specificity	O
of	O
arachidonic	O
acid	O
oxygenation	O
.	O

Interferon	B
-	I
gamma	I
-	I
induced	I
factor	I
binding	O
to	O
the	O
interleukin	B
-	I
4	I
-	I
responsive	I
element	I
of	O
CD23b	B
promoter	I
in	O
human	O
tonsillar	O
mononuclear	O
cells	O
:	O
role	O
in	O
transient	O
up	O
-	O
regulation	O
of	O
the	O
interleukin	B
-	I
4	I
-	I
induced	I
CD23b	I
mRNA	I
.	O

Activation	O
of	O
E2F	B
-	O
mediated	O
transcription	O
by	O
human	B
T	I
-	I
cell	I
leukemia	I
virus	I
type	I
I	I
Tax	I
protein	I
in	O
a	O
p16	O
(	O
INK4A	O
)	O
-	O
negative	O
T	O
-	O
cell	O
line	O
.	O

Consequently	O
,	O
Tax	B
can	O
activate	O
the	O
signaling	O
pathway	O
that	O
lead	O
to	O
the	O
release	O
of	O
E2F	B
that	O
in	O
turn	O
induces	O
expression	O
of	O
factors	O
required	O
for	O
cell	O
cycle	O
progression	O
.	O

In	O
addition	O
,	O
Tax	B
also	O
stimulates	O
the	O
transcription	O
of	O
the	O
E2F	B
-	I
1	I
gene	I
itself	O
.	O

Inducible	O
nitric	O
oxide	O
:	O
an	O
autoregulatory	O
feedback	O
inhibitor	O
of	O
vascular	O
inflammation	O
.	O

These	O
studies	O
indicate	O
that	O
iNO	O
attenuates	O
iNOS	B
expression	O
in	O
macrophages	O
and	O
inhibits	O
monocyte	O
adhesion	O
to	O
endothelial	O
cells	O
,	O
and	O
suggest	O
that	O
endogenously	O
derived	O
iNO	O
may	O
be	O
an	O
important	O
autoregulatory	O
inhibitor	O
of	O
vascular	O
inflammation	O

These	O
results	O
corroborate	O
previous	O
findings	O
that	O
the	O
presence	O
of	O
ER	B
variants	O
is	O
not	O
a	O
characteristic	O
of	O
breast	O
cancer	O
.	O

p21ras	B
initiates	O
Rac	B
-	I
1	I
but	O
not	O
phosphatidyl	B
inositol	I
3	I
kinase	I
/	I
PKB	I
,	O
mediated	O
signaling	O
pathways	O
in	O
T	O
lymphocytes	O
.	O

We	O
also	O
examined	O
the	O
possibility	O
that	O
Akt	B
/	I
PKB	I
is	O
regulated	O
by	O
Ras	O
signaling	O
pathways	O
in	O
T	O
lymphocytes	O
.	O

Moreover	O
,	O
neither	O
TCR	B
or	O
Ras	B
activation	O
of	O
AP	B
-	I
1	I
is	O
dependent	O
on	O
PtdIns	B
3	I
-	I
kinase	I
.	O

The	O
present	O
data	O
thus	O
highlight	O
that	O
PtdIns	B
3	I
-	I
kinase	I
and	O
Akt	B
/	I
PKB	I
are	O
not	O
universal	O
Ras	B
effector	I
molecules	I
.	O

LNCaP	O
cells	O
treated	O
with	O
prostaglandin	O
E2	O
showed	O
neither	O
a	O
reduction	O
in	O
proliferation	O
nor	O
a	O
down	O
-	O
regulation	O
of	O
AR	B
and	O
PSA	B
levels	O
.	O

In	O
addition	O
,	O
recombinant	O
IL	B
-	I
1beta	I
was	O
able	O
to	O
replace	O
MCM	O
for	O
the	O
inhibition	O
of	O
proliferation	O
and	O
down	O
-	O
regulation	O
of	O
AR	B
and	O
PSA	B
proteins	O
.	O

LNCaP	O
cells	O
were	O
shown	O
to	O
express	O
the	O
IL	B
-	I
1beta	I
receptor	O
type	O
1	O
,	O
which	O
transduces	O
IL	B
-	I
1beta	I
signal	O
.	O

Differential	O
responsiveness	O
of	O
the	O
IL	B
-	I
5	I
and	I
IL	I
-	I
4	I
genes	I
to	O
transcription	B
factor	I
GATA	I
-	I
3	I
.	O

Here	O
,	O
we	O
show	O
that	O
ectopic	O
expression	O
of	O
GATA	B
-	I
3	I
is	O
sufficient	O
to	O
drive	O
IL	B
-	I
5	I
but	O
not	O
IL	B
-	I
4	I
gene	O
expression	O
.	O

Mutations	O
of	O
sites	O
that	O
suppress	O
NF	B
-	I
AT	I
binding	O
impair	O
the	O
induction	O
and	O
strong	O
NF	B
-	I
ATp	I
-	O
mediated	O
transactivation	O
of	O
the	O
CD25	B
promoter	I
in	O
T	O
cells	O
.	O

Antibodies	B
to	O
Duffy	B
antigens	I
are	O
responsible	O
for	O
some	O
cases	O
of	O
transfusion	O
incompatibility	O
and	O
newborn	O
hemolytic	O
disease	O
.	O

The	O
Duffy	B
protein	I
is	O
a	O
receptor	O
for	O
the	O
Plasmodium	B
vivax	I
erythrocyte	I
-	I
binding	I
protein	I
and	O
is	O
also	O
a	O
receptor	O
for	O
various	O
chemokines	B
(	O
thus	O
renamed	O
Duffy	B
Antigen	I
Receptor	I
for	I
Chemokines	I
[	O
DARC	B
]	O
)	O
.	O

The	O
Fy	O
(	O
a	O
-	O
b	O
-	O
)	O
phenotype	O
is	O
the	O
predominant	O
one	O
in	O
populations	O
of	O
black	O
people	O
and	O
also	O
occurs	O
in	O
other	O
populations	O
,	O
including	O
some	O
non	O
-	O
Ashkenazi	O
Jewish	O
groups	O
.	O

The	O
Fy	O
(	O
a	O
-	O
b	O
-	O
)	O
phenotype	O
has	O
been	O
associated	O
with	O
a	O
mutation	O
in	O
the	O
FY	B
*	I
B	I
promoter	I
at	O
the	O
GATA	B
box	I
that	O
abolishes	O
the	O
expression	O
of	O
erythrocyte	B
Duffy	I
protein	I
.	O

The	O
271C	O
-	O
-	O
>	O
T	O
substitution	O
represents	O
a	O
considerable	O
change	O
in	O
chemical	O
nature	O
(	O
Arg91	O
-	O
-	O
>	O
Cys	O
)	O
,	O
one	O
which	O
may	O
affect	O
the	O
antigenic	O
determinants	O
of	O
DARC	B
,	O
and	O
thus	O
be	O
of	O
clinical	O
significance	O
.	O

The	O
functions	O
of	O
NFAT	B
proteins	I
are	O
directly	O
controlled	O
by	O
the	O
calcium	B
-	I
and	I
calmodulin	I
-	I
dependent	I
phosphatase	I
calcineurin	B
.	O

Expression	O
of	O
the	O
IL	B
-	I
2	I
gene	I
requires	O
activation	O
of	O
T	O
cells	O
through	O
stimulation	O
of	O
the	O
TCR	B
and	O
costimulation	O
through	O
accessory	B
receptors	I
.	O

In	O
this	O
study	O
,	O
we	O
analyzed	O
whether	O
activities	O
of	O
these	O
phosphatases	O
are	O
necessary	O
for	O
the	O
expression	O
of	O
the	O
IL	B
-	I
2	I
gene	I
.	O

In	O
both	O
activated	O
peripheral	O
blood	O
T	O
lymphocytes	O
and	O
activated	O
tumorigenic	O
T	O
cell	O
lines	O
,	O
IL	B
-	I
2	I
gene	O
expression	O
was	O
blocked	O
at	O
the	O
transcriptional	O
level	O
by	O
okadaic	O
acid	O
.	O

The	O
transcription	B
factors	I
active	O
at	O
the	O
IL	B
-	I
2	I
promoter	I
were	O
differentially	O
influenced	O
:	O
upon	O
down	O
-	O
modulation	O
of	O
okadaic	B
acid	I
-	I
sensitive	I
phosphatases	I
,	O
transactivation	O
by	O
octamer	O
,	O
NF	B
-	I
kappa	I
B	I
,	O
and	O
NF	B
of	I
activated	I
T	I
cells	I
proteins	I
was	O
abrogated	O
,	O
while	O
transactivation	O
by	O
AP	B
-	I
1	I
proteins	I
was	I
even	I
enhanced	I
.	I

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
examine	O
the	O
effects	O
of	O
bis	O
[	O
4	O
-	O
[	O
2	O
,	O
4	O
-	O
dioxo	O
-	O
5	O
-	O
thiazolidinyl	O
)	O
methyl	O
]	O
phenyl	O
]	O
methane	O
(	O
YM	O
-	O
268	O
)	O
,	O
a	O
thiazolidinedione	O
derivative	O
,	O
on	O
glucose	O
uptake	O
,	O
adipocyte	O
differentiation	O
through	O
peroxisome	B
proliferator	I
-	I
activated	I
receptor	I
gamma	I
(	O
PPARgamma	B
)	O
,	O
and	O
phosphatidylinositol	B
3	I
-	I
kinase	I
(	O
PI	B
3	I
-	I
kinase	I
)	O
activity	O
in	O
cultured	O
cells	O
.	O

YM268	O
and	O
pioglitazone	O
dose	O
-	O
dependently	O
increased	O
the	O
2	O
-	O
deoxyglucose	O
uptake	O
in	O
3T3	O
-	O
L1	O
cells	O
.	O

The	O
nuclear	B
receptor	I
PPARgamma	B
-	O
bigger	O
than	O
fat	O
.	O

PPARgamma	B
has	O
also	O
been	O
implicated	O
recently	O
in	O
the	O
biology	O
of	O
monocytes	O
and	O
in	O
cell	O
-	O
cycle	O
regulation	O
and	O
cancer	O
.	O

Although	O
common	O
members	O
of	O
the	O
apoptotic	O
cascade	O
are	O
shared	O
between	O
different	O
cell	O
types	O
,	O
it	O
appears	O
that	O
cell	B
-	I
specific	I
factors	I
can	O
influence	O
the	O
response	O
to	O
a	O
given	O
apoptotic	O
stimuli	O
.	O

These	O
results	O
establish	O
an	O
independent	O
role	O
for	O
enhanced	O
p75TNF	B
-	I
R	I
production	O
in	O
the	O
pathogenesis	O
of	O
inflammatory	O
disease	O
and	O
implicate	O
the	O
direct	O
involvement	O
of	O
this	O
receptor	O
in	O
a	O
wide	O
range	O
of	O
human	O
inflammatory	O
pathologies	O
.	O

Molecular	O
and	O
cellular	O
analysis	O
of	O
human	O
immunodeficiency	O
virus	O
-	O
induced	O
apoptosis	O
in	O
lymphoblastoid	B
T	I
-	I
cell	I
-	I
line	I
-	I
expressing	I
wild	I
-	I
type	I
and	I
mutated	I
CD4	I
receptors	I
.	O

We	O
have	O
determined	O
how	O
the	O
phosphorylation	O
of	O
the	O
retinoblastoma	B
family	I
(	O
pRb	B
,	O
p107	B
,	O
and	O
p130	B
)	O
is	O
governed	O
in	O
individual	O
cell	O
cycle	O
phases	O
of	O
Daudi	O
B	O
-	O
cells	O
during	O
cell	O
cycle	O
exit	O
triggered	O
by	O
alpha	B
-	I
interferon	I
(	O
alpha	B
-	I
IFN	I
)	O
.	O

alpha	B
-	I
IFN	I
causes	O
dephosphorylation	O
of	O
pRb	B
and	O
loss	O
of	O
p130	B
phosphorylated	I
Form	I
3	I
.	O

However	O
,	O
the	O
change	O
in	O
p130	B
phosphorylation	O
in	O
response	O
to	O
alpha	B
-	I
IFN	I
occurs	O
before	O
dephosphorylation	O
of	O
pRb	B
is	O
complete	O
because	O
loss	O
of	O
p130	B
Form	I
3	I
occurs	O
throughout	O
the	O
cell	O
cycle	O
prior	O
to	O
complete	O
arrest	O
in	O
G1	O
,	O
whereas	O
pRb	B
is	O
dephosphorylated	O
only	O
in	O
G1	O
.	O

p130	B
,	O
predominantly	O
in	O
Form	O
1	O
,	O
and	O
hypophosphorylated	B
pRb	I
bind	O
an	O
E2F	B
DNA	I
binding	I
site	I
;	O
p130	B
complexes	O
E2F	B
-	I
4	I
,	O
whereas	O
pRb	B
binds	O
both	O
E2F	O
-	O
4	O
and	O
E2F	B
-	I
1	I
.	O

The	O
phosphorylated	O
forms	O
of	O
E2F	B
-	I
4	I
that	O
bind	O
to	O
the	O
E2F	B
DNA	I
site	I
are	O
different	O
from	O
hyperphosphorylated	O
E2F	B
-	I
4	I
,	O
which	O
predominates	O
in	O
primary	O
hemopoietic	O
cells	O
in	O
G0	O
.	O

Macrophages	O
and	O
granulocytes	O
,	O
which	O
are	O
developed	O
from	O
a	O
common	O
progenitor	O
cell	O
,	O
are	O
the	O
cellular	O
components	O
of	O
the	O
specific	O
and	O
non	O
-	O
specific	O
immunoreaction	O
.	O

In	O
contrast	O
,	O
v	B
-	I
myb	I
reduces	O
MRP14	B
promoter	I
activity	O
.	O

Northern	O
blot	O
analysis	O
of	O
L132	O
cells	O
transfected	O
with	O
the	O
C	B
/	I
EBP	I
alpha	I
expression	O
vector	O
demonstrate	O
that	O
C	B
/	I
EBP	I
alpha	I
is	O
sufficient	O
to	O
enhance	O
MRP14	B
expression	O
in	O
the	O
context	O
of	O
the	O
whole	O
genome	O
.	O

This	O
observation	O
prompted	O
us	O
to	O
postulate	O
that	O
signal	O
2	O
(	O
costimulatory	O
signal	O
)	O
alone	O
without	O
signal	O
1	O
(	O
TCR	B
signal	O
)	O
can	O
activate	O
T	O
cells	O
.	O

This	O
pathway	O
resulted	O
in	O
the	O
induction	O
of	O
the	O
transcription	B
factors	I
NF	B
-	I
kappa	I
B	I
,	O
NF	B
-	I
AT	I
,	O
and	O
proteins	O
binding	O
to	O
the	O
CD28	B
response	O
element	O
of	O
the	O
IL	B
-	I
2	I
promoter	I
.	O

In	O
contrast	O
to	O
the	O
differential	O
signaling	O
of	O
BW	B
828	I
and	O
9	B
.	I
3	I
in	O
resting	O
T	O
cells	O
,	O
the	O
two	O
mAbs	O
exhibited	O
a	O
similar	O
pattern	O
of	O
early	O
signaling	O
events	O
in	O
activated	O
T	O
cells	O
and	O
Jurkat	O
cells	O
(	O
p56	B
(	I
lck	I
)	I
activation	O
,	O
association	O
of	O
phosphatidylinositol	B
3	I
-	I
kinase	I
with	O
CD28	B
)	O
,	O
indicating	O
that	O
the	O
signaling	O
capacity	O
of	O
CD28	B
changes	O
with	O
activation	O
.	O

IL	B
-	I
12	I
is	O
a	O
75	B
-	I
kDa	I
heterodimeric	I
cytokine	I
composed	O
of	O
two	O
covalently	O
linked	O
p35	B
and	I
p40	I
chains	I
.	O

Th1	O
cell	O
-	O
mediated	O
immune	O
responses	O
have	O
been	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
chronic	O
inflammatory	O
autoimmune	O
diseases	O
.	O

This	O
was	O
associated	O
with	O
the	O
down	O
-	O
regulation	O
of	O
IL	B
-	I
12p40	I
mRNA	I
expression	O
.	O

Metabolic	O
labeling	O
combined	O
with	O
pulse	O
-	O
chase	O
experiments	O
and	O
biochemical	O
analysis	O
showed	O
that	O
the	O
majority	O
of	O
class	B
II	I
molecules	I
in	O
infected	O
cells	O
became	O
resistant	O
to	O
endoglycosidase	B
H	I
,	O
consistent	O
with	O
normal	O
Golgi	O
processing	O
.	O

However	O
,	O
results	O
of	O
intracellular	O
staining	O
and	O
dual	O
color	O
confocal	O
microscopy	O
revealed	O
a	O
significant	O
defect	O
in	O
transport	O
of	O
newly	O
synthesized	O
class	B
II	I
molecules	I
through	O
the	O
endocytic	O
compartment	O
.	O

Thus	O
,	O
compared	O
with	O
findings	O
in	O
control	O
cells	O
,	O
class	B
II	I
molecules	I
in	O
infected	O
cells	O
colocalized	O
to	O
a	O
minimal	O
extent	O
with	O
a	O
lysosomal	B
-	I
associated	I
membrane	I
protein	I
-	I
1	I
+	O
endosomal	O
compartment	O
.	O

Analyzed	O
DNA	B
sequences	I
included	O
delta	B
and	I
beta	I
5	I
'	I
flanking	I
regions	I
extending	O
from	O
approximately	O
-	B
500	I
to	I
+	I
50bp	I
(	O
promoter	B
regions	I
)	O
,	O
truncated	O
delta	O
and	O
beta	B
5	I
'	I
flanking	I
regions	I
extending	O
from	O
approximately	O
-	B
250	I
to	I
+	I
50	I
bp	I
,	O
and	O
chimeric	B
promoter	I
constructions	I
,	O
which	O
consisted	O
of	O
a	O
distal	O
delta	B
or	I
beta	I
fragment	I
fused	O
to	O
a	O
proximal	B
beta	I
or	I
delta	I
sequence	I
.	O

In	O
CAT	B
reporter	I
constructions	I
no	O
appreciable	O
level	O
of	O
CAT	B
activity	O
was	O
supported	O
by	O
the	O
beta	B
globin	I
promoter	I
,	O
and	O
only	O
low	O
level	O
activity	O
by	O
the	O
delta	B
promoter	I
.	O

Fusion	O
of	O
the	O
upstream	B
portion	I
of	O
the	O
delta	B
promoter	I
to	O
the	O
truncated	O
beta	B
globin	I
promoter	I
yielded	O
a	O
modest	O
increase	O
in	O
promoter	O
strength	O
relative	O
to	O
the	O
truncated	B
beta	I
gene	I
promoter	I
,	O
indicating	O
the	O
presence	O
of	O
a	O
positive	B
transcriptional	I
element	I
(	O
s	O
)	O
in	O
the	O
upstream	B
delta	I
globin	I
regulatory	I
region	I
.	O

The	O
induction	O
of	O
IgE	B
by	O
IL	B
-	I
4	I
and	O
IL	B
-	I
13	I
occurs	O
through	O
the	O
activation	O
of	O
the	O
intracellular	B
signal	I
-	I
transducing	I
protein	I
Stat6	I
,	O
whereas	O
the	O
inhibition	O
of	O
IgE	B
class	O
switching	O
by	O
interferon	B
-	I
y	I
(	O
IFN	B
-	I
gamma	I
)	O
occurs	O
through	O
the	O
activation	O
of	O
Statl	B
.	O

NFAT	B
regulates	O
transcription	O
of	O
a	O
number	O
of	O
cytokine	O
and	O
other	O
immunoregulatory	B
genes	I
.	O

We	O
also	O
report	O
three	O
additional	O
isoforms	O
of	O
NFATx	B
,	O
designated	O
NFATx2	B
,	O
NFATx3	B
,	O
and	O
NFATx4	B
.	O

This	O
transactivation	O
sequence	O
is	O
altered	O
by	O
tissue	O
-	O
specific	O
alternative	O
splicing	O
in	O
newly	O
isolated	O
NFATx	B
isoforms	I
,	O
resulting	O
in	O
lower	O
transactivation	O
activity	O
in	O
Jurkat	O
T	O
cells	O
.	O

5	B
'	I
HS3	I
contains	O
six	O
G	O
-	O
rich	O
motifs	O
that	O
are	O
essential	O
for	O
its	O
activity	O
.	O

We	O
show	O
that	O
the	O
function	O
of	O
such	O
closely	O
related	O
proteins	O
can	O
be	O
distinguished	O
in	O
vivo	O
by	O
matching	O
point	O
mutations	O
in	O
5	B
'	I
HS3	I
with	O
amino	O
acid	O
changes	O
in	O
the	O
zinc	B
fingers	I
of	O
Sp1	B
and	O
EKLF	B
.	O

The	O
transition	O
of	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
from	O
latency	O
into	O
the	O
lytic	O
cycle	O
is	O
associated	O
with	O
the	O
expression	O
of	O
two	O
immediate	B
-	I
early	I
viral	I
genes	I
,	O
BZLF1	B
and	O
BRLF1	B
.	O

In	O
HH514	O
-	O
16	O
cells	O
,	O
transfection	O
of	O
Rta	B
leads	O
to	O
synthesis	O
of	O
ZEBRA	B
,	O
viral	O
DNA	O
replication	O
,	O
and	O
late	O
gene	O
expression	O
.	O

Expression	O
of	O
either	O
BZLF1	B
or	O
BRLF1	B
triggers	O
expression	O
of	O
the	O
other	O
immediate	B
-	I
early	I
factor	I
,	O
and	O
together	O
these	O
activators	O
act	O
individually	O
or	O
in	O
synergy	O
on	O
downstream	B
targets	I
to	O
activate	O
the	O
viral	O
lytic	O
cycle	O
.	O

We	O
first	O
demonstrate	O
,	O
in	O
human	O
and	O
mouse	O
intraspecies	O
hybrids	O
,	O
the	O
coordinate	O
suppression	O
of	O
MHC	B
class	I
II	I
,	O
Ii	B
(	O
invariant	B
chain	I
)	O
and	O
HLA	B
-	I
DM	I
gene	I
transcription	O
,	O
and	O
the	O
release	O
of	O
the	O
silencing	O
by	O
the	O
addition	O
of	O
interferon	B
gamma	I
.	O

These	O
data	O
indicate	O
that	O
the	O
IFN	B
-	I
gamma	I
-	O
independent	O
component	O
of	O
the	O
target	O
cell	O
HLA	B
-	I
DR	I
expression	O
induced	O
by	O
lymphocyte	O
adhesion	O
uses	O
a	O
signaling	O
pathway	O
that	O
is	O
distinct	O
from	O
the	O
IFN	B
-	I
gamma	I
-	O
dependent	O
mechanism	O
and	O
also	O
suggest	O
that	O
CIITA	B
is	O
not	O
required	O
.	O

In	O
this	O
report	O
expression	O
profiles	O
and	O
activation	O
of	O
PKC	B
were	O
analyzed	O
in	O
human	O
Raji	O
B	O
lymphoblastoid	O
cells	O
.	O

Transient	O
transfection	O
analysis	O
with	O
target	B
plasmids	I
containing	O
either	O
DRA	B
promoter	I
(	O
wild	O
-	O
type	O
or	O
mutated	O
)	O
or	O
TPA	B
response	I
elements	I
demonstrated	O
that	O
pretreatment	O
with	O
the	O
selective	O
PKC	B
inhibitor	O
GF	O
109203X	O
repressed	O
TPA	O
-	O
mediated	O
activation	O
.	O

Together	O
,	O
these	O
results	O
show	O
that	O
activated	O
HLA	B
-	I
DRA	I
expression	O
in	O
response	O
to	O
TPA	O
treatment	O
is	O
strictly	O
dependent	O
on	O
PKC	B
activation	O
acting	O
on	O
the	O
X2	B
box	I
of	O
the	O
DRA	B
promoter	I
and	O
that	O
selective	O
inhibition	O
of	O
PKC	B
enzymatic	O
activity	O
does	O
not	O
influence	O
subcellular	O
localization	O
of	O
expressed	O
PKC	B
isoenzymes	I
.	O

Multiple	O
cellular	B
DNA	I
-	I
binding	I
transcription	I
factors	I
are	O
required	O
by	O
HIV	O
type	O
1	O
for	O
RNA	O
synthesis	O
.	O

These	O
synthetic	O
ligands	O
specifically	O
inhibit	O
DNA	O
-	O
binding	O
of	O
each	O
transcription	B
factor	I
and	O
HIV	O
type	O
1	O
transcription	O
in	O
cell	O
-	O
free	O
assays	O
.	O

In	O
situ	O
hybridisation	O
revealed	O
musculin	B
expression	O
in	O
embryos	O
was	O
largely	O
restricted	O
to	O
the	O
embryonic	O
skeletal	O
muscle	O
lineage	O
.	O

While	O
all	O
skeletal	O
muscles	O
expressed	O
the	O
gene	O
,	O
only	O
a	O
subset	O
of	O
myocytes	O
within	O
each	O
muscle	O
were	O
positive	O
,	O
indicating	O
molecular	O
heterogeneity	O
within	O
fetal	O
muscle	O
.	O

All	O
Rights	O
Reserved	O
.	O

The	O
TT	O
-	O
selected	O
T	O
cell	O
line	O
could	O
be	O
rendered	O
unresponsive	O
to	O
its	O
dominant	O
epitope	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
(	O
IC50	O
=	O
0	O
.	O
03	O
microg	O
/	O
ml	O
)	O
.	O

JNK	B
enzymatic	O
activity	O
was	O
blocked	O
in	O
anergized	O
T	O
cells	O
.	O

Copyright	O
1998	O
Academic	O
Press	O
.	O

Previously	O
,	O
we	O
demonstrated	O
that	O
granulocyte	B
colony	I
-	I
stimulating	I
factor	I
(	I
G	I
-	I
CSF	I
)	I
receptor	I
mRNA	I
was	O
undetectable	O
and	O
granulocyte	O
maturation	O
blocked	O
in	O
CCAAT	B
enhancer	I
binding	I
protein	I
alpha	I
(	O
C	B
/	I
EBPalpha	I
)	O
-	O
deficient	O
mice	O
.	O

Although	O
bacterial	O
lipopolysaccharides	O
(	O
LPS	O
)	O
and	O
several	O
other	O
microbial	O
agonists	O
can	O
bind	O
to	O
mCD14	B
(	O
membrane	B
CD14	I
)	O
,	O
a	O
cell	O
-	O
surface	O
receptor	O
found	O
principally	O
on	O
monocytes	O
and	O
neutrophils	O
,	O
host	O
-	O
derived	O
mCD14	B
ligands	O
are	O
poorly	O
defined	O
.	O

We	O
report	O
here	O
that	O
phosphatidylinositol	O
(	O
PtdIns	O
)	O
,	O
phosphatidylinositol	O
-	O
4	O
-	O
phosphate	O
,	O
and	O
other	O
phosphatidylinositid	O
can	O
bind	O
to	O
mCD14	B
.	O

Despite	O
progress	O
in	O
understanding	O
the	O
death	O
signals	O
transduced	O
from	O
Fas	B
,	O
very	O
little	O
is	O
known	O
with	O
regard	O
to	O
the	O
mechanisms	O
by	O
which	O
Fas	B
expression	O
is	O
regulated	O
.	O

PKC	B
-	O
dependent	O
Fas	B
expression	O
was	O
also	O
observed	O
in	O
several	O
murine	O
and	O
human	O
tumor	O
cell	O
lines	O
.	O

Since	O
the	O
inhibition	O
of	O
Ca2	O
+	O
redistribution	O
by	O
an	O
inhibitor	O
of	O
intracellular	O
Ca2	O
+	O
mobilization	O
,	O
8	O
-	O
(	O
diethylamino	O
)	O
-	O
octyl	O
-	O
3	O
,	O
4	O
,	O
5	O
-	O
trimethoxybenzoate	O
hydrochloride	O
,	O
inhibited	O
TCR	B
-	I
induced	I
FasL	I
but	O
not	O
Fas	B
,	O
the	O
expression	O
of	O
Fas	B
appears	O
to	O
be	O
independent	O
of	O
Ca2	O
+	O
mobilization	O
.	O

Anti	B
-	I
CD40	I
+	O
IL	B
-	I
4	I
-	O
mediated	O
proliferation	O
of	O
PBMC	O
and	O
B	O
cells	O
was	O
inhibited	O
by	O
RA	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
,	O
with	O
maximal	O
inhibition	O
of	O
62	O
%	O
+	O
/	O
-	O
5	O
%	O
in	O
PBMC	O
and	O
55	O
%	O
+	O
/	O
-	O
4	O
.	O
4	O
%	O
in	O
B	O
cells	O
by	O
all	O
-	O
trans	O
RA	O
,	O
and	O
58	O
%	O
+	O
/	O
-	O
6	O
.	O
7	O
%	O
and	O
51	O
%	O
+	O
/	O
-	O
4	O
.	O
7	O
%	O
,	O
respectively	O
by	O
13	O
-	O
cis	O
RA	O
.	O

IgE	B
synthesis	O
was	O
even	O
more	O
markedly	O
inhibited	O
by	O
RA	O
starting	O
at	O
concentrations	O
of	O
>	O
10	O
(	O
-	O
14	O
)	O
mol	O
/	O
L	O
for	O
B	O
cells	O
and	O
>	O
10	O
(	O
-	O
10	O
)	O
mol	O
/	O
L	O
for	O
PBMC	O
.	O

Low	O
concentrations	O
of	O
RA	O
inhibiting	O
IgE	B
synthesis	O
(	O
10	O
(	O
-	O
10	O
)	O
mol	O
/	O
L	O
)	O
affected	O
neither	O
B	O
-	O
cell	O
proliferation	O
nor	O
the	O
production	O
of	O
IgA	B
,	O
IgG	B
,	O
and	O
IgM	B
.	O

To	O
differentiate	O
whether	O
the	O
RA	O
effect	O
was	O
mediated	O
by	O
RA	B
receptors	I
alpha	I
,	I
beta	I
,	I
and	I
gamma	I
,	O
the	O
expression	O
of	O
the	O
retinoic	B
acid	I
receptors	I
(	O
RAR	B
)	O
was	O
examined	O
by	O
reverse	B
transcriptase	I
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
.	O

Taken	O
together	O
,	O
this	O
study	O
shows	O
that	O
RA	O
inhibits	O
IgE	B
production	O
of	O
anti	O
-	O
CD40	O
+	O
IL	O
-	O
4	O
-	O
stimulated	O
B	O
cells	O
in	O
vitro	O
.	O

Copyright	O
1998	O
by	O
The	O
American	O
Society	O
of	O
Hematology	O
.	O

In	O
contrast	O
,	O
a	O
mutant	O
of	O
Tax	B
termed	O
M22	B
,	O
which	O
does	O
not	O
induce	O
NF	B
-	I
kappaB	I
,	O
fails	O
to	O
activate	O
either	O
IKKalpha	B
or	O
IKKbeta	B
.	O

The	O
pathological	O
alteration	O
of	O
this	O
cytokine	O
pathway	O
leading	O
to	O
NF	B
-	I
kappaB	I
activation	O
by	O
Tax	B
may	O
play	O
a	O
central	O
role	O
in	O
HTLV	O
-	O
1	O
-	O
mediated	O
transformation	O
of	O
human	O
T	O
cells	O
,	O
clinically	O
manifested	O
as	O
the	O
adult	O
T	O
-	O
cell	O
leukemia	O

Recently	O
,	O
we	O
have	O
reported	O
that	O
the	O
tumor	B
necrosis	I
factor	I
and	O
interleukin	B
1	I
signaling	O
pathways	O
activate	O
two	O
kinases	O
,	O
IKK1	B
and	O
IKK2	B
.	O

Here	O
,	O
we	O
report	O
that	O
LPS	O
induces	O
IKK	B
activity	O
in	O
human	O
monocytes	O
and	O
THP	O
-	O
1	O
monocytic	O
cells	O
.	O

In	O
contrast	O
,	O
a	O
dominant	O
negative	O
mutant	O
of	O
IKK2	B
inhibited	O
LPS	O
induction	O
of	O
kappaB	B
-	O
dependent	O
transcription	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

IL	B
-	I
7	I
did	O
not	O
maintain	O
v	B
-	I
Abl	I
-	O
mediated	O
differentiation	O
arrest	O
of	O
the	O
pre	O
-	O
B	O
cells	O
,	O
as	O
activation	O
of	O
NF	B
-	I
kappaB	I
and	O
RAG	B
gene	I
transcription	O
was	O
unaffected	O
by	O
IL	B
-	I
7	I
.	O

Functional	O
analysis	O
of	O
the	O
promoter	O
by	O
transient	O
transfection	O
assays	O
indicated	O
that	O
synergistic	O
action	O
between	O
an	O
SP	B
-	I
1	I
-	I
like	I
element	I
at	O
-	O
21	O
/	O
-	O
12	O
,	O
a	O
GATA	B
site	I
at	O
-	O
59	O
/	O
-	O
54	O
,	O
and	O
a	O
novel	B
regulatory	I
element	I
,	O
CPRE	B
(	O
-	O
GGACTACAG	B
-	O
)	O
at	O
-	O
49	O
/	O
-	O
41	O
,	O
is	O
essential	O
for	O
the	O
promoter	O
activity	O
in	O
murine	O
erythroleukemia	O
(	O
MEL	O
)	O
cells	O
.	O

Administration	O
of	O
the	O
cytokine	B
interleukin	I
-	I
2	I
(	O
IL	B
-	I
2	I
)	O
can	O
result	O
in	O
therapeutic	O
benefits	O
for	O
individuals	O
with	O
renal	O
cell	O
carcinoma	O
and	O
melanoma	O
.	O

Here	O
we	O
report	O
an	O
analysis	O
of	O
the	O
transcription	O
factor	O
families	O
AP	O
-	O
1	O
,	O
Sp1	O
,	O
NF	B
-	I
kappaB	I
,	O
and	O
signal	B
transducers	I
and	I
activators	I
of	I
transcription	I
(	O
STAT	B
)	O
in	O
cancer	O
patients	O
'	O
lymphocytes	O
before	O
and	O
after	O
IL	B
-	I
2	I
immunotherapy	O
,	O
as	O
assessed	O
by	O
a	O
gel	O
-	O
shift	O
assay	O
.	O

The	O
role	O
of	O
platelets	O
for	O
monocyte	B
chemotactic	I
protein	I
-	I
1	I
(	O
MCP	B
-	I
1	I
)	O
secretion	O
and	O
surface	O
expression	O
of	O
intercellular	O
adhesion	O
molecule	O
-	O
1	O
(	O
ICAM	B
-	I
1	I
)	O
on	O
endothelial	O
cells	O
has	O
been	O
assessed	O
.	O

Nuclear	B
receptors	I
are	O
important	O
regulators	O
of	O
erythroid	O
cell	O
development	O
.	O

Here	O
we	O
investigated	O
the	O
impact	O
of	O
retinoid	B
X	I
receptor	I
(	O
RXR	B
)	O
,	O
retinoic	B
acid	I
receptor	I
(	O
RAR	B
)	O
,	O
and	O
of	O
the	O
c	B
-	I
erbA	I
/	I
thyroid	I
hormone	I
(	I
T3	I
)	I
receptor	I
(	O
c	B
-	I
erbA	I
/	I
TR	I
)	O
on	O
growth	O
and	O
differentiation	O
of	O
erythroid	O
cells	O
using	O
an	O
in	O
vitro	O
culture	O
system	O
of	O
stem	O
cell	O
factor	O
-	O
dependent	O
erythroid	O
progenitors	O
.	O

RXR	B
,	O
RAR	B
,	O
and	O
c	B
-	I
erbA	I
/	I
TR	I
-	O
specific	O
ligands	O
were	O
found	O
to	O
induce	O
erythroid	B
-	I
specific	I
gene	I
expression	O
and	O
to	O
accelerate	O
erythroid	O
differentiation	O
in	O
culture	O
,	O
with	O
T3	O
being	O
most	O
effective	O
.	O

Thus	O
,	O
c	B
-	I
erbA	I
/	I
TR	I
appears	O
to	O
act	O
as	O
a	O
binary	O
switch	O
affecting	O
erythroid	O
cell	O
fate	O
:	O
unliganded	O
c	B
-	I
erbA	I
/	I
TR	I
supports	O
growth	O
while	O
ligand	O
-	O
activated	O
c	B
-	I
erbA	I
/	I
TR	I
induces	O
differentiation	O
.	O

In	O
marked	O
contrast	O
,	O
expression	O
of	O
the	O
dominant	B
interfering	I
deltaDNA	I
-	I
binding	I
domain	I
RXR	B
,	O
containing	O
a	O
deletion	O
of	O
the	O
entire	B
DNA	I
-	I
binding	I
domain	I
,	O
was	O
incompatible	O
with	O
erythroid	O
cell	O
growth	O
in	O
vitro	O
,	O
suggesting	O
a	O
pivotal	O
role	O
of	O
RXR	B
for	O
erythroid	O
cell	O
development	O
.	O

We	O
examined	O
signaling	O
molecules	O
of	O
peripheral	O
blood	O
T	O
lymphocytes	O
obtained	O
from	O
women	O
with	O
breast	O
cancer	O
.	O

This	O
observation	O
was	O
made	O
despite	O
normal	O
cytoplasmic	O
levels	O
of	O
the	O
Rel	B
-	I
A	I
protein	I
.	O

T	O
lymphocytes	O
from	O
6	O
of	O
the	O
14	O
patients	O
also	O
exhibited	O
an	O
increased	O
expression	O
of	O
the	O
dual	O
specificity	B
phosphatase	I
,	O
map	B
kinase	I
phosphatase	I
-	I
1	I
(	O
MKP	B
-	I
1	I
)	O
.	O

We	O
studied	O
the	O
number	O
of	O
glucocorticoid	B
receptors	I
and	O
dissociation	O
constant	O
in	O
isolated	O
human	O
lymphocytes	O
as	O
well	O
as	O
blood	O
concentrations	O
of	O
hormones	O
produced	O
by	O
the	O
hypothalamic	O
-	O
hypophyseal	O
-	O
adrenocortical	O
system	O
in	O
three	O
experimental	O
series	O
:	O
at	O
normal	O
(	O
17	O
subjects	O
)	O
,	O
decreased	O
(	O
10	O
subjects	O
,	O
a	O
360	O
-	O
d	O
head	O
-	O
down	O
bed	O
rest	O
)	O
and	O
increased	O
(	O
8	O
subjects	O
,	O
physical	O
exercise	O
on	O
bicycle	O
ergometer	O
)	O
levels	O
of	O
motor	O
activity	O
.	O

The	O
small	B
GTP	I
-	I
binding	I
protein	I
Rho	I
potentiates	O
AP	B
-	I
1	I
transcription	O
in	O
T	O
cells	O
.	O

The	O
effect	O
of	O
Rho	B
on	O
AP	B
-	I
1	I
is	O
independent	O
of	O
the	O
mitogen	B
-	I
activated	I
protein	I
kinase	I
pathway	O
,	O
as	O
a	O
dominant	B
-	I
negative	I
MEK	I
and	O
a	O
MEK	B
inhibitor	O
(	O
PD98059	O
)	O
did	O
not	O
affect	O
Rho	B
-	O
induced	O
AP	B
-	I
1	I
activity	O
.	O

These	O
cells	O
exhibit	O
many	O
alterations	O
in	O
function	O
compared	O
with	O
their	O
precursor	O
cells	O
,	O
blood	O
monocytes	O
.	O

To	O
evaluate	O
a	O
potential	O
mechanism	O
for	O
these	O
differences	O
in	O
function	O
,	O
we	O
evaluated	O
expression	O
of	O
protein	B
kinase	I
C	I
(	I
PKC	I
)	I
isoforms	I
.	O

Using	O
mRNA	O
differential	O
display	O
we	O
demonstrated	O
abnormally	O
high	O
expression	O
of	O
the	O
signal	B
transducer	I
and	I
activator	I
of	I
transcription	I
(	O
STAT1alpha	B
)	O
in	O
monocytes	O
from	O
the	O
proband	O
II	O
-	O
2	O
.	O

Analysis	O
of	O
monocytes	O
from	O
familial	O
hypercholesterolemic	O
(	O
FH	O
)	O
subjects	O
,	O
who	O
frequently	O
develop	O
xanthomatosis	O
,	O
revealed	O
a	O
significant	O
number	O
of	O
subjects	O
with	O
elevated	O
STAT1alpha	O
and	O
IP	O
-	O
10	O
expression	O
.	O

The	O
activation	O
of	O
NF	B
-	I
kappaB	I
has	O
been	O
recognized	O
to	O
regulate	O
a	O
number	O
of	O
genes	O
necessary	O
for	O
normal	O
T	O
cell	O
responses	O
including	O
IL	B
-	I
2	I
,	O
IL	B
-	I
6	I
,	O
IL	B
-	I
8	I
,	O
and	O
several	O
T	B
cell	I
surface	I
receptors	I
.	O

Uncoupling	O
of	O
nonreceptor	O
tyrosine	B
kinases	I
from	O
PLC	B
-	I
gamma1	I
in	O
an	O
SLP	O
-	O
76	O
-	O
deficient	O
T	O
cell	O
.	O

SLP	B
-	I
76	I
was	O
not	O
required	O
for	O
TCR	B
-	O
induced	O
tyrosine	O
phosphorylation	O
of	O
most	O
proteins	O
,	O
but	O
was	O
required	O
for	O
optimal	O
tyrosine	O
phosphorylation	O
and	O
activation	O
of	O
phospholipase	B
C	I
-	I
gamma1	I
(	O
PLC	B
-	I
gamma1	I
)	O
,	O
as	O
well	O
as	O
Ras	B
pathway	O
activation	O
.	O

Thus	O
,	O
coupling	O
of	O
TCR	B
-	I
regulated	I
PTKs	I
to	O
downstream	O
signaling	O
pathways	O
requires	O
SLP	B
-	I
76	I
.	O

In	O
addition	O
,	O
we	O
have	O
shown	O
that	O
Stat1alpha	B
,	O
but	O
not	O
Stat3	B
,	O
is	O
involved	O
in	O
EPO	B
-	O
induced	O
cellular	O
proliferation	O
.	O

Dominant	O
negative	O
forms	O
of	O
Stat1alpha	B
or	O
Stat3	B
promoted	O
the	O
EPO	B
-	O
induced	O
erythroid	O
differentiation	O
of	O
UT	O
-	O
7	O
/	O
GM	O
cells	O
,	O
even	O
in	O
the	O
presence	O
of	O
granulocyte	B
-	I
macrophage	I
colony	I
-	I
stimulating	I
factor	I
,	O
although	O
this	O
cytokine	O
never	O
induced	O
erythroid	O
differentiation	O
of	O
the	O
parent	O
UT	O
-	O
7	O
/	O
GM	O
cells	O
with	O
or	O
without	O
EPO	B
.	O

Taken	O
together	O
,	O
our	O
data	O
suggest	O
that	O
Stat1alpha	B
and	O
Stat3	B
act	O
as	O
negative	O
regulators	O
in	O
EPO	B
-	O
induced	O
erythroid	O
differentiation	O
.	O

Data	O
obtained	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
suggested	O
that	O
the	O
activated	B
Stat	I
-	I
3	I
protein	I
associates	O
with	O
the	O
human	B
serum	I
-	I
inducible	I
element	I
(	I
hSIE	I
)	I
DNA	I
-	I
probe	I
derived	O
from	O
the	O
interferon	B
-	I
gamma	I
activated	I
site	I
(	O
GAS	B
)	O
in	O
the	O
c	B
-	I
fos	I
promoter	I
,	O
a	O
common	O
DNA	O
sequence	O
for	O
Stat	B
protein	I
binding	O
.	O

In	O
conclusion	O
,	O
our	O
data	O
suggest	O
the	O
involvement	O
of	O
the	O
Jak	B
/	I
Stat	I
signal	O
pathway	O
in	O
MHC	B
-	I
I	I
-	O
induced	O
signal	O
transduction	O
in	O
T	O
cells	O
.	O

These	O
apparent	O
inconsistencies	O
reflect	O
the	O
complexity	O
of	O
the	O
DTCs	O
biological	O
activities	O
and	O
are	O
probably	O
due	O
in	O
part	O
to	O
differences	O
in	O
dose	O
,	O
route	O
of	O
exposure	O
,	O
animal	O
species	O
used	O
and	O
/	O
or	O
specific	O
compound	O
tested	O
.	O

The	O
studies	O
described	O
herein	O
were	O
undertaken	O
to	O
investigate	O
the	O
immunotoxicity	O
of	O
one	O
member	O
of	O
this	O
family	O
,	O
dimethyldithiocarbam	O
(	O
DMDTC	O
)	O
.	O

This	O
inhibition	O
is	O
not	O
accompanied	O
by	O
a	O
loss	O
in	O
viability	O
,	O
and	O
DMDTC	O
-	O
treated	O
T	O
cells	O
retain	O
other	O
active	O
signaling	O
pathways	O
throughout	O
the	O
exposure	O
duration	O
.	O

We	O
further	O
demonstrate	O
that	O
0	O
.	O
1	O
-	O
0	O
.	O
5	O
microM	O
DMDTC	O
inhibits	O
intracellular	O
IL	B
-	I
2	I
production	O
and	O
decreases	O
surface	O
expression	O
of	O
CD25	B
(	O
the	O
alpha	B
subunit	I
of	O
the	O
IL	B
-	I
2	I
receptor	I
)	O
in	O
T	O
cells	O
stimulated	O
with	O
phorbol	O
ester	O
.	O

Using	O
deletion	B
constructs	I
,	O
we	O
have	O
defined	O
an	O
active	B
promoter	I
region	I
of	O
1056	O
bp	O
.	O

Ex	O
vivo	O
activation	O
of	O
tumor	O
-	O
draining	O
lymph	O
node	O
T	O
cells	O
reverses	O
defects	O
in	O
signal	B
transduction	I
molecules	I
.	O

To	O
determine	O
whether	O
the	O
acquisition	O
of	O
antitumor	O
function	O
during	O
ex	O
vivo	O
activation	O
is	O
associated	O
with	O
modifications	O
in	O
signal	O
transduction	O
capacity	O
,	O
the	O
protein	O
tyrosine	B
kinases	I
p56lck	B
and	O
p59fyn	B
and	O
proteins	O
of	O
the	O
NF	B
-	I
kappaB	I
family	I
were	O
analyzed	O
in	O
tumor	O
-	O
draining	O
LN	O
T	O
cells	O
.	O

In	O
contrast	O
,	O
the	O
cytoplasmic	O
levels	O
of	O
c	B
-	I
Rel	I
and	O
Rel	B
A	I
were	O
normal	O
in	O
freshly	O
isolated	O
tumor	O
-	O
draining	O
LN	O
,	O
as	O
was	O
nuclear	O
kappaB	B
DNA	O
-	O
binding	O
activity	O
induced	O
by	O
anti	B
-	I
CD3	I
mAb	I
or	O
phorbol	O
myristate	O
acetate	O
.	O

BACKGROUND	O
:	O
The	O
class	B
II	I
transactivator	I
(	O
CIITA	B
)	O
is	O
a	O
bi	B
-	I
or	I
multifunctional	I
domain	I
protein	I
that	O
acts	O
as	O
a	O
transcriptional	B
activator	I
and	O
plays	O
a	O
critical	O
role	O
in	O
the	O
expression	O
of	O
MHC	B
class	I
II	I
genes	I
.	O

Porcine	B
MHC	I
class	I
II	I
antigens	I
are	O
potent	O
stimulators	O
of	O
direct	O
T	O
-	O
cell	O
recognition	O
by	O
human	O
CD4	O
+	O
T	O
cells	O
and	O
are	O
,	O
therefore	O
,	O
likely	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
rejection	O
responses	O
to	O
transgenic	O
pig	O
donors	O
in	O
clinical	O
xenotransplantation	O
.	O

Transient	O
transfectants	O
of	O
the	O
porcine	O
B	O
-	O
cell	O
line	O
L23	O
with	O
the	O
mutated	O
CIITA	B
constructs	I
were	O
tested	O
for	O
the	O
suppression	O
of	O
constitutive	O
SLA	O
-	O
DR	O
and	O
SLA	O
-	O
DQ	O
expression	O
.	O

Macrophages	O
in	O
human	O
atheroma	O
contain	O
PPARgamma	B
:	O
differentiation	B
-	I
dependent	I
peroxisomal	I
proliferator	I
-	I
activated	I
receptor	I
gamma	I
(	O
PPARgamma	B
)	O
expression	O
and	O
reduction	O
of	O
MMP	B
-	I
9	I
activity	O
through	O
PPARgamma	B
activation	O
in	O
mononuclear	O
phagocytes	O
in	O
vitro	O
.	O

Mononuclear	O
phagocytes	O
play	O
an	O
important	O
role	O
in	O
atherosclerosis	O
and	O
its	O
sequela	O
plaque	O
rupture	O
in	O
part	O
by	O
their	O
secretion	O
of	O
matrix	B
metalloproteinases	I
(	O
MMPs	B
)	O
,	O
including	O
MMP	B
-	I
9	I
.	O

The	O
role	O
of	O
PPARgamma	B
in	O
human	O
atherosclerosis	O
is	O
unexplored	O
.	O

In	O
addition	O
,	O
PPARgamma	B
mRNA	I
expression	O
in	O
U937	O
cells	O
increased	O
during	O
phorbol	O
12	O
-	O
myristate	O
13	O
acetate	O
-	O
induced	O
differentiation	O
.	O

We	O
examined	O
signaling	O
by	O
erythropoietin	B
in	O
highly	O
purified	O
human	O
colony	O
forming	O
unit	O
-	O
erythroid	O
cells	O
,	O
generated	O
in	O
vitro	O
from	O
CD34	O
(	O
+	O
)	O
cells	O
.	O

We	O
found	O
that	O
erythropoietin	B
induces	O
tyrosine	O
phosphorylation	O
of	O
Jak2	B
,	O
STAT5A	B
,	O
and	O
STAT5B	B
.	O

Tyrosine	O
phosphorylation	O
of	O
Jak2	B
reaches	O
a	O
peak	O
around	O
10	O
minutes	O
after	O
stimulation	O
and	O
is	O
maximum	O
at	O
5	O
U	O
/	O
mL	O
of	O
erythropoietin	B
.	O

Effects	O
of	O
oxidative	O
stress	O
on	O
stimulation	O
-	O
dependent	O
signal	O
transduction	O
,	O
leading	O
to	O
IL	B
-	I
2	I
expression	O
,	O
were	O
studied	O
.	O

The	O
cells	O
were	O
then	O
stimulated	O
for	O
6	O
h	O
.	O

Eosinophils	O
infiltrating	O
hamster	O
cutaneous	O
wounds	O
were	O
found	O
to	O
express	O
TGFs	B
sequentially	O
.	O

IL	B
-	I
3	I
,	O
IL	B
-	I
4	I
,	O
and	O
IL	B
-	I
5	I
independently	O
up	O
-	O
regulated	O
TGF	B
-	I
beta1	I
mRNA	I
and	O
product	O
expression	O
by	O
eosinophils	O
in	O
all	O
donors	O
.	O

The	O
observation	O
that	O
IL	B
-	I
4	I
can	O
differentially	O
regulate	O
the	O
expression	O
of	O
TGF	B
-	I
alpha	I
and	O
TGF	B
-	I
beta1	I
suggests	O
that	O
IL	B
-	I
4	I
may	O
serve	O
as	O
a	O
physiologic	O
molecular	O
switch	O
of	O
TGF	B
expression	O
by	O
the	O
infiltrating	O
eosinophils	O
in	O
wound	O
healing	O
and	O
carcinogenesis	O
.	O

A	O
recent	O
study	O
showed	O
a	O
MLL	B
/	I
AF10	I
fusion	I
in	O
all	O
cases	O
of	O
AML	O
with	O
t	B
(	I
10	I
;	I
11	I
)	I
and	O
various	O
breakpoints	O
on	O
chromosome	B
11	I
ranging	O
from	O
q13	B
to	O
q23	B
.	O

We	O
recently	O
cloned	O
CALM	B
(	O
Clathrin	B
Assembly	I
Lymphoid	I
Myeloid	I
leukemia	I
gene	I
)	O
,	O
the	O
fusion	O
partner	O
of	O
AF10	B
at	O
11q14	B
in	O
the	O
monocytic	O
cell	O
line	O
U937	O
.	O

MLL	O
was	O
rearranged	O
in	O
3	O
AML	O
with	O
myelomonocytic	O
differentiation	O
(	O
2	O
AML	O
-	O
M2	O
and	O
1	O
AML	O
-	O
M5	O
)	O
,	O
including	O
1	O
secondary	O
AML	O
.	O

For	O
the	O
7	O
AML	O
cases	O
that	O
were	O
uniformly	O
treated	O
according	O
to	O
the	O
AMLCG86	O
/	O
92	O
protocols	O
,	O
disease	O
-	O
free	O
and	O
overall	O
survival	O
was	O
significantly	O
worse	O
than	O
for	O
the	O
overall	O
study	O
group	O
(	O
P	O
=	O
.	O
03	O
and	O
P	O
=	O
.	O
01	O
,	O
respectively	O
)	O
.	O

We	O
conclude	O
that	O
the	O
t	B
(	I
10	I
;	I
11	I
)	I
(	I
p13	I
;	I
q14	I
)	I
indicates	O
CALM	B
and	I
MLL	I
rearrangements	I
in	O
morphologically	O
distinct	O
subsets	O
of	O
acute	O
leukemia	O
and	O
may	O
be	O
associated	O
with	O
a	O
poor	O
prognosis	O
.	O

In	O
particular	O
,	O
one	O
class	O
of	O
helix	B
-	I
loop	I
-	I
helix	I
proteins	I
,	O
termed	O
E	B
-	I
proteins	I
,	O
have	O
been	O
implicated	O
in	O
the	O
regulation	O
of	O
gene	O
expression	O
during	O
B	O
-	O
cell	O
development	O
.	O

Dominant	B
negative	I
mutants	I
of	O
NIK	B
,	O
IKKalpha	B
,	O
or	O
IKKbeta	B
substantially	O
inhibited	O
NF	B
-	I
kappaB	I
activation	O
by	O
LMP1	B
or	O
by	O
each	O
of	O
its	O
effector	B
sites	I
.	O

MyD88	B
,	O
originally	O
isolated	O
as	O
a	O
myeloid	O
differentiation	O
primary	B
response	I
gene	I
,	O
is	O
shown	O
to	O
act	O
as	O
an	O
adaptor	O
in	O
interleukin	B
-	I
1	I
(	O
IL	B
-	I
1	I
)	O
signaling	O
by	O
interacting	O
with	O
both	O
the	O
IL	B
-	I
1	I
receptor	I
complex	I
and	O
IL	B
-	I
1	I
receptor	I
-	I
associated	I
kinase	I
(	O
IRAK	B
)	O
.	O

In	O
vivo	O
Th1	O
response	O
is	O
also	O
impaired	O
.	O

Furthermore	O
,	O
IL	B
-	I
18	I
-	O
induced	O
activation	O
of	O
NF	B
-	I
kappaB	I
and	O
c	B
-	I
Jun	I
N	I
-	I
terminal	I
kinase	I
(	O
JNK	B
)	O
is	O
blocked	O
in	O
MyD88	O
-	O
/	O
-	O
Th1	O
-	O
developing	O
cells	O
.	O

Taken	O
together	O
,	O
these	O
results	O
demonstrate	O
that	O
MyD88	B
is	O
a	O
critical	O
component	O
in	O
the	O
signaling	O
cascade	O
that	O
is	O
mediated	O
by	O
IL	B
-	I
1	I
receptor	I
as	O
well	O
as	O
IL	B
-	I
18	I
receptor	I
.	O

In	O
addition	O
,	O
transcriptional	O
activity	O
of	O
IL	B
-	I
2	I
and	O
metallothionein	B
enhancer	I
and	I
promoter	I
regions	I
and	O
transcription	B
factors	I
AP	B
-	I
1	I
,	O
NF	B
-	I
kappaB	I
,	O
and	O
NF	B
-	I
AT	I
were	O
analyzed	O
by	O
chloramphenicol	B
acetyltransferase	I
(	O
CAT	B
)	O
and	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
respectively	O
.	O

The	O
concentration	O
of	O
c	B
-	I
fos	I
,	I
c	I
-	I
jun	I
,	I
c	I
-	I
myc	I
,	I
junB	I
,	I
and	I
fra	I
-	I
1	I
mRNAs	I
was	O
increased	O
in	O
activated	O
peripheral	O
blood	O
lymphocytes	O
incubated	O
with	O
ciprofloxacin	O
compared	O
to	O
that	O
in	O
untreated	O
controls	O
.	O

Simple	O
activation	O
of	O
RXRs	B
is	O
not	O
sufficient	O
to	O
induce	O
apoptosis	O
of	O
the	O
cells	O
.	O

Thrombopoietin	B
supports	O
in	O
vitro	O
erythroid	O
differentiation	O
via	O
its	O
specific	O
receptor	O
c	B
-	I
Mpl	I
in	O
a	O
human	O
leukemia	O
cell	O
line	O
.	O

More	O
than	O
50	O
%	O
of	O
TPO	O
-	O
treated	O
UT	O
-	O
7	O
/	O
GMT	O
cells	O
positively	O
stained	O
for	O
Hb	B
.	O

Because	O
the	O
GATA	B
-	I
1	I
gene	I
is	O
located	O
on	O
the	O
X	B
chromosome	I
,	O
which	O
is	O
randomly	O
inactivated	O
in	O
every	O
cell	O
,	O
heterozygous	O
females	O
can	O
bear	O
either	O
an	O
active	O
wild	O
-	O
type	O
or	O
mutant	O
(	O
referred	O
to	O
as	O
GATA	B
-	I
1	I
.	I
05	I
)	O
GATA	B
-	I
1	I
allele	O
,	O
consequently	O
leading	O
to	O
variable	O
anemic	O
severity	O
.	O

We	O
also	O
observed	O
hematopoiesis	O
outside	O
of	O
the	O
bone	O
marrow	O
in	O
the	O
affected	O
mutant	O
mice	O
.	O

The	O
GATA	B
-	I
1	I
heterozygous	O
mutant	O
mouse	O
shows	O
a	O
phenotype	O
that	O
is	O
analogous	O
to	O
human	O
myelodysplastic	O
syndrome	O
and	O
thus	O
may	O
serve	O
as	O
a	O
useful	O
model	O
for	O
this	O
disorder	O
.	O

Differential	O
regulation	O
of	O
the	O
Janus	B
kinase	I
-	B
STAT	I
pathway	O
and	O
biologic	O
function	O
of	O
IL	B
-	I
13	I
in	O
primary	O
human	O
NK	O
and	O
T	O
cells	O
:	O
a	O
comparative	O
study	O
with	O
IL	B
-	I
4	I
.	O

We	O
observed	O
that	O
Abs	O
directed	O
against	O
unique	O
domains	O
of	O
STAT6	B
have	O
differential	O
effects	O
on	O
complexes	O
in	O
T	O
cells	O
but	O
not	O
in	O
NK	O
cells	O
,	O
suggesting	O
different	O
STAT6	B
isoforms	I
.	O

These	O
findings	O
show	O
that	O
IL	B
-	I
13	I
and	O
IL	B
-	I
4	I
have	O
the	O
ability	O
to	O
regulate	O
NK	O
and	O
T	O
cell	O
activation	O
and	O
that	O
IL	B
-	I
13	I
is	O
a	O
potent	O
regulator	O
of	O
STAT6	B
and	O
JAK3	B
in	O
these	O
cell	O
types	O
.	O

NFkappaB	B
activity	O
is	O
independent	O
from	O
FADD	B
,	O
caspases	B
,	O
and	O
apoptosis	O
induction	O
.	O

To	O
study	O
the	O
influence	O
of	O
NFkappaB	B
activity	O
on	O
apoptosis	O
mediated	O
by	O
TRAIL	B
,	O
CD95	O
,	O
TNFalpha	B
,	O
or	O
doxorubicin	O
,	O
NFkappaB	B
activation	O
was	O
inhibited	O
using	O
the	O
proteasome	B
inhibitor	O
N	O
-	O
acetyl	O
-	O
L	O
-	O
leucinyl	O
-	O
L	O
-	O
leucinyl	O
-	O
L	O
-	O
norleucinal	O
or	O
transient	O
overexpression	O
of	O
mutant	B
IkappaBalpha	I
.	O

Sensitivity	O
for	O
induction	O
of	O
apoptosis	O
was	O
markedly	O
increased	O
by	O
these	O
treatments	O
in	O
apoptosis	O
sensitive	O
cell	O
lines	O
.	O

Loss	O
-	O
and	O
gain	O
-	O
of	O
-	O
function	O
mutations	O
reveal	O
an	O
important	O
role	O
of	O
BSAP	B
(	O
Pax	B
-	I
5	I
)	O
at	O
the	O
start	O
and	O
end	O
of	O
B	O
cell	O
differentiation	O
.	O

However	O
,	O
its	O
interactions	O
with	O
these	O
histone	B
acetyltransferases	I
are	O
not	O
equivalent	O
,	O
as	O
CBP	B
and	O
p300	B
,	O
but	O
not	O
P	B
/	I
CAF	I
,	O
utilize	O
EKLF	B
as	O
a	O
substrate	O
for	O
in	O
vitro	O
acetylation	O
within	O
its	O
trans	O
-	O
activation	B
region	I
.	O

We	O
conclude	O
that	O
contact	O
with	O
fibrinogen	B
-	I
derived	I
proteins	I
may	O
contribute	O
to	O
mononuclear	O
phagocyte	O
activation	O
by	O
signaling	O
through	O
CD11b	B
/	I
CD18	I
,	O
resulting	O
in	O
selective	O
activation	O
of	O
transcriptional	B
regulatory	I
factors	I
,	O
including	O
NF	B
-	I
kappa	I
B	I
.	O

OBJECTIVE	O
:	O
To	O
identify	O
and	O
characterize	O
estrogen	B
receptor	I
(	I
ER	I
)	I
transcripts	I
expressed	O
in	O
immune	O
cells	O
of	O
patients	O
with	O
systemic	O
lupus	O
erythematosus	O
(	O
SLE	O
)	O
and	O
healthy	O
donors	O
.	O

There	O
were	O
no	O
notable	O
differences	O
in	O
the	O
ER	B
transcripts	I
between	O
patients	O
and	O
healthy	O
controls	O
.	O

Variant	O
receptor	O
transcripts	O
lacking	O
exon	B
5	I
or	O
exon	B
7	I
,	O
which	O
encodes	O
the	O
hormone	O
binding	O
domain	O
,	O
were	O
identified	O
in	O
the	O
majority	O
of	O
the	O
cells	O
.	O

Whether	O
the	O
detected	O
transcripts	O
are	O
translated	O
into	O
functional	O
receptor	O
proteins	O
remains	O
to	O
be	O
determined	O
.	O

A	O
nondegradable	O
mutant	O
of	O
I	B
kappa	I
B	I
blocked	O
both	O
FasL	B
expression	O
and	O
apoptosis	O
induced	O
by	O
DNA	O
damage	O
but	O
not	O
Fas	B
ligation	O
.	O

These	O
stimuli	O
also	O
induced	O
the	O
stress	O
-	O
activated	O
kinase	O
pathway	O
(	O
SAPK	B
/	B
JNK	I
)	O
,	O
which	O
was	O
required	O
for	O
the	O
maximal	O
induction	O
of	O
apoptosis	O
.	O

Simultaneously	O
,	O
T	O
lymphocyte	O
subsets	O
and	O
NK	O
cells	O
from	O
the	O
peripheral	O
blood	O
(	O
PB	O
)	O
and	O
bone	O
marrow	O
(	O
BM	O
)	O
were	O
investigated	O
by	O
flow	O
cytometric	O
analysis	O
.	O

Four	O
of	O
the	O
eight	O
patients	O
in	O
LT	O
and	O
7	O
of	O
the	O
15	O
patients	O
in	O
ST	O
remission	O
were	O
MRD	O
-	O
positive	O
.	O

Thus	O
,	O
the	O
difference	O
of	O
the	O
possible	O
T	O
/	O
NK	O
-	O
cell	O
phenotype	O
in	O
the	O
BM	O
may	O
strongly	O
influence	O
clinical	O
and	O
molecular	O
remission	O
.	O

The	O
implication	O
of	O
protein	B
tyrosine	I
kinase	I
(	I
s	I
)	I
,	O
protein	B
kinase	I
A	I
and	O
/	O
or	O
protein	B
kinase	I
C	I
was	O
highlighted	O
by	O
the	O
abrogation	O
of	O
the	O
ManLAM	O
-	O
mediated	O
activation	O
of	O
HIV	B
-	I
1	I
LTR	I
-	I
driven	I
gene	I
expression	O
using	O
herbimycin	O
A	O
and	O
H7	O
.	O

These	O
findings	O
suggest	O
that	O
LTR	B
sequence	I
changes	O
can	O
significantly	O
affect	O
basal	O
LTR	B
function	O
and	O
transcription	B
factor	I
recruitment	O
,	O
which	O
may	O
,	O
in	O
turn	O
,	O
alter	O
the	O
course	O
of	O
viral	O
replication	O
in	O
cells	O
of	O
CNS	O
and	O
immune	O
system	O
origin	O
.	O

These	O
insights	O
in	O
the	O
molecular	O
events	O
that	O
are	O
involved	O
in	O
TCF	B
/	I
LEF	I
function	O
in	O
these	O
organisms	O
may	O
eventually	O
lead	O
to	O
the	O
understanding	O
of	O
the	O
function	O
of	O
these	O
HMG	B
box	I
proteins	I
in	O
lymphoid	O
development	O

Molecular	O
genetic	O
characterization	O
of	O
the	O
variant	B
allele	I
can	O
serve	O
as	O
a	O
primary	O
tool	O
for	O
diagnosis	O
and	O
subsequent	O
therapy	O
,	O
and	O
can	O
provide	O
a	O
basis	O
for	O
distinguishing	O
heterozygous	O
carriers	O
in	O
familial	O
androgen	O
resistance	O
.	O

In	O
this	O
study	O
,	O
the	O
proliferative	O
activity	O
of	O
129	O
primary	O
breast	O
cancers	O
was	O
investigated	O
,	O
and	O
the	O
results	O
were	O
related	O
to	O
prognosis	O
.	O

RESULTS	O
.	O

Elf	B
-	I
1	I
binds	O
exclusively	O
to	O
the	O
underphosphorylated	O
form	O
of	O
Rb	B
and	O
fails	O
to	O
bind	O
to	O
Rb	B
mutants	I
derived	O
from	O
patients	O
with	O
retinoblastoma	O
.	O

In	O
this	O
study	O
we	O
analyzed	O
the	O
T	B
cell	I
receptor	I
(	I
TcR	I
)	I
delta	I
transcripts	I
expressed	O
by	O
CD3	O
-	O
CD16	O
+	O
cells	O
and	O
we	O
investigated	O
whether	O
these	O
cells	O
expressed	O
the	O
hGATA	B
-	I
3	I
T	I
cell	I
transcription	I
factor	I
and	O
the	O
recombination	B
-	I
activating	I
gene	I
(	I
RAG	I
)	I
-	I
1	I
.	O

Sequence	O
analysis	O
of	O
nine	O
different	O
2	O
.	O
3	O
-	O
kb	O
cDNA	O
clones	O
obtained	O
from	O
NK	O
-	O
derived	O
polyA	O
+	O
RNA	O
confirmed	O
that	O
they	O
corresponded	O
to	O
an	O
unrearranged	O
TcR	B
delta	I
gene	I
.	O

However	O
,	O
only	O
that	O
located	O
at	O
the	O
3	O
'	O
end	O
appeared	O
to	O
be	O
utilized	O
in	O
the	O
2	B
.	I
3	I
-	I
kb	I
cDNA	I
.	O

All	O
NK	O
clones	O
and	O
cell	O
lines	O
studied	O
were	O
found	O
to	O
express	O
hGATA	B
-	I
3	I
-	I
specific	I
mRNA	I
,	O
suggesting	O
that	O
hGATA	B
-	I
3	I
may	O
be	O
involved	O
in	O
the	O
regulation	O
of	O
the	O
unrearranged	O
TcR	B
delta	I
gene	I
expression	O
in	O
NK	O
cells	O
.	O

To	O
correlate	O
changes	O
in	O
nuclear	O
factor	O
binding	O
in	O
vitro	O
with	O
transcriptional	O
activity	O
in	O
vivo	O
and	O
define	O
the	O
structural	O
requirements	O
for	O
IL	B
-	I
2	I
promoter	I
repression	O
,	O
we	O
used	O
transient	O
DNA	O
transfections	O
.	O

Jurkat	O
cells	O
were	O
transfected	O
with	O
plasmids	B
containing	O
either	O
the	O
intact	O
IL	B
-	I
2	I
promoter	I
or	O
its	O
AP	B
-	I
1	I
,	I
NF	I
-	I
AT	I
,	I
and	I
NF	I
-	I
kB	I
motifs	I
.	O

Other	O
bacterial	O
toxins	O
,	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
(	O
TNF	B
)	O
,	O
interleukin	B
-	I
1	I
(	O
IL	B
-	I
1	I
)	O
,	O
T	B
cell	I
mitogens	I
,	O
UV	O
light	O
,	O
gamma	O
rays	O
and	O
oxidative	O
stress	O
were	O
reported	O
to	O
induce	O
NF	B
-	I
kappa	I
B	I
.	O

We	O
further	O
characterize	O
which	O
AP1	B
family	I
members	I
can	O
assume	O
this	O
role	O
.	O

Antisera	O
to	O
Fos	B
inhibits	O
NF	B
-	I
AT	I
DNA	O
binding	O
as	O
does	O
an	O
oligonucleotide	O
containing	O
a	O
binding	B
site	I
for	I
AP1	I
.	O

The	O
patients	O
'	O
plasma	O
cortisol	O
concentrations	O
were	O
normal	O
or	O
slightly	O
elevated	O
.	O

Despite	O
a	O
wide	O
range	O
,	O
the	O
mean	O
GR	B
count	O
and	O
affinity	O
in	O
MNC	O
from	O
septic	O
patients	O
did	O
not	O
differ	O
from	O
those	O
in	O
normal	O
controls	O
,	O
suggesting	O
that	O
glucocorticoids	O
could	O
still	O
be	O
effective	O
in	O
the	O
hemodynamic	O
compensatory	O
phase	O
of	O
sepsis	O
.	O

Activation	O
of	O
the	O
HIV	O
-	O
1	O
provirus	O
correlated	O
with	O
the	O
activation	O
of	O
binding	O
of	O
55	B
-	I
and	I
85	I
-	I
kDa	I
proteins	I
to	O
the	O
kappa	B
B	I
enhancer	I
and	O
binding	O
of	O
the	O
50	B
-	I
kDa	I
HLP	I
-	I
1	I
protein	I
to	O
the	O
LBP	B
-	I
1	I
sequences	I
of	O
the	O
HIV	B
-	I
1	I
long	I
terminal	I
repeat	I
.	O

Surprisingly	O
,	O
the	O
NF	B
-	I
kappa	I
B	I
and	O
HLP	O
-	O
1	O
binding	O
activities	O
were	O
substantially	O
inhibited	O
in	O
acyclovir	O
-	O
treated	O
cells	O
.	O

Transcriptional	O
activation	O
of	O
the	O
macrophage	B
colony	I
-	I
stimulating	I
factor	I
gene	I
by	O
IL	B
-	I
2	I
is	O
associated	O
with	O
secretion	O
of	O
bioactive	O
macrophage	B
colony	I
-	I
stimulating	I
factor	I
protein	I
by	O
monocytes	O
and	O
involves	O
activation	O
of	O
the	O
transcription	B
factor	I
NF	B
-	I
kappa	I
B	I
.	O

Transcriptional	O
activation	O
of	O
the	O
M	B
-	I
CSF	I
gene	I
by	O
IL	B
-	I
2	I
is	O
preceded	O
by	O
enhanced	O
binding	O
activity	O
of	O
the	O
transcription	B
factor	I
NF	B
-	I
kappa	I
B	I
to	O
its	O
recognition	O
sequence	O
in	O
the	O
5	O
'	O
regulatory	O
enhancer	O
region	O
of	O
the	O
M	B
-	I
CSF	I
gene	I
.	O

We	O
localized	O
the	O
LAM	O
-	O
,	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-	O
,	O
and	O
TNF	B
-	I
alpha	I
-	B
inducible	I
promoter	I
activity	O
to	O
a	O
-	O
131	O
/	O
+	O
15	O
(	O
positions	O
-	O
131	O
to	O
+	O
15	O
)	O
DNA	O
fragment	O
of	O
the	O
IL	B
-	I
1	I
beta	I
gene	I
by	O
deletion	O
analysis	O
and	O
chloramphenicol	B
acetyltransferase	I
assay	O
.	O

Site	O
-	O
directed	O
mutagenesis	O
demonstrated	O
that	O
the	O
two	O
NF	B
-	I
IL	I
-	I
6	I
motifs	I
could	O
be	O
independently	O
activated	O
by	O
LAM	O
,	O
LPS	O
,	O
or	O
TNF	B
-	I
alpha	I
and	O
that	O
they	O
acted	O
in	O
an	O
orientation	O
-	O
independent	O
manner	O
.	O

Additionally	O
,	O
Nef	O
expressing	O
cells	O
were	O
transiently	O
transfected	O
with	O
a	O
plasmid	O
in	O
which	O
HIV	B
-	I
1	I
AP	I
-	I
1	I
DNA	I
recognition	I
sequences	I
were	O
cloned	O
downstream	O
of	O
the	O
chloramphenicol	B
acetyltransferase	I
(	O
CAT	B
)	O
gene	O
.	O

The	O
in	O
vitro	O
effect	O
of	O
17	O
beta	O
-	O
estradiol	O
on	O
NK	O
activity	O
was	O
studied	O
.	O

A	O
serum	B
response	I
element	I
and	O
a	O
binding	B
site	I
for	I
NF	I
-	I
Y	I
mediate	O
the	O
serum	O
response	O
of	O
the	O
human	B
thrombospondin	I
1	I
gene	I
.	O

Two	O
transcriptional	O
elements	O
in	O
the	O
TSP	B
1	I
promoter	O
,	O
a	O
distal	O
element	O
at	O
-	O
1280	O
and	O
a	O
proximal	O
element	O
at	O
-	O
65	O
,	O
were	O
required	O
for	O
the	O
response	O
of	O
the	O
human	O
TSP	O
1	O
gene	O
to	O
serum	O
.	O

Cell	O
-	O
type	O
-	O
specific	O
transactivation	O
of	O
the	O
parathyroid	B
hormone	I
-	I
related	I
protein	I
gene	I
promoter	I
by	O
the	O
human	B
T	I
-	I
cell	I
leukemia	I
virus	I
type	I
I	I
(	I
HTLV	I
-	I
I	I
)	I
tax	I
and	O
HTLV	B
-	I
II	I
tax	I
proteins	I
.	O

The	O
human	B
T	I
-	I
cell	I
leukemia	I
virus	I
type	I
I	I
(	I
HTLV	I
-	I
I	I
)	I
and	I
HTLV	I
-	I
II	I
Tax	I
proteins	I
are	O
potent	O
transactivators	B
of	O
viral	O
and	O
cellular	O
gene	O
expression	O
.	O

A	O
carboxy	B
terminal	I
Tax	I
deletion	I
mutant	I
was	O
deficient	O
in	O
transactivation	O
of	O
both	O
the	O
PTHrP	B
and	I
IL2R	I
alpha	I
promoters	I
but	O
not	O
the	O
HTLV	B
-	I
I	I
long	I
terminal	I
repeat	I
(	O
LTR	B
)	O
.	O

Here	O
we	O
have	O
investigated	O
the	O
transcriptional	O
regulation	O
of	O
the	O
gamma	B
chain	I
gene	O
by	O
analyzing	O
the	O
2	B
.	I
5	I
-	I
kilobase	I
sequence	I
upstream	O
of	O
the	O
transcription	O
start	O
site	O
.	O

This	O
sequence	O
contains	O
a	O
promoter	B
specific	O
to	O
cells	O
of	O
hematopoietic	O
lineage	O
.	O

However	O
,	O
the	O
tissue	O
specificity	O
of	O
this	O
promoter	B
is	O
only	O
partial	O
because	O
it	O
is	O
active	O
in	O
all	O
of	O
the	O
hematopoietic	O
cells	O
tested	O
here	O
,	O
regardless	O
of	O
whether	O
they	O
constitutively	O
express	O
Fc	O
epsilon	O
RI	O
-	O
gamma	B
chain	I
transcripts	O
.	O

Regression	O
analysis	O
of	O
our	O
data	O
revealed	O
slight	O
trends	O
for	O
some	O
of	O
the	O
biomarkers	O
(	O
e	O
.	O
g	O
.	O
CD45R0	O
+	O
)	O
.	O

HIV	O
-	O
1	O
can	O
also	O
establish	O
a	O
latent	O
or	O
persistent	O
infection	O
in	O
some	O
T	O
cell	O
lines	O
that	O
show	O
minimal	O
constitutive	O
virus	O
expression	O
.	O

On	O
the	O
basis	O
of	O
these	O
observations	O
,	O
it	O
has	O
been	O
proposed	O
that	O
reactivation	O
of	O
latent	O
HIV	O
-	O
1	O
harbored	O
in	O
chronically	O
infected	O
T	O
lymphocytes	O
,	O
monocytes	O
,	O
or	O
macrophages	O
plays	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
AIDS	O
.	O

ACH	O
-	O
2	O
can	O
be	O
converted	O
to	O
productive	O
infection	O
by	O
stimulation	O
of	O
the	O
cells	O
with	O
12	O
-	O
O	O
-	O
tetradecanoylphorbol	O
-	O
13	O
-	O
acetate	O
(	O
TPA	O
)	O
,	O
mitogen	O
or	O
cytokines	B
(	O
TNF	B
-	I
alpha	I
)	O
,	O
or	O
infection	O
with	O
HSV	O
.	O

Oxidoreductive	O
regulation	O
of	O
nuclear	B
factor	I
kappa	I
B	I
.	O

The	O
promoter	O
activity	O
from	O
HIV	B
long	I
terminal	I
repeat	I
was	O
greatly	O
augmented	O
by	O
co	O
-	O
transfecting	O
the	O
Trx	B
-	I
expressing	I
plasmid	I
,	O
whose	O
effect	O
was	O
dependent	O
on	O
the	O
NF	B
kappa	I
B	I
-	O
binding	O
sites	O
.	O

These	O
results	O
may	O
also	O
provide	O
a	O
clue	O
to	O
understanding	O
of	O
the	O
molecular	O
process	O
of	O
AIDS	O
pathogenesis	O
and	O
its	O
possible	O
biochemical	O
intervention	O
.	O

Synergism	O
between	O
the	O
CD3	O
antigen	O
-	O
and	O
CD2	O
antigen	O
-	O
derived	O
signals	O
.	O

We	O
have	O
demonstrated	O
earlier	O
that	O
the	O
crosslinkage	O
of	O
the	O
CD3	B
/	I
TCR	I
complex	I
with	O
the	O
CD2	B
antigen	I
results	O
in	O
the	O
proliferation	O
of	O
normal	O
human	O
T	O
cells	O
.	O

The	O
human	O
erythroleukemia	O
cell	O
line	O
K562	O
can	O
be	O
induced	O
to	O
differentiate	O
along	O
the	O
erythroid	O
and	O
megakaryocytic	O
lineages	O
.	O

This	O
was	O
accompanied	O
by	O
downregulation	O
of	O
two	O
transcription	B
factors	I
normally	O
expressed	O
in	O
erythroid	O
,	O
mast	O
and	O
megakaryocyte	O
lineages	O
.	O

Northern	O
analysis	O
demonstrated	O
coordinate	O
downregulation	O
of	O
alpha	B
globin	I
and	O
gamma	B
globin	I
in	O
addition	O
to	O
the	O
two	O
lineage	O
-	O
restricted	O
transcription	B
factors	I
,	O
SCL	B
and	O
GATA	B
-	I
1	I
.	O

Electron	O
microscopy	O
revealed	O
a	O
marked	O
increase	O
in	O
granules	O
resembling	O
those	O
specific	O
for	O
eosinophils	O
.	O

Surface	O
marker	O
analysis	O
showed	O
that	O
HMBA	O
-	O
induced	O
cells	O
expressed	O
reduced	O
levels	O
of	O
glycophorin	B
A	I
,	O
CD5	B
,	O
CD7	B
and	O
CD11b	B
.	O

Activation	O
of	O
primary	O
human	O
T	O
-	O
lymphocytes	O
through	O
CD2	B
plus	I
CD28	I
adhesion	I
molecules	I
induces	O
long	O
-	O
term	O
nuclear	O
expression	O
of	O
NF	B
-	I
kappa	I
B	I
.	O

Long	O
-	O
lasting	O
IL	B
-	I
2	I
receptivity	O
is	O
associated	O
with	O
high	O
-	O
level	O
expression	O
of	O
the	O
inducible	O
IL	B
-	I
2	I
receptor	I
alpha	I
chain	I
(	I
IL	I
-	I
2R	I
alpha	I
)	I
gene	I
that	O
is	O
regulated	O
at	O
both	O
transcriptional	O
and	O
posttranscriptional	O
levels	O
.	O

Resting	O
T	O
-	O
cell	O
nuclear	O
extracts	O
contained	O
KBF1	B
/	I
p50	I
homodimer	I
.	O

In	O
addition	O
,	O
an	O
inhibitor	O
of	O
PKC	B
blocked	O
both	O
activated	O
ras	B
and	O
phorbol	O
ester	O
stimulation	O
,	O
suggesting	O
a	O
role	O
for	O
ras	B
upstream	O
of	O
PKC	B
.	O

No	O
such	O
increase	O
was	O
observed	O
in	O
control	O
U937	O
cells	O
.	O

We	O
show	O
that	O
the	O
ability	O
to	O
detect	O
NF	B
-	I
ATp	I
in	O
a	O
gel	O
shift	O
assay	O
,	O
which	O
is	O
essential	O
for	O
purification	O
and	O
biochemical	O
studies	O
of	O
this	O
protein	O
,	O
is	O
strikingly	O
dependent	O
on	O
the	O
precise	O
sequence	O
of	O
the	O
NF	B
-	I
AT	I
oligonucleotide	O
used	O
as	O
the	O
labeled	O
probe	O
.	O

One	O
of	O
these	O
activities	O
was	O
found	O
to	O
be	O
a	O
novel	O
,	O
less	O
abundant	O
,	O
Rb	O
-	O
E2F	B
complex	O
.	O

The	O
most	O
prominent	O
E2F	B
activity	O
in	O
resting	O
T	O
cells	O
(	O
termed	O
complex	O
X	O
)	O
was	O
abundant	O
in	O
both	O
G0	O
and	O
G1	O
but	O
disappeared	O
as	O
cells	O
entered	O
S	O
phase	O
,	O
suggesting	O
a	O
possible	O
role	O
in	O
negatively	O
regulating	O
E2F	B
function	O
.	O

The	O
present	O
studies	O
have	O
examined	O
the	O
effects	O
of	O
vincristine	O
-	O
selected	O
,	O
multidrug	O
resistance	O
on	O
12	O
-	O
O	O
-	O
tetradecanoylphorbol	O
-	O
13	O
-	O
acetate	O
(	O
TPA	O
)	O
-	O
induced	O
HL	O
-	O
60	O
cell	O
differentiation	O
.	O

Since	O
TPA	O
activates	O
protein	B
kinase	I
C	I
(	O
PKC	B
)	O
,	O
we	O
examined	O
translocation	O
of	O
PKC	B
from	O
the	O
cytosol	O
to	O
the	O
membrane	O
fraction	O
.	O

To	O
determine	O
whether	O
the	O
defect	O
in	O
the	O
patient	O
'	O
s	O
T	O
lymphocytes	O
involved	O
a	O
trans	B
-	I
acting	I
factor	I
common	O
to	O
the	O
affected	O
lymphokine	B
genes	I
,	O
we	O
examined	O
the	O
ability	O
of	O
nuclear	B
factors	I
from	O
the	O
patient	O
'	O
s	O
T	O
lymphocytes	O
to	O
bind	O
response	O
elements	O
present	O
in	O
the	O
regulatory	B
region	I
of	O
IL2	B
.	O

In	O
contrast	O
,	O
the	O
binding	O
of	O
the	O
nuclear	B
factor	I
of	I
activated	I
T	I
cells	I
(	O
NF	B
-	I
AT	I
)	O
to	O
its	O
response	O
element	O
in	O
the	O
IL2	B
enhancer	I
and	O
to	O
an	O
NF	B
-	I
AT	I
-	I
like	I
response	I
element	I
present	O
in	O
the	O
IL4	B
enhancer	I
was	O
abnormal	O
.	O

They	O
do	O
not	O
directly	O
intercept	O
intracellular	O
signalling	O
molecules	O
.	O

Instead	O
,	O
they	O
form	O
tight	O
complexes	O
with	O
two	O
different	O
classes	O
of	O
abundant	O
cytosolic	B
receptors	I
called	O
immunophilins	B
upon	O
entering	O
the	O
cell	O
,	O
and	O
consequently	O
inhibit	O
their	O
peptidyl	B
prolyl	I
cis	I
-	I
trans	I
isomerase	I
activities	O
.	O

p105	B
and	O
p98	B
precursor	B
proteins	I
play	O
an	O
active	O
role	O
in	O
NF	B
-	I
kappa	I
B	I
-	O
mediated	O
signal	O
transduction	O
.	O

Association	O
with	O
the	O
precursors	O
is	O
sufficient	O
for	O
cytoplasmic	O
retention	O
of	O
either	O
p65	B
or	O
c	B
-	I
Rel	I
,	O
both	O
of	O
which	O
are	O
otherwise	O
nuclear	O
.	O

The	O
eukaryotic	O
transcription	B
factor	I
nuclear	B
factor	I
-	I
kappa	I
B	I
(	O
NF	B
-	I
kappa	I
B	I
)	O
participates	O
in	O
many	O
parts	O
of	O
the	O
genetic	O
program	O
mediating	O
T	O
lymphocyte	O
activation	O
and	O
growth	O
.	O

Transfection	O
studies	O
indicate	O
that	O
the	O
I	B
kappa	I
B	I
alpha	I
gene	I
is	O
specifically	O
induced	O
by	O
the	O
65	B
-	I
kilodalton	I
transactivating	I
subunit	I
of	O
NF	B
-	I
kappa	I
B	I
.	O

Together	O
,	O
these	O
results	O
show	O
that	O
NF	B
-	I
kappa	I
B	I
controls	O
the	O
expression	O
of	O
I	B
kappa	I
B	I
alpha	O
by	O
means	O
of	O
an	O
inducible	O
autoregulatory	O
pathway	O
.	O

A	O
cell	B
-	I
type	I
-	I
independent	I
lipopolysaccharide	I
(	I
LPS	I
)	I
-	I
responsive	I
enhancer	I
element	I
located	O
between	O
-	B
3757	I
and	I
-	I
2729	I
bp	I
upstream	I
from	O
the	O
transcription	B
start	I
site	I
(	O
cap	B
site	I
)	O
consisted	O
of	O
at	O
least	O
six	O
discrete	O
subregions	O
which	O
were	O
essential	O
to	O
the	O
maximal	O
induction	O
by	O
LPS	O
in	O
transfected	O
monocytes	O
.	O

The	O
assessment	O
of	O
synovial	O
lymphocyte	O
reactivity	O
to	O
adenovirus	O
antigen	O
stimulation	O
was	O
undertaken	O
in	O
patients	O
with	O
persistent	O
or	O
recurrent	O
inflammatory	O
arthritis	O
.	O

The	O
3H	O
-	O
thymidine	O
uptake	O
procedure	O
was	O
employed	O
,	O
incorporating	O
multiple	O
microbiological	B
antigens	I
.	O

Expression	O
of	O
PILOT	B
,	O
a	O
putative	O
transcription	B
factor	I
,	O
requires	O
two	O
signals	O
and	O
is	O
cyclosporin	O
A	O
sensitive	O
in	O
T	O
cells	O
.	O

Few	O
known	O
genes	B
(	O
IL	B
-	I
2	I
,	O
members	O
of	O
the	O
IL	B
-	I
8	I
family	I
,	O
interferon	B
-	I
gamma	I
)	O
are	O
induced	O
in	O
T	O
cells	O
only	O
through	O
the	O
combined	O
effect	O
of	O
phorbol	O
myristic	O
acetate	O
(	O
PMA	O
)	O
and	O
a	O
Ca	O
(	O
2	O
+	O
)	O
-	O
ionophore	O
,	O
and	O
expression	O
of	O
only	O
these	O
genes	B
can	O
be	O
fully	O
suppressed	O
by	O
Cyclosporin	O
A	O
(	O
CyA	O
)	O
.	O

The	O
PILOT	B
protein	O
has	O
a	O
calculated	O
M	O
(	O
r	O
)	O
of	O
42	O
.	O
6	O
kDa	O
and	O
contains	O
three	O
zinc	B
fingers	I
of	O
the	O
C2H2	B
-	I
type	I
at	O
the	O
carboxyl	B
-	I
terminus	I
which	O
are	O
highly	O
homologous	O
to	O
the	O
zinc	B
finger	I
regions	I
of	O
the	O
transcription	B
factors	I
EGR1	B
,	O
EGR2	B
,	O
and	O
pAT	B
133	I
.	O

In	O
contrast	O
to	O
T	O
cells	O
,	O
in	O
fibroblasts	O
PILOT	B
gene	O
expression	O
requires	O
only	O
one	O
signal	O
(	O
PMA	O
)	O
and	O
is	O
not	O
affected	O
by	O
CyA	O
.	O

NF	B
-	I
kappa	I
B	I
is	O
a	O
pleiotropic	B
regulator	I
of	O
a	O
variety	O
of	O
genes	O
implicated	O
in	O
the	O
cellular	O
response	O
to	O
injury	O
.	O

However	O
,	O
the	O
p65	B
antisense	O
phosphorothioate	O
oligodeoxynucleotide	O
had	O
no	O
significant	O
effect	O
on	O
the	O
production	O
of	O
reactive	O
oxygen	O
intermediates	O
or	O
on	O
phagocytosis	O
by	O
these	O
cells	O
.	O

These	O
findings	O
indicate	O
that	O
antisense	O
oligomers	O
to	O
p65	B
can	O
be	O
used	O
to	O
define	O
the	O
role	O
of	O
NF	B
-	I
kappa	I
B	I
in	O
the	O
activation	O
pathways	O
of	O
neutrophils	O
.	O

Overexpression	O
of	O
p65	B
increases	O
endogenous	O
I	B
kappa	I
B	I
protein	O
in	O
both	O
carcinoma	O
and	O
lymphoid	O
cells	O
by	O
two	O
mechanisms	O
:	O
protein	O
stabilization	O
and	O
increased	O
transcription	O
of	O
I	B
kappa	I
B	I
mRNA	I
.	O

The	O
precise	O
molecular	O
abnormalities	O
that	O
cause	O
primary	O
cortisol	O
resistance	O
have	O
not	O
been	O
completely	O
described	O
.	O

At	O
nucleotide	O
2	O
,	O
317	O
we	O
identified	O
a	O
homozygous	O
A	O
for	O
G	O
point	O
mutation	O
that	O
predicts	O
an	O
isoleucine	O
(	O
ATT	O
)	O
for	O
valine	O
(	O
GTT	O
)	O
substitution	O
at	O
amino	O
acid	O
729	O
.	O

When	O
the	O
wild	B
-	I
type	I
hGR	I
and	O
hGR	B
-	I
Ile	I
729	I
were	O
expressed	O
in	O
COS	O
-	O
1	O
cells	O
and	O
assayed	O
for	O
[	O
3H	O
]	O
-	O
Dexamethasone	O
binding	O
,	O
the	O
dissociation	O
constants	O
were	O
0	O
.	O
799	O
+	O
/	O
-	O
0	O
.	O
068	O
and	O
1	O
.	O
54	O
+	O
/	O
-	O
0	O
.	O
06	O
nM	O
(	O
mean	O
+	O
/	O
-	O
SEM	O
)	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
,	O
respectively	O
.	O

Transcriptional	O
regulation	O
of	O
interleukin	B
3	I
(	O
IL3	B
)	O
in	O
primary	O
human	O
T	O
lymphocytes	O
.	O

Dimerization	O
of	O
NF	B
-	I
KB2	I
with	O
RelA	B
(	I
p65	I
)	I
regulates	O
DNA	O
binding	O
,	O
transcriptional	O
activation	O
,	O
and	O
inhibition	O
by	O
an	O
I	B
kappa	I
B	I
-	I
alpha	I
(	O
MAD	B
-	I
3	I
)	O
.	O

We	O
have	O
previously	O
found	O
that	O
NFKB2	B
(	I
p49	I
/	I
p52	I
)	I
acts	O
in	O
concert	O
with	O
RelA	B
(	I
p65	I
)	I
to	O
stimulate	O
the	O
HIV	B
enhancer	I
in	O
Jurkat	O
T	O
-	O
leukemia	O
cells	O
.	O

Transcriptional	O
activation	O
of	O
the	O
HIV	O
enhancer	O
was	O
also	O
subject	O
to	O
regulation	O
by	O
recently	O
cloned	O
I	B
kappa	I
B	I
-	I
alpha	I
(	O
MAD	B
-	I
3	I
)	O
.	O

The	O
c	B
-	I
rel	I
protooncogene	I
product	I
represses	O
NF	B
-	I
kappa	I
B	I
p65	B
-	O
mediated	O
transcriptional	O
activation	O
of	O
the	O
long	O
terminal	O
repeat	O
of	O
type	O
1	O
human	O
immunodeficiency	O
virus	O
.	O

This	O
intracellular	O
signaling	O
complex	O
potently	O
stimulates	O
kappa	O
B	O
-	O
directed	O
transcription	O
from	O
either	O
the	O
HIV	B
-	I
1	I
LTR	I
or	O
the	O
IL	B
-	I
2R	I
alpha	I
promoter	I
via	O
the	O
strong	O
transactivation	O
domain	O
present	O
in	O
p65	B
.	O

We	O
now	O
demonstrate	O
that	O
nuclear	O
expression	O
of	O
human	O
c	B
-	I
Rel	I
,	O
which	O
is	O
induced	O
by	O
either	O
phorbol	O
ester	O
or	O
tumor	B
necrosis	I
factor	I
alpha	I
with	O
delayed	O
kinetics	O
relative	O
to	O
p65	B
,	O
markedly	O
represses	O
p65	B
-	O
mediated	O
activation	O
of	O
these	O
transcription	O
units	O
.	O

The	O
ras	O
-	O
transformed	O
lymphocytes	O
displayed	O
a	O
fully	O
functional	O
IL	B
-	I
2r	I
,	O
as	O
assessed	O
by	O
c	B
-	I
fos	I
induction	O
following	O
treatment	O
with	O
IL	B
-	I
2	I
;	O
nevertheless	O
,	O
they	O
were	O
not	O
growth	O
stimulated	O
by	O
this	O
lymphokine	B
.	O

Somewhat	O
unexpectedly	O
,	O
the	O
constitutive	O
p21ras	B
activity	O
did	O
not	O
cause	O
an	O
increased	O
DNA	O
binding	O
of	O
transcription	B
factors	I
PEA1	B
(	O
AP1	B
)	O
,	O
PEA3	B
,	O
Oct	B
-	I
2	I
or	O
NF	B
-	I
kB	I

Competition	O
with	O
an	O
AP	B
-	I
1	I
motif	I
or	O
with	O
anti	B
-	I
Jun	I
and	O
anti	B
-	I
Fos	I
antibodies	I
abolished	O
binding	O
to	O
the	O
NFAT	B
motif	I
in	O
both	O
T	O
and	O
B	O
cells	O
,	O
indicating	O
that	O
Jun	O
and	O
Fos	O
are	O
critical	O
for	O
NFAT	B
complex	I
formation	O
in	O
both	O
cell	O
types	O
.	O

However	O
,	O
when	O
combined	O
with	O
unstimulated	O
B	O
or	O
T	O
cell	O
extracts	O
,	O
full	O
-	O
length	O
,	O
but	O
not	O
truncated	O
,	O
Jun	O
/	O
Fos	O
heterodimers	O
were	O
able	O
to	O
form	O
an	O
NFAT	B
complex	I
,	O
indicating	O
the	O
presence	O
of	O
a	O
constitutively	B
expressed	I
nuclear	I
factor	I
(	O
s	O
)	O
in	O
B	O
and	O
T	O
cells	O
necessary	O
for	O
the	O
formation	O
of	O
the	O
NFAT	B
complex	I
in	O
both	O
cell	O
types	O
.	O

Differential	O
autoregulation	O
of	O
glucocorticoid	B
receptor	I
expression	O
in	O
human	O
T	O
-	O
and	O
B	O
-	O
cell	O
lines	O
.	O

In	O
contrast	O
to	O
the	O
decrease	O
in	O
GR	B
mRNA	I
seen	O
in	O
IM	O
-	O
9	O
cells	O
after	O
treatment	O
with	O
1	O
microM	O
dexamethasone	O
for	O
16	O
-	O
18	O
h	O
,	O
treatment	O
of	O
6TG1	O
.	O
1	O
cells	O
resulted	O
in	O
an	O
8	O
-	O
fold	O
increase	O
in	O
GR	B
mRNA	I
,	O
as	O
determined	O
by	O
Northern	O
blot	O
and	O
RNase	B
protection	O
analysis	O
,	O
with	O
a	O
corresponding	O
3	O
-	O
to	O
4	O
-	O
fold	O
increase	O
in	O
GR	B
protein	I
.	O

Induction	O
of	O
CD8	B
antigen	I
and	O
suppressor	O
activity	O
by	O
glucocorticoids	O
in	O
a	O
CEM	O
human	O
leukemic	O
cell	O
clone	O
.	O

It	O
has	O
been	O
thought	O
that	O
the	O
virally	O
induced	O
inhibition	O
of	O
IFN	B
-	O
MCP	O
is	O
secondary	O
to	O
the	O
shutdown	O
of	O
cellular	O
macromolecular	O
synthesis	O
that	O
accompanies	O
cytopathic	O
virus	O
infections	O
.	O

IFN	B
-	O
MCP	O
was	O
not	O
inhibited	O
by	O
infection	O
with	O
dl343	O
,	O
despite	O
the	O
production	O
of	O
large	O
amounts	O
of	O
both	O
early	O
(	O
E1B	B
,	O
p55	B
)	O
and	O
late	O
(	O
hexon	B
)	O
Ad	B
proteins	I
.	O

E1A	B
'	O
s	O
inhibition	O
of	O
IFN	B
-	O
MCP	O
has	O
the	O
net	O
effect	O
of	O
promoting	O
the	O
selective	O
NK	O
cell	O
-	O
mediated	O
clearance	O
of	O
Ad	O
-	O
infected	O
or	O
Ad	O
-	O
transformed	O
human	O
cells	O
.	O

Nuclear	B
factor	I
of	I
activated	I
T	I
cells	I
(	O
NF	B
-	I
AT	I
)	O
is	O
a	O
transcriptional	B
activator	I
involved	O
in	O
the	O
induction	O
of	O
IL	B
-	I
2	I
gene	O
expression	O
.	O

We	O
find	O
that	O
a	O
short	O
enhancer	O
element	O
containing	O
the	O
NF	B
-	I
kappa	I
B	I
binding	I
site	I
from	O
the	O
interleukin	B
-	I
2	I
receptor	I
alpha	I
-	I
chain	I
gene	I
(	O
IL	B
-	I
2R	I
alpha	I
)	O
is	O
preferentially	O
activated	O
in	O
T	O
cells	O
.	O

Serum	B
response	I
factor	I
(	O
SRF	B
)	O
binds	O
to	O
a	O
site	O
adjacent	O
to	O
the	O
NF	B
-	I
kappa	I
B	I
site	I
in	O
the	O
IL	B
-	I
2R	I
enhancer	I
,	O
and	O
both	O
sites	O
together	O
have	O
strong	O
transcriptional	O
activity	O
specifically	O
in	O
T	O
cells	O
.	O

Mutual	O
regulation	O
of	O
the	O
transcriptional	B
activator	I
NF	B
-	I
kappa	I
B	I
and	O
its	O
inhibitor	O
,	O
I	B
kappa	I
B	I
-	I
alpha	I
.	O

In	O
previous	O
transfection	O
analyses	O
using	O
the	O
chloramphenicol	B
acetyltransferase	I
reporter	B
gene	I
system	O
,	O
we	O
determined	O
that	O
linker	O
substitution	O
(	O
LS	O
)	O
mutations	O
between	O
-	B
201	I
and	I
-	I
130	I
(	O
relative	O
to	O
the	O
transcription	O
start	O
site	O
)	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
long	B
terminal	I
repeat	I
(	O
LTR	B
)	O
caused	O
moderate	O
decreases	O
in	O
LTR	B
transcriptional	O
activity	O
in	O
a	O
T	O
-	O
cell	O
line	O
(	O
S	O
.	O
L	O
.	O
Zeichner	O
,	O
J	O
.	O
Y	O
.	O
H	O
.	O
Kim	O
,	O
and	O
J	O
.	O
C	O
.	O
Alwine	O
,	O
J	O
.	O
Virol	O
.	O
65	O
:	O
2436	O
-	O
2444	O
,	O
1991	O
)	O
.	O

If	O
GATA	O
-	O
1	O
-	O
red	O
cells	O
were	O
available	O
,	O
the	O
analyses	O
would	O
involve	O
the	O
actual	O
transcription	O
of	O
or	O
chromatin	O
structure	O
surrounding	O
the	O
globin	B
genes	I
.	O

G0S24	B
is	O
a	O
member	O
of	O
a	O
set	O
of	O
genes	O
(	O
putative	B
G0	I
/	I
G1	I
switch	I
regulatory	I
genes	I
)	O
that	O
are	O
expressed	O
transiently	O
within	O
1	O
-	O
2	O
hr	O
of	O
the	O
addition	O
of	O
lectin	B
or	O
cycloheximide	O
to	O
human	O
blood	O
mononuclear	O
cells	O
.	O

Comparison	O
of	O
the	O
derived	O
protein	O
sequence	O
with	O
those	O
of	O
rodent	O
homologs	O
allows	O
classification	O
into	O
three	O
groups	O
.	O

Groups	O
1	O
and	O
2	O
have	O
a	O
serine	B
-	I
rich	I
region	I
and	O
an	O
`	O
`	O
arginine	B
element	I
`	O
`	O
(	O
RRLPIF	B
)	O
at	O
the	O
carboxyl	B
terminus	I
.	O

All	O
groups	O
contain	O
cysteine	B
-	I
and	I
histidine	I
-	I
rich	I
putative	I
zinc	I
finger	I
domains	I
and	O
a	O
serine	B
-	I
phenylalanine	I
`	I
`	I
SFS	I
'	I
'	I
domain	I
similar	O
to	O
part	O
of	O
the	O
large	O
subunit	O
of	O
eukaryotic	B
RNA	I
polymerase	I
II	I
.	O

Comparison	O
of	O
group	O
1	O
human	B
and	I
mouse	I
genomic	I
sequences	I
shows	O
high	O
conservation	O
in	O
the	O
5	B
'	I
flank	I
and	O
exons	B
.	O

A	O
CpG	O
island	O
suggests	O
expression	O
in	O
the	O
germ	O
line	O
.	O

A	O
microB	B
binding	I
protein	I
is	O
encoded	O
by	O
the	O
PU	B
.	I
1	I
/	I
Spi	I
-	I
1	I
proto	I
-	I
oncogene	I
.	O

One	O
enigmatic	O
aspect	O
of	O
GATA	B
factor	I
expression	O
is	O
that	O
several	O
GATA	B
proteins	I
,	O
which	O
ostensibly	O
share	O
the	O
same	O
DNA	B
-	I
binding	I
site	I
specificity	O
,	O
are	O
coexpressed	O
in	O
erythroid	O
cells	O
.	O

Thus	O
,	O
the	O
GATA	B
-	I
2	I
transcription	I
factor	I
appears	O
to	O
play	O
a	O
role	O
in	O
regulating	O
the	O
self	O
-	O
renewal	O
capacity	O
of	O
early	O
erythroid	O
progenitor	O
cells	O
.	O

Endothelial	O
cells	O
(	O
EC	O
)	O
act	O
as	O
APC	O
for	O
resting	O
PBL	O
in	O
vitro	O
,	O
and	O
may	O
have	O
important	O
roles	O
in	O
vivo	O
in	O
the	O
pathogenesis	O
of	O
allograft	O
rejection	O
and	O
delayed	O
hypersensitivity	O
.	O

PBL	O
constitutively	O
express	O
c	B
-	I
jun	I
transcripts	I
,	O
and	O
the	O
level	O
of	O
c	B
-	I
jun	I
mRNA	I
is	O
not	O
altered	O
by	O
PHA	B
activation	O
in	O
the	O
absence	O
or	O
presence	O
of	O
EC	O
.	O

In	O
contrast	O
,	O
c	B
-	I
fos	I
mRNA	I
is	O
absent	O
from	O
resting	O
T	O
cells	O
and	O
is	O
induced	O
on	O
PHA	B
activation	O
.	O

Site	O
-	O
directed	O
mutagenesis	O
demonstrated	O
that	O
this	O
HS	B
-	I
40	I
enhancer	O
-	O
zeta	B
2	I
globin	I
promoter	I
interaction	O
is	O
mediated	O
by	O
the	O
two	O
GATA	O
-	O
1	O
factor	O
binding	O
motifs	O
located	O
at	O
-	O
230	O
and	O
-	O
104	O
,	O
respectively	O
.	O

Site	O
-	O
directed	O
mutagenesis	O
further	O
demonstrated	O
that	O
the	O
enhancer	B
function	O
of	O
one	O
of	O
the	O
two	O
NF	O
-	O
E2	O
/	O
AP1	O
motifs	O
of	O
HS	B
-	I
40	I
is	O
mediated	O
through	O
its	O
binding	O
to	O
NF	B
-	I
E2	I
but	O
not	O
AP1	B
transcription	I
factor	I
.	O

We	O
report	O
the	O
characterization	O
of	O
the	O
cis	B
-	I
and	I
trans	I
-	I
acting	I
elements	I
involved	O
in	O
the	O
tissue	O
-	O
specific	O
activity	O
of	O
the	O
L	B
gene	I
erythroid	I
promoter	I
.	O

Within	O
this	O
region	O
,	O
we	O
define	O
a	O
minimal	B
promoter	I
(	O
-	O
62	O
to	O
+	O
54	O
)	O
that	O
displays	O
erythroid	O
-	O
specific	O
activity	O
and	O
contains	O
two	O
DNA	O
binding	O
sites	O
.	O

Mutations	O
and	O
deletions	O
of	O
both	O
sites	O
indicate	O
that	O
only	O
the	O
association	O
of	O
CCACC	B
/	I
Sp1	I
and	O
GATA	B
binding	I
sites	I
can	O
drive	O
efficient	O
and	O
tissue	O
-	O
specific	O
expression	O
of	O
this	O
R	B
-	I
PK	I
minimal	B
promoter	I
.	O

Protease	O
treatment	O
of	O
nuclear	O
extracts	O
distinguishes	O
between	O
class	B
II	I
MHC	I
X1	I
box	I
DNA	I
-	I
binding	I
proteins	I
in	O
wild	O
-	O
type	O
and	O
class	O
II	O
-	O
deficient	O
B	O
cells	O
.	O

The	O
X	B
box	I
region	I
is	O
critical	O
for	O
directing	O
the	O
expression	O
of	O
class	B
II	I
major	I
histocompatibility	I
complex	I
genes	I
in	O
B	O
lymphocytes	O
.	O

To	O
further	O
evaluate	O
the	O
role	O
of	O
X	B
box	I
DNA	I
-	I
binding	I
proteins	I
in	O
class	B
II	I
gene	I
expression	O
,	O
the	O
role	O
of	O
the	O
X	B
box	I
region	I
was	O
examined	O
in	O
both	O
class	O
II	O
-	O
positive	O
and	O
-	O
negative	O
lymphoid	O
cells	O
.	O

To	O
determine	O
whether	O
these	O
different	O
X1	O
box	O
activities	O
represented	O
distinct	O
DNA	B
binding	I
proteins	I
or	O
multimeric	O
forms	O
of	O
the	O
same	O
factor	O
(	O
s	O
)	O
,	O
protease	B
treatment	O
of	O
the	O
crude	O
nuclear	O
extracts	O
followed	O
by	O
DNA	O
-	O
binding	O
assays	O
were	O
carried	O
out	O
and	O
demonstrated	O
that	O
B	O
cell	O
extracts	O
contain	O
at	O
least	O
two	O
X1	B
-	I
specific	I
factors	I
.	O

A	O
similar	O
comparison	O
with	O
protease	O
-	O
treated	O
extracts	O
prepared	O
from	O
Jurkat	O
cells	O
demonstrated	O
the	O
presence	O
of	O
the	O
band	O
1pk	O
activity	O
despite	O
an	O
absence	O
of	O
the	O
native	O
RFX	B
activity	O
.	O

In	O
contrast	O
,	O
protease	O
treatment	O
and	O
analysis	O
of	O
SJO	O
extracts	O
showed	O
no	O
detectable	O
levels	O
of	O
the	O
band	O
1pk	O
activity	O
.	O

Human	O
immunodeficiency	O
viruses	O
containing	O
heterologous	B
enhancer	I
/	I
promoters	I
are	O
replication	O
competent	O
and	O
exhibit	O
different	O
lymphocyte	O
tropisms	O
.	O

Viruses	O
containing	O
the	O
human	B
cytomegalovirus	I
immediate	I
-	I
early	I
enhancer	I
exhibited	O
infectious	O
kinetics	O
similar	O
to	O
that	O
of	O
wild	O
-	O
type	O
HIV	O
in	O
activated	O
human	O
peripheral	O
blood	O
lymphocytes	O
and	O
AA2	O
cells	O
but	O
replicated	O
less	O
efficiently	O
in	O
H9	O
and	O
CEM	O
cells	O
.	O

Our	O
report	O
expands	O
current	O
knowledge	O
of	O
the	O
radiation	O
-	O
induced	O
signaling	O
cascade	O
by	O
clarifying	O
the	O
chronological	O
sequence	O
of	O
biochemical	O
events	O
that	O
follow	O
irradiation	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
a	O
more	O
sensitive	O
and	O
specific	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
assay	O
was	O
developed	O
to	O
detect	O
adenovirus	B
DNA	I
.	O

The	O
E1A	B
and	I
hexon	I
primers	I
amplified	O
DNA	O
from	O
representative	O
adenoviral	O
serotypes	O
in	O
all	O
six	O
adenoviral	O
groups	O
(	O
A	O
-	O
F	O
)	O
.	O

OBJECTIVE	O
:	O
To	O
examine	O
the	O
inter	O
-	O
relationship	O
between	O
HIV	O
-	O
1	O
infection	O
and	O
the	O
cell	O
surface	O
receptors	O
for	O
tumor	B
necrosis	I
factor	I
(	I
TNF	I
)	I
-	I
alpha	I
,	O
an	O
immunoregulatory	O
cytokine	O
that	O
can	O
enhance	O
HIV	O
-	O
1	O
replication	O
.	O

HIV	O
-	O
1	O
activation	O
and	O
expression	O
was	O
quantitated	O
by	O
reverse	B
transcriptase	I
assay	O
.	O

RESULTS	O
:	O
In	O
the	O
OM	O
-	O
10	O
.	O
1	O
promyelocytic	O
model	O
of	O
chronic	O
infection	O
,	O
TNF	O
-	O
alpha	O
-	O
induced	O
HIV	O
-	O
1	O
expression	O
also	O
resulted	O
in	O
a	O
substantial	O
increase	O
in	O
75	B
kd	I
TNF	I
receptor	I
(	O
TR75	B
)	O
expression	O
although	O
55	B
kD	I
TNF	I
receptor	I
(	O
TR55	B
)	O
levels	O
were	O
not	O
dramatically	O
altered	O
.	O

Enhanced	O
TR75	B
expression	O
on	O
OM	O
-	O
10	O
.	O
1	O
cells	O
followed	O
the	O
same	O
TNF	B
-	I
alpha	I
-	O
dose	O
dependency	O
as	O
that	O
observed	O
for	O
HIV	O
-	O
1	O
production	O
.	O

Although	O
TR55	B
expression	O
was	O
unaltered	O
during	O
TNF	B
-	I
alpha	I
-	O
induced	O
HIV	O
activation	O
,	O
this	O
receptor	O
was	O
still	O
involved	O
in	O
the	O
viral	O
activation	O
process	O
.	O

Surprisingly	O
,	O
this	O
was	O
the	O
case	O
even	O
when	O
an	O
antagonistic	B
anti	I
-	I
TR55	I
antibody	I
was	O
used	O
.	O

Anti	B
-	I
TR55	I
antibody	I
cross	O
-	O
linking	O
in	O
chronically	O
infected	O
U1	O
promonocytic	O
cultures	O
could	O
only	O
partially	O
substitute	O
for	O
TNF	O
-	O
alpha	O
-	O
induced	O
HIV	O
-	O
1	O
expression	O
.	O

We	O
have	O
used	O
in	O
situ	O
hybridization	O
to	O
define	O
these	O
rearrangements	O
at	O
the	O
molecular	O
level	O
.	O

A	O
reporter	B
gene	I
under	O
the	O
control	O
of	O
a	O
T	B
-	I
cell	I
antigen	I
receptor	I
element	I
was	O
activated	O
in	O
Jurkat	O
cells	O
by	O
antigen	O
receptor	O
triggering	O
or	O
by	O
a	O
combination	O
of	O
phorbol	O
myristate	O
acetate	O
,	O
which	O
activates	O
protein	B
kinase	I
C	I
,	O
and	O
a	O
calcium	O
ionophore	O
.	O

Both	O
these	O
signals	O
were	O
necessary	O
for	O
expression	O
of	O
the	O
reporter	B
gene	I
.	O

When	O
co	O
-	O
transfected	O
with	O
a	O
construct	O
capable	O
of	O
overexpressing	O
the	O
tyrosine	B
kinase	I
p59fyn	B
,	O
the	O
reporter	B
gene	I
was	O
activated	O
by	O
PMA	B
alone	O
.	O

Dependence	O
for	O
the	O
proliferative	O
response	O
to	O
erythropoietin	B
on	O
an	O
established	O
erythroid	O
differentiation	O
program	O
in	O
a	O
human	O
hematopoietic	O
cell	O
line	O
,	O
UT	O
-	O
7	O
.	O

UT	B
-	I
7	I
Epo	I
and	O
UT	O
-	O
7	O
expressed	O
similar	O
levels	O
of	O
GATA	B
-	I
1	I
mRNA	I
and	O
binding	O
activity	O
.	O

This	O
difference	O
in	O
the	O
number	O
of	O
binding	O
sites	O
could	O
be	O
due	O
to	O
differences	O
in	O
cell	O
surface	O
(	O
UT	O
-	O
7	O
cells	O
are	O
20	O
%	O
smaller	O
than	O
the	O
parental	O
UT	O
-	O
7	O
cells	O
)	O
or	O
in	O
receptor	O
turnover	O
.	O

By	O
Northern	O
analysis	O
,	O
UT	O
-	O
7	O
cells	O
expressed	O
detectable	O
levels	O
of	O
beta	B
-	I
and	I
gamma	I
-	I
globin	I
but	O
not	O
alpha	B
-	I
globin	I
.	O

Globin	B
chains	I
(	O
alpha	B
,	O
beta	B
and	O
gamma	B
)	O
were	O
clearly	O
detectable	O
by	O
affinity	O
chromatography	O
in	O
UT	B
-	I
7	I
Epo	I
but	O
not	O
in	O
UT	O
-	O
7	O
cells	O
.	O

The	O
myeloid	B
integrin	I
CD11b	I
is	O
expressed	O
selectively	O
on	O
the	O
surface	O
of	O
mature	O
macrophages	O
,	O
monocytes	O
,	O
neutrophils	O
,	O
and	O
natural	O
killer	O
cells	O
.	O

Recent	O
isolation	O
of	O
the	O
CD11b	B
promoter	I
shows	O
that	O
92	O
base	O
pairs	O
(	O
bp	O
)	O
of	O
5	B
'	I
-	I
flanking	I
DNA	I
are	O
sufficient	O
to	O
direct	O
myeloid	O
-	O
specific	O
expression	O
of	O
a	O
reporter	B
gene	I
.	O

Transcription	O
factor	O
jun	O
-	O
B	O
is	O
target	O
of	O
autoreactive	O
T	O
-	O
cells	O
in	O
IDDM	O
.	O

Target	O
antigens	O
defined	O
by	O
autoantibodies	B
in	O
IDDM	O
include	O
insulin	O
,	O
a	O
putative	O
glycolipid	O
that	O
reacts	O
with	O
islet	B
cell	I
antibodies	I
,	O
and	O
a	O
64	B
,	I
000	I
-	I
M	I
(	I
r	I
)	I
protein	I
recently	O
identified	O
as	O
glutamic	B
acid	I
decarboxylase	I
.	O

Okadaic	O
acid	O
increased	O
the	O
synthesis	O
of	O
the	O
interleukin	B
-	I
1	I
beta	I
precursor	O
and	O
mature	O
forms	O
and	O
their	O
secretion	O
.	O

Expression	O
of	O
tal	B
-	I
1	I
and	O
GATA	B
-	I
binding	I
proteins	I
during	O
human	O
hematopoiesis	O
.	O

Because	O
the	O
GATA	B
-	I
1	I
gene	I
is	O
known	O
to	O
transactivate	O
several	O
genes	O
specific	O
for	O
the	O
erythroid	O
,	O
megakaryocytic	O
,	O
and	O
mastocytic	O
/	O
basophilic	O
lineages	O
,	O
we	O
studied	O
GATA	B
-	I
1	I
expression	O
in	O
these	O
purified	O
hematopoietic	O
cells	O
.	O

The	O
lytic	O
transition	O
of	O
Epstein	O
-	O
Barr	O
virus	O
is	O
imitated	O
by	O
recombinant	O
B	O
-	O
cells	O
.	O

We	O
developed	O
eukaryotic	O
vectors	O
suitable	O
to	O
imitate	O
the	O
processes	O
involved	O
in	O
lytic	O
transition	O
in	O
cell	O
culture	O
systems	O
.	O

R7	O
-	O
57	O
reporter	O
cells	O
,	O
on	O
the	O
other	O
hand	O
,	O
signaled	O
induced	O
activity	O
of	O
the	O
lytic	B
origin	I
of	I
EBV	I
replication	I
(	O
ori	B
Lyt	I
)	O
.	O

Different	O
modes	O
,	O
like	O
chemical	O
induction	O
,	O
lytic	O
superinfection	O
with	O
EBV	O
and	O
single	O
gene	O
trans	O
-	O
activation	O
converted	O
the	O
recombinant	B
ori	I
Lyt	I
element	I
in	O
R7	O
-	O
57	O
reporter	O
cells	O
.	O

Costimulation	O
of	O
cAMP	O
and	O
protein	B
kinase	I
C	I
pathways	O
inhibits	O
the	O
CD3	B
-	O
dependent	O
T	O
cell	O
activation	O
and	O
leads	O
to	O
a	O
persistent	O
expression	O
of	O
the	O
AP	B
-	I
1	I
transcription	I
factor	I
.	O

Analysis	O
of	O
intracellular	O
Ca2	O
+	O
mobilization	O
suggested	O
that	O
the	O
CD3	B
/	O
TcR	B
-	O
dependent	O
signal	O
transduction	O
was	O
impaired	O
in	O
PMA	O
/	O
Bt2cAMP	O
-	O
treated	O
cells	O
.	O

The	O
observation	O
that	O
a	O
mutated	B
LT	I
-	I
kappa	I
B	I
construct	I
(	O
M1	B
-	I
CAT	I
)	O
was	O
inactive	O
in	O
C81	O
-	O
66	O
-	O
45	O
,	O
confirmed	O
the	O
importance	O
of	O
NF	B
-	I
kappa	I
B	I
in	O
LT	B
gene	O
expression	O
.	O

In	O
JM	O
T	O
cells	O
,	O
tax	B
induced	O
LT	B
-	I
293	I
activity	O
by	O
two	O
-	O
to	O
four	O
-	O
fold	O
,	O
though	O
there	O
was	O
no	O
induction	O
of	O
M1	B
-	I
CAT	I
.	O

We	O
combined	O
two	O
techniques	O
to	O
identify	O
the	O
productive	O
replicative	O
form	O
of	O
Epstein	B
-	I
Barr	I
viral	I
DNA	I
in	O
the	O
lytic	O
cycle	O
-	O
induced	O
cells	O
.	O

This	O
indicates	O
an	O
increase	O
in	O
either	O
episomal	B
DNA	I
or	O
concatameric	B
linear	I
DNA	I
.	O

This	O
paper	O
describes	O
how	O
the	O
expression	O
of	O
the	O
monocyte	B
-	I
macrophage	I
Ag	I
,	O
CD14	B
,	O
and	O
the	O
low	O
affinity	B
Fc	I
receptor	I
for	O
IgE	B
,	O
CD23	B
,	O
were	O
inversely	O
regulated	O
during	O
VitD3	O
-	O
and	O
RA	O
-	O
induced	O
monocytic	O
differentiation	O
of	O
human	O
U	O
-	O
937	O
monoblasts	O
.	O

The	O
results	O
suggest	O
that	O
there	O
exists	O
a	O
functional	O
antagonism	O
between	O
VitD3	O
and	O
RA	O
that	O
may	O
have	O
important	O
implications	O
for	O
the	O
regulation	O
of	O
certain	O
immune	O
and	O
inflammatory	O
responses	O
through	O
their	O
inverse	O
effects	O
on	O
CD14	O
and	O
CD23	O
gene	O
expression	O
.	O

Cell	O
-	O
specific	O
bifunctional	O
role	O
of	O
Jun	B
oncogene	I
family	I
members	I
on	O
glucocorticoid	B
receptor	I
-	O
dependent	O
transcription	O
.	O

Here	O
we	O
report	O
that	O
this	O
interference	O
is	O
cell	O
specific	O
,	O
as	O
TPA	O
augmented	O
dexamethasone	O
-	O
induced	O
transcriptional	O
activation	O
of	O
the	O
MMTV	B
LTR	I
in	O
several	O
T	O
cell	O
lines	O
but	O
was	O
inhibitory	O
in	O
NIH	O
-	O
3T3	O
fibroblasts	O
.	O

Increased	O
c	B
-	I
jun	I
,	O
jun	B
-	I
B	I
,	O
and	O
jun	B
-	I
D	I
expression	O
above	O
basal	O
levels	O
and	O
increased	O
transcriptional	O
activity	O
of	O
AP	B
-	I
1	I
/	I
TPA	I
responsive	I
elements	I
fused	O
to	O
chloramphenicol	B
acetyl	I
-	I
transferase	I
vectors	I
were	O
observed	O
in	O
T	O
cells	O
treated	O
with	O
TPA	O
alone	O
or	O
in	O
combination	O
with	O
dexamethasone	O
.	O

Studies	O
with	O
5	B
'	I
deletion	I
CD20	I
promoter	I
-	I
CAT	I
constructs	I
have	O
previously	O
revealed	O
two	O
regions	O
of	O
the	O
promoter	B
between	O
bases	O
-	O
186	O
and	O
-	O
280	O
and	O
between	O
bases	O
-	O
280	O
and	O
-	O
454	O
which	O
contained	O
positive	B
regulatory	I
elements	I
.	O

Cross	O
competition	O
experiments	O
with	O
an	O
octamer	O
sequence	O
from	O
the	O
Ig	O
heavy	O
chain	O
promoter	O
,	O
the	O
BAT	B
box	I
,	O
and	O
a	O
TA	O
-	O
rich	O
sequence	O
present	O
in	O
the	O
CD21	B
promoter	I
revealed	O
that	O
all	O
three	O
sequences	O
bound	O
the	O
same	O
nuclear	B
proteins	I
suggesting	O
that	O
the	O
BAT	B
box	I
binding	I
proteins	I
were	O
Oct	B
-	I
1	I
and	O
Oct	B
-	I
2	I
.	O

Despite	O
this	O
lower	O
affinity	O
,	O
a	O
trimer	O
of	O
the	O
BAT	B
box	I
sequence	I
was	O
as	O
efficiently	O
transactivated	O
by	O
an	O
Oct	B
-	I
2	I
expression	I
vector	I
as	O
was	O
a	O
trimer	O
of	O
the	O
octamer	B
sequence	I
in	O
HeLa	O
cells	O
.	O

Control	O
peptides	O
corresponding	O
to	O
the	O
normal	O
pml	B
and	O
RAR	B
alpha	I
proteins	I
were	O
not	O
recognized	O
.	O

One	O
cDNA	B
clone	I
of	O
a	O
primary	O
response	O
gene	O
,	O
expressed	O
upon	O
macrophage	O
differentiation	O
,	O
encoded	O
for	O
Egr	B
-	I
1	I
,	O
a	O
zinc	B
finger	I
transcription	I
factor	I
.	O

HL	O
-	O
60	O
cells	O
constitutively	O
expressing	O
an	O
Egr	B
-	I
1	I
transgene	I
(	O
HL	B
-	I
60Egr	I
-	I
1	I
)	O
could	O
be	O
induced	O
for	O
macrophage	O
,	O
but	O
not	O
granulocyte	O
,	O
differentiation	O
.	O

These	O
observations	O
indicate	O
that	O
expression	O
of	O
Egr	B
-	I
1	I
is	O
essential	O
for	O
and	O
restricts	O
differentiation	O
of	O
myeloblasts	O
along	O
the	O
macrophage	O
lineage	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
revealed	O
three	O
specific	O
protein	B
-	I
DNA	I
complexes	I
formed	O
with	O
sequences	O
of	O
the	O
EBNA2	B
responsive	I
element	I
.	O

Thus	O
,	O
these	O
experiments	O
demonstrate	O
that	O
EBNA2	B
interacts	O
with	O
an	O
EBNA2	B
responsive	I
cis	I
-	I
element	I
of	O
the	O
TP1	B
promoter	I

Agents	O
which	O
increased	O
cAMP	O
levels	O
,	O
including	O
cholera	O
toxin	O
,	O
pertussis	O
toxin	O
,	O
dibutyryl	O
cAMP	O
,	O
and	O
isoproterenol	O
mimicked	O
the	O
actions	O
of	O
MM	B
-	I
LDL	I
.	O

One	O
member	O
of	O
this	O
multigene	O
family	O
,	O
GATA	B
-	I
3	I
,	O
is	O
most	O
abundantly	O
expressed	O
in	O
T	O
lymphocytes	O
,	O
a	O
cellular	O
target	O
for	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
infection	O
and	O
replication	O
.	O

Cotransfection	O
of	O
an	O
hGATA	B
-	I
3	I
expression	I
plasmid	I
with	O
a	O
reporter	B
plasmid	I
whose	O
transcription	O
is	O
directed	O
by	O
the	O
HIV	B
-	I
1	I
LTR	I
resulted	O
in	O
6	O
-	O
to	O
10	O
-	O
fold	O
stimulation	O
of	O
LTR	B
-	O
mediated	O
transcription	O
,	O
whereas	O
site	O
specific	O
mutation	O
of	O
these	O
GATA	B
sites	I
resulted	O
in	O
virtual	O
abrogation	O
of	O
the	O
activation	O
by	O
hGATA	B
-	I
3	I
.	O

Conversely	O
,	O
several	O
cytokines	B
modulate	O
the	O
levels	O
of	O
HIV	O
expression	O
in	O
infected	O
cells	O
of	O
both	O
T	O
lymphocytic	O
and	O
mononuclear	O
phagocytic	O
lineage	O
.	O

Cloning	O
and	O
functional	O
characterization	O
of	O
early	B
B	I
-	I
cell	I
factor	I
,	O
a	O
regulator	O
of	O
lymphocyte	O
-	O
specific	O
gene	O
expression	O
.	O

Early	B
B	I
-	I
cell	I
factor	I
(	O
EBF	B
)	O
was	O
identified	O
previously	O
as	O
a	O
tissue	O
-	O
specific	O
and	O
differentiation	O
stage	O
-	O
specific	O
DNA	B
-	I
binding	I
protein	I
that	O
participates	O
in	O
the	O
regulation	O
of	O
the	O
pre	B
-	I
B	I
and	I
B	I
lymphocyte	I
-	I
specific	I
mb	I
-	I
1	I
gene	I
.	O

Partial	O
amino	O
acid	O
sequences	O
obtained	O
from	O
purified	O
EBF	B
were	O
used	O
to	O
isolate	O
cDNA	B
clones	I
,	O
which	O
by	O
multiple	O
criteria	O
encode	O
EBF	B
.	O

DNA	O
-	O
binding	O
assays	O
with	O
cotranslated	O
wild	O
-	O
type	O
and	O
truncated	O
forms	O
of	O
EBF	B
indicated	O
that	O
the	O
protein	O
interacts	O
with	O
its	O
site	O
as	O
a	O
homodimer	B
.	O

Deletions	O
delineated	O
a	O
carboxy	B
-	I
terminal	I
dimerization	I
region	I
containing	O
two	O
repeats	O
of	O
15	O
amino	O
acids	O
that	O
show	O
similarity	O
with	O
the	O
dimerization	B
domains	I
of	O
basic	B
-	I
helix	I
-	I
loop	I
-	I
helix	I
proteins	I
.	O

A	O
73	B
kDa	I
protein	I
was	O
identified	O
by	O
this	O
analysis	O
:	O
this	O
protein	O
is	O
highly	O
enriched	O
in	O
cell	O
lines	O
of	O
B	O
lymphoid	O
origin	O
as	O
compared	O
to	O
pancreatic	O
beta	O
-	O
cells	O
and	O
fibroblast	O
cells	O
.	O

The	O
detection	O
of	O
this	O
protein	O
selectively	O
in	O
extracts	O
of	O
lymphoid	O
cells	O
correlates	O
with	O
the	O
presence	O
of	O
the	O
E	B
box	I
-	O
binding	O
activity	O
LEF1	B
/	I
BCF1	I
in	O
these	O
cells	O
;	O
this	O
binding	O
activity	O
was	O
previously	O
shown	O
to	O
be	O
efficiently	O
recognized	O
by	O
antiserum	O
directed	O
against	O
E2A	B
gene	I
products	I
.	O

Pregnancy	O
-	O
induced	O
hypertension	O
(	O
PIH	O
)	O
is	O
a	O
frequent	O
cause	O
of	O
maternal	O
and	O
neonatal	O
morbidity	O
and	O
mortality	O
.	O

In	O
the	O
present	O
study	O
we	O
focused	O
on	O
the	O
pathophysiology	O
of	O
PIH	O
,	O
mainly	O
on	O
the	O
role	O
of	O
mineralocorticoids	O
,	O
reversed	O
blood	O
pressure	O
patterns	O
,	O
and	O
the	O
resulting	O
necessity	O
of	O
continuous	O
monitoring	O
of	O
the	O
preeclamptic	O
mother	O
.	O

Furthermore	O
,	O
we	O
evaluated	O
the	O
mineralocorticoid	B
receptor	I
(	O
MR	B
)	O
count	O
in	O
mononuclear	O
leukocytes	O
in	O
the	O
2	O
groups	O
.	O

Induction	O
by	O
hemin	O
increases	O
,	O
while	O
induction	O
with	O
12	O
-	O
O	O
-	O
tetradecanoylphorbol	O
-	O
13	O
-	O
acetate	O
(	O
TPA	O
)	O
represses	O
,	O
erythroid	B
-	I
specific	I
gene	I
expression	O
in	O
the	O
human	O
cell	O
line	O
K562	O
.	O

Hemin	O
induction	O
appears	O
to	O
nonspecifically	O
increase	O
the	O
expression	O
of	O
transiently	O
transfected	O
genes	O
in	O
K562	O
cells	O
.	O

The	O
divergent	O
effects	O
of	O
hemin	O
and	O
TPA	O
on	O
gene	O
expression	O
in	O
K562	O
cells	O
are	O
mediated	O
,	O
in	O
part	O
,	O
by	O
their	O
contrasting	O
effects	O
on	O
the	O
transcription	B
factor	I
NF	B
-	I
E2	I
.	O

We	O
studied	O
the	O
effect	O
of	O
interleukin	B
-	I
4	I
(	O
IL	B
-	I
4	I
)	O
on	O
the	O
lipopolysaccharide	O
(	O
LPS	O
)	O
induction	O
of	O
two	O
immediate	O
early	O
genes	O
c	B
-	I
fos	I
and	O
c	B
-	I
jun	I
.	O

The	O
inhibition	O
of	O
c	B
-	I
fos	I
and	O
c	O
-	O
jun	O
expression	O
by	O
IL	B
-	I
4	I
in	O
LPS	O
-	O
treated	O
cells	O
was	O
shown	O
to	O
be	O
due	O
to	O
a	O
lower	O
transcription	O
rate	O
of	O
the	O
c	B
-	I
fos	I
and	I
c	I
-	I
jun	I
genes	I
.	O

These	O
involve	O
activation	O
of	O
the	O
sodium	B
/	I
proton	I
exchanger	I
of	O
the	O
cell	O
membrane	O
at	O
very	O
low	O
,	O
physiological	O
concentrations	O
of	O
aldosterone	O
with	O
an	O
acute	O
onset	O
within	O
1	O
-	O
2	O
min	O
.	O

The	O
unique	O
characteristics	O
of	O
this	O
new	O
pathway	O
for	O
steroid	O
action	O
include	O
its	O
rapid	O
time	O
course	O
,	O
10	O
,	O
000	O
-	O
fold	O
selectivity	O
for	O
aldosterone	O
over	O
cortisol	O
and	O
the	O
ineffectiveness	O
of	O
spironolactones	O
,	O
classical	O
mineralocorticoid	O
antagonists	O
,	O
as	O
antagonists	O
of	O
the	O
response	O
.	O

Human	B
immunodeficiency	I
virus	I
type	I
1	I
Nef	I
protein	I
inhibits	O
NF	B
-	I
kappa	I
B	I
induction	O
in	O
human	O
T	O
cells	O
.	O

These	O
results	O
indicate	O
that	O
defective	O
recruitment	O
of	O
NF	B
-	I
kappa	I
B	I
may	O
underlie	O
Nef	B
'	O
s	O
negative	O
transcriptional	O
effects	O
on	O
the	O
HIV	B
-	I
1	I
and	I
interleukin	I
2	I
promoters	I
.	O

The	O
expression	O
of	O
c	B
-	I
fos	I
,	I
c	I
-	I
jun	I
and	I
jun	I
B	I
proto	I
-	I
oncogenes	I
was	O
studied	O
in	O
phytohemagglutinin	O
(	O
PHA	O
)	O
activated	O
peripheral	O
blood	O
lymphocytes	O
(	O
PBL	O
)	O
from	O
young	O
and	O
aged	O
humans	O
.	O

In	O
PHA	O
-	O
activated	O
PBL	O
,	O
no	O
age	O
-	O
related	O
differences	O
were	O
observed	O
in	O
c	O
-	O
fos	O
or	O
jun	O
B	O
mRNA	O
expression	O
.	O

Because	O
previous	O
work	O
has	O
demonstrated	O
that	O
T	O
cells	O
from	O
elderly	O
individuals	O
may	O
display	O
normal	O
proliferative	O
responses	O
when	O
activated	O
via	O
the	O
anti	B
-	I
CD2	I
pathway	O
,	O
c	O
-	O
jun	O
and	O
jun	O
B	O
mRNA	O
expression	O
was	O
also	O
studied	O
in	O
anti	O
-	O
CD2	O
-	O
activated	O
purified	O
T	O
cells	O
.	O

The	O
CD19	B
protein	I
is	O
expressed	O
on	O
the	O
surface	O
of	O
all	O
B	O
-	O
lymphoid	O
cells	O
with	O
the	O
exception	O
of	O
terminally	O
differentiated	O
plasma	O
cells	O
and	O
has	O
been	O
implicated	O
as	O
a	O
signal	O
-	O
transducing	O
receptor	O
in	O
the	O
control	O
of	O
proliferation	O
and	O
differentiation	O
.	O

This	O
high	B
-	I
affinity	I
site	I
has	O
been	O
conserved	O
in	O
the	O
promoters	B
of	O
both	O
human	B
and	I
mouse	I
CD19	I
genes	I
and	O
was	O
furthermore	O
shown	O
to	O
confer	O
B	O
-	O
cell	O
specificity	O
to	O
a	O
beta	O
-	O
globin	O
reporter	O
gene	O
in	O
transient	O
transfection	O
experiments	O
.	O

In	O
addition	O
,	O
BSAP	B
was	O
found	O
to	O
be	O
the	O
only	O
abundant	O
DNA	O
-	O
binding	O
activity	O
of	O
B	O
-	O
cell	O
nuclear	O
extracts	O
that	O
interacts	O
with	O
the	O
CD19	B
promoter	I
.	O

Compared	O
to	O
benign	O
tumor	O
or	O
mammary	O
reduction	O
test	O
material	O
the	O
eicosanoid	O
profile	O
of	O
tissue	O
obtained	O
from	O
malignant	O
mammary	O
tumors	O
showed	O
important	O
differences	O
.	O

The	O
implications	O
,	O
in	O
particular	O
,	O
in	O
relation	O
to	O
future	O
prognosis	O
of	O
the	O
patient	O
,	O
remain	O
obscure	O
.	O

To	O
examine	O
the	O
role	O
of	O
mineralocorticoids	O
in	O
the	O
pathophysiology	O
of	O
pregnancy	O
-	O
induced	O
hypertension	O
(	O
PIH	O
)	O
,	O
we	O
studied	O
plasma	O
aldosterone	O
and	O
18	O
-	O
hydroxycorticosteron	O
levels	O
in	O
25	O
women	O
with	O
PIH	O
and	O
25	O
normal	O
pregnant	O
women	O
,	O
as	O
controls	O
.	O

Plasma	O
18	O
-	O
hydroxycorticosteron	O
was	O
also	O
significantly	O
(	O
P	O
less	O
than	O
0	O
.	O
025	O
)	O
lower	O
(	O
PIH	O
,	O
1071	O
+	O
/	O
-	O
149	O
pmol	O
/	O
L	O
;	O
controls	O
,	O
1907	O
+	O
/	O
-	O
318	O
pmol	O
/	O
L	O
)	O
.	O

Small	O
apolar	O
substitutions	O
(	O
11	O
alpha	O
-	O
methyl	O
,	O
11	O
alpha	O
-	O
fluoromethyl	O
)	O
did	O
not	O
markedly	O
decrease	O
the	O
affinity	O
for	O
the	O
vitamin	B
D	I
receptor	I
,	O
but	O
larger	O
(	O
11	O
alpha	O
-	O
chloromethyl	O
or	O
11	O
alpha	O
-	O
or	O
11	O
beta	O
-	O
phenyl	O
)	O
or	O
more	O
polar	O
substitutions	O
(	O
11	O
alpha	O
-	O
hydroxymethyl	O
,	O
11	O
alpha	O
-	O
(	O
2	O
-	O
hydroxyethyl	O
]	O
decreased	O
the	O
affinity	O
to	O
less	O
than	O
5	O
%	O
of	O
that	O
of	O
1	O
alpha	O
,	O
25	O
-	O
OH	O
)	O
2D3	O
.	O

The	O
11	O
beta	O
-	O
methyl	O
analog	O
had	O
a	O
greater	O
than	O
10	O
-	O
fold	O
lower	O
activity	O
.	O

In	O
the	O
present	O
paper	O
,	O
the	O
binding	O
of	O
a	O
[	O
125I	O
]	O
-	O
labeled	O
aldosterone	O
derivative	O
to	O
plasma	O
membrane	O
rich	O
fractions	O
of	O
HML	O
was	O
studied	O
.	O

This	O
variation	O
was	O
the	O
result	O
of	O
a	O
duplication	O
of	O
a	O
short	B
DNA	I
sequence	I
(	O
CTG	B
-	I
motif	I
)	O
.	O

No	O
positive	O
effect	O
of	O
the	O
duplicated	O
CTG	B
-	I
motif	I
could	O
be	O
detected	O
.	O

Based	O
on	O
these	O
results	O
we	O
estimate	O
a	O
5	O
-	O
10	O
%	O
difference	O
in	O
virus	O
production	O
of	O
the	O
LTR	B
variants	I
when	O
compared	O
to	O
that	O
of	O
wild	O
-	O
type	O
.	O

The	O
helix	B
-	I
loop	I
-	I
helix	I
(	I
HLH	I
)	I
proteins	I
are	O
a	O
family	O
of	O
transcription	B
factors	I
that	O
include	O
proteins	O
critical	O
to	O
differentiation	O
and	O
development	O
in	O
species	O
ranging	O
from	O
plants	O
to	O
mammals	O
.	O

Glucocorticoid	B
receptor	I
in	O
patients	O
with	O
lupus	O
nephritis	O
:	O
relationship	O
between	O
receptor	O
levels	O
in	O
mononuclear	O
leukocytes	O
and	O
effect	O
of	O
glucocorticoid	O
therapy	O
.	O

We	O
investigated	O
the	O
clinical	O
significance	O
of	O
glucocorticoid	B
receptor	I
determination	O
in	O
20	O
patients	O
with	O
systemic	O
lupus	O
erythematosus	O
(	O
SLE	O
)	O
who	O
afterwards	O
developed	O
nephrotic	O
syndrome	O
.	O

Improvement	O
in	O
urinary	O
protein	O
excretion	O
and	O
in	O
disease	O
activity	O
,	O
which	O
was	O
scored	O
according	O
to	O
the	O
SLE	O
Disease	O
Activity	O
Index	O
system	O
of	O
the	O
University	O
of	O
Toronto	O
,	O
closely	O
related	O
to	O
the	O
glucocorticoid	B
receptor	I
concentrations	O
in	O
MNL	O
isolated	O
from	O
the	O
corresponding	O
patients	O
.	O

Possible	O
relationship	O
between	O
the	O
changes	O
in	O
IL	B
-	I
1	I
and	O
GR	B
in	O
aged	O
long	O
-	O
distance	O
runner	O
and	O
its	O
physiological	O
significance	O
are	O
discussed	O
.	O

Mineralocorticoid	O
effector	O
mechanism	O
in	O
preeclampsia	O
.	O

MR	B
were	O
reduced	O
before	O
delivery	O
(	O
96	O
+	O
/	O
-	O
27	O
receptors	O
/	O
cell	O
)	O
,	O
and	O
SPD	O
increased	O
(	O
64	O
+	O
/	O
-	O
8	O
mV	O
)	O
,	O
with	O
both	O
parameters	O
normalizing	O
after	O
delivery	O
(	O
MR	B
,	O
242	O
+	O
/	O
-	O
79	O
;	O
SPD	O
,	O
14	O
.	O
0	O
+	O
/	O
-	O
4	O
mV	O
)	O
.	O

Aldosterone	O
levels	O
returned	O
to	O
normal	O
nonpregnant	O
values	O
after	O
delivery	O
.	O

Kinetics	O
of	O
nuclear	O
translocation	O
and	O
turnover	O
of	O
the	O
vitamin	B
D	I
receptor	I
in	O
human	O
HL60	O
leukemia	O
cells	O
and	O
peripheral	O
blood	O
lymphocytes	O
-	O
-	O
coincident	O
rise	O
of	O
DNA	O
-	O
relaxing	O
activity	O
in	O
nuclear	O
extracts	O
.	O

HL60	O
cells	O
,	O
expressing	O
some	O
characteristics	O
of	O
promyelocytes	O
,	O
can	O
be	O
induced	O
to	O
monocytoid	O
differentiation	O
by	O
calcitriol	O
.	O

Pulse	O
exposure	O
of	O
HL60	O
to	O
radiolabeled	O
hormone	O
for	O
3	O
h	O
followed	O
by	O
culture	O
in	O
medium	O
without	O
serum	O
and	O
calcitriol	O
lead	O
to	O
nuclear	O
retention	O
of	O
approximately	O
1600	B
radiolabeled	I
VDR	I
by	O
8	O
h	O
and	O
approximately	O
1000	O
VDR	B
by	O
24	O
h	O
.	O

No	O
specific	O
translocation	O
into	O
the	O
nuclear	O
compartment	O
was	O
seen	O
when	O
isolated	O
nuclei	O
were	O
incubated	O
in	O
[	O
3H	O
]	O
calcitriol	O
.	O

Radiolabeled	B
hormone	I
/	I
receptor	I
complexes	I
of	O
nuclei	O
isolated	O
from	O
cells	O
exposed	O
for	O
3	O
h	O
to	O
radiolabeled	O
hormone	O
-	O
-	O
in	O
contrast	O
to	O
identical	O
experiments	O
with	O
intact	O
cells	O
-	O
-	O
did	O
not	O
disappear	O
from	O
the	O
nuclear	O
compartment	O
upon	O
incubation	O
of	O
nuclei	O
with	O
identical	O
concentrations	O
of	O
the	O
unlabeled	O
compound	O
.	O

We	O
conclude	O
that	O
a	O
specific	O
nuclear	O
translocation	O
mechanism	O
exists	O
for	O
calcitriol	O
in	O
both	O
cell	O
types	O
examined	O
,	O
most	O
likely	O
due	O
to	O
translocation	O
of	O
receptor	B
proteins	I
after	O
hormone	O
binding	O
.	O

Enhanced	O
activity	O
of	O
topoisomerases	B
in	O
nuclear	O
extracts	O
upon	O
translocation	O
of	O
VDR	B
might	O
reflect	O
interaction	O
of	O
both	O
within	O
the	O
nuclear	O
compartment	O
,	O
thus	O
initiating	O
DNA	O
-	O
unwinding	O
,	O
a	O
prerequisite	O
of	O
transcription	O
initiation	O
.	O

Estrogen	O
receptor	O
positive	O
(	O
ER	O
+	O
:	O
MCF	O
-	O
7	O
)	O
and	O
negative	O
(	O
ER	O
-	O
:	O
MDA	O
-	O
MB	O
-	O
231	O
)	O
human	O
breast	O
cancer	O
cell	O
lines	O
were	O
utilized	O
to	O
evaluate	O
the	O
effects	O
of	O
tamoxifen	O
(	O
TAM	O
)	O
and	O
estradiol	O
(	O
E2	O
)	O
on	O
modulation	O
of	O
breast	O
cancer	O
target	O
susceptibility	O
to	O
lysis	O
by	O
lymphokine	O
-	O
activated	O
killer	O
(	O
LAK	O
)	O
cells	O
.	O

E2	O
-	O
stimulated	O
ER	O
+	O
cells	O
were	O
more	O
susceptible	O
to	O
lysis	O
by	O
LAK	O
cells	O
than	O
corresponding	O
TAM	O
-	O
treated	O
or	O
control	O
cells	O
,	O
while	O
treatment	O
of	O
ER	O
-	O
cells	O
with	O
either	O
E2	O
or	O
TAM	O
alone	O
did	O
not	O
alter	O
from	O
control	O
their	O
susceptibility	O
to	O
this	O
immune	O
-	O
mediated	O
lysis	O
.	O

Regulation	O
of	O
replicative	O
functions	O
in	O
the	O
Epstein	B
-	I
Barr	I
virus	I
(	I
EBV	I
)	I
genome	I
is	O
mediated	O
through	O
activation	O
of	O
a	O
virally	B
encoded	I
transcription	I
factor	I
,	O
Z	B
(	O
BZLF1	B
)	O
.	O

The	O
long	B
terminal	I
repeat	I
(	I
LTR	I
)	I
region	I
of	O
HIV	B
proviral	I
DNA	I
contains	O
binding	O
sites	O
for	O
nuclear	B
factor	I
kappa	I
B	I
(	O
NF	B
-	I
kappa	I
B	I
)	O
,	O
and	O
this	O
transcriptional	B
activator	I
appears	O
to	O
regulate	O
HIV	O
activation	O
.	O

The	O
inhibitory	O
action	O
of	O
alpha	O
-	O
lipoic	O
acid	O
was	O
found	O
to	O
be	O
very	O
potent	O
as	O
only	O
4	O
mM	O
was	O
needed	O
for	O
a	O
complete	O
inhibition	O
,	O
whereas	O
20	O
mM	O
was	O
required	O
for	O
N	O
-	O
acetylcysteine	O
.	O

REV	B
LTRs	I
work	O
efficiently	O
in	O
human	O
lymphoid	O
cells	O
,	O
and	O
are	O
viable	O
alternatives	O
to	O
promoters	B
commonly	O
used	O
for	O
expression	O
of	O
cloned	B
genes	I
.	O

Human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
and	O
HIV	O
-	O
2	O
are	O
structurally	O
related	O
retroviruses	O
which	O
both	O
cause	O
AIDS	O
in	O
humans	O
.	O

Although	O
both	O
viruses	O
establish	O
latency	O
in	O
quiescent	O
human	O
-	O
peripheral	O
-	O
blood	O
T	O
cells	O
,	O
the	O
asymptomatic	O
phase	O
of	O
HIV	O
-	O
2	O
infection	O
may	O
be	O
more	O
prolonged	O
than	O
that	O
of	O
HIV	O
-	O
1	O
.	O

The	O
latent	O
phases	O
of	O
both	O
HIV	O
-	O
1	O
and	O
HIV	O
-	O
2	O
infection	O
have	O
been	O
shown	O
to	O
be	O
disrupted	O
by	O
T	O
-	O
cell	O
activation	O
,	O
a	O
process	O
that	O
requires	O
host	O
cell	O
transcription	O
factors	O
.	O

Thus	O
,	O
Elf	B
-	I
1	I
is	O
a	O
novel	B
transcription	I
factor	I
that	O
appears	O
to	O
be	O
required	O
for	O
the	O
T	O
-	O
cell	O
-	O
receptor	O
-	O
mediated	O
trans	O
activation	O
of	O
HIV	O
-	O
2	O
gene	O
expression	O
.	O

These	O
results	O
may	O
explain	O
differences	O
in	O
the	O
clinical	O
spectra	O
of	O
diseases	O
caused	O
by	O
HIV	O
-	O
1	O
and	O
HIV	O
-	O
2	O
and	O
may	O
also	O
have	O
implications	O
for	O
the	O
design	O
of	O
therapeutic	O
approaches	O
to	O
HIV	O
-	O
2	O
infection	O
.	O

Okadaic	O
acid	O
is	O
a	O
potent	O
inducer	O
of	O
AP	B
-	I
1	I
,	O
NF	B
-	I
kappa	I
B	I
,	O
and	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
in	O
human	O
B	O
lymphocytes	O
.	O

Treatment	O
of	O
human	O
B	O
lymphocytes	O
with	O
an	O
optimal	O
concentration	O
of	O
okadaic	O
acid	O
,	O
an	O
inhibitor	O
of	O
phosphatases	B
1	I
and	I
2A	I
,	O
resulted	O
in	O
the	O
induction	O
of	O
the	O
transcription	B
factor	I
,	O
AP	B
-	I
1	I
and	O
a	O
marked	O
increase	O
in	O
NF	B
-	I
kappa	I
B	I
levels	O
.	O

Although	O
okadaic	O
acid	O
provides	O
a	O
potent	O
inductive	O
signal	O
for	O
AP	B
-	I
1	I
and	O
NF	B
-	I
kappa	I
B	I
it	O
did	O
not	O
induce	O
either	O
B	O
cell	O
proliferation	O
or	O
immunoglobulin	B
secretion	O
.	O

c	B
-	I
myc	I
mRNA	I
expression	O
in	O
minor	O
salivary	O
glands	O
of	O
patients	O
with	O
Sjogren	O
'	O
s	O
syndrome	O
.	O

These	O
data	O
show	O
that	O
aged	O
subjects	O
have	O
reductions	O
of	O
corticosteroid	B
receptors	I
that	O
are	O
not	O
associated	O
with	O
increase	O
of	O
related	O
steroids	O
and	O
that	O
this	O
situation	O
probably	O
represents	O
a	O
concomitant	O
of	O
the	O
normal	O
aging	O
process	O
.	O

IL	B
-	I
4	I
secreted	O
by	O
activated	O
T	O
cells	O
is	O
a	O
pleiotropic	B
cytokine	I
affecting	O
growth	O
and	O
differentiation	O
of	O
diverse	O
cell	O
types	O
such	O
as	O
T	O
cells	O
,	O
B	O
cells	O
,	O
and	O
mast	O
cells	O
.	O

A	O
novel	B
T	I
cell	I
-	I
specific	I
negative	I
regulatory	I
element	I
(	O
NRE	B
)	O
composed	O
of	O
two	O
protein	O
-	O
binding	O
sites	O
were	O
mapped	O
in	O
the	O
5	O
'	O
flanking	O
region	O
of	O
the	O
IL	B
-	I
4	I
gene	I
:	O
-	O
311CTCCCTTCT	O
-	O
303	O
(	O
NRE	B
-	I
I	I
)	O
and	O
-	O
288CTTTTTGCTT	O
-	O
TGC	O
-	O
300	O
(	O
NRE	B
-	I
II	I
)	O
.	O

A	O
T	B
cell	I
-	I
specific	I
protein	I
Neg	B
-	I
1	I
and	O
a	O
ubiquitous	B
protein	I
Neg	B
-	I
2	I
binding	O
to	O
NRE	B
-	I
I	I
and	O
NRE	B
-	I
II	I
,	O
respectively	O
,	O
were	O
identified	O
.	O

The	O
addition	O
of	O
antisense	O
oligonucleotides	O
to	O
c	B
-	I
fos	I
significantly	O
inhibited	O
IL	B
6	I
-	O
induced	O
IgM	B
production	O
by	O
SKW	O
6	O
.	O
4	O
cells	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
,	O
whereas	O
control	O
oligonucleotides	O
had	O
no	O
inhibitory	O
effect	O
.	O

In	O
this	O
article	O
,	O
transcriptional	O
regulation	O
of	O
the	O
archetypal	B
T	I
-	I
cell	I
-	I
specific	I
gene	I
,	O
alpha	B
TCR	I
,	O
is	O
discussed	O
.	O

Sodium	O
dodecyl	O
sulfate	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
showed	O
significant	O
aldosterone	O
binding	O
at	O
a	O
molecular	O
weight	O
of	O
approximately	O
50000	O
Dalton	O
which	O
was	O
absent	O
with	O
1	O
microM	O
cold	O
aldosterone	O
,	O
but	O
not	O
cortisol	O
in	O
the	O
binding	O
media	O
.	O

We	O
used	O
phenolic	O
,	O
lipid	O
-	O
soluble	O
,	O
chain	O
-	O
breaking	O
antioxidants	O
(	O
butylated	O
hydroxyanisole	O
(	O
BHA	O
)	O
,	O
nordihydroquairetic	O
acid	O
,	O
or	O
alpha	O
-	O
tocopherol	O
(	O
vitamin	O
E	O
)	O
to	O
show	O
that	O
peroxyl	O
radical	O
scavenging	O
in	O
unstimulated	O
and	O
PMA	O
-	O
or	O
TNF	O
-	O
stimulated	O
cells	O
blocks	O
the	O
functions	O
depending	O
on	O
NF	B
-	I
kappa	I
B	I
activation	O
.	O

Rather	O
,	O
TNF	B
and	O
PMA	B
can	O
exert	O
their	O
effect	O
only	O
if	O
cells	O
are	O
in	O
an	O
appropriate	O
redox	O
status	O
,	O
because	O
prior	O
modification	O
toward	O
reduction	O
with	O
BHA	O
treatment	O
prevents	O
this	O
activation	O
.	O

Selection	O
of	O
optimal	O
kappa	O
B	O
/	O
Rel	O
DNA	O
-	O
binding	O
motifs	O
:	O
interaction	O
of	O
both	O
subunits	O
of	O
NF	B
-	I
kappa	I
B	I
with	O
DNA	O
is	O
required	O
for	O
transcriptional	O
activation	O
.	O

Analysis	O
of	O
the	O
p50	B
and	O
p65	B
subunits	I
of	O
the	O
NF	B
-	I
kappa	I
B	I
transcription	I
factor	I
complex	I
has	O
revealed	O
that	O
both	O
proteins	O
can	O
interact	O
with	O
related	O
DNA	O
sequences	O
through	O
either	O
homo	O
-	O
or	O
heterodimer	O
formation	O
.	O

However	O
,	O
these	O
studies	O
have	O
used	O
a	O
limited	O
number	O
of	O
known	O
kappa	O
B	O
DNA	O
motifs	O
,	O
and	O
the	O
question	O
of	O
the	O
optimal	O
DNA	O
sequences	O
preferred	O
by	O
each	O
homodimer	O
has	O
not	O
been	O
addressed	O
.	O

Using	O
purified	O
recombinant	O
p50	B
,	O
p65	B
,	O
and	O
c	B
-	I
Rel	I
proteins	I
,	O
optimal	O
DNA	O
-	O
binding	O
motifs	O
were	O
selected	O
from	O
a	O
pool	O
of	O
random	O
oligonucleotides	O
.	O

Differential	O
binding	O
affinities	O
were	O
also	O
obtained	O
with	O
p50	B
-	I
and	I
c	I
-	I
Rel	I
-	I
selected	I
sequences	I
.	O

These	O
findings	O
demonstrate	O
that	O
interaction	O
of	O
both	O
subunits	O
of	O
the	O
heterodimeric	B
NF	I
-	I
kappa	I
B	I
complex	I
with	O
DNA	O
is	O
required	O
for	O
DNA	O
binding	O
and	O
transcriptional	O
activation	O
and	O
suggest	O
that	O
transcriptional	O
activation	O
mediated	O
by	O
the	O
individual	O
rel	B
-	I
related	I
proteins	I
will	O
differ	O
dramatically	O
,	O
depending	O
on	O
the	O
specific	O
kappa	O
B	O
motifs	O
present	O
.	O

These	O
observations	O
indicate	O
that	O
during	O
chronic	O
HIV	O
infection	O
of	O
U937	O
cells	O
,	O
continuous	O
NF	B
-	I
kappa	I
B	I
(	O
p50	B
/	I
p65	I
)	O
translocation	O
results	O
in	O
p105	O
promoter	O
upregulation	O
with	O
subsequent	O
cytosolic	O
NF	B
-	I
kappa	I
B	I
accumulation	O
,	O
ready	O
for	O
further	O
translocation	O
.	O

Similarly	O
,	O
IL	B
-	I
2	I
activates	O
NF	B
-	I
kappa	I
B	I
in	O
the	O
human	O
monocytic	O
cell	O
line	O
U	O
937	O
,	O
but	O
not	O
in	O
resting	O
human	O
T	O
-	O
cells	O
.	O

Blockade	O
of	O
the	O
DNA	B
-	I
binding	I
complexes	I
with	O
an	O
anti	B
-	I
Fos	I
mAb	I
demonstrated	O
a	O
direct	O
participation	O
of	O
c	B
-	I
Fos	I
in	O
the	O
AP	B
-	I
1	I
complexes	I
induced	O
by	O
anti	B
-	I
AIM	I
mAb	I
.	O

These	O
data	O
provide	O
the	O
evidence	O
that	O
activation	O
of	O
human	O
peripheral	O
blood	O
T	O
cells	O
through	O
the	O
AIM	O
activation	O
pathway	O
regulate	O
the	O
activity	O
of	O
AP	B
-	I
1	I
.	O

Gangliosides	O
suppress	O
tumor	B
necrosis	I
factor	I
production	O
in	O
human	O
monocytes	O
.	O

Both	O
normal	O
and	O
malignant	O
cells	O
contain	O
gangliosides	O
as	O
important	O
cell	O
membrane	O
constituents	O
that	O
,	O
after	O
being	O
shed	O
,	O
may	O
influence	O
cells	O
of	O
the	O
immune	O
system	O
.	O

Although	O
under	O
standard	O
culture	O
conditions	O
,	O
bovine	O
brain	O
gangliosides	O
(	O
100	O
micrograms	O
/	O
ml	O
)	O
suppressed	O
LPS	O
-	O
stimulated	O
TNF	B
production	O
5	O
-	O
fold	O
in	O
PBMC	O
and	O
10	O
-	O
fold	O
in	O
Mono	O
Mac	O
6	O
cells	O
,	O
suppression	O
was	O
more	O
efficient	O
under	O
serum	O
-	O
free	O
conditions	O
.	O

The	O
suppressive	O
activity	O
was	O
lost	O
in	O
molecules	O
,	O
lacking	O
the	O
sugar	O
moiety	O
or	O
the	O
lipid	O
moiety	O
.	O

On	O
the	O
other	O
hand	O
,	O
phorbol	O
ester	O
-	O
induced	O
production	O
of	O
O2	O
-	O
was	O
similar	O
in	O
cells	O
treated	O
with	O
and	O
without	O
gangliosides	O
.	O

Taken	O
together	O
,	O
our	O
data	O
demonstrate	O
that	O
TNF	B
gene	O
expression	O
in	O
monocytes	O
induced	O
by	O
different	O
types	O
of	O
stimuli	O
can	O
be	O
blocked	O
by	O
gangliosides	O
at	O
an	O
early	O
step	O
of	O
signal	O
transduction	O
.	O

Immunoglobulin	B
molecules	I
on	O
the	O
surface	O
of	O
a	O
B	O
lymphocyte	O
are	O
the	O
endogenous	O
`	O
`	O
receptors	O
'	O
'	O
to	O
which	O
specific	O
antigens	O
bind	O
.	O

Because	O
of	O
the	O
efficient	O
binding	O
of	O
TG	B
by	O
surrogate	B
receptors	I
on	O
non	O
-	O
T	O
cells	O
,	O
we	O
assessed	O
the	O
ability	O
of	O
such	O
cells	O
to	O
present	O
TG	B
to	O
T	O
cells	O
.	O

Proliferation	O
in	O
response	O
to	O
TG	B
was	O
observed	O
in	O
T	O
cells	O
from	O
only	O
1	O
of	O
5	O
Hashimoto	O
patients	O
.	O

The	O
transcriptional	O
activity	O
of	O
the	O
heterodimer	O
is	O
regulated	O
by	O
signal	O
-	O
dependent	O
phosphorylation	O
and	O
dephosphorylation	O
events	O
.	O

A	O
PMA	B
responsive	I
element	I
was	O
localized	O
to	O
a	O
region	O
between	O
-	B
95	I
and	I
-	I
36	I
bp	I
relative	O
to	O
the	O
transcription	B
start	I
site	I
.	O

Within	O
this	O
region	O
,	O
single	O
AP	B
-	I
2	I
-	I
and	I
AP	I
-	I
1	I
-	I
like	I
consensus	I
sequences	I
were	O
noted	O
.	O

While	O
all	O
the	O
M10	O
-	O
expressing	O
cell	O
lines	O
remained	O
infectable	O
by	O
HIV	O
-	O
1	O
,	O
these	O
same	O
cells	O
failed	O
to	O
support	O
a	O
productive	O
replication	O
cycle	O
when	O
infected	O
with	O
a	O
cloned	O
isolate	O
of	O
HIV	O
-	O
1	O
.	O

Expression	O
of	O
M10	B
did	O
not	O
affect	O
induction	O
of	O
HIV	O
transcription	O
mediated	O
by	O
the	O
kappa	B
B	I
regulatory	I
element	I
or	O
Tat	B
.	O

The	O
inhibition	O
of	O
HIV	O
infection	O
in	O
cells	O
stably	O
expressing	O
a	O
transdominant	B
Rev	I
protein	I
,	O
in	O
the	O
absence	O
of	O
any	O
deleterious	O
effect	O
on	O
T	O
cell	O
function	O
,	O
suggests	O
that	O
such	O
a	O
strategy	O
could	O
provide	O
a	O
therapeutic	O
effect	O
in	O
the	O
T	O
lymphocytes	O
of	O
acquired	O
immunodeficiency	O
syndrome	O
patients	O
.	O

The	O
present	O
work	O
has	O
examined	O
the	O
effects	O
of	O
okadaic	O
acid	O
,	O
an	O
inhibitor	O
of	O
type	B
1	I
and	I
2A	I
protein	I
phosphatases	I
,	O
on	O
the	O
regulation	O
of	O
c	B
-	I
jun	I
expression	O
during	O
monocytic	O
differentiation	O
of	O
U	O
-	O
937	O
leukemia	O
cells	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Mitogen	O
stimulation	O
of	O
T	O
-	O
cells	O
increases	O
c	B
-	I
Fos	I
and	O
c	B
-	I
Jun	I
protein	O
levels	O
,	O
AP	O
-	O
1	O
binding	O
and	O
AP	O
-	O
1	O
transcriptional	O
activity	O
.	O

Both	O
c	B
-	I
Fos	I
and	O
c	B
-	I
Jun	I
protein	O
levels	O
were	O
increased	O
after	O
Con	O
A	O
and	O
PHA	O
stimulation	O
.	O

The	O
kinetics	O
of	O
expression	O
of	O
the	O
two	O
genes	O
were	O
also	O
slightly	O
different	O
,	O
with	O
c	B
-	I
fos	I
mRNA	I
reaching	O
a	O
peak	O
at	O
15	O
min	O
after	O
stimulation	O
and	O
c	B
-	I
jun	I
at	O
30	O
min	O
.	O

Nuclear	O
transcription	O
studies	O
in	O
vitro	O
showed	O
that	O
LTB4	O
increased	O
the	O
transcription	O
of	O
the	O
c	B
-	I
fos	I
gene	I
7	O
-	O
fold	O
and	O
the	O
c	B
-	I
jun	I
gene	I
1	O
.	O
4	O
-	O
fold	O
.	O

Modulation	O
of	O
normal	O
erythroid	O
differentiation	O
by	O
the	O
endogenous	O
thyroid	O
hormone	O
and	O
retinoic	B
acid	I
receptors	I
:	O
a	O
possible	O
target	O
for	O
v	B
-	I
erbA	I
oncogene	I
action	O
.	O

Thyroid	O
hormone	O
(	O
T3	O
)	O
alone	O
caused	O
similar	O
but	O
weaker	O
effects	O
.	O

Two	O
types	O
of	O
helper	O
T	O
cell	O
(	O
Th	O
)	O
clones	O
(	O
Th1	O
and	O
Th2	O
)	O
are	O
defined	O
on	O
the	O
basis	O
of	O
different	O
patterns	O
of	O
cytokine	B
(	O
lymphokine	B
)	O
secretion	O
.	O

Yet	O
phorbol	O
ester	O
alone	O
or	O
calcium	O
ionophore	O
alone	O
produce	O
several	O
lymphokines	B
.	O

GM2	B
defines	O
a	O
binding	B
site	I
for	O
protein	O
(	O
s	O
)	O
whose	O
binding	O
is	O
inducible	O
by	O
PMA	O
.	O

Mutations	O
in	O
the	O
Pit	B
-	I
1	I
gene	I
in	O
children	O
with	O
combined	O
pituitary	O
hormone	O
deficiency	O
.	O

Pit	B
-	I
1	I
is	O
a	O
pituitary	B
-	I
specific	I
transcription	I
factor	I
that	O
binds	O
to	O
and	O
transactivates	O
promoters	B
of	O
growth	B
hormone	I
and	I
prolactin	I
genes	I
.	O

Activation	O
of	O
protein	B
kinase	I
C	I
and	O
elevation	O
of	O
cAMP	O
interact	O
synergistically	O
to	O
raise	O
c	B
-	I
Fos	I
and	O
AP	B
-	I
1	I
activity	O
in	O
Jurkat	O
cells	O
.	O

We	O
have	O
earlier	O
found	O
that	O
in	O
Jurkat	O
cells	O
activation	O
of	O
protein	B
kinase	I
C	I
(	O
PKC	B
)	O
enhances	O
the	O
cyclic	O
adenosine	O
monophosphate	O
(	O
cAMP	O
)	O
accumulation	O
induced	O
by	O
adenosine	O
receptor	O
stimulation	O
or	O
activation	O
of	O
Gs	B
.	O

The	O
former	O
two	O
substances	O
interact	O
with	O
T	O
cells	O
via	O
the	O
glucocorticoid	B
and	I
beta	I
-	I
adrenergic	I
receptors	I
respectively	O
.	O

When	O
occupied	O
by	O
their	O
natural	O
ligands	O
,	O
glucocorticosteroids	O
and	O
catecholamines	O
,	O
these	O
receptors	O
have	O
a	O
role	O
in	O
modulating	O
T	O
-	O
cell	O
function	O
during	O
stress	O
.	O

3	O
.	O

Synergistic	O
suppression	O
of	O
T	O
-	O
cell	O
proliferation	O
was	O
observed	O
when	O
various	O
concentrations	O
of	O
DEX	O
and	O
PGE2	O
,	O
but	O
not	O
DEX	O
and	O
ISO	O
,	O
were	O
added	O
to	O
cultures	O
.	O

In	O
vivo	O
footprint	O
analysis	O
of	O
the	O
HLA	B
-	I
DRA	I
gene	I
promoter	I
:	O
cell	O
-	O
specific	O
interaction	O
at	O
the	O
octamer	B
site	I
and	O
up	O
-	O
regulation	O
of	O
X	O
box	O
binding	O
by	O
interferon	B
gamma	I
.	O

Danazol	O
bound	O
to	O
these	O
sites	O
in	O
high	O
concentration	O
(	O
10	O
(	O
-	O
6	O
)	O
M	O
,	O
clinical	O
serum	O
concentration	O
during	O
danazol	O
therapy	O
)	O
and	O
decreased	O
the	O
number	O
of	O
both	O
sites	O
.	O

Therefore	O
,	O
we	O
describe	O
a	O
microtitre	O
assay	O
system	O
for	O
glucocorticoid	B
receptors	I
which	O
is	O
a	O
whole	O
-	O
cell	O
competitive	O
binding	O
radioassay	O
using	O
[	O
3H	O
]	O
-	O
dexamethasone	O
as	O
radioligand	O
.	O

Thus	O
enabled	O
to	O
perform	O
the	O
test	O
on	O
multiple	O
blood	O
samples	O
in	O
parallel	O
,	O
we	O
investigated	O
cardiac	O
infarction	O
patients	O
over	O
a	O
12	O
-	O
day	O
period	O
to	O
test	O
if	O
glucocorticoid	B
receptor	I
binding	O
is	O
altered	O
in	O
this	O
'	O
stressful	O
'	O
disease	O
.	O

On	O
the	O
first	O
day	O
of	O
the	O
disease	O
,	O
glucocorticoid	B
receptor	I
capacity	O
was	O
significantly	O
decreased	O
without	O
alteration	O
of	O
the	O
receptor	O
-	O
ligand	O
affinity	O
,	O
whereas	O
on	O
days	O
4	O
and	O
12	O
the	O
number	O
of	O
receptor	O
sites	O
was	O
normal	O
again	O
.	O

CsA	O
was	O
found	O
not	O
to	O
inhibit	O
lck	B
gene	O
expression	O
,	O
nor	O
the	O
activity	O
of	O
the	O
lck	B
gene	I
product	O
.	O

The	O
IL	B
-	I
2	I
promoter	I
contains	O
binding	B
sites	I
for	O
nuclear	B
factors	I
including	O
NFAT	B
-	I
1	I
,	O
Oct	B
,	O
NF	B
-	I
kappa	I
B	I
,	O
and	O
AP	B
-	I
1	I
,	O
which	O
are	O
all	O
potentially	O
sensitive	O
to	O
activation	O
of	O
PKC	B
.	O

Our	O
results	O
indicate	O
that	O
the	O
AP	B
-	I
1	I
site	I
at	O
-	B
150	I
bp	I
represents	O
a	O
major	O
,	O
if	O
not	O
the	O
only	O
,	O
site	O
of	O
PKC	B
responsiveness	O
in	O
the	O
IL	B
-	I
2	I
promoter	I
.	O

Mice	O
transgenic	O
for	O
the	O
human	B
T	I
cell	I
leukemia	I
virus	I
(	I
HTLV	I
-	I
I	I
)	I
Tax	I
gene	I
develop	O
fibroblastic	O
tumors	O
that	O
express	O
NF	B
-	I
kappa	I
B	I
-	I
inducible	I
early	I
genes	I
.	O

Mice	O
treated	O
with	O
antisense	O
to	O
NF	B
-	I
kappa	I
B	I
ODNs	O
showed	O
rapid	O
regression	O
of	O
transplanted	O
fibrosarcomas	O
.	O

Binding	O
of	O
125I	O
-	O
labeled	O
aldosterone	O
to	O
plasma	O
membranes	O
of	O
HML	O
shares	O
important	O
features	O
with	O
these	O
functional	O
data	O
.	O

Leukotriene	O
B4	O
transcriptionally	O
activates	O
interleukin	B
-	I
6	I
expression	O
involving	O
NK	B
-	I
chi	I
B	I
and	O
NF	B
-	I
IL6	I
.	O

It	O
is	O
,	O
however	O
,	O
still	O
unclear	O
whether	O
LTB4	O
acts	O
in	O
this	O
regard	O
directly	O
or	O
indirectly	O
by	O
stimulating	O
the	O
release	O
of	O
chemotactic	O
and	O
inflammatory	B
cytokines	I
.	O

We	O
furthermore	O
demonstrate	O
that	O
this	O
process	O
involves	O
activation	O
of	O
the	O
transcription	B
factor	I
NF	B
-	I
chi	I
B	I
and	O
,	O
to	O
a	O
lesser	O
extent	O
,	O
of	O
NF	B
-	I
IL6	I
,	O
while	O
the	O
activity	O
of	O
the	O
transcription	B
factor	I
AP	B
-	I
1	I
,	O
shown	O
to	O
otherwise	O
confer	O
IL	B
-	I
6	I
inducibility	O
,	O
appeared	O
to	O
be	O
unaffected	O
by	O
LTB4	O
.	O

The	O
signaling	O
events	O
mediating	O
this	O
effect	O
appeared	O
to	O
involve	O
the	O
release	O
of	O
H2O2	O
,	O
since	O
LTB4	O
failed	O
to	O
induce	O
NF	B
-	I
chi	I
B	I
or	O
NF	B
-	I
IL6	I
in	O
the	O
presence	O
of	O
the	O
scavenger	O
of	O
H2O2	O
,	O
N	O
-	O
acetyl	O
-	O
L	O
-	O
cysteine	O
.	O

The	O
insertion	O
was	O
not	O
required	O
for	O
Fc	B
gamma	I
RII	I
to	O
modulate	O
surface	B
immunoglobulin	I
-	O
triggered	O
B	O
-	O
cell	O
activation	O
.	O

[	O
Age	O
-	O
related	O
changes	O
in	O
glucocorticoid	B
and	I
mineralocorticoid	I
receptors	I
in	O
lymphocytes	O
of	O
healthy	O
persons	O
and	O
patients	O
with	O
hypertension	O
]	O

Still	O
a	O
more	O
essential	O
rise	O
in	O
the	O
number	O
of	O
receptors	O
is	O
observed	O
in	O
mid	O
-	O
age	O
hypertensive	O
patients	O
than	O
in	O
elderly	O
ones	O
.	O

Here	O
,	O
Stuart	O
Schreiber	O
and	O
Gerald	O
Crabtree	O
review	O
recent	O
findings	O
that	O
indicate	O
CsA	O
and	O
FK506	O
operate	O
as	O
prodrugs	O
:	O
they	O
bind	O
endogenous	B
intracellular	I
receptors	I
,	O
the	O
immunophilins	B
,	O
and	O
the	O
resulting	O
complex	O
targets	O
the	O
protein	B
phosphatase	I
,	I
calcineurin	B
,	O
to	O
exert	O
the	O
immunosuppressive	O
effect	O
.	O

PLB	O
-	O
985	O
cells	O
represent	O
a	O
bipotential	O
myelomonoblastic	O
cell	O
population	O
capable	O
of	O
either	O
granulocytic	O
or	O
monocytic	O
differentiation	O
after	O
induction	O
with	O
appropriate	O
inducers	O
.	O

Mutations	O
affecting	O
the	O
5	B
'	I
guanine	I
residues	I
of	O
the	O
kappa	B
B	I
site	I
were	O
unable	O
to	O
compete	O
for	O
these	O
NF	B
-	I
kappa	I
B	I
-	I
related	I
proteins	I
.	O

Inducibility	O
of	O
endogenous	O
IFN	B
-	I
beta	I
and	I
IFN	I
-	I
alpha	I
RNA	I
was	O
also	O
increased	O
in	O
PLB	O
-	O
IIIB	O
cells	O
.	O

In	O
the	O
present	O
study	O
we	O
report	O
on	O
6	O
patients	O
(	O
2	O
males	O
and	O
4	O
females	O
)	O
with	O
the	O
syndrome	O
.	O

First	O
is	O
an	O
expansion	O
phase	O
prior	O
to	O
TCR	B
rearrangement	O
,	O
which	O
appears	O
to	O
be	O
correlated	O
with	O
programming	O
of	O
at	O
least	O
some	O
response	O
genes	O
for	O
inducibility	O
.	O

However	O
,	O
the	O
profound	O
T	O
cell	O
deficit	O
of	O
nude	O
mice	O
indicates	O
that	O
the	O
thymus	O
is	O
by	O
far	O
the	O
most	O
potent	O
site	O
for	O
inducing	O
the	O
expansion	O
per	O
se	O
,	O
even	O
if	O
other	O
sites	O
can	O
induce	O
some	O
response	O
acquisition	O
.	O

Second	O
is	O
a	O
controlled	O
phase	O
of	O
TCR	B
gene	I
rearrangement	O
.	O

It	O
seems	O
that	O
the	O
rearrangement	O
of	O
the	O
TCR	B
gamma	I
loci	I
in	O
the	O
gamma	O
delta	O
lineage	O
may	O
not	O
always	O
take	O
place	O
at	O
a	O
developmental	O
stage	O
strictly	O
equivalent	O
to	O
the	O
rearrangement	O
of	O
TCR	B
beta	I
in	O
the	O
alpha	O
beta	O
lineage	O
,	O
and	O
it	O
is	O
not	O
clear	O
just	O
how	O
early	O
the	O
two	O
lineages	O
diverge	O
.	O

The	O
genes	O
that	O
need	O
to	O
be	O
induced	O
for	O
this	O
response	O
are	O
not	O
yet	O
identified	O
,	O
but	O
it	O
is	O
unquestionably	O
a	O
form	O
of	O
activation	O
.	O

In	O
contrast	O
,	O
NF	B
-	I
kappa	I
B	I
p50	I
alone	O
fails	O
to	O
stimulate	O
kappa	O
B	O
-	O
directed	O
transcription	O
,	O
and	O
based	O
on	O
prior	O
in	O
vitro	O
studies	O
,	O
is	O
not	O
directly	O
regulated	O
by	O
I	B
kappa	I
B	I
.	O

Together	O
,	O
these	O
findings	O
suggest	O
that	O
the	O
nuclear	O
localization	O
signal	O
and	O
transactivation	B
domain	I
of	O
NF	B
-	I
kappa	I
B	I
p65	I
constitute	O
a	O
bipartite	O
system	O
that	O
is	O
critically	O
involved	O
in	O
the	O
inhibitory	O
function	O
of	O
I	B
kappa	I
B	I
/	I
MAD	I
-	I
3	I
.	O

This	O
interaction	O
is	O
functional	O
as	O
it	O
leads	O
to	O
retargeting	O
of	O
NF	B
-	I
kappa	I
B	I
p50	I
from	O
the	O
nucleus	O
to	O
the	O
cytoplasm	O
.	O

However	O
,	O
no	O
loss	O
of	O
DNA	O
binding	O
activity	O
is	O
observed	O
,	O
presumably	O
reflecting	O
the	O
unique	O
C	B
-	I
terminal	I
domain	I
that	O
is	O
distinct	O
from	O
that	O
present	O
in	O
NF	B
-	I
kappa	I
B	I
p65	I
.	O

We	O
have	O
biochemically	O
and	O
functionally	O
characterized	O
a	O
new	O
transcription	B
factor	I
,	O
NP	B
-	I
TCII	I
,	O
which	O
is	O
present	O
in	O
nuclei	O
from	O
unstimulated	O
T	O
and	O
B	O
lymphocytes	O
but	O
is	O
not	O
found	O
in	O
nonhematopoietic	O
cells	O
.	O

[	O
Mechanism	O
of	O
action	O
of	O
steroid	O
hormones	O
.	O
I	O
.	O
Estrogens	O
]	O

The	O
steroid	O
hormone	O
are	O
very	O
versatile	O
molecules	O
:	O
although	O
they	O
are	O
related	O
among	O
them	O
by	O
their	O
chemical	O
structure	O
,	O
they	O
have	O
very	O
diverse	O
functions	O
and	O
including	O
antagonic	O
.	O

Their	O
action	O
mechanism	O
is	O
not	O
completely	O
cleared	O
.	O

Chloramphenicol	B
acetyl	I
transferase	I
(	O
CAT	B
)	O
assays	O
using	O
the	O
HIV	B
-	I
1	I
(	I
-	I
139	I
)	I
long	I
terminal	I
repeat	I
-	I
CAT	I
construct	I
showed	O
no	O
PMA	O
induction	O
of	O
CAT	B
activity	O
in	O
these	O
subclones	O
(	O
unlike	O
the	O
parental	O
line	O
and	O
other	O
subclones	O
)	O
.	O

Although	O
NF	B
-	I
AT	I
has	O
not	O
been	O
cloned	O
or	O
purified	O
,	O
there	O
is	O
evidence	O
that	O
it	O
is	O
a	O
major	O
target	O
for	O
immunosuppression	O
by	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
and	O
FK506	O
(	O
refs	O
2	O
-	O
7	O
)	O
.	O

Although	O
it	O
has	O
been	O
previously	O
shown	O
that	O
the	O
IL	B
-	I
6	I
kappa	I
B	I
motif	I
functions	O
as	O
a	O
potent	O
IL	B
-	I
1	I
/	I
tumor	I
necrosis	I
factor	I
-	I
responsive	I
element	I
in	O
nonlymphoid	O
cells	O
,	O
its	O
activity	O
was	O
found	O
to	O
be	O
repressed	O
in	O
lymphoid	O
cells	O
such	O
as	O
a	O
Jurkat	O
T	O
-	O
cell	O
line	O
.	O

Cortisol	O
resistance	O
in	O
acquired	O
immunodeficiency	O
syndrome	O
.	O

An	O
acquired	O
form	O
of	O
peripheral	O
resistance	O
to	O
glucocorticoids	O
was	O
suspected	O
.	O

[	O
3H	O
]	O
Thymidine	O
incorporation	O
was	O
decreased	O
dose	O
-	O
dependently	O
by	O
dexamethasone	O
in	O
controls	O
and	O
patients	O
;	O
the	O
effect	O
was	O
significantly	O
blunted	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
in	O
group	O
1	O
patients	O
,	O
which	O
suggests	O
that	O
activation	O
of	O
glucocorticoid	B
receptor	I
is	O
impaired	O
as	O
a	O
result	O
of	O
the	O
glucocorticoid	B
receptor	I
abnormality	O
.	O

After	O
the	O
DNA	B
fragment	I
containing	O
the	O
CAG	B
repeats	I
is	O
amplified	O
by	O
the	O
polymerase	O
chain	O
reaction	O
,	O
a	O
primer	O
extension	O
is	O
carried	O
out	O
;	O
the	O
extension	O
of	O
the	O
end	B
-	I
labelled	I
reverse	I
primer	I
adjacent	O
to	O
3	B
'	I
end	I
of	O
CAG	B
repeats	I
stops	O
at	O
the	O
first	O
T	O
after	O
CAG	B
repeats	I
with	O
the	O
incorporation	O
of	O
dideoxy	O
ATP	O
in	O
the	O
reaction	O
mixture	O
.	O

Cells	O
of	O
monocyte	O
lineage	O
serve	O
as	O
effector	O
cells	O
in	O
the	O
cellular	O
immune	O
response	O
.	O

The	O
response	O
to	O
antigen	O
proceeds	O
at	O
the	O
T	O
helper	O
cell	O
level	O
through	O
two	O
independent	O
forms	O
of	O
cellular	O
collaboration	O
,	O
contact	O
and	O
lymphokine	B
.	O

It	O
is	O
evident	O
that	O
assembly	O
of	O
the	O
surface	B
domain	I
of	O
TF	B
with	O
VIIa	B
to	O
form	O
the	O
binary	O
TF	B
.	I
VIIa	I
complex	I
induces	O
a	O
significant	O
increase	O
in	O
the	O
Kcat	O
of	O
the	O
catalytic	B
domain	I
of	O
VIIa	B
for	O
small	O
peptidyl	O
substrates	O
and	O
more	O
profoundly	O
for	O
protein	B
substrate	I
.	O

It	O
is	O
also	O
evident	O
that	O
association	O
of	O
X	B
with	O
charged	O
phospholipid	O
surfaces	O
enhances	O
the	O
proteolytic	O
activation	O
of	O
this	O
zymogen	B
by	O
increasing	O
recognition	O
and	O
susceptibility	O
of	O
the	O
sessile	O
peptide	O
bond	O
deduced	O
from	O
the	O
markedly	O
decreased	O
Km	O
and	O
increased	O
Kcat	O
.	O

NF	B
kappa	I
B	I
is	O
a	O
potent	O
mediator	O
of	O
specific	O
gene	O
expression	O
in	O
human	O
monocytes	O
and	O
has	O
been	O
shown	O
to	O
play	O
a	O
role	O
in	O
transcription	O
of	O
the	O
HIV	O
-	O
1	O
genome	O
in	O
promonocytic	O
leukemias	O
.	O

There	O
is	O
little	O
information	O
available	O
on	O
the	O
response	O
of	O
NF	B
kappa	I
B	I
to	O
cytokines	B
in	O
normal	O
human	O
monocytes	O
.	O

In	O
THP	O
-	O
1	O
cells	O
,	O
TPA	O
also	O
induced	O
a	O
new	O
,	O
faster	B
-	I
migrating	I
NF	I
kappa	I
B	I
species	I
not	O
induced	O
in	O
monocytes	O
.	O

The	O
endothelium	O
plays	O
a	O
critical	O
role	O
in	O
inflammation	O
by	O
directing	O
circulating	O
leukocytes	O
into	O
extravascular	O
tissues	O
by	O
expressing	O
adhesive	B
molecules	I
for	O
leukocytes	O
[	O
e	O
.	O
g	O
.	O
,	O
endothelial	B
-	I
leukocyte	I
adhesion	I
molecule	I
1	I
(	O
ELAM	B
-	I
1	I
)	O
and	O
intercellular	B
adhesion	I
molecule	I
1	I
(	O
ICAM	B
-	I
1	I
)	O
]	O
.	O

In	O
contrast	O
,	O
sodium	O
salicylate	O
(	O
1	O
mM	O
)	O
inhibited	O
neither	O
adhesion	O
nor	O
expression	O
of	O
these	O
adhesion	B
molecules	I
.	O

These	O
studies	O
suggest	O
that	O
antagonism	O
by	O
dexamethasone	O
of	O
endotoxin	B
-	O
induced	O
inflammation	O
is	O
a	O
specific	O
instance	O
of	O
the	O
general	O
biological	O
principle	O
that	O
the	O
glucocorticoid	B
receptor	I
is	O
a	O
hormone	O
-	O
dependent	O
regulator	O
of	O
transcription	O
.	O

Biochemical	O
purification	O
and	O
cDNA	O
cloning	O
has	O
now	O
revealed	O
that	O
BSAP	B
belongs	O
to	O
the	O
family	O
of	O
paired	B
domain	I
proteins	I
.	O

BSAP	B
is	O
encoded	O
by	O
the	O
Pax	B
-	I
5	I
gene	I
and	O
has	O
been	O
highly	O
conserved	O
between	O
human	O
and	O
mouse	O
.	O

Later	O
,	O
the	O
expression	O
of	O
the	O
BSAP	B
gene	I
shifts	O
to	O
the	O
fetal	O
liver	O
where	O
it	O
correlates	O
with	O
the	O
onset	O
of	O
B	O
lymphopoiesis	O
.	O

Specific	O
NF	B
-	I
kappa	I
B	I
subunits	I
act	O
in	O
concert	O
with	O
Tat	B
to	O
stimulate	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
transcription	O
.	O

NF	B
-	I
kappa	I
B	I
is	O
a	O
protein	B
complex	I
which	O
functions	O
in	O
concert	O
with	O
the	O
tat	B
-	I
I	I
gene	I
product	I
to	O
stimulate	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
transcription	O
.	O

We	O
have	O
found	O
that	O
the	O
p49	B
(	I
100	I
)	I
DNA	I
binding	I
subunit	I
,	O
together	O
with	O
p65	B
,	O
can	O
act	O
in	O
concert	O
with	O
Tat	B
-	I
I	I
to	O
stimulate	O
the	O
expression	O
of	O
HIV	B
-	I
CAT	I
plasmid	I
.	O

Little	O
effect	O
was	O
observed	O
with	O
50	B
-	I
kDa	I
forms	I
of	O
p105	B
NF	B
-	I
kappa	I
B	I
or	O
rel	B
,	O
in	O
combination	O
with	O
p65	B
or	O
full	B
-	I
length	I
c	I
-	I
rel	I
,	O
which	O
do	O
not	O
stimulate	O
the	O
HIV	B
enhancer	I
in	O
these	O
cells	O
.	O

Stable	O
expression	O
of	O
HB24	B
,	O
a	O
diverged	B
human	I
homeobox	I
gene	I
,	O
in	O
T	O
lymphocytes	O
induces	O
genes	O
involved	O
in	O
T	O
cell	O
activation	O
and	O
growth	O
.	O

In	O
the	O
studies	O
described	O
in	O
this	O
report	O
,	O
we	O
have	O
identified	O
two	O
potential	O
Ets	B
binding	I
sites	I
,	O
EBS1	O
and	O
EBS2	B
,	O
which	O
are	O
conserved	O
in	O
both	O
the	O
human	B
and	I
murine	I
interleukin	I
-	I
2	I
enhancers	I
.	O

Possible	O
mechanisms	O
by	O
which	O
these	O
proteins	O
may	O
regulate	O
transcription	O
of	O
the	O
epsilon	B
-	I
globin	I
-	I
encoding	I
gene	I
in	O
erythroid	O
and	O
non	O
-	O
erythroid	O
cells	O
are	O
discussed	O
.	O

A	O
MEDLINE	O
search	O
of	O
the	O
English	O
-	O
language	O
literature	O
was	O
conducted	O
using	O
the	O
indexing	O
terms	O
'	O
immunology	O
,	O
calcitriol	O
and	O
vitamin	O
D	O
'	O
to	O
identify	O
studies	O
indicating	O
a	O
role	O
for	O
calcitriol	O
as	O
a	O
primary	O
immunomodulator	O
.	O

This	O
protein	O
is	O
distinct	O
from	O
other	O
members	O
of	O
the	O
steroid	B
/	I
thyroid	I
hormone	I
receptor	I
family	I
including	O
the	O
COUP	B
protein	I
which	O
has	O
a	O
closely	O
related	O
DNA	O
binding	O
specificity	O
.	O

A	O
Tat	B
-	I
responsive	I
element	I
is	O
found	O
upstream	O
within	O
the	O
viral	B
promoter	I
that	O
in	O
glial	O
-	O
derived	O
cell	O
lines	O
allows	O
transactivation	O
in	O
the	O
absence	O
of	O
TAR	B
.	O

Further	O
,	O
we	O
observe	O
that	O
TAR	B
-	I
deleted	I
mutants	I
of	O
HIV	O
-	O
1	O
demonstrate	O
normal	O
late	O
gene	O
expression	O
in	O
glial	O
cells	O
as	O
evidenced	O
by	O
syncytia	O
formation	O
and	O
production	O
of	O
viral	B
p24	I
antigen	I
.	O

At	O
least	O
two	O
21	B
bp	I
repeats	I
were	O
required	O
for	O
high	O
levels	O
of	O
AP	B
-	I
2	I
activation	O
and	O
mutagenesis	O
of	O
the	O
AP	B
-	I
2	I
consensus	I
binding	I
sequences	I
in	O
the	O
21	B
bp	I
repeats	I
eliminate	O
this	O
activation	O
.	O

Activation	O
of	O
the	O
human	B
immunodeficiency	I
virus	I
type	I
1	I
enhancer	I
is	O
not	O
dependent	O
on	O
NFAT	B
-	I
1	I
.	O

Activation	O
by	O
the	O
T	B
-	I
cell	I
antigen	I
receptor	I
is	O
minimal	O
in	O
Jurkat	O
cells	O
and	O
is	O
mediated	O
by	O
the	O
kappa	B
B	I
sites	I
.	O

The	O
promoter	O
of	O
the	O
major	B
histocompatibility	I
class	I
II	I
gene	I
DRA	B
contains	O
an	O
octamer	B
element	I
(	O
ATTTGCAT	O
)	O
that	O
is	O
required	O
for	O
efficient	O
DRA	B
expression	O
in	O
B	O
cells	O
.	O

In	O
vitro	O
transcription	O
analysis	O
using	O
protein	O
fractions	O
enriched	O
for	O
the	O
octamer	O
-	O
binding	O
protein	O
OTF	B
-	I
2	I
demonstrate	O
a	O
positive	O
functional	O
role	O
for	O
OTF	B
-	I
2	I
in	O
DRA	B
gene	I
transcription	O
.	O

Recombinant	B
OTF	I
-	I
2	I
protein	I
produced	O
by	O
in	O
vitro	O
transcription	O
/	O
translation	O
could	O
also	O
enhance	O
DRA	B
gene	I
transcription	O
in	O
vitro	O
.	O

However	O
,	O
the	O
increase	O
in	O
ISGF3	B
activity	O
ultimately	O
correlates	O
with	O
the	O
accumulation	O
of	O
ISGF3	B
gamma	I
induced	O
by	O
IFN	B
-	I
alpha	I
or	O
IFN	B
-	I
gamma	I
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

An	O
attempt	O
was	O
also	O
undertaken	O
to	O
use	O
a	O
cell	O
harvester	O
for	O
the	O
separation	O
of	O
cells	O
from	O
unbound	O
ligand	O
.	O

Glucocorticoid	B
receptor	I
and	O
inhibition	O
of	O
3	O
-	O
O	O
-	O
methyl	O
-	O
D	O
-	O
glucose	O
uptake	O
by	O
glucocorticoids	O
in	O
peripheral	O
blood	O
leukocytes	O
from	O
normal	O
humans	O
:	O
correlation	O
between	O
receptor	O
level	O
and	O
hormone	O
effect	O
in	O
vitro	O
.	O

It	O
was	O
found	O
that	O
lipopolysaccharide	O
induced	O
strongly	O
both	O
c	B
-	I
fos	I
and	O
c	B
-	I
jun	I
expression	O
as	O
well	O
as	O
AP1	B
formation	O
.	O

Regulation	O
of	O
interleukin	B
-	I
1	I
beta	I
production	O
by	O
glucocorticoids	O
in	O
human	O
monocytes	O
:	O
the	O
mechanism	O
of	O
action	O
depends	O
on	O
the	O
activation	O
signal	O
.	O

Nuclear	B
transcription	I
factors	I
that	O
bind	O
to	O
elements	O
of	O
the	O
IL	B
-	I
2	I
promoter	I
.	O

However	O
,	O
the	O
signaling	O
requirements	O
and	O
sensitivity	O
to	O
protein	O
synthesis	O
inhibitors	O
differ	O
considerably	O
.	O

In	O
addition	O
,	O
p65	B
gave	O
per	O
se	O
,	O
with	O
low	O
affinity	O
,	O
a	O
protein	B
-	I
DNA	I
complex	I
that	O
migrated	O
more	O
slowly	O
than	O
native	O
NF	B
-	I
GM2	I
complex	I
.	O

Furthermore	O
,	O
an	O
antiserum	O
against	O
KBF1	B
(	O
identical	O
to	O
50	B
kDa	I
NF	I
-	I
kappa	I
B	I
protein	I
)	O
reacted	O
with	O
the	O
p50	B
of	O
NF	B
-	I
GM2	I
,	O
indicating	O
that	O
the	O
NF	B
-	I
GM2	I
polypeptide	I
can	O
not	O
be	O
immunologically	O
differentiated	O
from	O
the	O
50	B
kDa	I
subunit	I
of	O
NF	B
-	I
kappa	I
B	I
.	O

This	O
suggests	O
that	O
the	O
activation	O
mechanism	O
of	O
the	O
GM	B
-	I
CSF	I
gene	I
through	O
the	O
GM2	B
/	I
GC	I
-	I
box	I
sequence	I
is	O
different	O
from	O
that	O
of	O
genes	O
carrying	O
the	O
kappa	B
B	I
enhancer	I
alone	O
.	O

Characterization	O
of	O
an	O
immediate	B
-	I
early	I
gene	I
induced	O
in	O
adherent	O
monocytes	O
that	O
encodes	O
I	B
kappa	I
B	I
-	O
like	O
activity	O
.	O

The	O
C	B
-	I
terminus	I
has	O
a	O
putative	O
protein	B
kinase	I
C	I
phosphorylation	I
site	I
.	O

In	O
both	O
wild	O
-	O
type	O
and	O
highly	O
dexamethasone	O
(	O
dex	O
)	O
-	O
resistant	O
clones	O
of	O
the	O
human	O
leukemic	O
cell	O
line	O
CEM	O
,	O
exposure	O
to	O
cortivazol	O
leads	O
to	O
cell	O
death	O
.	O

Permissiveness	O
to	O
replication	O
of	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
differs	O
in	O
T	O
lymphocytes	O
and	O
macrophages	O
.	O

A	O
DNA	B
probe	I
that	O
spanned	O
a	O
domain	O
conserved	O
among	O
the	O
proto	B
-	I
oncogene	I
c	I
-	I
rel	I
,	O
the	O
Drosophila	B
morphogen	I
dorsal	I
,	O
and	O
the	O
p50	B
DNA	I
binding	I
subunit	I
of	O
NF	B
-	I
kappa	I
B	I
was	O
generated	O
from	O
Jurkat	B
T	I
cell	I
complementary	I
DNA	I
with	O
the	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
and	O
degenerate	O
oligonucleotides	O
.	O

This	O
probe	O
was	O
used	O
to	O
identify	O
a	O
rel	B
-	I
related	I
complementary	I
DNA	I
that	O
hybridized	O
to	O
a	O
2	B
.	I
6	I
-	I
kilobase	I
messenger	I
RNA	I
present	O
in	O
human	O
T	O
and	O
B	O
lymphocytes	O
.	O

In	O
vitro	O
transcription	O
and	O
translation	O
of	O
the	O
complementary	B
DNA	I
resulted	O
in	O
the	O
synthesis	O
of	O
a	O
protein	O
with	O
an	O
apparent	O
molecular	O
size	O
of	O
65	B
kilodaltons	I
(	O
kD	O
)	O
.	O

This	O
protein	B
-	I
DNA	I
complex	I
comigrated	O
with	O
the	O
complex	O
obtained	O
with	O
the	O
purified	B
human	I
p65	I
NF	I
-	I
kappa	I
B	I
subunit	I
and	O
binding	O
was	O
inhibited	O
by	O
I	B
kappa	I
B	I
-	I
alpha	I
and	O
-	O
beta	O
proteins	O
.	O

Regulation	O
of	O
M	B
-	I
CSF	I
expression	O
by	O
M	B
-	I
CSF	I
:	O
role	O
of	O
protein	B
kinase	I
C	I
and	O
transcription	B
factor	I
NF	I
kappa	I
B	I
.	O

To	O
date	O
,	O
little	O
is	O
known	O
about	O
the	O
intracellular	O
pathway	O
of	O
M	B
-	I
CSF	I
signal	O
transduction	O
.	O

The	O
pAT	B
133	I
gene	I
is	O
immediately	O
induced	O
,	O
with	O
FOS	B
-	O
like	O
kinetics	O
,	O
in	O
human	O
T	O
cells	O
and	O
in	O
fibroblasts	O
.	O

However	O
,	O
upon	O
transition	O
from	O
a	O
proliferating	O
(	O
G1	O
)	O
to	O
a	O
resting	O
state	O
of	O
the	O
cell	O
cycle	O
the	O
three	O
genes	O
were	O
differently	O
regulated	O
.	O

v	B
-	I
erbA	I
overexpression	O
is	O
required	O
to	O
extinguish	O
c	B
-	I
erbA	I
function	O
in	O
erythroid	O
cell	O
differentiation	O
and	O
regulation	O
of	O
the	O
erbA	B
target	I
gene	I
CAII	B
.	O

The	O
v	B
-	I
erbA	I
oncoprotein	I
represents	O
a	O
retrovirus	O
-	O
transduced	O
oncogenic	O
version	O
of	O
the	O
thyroid	B
hormone	I
(	I
T3	I
/	I
T4	I
)	I
receptor	I
c	B
-	I
erbA	I
(	I
type	I
alpha	I
)	I
.	O

This	O
erbA	B
-	I
binding	I
site	I
confers	O
thyroid	O
hormone	O
responsiveness	O
to	O
a	O
heterologous	B
promoter	I
in	O
transient	O
expression	O
experiments	O
and	O
is	O
a	O
target	O
for	O
efficient	O
down	O
-	O
regulation	O
of	O
CAII	B
transcription	O
by	O
the	O
v	B
-	I
erbA	I
oncoprotein	I
.	O

The	O
CD2	B
T	I
lymphocyte	I
glycoprotein	I
surface	I
molecule	I
mediates	O
both	O
cell	O
to	O
cell	O
adhesion	O
and	O
T	O
cell	O
activation	O
,	O
two	O
processes	O
that	O
are	O
involved	O
in	O
the	O
spread	O
of	O
HIV	O
infection	O
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
micromolar	O
concentrations	O
of	O
H2O2	O
can	O
induce	O
the	O
expression	O
and	O
replication	O
of	O
HIV	O
-	O
1	O
in	O
a	O
human	O
T	O
cell	O
line	O
.	O

The	O
effect	O
is	O
mediated	O
by	O
the	O
NF	B
-	I
kappa	I
B	I
transcription	B
factor	I
which	O
is	O
potently	O
and	O
rapidly	O
activated	O
by	O
an	O
H2O2	O
treatment	O
of	O
cells	O
from	O
its	O
inactive	B
cytoplasmic	I
form	I
.	O

ROI	O
appear	O
to	O
serve	O
as	O
messengers	O
mediating	O
directly	O
or	O
indirectly	O
the	O
release	O
of	O
the	O
inhibitory	B
subunit	I
I	B
kappa	I
B	I
from	O
NF	B
-	I
kappa	I
B	I
.	O

Inhibition	O
of	O
transcription	B
factors	I
belonging	O
to	O
the	O
rel	B
/	I
NF	I
-	I
kappa	I
B	I
family	I
by	O
a	O
transdominant	B
negative	I
mutant	I
.	O

A	O
mutant	O
of	O
KBF1	B
/	I
p50	I
(	O
delta	B
SP	I
)	O
,	O
unable	O
to	O
bind	O
to	O
DNA	O
but	O
able	O
to	O
form	O
homo	O
-	O
or	O
heterodimers	B
,	O
has	O
been	O
constructed	O
.	O

One	O
gene	O
of	O
interest	O
is	O
the	O
glycoprotein	B
IIb	I
(	I
GPIIb	I
)	I
gene	I
;	O
GPIIb	B
,	O
the	O
alpha	B
subunit	I
of	O
the	O
platelet	B
cytoadhesin	I
GPIIb	I
-	I
IIIa	I
,	O
is	O
produced	O
in	O
megakaryocytes	O
at	O
an	O
early	O
stage	O
of	O
the	O
differentiation	O
,	O
whereas	O
the	O
other	O
subunit	O
of	O
this	O
complex	O
,	O
GPIIIa	B
,	O
is	O
expressed	O
in	O
other	O
cells	O
.	O

No	O
relationship	O
could	O
be	O
established	O
between	O
glucocorticoid	B
receptor	I
binding	O
and	O
antidepressant	O
medication	O
.	O

These	O
data	O
support	O
the	O
view	O
of	O
an	O
impaired	O
ligand	O
-	O
induced	O
plasticity	O
of	O
glucocorticoid	B
receptor	I
regulation	O
rather	O
than	O
the	O
hypothesis	O
of	O
decreased	O
glucocorticoid	B
receptor	I
numbers	O
during	O
depression	O
.	O

The	O
promoters	B
and	O
enhancers	B
of	O
cell	O
type	O
-	O
specific	O
genes	O
are	O
often	O
conserved	O
in	O
evolution	O
,	O
and	O
hence	O
one	O
might	O
expect	O
that	O
a	O
given	O
enhancer	B
has	O
evolved	O
to	O
work	O
best	O
with	O
its	O
own	O
promoter	B
.	O

Towards	O
a	O
molecular	O
understanding	O
of	O
T	O
-	O
cell	O
differentiation	O
.	O

Lymphoid	O
differentiation	O
is	O
one	O
of	O
the	O
best	O
studied	O
examples	O
of	O
mammalian	O
development	O
.	O

Circadian	O
rhythm	O
in	O
glucocorticoid	B
receptor	I
(	O
GR	B
)	O
was	O
studied	O
in	O
the	O
rat	O
liver	O
and	O
human	O
peripheral	O
leukocytes	O
.	O

The	O
conversion	O
of	O
the	O
TCEd	B
to	O
a	O
'	B
perfect	I
'	I
NF	I
-	I
kB	I
binding	I
site	I
leads	O
to	O
a	O
tighter	O
binding	O
of	O
NF	B
-	I
kB	I
to	O
TCEd	B
DNA	I
and	O
,	O
as	O
a	O
functional	O
consequence	O
,	O
to	O
the	O
activity	O
of	O
the	O
'	B
converted	I
'	I
TCEd	I
motifs	I
in	O
HeLa	O
cells	O
.	O

A	O
region	O
upstream	O
to	O
the	O
first	O
exon	O
,	O
and	O
highly	O
conserved	O
between	O
mouse	O
and	O
man	O
,	O
acts	O
as	O
an	O
erythroid	O
specific	O
enhancer	O
in	O
transient	O
assays	O
,	O
if	O
linked	O
to	O
the	O
GATA	B
-	I
1	I
or	O
to	O
the	O
SV40	O
promoter	O
.	O

More	O
strikingly	O
,	O
the	O
80	B
-	I
kDa	I
protein	I
was	O
downregulated	O
in	O
a	O
dose	O
-	O
dependent	O
fashion	O
by	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
;	O
this	O
effect	O
was	O
independent	O
of	O
the	O
mode	O
of	O
lymphocyte	O
activation	O
and	O
specific	O
for	O
the	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
metabolite	O
of	O
vitamin	O
D3	O
.	O

Prolonged	O
corticosteroid	O
treatment	O
resulted	O
in	O
down	O
-	O
regulation	O
of	O
GcR	B
,	O
while	O
the	O
mean	O
level	O
of	O
GcR	B
in	O
Cushing	O
'	O
s	O
disease	O
was	O
normal	O
.	O

Furthermore	O
,	O
GcR	B
were	O
unaltered	O
after	O
these	O
patients	O
received	O
ketoconazole	O
,	O
in	O
spite	O
of	O
a	O
marked	O
reduction	O
in	O
morning	O
plasma	O
cortisol	O
and	O
urinary	O
free	O
cortisol	O
.	O

Human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
1	O
(	O
HTLV	O
-	O
1	O
)	O
is	O
an	O
etiological	O
agent	O
of	O
adult	O
T	O
-	O
cell	O
leukemia	O
(	O
ATL	O
)	O
.	O

Previously	O
,	O
transcription	O
of	O
the	O
c	B
-	I
fos	I
gene	I
has	O
been	O
reported	O
to	O
be	O
transactivated	O
by	O
the	O
viral	B
transcription	I
factor	I
,	O
Tax1	B
.	O

Glucocorticoid	B
receptor	I
characteristics	O
in	O
monocytes	O
of	O
patients	O
with	O
corticosteroid	O
-	O
resistant	O
bronchial	O
asthma	O
.	O

Vitamin	B
D	I
receptor	I
expression	O
in	O
human	O
lymphocytes	O
.	O

Signal	O
requirements	O
and	O
characterization	O
by	O
western	O
blots	O
and	O
DNA	O
sequencing	O
.	O

However	O
,	O
combination	O
of	O
OKT3	B
and	O
phorbol	O
myristate	O
acetate	O
produced	O
a	O
concentration	O
of	O
binding	O
sites	O
similar	O
to	O
the	O
PHA	O
-	O
activated	O
cells	O
.	O

The	O
receptor	O
from	O
OKT3	B
and	O
OKT3	B
+	O
phorbol	O
myristate	O
acetate	O
-	O
activated	O
lymphocytes	O
exhibited	O
decreased	O
binding	O
to	O
DNA	O
-	O
cellulose	O
compared	O
to	O
PHA	O
-	O
activated	O
lymphocytes	O
.	O

In	O
lymphocytes	O
activated	O
either	O
by	O
PHA	B
or	O
OKT3	B
(	O
but	O
not	O
in	O
resting	O
cells	O
)	O
,	O
a	O
50	B
-	I
kDa	I
species	I
cross	O
-	O
reacting	O
with	O
a	O
monoclonal	B
antibody	I
against	O
the	O
intestinal	B
vitamin	I
D	I
receptor	I
was	O
detected	O
.	O

Finally	O
,	O
RNA	O
from	O
activated	O
lymphocytes	O
was	O
amplified	O
by	O
polymerase	O
chain	O
reaction	O
using	O
oligonucleotide	O
primers	O
flanking	O
the	O
196	B
base	I
pair	I
long	I
region	I
encoding	O
the	O
DNA	B
-	I
binding	I
domain	I
of	O
the	O
human	B
intestinal	I
receptor	I
.	O

These	O
findings	O
suggest	O
that	O
expression	O
of	O
the	O
1	B
,	I
25	I
-	I
(	I
OH	I
)	I
2D3	I
receptor	I
in	O
lymphocytes	O
is	O
triggered	O
by	O
distinct	O
and	O
contingent	O
signals	O
,	O
and	O
that	O
the	O
protein	O
and	O
the	O
mRNA	B
encoding	O
it	O
are	O
identical	O
to	O
the	O
classical	B
vitamin	I
D	I
receptor	I
.	O

The	O
kappa	B
B	I
sequence	I
(	O
GGGACTTTCC	O
)	O
binds	O
a	O
factor	O
,	O
NF	B
-	I
kappa	I
B	I
,	O
that	O
is	O
constitutively	O
found	O
in	O
its	O
functional	O
,	O
DNA	O
binding	O
form	O
only	O
in	O
B	O
lymphocytes	O
.	O

However	O
,	O
these	O
genes	O
are	O
not	O
constitutively	O
active	O
in	O
B	O
lymphocytes	O
,	O
suggesting	O
that	O
other	O
regulatory	O
mechanisms	O
must	O
play	O
a	O
role	O
in	O
determining	O
the	O
patterns	O
of	O
expression	O
.	O

We	O
have	O
investigated	O
the	O
constitutive	O
and	O
inducible	O
transcriptional	O
activity	O
mediated	O
by	O
five	O
kappa	B
B	I
-	I
related	I
sequence	I
elements	I
in	O
two	O
different	O
cell	O
types	O
.	O

However	O
,	O
in	O
either	O
EL	O
-	O
4	O
(	O
T	O
)	O
cells	O
or	O
S194	O
cells	O
,	O
both	O
lower	O
-	O
affinity	O
sites	O
can	O
be	O
significantly	O
induced	O
by	O
the	O
tax	B
gene	I
product	I
of	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
I	O
,	O
showing	O
that	O
NF	B
-	I
kappa	I
B	I
activity	O
can	O
be	O
modulated	O
even	O
in	O
a	O
B	O
-	O
cell	O
line	O
that	O
constitutively	O
expresses	O
this	O
factor	O
.	O

Previously	O
,	O
a	O
nuclear	B
factor	I
,	O
IRF	B
-	I
1	I
(	O
interferon	B
regulatory	I
factor	I
1	I
)	O
,	O
which	O
binds	O
to	O
type	B
I	I
IFN	I
and	O
some	O
IFN	B
-	I
inducible	I
gene	I
promoters	I
,	O
was	O
identified	O
and	O
cloned	O
.	O

A	O
dimerization	B
cofactor	I
of	O
HNF	B
-	I
1	I
alpha	I
(	O
DCoH	B
)	O
was	O
identified	O
that	O
displayed	O
a	O
restricted	O
tissue	O
distribution	O
and	O
did	O
not	O
bind	O
to	O
DNA	O
,	O
but	O
,	O
rather	O
,	O
selectively	O
stabilized	O
HNF	B
-	I
1	I
alpha	I
dimers	I
.	O

Previous	O
studies	O
have	O
shown	O
that	O
treatment	O
of	O
human	O
myeloid	O
leukemia	O
cells	O
with	O
12	O
-	O
O	O
-	O
tetradecanoylphorbol	O
-	O
13	O
-	O
acetate	O
(	O
TPA	O
)	O
is	O
associated	O
with	O
induction	O
of	O
monocytic	O
differentiation	O
and	O
expression	O
of	O
the	O
c	B
-	I
jun	I
and	I
c	I
-	I
fos	I
early	I
response	I
genes	I
.	O

Although	O
absent	O
in	O
nonexpressing	O
erythroleukemia	O
cell	O
lines	O
,	O
the	O
DNase	B
I	I
site	I
is	O
present	O
in	O
uninduced	O
myelomonocytic	O
cell	O
lines	O
and	O
is	O
not	O
changed	O
after	O
PMA	O
induction	O
.	O

The	O
nuclear	O
extracts	O
from	O
resting	O
and	O
induced	O
ML	O
-	O
1	O
cells	O
contain	O
proteins	O
binding	O
specifically	O
to	O
the	O
AP	B
-	I
1	I
,	I
AP	I
-	I
2	I
,	I
and	I
NF	I
kappa	I
B	I
sequence	I
located	O
within	O
the	O
TNF	B
promoter	I
.	O

Enhancement	O
of	O
human	O
immunodeficiency	O
virus	O
1	O
replication	O
in	O
monocytes	O
by	O
1	O
,	O
25	O
-	O
dihydroxycholecalcif	O
.	O

Human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
expression	O
and	O
replication	O
are	O
under	O
tight	O
regulatory	O
control	O
.	O

1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
is	O
therefore	O
one	O
of	O
the	O
most	O
potent	O
regulators	O
of	O
HIV	O
-	O
1	O
replication	O
described	O
to	O
date	O
.	O

Transforming	B
growth	I
factor	I
-	I
beta	I
suppresses	O
human	B
B	I
lymphocyte	I
Ig	I
production	O
by	O
inhibiting	O
synthesis	O
and	O
the	O
switch	O
from	O
the	O
membrane	B
form	I
to	O
the	O
secreted	B
form	I
of	O
Ig	B
mRNA	I
.	O

One	O
of	O
the	O
members	O
of	O
this	O
multigene	O
family	O
,	O
cGATA	B
-	I
3	I
,	O
is	O
most	O
abundantly	O
expressed	O
in	O
the	O
T	O
-	O
lymphocyte	O
cell	O
lineage	O
.	O

The	O
murine	B
and	I
human	I
factors	I
are	O
abundantly	O
expressed	O
in	O
a	O
variety	O
of	O
human	O
and	O
murine	O
T	O
-	O
cell	O
lines	O
and	O
can	O
activate	O
transcription	O
through	O
a	O
tissue	B
-	I
specific	I
GATA	I
-	I
binding	I
site	I
identified	O
within	O
the	O
human	B
T	I
-	I
cell	I
receptor	I
delta	I
gene	I
enhancer	I
.	O

The	O
expression	O
of	O
active	O
NF	B
-	I
kappa	I
B	I
might	O
therefore	O
also	O
be	O
regulated	O
by	O
the	O
extent	O
of	O
processing	O
of	O
p105	B
.	O

Levels	O
of	O
RNA	O
coding	O
for	O
the	O
receptor	B
were	O
not	O
modulated	O
by	O
exposure	O
to	O
high	O
levels	O
of	O
ligand	O
.	O

Expression	O
of	O
c	B
-	I
jun	I
,	I
jun	I
B	I
and	I
jun	I
D	I
proto	I
-	I
oncogenes	I
in	O
human	O
peripheral	O
-	O
blood	O
granulocytes	O
.	O

We	O
have	O
found	O
that	O
purified	O
human	O
peripheral	O
-	O
blood	O
granulocytes	O
express	O
constitutively	O
significant	O
levels	O
of	O
proto	B
-	I
oncogenes	I
c	B
-	I
jun	I
,	I
jun	I
B	I
and	I
jun	I
D	I
mRNA	I
.	O

The	O
29	B
-	I
kDa	I
proteins	I
phosphorylated	O
in	O
thrombin	O
-	O
activated	O
human	O
platelets	O
are	O
forms	O
of	O
the	O
estrogen	B
receptor	I
-	I
related	I
27	I
-	I
kDa	I
heat	I
shock	I
protein	I
.	O

We	O
have	O
isolated	O
a	O
human	B
cDNA	I
clone	I
encoding	O
a	O
zinc	B
finger	I
protein	I
(	O
NF	B
-	I
E1	I
)	O
that	O
binds	O
to	O
the	O
negative	B
-	I
acting	I
segment	I
of	O
the	O
kappa	B
E3	I
'	I
enhancer	I
.	O

This	O
protein	O
also	O
binds	O
to	O
the	O
immunoglobulin	B
heavy	I
-	I
chain	I
enhancer	I
mu	I
E1	I
site	I
.	O

NF	B
-	I
E1	I
is	O
also	O
the	O
human	B
homologue	I
of	O
the	O
mouse	B
delta	I
protein	I
,	O
which	O
binds	O
to	O
ribosomal	B
protein	I
gene	I
promoters	I
.	O

Cotransfection	O
studies	O
with	O
this	O
cDNA	B
indicate	O
that	O
it	O
can	O
repress	O
basal	B
promoter	I
activity	O
.	O

The	O
apparent	O
dual	O
function	O
of	O
this	O
protein	O
is	O
discussed	O
.	O

An	O
upstream	B
segment	I
contains	O
tandem	B
dinucleotide	I
repeats	I
(	B
CT	I
)	I
19	I
/	I
(	I
CA	I
)	I
16	I
.	O

There	O
is	O
a	O
suitably	O
located	O
TATA	B
box	I
,	O
but	O
potential	O
sites	O
for	O
CCAAT	B
-	I
box	I
binding	I
factors	I
are	O
far	O
upstream	O
,	O
embedded	O
in	O
a	O
42	B
-	I
nucleotide	I
repeat	I
element	I
.	O

HIV	B
-	I
TF1	I
had	O
a	O
molecular	O
weight	O
of	O
39	O
,	O
000	O
.	O

A	O
potentially	O
more	O
common	O
pharmacogenetic	O
syndrome	O
.	O

The	O
activity	O
of	O
dihydropyrimidine	B
dehydrogenase	I
(	O
DPD	B
)	O
,	O
the	O
initial	O
enzyme	B
of	O
pyrimidine	O
(	O
and	O
FUra	O
)	O
catabolism	O
,	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
was	O
measured	O
in	O
each	O
subject	O
by	O
a	O
specific	O
radiometric	O
assay	O
using	O
FUra	O
as	O
the	O
substrate	O
.	O

Monitoring	O
DPD	B
activity	O
may	O
be	O
important	O
in	O
the	O
management	O
of	O
patients	O
experiencing	O
severe	O
toxicity	O
secondary	O
to	O
FUra	O
chemotherapy	O
.	O

A	O
thymus	B
-	I
specific	I
member	I
of	O
the	O
HMG	B
protein	I
family	I
regulates	O
the	O
human	B
T	I
cell	I
receptor	I
C	I
alpha	I
enhancer	I
.	O

The	O
human	B
T	I
cell	I
-	I
specific	I
transcription	I
factor	I
TCF	B
-	I
1	I
alpha	I
plays	O
a	O
key	O
role	O
in	O
the	O
tissue	O
-	O
specific	O
activation	O
of	O
the	O
T	B
cell	I
receptor	I
(	O
TCR	B
)	O
C	O
alpha	O
enhancer	O
and	O
binds	O
to	O
pyrimidine	B
-	I
rich	I
elements	I
(	O
5	O
'	O
-	O
PyCTTTG	O
-	O
3	O
'	O
)	O
present	O
in	O
a	O
variety	O
of	O
other	O
T	B
cell	I
-	I
specific	I
control	I
regions	I
.	O

TCF	B
-	I
1	I
alpha	I
is	O
currently	O
unique	O
among	O
the	O
newly	O
emerging	O
family	O
of	O
DNA	B
-	I
binding	I
regulatory	I
proteins	I
that	O
share	O
the	O
HMG	B
motif	I
in	O
that	O
it	O
is	O
a	O
highly	B
tissue	I
-	I
specific	I
RNA	I
polymerase	I
II	I
transcription	B
factor	I
.	O

Ectopic	O
expression	O
of	O
cloned	B
Oct2	I
cDNA	I
was	O
shown	O
to	O
be	O
sufficient	O
to	O
reconstitute	O
at	O
least	O
some	O
aspects	O
of	O
this	O
regulation	O
in	O
non	O
-	O
lymphoid	O
cells	O
.	O

We	O
describe	O
the	O
isolation	O
and	O
characterization	O
of	O
multiple	B
cDNAs	I
encoding	O
mouse	B
Oct2	I
from	O
a	O
mature	O
B	O
-	O
cell	O
line	O
and	O
we	O
show	O
that	O
a	O
variety	O
of	O
isoforms	O
of	O
this	O
transcription	B
factor	I
is	O
generated	O
from	O
a	O
single	O
gene	O
by	O
an	O
alternative	O
splicing	O
mechanism	O
.	O

Different	O
amounts	O
of	O
the	O
various	O
isoforms	B
are	O
present	O
within	O
the	O
same	O
B	O
-	O
cell	O
regardless	O
of	O
the	O
developmental	O
stage	O
of	O
B	O
-	O
cell	O
differentiation	O
and	O
at	O
least	O
some	O
of	O
the	O
isoforms	B
are	O
conserved	O
between	O
mouse	O
and	O
humans	O
.	O

In	O
cotransfection	O
experiments	O
we	O
show	O
that	O
all	O
the	O
isoforms	B
are	O
able	O
to	O
activate	O
an	O
octamer	B
containing	O
promoter	B
element	I
in	O
fibroblasts	O
revealing	O
an	O
unexpected	O
functional	O
redundancy	O
.	O

[	O
Regulation	O
of	O
intracellular	O
cholesterol	O
synthesis	O
in	O
hypercholesterolemia	O
by	O
glucocorticoids	O
]	O

The	O
rate	O
of	O
endogenous	O
cholesterol	O
synthesis	O
in	O
blood	O
lymphocytes	O
and	O
skin	O
fibroblasts	O
from	O
patients	O
with	O
type	O
IIa	O
hyperlipidemia	O
was	O
found	O
to	O
be	O
increased	O
in	O
comparison	O
with	O
healthy	O
donors	O
.	O

The	O
decrease	O
of	O
the	O
number	O
of	O
glucocorticoid	B
receptors	I
in	O
patients	O
with	O
type	O
IIa	O
hyperlipidemia	O
seems	O
to	O
be	O
a	O
compensatory	O
response	O
of	O
cells	O
culminating	O
in	O
activation	O
of	O
endogenous	O
cholesterol	O
synthesis	O
.	O

These	O
differences	O
in	O
gene	O
expression	O
have	O
not	O
been	O
molecularly	O
defined	O
.	O

Thus	O
,	O
both	O
NF	B
-	I
kappa	I
B	I
-	I
binding	I
complexes	I
are	O
needed	O
for	O
optimal	O
viral	O
transcription	O
.	O

Binding	O
of	O
the	O
65	B
-	I
kDa	I
plus	O
50	B
-	I
kDa	I
heterodimer	I
to	O
the	O
HIV	B
-	I
1	I
enhancer	I
can	O
be	O
negatively	O
regulated	O
in	O
monocytes	O
,	O
providing	O
one	O
mechanism	O
restricting	O
HIV	B
-	I
1	I
gene	I
expression	O
.	O

An	O
age	O
-	O
related	O
decrease	O
in	O
the	O
number	O
of	O
GR	B
was	O
suggested	O
between	O
subjects	O
younger	O
than	O
20	O
years	O
and	O
elderly	O
subjects	O
;	O
there	O
was	O
no	O
apparent	O
seasonal	O
variation	O
in	O
GR	B
.	O

Eight	O
patients	O
with	O
dermatomyositis	O
/	O
polymyositis	O
were	O
examined	O
to	O
determine	O
whether	O
the	O
number	O
of	O
GR	B
in	O
MNL	O
could	O
be	O
down	O
-	O
regulated	O
by	O
their	O
cognate	O
ligands	O
.	O

Formation	O
of	O
the	O
protein	B
-	I
DNA	I
complex	I
with	O
the	O
C26	B
subfragment	I
was	O
positively	O
affected	O
by	O
p40tax	B
.	O

Human	O
tumor	B
necrosis	I
factor	I
alpha	I
gene	O
regulation	O
in	O
phorbol	O
ester	O
stimulated	O
T	O
and	O
B	O
cell	O
lines	O
.	O

Moreover	O
,	O
kappa	B
1	I
-	I
kappa	I
3	I
can	O
each	O
be	O
deleted	O
from	O
the	O
TNF	B
-	I
alpha	I
promoter	I
with	O
little	O
effect	O
on	O
the	O
gene	O
'	O
s	O
inducibility	O
by	O
PMA	O
.	O

We	O
have	O
generated	O
a	O
monoclonal	B
antibody	I
,	O
BZ1	B
,	O
to	O
BZLF1	B
which	O
reacts	O
in	O
immunohistology	O
,	O
immunoblotting	O
,	O
and	O
immunoprecipitation	O
and	O
which	O
recognizes	O
both	O
the	O
active	B
,	I
dimeric	I
form	I
and	O
the	O
inactive	B
,	I
monomeric	I
form	I
of	O
the	O
protein	O
.	O

The	O
hormone	B
receptors	I
of	O
the	O
primary	O
tumor	O
were	O
known	O
in	O
15	O
(	O
ER	B
)	O
and	O
14	O
(	O
PR	B
)	O
patients	O
,	O
respectively	O
.	O

In	O
each	O
cohort	O
there	O
was	O
only	O
one	O
case	O
with	O
a	O
negative	O
reaction	O
of	O
the	O
primary	O
tumor	O
and	O
a	O
positive	O
reaction	O
with	O
the	O
isolated	O
tumor	O
cells	O
from	O
the	O
pleural	O
effusions	O
.	O

NF	B
-	I
kB	I
is	O
a	O
eukaryotic	B
transcription	I
regulatory	I
factor	I
.	O

[	O
Regulatory	O
effect	O
of	O
insulin	B
on	O
glucocorticoid	B
receptor	I
in	O
human	O
peripheral	O
leukocytes	O
]	O

After	O
3	O
h	O
incubation	O
the	O
specific	O
binding	O
power	O
with	O
[	O
3H	O
]	O
Dex	O
was	O
decreased	O
by	O
23	O
.	O
3	O
+	O
/	O
-	O
10	O
.	O
0	O
,	O
32	O
.	O
2	O
+	O
/	O
-	O
13	O
.	O
2	O
and	O
54	O
.	O
3	O
+	O
/	O
-	O
9	O
.	O
2	O
%	O
(	O
P	O
greater	O
than	O
0	O
.	O
05	O
,	O
P	O
greater	O
than	O
0	O
.	O
05	O
and	O
P	O
less	O
than	O
0	O
.	O
01	O
as	O
compared	O
with	O
the	O
control	O
value	O
of	O
100	O
in	O
the	O
absence	O
of	O
insulin	B
)	O
respectively	O
in	O
the	O
presence	O
of	O
20	O
mU	O
/	O
L	O
(	O
physiological	O
testing	O
concentration	O
)	O
,	O
200	O
mU	O
/	O
L	O
(	O
physiological	O
upper	O
limit	O
)	O
and	O
2	O
,	O
000	O
mU	O
/	O
L	O
(	O
pharmacological	O
concentration	O
)	O
insulin	B
in	O
the	O
incubation	O
medium	O
.	O

Serum	O
Ig	O
levels	O
were	O
followed	O
up	O
to	O
two	O
years	O
after	O
or	O
during	O
the	O
therapy	O
.	O

Low	O
levels	O
of	O
c	B
-	I
jun	I
transcripts	I
were	O
detectable	O
in	O
resting	O
human	O
peripheral	O
blood	O
monocytes	O
.	O

Moreover	O
,	O
M	B
-	I
CSF	I
-	O
induced	O
expression	O
of	O
the	O
fos	B
-	I
related	I
gene	I
,	O
fra	B
-	I
1	I
,	O
was	O
delayed	O
compared	O
to	O
that	O
for	O
both	O
c	B
-	I
fos	I
and	O
fos	B
-	I
B	I
.	O

Glucocorticosteroids	O
remain	O
the	O
major	O
treatment	O
modality	O
for	O
systemic	O
lupus	O
erythematosus	O
(	O
SLE	O
)	O
,	O
but	O
their	O
mechanism	O
of	O
action	O
is	O
unclear	O
.	O

Over	O
the	O
past	O
decade	O
it	O
has	O
become	O
clear	O
that	O
glucocorticosteroid	B
receptors	I
play	O
a	O
significant	O
role	O
in	O
the	O
mechanism	O
of	O
glucocorticosteroid	O
action	O
.	O

Glucocorticosteroid	B
receptors	I
on	O
leukocytes	O
of	O
patients	O
with	O
SLE	O
were	O
significantly	O
higher	O
than	O
in	O
healthy	O
controls	O
(	O
4419	O
+	O
/	O
-	O
306	O
vs	O
3369	O
+	O
/	O
-	O
196	O
,	O
p	O
less	O
than	O
0	O
.	O
005	O
)	O
.	O

HIV1	O
infection	O
of	O
human	O
monocytes	O
and	O
macrophages	O
promotes	O
induction	O
or	O
translocation	O
of	O
NF	B
-	I
KB	I
-	I
related	I
factors	I
.	O

The	O
insertion	O
of	O
multiple	O
copies	O
of	O
the	O
binding	B
site	I
for	O
the	O
former	O
or	O
latter	O
factor	O
into	O
a	O
heterologous	B
promoter	I
reduced	O
the	O
promoter	O
activity	O
to	O
one	O
-	O
tenth	O
or	O
one	O
-	O
third	O
,	O
respectively	O
.	O

Other	O
cellular	O
parameters	O
,	O
such	O
as	O
glycosidase	O
activities	O
,	O
cytokine	B
release	O
,	O
and	O
filament	O
expression	O
,	O
returned	O
to	O
levels	O
similar	O
to	O
that	O
observed	O
in	O
uninduced	O
cells	O
.	O

Levels	O
of	O
c	B
-	I
fos	I
and	I
c	I
-	I
jun	I
transcripts	I
remained	O
elevated	O
during	O
periods	O
of	O
PKC	B
activation	O
and	O
also	O
returned	O
to	O
levels	O
observed	O
in	O
control	O
cells	O
by	O
30	O
-	O
36	O
days	O
,	O
when	O
the	O
cells	O
entered	O
retrodifferentiation	O
.	O

DNA	O
binding	O
by	O
all	O
four	O
of	O
these	O
Rel	B
-	I
related	I
factors	I
is	O
blocked	O
by	O
selective	O
chemical	O
modification	O
of	O
lysine	O
and	O
arginine	O
residues	O
,	O
suggesting	O
that	O
both	O
of	O
these	O
basic	O
amino	O
acids	O
are	O
required	O
for	O
binding	O
to	O
the	O
kappa	B
B	I
element	I
.	O

In	O
contrast	O
,	O
mild	O
oxidation	O
with	O
glucose	B
oxidase	I
selectively	O
inhibits	O
p75	B
and	O
p85	B
binding	O
while	O
not	O
blocking	O
p50	B
and	O
p55	B
interactions	O
.	O

[	O
Changes	O
in	O
leucocytic	O
estrogen	B
receptor	I
levels	O
in	O
patients	O
with	O
climacteric	O
syndrome	O
and	O
therapeutic	O
effect	O
of	O
liuwei	O
dihuang	O
pills	O
]	O

The	O
numbers	O
of	O
estrogen	B
receptor	I
(	O
ER	B
)	O
in	O
human	O
peripheral	O
leucocytes	O
in	O
22	O
women	O
with	O
climacteric	O
syndrome	O
were	O
measured	O
by	O
radioligand	O
method	O
.	O

This	O
may	O
be	O
the	O
basis	O
of	O
the	O
therapeutic	O
effect	O
on	O
the	O
disease	O
.	O

In	O
addition	O
,	O
cell	B
-	I
free	I
synthesized	I
hGR	I
was	O
capable	O
of	O
specific	O
binding	O
to	O
glucocorticoid	B
response	I
element	I
(	I
GRE	I
)	I
-	I
containing	I
DNA	I
fragments	I
.	O

DNA	O
binding	O
by	O
in	B
vitro	I
synthesized	I
GR	I
was	O
blocked	O
by	O
the	O
addition	O
of	O
sodium	O
molybdate	O
to	O
the	O
receptor	O
preparations	O
before	O
steroid	O
addition	O
and	O
thermal	O
activation	O
.	O

Addition	O
of	O
KCl	O
resulted	O
in	O
less	O
DNA	O
binding	O
either	O
due	O
to	O
blockage	O
of	O
DNA	O
-	O
receptor	B
complex	I
formation	O
or	O
disruption	O
of	O
the	O
complexes	O
.	O

Oligonucleotides	O
containing	O
the	O
consensus	B
GRE	I
were	O
the	O
most	O
efficient	O
competitors	O
,	O
and	O
fragments	O
containing	O
regulatory	B
sequences	I
from	O
glucocorticoid	B
-	I
repressible	I
genes	I
were	O
somewhat	O
competitive	O
,	O
whereas	O
single	O
stranded	O
oligonucleotides	O
were	O
unable	O
to	O
compete	O
for	O
mouse	B
mammary	I
tumor	I
virus	I
-	I
long	I
terminal	I
repeat	I
DNA	O
binding	O
,	O
except	O
when	O
competitor	O
was	O
present	O
at	O
extremely	O
high	O
concentrations	O
.	O

Expression	O
of	O
1	B
,	I
25	I
(	I
OH	I
)	I
2D3	I
receptors	I
on	O
alveolar	O
lymphocytes	O
from	O
patients	O
with	O
pulmonary	O
granulomatous	O
diseases	O
.	O

1	B
,	I
25	I
(	I
OH	I
)	I
2D3	I
receptors	I
were	O
expressed	O
to	O
a	O
greater	O
extent	O
on	O
CD8	O
+	O
T	O
-	O
lymphocytes	O
than	O
on	O
CD4	O
+	O
T	O
-	O
lymphocytes	O
in	O
sarcoidosis	O
,	O
whereas	O
a	O
greater	O
proportion	O
of	O
CD4	O
+	O
than	O
of	O
CD8	O
+	O
T	O
-	O
lymphocytes	O
from	O
patients	O
with	O
tuberculosis	O
were	O
receptor	O
-	O
positive	O
.	O

Role	O
for	O
the	O
Epstein	B
-	I
Barr	I
virus	I
nuclear	I
antigen	I
2	I
in	O
viral	B
promoter	I
switching	O
during	O
initial	O
stages	O
of	O
infection	O
.	O

These	O
studies	O
have	O
been	O
extended	O
to	O
show	O
that	O
(	O
i	O
)	O
a	O
mutant	O
EBV	O
strain	O
lacking	O
the	O
gene	O
encoding	O
EBNA	B
2	I
fails	O
to	O
switch	O
from	O
Wp	O
to	O
Cp	B
usage	O
in	O
primary	O
B	O
lymphocytes	O
,	O
although	O
the	O
virus	O
contains	O
a	O
functional	O
Cp	B
;	O
(	O
ii	O
)	O
a	O
region	O
from	O
-	B
429	I
to	I
-	I
245	I
base	I
pairs	I
upstream	O
of	O
Cp	B
is	O
essential	O
for	O
Cp	B
activity	O
in	O
B	O
lymphocytes	O
,	O
but	O
only	O
in	O
the	O
context	O
of	O
upstream	B
and	I
downstream	I
sequences	I
;	O
(	O
iii	O
)	O
this	O
region	O
contains	O
an	O
EBNA	B
2	I
-	I
dependent	I
enhancer	I
;	O
and	O
(	O
iv	O
)	O
DNase	B
I	I
protection	O
employing	O
nuclear	O
extracts	O
from	O
B	O
and	O
T	O
lymphocytes	O
revealed	O
a	O
B	B
-	I
cell	I
-	I
specific	I
footprint	I
in	O
the	O
region	O
of	O
the	O
EBNA	B
2	I
-	I
dependent	I
enhancer	I
.	O

Immune	O
response	O
of	O
peripheral	O
blood	O
mononuclear	O
cells	O
to	O
HBx	B
-	I
antigen	I
of	O
hepatitis	O
B	O
virus	O
.	O

Five	O
T	O
-	O
cell	O
clones	O
specific	O
for	O
a	O
T	B
-	I
cell	I
epitope	I
located	O
at	O
the	O
carboxyterminal	B
region	I
of	O
HBxAg	B
were	O
established	O
and	O
found	O
to	O
belong	O
to	O
the	O
CD2	O
/	O
CD4	O
-	O
positive	O
,	O
CD8	O
-	O
negative	O
subtype	O
.	O

[	O
Changes	O
in	O
leucocytic	B
estrogen	I
receptor	I
levels	O
in	O
patients	O
with	O
gynecomastia	O
]	O

The	O
NF	B
kappa	I
B	I
independent	I
cis	I
-	I
acting	I
sequences	I
in	O
HIV	B
-	I
1	I
LTR	I
responsive	O
to	O
T	O
-	O
cell	O
activation	O
.	O

The	O
rate	O
of	O
transcription	O
initiation	O
directed	O
by	O
the	O
long	B
terminal	I
repeat	I
(	O
LTR	O
)	O
of	O
HIV	O
-	O
1	O
increases	O
in	O
response	O
to	O
mitogenic	O
stimuli	O
of	O
T	O
cells	O
.	O

The	O
rate	O
of	O
LTR	B
-	O
directed	O
gene	O
expression	O
increased	O
in	O
response	O
to	O
treatment	O
with	O
either	O
a	O
phorbol	O
ester	O
or	O
tumor	B
necrosis	I
factor	I
alpha	I
if	O
either	O
the	O
NFAT	B
-	I
1	I
or	O
NF	B
kappa	I
B	I
binding	I
sites	I
were	O
deleted	O
,	O
but	O
failed	O
to	O
respond	O
to	O
these	O
mitogenic	O
stimuli	O
if	O
both	O
sequences	O
were	O
absent	O
.	O

Activation	O
of	O
proenkephalin	O
transcription	O
by	O
JunD	B
is	O
dependent	O
upon	O
a	O
previously	O
characterized	O
cAMP	B
-	I
,	I
phorbol	I
ester	I
-	I
,	I
and	I
Ca	I
(	I
2	I
+	I
)	I
-	I
inducible	I
enhancer	I
,	O
and	O
JunD	B
is	O
shown	O
to	O
bind	O
the	O
enhancer	B
as	O
a	O
homodimer	B
.	O

Plasma	O
cortisol	O
concentration	O
and	O
blood	O
leukocyte	O
content	O
of	O
glucocorticoid	B
receptors	I
(	O
GCR	B
)	O
were	O
assayed	O
in	O
20	O
patients	O
with	O
deficiency	O
syndromes	O
,	O
10	O
cold	O
in	O
property	O
(	O
deficiency	O
-	O
cold	O
)	O
,	O
the	O
other	O
10	O
hot	O
in	O
property	O
(	O
deficiency	O
-	O
heat	O
)	O
,	O
and	O
also	O
in	O
10	O
healthy	O
individuals	O
as	O
normal	O
control	O
for	O
the	O
purpose	O
of	O
investigating	O
the	O
nature	O
of	O
cold	O
and	O
heat	O
syndromes	O
.	O

Furthermore	O
,	O
the	O
ability	O
of	O
these	O
complexes	O
to	O
regulate	O
gene	O
expression	O
is	O
demonstrated	O
by	O
increased	O
transcription	O
from	O
an	O
AP	B
-	I
1	I
driven	I
reporter	I
construct	I
and	O
marked	O
increases	O
in	O
the	O
expression	O
of	O
endogenous	B
AP	I
-	I
1	I
regulated	I
genes	I
.	O

This	O
tight	O
correlation	O
between	O
c	B
-	I
jun	I
expression	O
,	O
the	O
generation	O
of	O
AP	B
-	I
1	I
activity	O
,	O
and	O
differentiation	O
suggests	O
a	O
critical	O
role	O
for	O
this	O
gene	O
and	O
transcriptional	B
complex	I
during	O
this	O
process	O
.	O

Cyclosporin	O
A	O
and	O
FK506	O
inhibit	O
T	O
-	O
and	O
B	O
-	O
cell	O
activation	O
and	O
other	O
processes	O
essential	O
to	O
an	O
effective	O
immune	O
response	O
.	O

A	O
transcription	B
factor	I
,	O
NF	B
-	I
AT	I
,	O
which	O
is	O
essential	O
for	O
early	O
T	O
-	O
cell	O
gene	O
activation	O
,	O
seems	O
to	O
be	O
a	O
specific	O
target	O
of	O
cyclosporin	O
A	O
and	O
FK506	O
action	O
because	O
transcription	O
directed	O
by	O
this	O
protein	O
is	O
blocked	O
in	O
T	O
cells	O
treated	O
with	O
these	O
drugs	O
,	O
with	O
little	O
or	O
no	O
effect	O
on	O
other	O
transcription	B
factors	I
such	O
as	O
AP	B
-	I
1	I
and	O
NF	B
-	I
kappa	I
B	I
.	O

Glucocorticoid	B
receptors	I
in	O
lymphocytes	O
in	O
anorexia	O
nervosa	O
.	O

CONCLUSIONS	O
Hypercortisolaemia	O
does	O
not	O
down	O
-	O
regulate	O
the	O
lymphocyte	O
glucocorticoid	B
receptors	I
in	O
anorexia	O
nervosa	O
and	O
a	O
post	O
-	O
receptor	O
defect	O
might	O
be	O
involved	O
in	O
peripheral	O
tissue	O
resistance	O
to	O
the	O
effects	O
of	O
glucocorticoid	O
hormones	O
in	O
undernutrition	O
.	O

The	O
induction	O
of	O
AP1	B
by	O
okadaic	O
acid	O
suggests	O
that	O
protein	B
phosphatases	I
1	I
and	I
2A	I
(	O
PP1	B
and	O
PP2A	B
)	O
may	O
be	O
involved	O
in	O
T	O
cell	O
activation	O
as	O
important	O
negative	O
regulators	O
of	O
the	O
transcription	B
factor	I
AP1	B
.	O

CD3	B
-	O
epsilon	O
gene	O
expression	O
is	O
confined	O
to	O
the	O
T	O
cell	O
lineage	O
.	O

TCF	B
-	I
1	I
belonged	O
to	O
a	O
novel	O
family	O
of	O
genes	O
that	O
contain	O
the	O
so	O
-	O
called	O
high	O
mobility	B
group	I
1	I
(	I
HMG	I
)	I
box	I
.	O

Two	O
splice	O
alternatives	O
were	O
identified	O
that	O
were	O
not	O
previously	O
observed	O
in	O
human	B
TCF	I
-	I
1	I
.	O

Third	O
,	O
TCF	B
-	I
1	I
bound	O
specifically	O
to	O
a	O
functional	O
T	B
cell	I
-	I
specific	I
element	I
in	O
the	O
T	B
cell	I
receptor	I
alpha	I
(	I
TCR	I
-	I
alpha	I
)	I
enhancer	I
.	O

Northern	O
blot	O
analysis	O
of	O
polyadenylated	B
RNA	I
purified	O
from	O
activated	O
human	O
B	O
cells	O
revealed	O
a	O
single	B
mRNA	I
transcript	I
of	O
approximately	O
2	O
.	O
3	O
kb	O
.	O

There	O
is	O
a	O
single	O
methionine	B
codon	I
-	I
initiated	I
open	I
reading	I
frame	I
of	O
1	O
,	O
458	O
nt	O
in	O
frame	O
with	O
a	O
homeobox	B
and	O
a	O
CAX	B
repeat	I
,	O
and	O
the	O
open	B
reading	I
frame	I
is	O
predicted	O
to	O
encode	O
a	O
protein	O
of	O
51	O
,	O
659	O
daltons	O
.	O

Characterization	O
of	O
HB24	B
expression	O
in	O
lymphoid	O
and	O
select	O
developing	O
tissues	O
was	O
performed	O
by	O
in	O
situ	O
hybridization	O
.	O

Platelet	B
-	I
activating	I
factor	I
induces	O
phospholipid	O
turnover	O
,	O
calcium	O
flux	O
,	O
arachidonic	O
acid	O
liberation	O
,	O
eicosanoid	O
generation	O
,	O
and	O
oncogene	B
expression	O
in	O
a	O
human	O
B	O
cell	O
line	O
.	O

Tandem	O
copies	O
of	O
this	O
67	B
-	I
bp	I
MnlI	I
-	I
AluI	I
fragment	I
,	O
when	O
fused	O
to	O
the	O
chloramphenicol	B
acetyltransferase	I
gene	I
driven	O
by	O
the	O
conalbumin	B
promoter	I
,	O
stimulated	O
transcription	O
in	O
B	O
cells	O
but	O
not	O
in	O
Jurkat	O
T	O
cells	O
or	O
HeLa	O
cells	O
.	O

Footprinting	O
analysis	O
revealed	O
that	O
the	O
identical	O
sequence	O
CCGAAACTGAAAAGG	O
,	O
designated	O
E6	B
,	O
was	O
protected	O
by	O
nuclear	O
extracts	O
from	O
B	O
cells	O
,	O
T	O
cells	O
,	O
or	O
HeLa	O
cells	O
.	O

Gel	O
mobility	O
shift	O
assays	O
using	O
a	O
synthetic	B
E6	I
motif	I
detected	O
a	O
B	B
-	I
cell	I
-	I
specific	I
complex	I
in	O
addition	O
to	O
a	O
ubiquitous	O
band	O
found	O
also	O
in	O
T	O
cells	O
and	O
HeLa	O
cells	O
.	O

In	O
agreement	O
with	O
the	O
results	O
of	O
gel	O
retardation	O
assays	O
,	O
tandem	O
copies	O
of	O
the	O
E6	B
motif	I
stimulated	O
transcription	O
in	O
ARH77	O
and	O
Raji	O
cells	O
but	O
not	O
in	O
Jurkat	O
or	O
HeLa	O
cells	O
.	O

Interestingly	O
,	O
the	O
MnlI	B
-	I
AluI	I
fragment	I
could	O
suppress	O
the	O
basal	O
-	O
level	O
activity	O
of	O
the	O
conalbumin	B
promoter	I
in	O
both	O
Jurkat	O
and	O
HeLa	O
cells	O
.	O

Thus	O
,	O
the	O
novel	O
enhancer	O
element	O
identified	O
in	O
this	O
study	O
is	O
probably	O
a	O
target	O
site	O
for	O
both	O
positive	B
and	I
negative	I
factors	I
.	O

Charybdotoxin	O
-	O
sensitive	O
,	O
Ca	O
(	O
2	O
+	O
)	O
-	O
dependent	O
membrane	O
potential	O
changes	O
are	O
not	O
involved	O
in	O
human	O
T	O
or	O
B	O
cell	O
activation	O
and	O
proliferation	O
.	O

The	O
involvement	O
of	O
ion	O
channels	O
in	O
B	O
and	O
T	O
lymphocyte	O
activation	O
is	O
supported	O
by	O
many	O
reports	O
of	O
changes	O
in	O
ion	O
fluxes	O
and	O
membrane	O
potential	O
after	O
mitogen	B
binding	O
.	O

However	O
,	O
blockade	O
of	O
the	O
Ca	B
(	I
2	I
+	I
)	I
-	I
activated	I
K	I
+	I
channel	I
is	O
not	O
associated	O
with	O
changes	O
in	O
cell	O
-	O
cycle	O
gene	O
activation	O
,	O
IL	B
-	I
2	I
production	O
,	O
IL	B
-	I
2R	I
expression	O
or	O
B	O
and	O
T	O
cell	O
mitogenesis	O
.	O

From	O
information	O
available	O
in	O
the	O
literature	O
on	O
the	O
substrate	O
specificity	O
of	O
the	O
three	O
enzymes	B
,	O
it	O
is	O
clear	O
that	O
a	O
cysteine	O
is	O
not	O
accepted	O
in	O
any	O
of	O
the	O
S2	B
,	I
S1	I
,	I
S1	I
'	I
,	I
and	I
S2	I
'	I
subsites	I
of	O
cathepsin	B
B	I
and	I
L	I
,	O
and	O
not	O
in	O
the	O
S1	B
and	O
S1	B
'	I
subsites	O
of	O
cathepsin	B
D	I
.	O

Starting	O
with	O
a	O
replication	O
-	O
incompetent	O
molecular	O
clone	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
,	O
lacking	O
all	O
the	O
NF	B
-	I
kappa	I
B	I
and	I
Sp1	I
binding	I
sites	I
present	O
in	O
the	O
native	B
long	I
terminal	I
repeat	I
(	O
LTR	B
)	O
,	O
proviruses	O
containing	O
reconstructed	B
LTRs	I
with	O
individual	O
or	O
combinations	O
of	O
NF	B
-	I
kappa	I
B	I
and	I
Sp1	I
elements	I
were	O
generated	O
and	O
evaluated	O
for	O
their	O
capacity	O
to	O
produce	O
virus	O
progeny	O
following	O
transfection	O
-	O
cocultivation	O
.	O

The	O
human	B
interferon	I
beta	I
(	I
IFN	I
-	I
beta	I
)	I
regulatory	I
element	I
consists	O
of	O
multiple	O
enhanson	B
domains	I
which	O
are	O
targets	O
for	O
transcription	B
factors	I
involved	O
in	O
inducible	O
expression	O
of	O
the	O
promoter	B
.	O

A	O
2	O
-	O
4	O
-	O
fold	O
increase	O
in	O
IFN	B
-	I
beta	I
promoter	I
transcription	O
was	O
observed	O
in	O
Sendai	O
virus	O
induced	O
extracts	O
,	O
and	O
deletion	O
of	O
PRDI	B
and	O
PRDII	B
elements	I
decreased	O
this	O
induced	O
level	O
of	O
transcription	O
.	O

When	O
purified	O
PRDII	B
and	I
tetrahexamer	I
binding	I
proteins	I
were	O
added	O
to	O
the	O
induced	O
extract	O
,	O
a	O
4	O
-	O
fold	O
increase	O
in	O
transcription	O
was	O
observed	O
.	O

Human	B
and	I
mouse	I
Rhom	I
-	I
2	I
are	O
highly	O
conserved	O
and	O
,	O
like	O
rhombotin	B
,	O
encode	O
two	O
tandem	B
cysteine	I
-	I
rich	I
LIM	I
domains	I
.	O

NF	B
-	I
kappa	I
B	I
activation	O
by	O
tumor	B
necrosis	I
factor	I
alpha	I
in	O
the	O
Jurkat	O
T	O
cell	O
line	O
is	O
independent	O
of	O
protein	B
kinase	I
A	I
,	O
protein	B
kinase	I
C	I
,	O
and	O
Ca	B
(	I
2	I
+	I
)	I
-	I
regulated	I
kinases	I
.	O

Furthermore	O
,	O
while	O
PMA	O
activation	O
was	O
inhibited	O
by	O
the	O
PKC	B
inhibitor	O
staurosporin	O
,	O
the	O
TNF	B
alpha	I
effect	O
was	O
unchanged	O
.	O

Here	O
we	O
investigated	O
the	O
transcriptional	O
basis	O
for	O
these	O
changes	O
.	O

Mutations	O
at	O
the	O
B2	B
site	O
abolish	O
this	O
transcriptional	O
activation	O
.	O

The	O
purified	O
homodimer	B
(	O
two	O
p50s	B
)	O
of	O
the	O
DNA	B
-	I
binding	I
subunit	I
of	O
NF	B
-	I
kappa	I
B	I
binds	O
the	O
B2	B
site	O
of	O
proenkephalin	O
relatively	O
better	O
than	O
does	O
the	O
heterotetramer	B
(	O
two	O
p65s	B
plus	O
two	O
p50s	B
)	O
form	O
of	O
the	O
factor	O
.	O

However	O
,	O
as	O
NF	B
-	I
kappa	I
B	I
is	O
ubiquitous	O
and	O
the	O
transcriptional	O
activation	O
through	O
the	O
B2	B
site	O
is	O
T	O
cell	O
specific	O
,	O
yet	O
another	O
T	B
-	I
cell	I
-	I
specific	I
factor	I
which	O
synergizes	O
with	O
NF	B
-	I
kappa	I
B	I
should	O
be	O
considered	O
.	O

In	O
nuclear	O
extracts	O
from	O
monocytes	O
or	O
macrophages	O
,	O
induction	O
of	O
NF	B
-	I
KB	I
occurred	O
only	O
if	O
the	O
cells	O
were	O
previously	O
infected	O
with	O
HIV	O
-	O
1	O
.	O

These	O
results	O
indicate	O
that	O
in	O
monocytic	O
cell	O
lineage	O
,	O
HIV	O
-	O
1	O
could	O
mimic	O
some	O
differentiation	O
/	O
activation	O
stimuli	O
allowing	O
nuclear	O
NF	B
-	I
KB	I
expression	O
.	O

Disruption	O
of	O
the	O
human	B
SCL	I
locus	I
by	O
`	O
`	O
illegitimate	O
'	O
'	O
V	O
-	O
(	O
D	O
)	O
-	O
J	O
recombinase	O
activity	O
.	O

The	O
fusion	B
cDNA	I
results	O
from	O
an	O
interstitial	O
deletion	O
between	O
a	O
previously	O
unknown	B
locus	I
,	O
SIL	B
(	O
SCL	B
interrupting	I
locus	I
)	O
,	O
and	O
the	O
5	B
'	I
untranslated	I
region	I
of	O
SCL	B
.	O

Thus	O
,	O
in	O
lymphocytes	O
,	O
growth	B
-	I
affecting	I
genes	I
other	O
than	O
immune	B
receptors	I
risk	O
rearrangements	O
.	O

This	O
was	O
compared	O
with	O
the	O
TREp	B
binding	O
of	O
reticulocyte	B
lysate	I
-	I
synthesized	I
TRs	I
.	O

Incubation	O
of	O
each	O
of	O
the	O
TRs	B
with	O
NE	O
from	O
COS	O
-	O
7	O
cells	O
,	O
which	O
do	O
not	O
possess	O
sufficient	O
endogenous	O
TRs	B
to	O
mediate	O
T3	O
-	O
responses	O
,	O
resulted	O
in	O
formation	O
of	O
a	O
new	O
,	O
more	O
greatly	B
shifted	I
complex	I
.	O

Cell	O
-	O
specific	O
differences	O
in	O
activation	O
of	O
NF	B
-	I
kappa	I
B	I
regulatory	I
elements	I
of	O
human	B
immunodeficiency	I
virus	I
and	I
beta	I
interferon	I
promoters	I
by	O
tumor	B
necrosis	I
factor	I
.	O

Tumor	B
necrosis	I
factor	I
alpha	I
(	I
TNF	I
-	I
alpha	I
)	I
mRNA	I
production	O
was	O
analyzed	O
by	O
polymerase	O
chain	O
reaction	O
amplification	O
in	O
monocytic	O
U937	O
cells	O
and	O
in	O
a	O
chronically	O
HIV	O
infected	O
U937	O
cell	O
line	O
(	O
U9	O
-	O
IIIB	O
)	O
.	O

Functional	O
analysis	O
of	O
cis	B
-	I
linked	I
regulatory	I
sequences	I
in	O
the	O
HLA	B
DRA	I
promoter	I
by	O
transcription	O
in	O
vitro	O
.	O

The	O
effect	O
of	O
LPS	O
on	O
HIV	O
-	O
1	O
replication	O
occurs	O
at	O
picogram	O
per	O
milliliter	O
concentrations	O
and	O
may	O
be	O
clinically	O
significant	O
in	O
understanding	O
the	O
variability	O
of	O
the	O
natural	O
history	O
of	O
HIV	O
-	O
1	O
infection	O
.	O

Inhibitory	O
drug	O
interactions	O
affecting	O
the	O
metabolism	O
of	O
methylprednisolone	O
(	O
MP	O
)	O
may	O
produce	O
either	O
steroid	O
sparing	O
or	O
adverse	O
effects	O
partly	O
by	O
increasing	O
the	O
exposure	O
time	O
to	O
the	O
steroid	O
.	O

This	O
phenomenon	O
can	O
be	O
mimicked	O
by	O
administering	O
MP	O
in	O
divided	O
doses	O
.	O

To	O
compare	O
extra	O
-	O
renal	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
production	O
in	O
different	O
types	O
of	O
granulomatous	O
disease	O
,	O
and	O
to	O
identify	O
the	O
cell	O
types	O
responsible	O
,	O
we	O
have	O
evaluated	O
the	O
conversion	O
of	O
25	O
(	O
OH	O
)	O
D3	O
in	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
by	O
uncultured	O
cells	O
recovered	O
by	O
bronchoalveolar	O
lavage	O
and	O
blood	O
mononuclear	O
cells	O
from	O
normocalcemic	O
patients	O
with	O
sarcoidosis	O
and	O
tuberculosis	O
.	O

1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
was	O
produced	O
both	O
by	O
lavage	O
cells	O
(	O
12	O
/	O
12	O
tuberculosis	O
patients	O
,	O
2	O
/	O
6	O
sarcoidosis	O
patients	O
)	O
and	O
blood	O
mononuclear	O
cells	O
(	O
3	O
/	O
5	O
tuberculosis	O
patients	O
,	O
0	O
/	O
3	O
sarcoidosis	O
patients	O
)	O
from	O
patients	O
but	O
not	O
controls	O
,	O
but	O
significantly	O
greater	O
amounts	O
were	O
produced	O
by	O
lavage	O
cells	O
from	O
tuberculosis	O
patients	O
than	O
those	O
of	O
sarcoidosis	O
patients	O
(	O
P	O
less	O
than	O
0	O
.	O
001	O
)	O
.	O

1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
production	O
by	O
lavage	O
cells	O
from	O
tuberculosis	O
patients	O
correlated	O
with	O
the	O
number	O
of	O
CD8	O
+	O
T	O
lymphocytes	O
present	O
but	O
not	O
other	O
cell	O
types	O
.	O

Because	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
can	O
improve	O
the	O
capacity	O
of	O
macrophages	O
to	O
kill	O
mycobacteria	O
,	O
our	O
results	O
support	O
the	O
conclusion	O
that	O
macrophage	O
-	O
lymphocyte	O
interactions	O
,	O
mediated	O
at	O
least	O
in	O
part	O
by	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
,	O
may	O
be	O
an	O
important	O
component	O
of	O
a	O
successful	O
antituberculous	O
immune	O
response	O
.	O

A	O
closely	O
related	O
(	O
if	O
not	O
identical	O
)	O
protein	O
is	O
found	O
in	O
both	O
a	O
human	O
megakaryocytic	O
cell	O
line	O
and	O
purified	O
human	O
megakaryocytes	O
;	O
it	O
binds	O
to	O
promoter	B
regions	I
of	O
two	O
megakaryocytic	B
-	I
specific	I
genes	I
.	O

Furthermore	O
,	O
point	O
mutations	O
that	O
abolish	O
binding	O
of	O
NF	B
-	I
E1	I
result	O
in	O
a	O
70	O
%	O
decrease	O
in	O
the	O
transcriptional	O
activity	O
of	O
a	O
megakaryocytic	B
-	I
specific	I
promoter	I
.	O

Transcriptional	O
down	O
-	O
regulation	O
of	O
c	B
-	I
myc	I
expression	O
by	O
protein	O
synthesis	O
-	O
dependent	O
and	O
-	O
independent	O
pathways	O
in	O
a	O
human	O
T	O
lymphoblastic	O
tumor	O
cell	O
line	O
.	O

We	O
studied	O
49	O
cases	O
of	O
B	O
-	O
cell	O
chronic	O
lymphocytic	O
leukemia	O
(	O
CLL	O
)	O
using	O
immunostaining	O
of	O
cytospin	O
preparations	O
.	O

In	O
30	O
of	O
these	O
cases	O
ER	B
enzyme	O
immunoassay	O
(	O
ER	B
-	O
EIA	O
)	O
was	O
also	O
performed	O
.	O

Type	B
-	I
II	I
estrogen	I
-	I
binding	I
sites	I
(	O
type	B
-	I
II	I
EBS	I
)	O
have	O
been	O
demonstrated	O
in	O
the	O
human	O
lymphoblastoid	O
cell	O
line	O
IM	O
-	O
9	O
using	O
a	O
whole	O
-	O
cell	O
assay	O
with	O
(	O
6	O
,	O
7	O
-	O
3H	O
)	O
estradiol	O
(	O
3H	O
-	O
E2	O
)	O
as	O
tracer	O
.	O

The	O
relative	O
binding	O
affinity	O
of	O
quercetin	O
,	O
rutin	O
,	O
DES	O
and	O
TAM	O
for	O
type	B
-	I
II	I
EBS	I
correlated	O
well	O
with	O
their	O
potency	O
as	O
cell	O
growth	O
inhibitors	O
.	O

Moreover	O
,	O
hesperidin	O
,	O
a	O
flavonoid	O
which	O
does	O
not	O
bind	O
to	O
type	B
-	I
II	I
EBS	I
,	O
was	O
ineffective	O
in	O
inhibiting	O
cell	O
growth	O
.	O

[	O
Glucocorticoid	B
receptors	I
in	O
peripheral	O
blood	O
lymphocytes	O
of	O
patients	O
with	O
bronchial	O
asthma	O
]	O

Quantitation	O
of	O
glucocorticoid	B
receptors	I
(	O
GCR	B
)	O
and	O
the	O
study	O
of	O
their	O
affinity	O
for	O
glucocorticosteroids	O
(	O
GCS	O
)	O
were	O
made	O
in	O
peripheral	O
blood	O
lymphocytes	O
of	O
bronchial	O
asthma	O
(	O
BA	O
)	O
patients	O
in	O
consideration	O
of	O
GCR	B
treatment	O
and	O
serum	O
levels	O
of	O
endogenous	O
cortisol	O
.	O

Two	O
glucocorticoid	B
binding	I
sites	I
on	O
the	O
human	B
glucocorticoid	I
receptor	I
.	O

Cortivazol	O
(	O
CVZ	O
)	O
is	O
a	O
unique	O
,	O
high	O
potency	O
synthetic	O
glucocorticoid	O
,	O
which	O
has	O
a	O
phenylpyrazol	O
fused	O
to	O
the	O
A	O
-	O
ring	O
of	O
the	O
steroid	O
nucleus	O
and	O
displays	O
binding	O
consistent	O
with	O
two	O
or	O
more	O
sites	O
in	O
the	O
cytosol	O
from	O
CEM	O
C7	O
cells	O
(	O
a	O
human	O
acute	O
lymphoblastic	O
T	O
-	O
cell	O
line	O
)	O
.	O

We	O
have	O
carried	O
out	O
experiments	O
to	O
define	O
the	O
nature	O
of	O
the	O
higher	B
affinity	I
CVZ	I
binding	I
site	I
.	O

These	O
data	O
indicate	O
that	O
CVZ	O
is	O
recognizing	O
two	O
glucocorticoid	B
binding	I
sites	I
on	O
the	O
human	O
GR	B
or	O
a	O
protein	O
very	O
similar	O
to	O
it	O
.	O

Retroviral	O
mediated	O
transfer	O
and	O
expression	O
of	O
exogenous	B
genes	I
in	O
primary	O
lymphoid	O
cells	O
:	O
assaying	O
for	O
a	O
viral	O
transactivator	B
activity	O
in	O
normal	O
and	O
malignant	O
cells	O
.	O

Incidence	O
of	O
HLA	B
antigens	I
was	O
determined	O
in	O
94	O
of	O
them	O
.	O

Several	O
mutants	O
derived	O
from	O
transformed	O
human	O
B	O
cell	O
lines	O
are	O
defective	O
in	O
expressing	O
major	B
histocompatibility	I
complex	I
(	I
MHC	I
)	I
class	I
II	I
genes	I
.	O

There	O
was	O
evidence	O
for	O
an	O
autosomal	O
recessive	O
form	O
of	O
inheritance	O
in	O
four	O
families	O
,	O
while	O
the	O
other	O
four	O
families	O
appeared	O
to	O
have	O
an	O
autosomal	O
dominant	O
mode	O
of	O
transmission	O
.	O

These	O
parents	O
were	O
entirely	O
asymptomatic	O
.	O

ER	B
content	O
in	O
lymphocytes	O
of	O
each	O
sample	O
was	O
expressed	O
by	O
both	O
fmol	O
/	O
mg	O
of	O
lymphocyte	B
cytosolic	I
protein	I
and	O
fmol	O
/	O
micrograms	O
of	O
lymphocyte	B
DNA	I
.	O

The	O
results	O
showed	O
that	O
there	O
was	O
no	O
significant	O
difference	O
between	O
the	O
ER	B
content	O
of	O
lymphocytes	O
from	O
the	O
controls	O
and	O
that	O
from	O
patients	O
with	O
SLE	O
.	O

We	O
used	O
mouse	O
embryonic	O
stem	O
(	O
ES	O
)	O
cells	O
to	O
study	O
globin	B
gene	I
expression	O
and	O
switching	O
in	O
vitro	O
.	O

We	O
show	O
that	O
ES	O
-	O
derived	O
embryoid	O
bodies	O
express	O
the	O
full	O
complement	O
of	O
mouse	B
embryonic	I
globin	I
genes	I
in	O
the	O
correct	O
temporal	O
order	O
and	O
that	O
on	O
further	O
differentiation	O
,	O
a	O
switch	O
occurs	O
to	O
the	O
fetal	B
/	I
adult	I
genes	I
.	O

When	O
the	O
human	B
epsilon	I
-	I
or	I
beta	I
-	I
globin	I
genes	I
driven	O
by	O
the	O
dominant	B
control	I
region	I
(	O
DCR	B
)	O
are	O
introduced	O
into	O
this	O
system	O
,	O
the	O
human	B
epsilon	I
-	I
globin	I
gene	I
,	O
in	O
contrast	O
to	O
the	O
beta	B
-	I
globin	I
gene	I
,	O
is	O
not	O
deregulated	O
by	O
the	O
presence	O
of	O
the	O
DCR	B
and	O
is	O
expressed	O
strictly	O
as	O
an	O
embryonic	B
gene	I
.	O

These	O
effects	O
of	O
aldosterone	O
were	O
blocked	O
by	O
the	O
aldosterone	O
antagonist	O
canrenone	O
(	O
140	O
nmol	O
/	O
l	O
)	O
.	O

Seventeen	O
cases	O
revealed	O
distinct	O
immunostaining	O
against	O
at	O
least	O
1	O
of	O
the	O
5	O
steroid	O
hormones	O
.	O

ZRE	B
-	I
B	I
is	O
therefore	O
not	O
part	O
of	O
the	O
R	B
-	I
inducible	I
enhancer	I
.	O

However	O
,	O
one	O
palindrome	B
,	O
either	O
alone	O
or	O
duplicated	O
,	O
or	O
the	O
overlapping	B
palindromes	I
did	O
not	O
respond	O
to	O
R	O
.	O

The	O
clinical	O
implications	O
of	O
nuclear	O
T3R	B
alterations	O
of	O
circulating	O
lymphocytes	O
in	O
hyperthyroidism	O
,	O
hypothyroidism	O
and	O
nonthyroidal	O
diseases	O
were	O
investigated	O
.	O

The	O
results	O
showed	O
that	O
in	O
hyper	O
-	O
and	O
hypothyroid	O
patients	O
the	O
nuclear	O
affinity	O
(	O
Ka	O
)	O
for	O
T3	O
was	O
similar	O
to	O
that	O
of	O
normal	O
subjects	O
.	O

In	O
a	O
fourth	O
cell	O
line	O
,	O
A1	O
-	O
VDR	O
,	O
the	O
receptor	O
for	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
had	O
a	O
low	O
binding	O
capacity	O
and	O
25	B
(	I
OH	I
)	I
D3	I
-	I
24	I
-	I
hydroxylase	I
activity	O
was	O
not	O
detectable	O
.	O

Binding	O
and	O
elution	O
properties	O
to	O
DNA	O
-	O
cellulose	O
,	O
however	O
,	O
differed	O
from	O
normal	O
in	O
both	O
Ro	O
-	O
VDR	O
and	O
A1	O
-	O
VDR	O
cells	O
where	O
elution	O
from	O
DNA	O
-	O
cellulose	O
occurred	O
at	O
a	O
lower	O
salt	O
concentration	O
than	O
is	O
typical	O
of	O
the	O
1	B
,	I
25	I
(	I
OH	I
)	I
2D3	I
receptor	I
.	O

We	O
studied	O
the	O
effects	O
of	O
TPA	O
on	O
the	O
regulation	O
of	O
c	B
-	I
jun	I
gene	O
expression	O
in	O
HL	O
-	O
60	O
cells	O
during	O
monocytic	O
differentiation	O
.	O

[	O
Hormonal	O
interactions	O
and	O
glucocorticoid	B
receptors	I
in	O
patients	O
with	O
the	O
nephrotic	O
syndrome	O
]	O

These	O
studies	O
detected	O
two	O
novel	B
domains	I
referred	O
to	O
as	O
L1	B
and	O
L2	B
with	O
a	O
variety	O
of	O
lymphoid	O
but	O
not	O
HeLa	O
extracts	O
.	O

Characterization	O
of	O
defensin	B
resistance	O
phenotypes	O
associated	O
with	O
mutations	O
in	O
the	O
phoP	B
virulence	I
regulon	I
of	O
Salmonella	O
typhimurium	O
.	O

The	O
defensin	B
sensitivities	O
of	O
Salmonella	O
typhimurium	O
strains	O
with	O
mutations	O
in	O
the	O
phoP	B
/	I
phoQ	I
two	I
-	I
component	I
virulence	I
regulon	I
were	O
tested	O
by	O
using	O
purified	B
defensins	I
NP	B
-	I
1	I
and	O
NP	B
-	I
2	I
.	O

The	O
predicted	O
periplasmic	B
domain	I
of	O
the	O
PhoQ	B
protein	I
contained	O
a	O
markedly	O
anionic	O
domain	O
that	O
could	O
interact	O
with	O
cationic	B
proteins	I
and	O
that	O
could	O
be	O
responsible	O
for	O
resistance	O
to	O
defensin	B
.	O

This	O
implied	O
that	O
a	O
pag	B
(	I
phoP	I
-	I
activated	I
gene	I
)	I
product	I
is	O
responsible	O
for	O
defensin	B
resistance	O
.	O

Stimulation	O
of	O
a	O
human	O
T	O
-	O
cell	O
clone	O
with	O
anti	B
-	I
CD3	I
or	O
tumor	B
necrosis	I
factor	I
induces	O
NF	B
-	I
kappa	I
B	I
translocation	O
but	O
not	O
human	O
immunodeficiency	O
virus	O
1	O
enhancer	O
-	O
dependent	O
transcription	O
.	O

The	O
two	O
latter	O
signals	O
were	O
nevertheless	O
able	O
to	O
induce	O
NF	B
-	I
kappa	I
B	I
translocation	O
with	O
a	O
pattern	O
in	O
the	O
band	O
-	O
shift	O
assay	O
indistinguishable	O
from	O
that	O
observed	O
using	O
phorbol	O
ester	O
.	O

However	O
,	O
the	O
resistance	O
to	O
vitamin	O
D	O
treatment	O
in	O
XLH	O
can	O
not	O
be	O
explained	O
by	O
hypophosphatemia	O
alone	O
.	O

Two	O
distinct	O
forms	O
of	O
active	B
transcription	I
factor	I
CREB	I
(	O
cAMP	B
response	I
element	I
binding	I
protein	I
)	O
.	O

The	O
two	O
proteins	O
differ	O
by	O
a	O
14	B
-	I
amino	I
acid	I
serine	I
-	I
rich	I
insertion	I
present	O
in	O
one	O
of	O
the	O
CREB	B
isoforms	I
.	O

Both	O
proteins	O
impart	O
cAMP	O
-	O
regulated	O
transcriptional	O
activity	O
to	O
a	O
heterologous	B
DNA	I
-	I
binding	I
domain	I
,	O
showing	O
that	O
cAMP	O
directly	O
modulates	O
the	O
transcriptional	O
stimulatory	O
activity	O
of	O
CREB	B
.	O

Competition	O
experiments	O
did	O
not	O
reveal	O
any	O
high	B
-	I
affinity	I
binding	I
site	I
for	O
BSAP	B
in	O
known	O
regulatory	B
regions	I
of	O
immunoglobulin	B
and	I
class	I
II	I
major	I
histocompatibility	I
(	I
MHC	I
)	I
genes	I
,	O
suggesting	O
that	O
BSAP	B
is	O
a	O
regulator	O
of	O
a	O
different	O
set	O
of	O
B	B
-	I
lymphoid	I
-	I
specific	I
genes	I
.	O

The	O
expression	O
of	O
the	O
antibody	B
-	I
encoding	I
genes	I
,	O
the	O
immunoglobulin	B
(	I
Ig	I
)	I
genes	I
,	O
is	O
also	O
restricted	O
to	O
B	O
cells	O
.	O

It	O
appears	O
that	O
the	O
B	O
cell	O
-	O
specific	O
expression	O
of	O
Ig	B
genes	I
is	O
mediated	O
at	O
least	O
in	O
part	O
by	O
cell	O
type	B
-	I
specific	I
Oct	I
factors	I
,	O
and	O
that	O
there	O
are	O
both	O
quantitative	O
and	O
qualitative	O
differences	O
between	O
Oct	B
-	I
1	I
and	O
Oct	B
-	I
2	I
factors	I
.	O

Recently	O
,	O
a	O
number	O
of	O
other	O
octamer	B
factor	I
variants	I
were	O
identified	O
.	O

Many	O
of	O
these	O
may	O
be	O
created	O
by	O
alternative	O
splicing	O
of	O
a	O
primary	B
transcript	I
of	O
one	O
Oct	O
factor	O
gene	O
and	O
may	O
serve	O
a	O
specific	O
function	O
in	O
the	O
fine	O
tuning	O
of	O
gene	O
expression	O
.	O

We	O
find	O
that	O
the	O
factor	O
that	O
binds	O
to	O
the	O
E3	B
enhancer	I
motif	I
,	O
CATGTGGC	O
,	O
is	O
a	O
ubiquitous	B
transcription	I
factor	I
.	O

However	O
,	O
despite	O
its	O
ability	O
to	O
activate	O
transcription	O
of	O
a	O
transfected	B
reporter	I
gene	I
,	O
the	O
factor	O
is	O
apparently	O
unable	O
to	O
bind	O
to	O
the	O
endogenous	B
Ig	I
heavy	I
chain	I
enhancer	I
in	O
non	O
-	O
lymphoid	O
cells	O
:	O
In	O
previous	O
experiments	O
by	O
others	O
,	O
the	O
characteristic	O
in	O
vivo	O
footprint	O
of	O
this	O
factor	O
,	O
designated	O
NF	B
-	I
muE3	I
,	O
was	O
detected	O
in	O
B	O
cells	O
but	O
not	O
in	O
non	O
-	O
B	O
cells	O
.	O

[	O
Endocrine	O
status	O
changes	O
in	O
children	O
with	O
bronchial	O
asthma	O
]	O

A	O
study	O
was	O
made	O
of	O
adrenocortical	O
function	O
by	O
measuring	O
blood	O
plasma	O
cortisol	O
concentration	O
and	O
amount	O
of	O
glucocorticoid	B
receptors	I
in	O
lymphocytes	O
as	O
well	O
as	O
thyroid	O
function	O
by	O
measuring	O
blood	O
plasma	O
triidothyronine	O
and	O
thyroxine	O
concentration	O
in	O
58	O
bronchial	O
asthma	O
children	O
aged	O
1	O
to	O
14	O
years	O
.	O

The	O
authors	O
revealed	O
alterations	O
in	O
the	O
functional	O
activity	O
of	O
the	O
indicated	O
endocrine	O
glands	O
depending	O
on	O
the	O
intensity	O
of	O
bronchial	O
patency	O
disorders	O
and	O
the	O
nature	O
of	O
the	O
therapeutic	O
measures	O
carried	O
out	O
.	O

TAR	B
independent	O
activation	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
in	O
phorbol	O
ester	O
stimulated	O
T	O
lymphocytes	O
.	O

Multiple	B
regulatory	I
elements	I
in	O
the	O
human	B
immunodeficiency	I
virus	I
long	I
terminal	I
repeat	I
(	O
HIV	B
LTR	I
)	O
are	O
required	O
for	O
activation	O
of	O
HIV	O
gene	O
expression	O
.	O

Results	O
in	O
all	O
cell	O
lines	O
indicated	O
that	O
mutations	O
of	O
the	O
SP1	B
,	O
TATA	B
and	O
the	O
TAR	O
loop	O
and	O
stem	O
secondary	O
structure	O
resulted	O
in	O
marked	O
decreases	O
in	O
gene	O
expression	O
while	O
mutations	O
of	O
the	O
enhancer	B
motif	I
or	O
TAR	B
primary	I
sequence	I
resulted	O
in	O
only	O
slight	O
decreases	O
.	O

The	O
clinical	O
course	O
and	O
the	O
laboratory	O
data	O
suggest	O
that	O
the	O
tachycardia	O
crises	O
are	O
the	O
consequence	O
of	O
a	O
hypersensitivity	O
of	O
the	O
heart	O
to	O
thyroid	O
hormones	O
,	O
associated	O
with	O
an	O
increased	O
number	O
of	O
T3	B
nuclear	I
receptor	I
sites	O
in	O
lymphocytes	O
.	O

Induction	O
of	O
immediate	B
early	I
response	I
genes	I
by	O
macrophage	B
colony	I
-	I
stimulating	I
factor	I
in	O
normal	O
human	O
monocytes	O
.	O

The	O
c	B
-	I
jun	I
gene	I
expression	O
was	O
very	O
transient	O
and	O
was	O
not	O
detectable	O
by	O
60	O
min	O
after	O
M	B
-	I
CSF	I
addition	O
.	O

The	O
protein	O
synthesis	O
inhibitor	O
cycloheximide	O
did	O
not	O
block	O
the	O
induction	O
of	O
any	O
of	O
these	O
genes	O
,	O
and	O
in	O
fact	O
,	O
super	O
-	O
induced	O
the	O
expression	O
of	O
c	B
-	I
jun	I
and	O
hck	B
.	O

These	O
genes	O
may	O
then	O
play	O
a	O
role	O
in	O
altering	O
the	O
physiologic	O
status	O
of	O
the	O
cells	O
in	O
response	O
to	O
CSF	B
.	O

Inducible	O
nuclear	B
factor	I
binding	O
to	O
the	O
kappa	B
B	I
elements	I
of	O
the	O
human	B
immunodeficiency	I
virus	I
enhancer	I
in	O
T	O
cells	O
can	O
be	O
blocked	O
by	O
cyclosporin	O
A	O
in	O
a	O
signal	O
-	O
dependent	O
manner	O
.	O

We	O
have	O
purified	O
a	O
new	O
T	B
-	I
cell	I
-	I
specific	I
factor	I
,	O
TCF	B
-	I
1	I
alpha	I
,	O
that	O
is	O
implicated	O
in	O
the	O
activation	O
of	O
genes	O
encoding	O
a	O
major	O
component	O
of	O
the	O
human	B
T	I
-	I
cell	I
receptor	I
(	O
TCR	B
)	O
.	O

Curiously	O
,	O
the	O
TCF	B
-	I
1	I
alpha	I
binding	O
element	O
was	O
inactive	O
in	O
vivo	O
when	O
removed	O
from	O
its	O
neighboring	O
elements	O
on	O
the	O
TCR	B
alpha	I
enhancer	I
and	O
positioned	O
in	O
one	O
or	O
more	O
copies	O
upstream	O
of	O
a	O
heterologous	B
promoter	I
.	O

A	O
powerful	O
enhancer	O
has	O
been	O
mapped	O
to	O
an	O
18	B
-	I
bp	I
DNA	I
segment	I
located	O
11	O
kb	O
5	O
'	O
to	O
the	O
human	B
epsilon	I
-	I
globin	I
gene	I
within	O
the	O
dominant	B
control	I
or	O
locus	B
-	I
activating	I
region	I
.	O

DNA	O
-	O
protein	O
binding	O
assays	O
with	O
nuclear	O
extracts	O
from	O
induced	O
cells	O
demonstrate	O
a	O
high	B
molecular	I
weight	I
complex	I
on	O
the	O
enhancer	B
.	O

The	O
tissue	O
-	O
specific	O
expression	O
of	O
the	O
MOPC	B
141	I
immunoglobulin	I
heavy	I
-	I
chain	I
gene	I
was	O
studied	O
by	O
using	O
in	O
vitro	O
transcription	O
.	O

Purified	O
OTF1	B
from	O
HeLa	O
cells	O
and	O
OTF1	B
and	O
OTF2	B
from	O
B	O
cells	O
bound	O
to	O
identical	O
sequences	O
within	O
the	O
heavy	B
-	I
chain	I
promoter	I
.	O

In	O
addition	O
to	O
these	O
elements	O
,	O
we	O
identified	O
a	O
second	O
regulatory	B
element	I
,	O
the	O
N	B
element	I
with	O
the	O
sequence	O
5	O
'	O
-	O
GGAACCTCCCCC	O
-	O
3	O
'	O
.	O

NF	B
-	I
kappa	I
B	I
as	O
inducible	O
transcriptional	B
activator	I
of	O
the	O
granulocyte	B
-	I
macrophage	I
colony	I
-	I
stimulating	I
factor	I
gene	I
.	O

The	O
same	O
agents	O
induce	O
transcription	O
from	O
the	O
interleukin	B
-	I
2	I
receptor	I
alpha	I
-	I
chain	I
and	I
interleukin	I
-	I
2	I
genes	I
,	O
depending	O
on	O
promoter	B
elements	I
that	O
bind	O
the	O
inducible	B
transcription	I
factor	I
NF	B
-	I
kappa	I
B	I
(	O
or	O
an	O
NF	B
-	I
kappa	I
B	I
-	I
like	I
factor	I
)	O
.	O

Two	O
kappa	B
B	I
-	I
like	I
motifs	I
at	O
positions	B
-	I
98	I
to	I
-	I
108	I
of	O
the	O
GM	B
-	I
CSF	I
promoter	I
were	O
also	O
recognized	O
but	O
with	O
much	O
lower	O
affinities	O
.	O

Effects	O
of	O
mitogenic	O
agents	O
upon	O
glucocorticoid	O
action	O
in	O
human	O
tonsillar	O
T	O
-	O
lymphocytes	O
.	O

PMA	O
enhanced	O
slightly	O
the	O
stimulatory	O
effect	O
of	O
PHA	B
.	O

Accordingly	O
,	O
the	O
same	O
set	O
of	O
words	O
and	O
phrases	O
(	O
oligopeptides	O
)	O
appear	O
in	O
totally	O
unrelated	O
proteins	O
.	O

Two	O
distinct	O
signal	O
transmission	O
pathways	O
in	O
T	O
lymphocytes	O
are	O
inhibited	O
by	O
complexes	O
formed	O
between	O
an	O
immunophilin	B
and	O
either	O
FK506	O
or	O
rapamycin	O
.	O

After	O
in	O
vitro	O
adherence	O
,	O
human	O
monocytes	O
had	O
a	O
biphasic	O
increase	O
in	O
PDGF	B
(	I
B	I
)	I
mRNA	I
with	O
peaks	O
at	O
6	O
h	O
and	O
13	O
d	O
.	O

Modulation	O
of	O
these	O
events	O
at	O
the	O
time	O
of	O
adherence	O
offers	O
a	O
mechanism	O
by	O
which	O
differential	O
priming	O
of	O
the	O
cells	O
may	O
be	O
accomplished	O
.	O

Unexpectedly	O
,	O
stimulation	O
of	O
cloned	O
stably	O
transfected	O
Jurkat	O
T	O
cells	O
leads	O
to	O
a	O
bimodal	O
pattern	O
of	O
beta	O
-	O
gal	O
expression	O
in	O
which	O
some	O
cells	O
express	O
no	O
beta	B
-	I
gal	I
and	O
others	O
express	O
high	O
levels	O
.	O

Further	O
results	O
,	O
in	O
which	O
beta	B
-	I
gal	I
activity	O
is	O
correlated	O
with	O
NF	B
-	I
AT	I
-	O
binding	O
activity	O
,	O
indicate	O
that	O
the	O
concentration	O
of	O
NF	B
-	I
AT	I
must	O
exceed	O
a	O
critical	O
threshold	O
before	O
transcription	O
initiates	O
.	O

Similar	O
constructs	O
controlled	O
by	O
NF	B
-	I
kappa	I
B	I
or	O
the	O
entire	O
interleukin	B
-	I
2	I
enhancer	I
show	O
bimodal	O
expression	O
patterns	O
during	O
induction	O
,	O
suggesting	O
that	O
thresholds	O
set	O
by	O
the	O
concentration	O
of	O
transcription	B
factors	I
may	O
be	O
a	O
common	O
property	O
of	O
inducible	B
genes	I
.	O

In	O
lymphoid	O
cells	O
,	O
Z	B
or	O
R	B
alone	O
produced	O
only	O
small	O
increases	O
in	O
EA	B
-	I
D	I
promoter	I
activity	O
,	O
whereas	O
both	O
transactivators	B
together	O
produced	O
a	O
large	O
stimulatory	O
effect	O
.	O

In	O
lymphoid	O
cells	O
,	O
only	O
the	O
upstream	B
sequences	I
are	O
required	O
for	O
transactivation	O
by	O
the	O
Z	B
/	I
R	I
combination	O
,	O
and	O
the	O
AP	B
-	I
1	I
site	I
is	O
dispensable	O
.	O

The	O
DNA	O
isolated	O
contained	O
an	O
open	O
reading	O
frame	O
encoding	O
108	O
amino	O
acid	O
residues	O
.	O

This	O
effect	O
was	O
comparable	O
to	O
or	O
even	O
stronger	O
than	O
the	O
effect	O
of	O
a	O
mutation	O
in	O
the	O
OCTA	B
site	I
.	O

DNase	O
footprinting	O
analysis	O
corroborated	O
the	O
functional	O
data	O
showing	O
that	O
a	O
lymphoid	B
-	I
specific	I
protein	I
binds	O
to	O
the	O
microB	B
DNA	I
motif	I
.	O

This	O
inducer	O
can	O
act	O
in	O
concert	O
with	O
the	O
HIV	B
-	I
2	I
tat	I
gene	I
and	O
T	O
-	O
cell	O
activation	O
in	O
enhancing	O
gene	O
expression	O
in	O
human	O
CD4	O
+	O
lymphocytes	O
.	O

Both	O
HIV	O
-	O
2	O
and	O
CMV	B
transactivators	I
enhance	O
HIV	O
-	O
2	O
gene	O
expression	O
by	O
transcriptional	O
activation	O
involving	O
transcript	O
initiation	O
as	O
well	O
as	O
elongation	O
,	O
with	O
CMV	B
transactivator	I
affecting	O
elongation	O
more	O
than	O
the	O
initiation	O
.	O

Inflammatory	O
infiltrates	O
were	O
analysed	O
in	O
tissue	O
sections	O
of	O
76	O
breast	O
carcinomas	O
by	O
counting	O
the	O
percentage	O
of	O
macrophages	O
,	O
IgA	O
+	O
and	O
IgG	O
+	O
plasma	O
cells	O
,	O
T	O
cells	O
with	O
their	O
subpopulations	O
,	O
and	O
natural	O
killer	O
cells	O
,	O
and	O
by	O
measuring	O
postcapillary	O
venules	O
(	O
PCVs	O
,	O
found	O
in	O
12	O
cases	O
)	O
within	O
the	O
infiltrates	O
.	O

In	O
addition	O
,	O
a	O
direct	O
correlation	O
exists	O
between	O
the	O
diameter	O
of	O
the	O
PCVs	O
and	O
both	O
the	O
percentage	O
of	O
the	O
OKT8	O
+	O
T	O
cells	O
(	O
P	O
less	O
than	O
0	O
.	O
04	O
)	O
and	O
the	O
Leu	O
-	O
7	O
+	O
natural	O
killer	O
cells	O
(	O
P	O
less	O
than	O
0	O
.	O
03	O
)	O
.	O

In	O
this	O
study	O
we	O
present	O
evidence	O
for	O
reactivity	O
of	O
pregnancy	O
lymphocytes	O
,	O
but	O
not	O
nonpregnancy	O
lymphocytes	O
,	O
with	O
the	O
progesterone	B
receptor	I
-	I
specific	I
monoclonal	I
antibody	I
mPRI	B
.	O

Depletion	O
of	O
CD8	O
+	O
cells	O
was	O
accompanied	O
by	O
62	O
+	O
/	O
-	O
18	O
%	O
loss	O
of	O
progesterone	O
receptor	O
-	O
bearing	O
cells	O
,	O
while	O
depletion	O
of	O
CD4	O
+	O
cells	O
resulted	O
in	O
a	O
twofold	O
increase	O
in	O
the	O
number	O
of	O
positively	O
staining	O
lymphocytes	O
.	O

Interaction	O
of	O
fibronectin	B
with	O
VLA	B
-	I
5	I
receptor	I
on	O
CD4	O
cells	O
induces	O
the	O
AP	B
-	I
1	I
transcription	I
factor	I
.	O

Int	B
-	I
2	I
was	O
amplified	O
in	O
13	O
.	O
1	O
%	O
and	O
c	B
-	I
myc	I
was	O
amplified	O
in	O
10	O
.	O
3	O
%	O
.	O

A	O
somewhat	O
surprising	O
finding	O
however	O
was	O
a	O
very	O
strong	O
association	O
between	O
oncogene	B
amplification	O
and	O
dense	O
lymphocyte	O
infiltration	O
of	O
the	O
tumor	O
(	O
P	O
=	O
.	O
05	O
)	O
.	O
This	O
correlation	O
is	O
even	O
stronger	O
when	O
only	O
high	O
levels	O
of	O
amplification	O
are	O
considered	O
,	O
either	O
for	O
each	O
oncogene	O
separately	O
(	O
P	O
=	O
.	O
0048	O
)	O
or	O
in	O
combination	O
(	O
P	O
=	O
.	O
0007	O
)	O
.	O

Suppression	O
of	O
signals	O
required	O
for	O
activation	O
of	O
transcription	B
factor	I
NF	I
-	I
kappa	I
B	I
in	O
cells	O
constitutively	O
expressing	O
the	O
HTLV	B
-	I
I	I
Tax	I
protein	I
.	O

Transcription	B
factor	I
IID	I
(	O
TFIID	B
)	O
binds	O
to	O
the	O
TATA	B
box	I
promoter	I
element	I
and	O
regulates	O
the	O
expression	O
of	O
most	O
eukaryotic	B
genes	I
transcribed	O
by	O
RNA	B
polymerase	I
II	I
.	O

Complementary	B
DNA	I
(	O
cDNA	B
)	O
encoding	O
a	O
human	B
TFIID	I
protein	I
has	O
been	O
cloned	O
.	O

Premenopausal	O
patients	O
with	O
neither	O
risk	O
factor	O
had	O
a	O
very	O
low	O
failure	O
rate	O
(	O
2	O
.	O
6	O
%	O
at	O
5	O
years	O
)	O
,	O
regardless	O
of	O
age	O
.	O

Second	O
,	O
TRE	B
-	I
DNA	I
binding	I
proteins	I
sedimented	O
through	O
a	O
glycerol	O
density	O
gradient	O
at	O
rates	O
corresponding	O
to	O
proteins	O
of	O
native	O
molecular	O
weights	O
of	O
35	O
to	O
50	O
kD	O
and	O
110	O
kD	O
.	O

Third	O
,	O
only	O
the	O
50	B
kD	I
protein	I
was	O
retained	O
on	O
a	O
biotinylated	O
DNA	O
-	O
streptavidin	O
matrix	O
when	O
the	O
DNA	O
fragment	O
contained	O
the	O
TRE	B
-	I
DNA	I
.	O

Fourth	O
,	O
extensive	O
purification	O
by	O
several	O
cycles	O
of	O
TRE	B
-	O
DNA	O
affinity	O
chromatography	O
resulted	O
in	O
the	O
32	B
,	I
36	I
to	I
42	I
and	I
110	I
kD	I
proteins	I
and	O
to	O
less	O
extent	O
the	O
50	B
kD	I
factor	I
.	O

Two	O
abundant	O
proteins	O
of	O
75	O
and	O
80	O
kD	O
were	O
competed	O
out	O
by	O
poly	O
[	O
d	O
(	O
I	O
-	O
C	O
)	O
]	O
in	O
all	O
reactions	O
.	O

The	O
cAMP	B
-	I
response	I
element	I
CRE	B
,	O
TGACGTCA	O
,	O
present	O
in	O
the	O
21	B
base	I
-	I
pair	I
sequence	I
,	O
appears	O
to	O
be	O
essential	O
for	O
specific	O
protein	O
-	O
TRE	B
-	O
DNA	O
interactions	O
because	O
mutation	O
of	O
the	O
two	O
G	O
'	O
s	O
destroys	O
this	O
complex	O
.	O

Activity	O
of	O
the	O
immunoglobulin	B
heavy	I
and	I
kappa	I
light	I
chain	I
gene	I
enhancers	I
depends	O
on	O
a	O
complex	O
interplay	O
of	O
ubiquitous	B
and	I
developmentally	I
regulated	I
proteins	I
.	O

Elevated	O
glucocorticoid	B
receptor	I
concentrations	O
before	O
and	O
after	O
glucocorticoid	O
therapy	O
in	O
peripheral	O
mononuclear	O
leukocytes	O
of	O
patients	O
with	O
atopic	O
dermatitis	O
.	O

Patients	O
with	O
AD	O
(	O
n	O
=	O
15	O
)	O
exhibited	O
significantly	O
more	O
glucocorticoid	B
receptors	I
(	O
GR	B
)	O
per	O
cell	O
than	O
the	O
control	O
group	O
(	O
n	O
=	O
22	O
)	O
,	O
while	O
the	O
GR	B
affinity	O
did	O
not	O
differ	O
.	O

Methylprednisolone	O
treatment	O
resulted	O
in	O
a	O
significant	O
reduction	O
of	O
the	O
GR	B
sites	O
per	O
cell	O
in	O
the	O
steroid	O
-	O
treated	O
control	O
group	O
(	O
n	O
=	O
10	O
)	O
in	O
contrast	O
to	O
the	O
patients	O
.	O

The	O
internal	O
methionine	O
codons	O
of	O
human	B
T	I
-	I
cell	I
leukemia	I
virus	I
type	I
II	I
rex	I
gene	I
are	O
not	O
required	O
for	O
p24rex	B
production	O
or	O
virus	O
replication	O
and	O
transformation	O
.	O

Human	O
T	O
-	O
cell	O
leukemia	O
virus	O
types	O
I	O
(	O
HTLV	O
-	O
I	O
)	O
and	O
II	O
(	O
HTLV	O
-	O
II	O
)	O
have	O
two	O
nonstructural	B
trans	I
-	I
acting	I
regulatory	I
genes	I
,	O
tax	B
and	O
rex	B
,	O
located	O
in	O
the	O
3	B
'	I
region	I
of	O
the	O
viral	B
genome	I
.	O

Rex	B
acts	O
posttranscriptionall	O
to	O
facilitate	O
accumulation	O
of	O
full	O
-	O
length	O
gag	B
/	I
pol	I
and	O
singly	O
spliced	O
env	B
mRNA	I
in	O
the	O
cytoplasm	O
of	O
HTLV	O
-	O
infected	O
cells	O
.	O

By	O
using	O
an	O
infectious	O
molecular	O
clone	O
of	O
HTLV	O
-	O
II	O
,	O
we	O
investigated	O
the	O
importance	O
of	O
the	O
internal	O
ATGs	O
of	O
the	O
rex	B
gene	I
on	O
Rex	B
protein	O
production	O
and	O
function	O
.	O

The	O
'	B
octamer	I
'	I
sequence	I
,	O
ATGCAAAT	O
or	O
its	O
complement	O
ATTTGCAT	O
,	O
is	O
a	O
key	O
element	O
for	O
the	O
transcriptional	O
regulation	O
of	O
immunoglobulin	B
genes	I
in	O
B	O
-	O
lymphocytes	O
as	O
well	O
as	O
a	O
number	O
of	O
housekeeping	B
genes	I
in	O
all	O
cell	O
types	O
.	O

In	O
lymphocytes	O
,	O
the	O
octamer	B
-	I
binding	I
protein	I
Oct	B
-	I
2A	I
and	O
variants	O
thereof	O
are	O
thought	O
to	O
contribute	O
to	O
the	O
B	B
-	I
cell	I
specific	I
gene	I
expression	O
,	O
while	O
the	O
ubiquitous	O
protein	O
Oct	O
-	O
1	O
seems	O
to	O
control	O
general	O
octamer	B
site	I
-	O
dependent	O
transcription	O
.	O

Therefore	O
,	O
the	O
phosphorylation	O
of	O
Rex	B
is	O
required	O
for	O
the	O
viral	O
RNA	O
partition	O
of	O
HTLV	O
-	O
I	O
.	O

Cell	O
proliferation	O
of	O
CEM	O
-	O
C7	O
cells	O
cultured	O
in	O
both	O
serum	O
-	O
free	O
media	O
has	O
been	O
sustained	O
for	O
3	O
mo	O
.	O

All	O
immunoglobulin	B
genes	I
contain	O
a	O
conserved	O
octanucleotide	B
promoter	I
element	I
,	O
ATGCAAAT	O
,	O
which	O
has	O
been	O
shown	O
to	O
be	O
required	O
for	O
their	O
normal	O
B	O
-	O
cell	O
-	O
specific	O
transcription	O
.	O

Proteins	O
that	O
bind	O
this	O
octamer	O
have	O
been	O
purified	O
,	O
and	O
cDNAs	B
encoding	O
octamer	B
-	I
binding	I
proteins	I
have	O
been	O
cloned	O
.	O

Addition	O
of	O
a	O
highly	O
enriched	O
preparation	O
of	O
OTF	B
-	I
1	I
made	O
from	O
one	O
of	O
these	O
pre	O
-	O
B	O
cells	O
or	O
from	O
HeLa	O
cells	O
specifically	O
stimulated	O
in	O
vitro	O
transcription	O
of	O
an	O
immunoglobulin	B
gene	I
.	O

In	O
vitro	O
binding	O
of	O
aldosterone	O
to	O
mineralocorticoid	B
receptors	I
on	O
human	O
mononuclear	O
leukocytes	O
(	O
HML	O
)	O
and	O
its	O
effects	O
on	O
the	O
intracellular	O
sodium	O
and	O
potassium	O
concentrations	O
of	O
HML	O
have	O
already	O
been	O
described	O
.	O

In	O
only	O
four	O
patients	O
sodium	O
in	O
HML	O
without	O
incubation	O
was	O
elevated	O
compared	O
with	O
the	O
range	O
for	O
normal	O
persons	O
.	O

A	O
decrease	O
of	O
intracellular	O
sodium	O
or	O
potassium	O
occurred	O
during	O
incubation	O
without	O
aldosterone	O
(	O
P	O
less	O
than	O
0	O
.	O
02	O
)	O
.	O

The	O
number	O
of	O
mineralocorticoid	B
receptors	I
/	O
cell	O
were	O
within	O
or	O
close	O
to	O
the	O
normal	O
range	O
(	O
n	O
=	O
9	O
)	O
.	O

It	O
is	O
proposed	O
that	O
the	O
character	O
of	O
their	O
expression	O
under	O
the	O
influence	O
of	O
vitamin	O
D	O
may	O
be	O
used	O
with	O
differential	O
diagnostic	O
purposes	O
in	O
view	O
.	O

Regulation	O
of	O
gene	O
expression	O
with	O
double	O
-	O
stranded	O
phosphorothioate	O
oligonucleotides	O
.	O

We	O
now	O
demonstrate	O
the	O
following	O
.	O

Thus	O
,	O
EBNA	B
-	I
2	I
transactivation	O
of	O
LMP1	B
amplifies	O
the	O
biological	O
impact	O
of	O
EBNA	B
-	I
2	I
and	O
underscores	O
its	O
central	O
role	O
in	O
EBV	O
-	O
induced	O
growth	O
transformation	O
.	O

Heat	O
shock	O
caused	O
an	O
increase	O
in	O
c	O
-	O
fos	O
and	O
c	O
-	O
jun	O
mRNA	O
levels	O
and	O
a	O
decrease	O
in	O
c	B
-	I
myc	I
mRNA	I
levels	O
in	O
pre	O
-	O
B	O
(	O
Hyon	O
)	O
and	O
T	O
(	O
DND	O
-	O
41	O
)	O
cell	O
lines	O
as	O
well	O
as	O
in	O
freshly	O
isolated	O
normal	O
human	O
thymocytes	O
.	O

Mapping	O
of	O
B	B
-	I
cell	I
epitopes	I
of	O
the	O
human	B
hepatitis	I
B	I
virus	I
X	I
protein	I
.	O

Anti	O
-	O
HBx	B
antibody	O
titers	O
as	O
revealed	O
by	O
peptide	O
ELISAs	O
were	O
highest	O
and	O
most	O
frequent	O
in	O
patients	O
with	O
chronic	O
hepatitis	O
and	O
usually	O
low	O
in	O
acutely	O
infected	O
patients	O
and	O
asymptomatic	O
carriers	O
.	O

Random	O
migration	O
(	O
RM	O
)	O
and	O
chemotactic	O
migration	O
(	O
ChtM	O
)	O
of	O
human	O
leukocytes	O
to	O
yeast	O
activated	O
serum	O
were	O
studied	O
with	O
the	O
modified	O
Boyden	O
chamber	O
method	O
.	O

The	O
difference	O
between	O
the	O
peak	O
(	O
0	O
:	O
00	O
)	O
and	O
trough	O
values	O
(	O
8	O
:	O
00	O
)	O
of	O
RM	O
and	O
ChtM	O
was	O
significant	O
statistically	O
(	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
.	O

ChtM	O
was	O
inhibited	O
by	O
hydrocortisone	O
(	O
F	O
)	O
of	O
physiological	O
concentration	O
(	O
10	O
(	O
-	O
9	O
)	O
-	O
10	O
(	O
-	O
7	O
)	O
mol	O
/	O
L	O
)	O
which	O
was	O
dose	O
-	O
dependent	O
and	O
completely	O
antagonized	O
by	O
the	O
competitive	O
antagonist	O
,	O
RU38486	O
.	O

The	O
inhibitory	O
effect	O
was	O
much	O
more	O
evident	O
with	O
higher	O
dose	O
(	O
more	O
than	O
10	O
(	O
-	O
5	O
)	O
mol	O
/	O
L	O
)	O
and	O
it	O
was	O
also	O
reversed	O
by	O
RU38486	O
,	O
but	O
only	O
partially	O
.	O

Lt	B
-	I
4	I
reacted	O
with	O
all	O
HTLV	O
-	O
I	O
-	O
bearing	O
cell	O
lines	O
tested	O
and	O
five	O
out	O
of	O
eight	O
simian	O
cell	O
lines	O
bearing	O
STLV	O
-	O
I	O
,	O
but	O
not	O
with	O
an	O
HTLV	O
-	O
II	O
-	O
bearing	O
cell	O
line	O
.	O

In	O
the	O
STLV	O
-	O
I	O
-	O
bearing	O
T	O
cell	O
lines	O
,	O
tax1	B
-	I
related	I
antigen	I
molecules	I
detected	O
by	O
Lt	B
-	I
4	I
were	O
heterogeneous	O
,	O
having	O
molecular	O
weights	O
in	O
the	O
range	O
of	O
36	O
-	O
41	O
kd	O
.	O

The	O
transcription	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
is	O
under	O
the	O
control	O
of	O
cellular	B
proteins	I
that	O
bind	O
to	O
the	O
viral	B
long	I
terminal	I
repeat	I
(	O
LTR	B
)	O
.	O

The	O
corresponding	O
region	O
in	O
the	O
second	O
AIDS	O
retrovirus	O
,	O
HIV	O
-	O
2	O
,	O
contains	O
a	O
conserved	O
and	O
a	O
divergent	O
NF	B
kappa	I
B	I
binding	I
site	I
.	O

Instead	O
of	O
NF	B
kappa	I
B	I
,	O
the	O
activator	B
protein	I
3	I
binds	O
to	O
the	O
divergent	O
site	O
in	O
HIV	O
-	O
2	O
.	O

Expression	O
cloning	O
of	O
c	B
-	I
Jun	I
.	O

Whereas	O
c	B
-	I
Fos	I
/	I
c	I
-	I
Jun	I
heterodimers	I
do	O
not	O
exist	O
in	O
B	O
cells	O
,	O
they	O
form	O
and	O
bind	O
to	O
the	O
X2	B
-	I
box	I
in	O
class	O
II	O
nonexpressing	O
cells	O
.	O

11	O
beta	O
,	O
19	O
-	O
epoxy	O
-	O
4	O
,	O
21	O
-	O
dihydroxypregn	O
-	O
4	O
-	O
ene	O
-	O
3	O
,	O
20	O
-	O
dione	O
(	O
2	O
)	O
was	O
hydrogenated	O
with	O
Pd	O
-	O
C	O
to	O
yield	O
a	O
mixture	O
of	O
all	O
four	O
dihydro	O
derivatives	O
5	O
,	O
accompanied	O
by	O
4	O
,	O
21	O
-	O
diacetoxy	O
-	O
11	O
beta	O
,	O
19	O
-	O
epoxy	O
-	O
3	O
-	O
hydroxypregnan	O
-	O
20	O
-	O
one	O
(	O
6	O
)	O
and	O
21	O
-	O
acetoxy	O
-	O
11	O
beta	O
,	O
19	O
-	O
epoxy	O
-	O
4	O
-	O
hydroxypregnane	O
-	O
3	O
,	O
20	O
-	O
dione	O
(	O
7	O
)	O
.	O

Treatment	O
of	O
10	O
with	O
warm	O
HCl	O
furnished	O
19	O
-	O
chloro	O
-	O
4	O
,	O
21	O
-	O
dihydroxypregna	O
-	O
4	O
,	O
9	O
(	O
11	O
)	O
-	O
diene	O
-	O
3	O
,	O
20	O
-	O
dione	O
(	O
13	O
)	O
.	O

When	O
tested	O
in	O
a	O
radioreceptor	O
assay	O
in	O
human	O
mononuclear	O
leukocytes	O
the	O
synthesized	O
compounds	O
showed	O
only	O
low	O
relative	O
binding	O
affinities	O
(	O
RBA	O
)	O
to	O
type	B
1	I
receptor	I
,	O
the	O
highest	O
being	O
0	O
.	O
72	O
%	O
for	O
13	O
(	O
aldosterone	O
=	O
100	O
%	O
)	O
.	O

We	O
have	O
developed	O
a	O
system	O
to	O
monitor	O
the	O
transcriptional	O
activity	O
of	O
NFAT	B
-	I
1	I
at	O
the	O
single	O
cell	O
level	O
in	O
whole	O
animals	O
.	O

This	O
report	O
represents	O
the	O
first	O
demonstration	O
that	O
a	O
multimerized	O
short	O
binding	O
motif	O
can	O
function	O
appropriately	O
in	O
transgenic	O
mice	O
.	O

This	O
similarity	O
in	O
expression	O
and	O
the	O
fact	O
that	O
NFAT	B
-	I
1	I
has	O
been	O
shown	O
to	O
bind	O
functional	B
sequences	I
in	O
HIV	B
-	I
LTR	I
suggest	O
a	O
role	O
for	O
NFAT	B
-	I
1	I
in	O
dermal	O
activation	O
of	O
the	O
HIV	B
-	I
LTR	I
.	O

A	O
novel	O
T	B
-	I
cell	I
protein	I
recognized	O
the	O
palindromic	B
sequence	I
within	O
site	B
B	I
and	O
also	O
bound	O
estrogen	B
-	I
or	I
thyroid	I
hormone	I
-	I
response	I
elements	I
with	O
lower	O
affinity	O
.	O

The	O
effects	O
of	O
a	O
competitive	O
progesterone	O
antagonist	O
(	O
RU486	O
)	O
and	O
a	O
specific	O
glucocorticoid	B
receptor	I
blocker	O
(	O
RU43044	O
)	O
were	O
tested	O
on	O
the	O
release	O
of	O
a	O
blocking	B
factor	I
by	O
progesterone	O
-	O
treated	O
pregnancy	O
lymphocytes	O
.	O

It	O
has	O
previously	O
been	O
shown	O
that	O
9S	B
,	O
untransformed	B
progestin	I
,	I
estrogen	I
,	I
androgen	I
,	I
and	I
glucocorticoid	I
receptor	I
complexes	I
in	O
rabbit	O
uterine	O
and	O
liver	O
cytosols	O
contain	O
a	O
59	B
-	I
kDa	I
protein	I
[	O
Tai	O
,	O
P	O
.	O
K	O
.	O
,	O
Maeda	O
,	O
Y	O
.	O
,	O
Nakao	O
,	O
K	O
.	O
,	O
Wakim	O
,	O
N	O
.	O
G	O
.	O
,	O
Duhring	O
,	O
J	O
.	O
L	O
.	O
,	O
&	O
Faber	O
,	O
L	O
.	O
E	O
.	O
(	O
1986	O
)	O
Biochemistry	O
25	O
,	O
5269	O
-	O
5275	O
]	O
.	O

Sequence	O
-	O
specific	O
DNA	O
binding	O
of	O
the	O
proto	B
-	I
oncoprotein	I
ets	B
-	I
1	I
defines	O
a	O
transcriptional	B
activator	I
sequence	I
within	O
the	O
long	B
terminal	I
repeat	I
of	O
the	O
Moloney	O
murine	O
sarcoma	O
virus	O
.	O

A	O
mutant	B
LTR	I
containing	O
four	O
base	O
pair	O
substitutions	O
in	O
the	O
ets	B
-	I
1	I
binding	I
site	I
was	O
constructed	O
and	O
was	O
shown	O
to	O
have	O
reduced	O
binding	O
in	O
vitro	O
.	O

We	O
propose	O
that	O
ets	B
-	I
1	I
functions	O
as	O
a	O
transcriptional	O
activator	O
of	O
mammalian	O
type	O
-	O
C	O
retroviruses	O
and	O
speculate	O
that	O
ets	B
-	I
related	I
genes	I
constitute	O
a	O
new	O
group	O
of	O
eukaryotic	B
DNA	I
-	I
binding	I
proteins	I
.	O

We	O
have	O
previously	O
reported	O
that	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
contain	O
type	O
II	B
estrogen	I
binding	I
sites	I
(	O
type	B
II	I
EBS	I
)	O
.	O

In	O
postmenopausal	O
women	O
the	O
mean	O
type	B
II	I
EBS	I
levels	O
were	O
similar	O
to	O
those	O
observed	O
in	O
the	O
follicular	O
phase	O
of	O
the	O
cycle	O
.	O

Tamoxifen	O
was	O
also	O
found	O
to	O
compete	O
with	O
17	O
beta	O
-	O
estradiol	O
for	O
type	B
II	I
EBS	I
in	O
PBMC	O
,	O
although	O
to	O
a	O
lesser	O
extent	O
than	O
diethylstilbestrol	O
.	O

These	O
results	O
do	O
not	O
lend	O
support	O
to	O
previous	O
reports	O
suggesting	O
that	O
GC	O
resistance	O
in	O
MDD	O
results	O
from	O
a	O
GC	O
receptor	O
-	O
binding	O
abnormality	O
,	O
and	O
they	O
emphasize	O
the	O
importance	O
of	O
considering	O
receptor	O
studies	O
in	O
the	O
context	O
of	O
GC	O
-	O
mediated	O
cell	O
processes	O
in	O
order	O
to	O
identify	O
the	O
exact	O
cellular	O
defect	O
(	O
s	O
)	O
leading	O
to	O
GC	O
resistance	O
.	O

Proteins	O
exist	O
in	O
leukocytes	O
able	O
to	O
modify	O
GTP	B
-	I
binding	I
protein	I
function	O
in	O
this	O
manner	O
,	O
and	O
their	O
activity	O
may	O
be	O
regulated	O
by	O
signals	O
generated	O
on	O
phagocyte	O
stimulation	O
.	O

Proteins	O
of	O
the	O
Ras	B
superfamily	I
are	O
likely	O
to	O
be	O
involved	O
in	O
a	O
variety	O
of	O
normal	O
phagocyte	O
functions	O
through	O
their	O
ability	O
to	O
modulate	O
the	O
assembly	O
of	O
actin	B
filaments	I
,	O
direct	O
vesicle	O
trafficking	O
and	O
fusion	O
,	O
and	O
so	O
forth	O
.	O

The	O
effect	O
of	O
1	O
,	O
25	O
-	O
dihydroxyvitamin	O
D3	O
[	O
1	O
,	O
25	O
(	O
OH	O
)	O
2	O
)	O
D3	O
]	O
,	O
a	O
steroid	O
hormone	O
with	O
immunomodulating	O
properties	O
,	O
on	O
nuclear	B
factor	I
kappa	I
B	I
(	O
NF	B
-	I
kappa	I
B	I
)	O
proteins	O
was	O
examined	O
in	O
in	O
vitro	O
activated	O
normal	O
human	O
lymphocytes	O
by	O
Western	O
blot	O
analysis	O
.	O

Over	O
a	O
72	O
-	O
hr	O
period	O
of	O
activation	O
,	O
the	O
expression	O
of	O
the	O
50	B
-	I
kDa	I
NF	I
-	I
kappa	I
B	I
,	O
p50	B
,	O
and	O
its	O
precursor	O
,	O
p105	B
,	O
was	O
increased	O
progressively	O
.	O

When	O
cells	O
were	O
activated	O
in	O
the	O
presence	O
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
,	O
the	O
levels	O
of	O
the	O
mature	O
protein	O
as	O
well	O
as	O
its	O
precursor	O
were	O
decreased	O
.	O

Further	O
,	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
inhibited	O
the	O
transcriptional	O
activity	O
of	O
NF	B
-	I
kappa	I
B	I
in	O
Jurkat	O
cells	O
transiently	O
transfected	O
with	O
a	O
construct	B
containing	O
four	O
tandem	B
repeats	I
of	O
the	O
NF	B
-	I
kappa	I
B	I
binding	I
sequence	I
of	O
the	O
immunoglobulin	B
kappa	I
light	I
chain	I
gene	I
linked	O
to	O
the	O
chloramphenicol	B
acetyltransferase	I
reporter	I
gene	I
.	O

These	O
observations	O
demonstrate	O
directly	O
that	O
there	O
is	O
de	O
novo	O
synthesis	O
of	O
NF	B
-	I
kappa	I
B	I
during	O
human	O
lymphocyte	O
activation	O
and	O
suggest	O
that	O
this	O
process	O
is	O
hormonally	O
regulated	O
.	O

We	O
previously	O
identified	O
the	O
DNA	B
consensus	I
binding	I
site	I
recognized	O
by	O
the	O
two	O
DNA	B
binding	I
domains	I
.	O

The	O
expression	O
vector	O
was	O
cotransfected	O
with	O
the	O
chloramphenicol	B
acetyl	I
transferase	I
(	I
CAT	I
)	I
reporter	I
gene	I
regulated	O
by	O
the	O
thymidine	B
kinase	I
promoter	I
containing	O
GAL4	B
DNA	I
binding	I
sites	I
into	O
NIH	O
3T3	O
,	O
293	O
,	O
K562	O
,	O
and	O
Jurkat	O
cell	O
lines	O
.	O

In	O
contrast	O
,	O
MZF	B
-	I
1	I
activates	O
CAT	B
reporter	I
gene	I
expression	O
in	O
the	O
hematopoietic	O
cell	O
lines	O
K562	O
and	O
Jurkat	O
.	O

The	O
MZF	B
-	I
1	I
binding	I
sites	I
are	O
present	O
in	O
the	O
promoters	B
of	O
several	O
genes	B
expressed	O
during	O
myeloid	O
differentiation	O
,	O
including	O
the	O
CD34	B
promoter	I
.	O

This	O
induction	O
was	O
not	O
inhibited	O
by	O
treatment	O
of	O
the	O
cells	O
with	O
a	O
protein	O
synthesis	O
inhibitor	O
,	O
cycloheximide	O
.	O

The	O
role	O
of	O
BSAP	B
(	O
Pax	B
-	I
5	I
)	O
in	O
B	O
-	O
cell	O
development	O
.	O

Analysis	O
of	O
the	O
biochemical	O
and	O
cell	O
biological	O
properties	O
of	O
these	O
HSFs	B
reveals	O
that	O
HSF3	B
has	O
properties	O
in	O
common	O
with	O
both	O
HSF1	B
and	O
HSF2	B
and	O
yet	O
has	O
features	O
which	O
are	O
distinct	O
from	O
both	O
.	O

HSF3	B
is	O
constitutively	O
expressed	O
in	O
the	O
erythroblast	O
cell	O
line	O
HD6	O
,	O
the	O
lymphoblast	O
cell	O
line	O
MSB	O
,	O
and	O
embryo	O
fibroblasts	O
,	O
and	O
yet	O
its	O
DNA	O
-	O
binding	O
activity	O
is	O
induced	O
only	O
upon	O
exposure	O
of	O
HD6	O
cells	O
to	O
heat	O
shock	O
.	O

Nuclear	B
factor	I
of	I
activated	I
T	I
cells	I
(	O
NFAT	B
)	O
regulates	O
transcription	O
of	O
a	O
number	O
of	O
cytokine	B
genes	I
,	O
and	O
NFAT	B
DNA	O
binding	O
activity	O
is	O
stimulated	O
following	O
T	O
cell	O
activation	O
.	O

Treatment	O
of	O
immunoprecipitated	O
NFATp	B
from	O
untreated	O
HT	O
-	O
2	O
cells	O
with	O
calcineurin	B
resulted	O
in	O
the	O
dephosphorylation	O
of	O
NFATp	B
,	O
demonstrating	O
that	O
NFATp	B
is	O
an	O
in	O
vitro	O
substrate	O
for	O
calcineurin	B
.	O

Both	O
of	O
these	O
events	O
were	O
blocked	O
by	O
preincubation	O
of	O
the	O
cells	O
with	O
FK506	O
,	O
a	O
calcineurin	B
inhibitor	O
,	O
consistent	O
with	O
the	O
hypothesis	O
that	O
NFATp	B
is	O
a	O
calcineurin	B
substrate	O
in	O
cells	O
.	O

Activation	O
and	O
expression	O
of	O
the	O
nuclear	B
factors	I
of	O
activated	O
T	O
cells	O
,	O
NFATp	B
and	O
NFATc	B
,	O
in	O
human	O
natural	O
killer	O
cells	O
:	O
regulation	O
upon	O
CD16	B
ligand	O
binding	O
.	O

The	O
results	O
of	O
supershift	O
assays	O
using	O
NFATp	B
-	I
and	I
NFATc	I
-	I
specific	I
antibodies	I
indicate	O
that	O
NK	O
cell	O
activation	O
early	O
after	O
CD16	B
ligand	O
binding	O
involves	O
primarily	O
,	O
if	O
not	O
exclusively	O
,	O
NFATp	B
,	O
and	O
Western	O
blot	O
analysis	O
shows	O
that	O
this	O
has	O
the	O
same	O
electrophoretic	O
mobility	O
(	O
approximately	O
120	O
kD	O
)	O
as	O
that	O
of	O
T	O
lymphocytes	O
.	O

Since	O
many	O
cytokines	B
that	O
activate	O
Jak	B
kinases	I
also	O
lead	O
to	O
the	O
tyrosine	O
phosphorylation	O
and	O
activation	O
of	O
members	O
of	O
the	O
Stat	B
family	I
of	O
transcription	B
factors	I
,	O
the	O
ability	O
of	O
IL	B
-	I
2	I
to	O
trigger	O
Stat	O
phosphorylation	O
was	O
examined	O
.	O

Exposure	O
of	O
activated	O
human	O
T	O
lymphocytes	O
or	O
of	O
a	O
natural	O
killer	O
cell	O
line	O
(	O
NKL	O
)	O
to	O
IL	B
-	I
2	I
leads	O
to	O
the	O
phosphorylation	O
of	O
Stat1	B
alpha	I
,	O
Stat1	O
beta	O
,	O
and	O
Stat3	B
,	O
as	O
well	O
as	O
of	O
two	O
Stat	B
-	I
related	I
proteins	I
,	O
p94	B
and	O
p95	B
.	O

These	O
Stat	B
proteins	I
were	O
found	O
to	O
translocate	O
to	O
the	O
nucleus	O
and	O
to	O
bind	O
to	O
a	O
specific	B
DNA	I
sequence	I
.	O

Results	O
indicated	O
that	O
(	O
i	O
)	O
constitutive	O
c	B
-	I
fos	I
transcript	I
levels	O
are	O
significantly	O
higher	O
in	O
patients	O
subsequently	O
responding	O
to	O
IFN	B
-	I
alpha	I
therapy	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
and	O
positively	O
correlated	O
with	O
the	O
proportion	O
of	O
lymphocytes	O
(	O
r	O
=	O
0	O
.	O
6895	O
,	O
p	O
<	O
0	O
.	O
01	O
)	O
and	O
negatively	O
with	O
the	O
proportion	O
of	O
immature	O
cells	O
(	O
r	O
=	O
-	O
0	O
.	O
568	O
,	O
p	O
<	O
0	O
.	O
01	O
)	O
contained	O
in	O
the	O
pbmc	O
preparations	O
tested	O
,	O
(	O
ii	O
)	O
constitutive	B
mRNA	I
levels	O
of	O
the	O
hybrid	B
bcr	I
/	I
abl	I
,	O
c	B
-	I
myc	I
and	O
p53	B
are	O
positively	O
correlated	O
with	O
each	O
other	O
,	O
but	O
failed	O
to	O
relate	O
to	O
disease	O
parameters	O
,	O
and	O
(	O
iii	O
)	O
acute	O
and	O
chronic	O
in	O
vivo	O
exposure	O
to	O
IFN	B
-	I
alpha	I
is	O
accompanied	O
by	O
upregulation	O
of	O
c	B
-	I
fos	I
and	O
downregulation	O
of	O
c	B
-	I
myc	I
mRNA	I
levels	O
in	O
responder	O
patients	O
.	O

In	O
parallel	O
experiments	O
,	O
IL	B
-	I
2	I
-	O
driven	O
proliferation	O
was	O
inhibited	O
significantly	O
.	O

Yet	O
,	O
IL	B
-	I
2	I
-	O
driven	O
proliferation	O
remained	O
profoundly	O
inhibited	O
,	O
suggesting	O
that	O
signaling	O
events	O
other	O
than	O
Jak3	B
/	B
Stat	I
activation	O
had	O
also	O
been	O
changed	O
following	O
SE	B
stimulation	O
.	O

In	O
contrast	O
to	O
hematopoietic	O
cells	O
,	O
I	O
kappa	O
B	O
alpha	O
-	O
/	O
-	O
embryonic	O
fibroblasts	O
show	O
minimal	O
constitutive	B
NF	I
-	I
kappa	I
B	I
,	O
as	O
well	O
as	O
normal	O
signal	O
-	O
dependent	O
NF	B
-	I
kappa	I
B	I
activation	O
that	O
is	O
concomitant	O
with	O
I	B
kappa	I
B	I
beta	I
degradation	O
.	O

Moreover	O
,	O
the	O
induction	O
of	O
both	O
Jak	B
1	I
and	I
3	I
,	O
and	O
STAT	B
5	I
activity	O
strongly	O
correlated	O
with	O
the	O
growth	O
-	O
promoting	O
effects	O
of	O
IL	B
-	I
7	I
,	O
suggesting	O
that	O
this	O
signal	O
transduction	O
mechanism	O
may	O
play	O
a	O
key	O
role	O
in	O
IL	B
-	I
7	I
-	O
induced	O
proliferation	O
.	O

Cytokine	B
-	O
modulating	O
activity	O
of	O
tepoxalin	O
,	O
a	O
new	O
potential	O
antirheumatic	O
.	O

In	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
stimulated	O
with	O
OKT3	O
/	O
PMA	O
,	O
tepoxalin	O
inhibited	O
lymphocyte	O
proliferation	O
with	O
an	O
IC50	O
of	O
6	O
microM	O
.	O

Cytotoxicity	O
was	O
not	O
demonstrated	O
at	O
these	O
concentrations	O
.	O

Tepoxalin	O
also	O
inhibits	O
the	O
activation	O
of	O
NF	B
kappa	I
B	I
,	O
a	O
transcription	B
factor	I
which	O
acts	O
on	O
several	O
cytokine	B
genes	I
.	O

Analysis	O
of	O
the	O
expression	O
of	O
human	B
I	I
kappa	I
B	I
alpha	I
protein	I
in	O
stable	O
transfectants	O
of	O
mouse	O
70Z	O
/	O
3	O
cells	O
shows	O
that	O
,	O
as	O
for	O
the	O
endogenous	O
murine	O
protein	O
,	O
exogenous	O
I	B
kappa	I
B	I
alpha	I
is	O
degraded	O
in	O
response	O
to	O
inducers	O
of	O
NF	B
-	I
kappa	I
B	I
activity	O
,	O
such	O
as	O
phorbol	O
myristate	O
acetate	O
or	O
lipopolysaccharide	O
.	O

By	O
expressing	O
mutant	O
forms	O
of	O
the	O
human	O
protein	O
in	O
this	O
cell	O
line	O
,	O
we	O
have	O
been	O
able	O
to	O
delineate	O
the	O
sequences	O
responsible	O
for	O
both	O
the	O
ligand	O
-	O
induced	O
phosphorylation	O
and	O
the	O
degradation	O
of	O
I	B
kappa	I
B	I
alpha	I
.	O

Interestingly	O
,	O
microtubule	B
disruption	O
also	O
decreased	O
monocyte	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
synthesis	O
,	O
not	O
by	O
decreasing	O
the	O
Vmax	O
of	O
monocyte	B
mitochondrial	I
1	I
alpha	I
-	I
hydroxylase	I
but	O
through	O
an	O
increase	O
in	O
the	O
Km	O
for	O
25	O
(	O
OH	O
)	O
2D3	O
.	O

We	O
examined	O
25	O
(	O
OH	O
)	O
D3	O
transport	O
.	O

Finally	O
,	O
by	O
studying	O
a	O
further	O
series	O
of	O
patients	O
,	O
we	O
could	O
confirm	O
that	O
the	O
decrease	O
in	O
Rap1	B
protein	I
expression	O
in	O
heart	O
failure	O
,	O
whatever	O
its	O
extent	O
,	O
was	O
variable	O
,	O
and	O
could	O
strictly	O
correlate	O
the	O
expression	O
of	O
Rap1	B
protein	I
with	O
the	O
stimulatory	O
effect	O
of	O
C	B
.	I
Sub	I
.	I
on	O
Ca2	O
+	O
transport	O
.	O

An	O
IRF	B
-	I
1	I
-	O
dependent	O
pathway	O
of	O
DNA	O
damage	O
-	O
induced	O
apoptosis	O
in	O
mitogen	O
-	O
activated	O
T	O
lymphocytes	O
.	O

Here	O
we	O
show	O
DNA	O
damage	O
-	O
induced	O
apoptosis	O
in	O
these	O
T	O
lymphocytes	O
is	O
dependent	O
on	O
the	O
antioncogenic	B
transcription	I
factor	I
interferon	I
regulatory	I
factor	I
(	B
IRF	I
)	I
-	I
1	I
.	O

Activation	O
through	O
the	O
Ca2	O
+	O
/	O
calcineurin	B
pathway	O
is	O
essential	O
to	O
the	O
transcription	O
of	O
many	O
cytokine	B
genes	I
.	O

Results	O
from	O
site	O
-	O
directed	O
mutations	O
and	O
electrophoretic	O
mobility	O
shift	O
assays	O
strongly	O
suggest	O
that	O
this	O
sequence	O
mediates	O
the	O
ionomycin	O
-	O
induced	O
activation	O
of	O
the	O
TCRG	B
enhancer	I
.	O

Our	O
studies	O
provide	O
an	O
explanation	O
for	O
a	O
previous	O
observation	O
that	O
TCRG	B
mRNA	I
levels	O
,	O
but	O
not	O
mRNA	O
levels	O
for	O
T	B
cell	I
receptor	I
alpha	I
and	I
-	I
beta	I
,	O
are	O
increased	O
by	O
ionomycin	O
treatment	O
.	O

Coexpression	O
of	O
NF	B
-	I
kappa	I
B	I
/	I
Rel	I
and	O
Sp1	B
transcription	B
factors	I
in	O
human	O
immunodeficiency	O
virus	O
1	O
-	O
induced	O
,	O
dendritic	O
cell	O
-	O
T	O
-	O
cell	O
syncytia	O
.	O

These	O
syncytia	O
lack	O
activated	O
cells	O
as	O
determined	O
by	O
an	O
absence	O
of	O
staining	O
for	O
Ki	O
-	O
67	O
cell	O
cycle	O
antigen	O
.	O

We	O
have	O
used	O
immunolabeling	O
,	O
Western	O
blot	O
analysis	O
,	O
and	O
electrophoretic	O
mobility	O
shift	O
and	O
supershift	O
assays	O
.	O

T	O
cells	O
lack	O
active	O
NF	B
-	I
kappa	I
B	I
but	O
express	O
Sp1	B
as	O
expected	O
.	O

Therefore	O
,	O
HIV	O
-	O
1	O
-	O
induced	O
cell	O
fusion	O
brings	O
together	O
factors	O
that	O
upregulate	O
virus	O
transcription	O
.	O

Deoxycholate	O
treatment	O
of	O
the	O
cytoplasmic	O
extract	O
prepared	O
from	O
cells	O
stimulated	O
by	O
TNF	B
-	I
alpha	I
in	O
the	O
presence	O
of	O
Cu2	O
+	O
resulted	O
in	O
the	O
release	O
of	O
NF	B
kappa	I
B	I
from	O
I	B
kappa	I
B	I
alpha	I
,	O
indicating	O
that	O
Cu2	O
+	O
interferes	O
with	O
the	O
dissociation	O
of	O
the	O
NF	B
kappa	I
B	I
-	I
I	I
kappa	I
B	I
complex	I
.	O

Neither	O
phosphorylation	O
nor	O
degradation	O
of	O
I	B
kappa	I
B	I
alpha	I
was	O
observed	O
upon	O
TNF	B
-	I
alpha	I
stimulation	O
in	O
the	O
presence	O
of	O
Cu2	O
+	O
.	O

Cloning	O
a	O
cDNA	B
from	O
human	O
NK	O
/	O
T	O
cells	O
which	O
codes	O
for	O
a	O
protein	O
with	O
high	O
proline	O
content	O
.	O

The	O
present	O
study	O
verified	O
the	O
ability	O
of	O
IL	B
-	I
2	I
to	O
cause	O
tyrosine	O
phosphorylation	O
and	O
activation	O
of	O
JAK1	B
and	O
JAK3	B
,	O
but	O
demonstrated	O
that	O
IL	B
-	I
2	I
stimulated	O
JAK3	B
to	O
a	O
significantly	O
larger	O
extent	O
than	O
JAK1	B
in	O
human	O
T	O
lymphocytes	O
and	O
the	O
YT	O
cell	O
line	O
.	O

Nonetheless	O
,	O
a	O
membrane	B
-	I
proximal	I
region	I
of	O
human	O
IL	B
-	I
2R	I
beta	I
(	O
Asn240	B
-	I
Leu335	I
)	O
was	O
critical	O
for	O
JAK3	B
activation	O
,	O
and	O
the	O
amount	O
of	O
JAK3	B
present	O
in	O
activated	O
IL	B
-	I
2	I
receptor	I
complexes	I
increased	O
with	O
time	O
,	O
suggesting	O
that	O
stabilization	O
of	O
JAK3	B
binding	O
to	O
the	O
receptor	B
complex	I
relies	O
on	O
both	O
IL	B
-	I
2R	I
beta	I
and	O
IL	B
-	I
2R	I
gamma	I
.	O

DHEA	O
binding	O
sites	O
were	O
examined	O
using	O
a	O
whole	O
-	O
cell	O
binding	O
assay	O
in	O
a	O
human	O
T	O
lymphoid	O
cell	O
line	O
,	O
PEER	O
,	O
revealing	O
that	O
a	O
single	O
class	O
of	O
high	O
-	O
affinity	O
binding	O
sites	O
for	O
DHEA	O
(	O
dissociation	O
constant	O
=	O
7	O
.	O
4	O
+	O
/	O
-	O
0	O
.	O
53	O
nmol	O
/	O
L	O
,	O
mean	O
+	O
/	O
-	O
SE	O
,	O
n	O
=	O
4	O
)	O
was	O
greatly	O
increased	O
when	O
treated	O
with	O
DHEA	O
,	O
phorbol	O
-	O
12	O
-	O
myristate	O
-	O
13	O
-	O
acetate	O
,	O
and	O
the	O
Ca2	O
+	O
ionophore	O
A23187	O
.	O

In	O
most	O
cases	O
,	O
the	O
transcriptional	B
factor	I
NF	B
-	I
kappa	I
B	I
is	O
a	O
heterodimer	B
consisting	O
of	O
two	O
subunits	O
,	O
p50	B
and	O
p65	B
,	O
which	O
are	O
encoded	O
by	O
two	O
distinct	O
genes	O
of	O
the	O
Rel	B
family	I
.	O

It	O
has	O
been	O
suggested	O
that	O
the	O
ubiquitin	B
-	B
proteasome	I
system	O
is	O
involved	O
in	O
the	O
process	O
;	O
however	O
,	O
the	O
specific	O
enzymes	B
involved	O
and	O
the	O
mechanism	O
of	O
limited	O
proteolysis	O
,	O
in	O
which	O
half	O
of	O
the	O
molecule	O
is	O
spared	O
,	O
have	O
been	O
obscure	O
.	O

This	O
novel	O
enzyme	O
is	O
distinct	O
from	O
E6	B
-	I
AP	I
,	O
the	O
p53	B
-	I
conjugating	I
ligase	I
,	O
and	O
from	O
E3	B
alpha	I
,	O
the	O
`	B
`	I
N	I
-	I
end	I
rule	I
'	I
'	I
ligase	I
.	O

Cycles	O
remained	O
ovulatory	O
.	O

Before	O
treatment	O
,	O
the	O
number	O
of	O
androgen	B
receptors	I
was	O
higher	O
in	O
the	O
luteal	O
than	O
in	O
the	O
follicular	O
phase	O
.	O

CONCLUSIONS	O
:	O
Flutamide	O
is	O
effective	O
in	O
the	O
treatment	O
of	O
hirsutism	O
but	O
requires	O
constant	O
surveillance	O
of	O
liver	O
function	O
.	O

An	O
increased	O
growth	O
rate	O
of	O
these	O
Jurkat	O
-	O
tat	O
cell	O
lines	O
as	O
compared	O
with	O
control	O
cell	O
lines	O
was	O
observed	O
.	O

To	O
identify	O
osteoblast	B
-	I
specific	I
cis	I
-	I
acting	I
elements	I
and	O
trans	B
-	I
acting	I
factors	I
,	O
we	O
initiated	O
an	O
analysis	O
of	O
the	O
promoter	B
of	O
a	O
mouse	B
osteocalcin	I
gene	I
,	O
an	O
osteoblast	B
-	I
specific	I
gene	I
.	O

By	O
DNA	O
cotransfection	O
experiments	O
,	O
we	O
also	O
demonstrate	O
that	O
AML	B
-	I
1B	I
can	O
increase	O
the	O
activity	O
of	O
a	O
short	O
osteocalcin	B
promoter	I
through	O
its	O
binding	O
to	O
OSE2	O
.	O

A	O
variety	O
of	O
other	O
cells	O
,	O
including	O
transformed	O
erythroid	O
precursors	O
,	O
do	O
not	O
have	O
IBR	B
but	O
a	O
factor	O
referred	O
to	O
as	O
IBF	B
(	O
68	O
to	O
70	O
kDa	O
)	O
that	O
recognizes	O
the	O
same	O
IBR	B
sites	O
.	O

IBR	B
is	O
a	O
503	B
-	I
amino	I
-	I
acid	I
-	I
long	I
acidic	I
protein	I
which	O
is	O
99	O
.	O
0	O
%	O
identical	O
to	O
the	O
recently	O
reported	O
human	B
NRF	I
-	I
1	I
/	I
alpha	I
-	I
Pal	I
factor	I
and	O
highly	O
related	O
to	O
the	O
invertebrate	O
transcription	B
factors	I
P3A2	B
and	O
erected	B
wing	I
gene	I
product	I
(	O
EWG	B
)	O
.	O

We	O
present	O
evidence	O
that	O
IBR	B
and	O
IBF	B
are	O
most	O
likely	O
identical	O
proteins	O
,	O
differing	O
in	O
their	O
degree	O
of	O
glycosylation	O
.	O

Mutation	O
of	O
Jak3	B
in	O
a	O
patient	O
with	O
SCID	O
:	O
essential	O
role	O
of	O
Jak3	B
in	O
lymphoid	O
development	O
.	O

A	O
girl	O
with	O
immunological	O
features	O
indistinguishable	O
from	O
those	O
of	O
XSCID	O
was	O
therefore	O
selected	O
for	O
analysis	O
.	O

The	O
lack	O
of	O
Jak3	B
expression	O
correlated	O
with	O
impaired	O
B	O
cell	O
signaling	O
,	O
as	O
demonstrated	O
by	O
the	O
inability	O
of	O
IL	B
-	I
4	I
to	O
activate	O
Stat6	B
in	O
the	O
EBV	O
-	O
transformed	O
cell	O
line	O
from	O
the	O
patient	O
.	O
These	O
observations	O
indicate	O
that	O
the	O
functions	O
of	O
gamma	B
c	I
are	O
dependent	O
on	O
Jak3	B
and	O
that	O
Jak3	B
is	O
essential	O
for	O
lymphoid	O
development	O
and	O
signaling	O
.	O

L	B
-	I
selectin	I
is	O
an	O
adhesion	O
molecule	O
of	O
the	O
selectin	O
family	O
that	O
mediates	O
the	O
initial	O
step	O
of	O
leukocyte	O
adhesion	O
to	O
vascular	O
endothelium	O
.	O

Upon	O
cellular	O
activation	O
,	O
expression	O
of	O
the	O
L	B
-	I
selectin	I
gene	I
is	O
downregulated	O
at	O
both	O
the	O
protein	O
and	O
mRNA	O
levels	O
.	O

The	O
induction	O
of	O
Tax	B
expression	O
in	O
JPX9	O
cells	O
resulted	O
in	O
about	O
a	O
twofold	O
increase	O
in	O
the	O
mRNA	B
expression	O
levels	O
compared	O
with	O
the	O
basal	O
level	O
.	O

These	O
results	O
indicated	O
that	O
ATL	O
cells	O
constitutively	O
overexpress	O
the	O
L	B
-	I
selectin	I
gene	I
that	O
can	O
be	O
transactivated	O
by	O
HTLV	O
-	O
1	O
Tax	B
.	O

Human	O
herpesvirus	O
6	O
,	O
a	O
predominantly	O
T	O
lymphotropic	O
virus	O
,	O
has	O
been	O
recently	O
shown	O
to	O
infect	O
some	O
EBV	O
-	O
positive	O
B	O
cell	O
lines	O
,	O
and	O
to	O
induce	O
in	O
them	O
the	O
activation	O
of	O
the	O
EBV	O
lytic	O
cycle	O
.	O

Here	O
we	O
have	O
confirmed	O
and	O
extended	O
such	O
observations	O
,	O
showing	O
that	O
(	O
1	O
)	O
this	O
phenomenon	O
is	O
restricted	O
to	O
the	O
variant	O
A	O
of	O
HHV	O
-	O
6	O
:	O
in	O
fact	O
two	O
isolates	O
belonging	O
to	O
the	O
HHV	O
-	O
6	O
variant	O
B	O
(	O
BA92	O
and	O
Z29	O
)	O
were	O
neither	O
able	O
to	O
infect	O
any	O
B	O
cell	O
line	O
,	O
independently	O
of	O
the	O
EBV	O
status	O
,	O
nor	O
to	O
induce	O
the	O
EBV	O
genome	O
expression	O
.	O

Evidence	O
for	O
normal	O
vitamin	B
D	I
receptor	I
messenger	I
ribonucleic	I
acid	I
and	O
genotype	O
in	O
absorptive	O
hypercalciuria	O
.	O

There	O
was	O
no	O
difference	O
between	O
the	O
distribution	O
of	O
the	O
VDR	B
alleles	O
in	O
the	O
patient	O
population	O
when	O
compared	O
with	O
the	O
normal	O
population	O
.	O

Sequence	O
analysis	O
of	O
the	O
5	B
'	I
-	I
flanking	I
region	I
of	O
the	O
CD69	B
gene	I
revealed	O
the	O
presence	O
of	O
a	O
potential	O
TATA	B
element	I
30	B
base	I
pairs	I
upstream	I
of	O
the	O
major	O
transcription	B
initiation	I
site	I
and	O
several	O
putative	O
binding	O
sequences	O
for	O
inducible	O
transcription	B
factors	I
(	O
NF	B
-	I
kappa	I
B	I
,	O
Egr	B
-	I
1	I
,	O
AP	B
-	I
1	I
)	O
,	O
which	O
might	O
mediate	O
the	O
inducible	O
expression	O
of	O
this	O
gene	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

The	O
exon	B
-	I
intron	I
structure	I
of	O
the	O
5	B
'	I
portion	I
of	O
the	O
thromboxane	B
receptor	I
gene	I
was	O
determined	O
initially	O
by	O
comparing	O
the	O
nucleotide	B
sequence	I
of	O
the	O
5	B
'	I
flanking	I
genomic	I
clone	I
with	O
that	O
of	O
a	O
novel	B
human	I
uterine	I
thromboxane	I
receptor	I
cDNA	I
that	O
extended	O
the	O
mRNA	B
141	B
bp	I
further	I
upstream	I
than	O
the	O
previously	B
identified	I
human	I
placental	I
cDNA	I
.	O

Promoter	O
function	O
of	O
the	O
5	B
'	I
flanking	I
region	I
of	O
the	O
thromboxane	B
receptor	I
gene	I
was	O
evaluated	O
by	O
transfection	O
of	O
thromboxane	B
receptor	I
gene	I
promoter	I
/	I
chloramphenicol	I
acetyltransferase	I
(	I
CAT	I
)	I
chimera	I
plasmids	I
into	O
platelet	O
-	O
like	O
K562	O
cells	O
.	O

These	O
studies	O
are	O
the	O
first	O
to	O
determine	O
the	O
structure	O
and	O
organization	O
of	O
the	O
5	O
'	O
end	O
of	O
the	O
thromboxane	B
receptor	I
gene	I
and	O
demonstrate	O
that	O
thromboxane	B
receptor	I
gene	I
expression	O
can	O
be	O
regulated	O
by	O
activation	O
of	O
protein	B
kinase	I
C	I
via	O
induction	O
of	O
an	O
AP	B
-	I
2	I
-	I
like	I
nuclear	I
factor	I
binding	O
to	O
upstream	B
promoter	I
elements	I
.	O

Proteins	O
in	O
the	O
first	O
group	O
contain	O
multiple	O
HMG	B
boxes	I
,	O
are	O
non	O
-	O
sequence	O
-	O
specific	O
,	O
and	O
recognize	O
structural	O
features	O
as	O
found	O
in	O
cruciform	B
DNA	I
and	O
cross	B
-	I
over	I
DNA	I
.	O

The	O
abundant	O
chromosomal	B
protein	I
HMG	B
-	I
1	I
belongs	O
to	O
this	O
subgroup	O
.	O

As	O
in	O
HMG1B	B
,	O
the	O
overall	O
structure	O
of	O
the	O
Sox	B
-	I
4	I
HMG	B
box	I
is	O
L	O
-	O
shaped	O
and	O
is	O
maintained	O
by	O
a	O
cluster	O
of	O
conserved	O
,	O
mainly	O
aromatic	O
residues	O
.	O

Nuclear	B
factor	I
kappa	I
B	I
(	O
NF	B
-	I
kappa	I
B	I
)	O
is	O
stored	O
in	O
the	O
cytoplasm	O
as	O
an	O
inactive	O
form	O
through	O
interaction	O
with	O
I	B
kappa	I
B	I
.	O

We	O
have	O
recently	O
reported	O
the	O
establishment	O
of	O
a	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-	O
dependent	O
cell	O
-	O
free	O
activation	O
system	O
of	O
NF	B
-	I
kappa	I
B	I
in	O
association	O
with	O
the	O
induction	O
of	O
I	B
kappa	I
B	I
alpha	I
phosphorylation	O
.	O

This	O
death	O
-	O
promoting	O
activity	O
of	O
Bik	B
can	O
be	O
suppressed	O
by	O
coexpression	O
of	O
Bcl	B
-	I
2	I
,	O
Bcl	B
-	I
XL	I
,	O
EBV	B
-	I
BHRF1	I
and	O
E1B	B
-	I
19	I
kDa	I
proteins	O
suggesting	O
that	O
Bik	B
may	O
be	O
a	O
common	O
target	O
for	O
both	O
cellular	B
and	I
viral	I
anti	I
-	I
apoptotic	I
proteins	I
.	O

TCF	B
-	I
1	I
mRNA	I
was	O
originally	O
found	O
to	O
be	O
expressed	O
in	O
a	O
T	O
cell	O
-	O
specific	O
fashion	O
within	O
a	O
set	O
of	O
human	O
and	O
mouse	O
cell	O
lines	O
.	O

In	O
contrast	O
,	O
expression	O
reportedly	O
occurs	O
in	O
multiple	O
nonlymphoid	O
tissues	O
during	O
murine	O
embryogenesis	O
.	O

Immunohistochemistry	O
on	O
a	O
panel	O
of	O
human	O
tissues	O
revealed	O
that	O
the	O
TCF	B
-	I
1	I
protein	I
was	O
found	O
exclusively	O
in	O
thymocytes	O
and	O
in	O
CD3	O
+	O
T	O
cells	O
in	O
peripheral	O
lymphoid	O
tissues	O
.	O

Signalling	O
via	O
CD28	B
of	O
human	O
naive	O
neonatal	O
T	O
lymphocytes	O
.	O

We	O
have	O
examined	O
the	O
role	O
of	O
CD28	B
in	O
modulating	O
the	O
'	O
naive	O
'	O
neonatal	O
T	O
cell	O
response	O
to	O
anti	B
-	I
CD2	I
-	O
mediated	O
activation	O
.	O

Costimulation	O
with	O
anti	B
-	I
CD28	I
MoAb	I
greatly	O
enhanced	O
the	O
proliferative	O
response	O
of	O
neonatal	O
T	O
cells	O
to	O
levels	O
equivalent	O
to	O
those	O
of	O
adult	O
T	O
cells	O
,	O
whereas	O
adult	O
T	O
cells	O
showed	O
only	O
slight	O
increases	O
.	O

Although	O
IL	B
-	I
2	I
secretion	O
was	O
increased	O
in	O
the	O
presence	O
of	O
anti	B
-	I
CD28	I
MoAb	I
,	O
neonatal	O
T	O
cell	O
IL	B
-	I
2	I
production	O
remained	O
lower	O
than	O
in	O
adults	O
.	O

TCL1	O
oncogene	O
activation	O
in	O
preleukemic	O
T	O
cells	O
from	O
a	O
case	O
of	O
ataxia	O
-	O
telangiectasia	O
.	O

We	O
have	O
analyzed	O
the	O
expression	O
of	O
TCL1	B
mRNA	I
and	O
protein	B
in	O
peripheral	O
blood	O
lymphocytes	O
(	O
PBLs	O
)	O
from	O
four	O
AT	O
cases	O
and	O
from	O
healthy	O
controls	O
.	O

We	O
found	O
that	O
the	O
TCL1	B
gene	I
was	O
overexpressed	O
in	O
the	O
PBLs	O
of	O
an	O
AT	O
patient	O
with	O
a	O
large	O
clonal	O
T	O
-	O
cell	O
population	O
exhibiting	O
the	O
t	O
(	O
14	O
;	O
14	O
)	O
translocation	O
but	O
not	O
in	O
the	O
lymphocytes	O
of	O
the	O
other	O
cases	O
.	O

Fluorescence	O
in	O
situ	O
hybridization	O
of	O
the	O
TCL1	B
genomic	I
locus	I
to	O
lymphocyte	O
metaphases	O
from	O
the	O
AT	O
patient	O
with	O
the	O
T	O
-	O
cell	O
clonal	O
expansion	O
showed	O
that	O
the	O
breakpoint	O
of	O
the	O
t	O
(	O
14	O
;	O
14	O
)	O
translocation	O
lies	O
within	O
the	O
TCL1	B
locus	I
and	O
is	O
accompanied	O
by	O
an	O
inverted	O
duplication	O
of	O
the	O
distal	B
part	I
of	O
chromosome	B
14	I
.	O

Deregulation	O
of	O
TCL1	B
is	O
the	O
first	O
event	O
in	O
the	O
initiation	O
of	O
malignancy	O
in	O
these	O
types	O
of	O
leukemias	O
and	O
represents	O
a	O
potential	O
tool	O
for	O
clinical	O
evaluation	O
.	O

Inhibition	O
of	O
endogenous	B
C	I
/	I
EBP	I
proteins	I
,	O
using	O
either	O
an	O
excess	O
of	O
C	B
/	I
EBP	I
binding	I
sites	I
or	O
a	O
trans	B
-	I
dominant	I
negative	I
inhibitor	I
,	O
demonstrated	O
that	O
C	B
/	I
EBP	I
proteins	I
are	O
required	O
for	O
basal	O
and	O
activated	O
levels	O
of	O
HIV	B
-	I
1	I
LTR	I
transcription	O
in	O
the	O
promonocytic	O
cell	O
line	O
U937	O
.	O

Northern	O
(	O
RNA	O
)	O
blots	O
and	O
binding	O
assays	O
showed	O
that	O
NF	B
-	I
IL6	I
is	O
the	O
only	O
known	O
C	B
/	I
EBP	I
family	I
member	I
which	O
is	O
increased	O
when	O
U937	O
cells	O
are	O
activated	O
.	O

However	O
,	O
transcription	O
from	O
crippled	B
HIV	I
-	I
1	I
LTRs	I
lacking	O
C	B
/	I
EBP	I
sites	I
can	O
still	O
be	O
induced	O
following	O
activation	O
of	O
U937	O
cells	O
.	O

Since	O
expression	O
of	O
the	O
viruses	O
is	O
in	O
large	O
part	O
regulated	O
by	O
the	O
sequence	B
elements	I
in	O
their	O
long	B
terminal	I
repeats	I
(	O
LTRs	B
)	O
,	O
this	O
study	O
was	O
directed	O
to	O
an	O
analysis	O
of	O
the	O
regulatory	B
elements	I
in	O
the	O
HIV	B
-	I
2	I
LTR	I
.	O

The	O
HIV	B
-	I
2	I
LTR	I
was	O
found	O
to	O
contain	O
two	O
enhancers	B
.	O

We	O
report	O
here	O
that	O
both	O
NF	B
-	I
M	I
-	I
dependent	I
promoter	I
constructs	I
and	O
resident	O
genes	O
could	O
be	O
activated	O
by	O
addition	O
of	O
beta	O
-	O
estradiol	O
to	O
the	O
NF	O
-	O
M	O
-	O
estrogen	O
receptor	O
expressing	O
progenitors	O
.	O

In	O
addition	O
to	O
the	O
onset	O
of	O
differentiation	O
,	O
cell	O
death	O
was	O
induced	O
with	O
typical	O
apoptotic	O
features	O
.	O

A	O
comparison	O
with	O
the	O
Stat	B
proteins	I
induced	O
by	O
interferon	B
-	I
gamma	I
,	O
PRL	B
,	O
and	O
IL	B
-	I
6	I
in	O
T47D	O
mammary	O
tumor	O
cells	O
was	O
made	O
.	O

Activation	O
of	O
a	O
second	O
protein	O
related	O
to	O
Stat1	B
was	O
also	O
observed	O
.	O

Granulocyte	B
-	I
macrophage	I
colony	I
-	I
stimulating	I
factor	I
(	O
GM	B
-	I
CSF	I
)	O
is	O
one	O
such	O
cytokine	B
whose	O
increased	O
expression	O
results	O
partly	O
from	O
increases	O
in	O
transcription	O
.	O

A	O
number	O
of	O
the	O
ETS	B
family	I
of	O
transcription	B
factors	I
are	O
expressed	O
in	O
T	O
cells	O
,	O
including	O
ETS1	B
and	O
ELF1	B
.	O

Other	O
unidentified	O
ETS	B
-	I
like	I
factors	I
present	O
in	O
Jurkat	O
cells	O
are	O
also	O
capable	O
of	O
binding	O
GM5	B
.	O

No	O
up	O
-	O
regulation	O
of	O
hTR	B
beta	I
1	I
was	O
seen	O
in	O
hypothyroid	O
relative	O
to	O
euthyroid	O
patients	O
.	O

Using	O
varying	O
conditions	O
,	O
three	O
distinct	O
complexes	O
were	O
shown	O
to	O
interact	O
specifically	O
with	O
the	O
NIP	B
region	I
,	O
although	O
only	O
one	O
correlates	O
with	O
repressor	O
activity	O
.	O

DNA	O
binding	O
specificity	O
of	O
complex	O
3	O
overlaps	O
with	O
that	O
of	O
upstream	B
stimulatory	I
factor	I
but	O
is	O
clearly	O
distinct	O
.	O

Functional	O
specificity	O
for	O
repression	O
matches	O
the	O
DNA	O
binding	O
specificity	O
of	O
complex	B
3	I
;	O
both	O
repressor	O
activity	O
and	O
complex	B
3	I
binding	O
require	O
the	O
consensus	B
sequence	I
CTCACNTNC	O
.	O

The	O
hematopoietic	B
transcription	I
factor	I
PU	B
.	I
1	I
is	O
downregulated	O
in	O
human	O
multiple	O
myeloma	O
cell	O
lines	O
.	O

PU	B
.	I
1	I
is	O
a	O
hematopoietic	B
transcription	I
factor	I
belonging	O
to	O
the	O
Ets	B
-	I
family	I
.	O

It	O
binds	O
the	O
so	O
-	O
called	O
Pu	B
box	I
,	O
an	O
important	O
tissue	B
-	I
specific	I
regulatory	I
DNA	I
element	I
present	O
in	O
a	O
number	O
of	O
genes	O
expressed	O
in	O
these	O
cell	O
lineages	O
.	O

We	O
have	O
analyzed	O
the	O
expression	O
and	O
activity	O
of	O
PU	B
.	I
1	I
during	O
human	O
B	O
-	O
cell	O
development	O
using	O
a	O
panel	O
of	O
B	O
-	O
cell	O
lines	O
representing	O
different	O
stages	O
of	O
maturation	O
,	O
from	O
early	O
precursors	O
to	O
differentiated	O
plasma	O
cells	O
.	O

The	O
effects	O
of	O
CsA	O
on	O
endothelial	O
cells	O
were	O
also	O
detected	O
at	O
the	O
chromatin	B
structure	O
level	O
,	O
as	O
DNasel	B
hypersensitive	I
sites	I
within	O
both	O
the	O
GM	B
-	I
CSF	I
enhancer	O
and	O
the	O
E	B
-	I
selectin	I
promoter	I
were	O
suppressed	O
by	O
CsA	O
.	O

Protein	O
phosphorylation	O
has	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
these	O
two	O
factors	O
:	O
(	O
1	O
)	O
it	O
induces	O
the	O
transactivating	O
capacity	O
of	O
the	O
AP	B
-	I
1	I
protein	I
c	B
-	I
Jun	I
;	O
and	O
(	O
2	O
)	O
it	O
is	O
involved	O
in	O
the	O
release	O
of	O
the	O
cytoplasmic	B
inhibitor	I
,	O
I	B
kappa	I
B	I
,	O
from	O
NF	B
-	I
kappa	I
B	I
,	O
allowing	O
translocation	O
of	O
the	O
latter	O
into	O
the	O
nucleus	O
.	O

We	O
have	O
recently	O
shown	O
that	O
both	O
phosphorylation	O
processes	O
require	O
T	O
-	O
cell	O
costimulation	O
.	O

According	O
to	O
our	O
results	O
,	O
however	O
,	O
the	O
kinases	O
responsible	O
for	O
the	O
two	O
processes	O
are	O
distinct	O
entities	O
.	O

We	O
,	O
therefore	O
,	O
propose	O
the	O
activation	O
scheme	O
presented	O
in	O
FIGURE	O
3	O
for	O
T	O
-	O
cell	O
costimulation	O
.	O

Integration	O
of	O
the	O
signals	O
generated	O
by	O
TCR	B
and	O
CD28	B
engagement	O
occurs	O
along	O
this	O
pathway	O
,	O
which	O
then	O
bifurcates	O
to	O
induce	O
I	B
kappa	I
B	I
phosphorylation	O
and	O
NF	B
-	I
kappa	I
B	I
activation	O
on	O
the	O
one	O
hand	O
,	O
and	O
JNK	B
activation	O
and	O
c	B
-	I
Jun	I
phosphorylation	O
on	O
the	O
other	O
.	O

We	O
are	O
currently	O
engaged	O
in	O
defining	O
where	O
the	O
two	O
signals	O
integrate	O
along	O
the	O
AP	B
-	I
1	I
/	O
NF	B
-	I
kappa	I
B	I
pathway	O
.	O

Enhancement	O
of	O
HIV	O
-	O
1	O
replication	O
is	O
related	O
in	O
part	O
to	O
increased	O
DNA	O
-	O
binding	O
activity	O
of	O
cellular	B
transcription	I
factors	I
such	O
as	O
NF	B
-	I
kappa	I
B	I
.	O

Increased	O
intracellular	O
stores	O
of	O
latent	B
NF	I
-	I
kappa	I
B	I
may	O
also	O
result	O
in	O
rapid	O
inducibility	O
of	O
NF	B
-	I
kappa	I
B	I
-	O
dependent	O
cytokine	B
gene	O
expression	O
.	O

Elevated	O
levels	O
of	O
several	O
inflammatory	B
cytokines	I
have	O
been	O
detected	O
in	O
the	O
sera	O
of	O
HIV	O
-	O
1	O
-	O
infected	O
individuals	O
.	O

We	O
measured	O
steroid	O
mediated	O
lysis	O
,	O
receptor	O
number	O
and	O
induction	O
of	O
glutamine	B
synthetase	I
in	O
the	O
transfected	O
cells	O
.	O

The	O
DNA	B
binding	I
region	I
specifying	O
high	O
affinity	O
for	O
GRE	B
sites	I
is	O
required	O
.	O

Our	O
data	O
support	O
the	O
view	O
that	O
steroid	O
-	O
mediated	O
cell	O
death	O
occurs	O
by	O
a	O
process	O
requiring	O
direct	O
interaction	O
of	O
steroid	B
-	I
receptor	I
complexes	I
with	O
the	O
genome	O
.	O

Full	O
-	O
length	O
cDNAs	B
and	O
genomic	B
clones	I
were	O
isolated	O
,	O
and	O
the	O
gene	O
structure	O
was	O
determined	O
.	O
Comparison	O
of	O
the	O
deduced	O
amino	O
acids	O
shows	O
88	O
%	O
sequence	O
identity	O
between	O
mouse	B
and	I
human	I
BOB	I
.	I
1	I
/	I
OBF	I
.	I
1	I
.	O

The	O
NH2	B
-	I
terminal	I
126	I
amino	I
acids	I
of	O
BOB	B
.	I
1	I
/	I
OBF	I
.	I
1	I
are	O
both	O
essential	O
and	O
sufficient	O
for	O
interaction	O
with	O
the	O
POU	B
domains	I
of	O
either	O
Oct1	B
or	O
Oct2	B
.	O

As	O
this	O
phosphorylation	O
was	O
independent	O
of	O
protein	B
kinase	I
C	I
activity	O
,	O
we	O
tested	O
whether	O
a	O
calcium	B
/	I
calmodulin	I
-	I
dependent	I
protein	I
kinase	I
(	O
CaM	B
kinase	I
)	O
might	O
phosphorylate	O
the	O
Ets	B
-	I
1	I
protein	I
after	O
elevation	O
of	O
intracellular	O
free	O
calcium	O
concentrations	O
.	O

Furthermore	O
,	O
we	O
identified	O
a	O
repression	O
domain	O
at	O
the	O
N	O
-	O
terminus	O
of	O
Oct	B
-	I
2a	I
.	O

Whereas	O
the	O
mechanism	O
of	O
nonopsonic	O
phagocytosis	O
of	O
Pseudomonas	O
aeruginosa	O
has	O
been	O
described	O
,	O
the	O
bacterial	O
ligands	O
required	O
are	O
poorly	O
understood	O
.	O

GP	B
Ib	I
alpha	I
promoter	I
activity	O
was	O
evaluated	O
by	O
transfection	O
of	O
human	O
erythroleukemia	O
cells	O
with	O
reporter	O
plasmids	O
coding	O
for	O
the	O
enzyme	B
,	O
luciferase	B
.	O

The	O
results	O
define	O
essential	O
cis	B
-	I
acting	I
elements	I
responsible	O
for	O
the	O
expression	O
of	O
GP	B
Ib	I
alpha	I
and	O
provide	O
insights	O
into	O
molecular	O
events	O
coinciding	O
with	O
the	O
release	O
of	O
normal	O
platelets	O
into	O
the	O
bloodstream	O
.	O

CD30	B
is	O
a	O
recently	O
described	O
member	O
of	O
the	O
tumor	B
necrosis	I
factor	I
/	I
nerve	I
growth	I
factor	I
receptor	I
superfamily	I
.	O

In	O
all	O
cell	O
lines	O
investigated	O
,	O
the	O
NF	B
-	I
kappa	I
B	I
complexes	I
induced	O
following	O
CD30	B
engagement	O
were	O
shown	O
to	O
contain	O
p50	B
NF	I
-	I
kappa	I
B1	I
,	O
p65	B
RelA	I
,	O
and	O
possibly	O
other	O
transcription	B
factors	I
.	O

Estrogen	B
and	O
progesterone	B
receptors	I
in	O
vernal	O
keratoconjunctivitis	O
.	O

RESULTS	O
:	O
Both	O
the	O
epithelium	O
and	O
subepithelium	O
of	O
the	O
tarsal	O
and	O
bulbar	O
conjunctiva	O
of	O
patients	O
with	O
VKC	O
,	O
but	O
not	O
those	O
of	O
four	O
nonatopic	O
control	O
subjects	O
,	O
showed	O
intense	O
positive	O
staining	O
for	O
estrogen	O
and	O
progesterone	B
receptors	I
.	O

The	O
expression	O
of	O
MHC	B
class	I
II	I
genes	I
in	O
mouse	O
T	O
cells	O
can	O
be	O
reconstituted	O
upon	O
transfection	O
with	O
the	O
human	B
CIITA	I
cDNA	I
.	O

Because	O
HLA	B
class	I
II	I
molecules	I
present	O
antigen	O
to	O
T	B
cell	I
receptors	I
(	O
TCRs	B
)	O
,	O
we	O
have	O
searched	O
for	O
a	O
TCR	B
gene	I
associated	O
with	O
the	O
production	O
of	O
anti	B
-	I
Ro	I
(	I
SSA	I
)	I
antibodies	I
.	O

This	O
RFLP	B
pair	I
occurs	O
in	O
76	O
%	O
of	O
patients	O
with	O
Ro	B
(	I
SSA	I
)	I
precipitins	O
,	O
84	O
%	O
of	O
anti	O
-	O
Ro	B
(	I
SSA	I
)	I
-	O
positive	O
patients	O
lacking	O
La	B
(	I
SSB	I
)	I
precipitins	B
,	O
but	O
only	O
41	O
%	O
of	O
the	O
patients	O
lacking	O
both	O
precipitins	B
(	O
P	O
=	O
0	O
.	O
0004	O
)	O
.	O

The	O
majority	O
of	O
patients	O
who	O
have	O
these	O
RFLPs	B
and	O
HLA	B
class	I
II	I
antigens	I
previously	O
associated	O
with	O
the	O
anti	O
-	O
Ro	B
(	I
SSA	I
)	I
response	O
make	O
this	O
antibody	O
,	O
suggesting	O
that	O
interactions	O
between	O
products	O
of	O
these	O
loci	B
occur	I
in	O
response	O
to	O
Ro	B
(	I
SSA	I
)	I
.	O

However	O
,	O
while	O
IL2	B
expression	O
requires	O
the	O
contribution	O
of	O
Ca	O
(	O
2	O
+	O
)	O
-	O
and	O
protein	B
kinase	I
C	I
-	O
dependent	O
signals	O
,	O
we	O
report	O
that	O
activation	O
of	O
human	B
IL4	I
transcription	O
through	O
the	O
Ca	O
(	O
2	O
+	O
)	O
-	O
dependent	O
pathway	O
is	O
diminished	O
by	O
protein	B
kinase	I
C	I
stimulation	O
in	O
Jurkat	O
T	O
cells	O
.	O

Human	B
IL4	I
promoter	I
-	O
mediated	O
transcription	O
is	O
downregulated	O
in	O
Jurkat	O
cells	O
stimulated	O
with	O
the	O
NF	B
-	I
kappa	I
B	I
-	I
activating	I
cytokine	I
tumor	B
necrosis	I
factor	I
alpha	I
and	O
suppressed	O
in	O
RelA	O
-	O
overexpressing	O
cells	O
.	O

Many	O
cytokines	B
activate	O
signal	B
transducer	I
and	I
activation	I
of	I
transcription	I
(	I
STAT	I
)	I
transcription	I
factors	I
,	O
which	O
,	O
in	O
turn	O
,	O
activate	O
transcription	O
of	O
inflammatory	O
effector	O
genes	O
.	O

The	O
present	O
study	O
demonstrates	O
that	O
triggering	O
of	O
complement	B
receptors	I
CR1	B
(	O
CD35	B
)	O
and	O
CR3	B
(	O
CD11b	B
/	I
CD18	I
)	O
enhances	O
viral	O
replication	O
in	O
HIV	O
-	O
infected	O
human	O
monocytic	O
cells	O
.	O

Monocytic	O
cell	O
lines	O
and	O
normal	O
peripheral	O
blood	O
monocytes	O
were	O
infected	O
with	O
HIV	O
-	O
1	O
in	O
vitro	O
and	O
cultured	O
in	O
the	O
presence	O
or	O
absence	O
of	O
F	B
(	I
ab	I
'	I
)	I
2	I
fragments	I
of	O
monoclonal	B
anti	I
-	I
CR1	I
or	O
anti	B
-	I
CR3	I
Abs	I
or	O
with	O
C3	B
fragments	I
.	O

In	O
contrast	O
,	O
in	O
cells	O
infected	O
with	O
L	O
.	O
donovani	O
,	O
tyrosine	O
phosphorylation	O
of	O
Jak1	B
,	O
Jak2	B
,	O
and	O
Stat1	B
was	O
markedly	O
impaired	O
.	O

Unresponsiveness	O
to	O
gamma	B
interferon	I
for	O
activation	O
of	O
this	O
pathway	O
may	O
explain	O
impaired	O
transcriptional	O
responses	O
in	O
leishmania	O
-	O
infected	O
cells	O
.	O

Mutually	O
exclusive	O
interaction	O
of	O
a	O
novel	O
matrix	B
attachment	I
region	I
binding	I
protein	I
and	O
the	O
NF	B
-	I
muNR	I
enhancer	I
repressor	I
.	O

Implications	O
for	O
regulation	O
of	O
immunoglobulin	B
heavy	I
chain	I
expression	O
.	O

To	O
understand	O
the	O
role	O
of	O
MARs	B
in	O
IgH	B
enhancer	I
regulation	O
,	O
we	O
have	O
identified	O
a	O
novel	O
MAR	B
-	I
binding	I
protein	I
,	O
MAR	B
-	I
BP1	I
,	O
from	O
soluble	O
nuclear	O
matrix	O
preparations	O
based	O
on	O
its	O
ability	O
to	O
bind	O
to	O
the	O
MARs	B
associated	O
with	O
the	O
IgH	B
enhancer	I
.	O

Purified	O
MAR	B
-	I
BP1	I
migrates	O
as	O
a	O
33	B
-	I
kDa	I
protein	I
,	O
and	O
it	O
can	O
be	O
found	O
in	O
nuclear	O
matrix	O
preparations	O
from	O
a	O
number	O
of	O
different	O
types	O
of	O
lymphoid	O
cell	O
lines	O
.	O

The	O
GM	B
-	I
CSF	I
receptor	I
alpha	I
promoter	I
contains	O
an	O
important	O
functional	O
site	O
between	O
positions	O
-	O
53	O
and	O
-	O
41	O
as	O
identified	O
by	O
deletion	O
analysis	O
of	O
reporter	B
constructs	I
.	O

C	B
/	I
EBP	I
alpha	I
is	O
the	O
major	O
CCAAT	B
/	I
enhancer	I
-	I
binding	I
protein	I
(	O
C	B
/	I
EBP	I
)	O
form	O
binding	O
to	O
this	O
site	O
in	O
nuclear	O
extracts	O
of	O
U937	O
cells	O
.	O

Tyrosine	O
phosphorylation	O
of	O
this	O
protein	O
could	O
also	O
be	O
induced	O
in	O
Balb	O
/	O
c3T3	O
cells	O
using	O
a	O
supernatant	O
from	O
the	O
B	O
line	O
,	O
which	O
was	O
associated	O
with	O
induction	O
of	O
cell	O
proliferation	O
.	O

Regulation	O
of	O
c	B
-	I
jun	I
mRNA	I
expression	O
by	O
hydroxyurea	O
in	O
human	O
K562	O
cells	O
during	O
erythroid	O
differentiation	O
[	O
published	O
erratum	O
appears	O
in	O
Biochim	O
Biophys	O
Acta	O
1995	O
Dec	O
27	O
;	O
1264	O
(	O
3	O
)	O
:	O
409	O
]	O

In	O
addition	O
,	O
HU	O
stimulates	O
the	O
synthesis	O
of	O
fetal	B
hemoglobin	I
in	O
sickle	O
cell	O
anemia	O
patients	O
.	O

HU	O
induced	O
a	O
dose	O
-	O
dependent	O
stimulation	O
of	O
c	B
-	I
jun	I
synthesis	O
.	O

Glucocorticoid	O
effects	O
were	O
assessed	O
in	O
vivo	O
by	O
depletion	O
of	O
endogenous	O
glucocorticoids	O
after	O
oral	O
administration	O
of	O
1	O
.	O
5	O
g	O
metyrapone	O
(	O
MET	O
)	O
and	O
subsequent	O
glucocorticoid	O
replacement	O
,	O
and	O
in	O
vitro	O
by	O
incubation	O
of	O
the	O
cells	O
with	O
different	O
doses	O
of	O
dexamethasone	O
(	O
DEX	O
)	O
.	O

In	O
comparison	O
,	O
isolated	O
nuclei	O
of	O
human	O
lymphocytes	O
in	O
which	O
no	O
need	O
for	O
the	O
expression	O
of	O
this	O
gene	O
exists	O
,	O
show	O
barely	O
hybridization	O
signals	O
.	O

Because	O
NF	B
-	I
kappa	I
B	I
activates	O
many	O
immunoregulatory	B
genes	I
in	O
response	O
to	O
pro	O
-	O
inflammatory	O
stimuli	O
,	O
the	O
inhibition	O
of	O
its	O
activity	O
can	O
be	O
a	O
major	O
component	O
of	O
the	O
anti	O
-	O
inflammatory	O
activity	O
of	O
glucocorticoids	O
.	O

Transcriptional	O
repression	O
of	O
the	O
interleukin	B
-	I
2	I
gene	I
by	O
vitamin	O
D3	O
:	O
direct	O
inhibition	O
of	O
NFATp	B
/	I
AP	I
-	I
1	I
complex	I
formation	O
by	O
a	O
nuclear	B
hormone	I
receptor	I
.	O

We	O
therefore	O
examined	O
vitamin	O
D3	O
-	O
mediated	O
repression	O
of	O
activated	O
IL	B
-	I
2	I
expression	O
by	O
cotransfecting	O
Jurkat	O
cells	O
with	O
IL	B
-	I
2	I
promoter	I
/	I
reporter	I
constructs	I
and	O
a	O
VDR	B
overexpression	I
vector	I
and	O
by	O
DNA	O
binding	O
.	O

The	O
5	B
'	I
flanking	I
DNA	I
also	O
contains	O
a	O
cluster	O
of	O
three	O
binding	B
sites	I
for	O
the	O
GATA	B
family	I
of	O
transcription	B
factors	I
.	O

This	O
effect	O
is	O
thought	O
to	O
be	O
largely	O
mediated	O
through	O
inactivation	O
of	O
the	O
phosphatase	O
calcineurin	B
,	O
which	O
in	O
turn	O
inhibits	O
translocation	O
of	O
an	O
NFAT	B
component	O
to	O
the	O
nucleus	O
.	O

These	O
data	O
point	O
to	O
a	O
new	O
mechanism	O
for	O
CsA	O
-	O
sensitive	O
regulation	O
of	O
NFATp	B
in	O
which	O
dephosphorylation	O
is	O
critical	O
for	O
DNA	O
binding	O
.	O

Cysteamine	O
treatment	O
inhibited	O
both	O
expression	O
of	O
the	O
IL	B
-	I
2	I
mRNA	I
and	O
secretion	O
of	O
IL	B
-	I
2	I
into	O
the	O
culture	O
medium	O
.	O

The	O
mean	O
dissociation	O
constant	O
(	O
Kd	O
)	O
was	O
similar	O
in	O
both	O
sexes	O
(	O
1	O
.	O
35	O
+	O
/	O
-	O
0	O
.	O
70	O
x	O
10	O
(	O
-	O
10	O
)	O
M	O
in	O
males	O
,	O
1	O
.	O
13	O
+	O
/	O
-	O
0	O
.	O
66	O
x	O
10	O
(	O
-	O
10	O
)	O
M	O
in	O
females	O
)	O
,	O
but	O
the	O
concentration	O
of	O
binding	O
sites	O
(	O
Nmax	O
)	O
was	O
significantly	O
lower	O
in	O
females	O
(	O
2	O
.	O
32	O
+	O
/	O
-	O
0	O
.	O
92	O
fmol	O
/	O
10	O
(	O
7	O
)	O
PBMC	O
vs	O
4	O
.	O
43	O
+	O
/	O
-	O
1	O
.	O
38	O
fmol	O
/	O
10	O
(	O
7	O
)	O
PBMC	O
in	O
males	O
;	O
p	O
=	O
0	O
.	O
0001	O
)	O
.	O

Neither	O
Kd	O
nor	O
Nmax	O
were	O
significantly	O
correlated	O
with	O
age	O
.	O

We	O
examined	O
by	O
northern	O
hybridization	O
the	O
expression	O
of	O
Id2	B
and	I
Id3	I
mRNA	I
in	O
human	O
leukemia	O
/	O
lymphoma	O
lines	O
and	O
patient	O
samples	O
,	O
as	O
well	O
as	O
resting	O
and	O
activated	O
normal	O
human	O
lymphocytes	O
from	O
peripheral	O
blood	O
(	O
PBL	O
)	O
.	O

The	O
Id2	B
mRNA	I
was	O
abundantly	O
expressed	O
in	O
5	O
/	O
12	O
T	O
-	O
cell	O
and	O
3	O
/	O
4	O
B	O
-	O
cell	O
lines	O
,	O
and	O
Id3	B
mRNA	I
was	O
detected	O
in	O
4	O
/	O
12	O
T	O
-	O
cell	O
and	O
3	O
/	O
4	O
B	O
-	O
cell	O
lines	O
.	O

In	O
addition	O
,	O
resting	O
PBL	O
constitutively	O
expressed	O
prominent	O
levels	O
of	O
Id2	B
mRNA	I
,	O
but	O
not	O
Id3	B
mRNA	I
.	O

Salicylates	O
inhibit	O
lipopolysaccharide	O
-	O
induced	O
transcriptional	O
activation	O
of	O
the	O
tissue	O
factor	O
gene	O
in	O
human	O
monocytic	O
cells	O
.	O

Here	O
,	O
we	O
report	O
that	O
a	O
family	O
of	O
anti	O
-	O
inflammatory	O
agents	O
,	O
known	O
as	O
the	O
salicylates	O
,	O
inhibited	O
LPS	O
induction	O
of	O
TF	O
activity	O
and	O
TF	B
gene	I
transcription	O
in	O
human	O
monocytes	O
and	O
monocytic	O
THP	O
-	O
1	O
cells	O
at	O
clinically	O
relevant	O
doses	O
.	O

Furthermore	O
,	O
sodium	O
salicylate	O
blocked	O
the	O
LPS	O
-	O
induced	O
proteolytic	O
degradation	O
of	O
I	B
kappa	I
B	I
alpha	I
,	O
which	O
prevented	O
the	O
nuclear	O
translocation	O
of	O
c	B
-	I
Rel	I
/	I
p65	I
heterodimers	I
.	O

In	O
contrast	O
,	O
two	O
other	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
drugs	O
,	O
ibuprofen	O
and	O
indomethacin	O
,	O
did	O
not	O
inhibit	O
LPS	O
induction	O
of	O
the	O
TF	B
gene	I
.	O

Critical	O
role	O
for	O
IL	B
-	I
6	I
.	O

The	O
T	O
cell	O
activation	O
is	O
initiated	O
by	O
interaction	O
of	O
specific	O
Ags	B
with	O
TCR	B
,	O
followed	O
by	O
activation	O
of	O
intracellular	O
biochemical	O
events	O
leading	O
to	O
activation	O
of	O
several	O
genes	O
.	O

As	O
neutralizing	B
anti	I
-	I
IL	I
-	I
6	I
Abs	I
effectively	O
down	O
-	O
regulated	O
the	O
early	O
induction	O
of	O
STAT	B
proteins	I
and	O
as	O
exogenously	O
added	O
IL	B
-	I
6	I
rapidly	O
activated	O
DNA	O
binding	O
similar	O
to	O
TCR	B
-	O
mediated	O
bindings	O
,	O
it	O
can	O
be	O
concluded	O
that	O
IL	B
-	I
6	I
is	O
the	O
factor	O
responsible	O
for	O
the	O
activation	O
of	O
STAT	B
proteins	I
in	O
a	O
primary	O
T	O
cell	O
response	O
.	O

Our	O
data	O
suggest	O
an	O
involvement	O
of	O
BLR2	B
in	O
the	O
regulation	O
of	O
migration	O
in	O
activated	O
lymphocytes	O
and	O
in	O
viral	O
pathogenesis	O
.	O

A	O
central	O
role	O
for	O
a	O
single	B
c	I
-	I
Myb	I
binding	I
site	I
in	O
a	O
thymic	B
locus	I
control	I
region	I
.	O

We	O
now	O
show	O
that	O
the	O
core	O
contains	O
a	O
single	O
critical	O
c	B
-	I
Myb	I
binding	I
site	I
.	O

c	B
-	I
Myb	I
protein	I
was	O
strongly	O
evident	O
in	O
T	O
lymphoblasts	O
in	O
which	O
the	O
enhancer	B
was	O
active	O
and	O
was	O
localized	O
within	O
discrete	O
nuclear	O
structures	O
.	O

Lymphoid	B
enhancer	I
-	I
binding	I
factor	I
1	I
(	O
LEF	B
-	I
1	I
)	O
is	O
a	O
regulatory	B
high	I
mobility	I
group	I
(	I
HMG	I
)	I
protein	I
that	O
activates	O
the	O
T	B
cell	I
receptor	I
alpha	I
(	I
TCR	I
alpha	I
)	I
enhancer	I
in	O
a	O
context	O
-	O
restricted	O
manner	O
in	O
T	O
cells	O
.	O

We	O
conclude	O
that	O
transcription	O
activation	O
by	O
LEF	B
-	I
1	I
in	O
vitro	O
is	O
a	O
chromatin	B
-	O
dependent	O
process	O
that	O
requires	O
a	O
functional	O
trans	B
-	I
activation	I
domain	I
in	O
addition	O
to	O
the	O
HMG	B
domain	I
.	O

HIV	B
-	I
1	I
envelope	I
glycoproteins	I
induce	O
activation	O
of	O
activated	O
protein	B
-	I
1	I
in	O
CD4	O
+	O
T	O
cells	O
[	O
published	O
erratum	O
appears	O
in	O
J	O
Biol	O
Chem	O
1995	O
Dec	O
1	O
;	O
270	O
(	O
48	O
)	O
:	O
29038	O
]	O

Immunoprecipitation	O
of	O
the	O
gp	B
160	I
-	O
induced	O
nuclear	O
extracts	O
with	O
polyclonal	B
antibodies	I
to	O
Fos	B
and	O
Jun	B
proteins	I
indicates	O
that	O
AP	B
-	I
1	I
complex	I
is	O
comprised	O
of	O
members	O
of	O
these	O
family	O
of	O
proteins	O
.	O

This	O
stimulation	O
can	O
also	O
be	O
abolished	O
by	O
inhibitors	O
of	O
protein	B
kinase	I
C	I
,	O
but	O
it	O
is	O
unaffected	O
by	O
calcium	O
channel	O
blocker	O
or	O
cyclosporine	O
A	O
.	O

